cerqcerghmjcuqokcglqwehigenctmxavgogxmxq length 7 1579949 page 1579949 <!DOCTYPE html>
<html lang="en" class="nytapp-vi-interactive" xmlns:og="http://opengraphprotocol.org/schema/">
  <head>
    <meta charset="utf-8" />
    <title data-rh="true">Covid-19 Vaccine Tracker: Latest Updates - The New York Times</title>
    <meta data-rh="true" name="robots" content="noarchive, max-image-preview:large"/><meta data-rh="true" name="description" content="A look at all the vaccines that have reached trials in humans."/><meta data-rh="true" property="og:url" content="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html"/><meta data-rh="true" property="og:type" content="article"/><meta data-rh="true" property="og:title" content="Coronavirus Vaccine Tracker (Published 2022)"/><meta data-rh="true" property="og:image" content="https://static01.nyt.com/images/2020/09/18/us/coronavirus-vaccine-tracker-promo-1600439734668/coronavirus-vaccine-tracker-promo-1600439734668-facebookJumbo-v187.png?year=2022&amp;h=549&amp;w=1050&amp;s=a45f2d8e0fd7c3985fb7c9a253afa2a1715c47bc2b6052ff3728bd22f255fc94&amp;k=ZQJBKqZ0VN"/><meta data-rh="true" property="og:image:alt" content=""/><meta data-rh="true" property="og:description" content="A look at all the vaccines that have reached trials in humans."/><meta data-rh="true" property="twitter:url" content="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html"/><meta data-rh="true" property="twitter:title" content="Coronavirus Vaccine Tracker (Published 2022)"/><meta data-rh="true" property="twitter:description" content="A look at all the vaccines that have reached trials in humans."/><meta data-rh="true" property="twitter:image" content="https://static01.nyt.com/images/2020/09/18/us/coronavirus-vaccine-tracker-promo-1600439734668/coronavirus-vaccine-tracker-promo-1600439734668-videoSixteenByNineJumbo1600-v205.png?year=2022&amp;h=901&amp;w=1600&amp;s=10fb2fa2eba7e5301835b7b6844c00334e04a4beee7fd6add219ef638570a76f&amp;k=ZQJBKqZ0VN&amp;tw=1"/><meta data-rh="true" property="twitter:image:alt" content=""/><meta data-rh="true" property="twitter:card" content="summary_large_image"/> <link data-rh="true" rel="canonical" href="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html"/> <script data-rh="true" type="application/ld+json">{"@context":"https://schema.org","@type":"NewsArticle","description":"A look at all the vaccines that have reached trials in humans.","image":[{"@context":"https://schema.org","@type":"ImageObject","url":"https://static01.nyt.com/images/2020/09/18/us/coronavirus-vaccine-tracker-promo-1600439734668/coronavirus-vaccine-tracker-promo-1600439734668-videoSixteenByNineJumbo1600-v205.png","height":901,"width":1600,"contentUrl":"https://static01.nyt.com/images/2020/09/18/us/coronavirus-vaccine-tracker-promo-1600439734668/coronavirus-vaccine-tracker-promo-1600439734668-videoSixteenByNineJumbo1600-v205.png","creditText":" "},{"@context":"https://schema.org","@type":"ImageObject","url":"https://static01.nyt.com/images/2020/09/18/us/coronavirus-vaccine-tracker-promo-1600439734668/coronavirus-vaccine-tracker-promo-1600439734668-superJumbo-v132.png","height":1331,"width":2000,"contentUrl":"https://static01.nyt.com/images/2020/09/18/us/coronavirus-vaccine-tracker-promo-1600439734668/coronavirus-vaccine-tracker-promo-1600439734668-superJumbo-v132.png","creditText":" "},{"@context":"https://schema.org","@type":"ImageObject","url":"https://static01.nyt.com/images/2020/09/18/us/coronavirus-vaccine-tracker-promo-1600439734668/coronavirus-vaccine-tracker-promo-1600439734668-mediumSquareAt3X-v132.png","height":1331,"width":1331,"contentUrl":"https://static01.nyt.com/images/2020/09/18/us/coronavirus-vaccine-tracker-promo-1600439734668/coronavirus-vaccine-tracker-promo-1600439734668-mediumSquareAt3X-v132.png","creditText":" "}],"mainEntityOfPage":"https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html","url":"https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html","inLanguage":"en-US","author":[{"@context":"https://schema.org","@type":"Person","url":"https://www.nytimes.com/by/carl-zimmer","name":"Carl Zimmer"},{"@context":"https://schema.org","@type":"Person","url":"https://www.nytimes.com/by/jonathan-corum","name":"Jonathan Corum"},{"@context":"https://schema.org","@type":"Person","url":"https://www.nytimes.com/by/sui-lee-wee","name":"Sui-Lee Wee"},{"@context":"https://schema.org","@type":"Person","url":"","name":"Matthew Kristoffersen"}],"dateModified":"2022-08-31T17:51:03.474Z","datePublished":"2020-06-10T09:01:01.000Z","headline":"Covid-19 Vaccine Tracker: Latest Updates","alternativeHeadline":"Coronavirus Vaccine Tracker","publisher":{"@id":"https://www.nytimes.com/#publisher","name":"The New York Times"},"hasPart":{"@type":"WebPageElement","isAccessibleForFree":false,"cssSelector":".meteredContent"},"copyrightHolder":{"@id":"https://www.nytimes.com/#publisher","name":"The New York Times"},"sourceOrganization":{"@id":"https://www.nytimes.com/#publisher","name":"The New York Times"},"copyrightYear":2024,"isAccessibleForFree":false,"isPartOf":{"@type":["CreativeWork","Product"],"name":"The New York Times","productID":"nytimes.com:basic"}}</script><script data-rh="true" type="application/ld+json">{"@context":"https://schema.org","@type":"NewsMediaOrganization","name":"The New York Times","logo":{"@context":"https://schema.org","@type":"ImageObject","url":"https://static01.nyt.com/images/icons/t_logo_291_black.png","height":291,"width":291,"contentUrl":"https://static01.nyt.com/images/icons/t_logo_291_black.png","creditText":"The New York Times"},"url":"https://www.nytimes.com/","@id":"https://www.nytimes.com/#publisher","diversityPolicy":"https://www.nytco.com/company/diversity-and-inclusion/","ethicsPolicy":"https://www.nytco.com/company/standards-ethics/","masthead":"https://www.nytimes.com/interactive/2023/01/28/admin/the-new-york-times-masthead.html","foundingDate":"1851-09-18","sameAs":"https://en.wikipedia.org/wiki/The_New_York_Times"}</script>
    <meta data-rh="true" property="article:published_time" content="2020-06-10T09:01:01.000Z"/><meta data-rh="true" property="article:modified_time" content="2022-08-31T17:51:03.474Z"/><meta data-rh="true" http-equiv="Content-Language" content="en"/><meta data-rh="true" name="articleid" content="100000007182188"/><meta data-rh="true" name="nyt_uri" content="nyt://interactive/417d1099-2aac-55d9-a834-9a011581411e"/><meta data-rh="true" name="pubp_event_id" content="pubp://event/a73cbbd674f54c1ab739975dd616c8f7"/><meta data-rh="true" name="image" content="https://static01.nyt.com/images/2020/09/18/us/coronavirus-vaccine-tracker-promo-1600439734668/coronavirus-vaccine-tracker-promo-1600439734668-facebookJumbo-v187.png?year=2022&amp;h=549&amp;w=1050&amp;s=a45f2d8e0fd7c3985fb7c9a253afa2a1715c47bc2b6052ff3728bd22f255fc94&amp;k=ZQJBKqZ0VN"/><meta data-rh="true" name="byl" content="By Carl Zimmer, Jonathan Corum, Sui-Lee Wee and Matthew Kristoffersen"/><meta data-rh="true" name="news_keywords" content="Coronavirus;COVID-19;Pandemic,Clinical trial,Vaccines Immunization,Immune system,Public-Private Partnerships,Moderna,BioNTech,Pfizer,Shanghai Fosun Pharmaceutical,Zydus Cadila,Morningside Ventures,Imperial College London,Osaka University,AnGes,Takara Bio,Arcturus Therapeutics,Inovio Pharmaceuticals,Genexine,Suzhou Abogen Biosciences,Chulalongkorn University,Sanofi,CanSino Biologics,Johnson &amp; Johnson,AstraZeneca,ReiThera,Vaxart,,Novartis,Sinovac Biotech,Bharat Biotech"/><meta data-rh="true" name="pdate" content="20200610"/><meta data-rh="true" property="article:section" content="Science"/><meta data-rh="true" property="article:tag" content="Coronavirus (2019-nCoV)"/><meta data-rh="true" property="article:tag" content="Clinical Trials"/><meta data-rh="true" property="article:tag" content="Vaccination and Immunization"/><meta data-rh="true" property="article:tag" content="Immune System"/><meta data-rh="true" property="article:tag" content="Public-Private Sector Cooperation"/><meta data-rh="true" property="article:tag" content="Moderna Inc"/><meta data-rh="true" property="article:tag" content="BioNTech SE"/><meta data-rh="true" property="article:tag" content="Pfizer Inc"/><meta data-rh="true" property="article:tag" content="Shanghai Fosun Pharmaceutical Group"/><meta data-rh="true" property="article:tag" content="Cadila Healthcare"/><meta data-rh="true" property="article:tag" content="Morningside Ventures Inc"/><meta data-rh="true" property="article:tag" content="Imperial College London"/><meta data-rh="true" property="article:tag" content="Osaka University"/><meta data-rh="true" property="article:tag" content="AnGes MG Inc"/><meta data-rh="true" property="article:tag" content="Takara Bio"/><meta data-rh="true" property="article:tag" content="Arcturus Therapeutics"/><meta data-rh="true" property="article:tag" content="Inovio Pharmaceuticals"/><meta data-rh="true" property="article:tag" content="Genexine"/><meta data-rh="true" property="article:tag" content="Suzhou Abogen Biosciences"/><meta data-rh="true" property="article:tag" content="Chulalongkorn University"/><meta data-rh="true" property="article:tag" content="Sanofi SA"/><meta data-rh="true" property="article:tag" content="CanSino Biologics"/><meta data-rh="true" property="article:tag" content="Johnson &amp; Johnson"/><meta data-rh="true" property="article:tag" content="AstraZeneca PLC"/><meta data-rh="true" property="article:tag" content="ReiThera Srl"/><meta data-rh="true" property="article:tag" content="Vaxart Inc"/><meta data-rh="true" property="article:tag" content="Merck &amp; Company Inc"/><meta data-rh="true" property="article:tag" content="Novartis AG"/><meta data-rh="true" property="article:tag" content="Sinovac Biotech Ltd"/><meta data-rh="true" property="article:tag" content="Bharat Biotech Ltd"/><meta data-rh="true" property="article:opinion" content="false"/><meta data-rh="true" property="article:content_tier" content="metered"/><meta data-rh="true" name="CG" content="science"/><meta data-rh="true" name="SCG" content=""/><meta data-rh="true" name="CN" content=""/><meta data-rh="true" name="CT" content=""/>
    
<meta name="viewport" content="width=device-width, initial-scale=1" />
<meta property="fb:app_id" content="9869919170" />
<meta name="twitter:site" content="@nytimes" />
<meta name="slack-app-id" content="A0121HXPPTQ" />
    
    <script>
      
      const override = (new URL(window.location)).searchParams.get('sentryOverride');
      if (override || Math.floor(Math.random() * 100) <= 1) {
        document.write('<script src="https://js.sentry-cdn.com/7bc8bccf5c254286a99b11c68f6bf4ce.min.js" crossorigin="anonymous">' + '<' + '/script>');
      }
    </script>
    <script>

      if (window.Sentry) {
        window.Sentry.onLoad(function() {
          window.Sentry.init({
            maxBreadcrumbs: 30,
            release: '03cce1e7203a898cba8bffea0e231b4698a1d4eb',
            environment: 'prd',
            beforeSend: function(evt, hint) {
              if (/amazon-adsystem|ads-us|ampproject|amp4ads|pubads|2mdn|chartbeat|gsi|bk_addPageCtx|yimg|BOOMR|boomerang/.test(hint.originalException && hint.originalException.stack || '')) return null;
              return evt;
            },

            
            integrations: [
              Sentry.browserTracingIntegration({
                enableInp: true,
              }),
            ],
          });
        });
      }
    </script>
  
    
    <script>
      
      (function(h,o,u,n,d) {
        h=h[d]=h[d]||{q:[],onReady:function(c){h.q.push(c)}}
        d=o.createElement(u);d.async=1;d.src=n
        n=o.getElementsByTagName(u)[0];n.parentNode.insertBefore(d,n)
      })(window,document,'script','https://www.datadoghq-browser-agent.com/us1/v5/datadog-rum.js','DD_RUM')

      window.DD_RUM.onReady(function() {
        window.DD_RUM.init({
          clientToken: 'pube5bf68ea68edb54c35106f34e32ff07c',
          applicationId: '7d0602a0-8ef8-4d39-985b-c3188887e5b3',
          site: 'datadoghq.com',
          service: 'vi-client',
          env: 'prd',
          version: 'vi-newsreader@v4780-03cce1e',
          sessionSampleRate: 0.1,
          sessionReplaySampleRate: 100,
          trackUserInteractions: true,
          trackResources: true,
          trackLongTasks: true,
          trackViewsManually: true,
          defaultPrivacyLevel: 'mask-user-input',

          
          allowedTracingUrls: [/https:\/\/samizdat-graphql.*\.nytimes\.com/],
          traceSampleRate: 20,

          
          useCrossSiteSessionCookie: true,
          useSecureSessionCookie: true
        });

        
        window.DD_RUM.setGlobalContextProperty('nyt', {
          billing: {
            environment: 'prd',
            deployment: {
              id: 'aws-491988406224'
            }
          },
          dvsp: {
            tenant: 'web-platforms'
          }
        });

        
        window.DD_RUM.startView({name: 'vi-interactive'});

        
        const id = /nyt-a=(.*?)(;|$)/.exec(document.cookie);
        if (id !== null) window.DD_RUM.setUser({ id: id[1] });
      })
    </script>
  

    <link data-rh="true" rel="shortcut icon" href="/vi-assets/static-assets/favicon-d2483f10ef688e6f89e23806b9700298.ico"/><link data-rh="true" rel="apple-touch-icon" href="/vi-assets/static-assets/apple-touch-icon-28865b72953380a40aa43318108876cb.png"/><link data-rh="true" rel="apple-touch-icon-precomposed" sizes="144×144" href="/vi-assets/static-assets/ios-ipad-144x144-28865b72953380a40aa43318108876cb.png"/><link data-rh="true" rel="apple-touch-icon-precomposed" sizes="114×114" href="/vi-assets/static-assets/ios-iphone-114x144-080e7ec6514fdc62bcbb7966d9b257d2.png"/><link data-rh="true" rel="apple-touch-icon-precomposed" href="/vi-assets/static-assets/ios-default-homescreen-57x57-43808a4cd5333b648057a01624d84960.png"/>
    <link href="https://g1.nyt.com/fonts/css/web-fonts.7705b21d4573b168a8aaebc4ff17d395d2458dca.css" rel="stylesheet" type="text/css" />
    <link rel="stylesheet" href="/vi-assets/static-assets/global-f449cfd9976ad673ef2b7ab5098b85be.css" />
    <style>[data-timezone] { display: none }</style>
    <style data-lights-css="1dv1kvn nuvmzp pzrpby 1pd1msn kgn7zc 1hyfx7x 1jmk4jh 1e1s8k7 1qa4qp6 jq1cx6 17ih8de 1sm67ns 1xltzhg vxcmzt 79elbk 1baulvz 1eeh360 1yhvmgx 1liwv7v 2ykviq 1nurhyi 1rxm0ex knunh2 etxl5s m3796d 1qej4jr go3nob 1doru00 1nkuxcu 136d4fr 777zgl rfqw0c l9onyx 16td4bv 1kylsam wcxsge 1iruc8t 1rr4qq7 sg7scw jxzr5i oylsik 1otr2jl 184m8ie qtw155 v0l3hm g4gku8 6xhk3s 1onhbft tj0ten ist4u3 1gprdgz 10t7hia e9w26l yk8vb4 z6qatp 1ea6cym 6td9kr 1o03u4n nhjhh0 1ho5u4o t8x4fj a7htku 1bymuyk ui9rw0 1f7ibof 1wr3we4 10698na 1awy3rz c5j6tx vfkorq 1bvtpon mfml7 1gh9hw8 zd9juy lu72is eap6fy n8ff4n 10i3hc sxwst7 1a5mdf6 nfyi9h 103u2dt fi5tub 1l8buln qz70u6 1hm40t9 1660cld zack8m n7z2yi 1rgojku uc81c">.css-1dv1kvn{border:0;-webkit-clip:rect(0 0 0 0);clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px;}.css-nuvmzp{font-size:14.25px;font-family:nyt-franklin,helvetica,arial,sans-serif;font-weight:700;text-transform:uppercase;-webkit-letter-spacing:0.7px;-moz-letter-spacing:0.7px;-ms-letter-spacing:0.7px;letter-spacing:0.7px;line-height:19px;}.css-nuvmzp:hover{-webkit-text-decoration:underline;text-decoration:underline;}.css-pzrpby{display:none;font-size:10px;margin-left:auto;text-transform:uppercase;}.hasLinks .css-pzrpby{display:block;min-height:10px;}@media (min-width:740px){.hasLinks .css-pzrpby{margin:none;position:absolute;right:20px;}}@media (min-width:1024px){.hasLinks .css-pzrpby{display:none;min-height:0;}}.css-1pd1msn{display:inline-block;font-size:0.875rem;line-height:1.25rem;-webkit-transition:color 0.6s ease;transition:color 0.6s ease;color:#121212;}.css-1pd1msn:hover{color:#666;}.css-kgn7zc{border:0;-webkit-clip:rect(0 0 0 0);clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px;border-radius:3px;cursor:pointer;font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-transition:ease 0.6s;transition:ease 0.6s;white-space:nowrap;vertical-align:middle;background-color:transparent;color:#000;font-size:11px;line-height:11px;font-weight:700;-webkit-letter-spacing:0.02em;-moz-letter-spacing:0.02em;-ms-letter-spacing:0.02em;letter-spacing:0.02em;padding:11px 12px 8px;background:#fff;display:inline-block;left:44px;text-transform:uppercase;-webkit-transition:none;transition:none;z-index:5;}.css-kgn7zc:active,.css-kgn7zc:focus{-webkit-clip:auto;clip:auto;overflow:visible;width:auto;height:auto;}.css-kgn7zc::-moz-focus-inner{padding:0;border:0;}.css-kgn7zc:-moz-focusring{outline:1px dotted;}.css-kgn7zc:disabled,.css-kgn7zc.disabled{opacity:0.5;cursor:default;}.css-kgn7zc:active,.css-kgn7zc.active{background-color:#f7f7f7;}@media (min-width:740px){.css-kgn7zc:hover{background-color:#f7f7f7;}}.css-kgn7zc:focus{margin-top:3px;padding:8px 8px 6px;}@media (max-width:600px){.css-kgn7zc:focus{margin-top:12px;margin-left:9px;}}@media (min-width:1024px){.css-kgn7zc{left:112px;}}.css-1hyfx7x{display:none;}@media (min-width:1150px){.css-1jmk4jh{margin:0 auto;max-width:1200px;padding:0 3% 9px;}}.NYTApp .css-1jmk4jh{display:none;}@media print{.css-1jmk4jh{display:none;}}.css-1e1s8k7{font-size:11px;text-align:center;padding-bottom:25px;}@media (min-width:1024px){.css-1e1s8k7{padding:0 3% 9px;}}.css-1e1s8k7.dockVisible{padding-bottom:45px;}@media (min-width:1024px){.css-1e1s8k7.dockVisible{padding:0 3% 45px;}}@media (min-width:1150px){.css-1e1s8k7{margin:0 auto;max-width:1200px;}}.NYTApp .css-1e1s8k7{display:none;}@media print{.css-1e1s8k7{display:none;}}.css-1qa4qp6{border-top:1px solid #ebebeb;padding-top:9px;margin:0 0 35px;}.css-jq1cx6{color:#666;font-family:nyt-franklin,helvetica,arial,sans-serif;padding:10px 0;-webkit-text-decoration:none;text-decoration:none;white-space:nowrap;}.css-jq1cx6:hover{-webkit-text-decoration:underline;text-decoration:underline;}.css-17ih8de{box-sizing:border-box;vertical-align:top;}.NYTApp .css-1sm67ns{display:none;}.css-1xltzhg{margin-top:0;margin-bottom:0;}@media (min-width:1024px){.css-1xltzhg{height:43px;}}.css-vxcmzt{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;}.css-79elbk{position:relative;}.css-1baulvz{display:inline-block;}.css-1eeh360{height:auto;width:auto;border-radius:30px;}.css-1eeh360:focus{outline:none;box-shadow:0 0 4px 1px rgb(0 95 204);}@supports selector(:focus-visible){.css-1eeh360:focus{box-shadow:none;}.css-1eeh360:focus-visible{box-shadow:0 0 4px 1px rgb(0 95 204);}}.css-1yhvmgx{height:auto;width:auto;border:solid 1px var(--color-stroke-quaternary,#DFDFDF);background-color:var(--color-background-primary,#FFFFFF);border-radius:30px;font-size:0.75rem;font-family:nyt-franklin,helvetica,arial,sans-serif;text-transform:uppercase;}.css-1yhvmgx:hover{background-color:var(--color-background-tertiary,#EBEBEB);border:1px solid var(--color-background-tertiary,#EBEBEB);}.css-1yhvmgx .hiddenClass{display:none;}.css-1yhvmgx[aria-checked='true'] .saved-fill{fill:var(--color-stroke-primary,#121212);}.css-1yhvmgx[aria-checked='true'] .saved-stroke{fill:var(--color-stroke-primary,#121212);}.css-1yhvmgx[aria-checked='false'] .saved-fill{fill:none;}.css-1yhvmgx[aria-checked='false'] .saved-stroke{fill:var(--color-stroke-primary,#121212);}.css-1yhvmgx[aria-busy='true']{cursor:default;background-color:var(--color-background-tertiary,#EBEBEB);}.css-1liwv7v{padding:0;margin-left:0;margin-right:0;}@media (max-width:420px){.css-1liwv7v{margin-left:-9px;margin-right:-20px;}}.css-2ykviq{color:#999;display:inline;margin-right:12px;width:100%;}.unlimited-gift .css-2ykviq.sha-std-share{display:none;}@media (max-width:420px){.css-2ykviq{margin-right:6px;}}.css-2ykviq > a,.css-2ykviq > button{-webkit-text-decoration:none;text-decoration:none;}.css-2ykviq > a:focus,.css-2ykviq > button:focus{display:inline-block;outline:none;box-shadow:0 0 2px 1px rgb(0 95 204);}@supports selector(:focus-visible){.css-2ykviq > a:focus,.css-2ykviq > button:focus{box-shadow:none;}.css-2ykviq > a:focus-visible,.css-2ykviq > button:focus-visible{box-shadow:0 0 2px 1px rgb(0 95 204);}}.css-2ykviq > a:focus{border-radius:100%;}.css-2ykviq:last-of-type{margin-right:0;}.css-1nurhyi{height:auto;width:auto;border-radius:100%;background-color:transparent;}.css-1rxm0ex{display:block;}@media (min-width:1024px){.css-1rxm0ex{display:inline-block;white-space:pre;}}.css-knunh2{padding-bottom:1px;}@media (min-width:600px){.css-knunh2:hover{color:var(--color-content-tertiary,#5A5A5A);border-bottom:1px solid var(--color-content-tertiary,#5A5A5A);}}.css-etxl5s{-webkit-text-decoration:none;text-decoration:none;color:var(--color-content-primary,#121212);}.css-m3796d{min-width:unset;padding:0.5px 0 0.5px 20px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:left;-webkit-justify-content:left;-ms-flex-pack:left;justify-content:left;overflow-x:auto;white-space:nowrap;-webkit-scrollbar-width:none;-moz-scrollbar-width:none;-ms-scrollbar-width:none;scrollbar-width:none;}@media (min-width:620px){.css-m3796d{min-width:620px;}}.css-m3796d::-webkit-scrollbar{display:none;}@media (pointer:coarse){.css-m3796d{overflow-x:scroll;-webkit-overflow-scrolling:touch;}}@media (min-width:1024px){.css-m3796d{-webkit-align-items:baseline;-webkit-box-align:baseline;-ms-flex-align:baseline;align-items:baseline;}}@media (max-width:599px){.css-m3796d::after{content:'';background:linear-gradient(90deg,rgba(255,255,255,0),var(--color-background-elevated,#FFFFFF));height:40px;position:absolute;right:0;width:24px;z-index:2;}@media (prefers-color-scheme:dark){.NYTApp .css-m3796d::after{background:linear-gradient(90deg,rgba(42,42,42,0),var(--color-background-elevated,#FFFFFF));}}}.css-1qej4jr{padding:1em 0;margin-right:1.4em;}.css-1qej4jr:last-child{margin-right:20px;}.css-go3nob{font-family:nyt-franklin,helvetica,arial,sans-serif;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;width:auto;list-style:none;padding-left:0;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;-webkit-align-items:baseline;-webkit-box-align:baseline;-ms-flex-align:baseline;align-items:baseline;}.css-1doru00{position:relative;color:#08f;left:0;}.css-1nkuxcu{width:25px;height:25px;border-radius:3px;cursor:pointer;font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-transition:ease 0.6s;transition:ease 0.6s;white-space:nowrap;vertical-align:middle;background-color:transparent;color:#000;font-size:11px;line-height:11px;font-weight:700;-webkit-letter-spacing:0.02em;-moz-letter-spacing:0.02em;-ms-letter-spacing:0.02em;letter-spacing:0.02em;padding:11px 12px 8px;padding:10px;}.css-1nkuxcu::-moz-focus-inner{padding:0;border:0;}.css-1nkuxcu:-moz-focusring{outline:1px dotted;}.css-1nkuxcu:disabled,.css-1nkuxcu.disabled{opacity:0.5;cursor:default;}.css-1nkuxcu:active,.css-1nkuxcu.active{background-color:#f7f7f7;}@media (min-width:740px){.css-1nkuxcu:hover{background-color:#f7f7f7;}}.css-136d4fr{padding:0 10px;height:55px;position:absolute;left:0;top:0;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;background:#fff;display:none;}@media (min-width:1150px){.css-136d4fr{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}}.css-777zgl{position:absolute;width:1px;height:1px;margin:-1px;padding:0;border:0;-webkit-clip:rect(0 0 0 0);clip:rect(0 0 0 0);overflow:hidden;text-align:center;}.css-777zgl:focus-visible{background-color:#fff;border-radius:3px;height:auto;width:auto;-webkit-clip:auto;clip:auto;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:0.6875rem;font-weight:700;left:50%;padding:8px 8px 6px;-webkit-transform:translateX(-50%);-ms-transform:translateX(-50%);transform:translateX(-50%);top:5px;}.css-rfqw0c{text-align:center;height:100%;display:block;}.css-l9onyx{color:#ccc;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:0.5625rem;font-weight:300;-webkit-letter-spacing:0.05rem;-moz-letter-spacing:0.05rem;-ms-letter-spacing:0.05rem;letter-spacing:0.05rem;line-height:0.5625rem;margin-bottom:9px;text-align:center;text-transform:uppercase;}.css-16td4bv{width:calc(100% - 40px);max-width:600px;margin-left:20px;margin-bottom:1.375rem;color:#333;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:start;-webkit-justify-content:start;-ms-flex-pack:start;justify-content:start;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;text-align:left;}.css-16td4bv .e16638kd0{font-size:0.8125rem;line-height:1.125rem;}.css-16td4bv .ed0j4n70{font-weight:600;font-size:0.875rem;line-height:1.125rem;}@media (min-width:740px){.css-16td4bv{max-width:720px;margin-left:auto;margin-bottom:1.5rem;text-align:center;}}@media (min-width:600px){.css-16td4bv{margin-left:auto;margin-right:auto;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;}}.css-1kylsam{margin:0 auto 1.375rem;text-align:left;width:calc(100% - 40px);max-width:600px;margin-left:20px;margin-right:20px;}.NYTApp .css-1kylsam{display:none;}@media (min-width:600px){.css-1kylsam{margin-left:auto;margin-right:auto;}}@media (min-width:740px){.css-1kylsam{margin-bottom:1.5rem;}}.css-wcxsge{font-weight:500;text-transform:capitalize;margin-right:0.15em;}.css-1iruc8t{list-style:none;margin:0;padding:0;}.css-1rr4qq7{-webkit-flex:1;-ms-flex:1;flex:1;}.css-sg7scw{padding:0 20px;}.css-sg7scw::before{background-color:#fff;border-bottom:1px solid #e2e2e2;border-top:2px solid #e2e2e2;content:'';display:block;height:1px;margin-top:0;}@media (min-width:740px){.css-sg7scw{padding:0 3%;}}@media (min-width:1150px){.css-sg7scw{padding:0;}}.css-jxzr5i{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-flow:row;-ms-flex-flow:row;flex-flow:row;}.css-oylsik{display:block;height:44px;vertical-align:middle;width:184px;}.css-1otr2jl{margin:18px 0 0 auto;}.css-184m8ie{color:#567b95;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:11px;font-style:normal;font-weight:400;line-height:11px;-webkit-text-decoration:none;text-decoration:none;}.css-qtw155{display:block;}@media (min-width:1150px){.css-qtw155{display:none;}}.css-v0l3hm{display:none;}@media (min-width:1150px){.css-v0l3hm{display:block;}}.css-g4gku8{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin-top:10px;min-width:600px;}.css-6xhk3s{border-left:1px solid #e2e2e2;-webkit-flex:1;-ms-flex:1;flex:1;padding-left:15px;}.css-1onhbft{color:#333;font-size:13px;font-weight:700;font-family:nyt-franklin,helvetica,arial,sans-serif;height:25px;line-height:15px;margin:0;text-transform:uppercase;width:150px;}.css-tj0ten{margin-bottom:5px;white-space:nowrap;}.css-tj0ten:last-child{margin-bottom:10px;}.css-ist4u3.desktop{display:none;}@media (min-width:740px){.css-ist4u3.desktop{display:block;}.css-ist4u3.smartphone{display:none;}}.css-1gprdgz{list-style:none;margin:0;padding:0;-webkit-columns:2;columns:2;padding:0 0 15px;}.css-10t7hia{height:34px;line-height:34px;list-style-type:none;}.css-10t7hia.desktop{display:none;}@media (min-width:740px){.css-10t7hia.desktop{display:block;}.css-10t7hia.smartphone{display:none;}}.css-e9w26l{color:#333;display:block;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:15px;font-weight:500;height:34px;line-height:34px;-webkit-text-decoration:none;text-decoration:none;text-transform:capitalize;}.css-yk8vb4{color:#000;display:inline-block;font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-text-decoration:none;text-decoration:none;width:150px;font-size:14px;font-weight:500;height:23px;line-height:16px;}.css-yk8vb4:hover{cursor:pointer;-webkit-text-decoration:underline;text-decoration:underline;}body.dark .css-yk8vb4{color:#fff;}.css-z6qatp{color:#000;display:inline-block;font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-text-decoration:none;text-decoration:none;width:150px;font-size:16px;font-weight:700;height:25px;line-height:15px;padding-bottom:0;}.css-z6qatp:hover{cursor:pointer;-webkit-text-decoration:underline;text-decoration:underline;}body.dark .css-z6qatp{color:#fff;}.css-1ea6cym{color:#000;display:inline-block;font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-text-decoration:none;text-decoration:none;width:150px;font-size:11px;font-weight:500;height:23px;line-height:21px;}.css-1ea6cym:hover{cursor:pointer;-webkit-text-decoration:underline;text-decoration:underline;}body.dark .css-1ea6cym{color:#fff;}.css-6td9kr{list-style:none;margin:0;padding:0;border-top:1px solid #e2e2e2;margin-top:2px;padding-top:10px;}.css-1o03u4n{display:inline-block;height:13px;width:13px;margin-right:7px;vertical-align:middle;}.css-nhjhh0{display:block;width:189px;height:26px;margin:5px auto 0;}@media (min-width:740px){.css-nhjhh0{width:225px;height:31px;margin:4px auto 0;}}@media (min-width:1024px){.css-nhjhh0{width:195px;height:26px;margin:6px auto 0;}}.css-1ho5u4o{list-style:none;margin:0 0 15px;padding:0;}@media (min-width:600px){.css-1ho5u4o{display:inline-block;}}.css-t8x4fj{list-style:none;line-height:8px;padding:0;}.css-t8x4fj:last-child > li{margin:16px 0 0 0;}@media (min-width:600px){.css-t8x4fj{display:inline-block;}}.css-a7htku{display:inline-block;line-height:20px;padding:0 10px;}.css-a7htku:first-child{border-left:none;}.css-a7htku.desktop{display:none;}@media (min-width:740px){.css-a7htku.smartphone{display:none;}.css-a7htku.desktop{display:inline-block;}.css-a7htku.mobileOnly{display:none;}}@media (min-width:1024px){.css-1bymuyk{position:relative;border-bottom:1px solid #e2e2e2;}}.css-ui9rw0{background:#fff;border-bottom:1px solid #e2e2e2;height:36px;padding:8px 15px 3px;position:relative;}@media (min-width:740px){.css-ui9rw0{background:#fff;padding:10px 15px 6px;}}@media (min-width:1024px){.css-ui9rw0{background:transparent;border-bottom:0;padding:4px 15px 2px;}}@media (min-width:1024px){.css-ui9rw0{margin:0 auto;max-width:1605px;}}.css-1f7ibof{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:space-around;-webkit-justify-content:space-around;-ms-flex-pack:space-around;justify-content:space-around;left:10px;position:absolute;}@media print{.css-1f7ibof{display:none;}}.css-1wr3we4{display:none;}@media (min-width:1024px){.css-1wr3we4{display:block;position:absolute;left:105px;line-height:19px;top:10px;}}.css-10698na{text-align:center;}@media (min-width:740px){.css-10698na{padding-top:0;}}@media print{.css-10698na a[href]::after{content:'';}.css-10698na svg{fill:black;}}.css-1awy3rz{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:space-around;-webkit-justify-content:space-around;-ms-flex-pack:space-around;justify-content:space-around;position:absolute;right:10px;top:8px;}@media (min-width:740px){.css-1awy3rz{top:10px;}}@media (min-width:1024px){.css-1awy3rz{top:4px;}}@media print{.css-1awy3rz{display:none;}}.css-c5j6tx{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:11px;-webkit-box-pack:space-around;-webkit-justify-content:space-around;-ms-flex-pack:space-around;justify-content:space-around;padding:13px 20px 12px;}@media (min-width:740px){.css-c5j6tx{position:relative;}}@media (min-width:1024px){.css-c5j6tx{-webkit-box-pack:justify;-webkit-justify-content:space-between;-ms-flex-pack:justify;justify-content:space-between;border:none;padding:0;height:0;-webkit-transform:translateY(48px);-ms-transform:translateY(48px);transform:translateY(48px);-webkit-align-items:flex-end;-webkit-box-align:flex-end;-ms-flex-align:flex-end;align-items:flex-end;}}@media print{.css-c5j6tx{display:none;}}.css-vfkorq{color:#121212;font-size:0.6875rem;font-family:nyt-franklin,helvetica,arial,sans-serif;display:none;width:auto;font-weight:700;}@media (min-width:740px){.css-vfkorq{text-align:center;width:100%;font-weight:700;}}@media (min-width:1024px){.css-vfkorq{font-size:0.875rem;line-height:1.25rem;width:auto;margin-bottom:4px;font-weight:400;}}.css-1bvtpon{display:none;}.css-mfml7 .actionbar-button{background:var(--color-background-primary,#FFFFFF);border:1px solid var(--color-stroke-quaternary,#DFDFDF);color:var(--color-content-primary,#121212);box-shadow:none;}.css-mfml7 .actionbar-button svg > path{fill:var(--color-stroke-primary,#121212);}.css-mfml7 .actionbar-button:hover{border:1px solid var(--color-stroke-quaternary,#DFDFDF);background-color:var(--color-background-tertiary,#EBEBEB);color:var(--color-content-primary,#121212);}.css-mfml7 .actionbar-button:hover svg > path{fill:var(--color-stroke-primary,#121212);}.css-mfml7 .actionbar-button:hover svg > g{stroke:var(--color-stroke-primary,#121212);}.css-mfml7 .actionbar-button[aria-checked='true'] .saved-fill{fill:var(--color-stroke-primary,#121212);}.css-mfml7 .actionbar-button[aria-checked='true'] .saved-stroke{fill:var(--color-stroke-primary,#121212);}.css-mfml7 .actionbar-button[aria-checked='true']:hover .saved-fill{fill:var(--color-stroke-primary,#121212);}.css-mfml7 .actionbar-button[aria-checked='true']:hover .saved-stroke{fill:var(--color-stroke-primary,#121212);}.css-mfml7 .actionbar-button[aria-checked='false'] .saved-fill{fill:none;}.css-mfml7 .actionbar-button[aria-checked='false'] .saved-stroke{fill:var(--color-stroke-primary,#121212);}.css-mfml7 .actionbar-button[aria-checked='false']:hover .saved-stroke{fill:var(--color-stroke-primary,#121212);}.css-mfml7 .actionbar-button:focus{box-shadow:0 0 2px 1px rgb(0 95 204);outline:3px solid transparent;outline-offset:2px;}@supports selector(:focus-visible){.css-mfml7 .actionbar-button:focus{box-shadow:none;}.css-mfml7 .actionbar-button:focus-visible{box-shadow:0 0 2px 1px rgb(0 95 204);outline:3px solid transparent;outline-offset:2px;}}.css-1gh9hw8{color:#999;display:inline;margin-right:12px;width:100%;position:relative;}.unlimited-gift .css-1gh9hw8.sha-std-share{display:none;}@media (max-width:420px){.css-1gh9hw8{margin-right:6px;}}.css-1gh9hw8 > a,.css-1gh9hw8 > button{-webkit-text-decoration:none;text-decoration:none;}.css-1gh9hw8 > a:focus,.css-1gh9hw8 > button:focus{display:inline-block;outline:none;box-shadow:0 0 2px 1px rgb(0 95 204);}@supports selector(:focus-visible){.css-1gh9hw8 > a:focus,.css-1gh9hw8 > button:focus{box-shadow:none;}.css-1gh9hw8 > a:focus-visible,.css-1gh9hw8 > button:focus-visible{box-shadow:0 0 2px 1px rgb(0 95 204);}}.css-1gh9hw8 > a:focus{border-radius:100%;}.css-1gh9hw8:last-of-type{margin-right:0;}.css-zd9juy{display:inline-block;vertical-align:middle;width:20px;border-radius:100%;padding:6px;overflow:initial;vertical-align:middle;height:20px;}.css-zd9juy path{fill:var(--color-content-primary,#121212);}.css-lu72is{direction:ltr;display:inline-block;vertical-align:middle;border-radius:30px;padding:6px 10px 6px;font-size:0.75rem;font-family:nyt-franklin,helvetica,arial,sans-serif;line-height:0.9375rem;text-align:right;font-weight:500;}.css-lu72is:hover .gift-count{background-color:#fafafa;}@media (max-width:600px){.css-lu72is{padding:6px 7px 5px;}}.css-lu72is svg{margin-right:5px;vertical-align:-6px;height:20px;}.css-lu72is .sha-arrow-icon{display:none;}.unlimited-gift .css-lu72is .sha-gift-icon{display:none;}.unlimited-gift .css-lu72is .sha-arrow-icon{display:inline-block;}.css-eap6fy{height:18px;width:18px;padding:7px;overflow:visible;vertical-align:middle;cursor:not-allowed;}.css-eap6fy g{stroke-width:0.1px;}@media (min-width:1150px){.css-eap6fy:hover g,.css-eap6fy:focus g{stroke:var(--color-stroke-secondary,#8B8B8B);opacity:1;}}.css-n8ff4n{color:inherit;-webkit-text-decoration:underline;text-decoration:underline;text-underline-offset:1px;-webkit-text-decoration-thickness:1px;text-decoration-thickness:1px;-webkit-text-decoration-color:var(--color-content-quaternary,#727272);text-decoration-color:var(--color-content-quaternary,#727272);}.css-n8ff4n:hover,.css-n8ff4n:focus{-webkit-text-decoration:none;text-decoration:none;}.css-10i3hc{color:#999;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:17px;margin-bottom:5px;width:calc(100% - 40px);max-width:600px;margin:1.5rem auto 2rem;margin-bottom:1rem;}@media print{.css-10i3hc{display:none;}}@media (min-width:1440px){.css-10i3hc{width:600px;max-width:600px;}}@media (min-width:600px){.css-10i3hc{-webkit-box-pack:start;-webkit-justify-content:flex-start;-ms-flex-pack:start;justify-content:flex-start;}}.css-10i3hc:empty{display:none;}@media (min-width:600px){.css-10i3hc{margin-bottom:1rem;}}.css-sxwst7{background-color:#f7f7f7;border-bottom:1px solid #f3f3f3;border-top:1px solid #f3f3f3;margin:2rem auto;padding-bottom:30px;padding-top:12px;text-align:center;position:relative;margin-top:60px;min-height:280px;}@media (min-width:740px){.css-sxwst7{margin:3rem auto;}}@media print{.css-sxwst7{display:none;}}@media (min-width:740px){.css-sxwst7{margin-bottom:0;margin-top:0;}}.css-1a5mdf6{cursor:pointer;margin:0;border-top:1px solid #ebebeb;color:#333;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:13px;font-weight:700;height:44px;-webkit-letter-spacing:0.04rem;-moz-letter-spacing:0.04rem;-ms-letter-spacing:0.04rem;letter-spacing:0.04rem;line-height:44px;text-transform:uppercase;}.accordionExpanded .css-1a5mdf6{color:#b3b3b3;}.css-nfyi9h{-webkit-text-decoration:none;text-decoration:none;color:unset;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:0.875rem;line-height:0.875rem;font-weight:700;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;width:auto;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin-right:16px;padding-right:15px;color:var(--color-content-primary,#121212);background-color:var(--color-background-elevated,#FFFFFF);box-shadow:4px 0 7px 10px var(--color-background-elevated,#FFFFFF);border-right:1px solid var(--color-stroke-quaternary,#DFDFDF);color:var(--color-content-primary,#121212);}@media (min-width:600px){.css-nfyi9h{font-size:0.9375rem;line-height:0.9375rem;}}.css-103u2dt{padding-bottom:0;}@media (min-width:600px){.css-103u2dt:hover,.css-103u2dt:focus,.css-103u2dt:active{padding-bottom:1px;color:var(--color-content-tertiary,#5A5A5A);border-bottom:2px solid var(--color-content-tertiary,#5A5A5A);}}.css-103u2dt span:last-of-type::after{content:'›';font-weight:500;font-size:1.125rem;margin-left:4px;color:inherit;position:relative;bottom:-1px;}@media (min-width:600px){.css-103u2dt span:last-of-type::after{font-size:1.1875rem;}}.css-fi5tub{font-family:nyt-franklin,helvetica,arial,sans-serif;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:0.8125rem;font-weight:500;color:var(--color-content-primary,#121212);}@media (min-width:600px){.css-fi5tub{font-size:0.875rem;}}.css-1l8buln{color:var(--color-content-primary,#121212);font-family:nyt-cheltenham,georgia,'times new roman',times,serif;font-weight:700;font-style:italic;font-size:1.9375rem;line-height:2.25rem;text-align:left;}@media (min-width:740px){.css-1l8buln{font-size:2.5rem;line-height:2.875rem;}}@media print{.css-qz70u6{display:none;}}@media (min-width:1024px){.css-qz70u6{position:fixed;width:100%;top:0;left:0;z-index:200;background-color:#fff;border-bottom:none;-webkit-transition:all 0.2s ease-in-out;transition:all 0.2s ease-in-out;}}.NYTApp .css-qz70u6{display:none;}.css-1hm40t9{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:left;-webkit-justify-content:left;-ms-flex-pack:left;justify-content:left;background:var(--color-background-elevated,#FFFFFF);border-bottom:1px solid var(--color-stroke-quaternary,#DFDFDF);min-height:55px;position:relative;border-bottom:1px solid var(--color-stroke-quaternary,#DFDFDF);}@media (min-width:600px){.css-1hm40t9{-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;}}@media print{.css-1hm40t9{display:none;}}.css-1hm40t9::after{content:'';position:absolute;top:0;left:0;height:100%;width:100%;z-index:-1;box-shadow:0 0 transparent,0 0 transparent,1px 3px 6px #00000026;opacity:0;-webkit-transition:opacity 200ms ease-out;transition:opacity 200ms ease-out;}@media (prefers-color-scheme:dark){.NYTApp .css-1hm40t9::after{box-shadow:none;}}.css-1hm40t9::after{box-shadow:none;}.css-1660cld{margin-top:1.5625rem;}@media (min-width:740px){.css-1660cld{margin-top:3.75rem;}}.css-1660cld .e6idgb70{color:var(--color-content-primary,#121212);font-weight:700;line-height:0.75rem;margin-bottom:1.25rem;margin-top:0;}@media print{.css-1660cld .e6idgb70{margin-left:0;margin-right:0;width:100%;max-width:100%;}}.css-1660cld .e1h9rw200{margin-bottom:20px;}@media (min-width:740px){.css-1660cld .e1h9rw200{position:relative;}}.css-1660cld .ezdmqqa0{margin-bottom:3px;}@media (min-width:600px){.css-1660cld .ezdmqqa0{margin-bottom:0;}}.css-1660cld .e1wiw3jv0{color:var(--color-content-secondary,#363636);}.css-1660cld .e16638kd0{display:inline-block;}.css-1660cld .eakwutd0{margin-bottom:20px;color:var(--color-content-primary,#121212);}@media print{.css-1660cld .eakwutd0{margin-left:0;margin-right:0;width:100%;max-width:100%;}}@media (min-width:600px){.css-1660cld{margin-top:45px;}}.NYTApp .css-1660cld{margin-top:55px;}.css-1660cld .e6idgb70{font-size:0.75rem;line-height:0.875rem;color:#121212;margin-top:20px;margin-bottom:10px;text-align:center;width:calc(100% - 40px);max-width:600px;margin-left:20px;margin-right:20px;}@media (min-width:600px){.css-1660cld .e6idgb70{font-size:0.875rem;line-height:1.125rem;margin-top:35px;}}@media (min-width:600px){.css-1660cld .e6idgb70{margin-left:auto;margin-right:auto;}}@media (min-width:1024px){.css-1660cld .e6idgb70{width:600px;}}@media (min-width:1440px){.css-1660cld .e6idgb70{width:600px;max-width:600px;}}.css-1660cld .e1h9rw200{font-size:1.8125rem;line-height:2.0625rem;margin-bottom:1.125rem;text-align:left;width:calc(100% - 40px);max-width:600px;margin-left:20px;margin-right:20px;}@media (min-width:600px){.css-1660cld .e1h9rw200{margin-left:auto;margin-right:auto;}}@media (min-width:740px){.css-1660cld .e1h9rw200{width:720px;max-width:720px;font-size:2.5rem;line-height:2.75rem;text-align:center;margin-bottom:1.25rem;}}.css-1660cld .e16638kd0{text-transform:capitalize;}.css-1660cld .e16638kd0 span:last-of-type{margin-right:0;}@media (min-width:600px){.css-1660cld .e16638kd0{margin-top:0;}}@media (min-width:740px){.css-1660cld .e16638kd0{margin-right:auto;}}.css-zack8m{display:inline-block;margin:0;font-size:0.875rem;line-height:1.125rem;font-family:nyt-franklin,helvetica,arial,sans-serif;font-weight:700;color:var(--color-content-secondary,#363636);}@media (min-width:740px){.css-zack8m{font-size:0.9375rem;line-height:1.25rem;}}@media (min-width:740px){.css-zack8m{margin-left:auto;}}@media (min-width:740px){.css-zack8m{margin-left:auto;margin-right:auto;}}.css-zack8m .last-byline{padding-right:10px;}.css-n7z2yi{color:#999;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:17px;margin-bottom:5px;height:32px;}@media print{.css-n7z2yi{display:none;}}@media (min-width:740px){.css-n7z2yi{-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;}}.css-1rgojku{color:#999;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:17px;margin-bottom:5px;height:32px;width:calc(100% - 40px);max-width:600px;margin:1.5rem auto 2rem;}@media print{.css-1rgojku{display:none;}}@media (min-width:740px){.css-1rgojku{-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;}}@media (min-width:1440px){.css-1rgojku{width:600px;max-width:600px;}}@media (min-width:600px){.css-1rgojku{-webkit-box-pack:start;-webkit-justify-content:flex-start;-ms-flex-pack:start;justify-content:flex-start;}}.css-uc81c{width:100%;margin:0 auto;height:auto;max-width:1600px;margin:1.5rem auto;max-width:1600px;width:calc(100% - 20px);}@media (min-width:340px) and (max-width:630px){.css-uc81c{width:calc(100% - 40px);}}</style>
    
    

    <script type="text/javascript">
    (function fidesScript(a,b){function c(){if(!g()&&f()){var c=document.createElement("script");c.id="nyt-fides",c.src=a,b.document.head.appendChild(c)}}var d=new URLSearchParams(b.location.search),e=function(a){var c=b.document.cookie.split(";").find(function(b){return b.includes(a)})||"";return c.replace(a,"").trim().charAt(16)},f=function(){var a,c,f,g=d.get("fides-override"),h=e("nyt-purr="),i=e("override-purr="),j=0<(null===(a=b.config)||void 0===a||null===(c=a.tc_info)||void 0===c||null===(f=c.fides_string)||void 0===f?void 0:f.length);return j||"s"===i||"s"===h||"true"===g},g=function(){return null!==b.document.getElementById("nyt-fides")};c(),b.addEventListener("initWebview:ios",c),b.fidesUtils={isFidesEligible:f}})('https://static01.nyt.com/vi-assets/static-assets/fides-675e7fcafce283a12aba8ba28db11d1d.js', window);
    (function fidesTracking(a){function b(a){var b=a.layerType;return{event:"impression",priority:!0,module:{name:b,label:b,region:"bottom"}}}function c(a){var b=a.actionType,c=void 0===b?"":b,d=a.layerType,e=void 0===d?"":d;return{event:"moduleInteraction",eventData:{trigger:"module",type:"click"},module:{name:e,label:e,element:{name:c,label:c}}}}function d(a){var b=a.actionType,c=void 0===b?"":b,d=a.layerType,e=void 0===d?"":d;return{subject:"interaction",data:{name:e,label:e,element:{name:c,label:c}}}}function e(b){var c=a.dataLayer||(a.dataLayer=[]);c.push(b)}function f(b){var c=a.document.getElementById("fides-banner"),d=a.document.getElementById("fides-modal"),e=a.document.getElementById("fides-embed-container"),f="true"===(null===d||void 0===d?void 0:d.getAttribute("aria-hidden"));if(e)return"cmp_layer_2";if(null!==b){if(!c||!d)return"";if(c.contains(b))return"cmp_layer_1";if(d.contains(b))return"cmp_layer_2"}return f?"cmp_layer_1":"cmp_layer_2"}function g(a){var b=a.textContent.toLowerCase();return{"accept all":"accept_all","reject all":"reject_all","manage preferences":"manage_prefs","cookie policy":"cookie_policy","privacy policy":"privacy_policy",purposes:"purposes",features:"features",vendors:"vendors",save:"save"}[b]||""}// dispatch event for iOS and Android to listen to.
function h(b){var c=new CustomEvent("NYTFidesUpdated",{detail:b});a.dispatchEvent(c)}var i;!0===(null===(i=a.fidesUtils)||void 0===i?void 0:i.isFidesEligible())&&(a.addEventListener("FidesUIShown",function(a){var c,d=null===a||void 0===a||null===(c=a.detail)||void 0===c?void 0:c.extraDetails,f=d.servingComponent,g=void 0===f?"":f;if("tcf_banner"===g){var h=b({layerType:"cmp_layer_1"});e(h)}}),a.addEventListener("click",function(a){var b=a.target,i="button"===b.type,j="a"===b.nodeName.toLowerCase();if(i||j){var k=g(b),l=f(b);if(k){var m=c({actionType:k,layerType:l});e(m);var n=d({actionType:k,layerType:l});h(n),a.stopPropagation()}}}),a.addEventListener("beforeunload",function(){var a=f(null),c=b({layerType:"".concat(a,"_exit")});e(c)}))})(window);
  </script>
    
    
    <script type="text/javascript">
      // 38.235kB
      window.viHeadScriptSize = 38.235;
      window.NYTD = {};
      window.vi = window.vi || {};
      window.vi.pageType = { type: '', edge: 'vi-interactive-standard'};
      (function () { var userAgent=window.navigator.userAgent||window.navigator.vendor||window.opera||"",inNewsreaderApp=userAgent.includes("nytios")||userAgent.includes("nyt_android"),inXWordsApp=userAgent.includes("nyt_xwords_ios")||userAgent.includes("Crosswords"),inAndroid=userAgent.includes("nyt_android")||userAgent.includes("Crosswords"),iniOS=userAgent.includes("nytios")||userAgent.includes("nyt_xwords_ios"),isInWebviewByUserAgent=(inAndroid||iniOS)&&(inNewsreaderApp||inXWordsApp);function appType(){return inNewsreaderApp?"newsreader":inXWordsApp?"crosswords":""}function deviceType(){return inAndroid?"ANDROID":iniOS?"IOS":""}var _f=function(e){window.vi.webviewEnvironment={appType:appType(),deviceType:deviceType(),isInWebview:e.webviewEnvironment.isInWebview||isInWebviewByUserAgent,isPreloaded:e.webviewEnvironment.isPreloaded}};;_f.apply(null, [{"gqlUrlClient":"https://samizdat-graphql.nytimes.com/graphql/v2","gqlRequestHeaders":{"nyt-app-type":"project-vi","nyt-app-version":"0.0.5","nyt-token":"MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEAs+/oUCTBmD/cLdmcecrnBMHiU/pxQCn2DDyaPKUOXxi4p0uUSZQzsuq1pJ1m5z1i0YGPd1U1OeGHAChWtqoxC7bFMCXcwnE1oyui9G1uobgpm1GdhtwkR7ta7akVTcsF8zxiXx7DNXIPd2nIJFH83rmkZueKrC4JVaNzjvD+Z03piLn5bHWU6+w+rA+kyJtGgZNTXKyPh6EC6o5N+rknNMG5+CdTq35p8f99WjFawSvYgP9V64kgckbTbtdJ6YhVP58TnuYgr12urtwnIqWP9KSJ1e5vmgf3tunMqWNm6+AnsqNj8mCLdCuc5cEB74CwUeQcP2HQQmbCddBy2y0mEwIDAQAB"},"gqlFetchTimeout":1500,"disablePersistedQueries":false,"initialDeviceType":"smartphone","fastlyAbraConfig":{".ver":"18076.000","AMS_FrictionCircumventionDesktop_cwv":"2_low-mid-truncation","AMS_FrictionCircumventionMobile_cwv":"2_low-mid-truncation","DFP_TopAd_Anon_0124":"","HOME_cwv_chartbeat":"0_Control","MX_NewArchitecture_PostLoginOffer":"1_variant","MX_NewArchitecture_WirecutterLP":"","STYLN_synth_voice_web":"1_synth"},"fastlyEntitlements":[],"internalPreviewConfig":{},"webviewEnvironment":{"isInWebview":false,"isPreloaded":false},"isOptimisticallyTruncated":false,"optimisticTruncationDropzone":6,"requestPath":"/interactive/2020/science/coronavirus-vaccine-tracker.html","isProvisionallyLoggedIn":false,"serviceWorkerFile":"service-worker-test-1714680954976.js"}]); })();;(function () { var _f=function(i,w){window.vi=window.vi||{},window.vi.env=Object.freeze(i),window.hybrid=w};;_f.apply(null, [{"JKIDD_PATH":"https://a.nytimes.com/svc/nyt/data-layer","ET2_URL":"https://a.et.nytimes.com","ALS_URL":"https://als-svc.nytimes.com","WEDDINGS_PATH":"https://content.api.nytimes.com","GDPR_PATH":"https://us-central1-nyt-dsra-prd.cloudfunctions.net/datagov-dsr-formhandler","RECAPTCHA_SITEKEY":"6LevSGcUAAAAAF-7fVZF05VTRiXvBDAY4vBSPaTF","ABRA_ET_URL":"//et.nytimes.com","NODE_ENV":"production","EXPERIMENTAL_ROUTE_PREFIX":"","ENVIRONMENT":"prd","RELEASE":"03cce1e7203a898cba8bffea0e231b4698a1d4eb","RELEASE_TAG":"","AUTH_HOST":"https://myaccount.nytimes.com","METER_HOST":"https://meter-svc.nytimes.com","MESSAGING_LANDING_PAGE_HOST":"https://www.nytimes.com","CAPI_HOST":"https://mwcm.nytimes.com","SWG_PUBLICATION_ID":"nytimes.com","GQL_FETCH_TIMEOUT":"1500","GOOGLE_CLIENT_ID":"1005640118348-amh5tgkq641oru4fbhr3psm3gt2tcc94.apps.googleusercontent.com","STORY_SURROGATE_CONTROL":"max-age=300, stale-if-error=259200, stale-while-revalidate=259200","ONBOARDING_API_KEY":""},false]); })();;(function () { var _f=function(){var e=window;e.initWebview=function(e){var t=document.documentElement;if(e.OS){var i=e.OS.toUpperCase();t.classList.add(i)}if(e.BaseFontSize&&(t.dataset.baseFontSize=e.BaseFontSize),e.trackingSensitive&&(t.dataset.trackingSensitive=!0),e.hasOptedOutOfTracking&&(t.dataset.hasOptedOutOfTracking=!0),e.PurrDirectives){var a=e.PurrDirectives.PURR_AdConfiguration_v3||e.PurrDirectives.PURR_AdConfiguration_v2;a&&(t.dataset.optedOutOfAds=["adluce","adluce-socrates"].includes(a))}e.OS&&"IOS"===e.OS.toUpperCase()&&window.dispatchEvent(new CustomEvent("initWebview:ios",{detail:e}))};var t=e.navigator.userAgent.toLowerCase();/iphone|ipod|ipad/.test(t)||void 0===e.config||e.initWebview(e.config)};;_f.apply(null, []); })();;
!function(a){var s,c,p,_,d,l,u=[],f={pv_id:"",ctx_id:"",intra:!1,force_xhr:!1,store_last_response:!1
},g="object"==typeof a.navigator&&"string"==typeof a.navigator.userAgent&&/iP(ad|hone|od)/.test(
a.navigator.userAgent),y="object"==typeof a.navigator&&a.navigator.sendBeacon,
v=y?g?"xhr_ios":"beacon":"xhr";function h(){var e,t,n=a.crypto||a.msCrypto;if(n)t=n.getRandomValues(
new Uint8Array(18));else for(t=[];t.length<18;)t.push(256*Math.random()^255&(e=e||+new Date)),
e=Math.floor(e/256);return btoa(String.fromCharCode.apply(String,t)).replace(/\+/g,"-").replace(
/\//g,"_")}if(a.nyt_et)try{console.warn("et2 snippet should only load once per page")}catch(e
){}else a.nyt_et=function(){var e,t,n,o=arguments;function r(e){var t,n,o,r,i;u.length&&(t=s+"track"
,n=JSON.stringify(u),e=e,o=f.force_xhr,r=f.store_last_response,!o&&("beacon"===v||y&&e)?(
o=a.navigator.sendBeacon(t,n),r&&(l=o)):((
i="undefined"!=typeof XMLHttpRequest?new XMLHttpRequest:new ActiveXObject("Microsoft.XMLHTTP")
).open("POST",t),i.withCredentials=!0,i.setRequestHeader("Accept","*/*"),
"string"==typeof n?i.setRequestHeader("Content-Type","text/plain;charset=UTF-8"
):"[object Blob]"==={}.toString.call(n)&&n.type&&i.setRequestHeader("Content-Type",n.type),
r&&!i.onload&&(i.onload=function(){l=i.response},i.onerror=function(e){l=!1}),i.send(n)),u.length=0,
clearTimeout(d),d=null)}if("string"==typeof o[0]&&/init/.test(o[0])&&(f=function(e,t){var n="",o="",
r=!1,i=!1,a=!1;if("string"==typeof e&&"init"==e&&"object"==typeof t&&(
"boolean"==typeof t.intranet&&t.intranet&&(r=!0),"boolean"==typeof t.force_xhr&&t.force_xhr&&(i=!0),
"boolean"==typeof t.store_last_response&&t.store_last_response&&(a=!0),
"string"==typeof t.pv_id_override&&"string"==typeof t.ctx_id_override))if(
24<=t.pv_id_override.length&&24<=t.ctx_id_override.length)n=t.pv_id_override,
o=t.ctx_id_override;else try{console.warn("override id(s) must be >= 24 chars long")}catch(e){}
return{pv_id:n,ctx_id:o,intra:r,store_last_response:a,force_xhr:i}}(o[0],o[3]),p=f.pv_id||h(),
"init"==o[0]&&!c)){if(c=f.ctx_id||h(),"string"!=typeof o[1]||!/^http/.test(o[1]))throw new Error(
"init must include an et host url");if(s=String(o[1]).replace(/([^\/])$/,"$1/"),
"string"!=typeof o[2])throw new Error("init must include a source app name");_=o[2]}var i=o.length-1
;(e=o[i]&&"object"==typeof o[i]?o[i]:e)||/init/.test(o[0])?e&&!e.subject&&console.warn(
"event data {} must include a subject"):console.warn(
"when invoked without 'init' or 'pageinit', nyt_et() must include a event data"),s&&e&&e.subject&&(
i=e.subject,delete e.subject,n="page_exit"==i||"ob_click"==(e.eventData||{}).type,
t="page"==i||"page_soft"==i?p:h(),u.push({context_id:c,pageview_id:p,event_id:t,client_lib:"v1.3.0",
sourceApp:_,intranet:f.intra?1:void 0,subject:i,how:n&&g&&y?"beacon_ios":v,client_ts:+new Date,
data:JSON.parse(JSON.stringify(e))}),"send"==o[0]||t==p||n?r(n):("soon"==o[0]&&(clearTimeout(d),
d=setTimeout(r,200)),d=d||setTimeout(r,5500)))},a.nyt_et.get_pageview_id=function(){return p},
a.nyt_et.get_context_id=function(){return c},a.nyt_et.get_host=function(){return s},
a.nyt_et.get_last_send_response=function(){var e=l;return e&&(l=null),e}}(window);
;(function initWebUnifiedTracking(root) {
  var _root;
  root = root || (typeof window !== 'undefined' ? window : undefined);
  var UnifiedTracking = ((_root = root) === null || _root === void 0 ? void 0 : _root.UnifiedTracking) || {};
  UnifiedTracking.context = 'web';
  if (!root) {
    return UnifiedTracking;
  }
  root.UnifiedTracking = UnifiedTracking;
  UnifiedTracking.sendAnalytic = function sendAnalytic(eventName, dataBlob) {
    root.dataLayer = root.dataLayer || [];
    if (Array.isArray(root.dataLayer)) {
      // Don't use a spread operator here for babel reasons
      dataBlob.event = dataBlob.event || eventName;
      root.dataLayer.push(dataBlob);
    }
    return Promise.resolve({
      success: true
    });
  };
  return UnifiedTracking;
})(window);!function(r){var n,t;r=r||self,n=r.Abra,(t=r.Abra=function(){"use strict";var r=Array.isArray,n=function(r,n,t){var e=r(t,n),u=e[0],o=e[1];if(null==u||""===u)return n;for(var i=String(u).split("."),a=0;a<i.length&&(n=n[i[a]]);a++);return null==n&&(n=o),null!=n?n:null},t=function(r,n,t){return r(t,n).reduce((function(r,n){return parseFloat(r)+parseFloat(n)}),0)},e=function(r,n,t){var e=r(t,n);return e[0]/e[1]},u=function(r,n,t){var e=r(t,n);return e[0]%e[1]},o=function(r,n,t){return r(t,n).reduce((function(r,n){return parseFloat(r)*parseFloat(n)}),1)},i=function(r,n,t){var e=r(t,n),u=e[0],o=e[1];return void 0===o?-u:u-o};function a(n){return!(r(n)&&0===n.length||!n)}var f=function(r,n,t){for(var e,u=0;u<t.length;u++)if(!a(e=r(t[u],n)))return e;return e},c=function(r,n,t){var e;for(e=0;e<t.length-1;e+=2)if(a(r(t[e],n)))return r(t[e+1],n);return t.length===e+1?r(t[e],n):null},l=function(r,n,t){return!a(r(t,n)[0])},v=function(r,n,t){for(var e,u=0;u<t.length;u++)if(a(e=r(t[u],n)))return e;return e},d=function(r,n,t){var e=r(t,n);return e[0]===e[1]},s=function(r,n,t){var e=r(t,n);return e[0]!==e[1]},h=function(r,n,t){var e=r(t,n),u=e[0],o=e[1];return!(!o||void 0===o.indexOf)&&-1!==o.indexOf(u)},g=function(r,n,t){var e=r(t,n);return e[0]>e[1]},p=function(r,n,t){var e=r(t,n);return e[0]>=e[1]},b=function(r,n,t){var e=r(t,n),u=e[0],o=e[1],i=e[2];return void 0===i?u<o:u<o&&o<i},w=function(r,n,t){var e=r(t,n),u=e[0],o=e[1],i=e[2];return void 0===i?u<=o:u<=o&&o<=i},y=function(r,n,t){var e=t[0],u=t[1],o=t.slice(2),i=r(e,n);if(!i)return null;if(0===o.length)return null;if(1===o.length)return r(o[0],n);if(4294967295===o[0])return r(o[1],n);for(var a=function(r){var n,t,e,u,o,i=[],a=[t=1732584193,e=4023233417,~t,~e,3285377520],f=[],c=unescape(encodeURI(r))+"\x80",l=c.length;for(f[r=--l/4+2|15]=8*l;~l;)f[l>>2]|=c.charCodeAt(l)<<8*~l--;for(n=l=0;n<r;n+=16){for(t=a;l<80;t=[t[4]+(i[l]=l<16?~~f[n+l]:2*c|c<0)+1518500249+[e&u|~e&o,c=341275144+(e^u^o),882459459+(e&u|e&o|u&o),c+1535694389][l++/5>>2]+((c=t[0])<<5|c>>>27),c,e<<30|e>>>2,u,o])c=i[l-3]^i[l-8]^i[l-14]^i[l-16],e=t[1],u=t[2],o=t[3];for(l=5;l;)a[--l]+=t[l]}return a[0]>>>0}(i+" "+r(u,n));o.length>1;){var f=o.splice(0,2),c=f[0],l=f[1];if(a<=r(c,n))return r(l,n)}return 0===o.length?null:r(o[0],n)},k=function(r,n,t){var e=t[0],u=t[1],o=r(e,n);return null==o?null:new RegExp(u).test(o)};return function(a,m,O,A){void 0===a&&(a={}),void 0===m&&(m={}),void 0===O&&(O={}),void 0===A&&(A=!1);var j=function(){var r={},n=function(n){if(n)for(var t,e=decodeURIComponent(n[1]),u=/(?:^|,)([^,=]+)=([^,]*)/g;t=u.exec(e);){var o=t,i=o[1],a=o[2];r[i]=a||null}};n(document.cookie.match(/(?:^|;) *abra-overrides=([^;]+)/)),n(window.location.search.match(/(?:\?|&)abra-overrides=([^&]+)/));var t=/(?:^|;) *abra-nuke=true(?:;|$)/.test(document.cookie)||/(?:\?|&)abra-nuke=true(?:&|$)/.test(window.location.search);return[r,t]}(),x=j[0],E=j[1];Object.keys(O).forEach((function(r){x[r]=O[r]}));var F,C=A||E,R=(F={var:n,if:c,"===":d,"!==":s,and:f,or:v,"!":l,">":g,">=":p,"<":b,"<=":w,"+":t,"-":i,"*":o,"/":e,"%":u,in:h,abtest_partition:y,regex_match:k,ref:function(r,n,t){var e=r(t,n)[0];return U(e)}},function n(t,e){if(e||(e={}),r(t))return t.map((function(r){return n(r,e)}));if(!function(n){return"object"==typeof n&&null!==n&&!r(n)&&1===Object.keys(n).length}(t))return t;var u=function(r){return Object.keys(r)[0]}(t),o=t[u];r(o)||(o=[o]);var i=F[u];if(!i)throw new Error("Unrecognized operation "+u);return i(n,e,o)}),U=function(r){if(!r)return null;var n=x[r];if(void 0===n){if(!C){if(Object.prototype.hasOwnProperty.call(x,r))throw new Error("circular logic");x[r]=void 0,n=R(a[r],m)}void 0===n&&(n=null),x[r]=n}return n};return U}}()).noConflict=function(){return r.Abra=n,t}}(this);
;(function () { var NYTD="undefined"!=typeof window&&window.NYTD?window.NYTD:{};function setupTimeZone(){var e='[data-timezone][data-timezone~="'+(new Date).getHours()+'"] { display: block }',t=document.createElement("style");t.innerHTML=e,document.head.appendChild(t)}function addNYTAppClass(){var e=window.vi&&window.vi.webviewEnvironment||{};e&&e.isInWebview&&document.documentElement.classList.add("NYTApp"),e&&e.isPreloaded&&document.documentElement.classList.add("NYTAppPreloaded"),e&&e.deviceType&&document.documentElement.classList.add(window.vi.webviewEnvironment.deviceType)}function addNYTPageTypeClass(){var e=window.vi.pageType.edge;e&&document.documentElement.classList.add("nytapp-"+e)}function setupPageViewId(){NYTD.PageViewId={},NYTD.PageViewId.update=function(){return"undefined"!=typeof nyt_et&&"function"==typeof window.nyt_et.get_pageview_id?(window.nyt_et("pageinit"),NYTD.PageViewId.current=window.nyt_et.get_pageview_id()):NYTD.PageViewId.current="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx".replace(/[xy]/g,function(e){var t=16*Math.random()|0;return("x"===e?t:3&t|8).toString(16)}),NYTD.PageViewId.current}}var _f=function(){try{document.domain="nytimes.com"}catch(e){}window.swgUserInfoXhrObject=new XMLHttpRequest,setupPageViewId(),setupTimeZone(),addNYTAppClass(),addNYTPageTypeClass(),window.nyt_et&&"function"==typeof window.nyt_et&&window.nyt_et("init",vi.env.ET2_URL,"nyt-vi",{subject:"page",canonicalUrl:(document.querySelector("link[rel=canonical]")||{}).href,articleId:(document.querySelector("meta[name=articleid]")||{}).content,nyt_uri:(document.querySelector("meta[name=nyt_uri]")||{}).content,pubpEventId:(document.querySelector("meta[name=pubp_event_id]")||{}).content,url:location.href,referrer:document.referrer||void 0,client_tz_offset:(new Date).getTimezoneOffset()}),"undefined"!=typeof nyt_et&&"function"==typeof window.nyt_et.get_pageview_id?NYTD.PageViewId.current=window.nyt_et.get_pageview_id():NYTD.PageViewId.update();var e=window.reportError;window.reportError=function(){var t=Array.prototype.slice.call(arguments),n=t[0];(n.message.includes("root will switch to client rendering.")||n.message.includes("Minified React error #423"))&&window.dispatchEvent(new CustomEvent("react-hydration-error")),e.apply(null,t)}};;_f.apply(null, []); })();;(function () { var NYTD="undefined"!=typeof window&&window.NYTD?window.NYTD:{};var _f=function(n){var t=window.vi&&window.vi.webviewEnvironment&&window.vi.webviewEnvironment.isPreloaded;function e(){if(window.Abra&&"function"==typeof window.Abra){NYTD.Abra=function(){var e=t?window.getNativeBridgeCookie("nyt-a"):(window.document.cookie.match(/(?:^|;) *nyt-a=([^;]*)/)||[])[1],o=[];window.dataLayer=window.dataLayer||[],c.config=n.abraConfig||{},c.reportedAllocations={},c.reportedExposures={};var a=(n.abraURL||"").match(/current[/]([a-zA-Z-]+).json/i);c.integration=a&&a.length>1?a[1]:"";try{c.version=window.Abra(c.config)(".ver")}catch(n){c.version=0}var r=c.config,i={agent_id:e},d=window.Abra(r,i);function c(n){return c.getAbraSync(n).variant}return c.getAbraSync=function(n){var t=c.reportedAllocations[n];if(void 0!==t)return{variant:t,allocated:!0};var e=null,o=!1;try{e=d(n),o=!0}catch(n){}return{variant:e,allocated:o}},c.reportExposure=function(n){var t=c.getAbraSync(n).variant;null!=t&&(void 0!==c.reportedExposures[n]&&t===c.reportedExposures[n]||(c.reportedExposures[n]=t,window.dataLayer.push({event:"ab-expose",abtest:{test:n,variant:t,config_ver:c.version,integration:c.integration}})))},c.alloc=function(){Object.keys(c.config).filter(function(n){return!n.includes(".")}).forEach(function(n){var t=c.getAbraSync(n);t.allocated&&(c.reportedAllocations[n]=t.variant,o.push({test:n,variant:t.variant}))}),window.dataLayer.push({event:"ab-alloc",abtest:{batch:o}})},c.alloc(),c}(),window.NYTD=NYTD||{};var e="SJ_xpn_storylines_desktop_cwv_0124";if("1_xpn_in_story"===window.NYTD.Abra.getAbraSync(e).variant){document.documentElement.classList.add("SJ_xpn_storylines_desktop_cwv_0124-1_xpn_in_story")}if("2_xpn_hamburger"===window.NYTD.Abra.getAbraSync(e).variant){document.documentElement.classList.add("SJ_xpn_storylines_desktop_cwv_0124-2_xpn_hamburger")}if("3_xpn_top_only"===window.NYTD.Abra.getAbraSync(e).variant){document.documentElement.classList.add("SJ_xpn_storylines_desktop_cwv_0124-3_xpn_top_only")}if("1_xpn_in_story"===window.NYTD.Abra.getAbraSync("SJ_xpn_standard_story_0424").variant){document.documentElement.classList.add("SJ_xpn_standard_story_0424-1_xpn_in_story")}if("2_xpn_hamburger"===window.NYTD.Abra.getAbraSync("SJ_xpn_standard_story_0424").variant){document.documentElement.classList.add("SJ_xpn_standard_story_0424-2_xpn_hamburger")}window.NYTD.Abra.config&&Object.prototype.hasOwnProperty.call(window.NYTD.Abra.config,"SHA_UnlimitedGift_0124")&&document.cookie.includes("SHA_UGT=1")&&document.documentElement.classList.add("unlimited-gift")}}t&&!window.nativeBridgeCookies?window.initNativeBridgeCookies(e):e()};;_f.apply(null, [{"abraConfig":{".ver":18272,"UPSHOT_wordleStateV2_0306":{"abtest_partition":[{"var":"agent_id"},"UPSHOT_wordleStateV2_0306",4294967295,"0_Control"]},"UPSHOT_wordlebotGuessDetail_013024":{"abtest_partition":[{"var":"agent_id"},"UPSHOT_wordlebotGuessDetail_013024",3650722201,"0_Control",3865470565,"1_ShowDetail",4080218930,"2_ShowSomeDetail",4294967295,"3_ShowReaderDetail"]},"UPSHOT_wordlebotGuessDetail_011624":{"abtest_partition":[{"var":"agent_id"},"UPSHOT_wordlebotGuessDetail_011624",3865470565,"0_Control",4080218930,"1_ShowDetail",4294967295,"0_Control"]},"SUBX_regi_alloc_holdout_2024H1":{"abtest_partition":[{"var":"regi_id"},"SUBX_regi_alloc_holdout_2024H1",214748364,"0_holdout",429496729,"1_best_experience",4294967295,"2_testing"]},"SUBX_agent_alloc_holdout_2024H1":{"abtest_partition":[{"var":"agent_id"},"SUBX_agent_alloc_holdout_2024H1",214748364,"0_holdout",429496729,"1_best_experience",4294967295,"2_testing"]},"SUBCON_RES_AIG_SURVEY_228":{"abtest_partition":[{"var":"agent_id"},"SUBCON_RES_AIG_SURVEY_228",4080218930,"0_Control",4294967295,"1_Variant"]},"STYLN_user_state_api_1122":{"abtest_partition":[{"var":"regi_id"},"STYLN_user_state_api_1122",4294967295,"1_User_State"]},"STYLN_synth_voice_web":{"abtest_partition":[{"var":"agent_id"},"STYLN_synth_voice_web2",42949672,"0_control",85899345,"1_synth",450971565,"0_control",816043785,"1_synth",858993458,"0_control",901943131,"1_synth",923417968,"0_control",944892804,"1_synth",1009317314,"0_control",1073741823,"1_synth",1095216659,"0_control",1116691496,"1_synth",1181116005,"0_control",1245540515,"1_synth",1267015351,"0_control",1288490188,"1_synth",1395864370,"0_control",1503238553,"1_synth",1524713389,"0_control",1546188226,"1_synth",1589137899,"0_control",1632087571,"1_synth",1696512081,"0_control",1760936590,"1_synth",1803886263,"0_control",1846835936,"1_synth",1889785609,"0_control",1932735282,"1_synth",1975684955,"0_control",2018634628,"1_synth",2104533974,"0_control",2190433320,"1_synth",2233382993,"0_control",2276332666,"1_synth",2319282339,"0_control",2362232012,"1_synth",2405181685,"0_control",2448131358,"1_synth",2512555867,"0_control",2576980377,"1_synth",2619930050,"0_control",2662879723,"1_synth",2705829395,"0_control",2748779068,"1_synth",2791728741,"0_control",2834678414,"1_synth",2877628087,"0_control",2920577760,"1_synth",2942052597,"0_control",2963527433,"1_synth",2985002270,"0_control",3006477106,"1_synth",3049426779,"0_control",3092376452,"1_synth",3135326125,"0_control",3178275798,"1_synth",3199750635,"0_control",3221225471,"1_synth",3242700307,"0_control",3264175144,"1_synth",3285649980,"0_control",3307124817,"1_synth",3328599653,"0_control",3350074490,"1_synth",3371549326,"0_control",3393024163,"1_synth",3435973836,"0_control",3478923509,"1_synth",3500398345,"0_control",3521873182,"1_synth",3543348018,"0_control",3564822855,"1_synth",3586297691,"0_control",3607772528,"1_synth",3629247364,"0_control",3650722201,"1_synth",3672197037,"0_control",3693671874,"1_synth",3758096383,"0_control",3822520892,"1_synth",3865470565,"0_control",3908420238,"1_synth",3929895075,"0_control",3951369911,"1_synth",3972844748,"0_control",3994319584,"1_synth",4015794421,"0_control",4037269257,"1_synth",4058744094,"0_control",4080218930,"1_synth",4101693767,"0_control",4123168603,"1_synth",4144643440,"0_control",4166118276,"1_synth",4187593113,"0_control",4209067949,"1_synth",4230542786,"0_control",4252017622,"1_synth",4273492459,"0_control",4294967295,"1_synth"]},"STYLN_ad_placement_0424":{"abtest_partition":[{"var":"agent_id"},"STYLN_ad_placement_0424",1073741823,"0_control",2147483647,"1_pattern",3221225471,"2_distance",4294967295,"3_both"]},"STORY_inlineModules_0124":{"abtest_partition":[{"var":"agent_id"},"STORY_inlineModules_0124",4294967295,"0_unstructured_modules"]},"STANDCON_CONV_EXISTING_SUBS_BAR1_EXPERIMENT_2212":{"abtest_partition":[{"var":"agent_id"},"STANDCON_CONV_EXISTING_SUBS_BAR1_EXPERIMENT_2212",3006477106,"v7",3221225471,"v0",3865470565,"v0",4294967295,"v4"]},"SJ_xpn_standard_story_0424":{"abtest_partition":[{"var":"agent_id"},"SJ_xpn_standard_story_0424",214791313,"0_Control",429518203,"1_xpn_in_story",644245093,"2_xpn_hamburger"]},"SJ_regiOnboardingAppDownloadKnockout_0424":{"if":[{"and":[{"!":{"in":[{"ref":"SUBX_regi_alloc_holdout_2024H1"},["1_best_experience","0_holdout"]]}},{"!":{"in":[{"ref":"SJ_RegiAppDownloadDisrupter_0424"},["0_control","1_disrupter"]]}}]},{"abtest_partition":[{"var":"regi_id"},"SJ_regiOnboardingAppDownloadKnockout_0424",1245540515,"0_control",2491081031,"1_app_download_knockout"]}]},"SJ_RegiAppDownloadDisrupter_0424":{"abtest_partition":[{"var":"regi_id"},"SJ_RegiAppDownloadDisrupter_0424",279172873,"0_control",558345747,"1_disrupter"]},"SJ_mum_app_download_0301":{"if":[{"and":[{"!":{"in":[{"ref":"SUBX_regi_alloc_holdout_2024H1"},["0_holdout","1_best_experience"]]}}]},{"abtest_partition":[{"var":"regi_id"},"SJ_mum_app_download_0301",10737417,"0_control",21474835,"1_barone",32212254,"2_account_notification",42949672,"3_barone_account_notification",64424508,"0_control",85899345,"1_barone",107374181,"2_account_notification",128849018,"3_barone_account_notification",139586436,"0_control",150323854,"1_barone",161061273,"2_account_notification",171798691,"3_barone_account_notification",182536109,"0_control",193273527,"1_barone",204010946,"2_account_notification",214748364,"3_barone_account_notification",225485782,"0_control",236223200,"1_barone",246960619,"2_account_notification",257698037,"3_barone_account_notification",268435455,"0_control",279172873,"1_barone",289910291,"2_account_notification",300647710,"3_barone_account_notification",311385128,"0_control",322122546,"1_barone",332859964,"2_account_notification",343597383,"3_barone_account_notification",354334801,"0_control",365072219,"1_barone",375809637,"2_account_notification",386547056,"3_barone_account_notification",397284474,"0_control",408021892,"1_barone",418759310,"2_account_notification",429496729,"3_barone_account_notification",440234147,"0_control",450971565,"1_barone",461708983,"2_account_notification",472446402,"3_barone_account_notification",483183820,"0_control",493921238,"1_barone",504658656,"2_account_notification",515396075,"3_barone_account_notification",526133493,"0_control",536870911,"1_barone",547608329,"2_account_notification",558345747,"3_barone_account_notification",569083166,"0_control",579820584,"1_barone",590558002,"2_account_notification",601295420,"3_barone_account_notification",612032839,"0_control",622770257,"1_barone",633507675,"2_account_notification",644245093,"3_barone_account_notification",654982512,"0_control",665719930,"1_barone",676457348,"2_account_notification",687194766,"3_barone_account_notification",697932185,"0_control",708669603,"1_barone",719407021,"2_account_notification",730144439,"3_barone_account_notification",740881858,"0_control",751619276,"1_barone",762356694,"2_account_notification",773094112,"3_barone_account_notification",783831531,"0_control",794568949,"1_barone",805306367,"2_account_notification",816043785,"3_barone_account_notification",826781203,"0_control",837518622,"1_barone",848256040,"2_account_notification",858993458,"3_barone_account_notification",869730876,"0_control",880468295,"1_barone",891205713,"2_account_notification",901943131,"3_barone_account_notification",912680549,"0_control",923417968,"1_barone",934155386,"2_account_notification",944892804,"3_barone_account_notification",955630222,"0_control",966367641,"1_barone",977105059,"2_account_notification",987842477,"3_barone_account_notification",998579895,"0_control",1009317314,"1_barone",1020054732,"2_account_notification",1030792150,"3_barone_account_notification",1041529568,"0_control",1052266987,"1_barone",1063004405,"2_account_notification",1073741823,"3_barone_account_notification",1084479241,"0_control",1095216659,"1_barone",1105954078,"2_account_notification",1116691496,"3_barone_account_notification",1127428914,"0_control",1138166332,"1_barone",1148903751,"2_account_notification",1159641169,"3_barone_account_notification",1170378587,"0_control",1181116005,"1_barone",1191853424,"2_account_notification",1202590842,"3_barone_account_notification",1213328260,"0_control",1224065678,"1_barone",1234803097,"2_account_notification",1245540515,"3_barone_account_notification",1256277933,"0_control",1267015351,"1_barone",1277752770,"2_account_notification",1288490188,"3_barone_account_notification",1299227606,"0_control",1309965024,"1_barone",1320702443,"2_account_notification",1331439861,"3_barone_account_notification",1406601788,"0_control",1481763716,"1_barone",1556925644,"2_account_notification",1632087571,"3_barone_account_notification",1825361100,"0_control",2018634628,"1_barone",2211908156,"2_account_notification",2405181685,"3_barone_account_notification",2738041650,"0_control",3070901616,"1_barone",3403761581,"2_account_notification",3736621547,"3_barone_account_notification",3876207984,"0_control",4015794421,"1_barone",4155380858,"2_account_notification",4294967295,"3_barone_account_notification"]}]},"SJ_disrupter_V2_increased_cadence":{"if":[{"and":[{"!":{"in":[{"ref":"SUBX_regi_alloc_holdout_2024H1"},["0_holdout"]]}}]},{"abtest_partition":[{"var":"regi_id"},"SJ_disrupter_V2_increased_cadence",4294967295,"2_high_intensity"]}]},"SJ_bottom_sheet_rollout_0626":{"if":[{"and":[{"===":[{"var":"user_type"},"sub"]},{"===":[{"ref":"SJ_universal_holdout_0722"},"1_test"]}]},{"abtest_partition":[{"var":"regi_id"},"SJ_bottom_sheet_rollout_0626",429496729,"0_Control",4294967295,"1_Test"]}]},"SHA_closePanel_cwv_0423":{"abtest_partition":[{"var":"agent_id"},"SHA_closePanel_cwv_0423",4294966,"0_Control",42949672,"1_Spinner",81604378,"0_Control",429496729,"1_Spinner",816043785,"0_Control",4294967295,"1_Spinner"]},"SEO_timesTagsToCollectionsBarRollout_cwv_0424":{"abtest_partition":[{"var":"agent_id"},"SEO_timesTagsToCollectionsBarRollout_cwv_0424",2147483647,"0_Control",4294967295,"1_Rollout"]},"Price_Step_Up_Representation_ACCT_GROWTH_4-22":{"abtest_partition":[{"var":"regi_id"},"83a8af2b-796d-4306-9774-6a2a1d281e28",1073741823,"0_Control",4294967295,"1_Price_Increase"]},"ON_news_upsell_sale":{"abtest_partition":[{"var":"agent_id"},"ON_news_upsell_sale",3865470565,"1_news_upsell",4294967295,"1_news_upsell"]},"OMA_FEDERATED_QUERY":{"abtest_partition":[{"var":"agent_id"},"OMA_FEDERATED_QUERY"]},"MX_Turn_Off_CAPI_0324":{"abtest_partition":[{"var":"agent_id"},"MX_Turn_Off_CAPI_0324",4294967295,"0_no_capi"]},"MX_OMA_HomeDock_12_24":{"abtest_partition":[{"var":"agent_id"},"MX_OMA_HomeDock_12_24_1",4294967295,"0_Control"]},"MX_OMA_DOCK_TEST":{"abtest_partition":[{"var":"agent_id"},"MX_OMA_DOCK_TEST",4294967295,"1_Variant"]},"MX_NewArchitecture_WirecutterLP":{"abtest_partition":[{"var":"agent_id"},"MX_NewArchitecture_WirecutterLP",214748364,"0_control",408021892,null,622770257,"1_variant"]},"MX_NewArchitecture_PostLoginOffer":{"abtest_partition":[{"var":"agent_id"},"MX_NewArchitecture_PostLoginOffer",21474835,"1_variant",42949672,"1_variant",536870911,"1_variant",901943131,"1_variant",923417968,"1_variant",944892804,"1_variant",966367641,"1_variant",987842477,"1_variant",1009317314,"1_variant",1030792150,"1_variant",1052266987,"1_variant",1073741823,"1_variant",1095216659,"1_variant",1116691496,"1_variant",1159641169,"1_variant",1202590842,"1_variant",1267015351,"1_variant",1352914697,"1_variant",1417339207,"1_variant",1503238553,"1_variant",1567663062,"1_variant",1632087571,"1_variant",1696512081,"1_variant",1739461754,"1_variant",1803886263,"1_variant",1846835936,"1_variant",1889785609,"1_variant",1932735282,"1_variant",1975684955,"1_variant",2040109465,"1_variant",2083059138,"1_variant",4294967295,"1_variant"]},"MX_NewArchitecture_gateway":{"if":[{"and":[{"===":[{"ref":"MX_NewArchitecture_MeterReal"},"1_variant"]}]},{"abtest_partition":[{"var":"agent_id"},"MX_NewArchitecture_gateway",21474835,"1_variant",107374181,"1_variant",1073741823,"1_variant",1116691496,"1_variant",1159641169,"1_variant",1267015351,"1_variant",1503238553,"1_variant",1717986917,"1_variant",1932735282,"1_variant",2126008811,"1_variant",4294967295,"1_variant"]}]},"MX_FF_WELCOME_AD":{"abtest_partition":[{"var":"agent_id"},"MX_FF_WELCOME_AD",4294967295,"1_Variant"]},"MKT_not_ready_to_sub_survey":{"abtest_partition":[{"var":"agent_id"},"MKT_not_ready_to_sub_survey",3221225471,"0_control",3435973836,"1_survey",4294967295,"0_control"]},"example_feature_VIZEX_DATA_4-22":{"abtest_partition":[{"var":"agent_id"},"5db6befa-6786-4bd2-a26c-884da524b645",858993458,"0_Control",1717986917,"1_Variant"]},"Election_PW_AA_SUBCON_GROWTH_3-15":{"abtest_partition":[{"var":"agent_id"},"57f8e651-67fc-406c-bc35-316e9447b872",1434519076,"0_control",2864743185,"1_variant",4294967295,"2_variant"]},"disrupter_framing_SUJO_SUBX_4-25":{"if":[{"or":[{"and":[{"===":[{"var":"user_type"},"sub"]},{"!":{"in":[{"ref":"SUBX_regi_alloc_holdout_2024H1"},["0_holdout","1_best_experience"]]}}]}]},{"abtest_partition":[{"var":"regi_id"},"246b6572-2795-4c87-aab8-e5d13f31d3dc",1434519076,"0_control",2864743185,"1_get_most",4294967295,"2_not_getting"]}]},"dfp_mkt_dispannualoffer_0424":{"if":[{"and":[{"!":{"in":[{"var":"geo_country"},["US"]]}}]},{"abtest_partition":[{"var":"agent_id"},"dfp_mkt_dispannualoffer_0424",2147483647,"0_Control_Week",4294967295,"1_Variant_Annual"]}]},"CONV_GUAC_PLOPRO_SLAYER_0224":{"abtest_partition":[{"var":"agent_id"},"CONV_GUAC_PLOPRO_SLAYER_0224",4294967295,"1_slayer"]},"CONV_GUAC_NewsPaywall_SLAYER_0324":{"abtest_partition":[{"var":"agent_id"},"CONV_GUAC_NewsPaywall_SLAYER_0324",4294967295,"1_Slayer"]},"CONV_GUAC_Dock_HDUpsell_0524":{"abtest_partition":[{"var":"regi_id"},"CONV_GUAC_Dock_HDUpsell_0524_1",1460288880,"0_control",2877628087,"1_upgrade",4294967295,"2_sunday_hook"]},"CONV_GUAC_CKLP_ExpressCheckOut_RollOut_0124":{"abtest_partition":[{"var":"agent_id"},"CONV_GUAC_CKLP_ExpressCheckOut_RollOut_0124",4294967295,"1_expresscheckout"]},"CONV_GUAC_CKLP_Annual_Offer_Prominence_Test_0524":{"abtest_partition":[{"var":"agent_id"},"CONV_GUAC_CKLP_Annual_Offer_Prominence_Test_0524",10737417,"0_control",21474835,"1_annual_top",32212254,"2_best_value",42949672,"3_annual_top_best_value",53687090,"0_control",64424508,"1_annual_top",75161927,"2_best_value",85899345,"3_annual_top_best_value",150323854,"0_control",214748364,"1_annual_top",279172873,"2_best_value",343597383,"3_annual_top_best_value",493921238,"0_control",644245093,"1_annual_top",794568949,"2_best_value",944892804,"3_annual_top_best_value",1116691496,"0_control",1288490188,"1_annual_top",1460288880,"2_best_value",1632087571,"3_annual_top_best_value",1836098518,"0_control",2040109465,"1_annual_top",2244120411,"2_best_value",2448131358,"3_annual_top_best_value",2727304232,"0_control",3006477106,"1_annual_top",3285649980,"2_best_value",3564822855,"3_annual_top_best_value",3747358965,"0_control",3929895075,"1_annual_top",4112431185,"2_best_value",4294967295,"3_annual_top_best_value"]},"CONV_GUAC_CK_AA_Intl_AnnualOffer_0524":{"abtest_partition":[{"var":"agent_id"},"CONV_GUAC_CK_AA_Intl_AnnualOffer_0524"]},"CONV_GUAC_AALP_SLAYER_0224":{"abtest_partition":[{"var":"agent_id"},"CONV_GUAC_AALP_SLAYER_0224",4294967295,"1_slayer"]},"CONV_GUAC_AALP_HDAnchor_Test_0424":{"abtest_partition":[{"var":"agent_id"},"CONV_GUAC_AALP_HDAnchor_Test_0424",1417339207,"1_anchor",4294967295,"1_anchor"]},"CONV_GUAC_AADock_SLAYER_0324":{"abtest_partition":[{"var":"regi_id"},"CONV_GUAC_AADock_SLAYER_0324",4294967295,"1_slayer"]},"clone_synth_web_VIZEX_DATA_4-23":{"abtest_partition":[{"var":"agent_id"},"e581a582-5f64-43ad-b2a5-872d6840a7bd",429496729,"0_control",858993458,"1_synth"]},"AMS_FrictionCircumventionMobile_cwv":{"abtest_partition":[{"var":"agent_id"},"AMS_FrictionCircumventionMobile_cwv",14315125,"2_low-mid-truncation",214726889,"2_low-mid-truncation",243357141,"2_low-mid-truncation",257672267,"2_low-mid-truncation",271987393,"2_low-mid-truncation",286302519,"2_low-mid-truncation",300617645,"2_low-mid-truncation",314932771,"2_low-mid-truncation",329247897,"2_low-mid-truncation",343563023,"2_low-mid-truncation",357878149,"2_low-mid-truncation",372193275,"2_low-mid-truncation",386508401,"2_low-mid-truncation",400823527,"2_low-mid-truncation",415138653,"2_low-mid-truncation",429453779,"2_low-mid-truncation",443768905,"2_low-mid-truncation",558289913,"2_low-mid-truncation",830277307,"2_low-mid-truncation",1259731087,"2_low-mid-truncation",4294967295,"2_low-mid-truncation"]},"AMS_FrictionCircumventionDesktop_cwv":{"abtest_partition":[{"var":"agent_id"},"AMS_FrictionCircumventionDesktop_cwv",14315125,"2_low-mid-truncation",214726889,"2_low-mid-truncation",243357141,"2_low-mid-truncation",257672267,"2_low-mid-truncation",271987393,"2_low-mid-truncation",286302519,"2_low-mid-truncation",300617645,"2_low-mid-truncation",314932771,"2_low-mid-truncation",329247897,"2_low-mid-truncation",343563023,"2_low-mid-truncation",357878149,"2_low-mid-truncation",372193275,"2_low-mid-truncation",386508401,"2_low-mid-truncation",400823527,"2_low-mid-truncation",415138653,"2_low-mid-truncation",429453779,"2_low-mid-truncation",443768905,"2_low-mid-truncation",458084031,"2_low-mid-truncation",644180669,"2_low-mid-truncation",844592433,"2_low-mid-truncation",1245415961,"2_low-mid-truncation",4294967295,"2_low-mid-truncation"]},"ACCT_Profile_Section_0324":{"abtest_partition":[{"var":"regi_id"},"ACCT_Profile_Section_0324",4294967295,"1_Display_Profile"]},"AA_OnboardingFlow_MVPFlowAppSequence_WebandApp_V1":{"if":[{"and":[{"regex_match":[{"var":"user_entitlements"},"(^|\\W)MM($|\\W)"]},{"regex_match":[{"var":"user_entitlements"},"(^|\\W)CKG($|\\W)"]},{"regex_match":[{"var":"user_entitlements"},"(^|\\W)ATH($|\\W)"]},{"regex_match":[{"var":"user_entitlements"},"(^|\\W)WC($|\\W)"]},{"regex_match":[{"var":"user_entitlements"},"(^|\\W)XWD($|\\W)"]},{"!":{"in":[{"ref":"SUBX_regi_alloc_holdout_2024H1"},["0_holdout"]]}},{"!==":[{"var":"app_version"},"10.44.0"]}]},{"abtest_partition":[{"var":"regi_id"},"AA_OnboardingFlow_MVPFlowAppSequence_WebandApp_V1",773094112,"2_appLater",1275605286,"2_appLater",1346472246,"2_appLater",1360645638,"2_appLater",1374819030,"2_appLater",1388992423,"2_appLater",1403165815,"2_appLater",4294967295,"2_appLater"]}]}},"abraURL":"https://a1.nyt.com/abra-config/current/vi-prd.json"}]); })();;(function () { var _f=function(e){var i=window.vi&&window.vi.webviewEnvironment&&window.vi.webviewEnvironment.isPreloaded,n=function(){var n=e.url;try{n+=window.location.search.slice(1).split("&").reduce(function(e,i){return"ip-override"===i.split("=")[0]?"?"+i:e},"")}catch(e){console.warn(e)}var r=new XMLHttpRequest;for(var t in r.withCredentials=!0,r.open("POST",n,!0),r.setRequestHeader("Content-Type","application/json"),i&&(r.setRequestHeader("NYT-User-Token",window.getNativeBridgeCookie("NYT-S")),r.setRequestHeader("NYT-Agent-ID",window.getNativeBridgeCookie("nyt-a"))),e.headers)r.setRequestHeader(t,e.headers[t]);return r.send(e.body),r};i&&!window.nativeBridgeCookies?window.initNativeBridgeCookies(function(){window.userXhrObject=n()}):window.userXhrObject=n(),window.userXhrRefresh=function(){return window.userXhrObject=n(),window.userXhrObject}};;_f.apply(null, [{"url":"https://samizdat-graphql.nytimes.com/graphql/v2","body":"{\"operationName\":\"UserQuery\",\"variables\":{},\"query\":\"   query UserQuery {     user {       __typename       profile {         displayName         email       }       userInfo {         regiId         entitlements         demographics {           emailSubscriptions           wat         }       }       subscriptionDetails {         bundleType         cancellationDate         graceStartDate         graceEndDate         isFreeTrial         hasQueuedSub         startDate         endDate         status         hasActiveEntitlements         entitlements         billingSource         promotionTierType         subscriptionName         subscriptionProducts         subscriptionLabels       }     }   } \"}","headers":{"nyt-app-type":"project-vi","nyt-app-version":"0.0.5","nyt-token":"MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEAs+/oUCTBmD/cLdmcecrnBMHiU/pxQCn2DDyaPKUOXxi4p0uUSZQzsuq1pJ1m5z1i0YGPd1U1OeGHAChWtqoxC7bFMCXcwnE1oyui9G1uobgpm1GdhtwkR7ta7akVTcsF8zxiXx7DNXIPd2nIJFH83rmkZueKrC4JVaNzjvD+Z03piLn5bHWU6+w+rA+kyJtGgZNTXKyPh6EC6o5N+rknNMG5+CdTq35p8f99WjFawSvYgP9V64kgckbTbtdJ6YhVP58TnuYgr12urtwnIqWP9KSJ1e5vmgf3tunMqWNm6+AnsqNj8mCLdCuc5cEB74CwUeQcP2HQQmbCddBy2y0mEwIDAQAB"}}]); })();;(function () { var registry=window._interactiveRegistry={};function getId(e){for(;(e=e.parentElement)&&!e.matches("[data-sourceid].interactive-body"););return e?e.getAttribute("data-sourceid"):null}window.registerInteractive=function(e){var t={_subs:{cleanup:[],remount:[]},id:e,on:function(e,r){return this._subs[e].push(r),t},errorFound:!1},r=document.getElementById("embed-id-"+e),n=new MutationObserver(function(){(r.textContent.includes("500 Internal Error")||r.textContent.includes("200 undefined"))&&(t.errorFound||(window.dispatchEvent(new CustomEvent("trigger-embed-hydration-"+e)),window.Sentry&&window.Sentry.captureException&&window.Sentry.captureException(new Error("Embed load error, triggered manual rehydration: "+e)),t.errorFound=!0))});r&&n.observe(r,{characterData:!0,attributes:!1,childList:!0,subtree:!0}),registry[e]=t},window.getInteractiveBridge=function(e){var t="string"==typeof e?e:getId(e);return registry[t]}; })();;(function () { var _f=function(){"function"!=typeof window.onInitNativeAds&&(window.onInitNativeAds=function(){})};;_f.apply(null, []); })();
    </script>
    
    
    

    
    
  </head>
  <body>
    <div id="app"><div id="standalone-header"><div data-testid="masthead-container" class="interactive-masthead NYTAppHideMasthead css-qz70u6 e1m0pzr40"><header class="css-1bymuyk e1m0pzr41"><section class="css-ui9rw0 e1m0pzr42"><div class="css-1f7ibof ea180rp0"><a class="css-kgn7zc" href="#site-content">Skip to content</a><a class="css-kgn7zc" href="#site-index">Skip to site index</a></div><div id="masthead-section-label" class="css-1wr3we4 ek6sfxi0"><a href="https://www.nytimes.com/section/science" class="css-nuvmzp">Science</a></div><div class="css-10698na ell52qj0"><a data-testid="masthead-mobile-logo" aria-label="New York Times homepage" class="css-nhjhh0 ell52qj1" href="/"><svg viewBox="0 0 184 25" fill="#000" aria-hidden="true"><path d="M14.57,2.57C14.57,.55,12.65-.06,11.04,.01V.19c.96,.07,1.7,.46,1.7,1.11,0,.45-.32,1.01-1.28,1.01-.76,0-2.02-.45-3.2-.84-1.3-.45-2.54-.87-3.57-.87-2.02,0-3.55,1.5-3.55,3.36,0,1.5,1.16,2.02,1.63,2.21l.03-.07c-.3-.2-.49-.42-.49-1.06,0-.54,.39-1.26,1.43-1.26,.94,0,2.17,.42,3.8,.88,1.4,.39,2.91,.76,3.75,.87v3.28l-1.58,1.3,1.58,1.36v4.49c-.81,.46-1.75,.61-2.56,.61-1.5,0-2.88-.42-4.02-1.68l4.26-2.07V5.73l-5.2,2.32c.54-1.38,1.55-2.41,2.66-3.08l-.03-.08C3.31,5.73,.5,8.56,.5,12.06c0,4.19,3.35,7.3,7.22,7.3,4.19,0,6.65-3.28,6.61-6.75h-.08c-.61,1.33-1.63,2.59-2.78,3.25v-4.38l1.65-1.33-1.65-1.33v-3.28c1.53,0,3.11-1.01,3.11-2.96M5.8,14.13l-1.21,.61c-.74-.96-1.23-2.32-1.23-4.07,0-.72,.08-1.7,.32-2.39l2.14-.96-.03,6.8h0Zm19.47-5.76l-.81,.64-2.47-2.2-2.86,2.21V.48l-3.89,2.69c.45,.15,.99,.39,.99,1.43v11.81l-1.33,1.01,.12,.12,.67-.46,2.32,2.12,3.11-2.07-.1-.15-.79,.52-1.08-1.08v-7.12l.74-.54,1.7,1.48v6.19c0,3.92-.87,4.73-2.63,5.37v.1c2.93,.12,5.57-.87,5.57-5.89v-6.75l.88-.72-.12-.15h0Zm5.22,10.8l4.51-3.62-.12-.17-2.36,1.87-2.71-2.14v-1.33l4.68-3.3-2.36-3.67-5.2,2.86v6.8l-1.01,.79,.12,.15,.96-.76,3.5,2.54h-.01Zm-.69-5.67v-5.15l2.27,3.55-2.27,1.6ZM53.65,1.61c0-.32-.08-.59-.2-.96h-.07c-.32,.87-.67,1.33-1.68,1.33-.88,0-1.58-.54-1.95-.94,0,.03-2.96,3.42-2.96,3.42l.15,.12,.84-.96c.64,.49,1.21,1.06,2.63,1.08V13.34l-6.06-10.5c-.47-.79-1.28-1.97-2.66-1.97-1.63,0-2.86,1.4-2.66,3.77h.1c.12-.59,.47-1.33,1.18-1.33,.57,0,1.03,.54,1.3,1.03v3.38c-1.87,0-2.93,.87-2.93,2.34,0,.61,.45,1.94,1.72,2.17v-.07c-.17-.17-.34-.32-.34-.67,0-.57,.42-.88,1.18-.88,.12,0,.3,.03,.37,.05v4.38c-2.2,.03-3.89,1.23-3.89,3.31s1.7,2.88,3.47,2.78v-.07c-1.11-.12-1.68-.69-1.68-1.5,0-.88,.64-1.36,1.45-1.36s1.43,.52,1.95,1.11l2.96-3.33-.12-.12-.76,.87c-1.14-1.01-1.87-1.48-3.18-1.68V4.67l8.36,14.57h.45V4.72c1.6-.1,3.03-1.3,3.03-3.11m2.81,17.54l4.51-3.62-.12-.17-2.36,1.87-2.71-2.14v-1.33l4.68-3.3-2.36-3.67-5.2,2.86v6.8l-1.01,.79,.12,.15,.96-.76,3.5,2.54h0Zm-.69-5.67v-5.15l2.27,3.55-2.27,1.6Zm21.22-5.52l-.69,.52-1.97-1.68-2.29,2.07,.94,.88v7.72l-2.34-1.6v-6.26l.81-.57-2.41-2.24-2.24,2.07,.94,.88v7.46l-.15,.1-2.2-1.6v-6.13c0-1.43-.72-1.85-1.63-2.41-.76-.47-1.16-.91-1.16-1.63,0-.79,.69-1.11,.91-1.23-.79-.03-2.98,.76-3.03,2.76-.03,1.03,.47,1.48,.99,1.97,.52,.49,1.01,.96,1.01,1.83v6.01l-1.06,.84,.12,.12,1.01-.79,2.63,2.14,2.51-1.75,2.76,1.75,5.42-3.2v-6.95l1.21-.94-.1-.15h0Zm18.15-5.84l-1.03,.94-2.32-2.02-3.13,2.51V1.19h-.19V18.12c-.34-.05-1.06-.25-1.85-.37V3.58c0-1.03-.74-2.47-2.59-2.47s-3.01,1.56-3.01,2.91h.08c.1-.61,.52-1.16,1.13-1.16s1.18,.39,1.18,1.78v4.04c-1.75,.07-2.81,1.16-2.81,2.34,0,.67,.42,1.92,1.75,1.97v-.1c-.45-.19-.54-.42-.54-.67,0-.59,.57-.79,1.36-.79h.19v6.51c-1.5,.52-2.2,1.53-2.2,2.78,0,1.72,1.38,3.05,3.4,3.05,1.43,0,2.44-.25,3.75-.54,1.06-.22,2.21-.47,2.83-.47,.79,0,1.14,.35,1.14,.91,0,.72-.27,1.08-.69,1.21v.1c1.7-.32,2.69-1.3,2.69-2.83s-1.5-2.54-3.18-2.54c-.87,0-2.44,.27-3.72,.57-1.43,.32-2.66,.47-3.11,.47-.72,0-1.6-.32-1.6-1.28,0-.87,.72-1.56,2.49-1.56,.96,0,1.9,.15,3.08,.42,1.26,.27,2.12,.64,3.2,.64,1.5,0,2.71-.54,2.71-2.74V3.29l1.11-1.01-.12-.15h0Zm-4.24,6.78c-.27,.3-.59,.54-1.11,.54-.57,0-.87-.3-1.14-.54V3.81l.74-.59,1.5,1.28v4.41h0Zm0,2.41c-.25-.25-.57-.47-1.11-.47s-.91,.27-1.14,.47v-2.17c.22,.19,.59,.49,1.14,.49s.87-.25,1.11-.49v2.17Zm0,5.1c0,.84-.42,1.78-1.5,1.78-.17,0-.57-.03-.74-.05v-6.58c.25-.22,.57-.52,1.14-.52,.52,0,.81,.25,1.11,.52v4.86h0Zm8.78,2.74l5.03-3.13v-6.85l-3.25-2.39-5.03,2.88v6.78l-.99,.79,.1,.15,.81-.67,3.33,2.44h0Zm-.37-3.55v-7.3l2.51,1.87v7.3l-2.51-1.87Zm15.01-8.65c-.39,.27-.74,.42-1.11,.42-.39,0-.88-.25-1.14-.57,0,.03-1.87,2.02-1.87,2.02l-1.87-2.02-3.05,2.12,.1,.17,.81-.54,1.11,1.21v6.63l-1.33,1.01,.12,.12,.67-.46,2.49,2.12,3.15-2.09-.1-.15-.81,.49-1.28-1.16v-7.28c.52,.57,1.11,1.06,1.82,1.06,1.28,0,2.14-1.53,2.29-3.11m11.88,9.81l-.94,.59-5.2-7.76,.27-.37c.57,.34,1.08,.81,2.17,.81s2.47-1.14,2.59-3.23c-.27,.37-.81,.81-1.7,.81-.64,0-1.28-.42-1.67-.81l-3.55,5.22,4.71,7.17,3.42-2.27-.1-.17h0Zm-6.31,.19l-.79,.52-1.08-1.08V.48l-3.89,2.69c.45,.15,.99,.39,.99,1.43v11.81l-1.33,1.01,.12,.12,.67-.46,2.32,2.12,3.11-2.07-.1-.15h0Zm22.89-14.39c0-2.02-1.92-2.63-3.53-2.56V.19c.96,.07,1.7,.46,1.7,1.11,0,.45-.32,1.01-1.28,1.01-.76,0-2.02-.45-3.2-.84-1.3-.45-2.54-.87-3.57-.87-2.02,0-3.55,1.5-3.55,3.35,0,1.5,1.16,2.02,1.63,2.21l.03-.07c-.3-.2-.49-.42-.49-1.06,0-.54,.39-1.26,1.43-1.26,.94,0,2.17,.42,3.8,.88,1.4,.39,2.91,.76,3.75,.87v3.28l-1.58,1.3,1.58,1.36v4.49c-.81,.46-1.75,.61-2.56,.61-1.5,0-2.89-.42-4.02-1.68l4.26-2.07V5.73l-5.2,2.32c.54-1.38,1.55-2.41,2.66-3.08l-.03-.08c-3.08,.84-5.89,3.67-5.89,7.17,0,4.19,3.35,7.3,7.22,7.3,4.19,0,6.65-3.28,6.61-6.75h-.07c-.61,1.33-1.63,2.59-2.78,3.25v-4.38l1.65-1.33-1.65-1.33v-3.28c1.53,0,3.11-1.01,3.11-2.96m-8.78,11.56l-1.21,.61c-.74-.96-1.23-2.32-1.23-4.07,0-.72,.07-1.7,.32-2.39l2.14-.96-.03,6.8h0Zm11.93-12.31l-2.17,1.82,1.85,2.09,2.17-1.82-1.85-2.09Zm3.3,15.15l-.79,.52-1.08-1.08v-7.17l.91-.72-.12-.15-.76,.59-1.8-2.14-2.96,2.07,.1,.17,.74-.49,.99,1.23v6.61l-1.33,1.01,.12,.12,.67-.46,2.32,2.12,3.11-2.07-.1-.15h0Zm16.63-.1l-.74,.49-1.16-1.11v-7.03l.94-.72-.12-.15-.84,.64-2.47-2.2-2.78,2.17-2.44-2.17-2.74,2.14-1.85-2.14-2.96,2.07,.1,.17,.74-.49,1.06,1.21v6.61l-.81,.81,2.36,2,2.29-2.07-.94-.88v-7.04l.61-.45,1.7,1.48v6.16l-.79,.81,2.39,2,2.24-2.07-.94-.88v-7.04l.59-.47,1.72,1.5v6.06l-.69,.72,2.41,2.2,3.18-2.17-.1-.15h.02Zm8.6-1.5l-2.36,1.87-2.71-2.14v-1.33l4.68-3.3-2.36-3.67-5.2,2.86v6.93l3.57,2.59,4.51-3.62-.12-.17h0Zm-5.08-1.88v-5.15l2.27,3.55-2.27,1.6Zm14.12-.97l-2-1.53c1.33-1.16,1.8-2.63,1.8-3.69,0-.15-.03-.42-.05-.67h-.08c-.19,.54-.72,1.01-1.53,1.01s-1.26-.45-1.75-.99l-4.58,2.54v3.72l1.75,1.38c-1.75,1.55-2.09,2.51-2.09,3.4s.52,1.67,1.41,2.02l.07-.12c-.22-.19-.42-.32-.42-.79,0-.34,.35-.88,1.14-.88,1.01,0,1.63,.69,1.95,1.06,0-.03,4.38-2.69,4.38-2.69v-3.77h0Zm-1.03-3.05c-.69,1.23-2.21,2.44-3.11,3.13l-1.11-.94v-3.62c.45,.99,1.36,1.82,2.54,1.82,.69,0,1.14-.12,1.67-.39m-1.9,8.13c-.52-1.16-1.63-2-2.86-2-.3,0-1.21-.03-2,.46,.47-.79,1.87-2.21,3.65-3.28l1.21,1.01v3.8Z"></path></svg></a></div><div class="css-1awy3rz e1j3jvdr1"></div></section><section id="masthead-bar-one" class="hasLinks css-c5j6tx e1pjtsj62"><div><div class="css-vfkorq e1pjtsj60"></div><div class="css-1bvtpon e1pjtsj61"><a href="https://www.nytimes.com/section/todayspaper" class="css-1pd1msn">Today’s Paper</a></div></div><div class="css-pzrpby"></div></section></header></div><div id="interactive-masthead-spacer" class="css-1xltzhg"></div><style>#masthead-section-label, #masthead-bar-one { display: none }</style><div><div class="css-1hm40t9"><span class="css-136d4fr"><a href="/" data-testid="tlogo-home-link" aria-label="The New York Times Home Page"><svg viewBox="0 0 44 57" class="css-1nkuxcu" aria-hidden="true"><defs></defs><g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"><g fill="#000"><path d="M43.6284633,34.8996508 C41.83393,39.6379642 38.53153,43.2989842 33.7932167,45.2371375 L33.7932167,34.8996508 L39.46463,29.8027175 L33.7932167,24.7777375 L33.7932167,17.6709842 C38.9621033,17.3120775 42.5514567,13.5074375 42.5514567,8.84136417 C42.5514567,2.73966417 36.7369967,0.5859375 33.4345967,0.5859375 C32.71707,0.5859375 31.9270167,0.5859375 30.7789167,0.872890833 L30.7789167,1.16013083 C31.20949,1.16013083 31.8550633,1.08846417 32.0709233,1.08846417 C34.36827,1.08846417 36.0911367,2.16518417 36.0911367,4.2469575 C36.0911367,5.82620417 34.7988433,7.40545083 32.5017833,7.40545083 C26.83037,7.40545083 20.15419,2.81133083 12.9038167,2.81133083 C6.44292333,2.81133083 1.99242333,7.6207375 1.99242333,12.5023842 C1.99242333,17.3120775 4.79201,18.8913242 7.73521667,19.9680442 L7.80717,19.6808042 C6.87378333,19.1066108 6.22763667,18.1018442 6.22763667,16.5223108 C6.22763667,14.3688708 8.23774333,12.5743375 10.7503767,12.5743375 C16.8520767,12.5743375 26.68675,17.6709842 32.7887367,17.6709842 L33.36293,17.6709842 L33.36293,24.8496908 L27.6918033,29.8027175 L33.36293,34.8996508 L33.36293,45.3804708 C30.9942033,46.2416175 28.5532367,46.6010975 26.0406033,46.6010975 C16.5648367,46.6010975 10.53509,40.8577308 10.53509,31.3102975 C10.53509,29.0135242 10.8220433,26.7878442 11.46819,24.6341175 L16.20593,22.5526308 L16.20593,43.6576042 L25.8253167,39.4226775 L25.8253167,17.8146042 L11.6834767,24.1315908 C13.1191033,19.9680442 16.06231,16.9531708 19.5799967,15.2303042 L19.50833,15.0150175 C10.0322767,17.0967908 0.84375,24.2754975 0.84375,35.0432708 C0.84375,47.4622442 11.32457,56.0768642 23.5285433,56.0768642 C36.4497567,56.0768642 43.7720833,47.4622442 43.84375,34.8996508 L43.6284633,34.8996508 Z"></path></g></g></svg></a></span><nav class="css-m3796d" aria-labelledby="storyline-menu-title" role="navigation"><p id="storyline-menu-title" class=""><a href="https://www.nytimes.com/news-event/coronavirus" class="css-nfyi9h"><span class="css-103u2dt"><span class="css-1rxm0ex" data-testid="text-balancer">Covid-19</span><span class="css-1rxm0ex" data-testid="text-balancer"> Guidance</span></span></a></p><ul class="css-go3nob" role="menu"><li class="css-1qej4jr"><span class="css-fi5tub" data-testid="menu-link"><a class="css-etxl5s" role="menuitem" href="https://www.nytimes.com/article/covid-symptoms-treatment.html"><span class="css-knunh2">Symptoms and Treatment</span></a></span></li><li class="css-1qej4jr"><span class="css-fi5tub" data-testid="menu-link"><a class="css-etxl5s" role="menuitem" href="https://www.nytimes.com/2024/02/14/well/live/jn1-covid-infection-vaccine.html"><span class="css-knunh2">JN.1 Variant</span></a></span></li><li class="css-1qej4jr"><span class="css-fi5tub" data-testid="menu-link"><a class="css-etxl5s" role="menuitem" href="https://www.nytimes.com/2024/03/25/well/fda-covid-medicine-immunocompromised.html"><span class="css-knunh2">A New Drug</span></a></span></li><li class="css-1qej4jr"><span class="css-fi5tub" data-testid="menu-link"><a class="css-etxl5s" role="menuitem" href="https://www.nytimes.com/2023/09/11/well/live/covid-vaccine-booster-fall.html"><span class="css-knunh2">Updated Shots</span></a></span></li><li class="css-1qej4jr"><span class="css-fi5tub" data-testid="menu-link"><a class="css-etxl5s" role="menuitem" href="https://www.nytimes.com/2024/02/07/well/live/long-covid-children.html"><span class="css-knunh2">Long Covid in Kids</span></a></span></li><li class="css-1qej4jr"><span class="css-fi5tub" data-testid="menu-link"><a class="css-etxl5s" role="menuitem" href="https://www.nytimes.com/2024/01/11/well/covid-paxlovid-treatment.html"><span class="css-knunh2">Paxlovid</span></a></span></li><li class="css-1qej4jr"><span class="css-fi5tub" data-testid="menu-link"><a class="css-etxl5s" role="menuitem" href="https://www.nytimes.com/2023/08/29/well/live/covid-masks-guidance.html"><span class="css-knunh2">Masks</span></a></span></li></ul></nav></div></div><span title="ScoopHelper edit storyline button" class="styln-edit-storyline css-1doru00" data-storyline-uri="nyt://storyline/96ae4135-bbe2-48c4-a9fb-fefe09c1fc3b" data-storyline-module-name="menu"></span></div><main id="site-content"><article id="interactive" class="interactive"><header id="interactive-header" class="dish interactive-header css-1660cld ed0j4n71"><h1 id="interactive-heading" class="interactive-heading css-1l8buln e1h9rw200" data-testid="headline">Coronavirus Vaccine Tracker</h1><div class="css-16td4bv interactive-byline-container"><p id="interactive-byline" class="interactive-byline ed0j4n70 css-zack8m e1jsehar1"><span class="byline-prefix">By </span><span class="css-1baulvz" itemProp="name"><a href="https://www.nytimes.com/by/carl-zimmer" class="css-n8ff4n e1jsehar0">Carl Zimmer</a>, </span><span class="css-1baulvz" itemProp="name"><a href="https://www.nytimes.com/by/jonathan-corum" class="css-n8ff4n e1jsehar0">Jonathan Corum</a>, </span><span class="css-1baulvz" itemProp="name"><a href="https://www.nytimes.com/by/sui-lee-wee" class="css-n8ff4n e1jsehar0">Sui-Lee Wee</a></span> and <span class="css-1baulvz last-byline" itemProp="name">Matthew Kristoffersen</span><time id="interactive-timestamp-updated" class="interactive-timestamp-updated css-wcxsge">Updated <!-- -->Aug. 31, 2022</time></p></div><div id="interactive-standalone-sharetools" class="css-1kylsam"><div class="css-1sm67ns"><div role="toolbar" data-testid="share-tools" aria-label="Social Media Share buttons, Save button, and Comments Panel with current comment count" class="css-mfml7"><div class="interactive-sharetools css-n7z2yi"><ul class="css-1liwv7v"><li class="css-1gh9hw8"><div class="css-vxcmzt"><div class="css-79elbk"><button type="button" aria-label="" aria-expanded="false" class="css-1eeh360 actionbar-button" data-testid="gift-article-button"><span class="css-lu72is"><svg aria-hidden="true" width="19" height="19" viewBox="0 0 19 19" class="sha-gift-icon"><path d="M18.04 5.293h-2.725c.286-.34.493-.74.606-1.17a2.875 2.875 0 0 0-.333-2.322A2.906 2.906 0 0 0 13.64.48a3.31 3.31 0 0 0-2.372.464 3.775 3.775 0 0 0-1.534 2.483l-.141.797-.142-.847A3.745 3.745 0 0 0 7.927.923 3.31 3.31 0 0 0 5.555.459 2.907 2.907 0 0 0 3.607 1.78a2.877 2.877 0 0 0-.333 2.321c.117.429.324.828.606 1.171H1.155a.767.767 0 0 0-.757.757v3.674a.767.767 0 0 0 .757.757h.424v7.53A1.01 1.01 0 0 0 2.588 19h14.13a1.01 1.01 0 0 0 1.01-.959v-7.56h.424a.758.758 0 0 0 .757-.757V6.05a.759.759 0 0 0-.868-.757Zm-7.196-1.625a2.665 2.665 0 0 1 1.01-1.736 2.24 2.24 0 0 1 1.574-.313 1.817 1.817 0 0 1 1.211.818 1.857 1.857 0 0 1 .202 1.453 2.2 2.2 0 0 1-.838 1.191h-3.431l.272-1.413ZM4.576 2.386a1.837 1.837 0 0 1 1.221-.817 2.23 2.23 0 0 1 1.565.313 2.624 2.624 0 0 1 1.01 1.736l.242 1.453H5.182a2.2 2.2 0 0 1-.838-1.19 1.857 1.857 0 0 1 .202-1.495h.03ZM1.548 6.424h7.54V9.39h-7.58l.04-2.967Zm1.181 4.128h6.359v7.287H2.729v-7.287Zm13.777 7.287h-6.348v-7.307h6.348v7.307Zm1.181-8.468h-7.53V6.404h7.53V9.37Z" fill="#121212" fill-rule="nonzero"></path></svg><svg aria-hidden="true" width="23" height="18" viewBox="0 0 23 18" class="sha-arrow-icon"><path d="M1.357 17.192a.663.663 0 0 1-.642-.81c1.82-7.955 6.197-12.068 12.331-11.68V1.127a.779.779 0 0 1 .42-.653.726.726 0 0 1 .78.106l8.195 6.986a.81.81 0 0 1 .253.557.82.82 0 0 1-.263.547l-8.196 6.955a.83.83 0 0 1-.779.105.747.747 0 0 1-.42-.663V11.29c-8.418-.905-10.974 5.177-11.08 5.45a.662.662 0 0 1-.6.453Zm10.048-7.26a16.37 16.37 0 0 1 2.314.158.81.81 0 0 1 .642.726v3.02l6.702-5.682-6.702-5.692v2.883a.767.767 0 0 1-.242.536.747.747 0 0 1-.547.18c-4.808-.537-8.364 1.85-10.448 6.922a11.679 11.679 0 0 1 8.28-3.093v.042Z" fill="#000" fill-rule="nonzero"></path></svg>Share full article</span></button></div></div></li><li class="css-2ykviq sha-std-share"><div class="css-vxcmzt"><div class="css-79elbk"><button type="button" aria-label="More sharing options ..." aria-expanded="false" class="css-1nurhyi actionbar-button"><svg aria-hidden="true" width="23" height="18" viewBox="0 0 23 18" class="css-zd9juy"><path d="M1.357 17.192a.663.663 0 0 1-.642-.81c1.82-7.955 6.197-12.068 12.331-11.68V1.127a.779.779 0 0 1 .42-.653.726.726 0 0 1 .78.106l8.195 6.986a.81.81 0 0 1 .253.557.82.82 0 0 1-.263.547l-8.196 6.955a.83.83 0 0 1-.779.105.747.747 0 0 1-.42-.663V11.29c-8.418-.905-10.974 5.177-11.08 5.45a.662.662 0 0 1-.6.453Zm10.048-7.26a16.37 16.37 0 0 1 2.314.158.81.81 0 0 1 .642.726v3.02l6.702-5.682-6.702-5.692v2.883a.767.767 0 0 1-.242.536.747.747 0 0 1-.547.18c-4.808-.537-8.364 1.85-10.448 6.922a11.679 11.679 0 0 1 8.28-3.093v.042Z" fill="#000" fill-rule="nonzero"></path></svg></button></div></div></li><li class="css-2ykviq save-button"><button type="button" role="switch" class="css-1yhvmgx actionbar-button" data-testid="save-article-button" aria-label="Save article for reading later..." aria-checked="false" disabled="" aria-busy="false" aria-live="polite"><svg width="12" height="18" viewBox="0 0 12 18" class="css-eap6fy"><g fill-rule="nonzero"><path class="saved-fill" d="M1.157 1.268v14.288l4.96-3.813 4.753 3.843V1.268z"></path><path class="saved-stroke" d="m12 18-5.9-4.756L0 17.98V1.014C0 .745.095.487.265.297.435.107.664 0 .904 0h10.192c.24 0 .47.107.64.297.169.19.264.448.264.717V18ZM1.157 1.268v14.288l4.96-3.813 4.753 3.843V1.268H1.158Z"></path></g></svg></button></li></ul></div></div></div></div></header><section data-testid="inline-interactive" id="coronavirus-vaccine-tracker" data-id="100000007182188" data-source-id="100000007182188" class="interactive-standard meteredContent interactive-content interactive-size-scoop css-uc81c"><div class="css-17ih8de interactive-body"><!--

======================================================

THIS IS A GENERATED TEMPLATE FILE. DO NOT EDIT.

======================================================

-->



  <!-- critical path preloads -->
  <link rel="preload" href="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/build/js/main.js" as="script">
  <link rel="preload" href="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/build/js/freebird.js" as="script">


<!-- css generated from src/style.scss, text-balancer, and svelte component CSS -->

<link id="nytg-rendered-css" href="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/style.css" rel="stylesheet">



<link href="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/build/components.css" rel="stylesheet">





<!-- sprites, polyfills, imports -->


<script>
  if (!window.Promise || !window.fetch || !window.URL) {
    document.write('<script src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/polyfills.js"><\/script>');
  }
</script>

<script>
  (function() {
    window.NYTG = window.NYTG || {};
    window.NYTG.ASSETS = "https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/".slice(0, -1);
    window.NYTG.BIG_ASSETS = "https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/".slice(0, -1);

    var supports_import = false;
    var can_use_import = location.hostname.indexOf('preview.n' + 'yt.net') == -1;
    var shimport_url = window.NYTG.ASSETS + "/shimport@1.0.1.js";
    var shimport_promise;

    try {
      new Function("if(0)import('')")();
      supports_import = true;
    } catch(e) { }

    if (!can_use_import || !supports_import) {
      shimport_promise = new Promise(function(fulfil, reject) {
        var s = document.createElement("script");
        s.src = shimport_url;
        s.onload = function() {
          fulfil(__shimport__);
        };
        s.onerror = reject;

        document.head.appendChild(s);
      });
    }

    window.NYTG.load = function(module) {
      var url = new URL(module, location.href).href;

      if (can_use_import && supports_import) {
        return eval("import('" + url + "')");
      } else {
        return shimport_promise.then(function(shimport) {
          return shimport.load(url);
        });
      }
    };

    // for --live
    window.NYTG.subscribers = {};
    window.NYTG.watch = function(url, cb) {
      if (!window.NYTG.subscribers[url]) window.NYTG.subscribers[url] = [];
      window.NYTG.subscribers[url].push(cb);
      window.NYTG.load(url).then(cb);
    };
  }());
</script>

<script id="nytg-dynamic-script_template-options">
  (function() {
    // Check for template type: standard, minimal, or blank
    var templateType   = "template-" + ("" || "standard");
    // Check for icon style options
    var templateStyle  = "template-option-" + ("HIDE_TOP_AD" || "black-icons");
    // Check for dark mode flag
    var isDarkMode     = "".match(/y|yes|true/) !== null;
    var darkMode       = (isDarkMode) ? " " + "template-mode-dark" : "";
    // Check for feature style flag
    var isFeatureStyle = "".toLowerCase().match(/feature|featured|feat/) !== null;
    var featureStyle   = (isFeatureStyle) ? "template-style-feature" : "template-style-standard";
    // Set classes on body element
    var tBody          = document.body.classList.add(...[templateType.trim(), templateStyle.trim(),
      darkMode.trim(), featureStyle.trim()].filter(d => !!d));
  })();
</script>


<!-- story top/cover and links -->








  

  


  
    <div class="g-top-asset g-top " style="max-width:600px; ">

    <!-- open g-cover-asset -->
    

    

      

    

    






<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-embed g-asset-width-full"  style="">

<!-- Intro elements -->








<div role="region">


<!-- data processed in process/freebird/process-image.js -->

    

		

		<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/start-77a20309.js">
		<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/vendor-06fa5620.js">
		<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/preload-helper-11d3297a.js">
		<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/singletons-12a22614.js">
		<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/paths-6758d194.js">
		<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/pages/__layout.svelte-0993d16b.js">
		<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/env-984c559a.js">
		<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/index-19eafa6f.js">
		<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/index-a531160c.js">
		<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/pages/embeds/top-nav/index.html.svelte-eff2a63c.js">
		<link rel="stylesheet" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/start-61d1577b.css">
		<link rel="stylesheet" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/pages/__layout.svelte-04417c8d.css">
		<link rel="stylesheet" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index-b19a7dbe.css">
		<link rel="stylesheet" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index-78905180.css">

		<script type="module">
			import { start } from "https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/start-77a20309.js";
			const target = document.querySelector('#svelte-1m0nqup');
			target.removeAttribute('id');
			start({
				target,
				paths: {"base":"/interactive/2021","assets":"https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking"},
				session: {},
				host: location.host,
				route: false,
				spa: false,
				trailing_slash: "never",
				hydrate: {
					status: 200,
					error: null,
					nodes: [
						import("https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/pages/__layout.svelte-0993d16b.js"),
						import("https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/pages/embeds/top-nav/index.html.svelte-eff2a63c.js")
					],
					page: {
						host: location.host, // TODO this is redundant
						path: "\u002Fembeds\u002Ftop-nav.html",
						query: new URLSearchParams(""),
						params: {}
					}
				}
			});
		</script>
    
<script type="text/plain" data-attr="nyt-asset-manifest">{"css":["https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/start-61d1577b.css","https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/pages/__layout.svelte-04417c8d.css","https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index-b19a7dbe.css","https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index-78905180.css"],"images":[]}</script>
<!-- publish_time: Mon Nov 29 2021 10:37:21 GMT+0000 (Coordinated Universal Time) -->

              <div id="svelte-1m0nqup" class="covid-tracker-wrapper">
                


<main class="covid-tracker" id="embeds/top-nav"><div class="g-column"><nav class="svelte-173co1c"><input id="nav-dummy" type="radio" name="nav" tabindex="-1" class="svelte-173co1c">

	<div class="tab svelte-173co1c"><input type="radio" id="nav-usa" name="nav" class="svelte-173co1c">

			<label for="nav-usa" style="left: 0%" class="svelte-173co1c"><div class="button svelte-173co1c" style="--icon: url('https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/maps/USA/hotspots-state.png')">U.S.A.</div>
				<label class="reset svelte-173co1c" for="nav-dummy">Close nav</label></label>

			<div class="content svelte-173co1c"><ul class="primary svelte-173co1c"><li class="svelte-173co1c"><a rel="" href="https://www.nytimes.com/interactive/2021/us/covid-cases.html" class="svelte-173co1c">Latest Maps and Data</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html" class="svelte-173co1c">Vaccinations by State</a></li><li class="svelte-173co1c"><a rel="" href="https://www.nytimes.com/interactive/2021/us/covid-cases-deaths-tracker.html" class="svelte-173co1c">Your Places</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2021/us/cdc-mask-guidance-states.html" class="svelte-173co1c">Mask Mandates</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2020/us/covid-hospitals-near-you.html" class="svelte-173co1c">Hospitals</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2021/us/covid-risk-map.html" class="svelte-173co1c">County-Level Risk Map</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2020/us/coronavirus-nursing-homes.html" class="svelte-173co1c">Nursing Homes</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2021/us/college-covid-tracker.html" class="svelte-173co1c">Colleges and Universities</a></li></ul>

				<div class="autocomplete-wrapper svelte-173co1c">

<div class="autocomplete svelte-14enwtd"><input disabled placeholder="Search to find your county" autocomplete="none" class="svelte-14enwtd" value="">

	

	<div class="options svelte-14enwtd"></div></div>

<noscript><style>.autocomplete input {
			background: none;
		}
	</style>
</noscript>
					</div>

				<ul class="secondary svelte-173co1c"><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/alabama-covid-cases.html" class="svelte-173co1c">Alabama</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/alaska-covid-cases.html" class="svelte-173co1c">Alaska</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/arizona-covid-cases.html" class="svelte-173co1c">Arizona</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/arkansas-covid-cases.html" class="svelte-173co1c">Arkansas</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/california-covid-cases.html" class="svelte-173co1c">California</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/colorado-covid-cases.html" class="svelte-173co1c">Colorado</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/connecticut-covid-cases.html" class="svelte-173co1c">Connecticut</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/delaware-covid-cases.html" class="svelte-173co1c">Delaware</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/florida-covid-cases.html" class="svelte-173co1c">Florida</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/georgia-covid-cases.html" class="svelte-173co1c">Georgia</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/guam-covid-cases.html" class="svelte-173co1c">Guam</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/hawaii-covid-cases.html" class="svelte-173co1c">Hawaii</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/idaho-covid-cases.html" class="svelte-173co1c">Idaho</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/illinois-covid-cases.html" class="svelte-173co1c">Illinois</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/indiana-covid-cases.html" class="svelte-173co1c">Indiana</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/iowa-covid-cases.html" class="svelte-173co1c">Iowa</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/kansas-covid-cases.html" class="svelte-173co1c">Kansas</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/kentucky-covid-cases.html" class="svelte-173co1c">Kentucky</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/louisiana-covid-cases.html" class="svelte-173co1c">Louisiana</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/maine-covid-cases.html" class="svelte-173co1c">Maine</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/maryland-covid-cases.html" class="svelte-173co1c">Maryland</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/massachusetts-covid-cases.html" class="svelte-173co1c">Massachusetts</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/michigan-covid-cases.html" class="svelte-173co1c">Michigan</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/minnesota-covid-cases.html" class="svelte-173co1c">Minnesota</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/mississippi-covid-cases.html" class="svelte-173co1c">Mississippi</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/missouri-covid-cases.html" class="svelte-173co1c">Missouri</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/montana-covid-cases.html" class="svelte-173co1c">Montana</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/nebraska-covid-cases.html" class="svelte-173co1c">Nebraska</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/nevada-covid-cases.html" class="svelte-173co1c">Nevada</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/new-hampshire-covid-cases.html" class="svelte-173co1c">New Hampshire</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/new-jersey-covid-cases.html" class="svelte-173co1c">New Jersey</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/new-mexico-covid-cases.html" class="svelte-173co1c">New Mexico</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/new-york-covid-cases.html" class="svelte-173co1c">New York</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/north-carolina-covid-cases.html" class="svelte-173co1c">North Carolina</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/north-dakota-covid-cases.html" class="svelte-173co1c">North Dakota</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/northern-mariana-islands-covid-cases.html" class="svelte-173co1c">Northern Mariana Islands</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/ohio-covid-cases.html" class="svelte-173co1c">Ohio</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/oklahoma-covid-cases.html" class="svelte-173co1c">Oklahoma</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/oregon-covid-cases.html" class="svelte-173co1c">Oregon</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/pennsylvania-covid-cases.html" class="svelte-173co1c">Pennsylvania</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/puerto-rico-covid-cases.html" class="svelte-173co1c">Puerto Rico</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/rhode-island-covid-cases.html" class="svelte-173co1c">Rhode Island</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/south-carolina-covid-cases.html" class="svelte-173co1c">South Carolina</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/south-dakota-covid-cases.html" class="svelte-173co1c">South Dakota</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/tennessee-covid-cases.html" class="svelte-173co1c">Tennessee</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/texas-covid-cases.html" class="svelte-173co1c">Texas</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/virgin-islands-covid-cases.html" class="svelte-173co1c">U.S. Virgin Islands</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/utah-covid-cases.html" class="svelte-173co1c">Utah</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/vermont-covid-cases.html" class="svelte-173co1c">Vermont</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/virginia-covid-cases.html" class="svelte-173co1c">Virginia</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/washington-covid-cases.html" class="svelte-173co1c">Washington</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/washington-district-of-columbia-covid-cases.html" class="svelte-173co1c">Washington, D.C.</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/west-virginia-covid-cases.html" class="svelte-173co1c">West Virginia</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/wisconsin-covid-cases.html" class="svelte-173co1c">Wisconsin</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/us/wyoming-covid-cases.html" class="svelte-173co1c">Wyoming</a>
							</li>
					</ul></div>
		</div><div class="tab svelte-173co1c"><input type="radio" id="nav-world" name="nav" class="svelte-173co1c">

			<label for="nav-world" style="left: 33.333333333333336%" class="svelte-173co1c"><div class="button svelte-173co1c" style="--icon: url('https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/maps/NYT-World/hotspots.png')">World</div>
				<label class="reset svelte-173co1c" for="nav-dummy">Close nav</label></label>

			<div class="content svelte-173co1c"><ul class="primary svelte-173co1c"><li class="svelte-173co1c"><a rel="" href="https://www.nytimes.com/interactive/2021/world/covid-cases.html" class="svelte-173co1c">Latest Maps and Data</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html" class="svelte-173co1c">Vaccinations by Country</a></li></ul>

				

				<ul class="secondary svelte-173co1c"><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/australia-covid-cases.html" class="svelte-173co1c">Australia</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/brazil-covid-cases.html" class="svelte-173co1c">Brazil</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/canada-covid-cases.html" class="svelte-173co1c">Canada</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/france-covid-cases.html" class="svelte-173co1c">France</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/germany-covid-cases.html" class="svelte-173co1c">Germany</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/india-covid-cases.html" class="svelte-173co1c">India</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/italy-covid-cases.html" class="svelte-173co1c">Italy</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/japan-covid-cases.html" class="svelte-173co1c">Japan</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/mexico-covid-cases.html" class="svelte-173co1c">Mexico</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/spain-covid-cases.html" class="svelte-173co1c">Spain</a>
							</li><li class="svelte-173co1c"><a rel="" href="/interactive/2021/world/united-kingdom-covid-cases.html" class="svelte-173co1c">U.K.</a>
							</li>
					</ul></div>
		</div><div class="tab svelte-173co1c"><input type="radio" id="nav-health" name="nav" class="svelte-173co1c">

			<label for="nav-health" style="left: 66.66666666666667%" class="svelte-173co1c"><div class="button svelte-173co1c" style="--icon: url('https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/health-icon.png')">Health</div>
				<label class="reset svelte-173co1c" for="nav-dummy">Close nav</label></label>

			<div class="content svelte-173co1c"><ul class="primary svelte-173co1c"><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html" class="svelte-173co1c">Vaccine Development</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html" class="svelte-173co1c">Coronavirus Variants</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html" class="svelte-173co1c">Treatments</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2020/world/coronavirus-tips-advice.html" class="svelte-173co1c">Answers to Your Covid-19 Questions</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html" class="svelte-173co1c">How the Covid-19 Vaccines Work</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2020/08/05/well/covid-19-symptoms.html" class="svelte-173co1c">Symptoms of Covid-19</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2020/10/02/science/charting-a-coronavirus-infection.html" class="svelte-173co1c">What Happens in an Infection</a></li><li class="svelte-173co1c"><a rel="external" href="https://www.nytimes.com/interactive/2020/10/30/science/wear-mask-covid-particles-ul.html" class="svelte-173co1c">How Masks Work</a></li></ul>

				

				</div>
		</div>
</nav></div></main>





			<script type="application/json" data-type="svelte-data" data-url="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/page/navigation.json">{"status":200,"statusText":"","headers":{"content-type":"application/json"},"body":"{\"sections\":[{\"icon\":\"images\u002Fmaps\u002FUSA\u002Fhotspots-state.png\",\"section\":\"usa\",\"primary\":[{\"name\":\"Latest Maps and Data\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcovid-cases.html\",\"rel\":\"\"},{\"name\":\"Vaccinations by State\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fus\u002Fcovid-19-vaccine-doses.html\",\"rel\":\"external\"},{\"name\":\"Your Places\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcovid-cases-deaths-tracker.html\",\"rel\":\"\"},{\"name\":\"Mask Mandates\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcdc-mask-guidance-states.html\",\"rel\":\"external\"},{\"name\":\"Hospitals\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fus\u002Fcovid-hospitals-near-you.html\",\"rel\":\"external\"},{\"name\":\"County-Level Risk Map\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcovid-risk-map.html\",\"rel\":\"external\"},{\"name\":\"Nursing Homes\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fus\u002Fcoronavirus-nursing-homes.html\",\"rel\":\"external\"},{\"name\":\"Colleges and Universities\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcollege-covid-tracker.html\",\"rel\":\"external\"}],\"secondary\":[{\"name\":\"Alabama\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Falabama-covid-cases.html\",\"slug\":\"us\u002Falabama-covid-cases\",\"rel\":\"\"},{\"name\":\"Alaska\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Falaska-covid-cases.html\",\"slug\":\"us\u002Falaska-covid-cases\",\"rel\":\"\"},{\"name\":\"Arizona\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Farizona-covid-cases.html\",\"slug\":\"us\u002Farizona-covid-cases\",\"rel\":\"\"},{\"name\":\"Arkansas\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Farkansas-covid-cases.html\",\"slug\":\"us\u002Farkansas-covid-cases\",\"rel\":\"\"},{\"name\":\"California\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcalifornia-covid-cases.html\",\"slug\":\"us\u002Fcalifornia-covid-cases\",\"rel\":\"\"},{\"name\":\"Colorado\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcolorado-covid-cases.html\",\"slug\":\"us\u002Fcolorado-covid-cases\",\"rel\":\"\"},{\"name\":\"Connecticut\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fconnecticut-covid-cases.html\",\"slug\":\"us\u002Fconnecticut-covid-cases\",\"rel\":\"\"},{\"name\":\"Delaware\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fdelaware-covid-cases.html\",\"slug\":\"us\u002Fdelaware-covid-cases\",\"rel\":\"\"},{\"name\":\"Florida\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fflorida-covid-cases.html\",\"slug\":\"us\u002Fflorida-covid-cases\",\"rel\":\"\"},{\"name\":\"Georgia\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fgeorgia-covid-cases.html\",\"slug\":\"us\u002Fgeorgia-covid-cases\",\"rel\":\"\"},{\"name\":\"Guam\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fguam-covid-cases.html\",\"slug\":\"us\u002Fguam-covid-cases\",\"rel\":\"\"},{\"name\":\"Hawaii\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fhawaii-covid-cases.html\",\"slug\":\"us\u002Fhawaii-covid-cases\",\"rel\":\"\"},{\"name\":\"Idaho\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fidaho-covid-cases.html\",\"slug\":\"us\u002Fidaho-covid-cases\",\"rel\":\"\"},{\"name\":\"Illinois\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fillinois-covid-cases.html\",\"slug\":\"us\u002Fillinois-covid-cases\",\"rel\":\"\"},{\"name\":\"Indiana\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Findiana-covid-cases.html\",\"slug\":\"us\u002Findiana-covid-cases\",\"rel\":\"\"},{\"name\":\"Iowa\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fiowa-covid-cases.html\",\"slug\":\"us\u002Fiowa-covid-cases\",\"rel\":\"\"},{\"name\":\"Kansas\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fkansas-covid-cases.html\",\"slug\":\"us\u002Fkansas-covid-cases\",\"rel\":\"\"},{\"name\":\"Kentucky\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fkentucky-covid-cases.html\",\"slug\":\"us\u002Fkentucky-covid-cases\",\"rel\":\"\"},{\"name\":\"Louisiana\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Flouisiana-covid-cases.html\",\"slug\":\"us\u002Flouisiana-covid-cases\",\"rel\":\"\"},{\"name\":\"Maine\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmaine-covid-cases.html\",\"slug\":\"us\u002Fmaine-covid-cases\",\"rel\":\"\"},{\"name\":\"Maryland\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmaryland-covid-cases.html\",\"slug\":\"us\u002Fmaryland-covid-cases\",\"rel\":\"\"},{\"name\":\"Massachusetts\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmassachusetts-covid-cases.html\",\"slug\":\"us\u002Fmassachusetts-covid-cases\",\"rel\":\"\"},{\"name\":\"Michigan\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmichigan-covid-cases.html\",\"slug\":\"us\u002Fmichigan-covid-cases\",\"rel\":\"\"},{\"name\":\"Minnesota\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fminnesota-covid-cases.html\",\"slug\":\"us\u002Fminnesota-covid-cases\",\"rel\":\"\"},{\"name\":\"Mississippi\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmississippi-covid-cases.html\",\"slug\":\"us\u002Fmississippi-covid-cases\",\"rel\":\"\"},{\"name\":\"Missouri\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmissouri-covid-cases.html\",\"slug\":\"us\u002Fmissouri-covid-cases\",\"rel\":\"\"},{\"name\":\"Montana\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmontana-covid-cases.html\",\"slug\":\"us\u002Fmontana-covid-cases\",\"rel\":\"\"},{\"name\":\"Nebraska\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnebraska-covid-cases.html\",\"slug\":\"us\u002Fnebraska-covid-cases\",\"rel\":\"\"},{\"name\":\"Nevada\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnevada-covid-cases.html\",\"slug\":\"us\u002Fnevada-covid-cases\",\"rel\":\"\"},{\"name\":\"New Hampshire\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnew-hampshire-covid-cases.html\",\"slug\":\"us\u002Fnew-hampshire-covid-cases\",\"rel\":\"\"},{\"name\":\"New Jersey\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnew-jersey-covid-cases.html\",\"slug\":\"us\u002Fnew-jersey-covid-cases\",\"rel\":\"\"},{\"name\":\"New Mexico\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnew-mexico-covid-cases.html\",\"slug\":\"us\u002Fnew-mexico-covid-cases\",\"rel\":\"\"},{\"name\":\"New York\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnew-york-covid-cases.html\",\"slug\":\"us\u002Fnew-york-covid-cases\",\"rel\":\"\"},{\"name\":\"North Carolina\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnorth-carolina-covid-cases.html\",\"slug\":\"us\u002Fnorth-carolina-covid-cases\",\"rel\":\"\"},{\"name\":\"North Dakota\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnorth-dakota-covid-cases.html\",\"slug\":\"us\u002Fnorth-dakota-covid-cases\",\"rel\":\"\"},{\"name\":\"Northern Mariana Islands\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnorthern-mariana-islands-covid-cases.html\",\"slug\":\"us\u002Fnorthern-mariana-islands-covid-cases\",\"rel\":\"\"},{\"name\":\"Ohio\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fohio-covid-cases.html\",\"slug\":\"us\u002Fohio-covid-cases\",\"rel\":\"\"},{\"name\":\"Oklahoma\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Foklahoma-covid-cases.html\",\"slug\":\"us\u002Foklahoma-covid-cases\",\"rel\":\"\"},{\"name\":\"Oregon\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Foregon-covid-cases.html\",\"slug\":\"us\u002Foregon-covid-cases\",\"rel\":\"\"},{\"name\":\"Pennsylvania\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fpennsylvania-covid-cases.html\",\"slug\":\"us\u002Fpennsylvania-covid-cases\",\"rel\":\"\"},{\"name\":\"Puerto Rico\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fpuerto-rico-covid-cases.html\",\"slug\":\"us\u002Fpuerto-rico-covid-cases\",\"rel\":\"\"},{\"name\":\"Rhode Island\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Frhode-island-covid-cases.html\",\"slug\":\"us\u002Frhode-island-covid-cases\",\"rel\":\"\"},{\"name\":\"South Carolina\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fsouth-carolina-covid-cases.html\",\"slug\":\"us\u002Fsouth-carolina-covid-cases\",\"rel\":\"\"},{\"name\":\"South Dakota\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fsouth-dakota-covid-cases.html\",\"slug\":\"us\u002Fsouth-dakota-covid-cases\",\"rel\":\"\"},{\"name\":\"Tennessee\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Ftennessee-covid-cases.html\",\"slug\":\"us\u002Ftennessee-covid-cases\",\"rel\":\"\"},{\"name\":\"Texas\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Ftexas-covid-cases.html\",\"slug\":\"us\u002Ftexas-covid-cases\",\"rel\":\"\"},{\"name\":\"U.S. Virgin Islands\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fvirgin-islands-covid-cases.html\",\"slug\":\"us\u002Fvirgin-islands-covid-cases\",\"rel\":\"\"},{\"name\":\"Utah\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Futah-covid-cases.html\",\"slug\":\"us\u002Futah-covid-cases\",\"rel\":\"\"},{\"name\":\"Vermont\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fvermont-covid-cases.html\",\"slug\":\"us\u002Fvermont-covid-cases\",\"rel\":\"\"},{\"name\":\"Virginia\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fvirginia-covid-cases.html\",\"slug\":\"us\u002Fvirginia-covid-cases\",\"rel\":\"\"},{\"name\":\"Washington\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fwashington-covid-cases.html\",\"slug\":\"us\u002Fwashington-covid-cases\",\"rel\":\"\"},{\"name\":\"Washington, D.C.\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fwashington-district-of-columbia-covid-cases.html\",\"slug\":\"us\u002Fwashington-district-of-columbia-covid-cases\",\"rel\":\"\"},{\"name\":\"West Virginia\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fwest-virginia-covid-cases.html\",\"slug\":\"us\u002Fwest-virginia-covid-cases\",\"rel\":\"\"},{\"name\":\"Wisconsin\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fwisconsin-covid-cases.html\",\"slug\":\"us\u002Fwisconsin-covid-cases\",\"rel\":\"\"},{\"name\":\"Wyoming\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fwyoming-covid-cases.html\",\"slug\":\"us\u002Fwyoming-covid-cases\",\"rel\":\"\"}]},{\"icon\":\"images\u002Fmaps\u002FNYT-World\u002Fhotspots.png\",\"section\":\"world\",\"primary\":[{\"name\":\"Latest Maps and Data\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fcovid-cases.html\",\"rel\":\"\"},{\"name\":\"Vaccinations by Country\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fcovid-vaccinations-tracker.html\",\"rel\":\"external\"}],\"secondary\":[{\"name\":\"Australia\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Faustralia-covid-cases.html\",\"slug\":\"world\u002Faustralia-covid-cases\",\"rel\":\"\"},{\"name\":\"Brazil\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fbrazil-covid-cases.html\",\"slug\":\"world\u002Fbrazil-covid-cases\",\"rel\":\"\"},{\"name\":\"Canada\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fcanada-covid-cases.html\",\"slug\":\"world\u002Fcanada-covid-cases\",\"rel\":\"\"},{\"name\":\"France\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Ffrance-covid-cases.html\",\"slug\":\"world\u002Ffrance-covid-cases\",\"rel\":\"\"},{\"name\":\"Germany\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fgermany-covid-cases.html\",\"slug\":\"world\u002Fgermany-covid-cases\",\"rel\":\"\"},{\"name\":\"India\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Findia-covid-cases.html\",\"slug\":\"world\u002Findia-covid-cases\",\"rel\":\"\"},{\"name\":\"Italy\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fitaly-covid-cases.html\",\"slug\":\"world\u002Fitaly-covid-cases\",\"rel\":\"\"},{\"name\":\"Japan\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fjapan-covid-cases.html\",\"slug\":\"world\u002Fjapan-covid-cases\",\"rel\":\"\"},{\"name\":\"Mexico\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fmexico-covid-cases.html\",\"slug\":\"world\u002Fmexico-covid-cases\",\"rel\":\"\"},{\"name\":\"Spain\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fspain-covid-cases.html\",\"slug\":\"world\u002Fspain-covid-cases\",\"rel\":\"\"},{\"name\":\"U.K.\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Funited-kingdom-covid-cases.html\",\"slug\":\"world\u002Funited-kingdom-covid-cases\",\"rel\":\"\"}]},{\"icon\":\"images\u002Fhealth-icon.png\",\"section\":\"health\",\"primary\":[{\"name\":\"Vaccine Development\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fscience\u002Fcoronavirus-vaccine-tracker.html\",\"rel\":\"external\"},{\"name\":\"Coronavirus Variants\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fhealth\u002Fcoronavirus-variant-tracker.html\",\"rel\":\"external\"},{\"name\":\"Treatments\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fscience\u002Fcoronavirus-drugs-treatments.html\",\"rel\":\"external\"},{\"name\":\"Answers to Your Covid-19 Questions\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fworld\u002Fcoronavirus-tips-advice.html\",\"rel\":\"external\"},{\"name\":\"How the Covid-19 Vaccines Work\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fhealth\u002Fhow-covid-19-vaccines-work.html\",\"rel\":\"external\"},{\"name\":\"Symptoms of Covid-19\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002F08\u002F05\u002Fwell\u002Fcovid-19-symptoms.html\",\"rel\":\"external\"},{\"name\":\"What Happens in an Infection\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002F10\u002F02\u002Fscience\u002Fcharting-a-coronavirus-infection.html\",\"rel\":\"external\"},{\"name\":\"How Masks Work\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002F10\u002F30\u002Fscience\u002Fwear-mask-covid-particles-ul.html\",\"rel\":\"external\"}],\"secondary\":[]}]}"}</script>

	<script type="application/json" data-type="svelte-data" data-url="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/page/navigation.json">{"status":200,"statusText":"","headers":{"content-type":"application/json"},"body":"{\"sections\":[{\"icon\":\"images\u002Fmaps\u002FUSA\u002Fhotspots-state.png\",\"section\":\"usa\",\"primary\":[{\"name\":\"Latest Maps and Data\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcovid-cases.html\",\"rel\":\"\"},{\"name\":\"Vaccinations by State\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fus\u002Fcovid-19-vaccine-doses.html\",\"rel\":\"external\"},{\"name\":\"Your Places\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcovid-cases-deaths-tracker.html\",\"rel\":\"\"},{\"name\":\"Mask Mandates\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcdc-mask-guidance-states.html\",\"rel\":\"external\"},{\"name\":\"Hospitals\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fus\u002Fcovid-hospitals-near-you.html\",\"rel\":\"external\"},{\"name\":\"County-Level Risk Map\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcovid-risk-map.html\",\"rel\":\"external\"},{\"name\":\"Nursing Homes\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fus\u002Fcoronavirus-nursing-homes.html\",\"rel\":\"external\"},{\"name\":\"Colleges and Universities\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcollege-covid-tracker.html\",\"rel\":\"external\"}],\"secondary\":[{\"name\":\"Alabama\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Falabama-covid-cases.html\",\"slug\":\"us\u002Falabama-covid-cases\",\"rel\":\"\"},{\"name\":\"Alaska\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Falaska-covid-cases.html\",\"slug\":\"us\u002Falaska-covid-cases\",\"rel\":\"\"},{\"name\":\"Arizona\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Farizona-covid-cases.html\",\"slug\":\"us\u002Farizona-covid-cases\",\"rel\":\"\"},{\"name\":\"Arkansas\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Farkansas-covid-cases.html\",\"slug\":\"us\u002Farkansas-covid-cases\",\"rel\":\"\"},{\"name\":\"California\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcalifornia-covid-cases.html\",\"slug\":\"us\u002Fcalifornia-covid-cases\",\"rel\":\"\"},{\"name\":\"Colorado\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fcolorado-covid-cases.html\",\"slug\":\"us\u002Fcolorado-covid-cases\",\"rel\":\"\"},{\"name\":\"Connecticut\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fconnecticut-covid-cases.html\",\"slug\":\"us\u002Fconnecticut-covid-cases\",\"rel\":\"\"},{\"name\":\"Delaware\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fdelaware-covid-cases.html\",\"slug\":\"us\u002Fdelaware-covid-cases\",\"rel\":\"\"},{\"name\":\"Florida\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fflorida-covid-cases.html\",\"slug\":\"us\u002Fflorida-covid-cases\",\"rel\":\"\"},{\"name\":\"Georgia\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fgeorgia-covid-cases.html\",\"slug\":\"us\u002Fgeorgia-covid-cases\",\"rel\":\"\"},{\"name\":\"Guam\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fguam-covid-cases.html\",\"slug\":\"us\u002Fguam-covid-cases\",\"rel\":\"\"},{\"name\":\"Hawaii\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fhawaii-covid-cases.html\",\"slug\":\"us\u002Fhawaii-covid-cases\",\"rel\":\"\"},{\"name\":\"Idaho\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fidaho-covid-cases.html\",\"slug\":\"us\u002Fidaho-covid-cases\",\"rel\":\"\"},{\"name\":\"Illinois\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fillinois-covid-cases.html\",\"slug\":\"us\u002Fillinois-covid-cases\",\"rel\":\"\"},{\"name\":\"Indiana\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Findiana-covid-cases.html\",\"slug\":\"us\u002Findiana-covid-cases\",\"rel\":\"\"},{\"name\":\"Iowa\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fiowa-covid-cases.html\",\"slug\":\"us\u002Fiowa-covid-cases\",\"rel\":\"\"},{\"name\":\"Kansas\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fkansas-covid-cases.html\",\"slug\":\"us\u002Fkansas-covid-cases\",\"rel\":\"\"},{\"name\":\"Kentucky\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fkentucky-covid-cases.html\",\"slug\":\"us\u002Fkentucky-covid-cases\",\"rel\":\"\"},{\"name\":\"Louisiana\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Flouisiana-covid-cases.html\",\"slug\":\"us\u002Flouisiana-covid-cases\",\"rel\":\"\"},{\"name\":\"Maine\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmaine-covid-cases.html\",\"slug\":\"us\u002Fmaine-covid-cases\",\"rel\":\"\"},{\"name\":\"Maryland\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmaryland-covid-cases.html\",\"slug\":\"us\u002Fmaryland-covid-cases\",\"rel\":\"\"},{\"name\":\"Massachusetts\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmassachusetts-covid-cases.html\",\"slug\":\"us\u002Fmassachusetts-covid-cases\",\"rel\":\"\"},{\"name\":\"Michigan\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmichigan-covid-cases.html\",\"slug\":\"us\u002Fmichigan-covid-cases\",\"rel\":\"\"},{\"name\":\"Minnesota\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fminnesota-covid-cases.html\",\"slug\":\"us\u002Fminnesota-covid-cases\",\"rel\":\"\"},{\"name\":\"Mississippi\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmississippi-covid-cases.html\",\"slug\":\"us\u002Fmississippi-covid-cases\",\"rel\":\"\"},{\"name\":\"Missouri\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmissouri-covid-cases.html\",\"slug\":\"us\u002Fmissouri-covid-cases\",\"rel\":\"\"},{\"name\":\"Montana\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fmontana-covid-cases.html\",\"slug\":\"us\u002Fmontana-covid-cases\",\"rel\":\"\"},{\"name\":\"Nebraska\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnebraska-covid-cases.html\",\"slug\":\"us\u002Fnebraska-covid-cases\",\"rel\":\"\"},{\"name\":\"Nevada\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnevada-covid-cases.html\",\"slug\":\"us\u002Fnevada-covid-cases\",\"rel\":\"\"},{\"name\":\"New Hampshire\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnew-hampshire-covid-cases.html\",\"slug\":\"us\u002Fnew-hampshire-covid-cases\",\"rel\":\"\"},{\"name\":\"New Jersey\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnew-jersey-covid-cases.html\",\"slug\":\"us\u002Fnew-jersey-covid-cases\",\"rel\":\"\"},{\"name\":\"New Mexico\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnew-mexico-covid-cases.html\",\"slug\":\"us\u002Fnew-mexico-covid-cases\",\"rel\":\"\"},{\"name\":\"New York\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnew-york-covid-cases.html\",\"slug\":\"us\u002Fnew-york-covid-cases\",\"rel\":\"\"},{\"name\":\"North Carolina\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnorth-carolina-covid-cases.html\",\"slug\":\"us\u002Fnorth-carolina-covid-cases\",\"rel\":\"\"},{\"name\":\"North Dakota\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnorth-dakota-covid-cases.html\",\"slug\":\"us\u002Fnorth-dakota-covid-cases\",\"rel\":\"\"},{\"name\":\"Northern Mariana Islands\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fnorthern-mariana-islands-covid-cases.html\",\"slug\":\"us\u002Fnorthern-mariana-islands-covid-cases\",\"rel\":\"\"},{\"name\":\"Ohio\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fohio-covid-cases.html\",\"slug\":\"us\u002Fohio-covid-cases\",\"rel\":\"\"},{\"name\":\"Oklahoma\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Foklahoma-covid-cases.html\",\"slug\":\"us\u002Foklahoma-covid-cases\",\"rel\":\"\"},{\"name\":\"Oregon\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Foregon-covid-cases.html\",\"slug\":\"us\u002Foregon-covid-cases\",\"rel\":\"\"},{\"name\":\"Pennsylvania\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fpennsylvania-covid-cases.html\",\"slug\":\"us\u002Fpennsylvania-covid-cases\",\"rel\":\"\"},{\"name\":\"Puerto Rico\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fpuerto-rico-covid-cases.html\",\"slug\":\"us\u002Fpuerto-rico-covid-cases\",\"rel\":\"\"},{\"name\":\"Rhode Island\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Frhode-island-covid-cases.html\",\"slug\":\"us\u002Frhode-island-covid-cases\",\"rel\":\"\"},{\"name\":\"South Carolina\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fsouth-carolina-covid-cases.html\",\"slug\":\"us\u002Fsouth-carolina-covid-cases\",\"rel\":\"\"},{\"name\":\"South Dakota\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fsouth-dakota-covid-cases.html\",\"slug\":\"us\u002Fsouth-dakota-covid-cases\",\"rel\":\"\"},{\"name\":\"Tennessee\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Ftennessee-covid-cases.html\",\"slug\":\"us\u002Ftennessee-covid-cases\",\"rel\":\"\"},{\"name\":\"Texas\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Ftexas-covid-cases.html\",\"slug\":\"us\u002Ftexas-covid-cases\",\"rel\":\"\"},{\"name\":\"U.S. Virgin Islands\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fvirgin-islands-covid-cases.html\",\"slug\":\"us\u002Fvirgin-islands-covid-cases\",\"rel\":\"\"},{\"name\":\"Utah\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Futah-covid-cases.html\",\"slug\":\"us\u002Futah-covid-cases\",\"rel\":\"\"},{\"name\":\"Vermont\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fvermont-covid-cases.html\",\"slug\":\"us\u002Fvermont-covid-cases\",\"rel\":\"\"},{\"name\":\"Virginia\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fvirginia-covid-cases.html\",\"slug\":\"us\u002Fvirginia-covid-cases\",\"rel\":\"\"},{\"name\":\"Washington\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fwashington-covid-cases.html\",\"slug\":\"us\u002Fwashington-covid-cases\",\"rel\":\"\"},{\"name\":\"Washington, D.C.\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fwashington-district-of-columbia-covid-cases.html\",\"slug\":\"us\u002Fwashington-district-of-columbia-covid-cases\",\"rel\":\"\"},{\"name\":\"West Virginia\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fwest-virginia-covid-cases.html\",\"slug\":\"us\u002Fwest-virginia-covid-cases\",\"rel\":\"\"},{\"name\":\"Wisconsin\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fwisconsin-covid-cases.html\",\"slug\":\"us\u002Fwisconsin-covid-cases\",\"rel\":\"\"},{\"name\":\"Wyoming\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fus\u002Fwyoming-covid-cases.html\",\"slug\":\"us\u002Fwyoming-covid-cases\",\"rel\":\"\"}]},{\"icon\":\"images\u002Fmaps\u002FNYT-World\u002Fhotspots.png\",\"section\":\"world\",\"primary\":[{\"name\":\"Latest Maps and Data\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fcovid-cases.html\",\"rel\":\"\"},{\"name\":\"Vaccinations by Country\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fcovid-vaccinations-tracker.html\",\"rel\":\"external\"}],\"secondary\":[{\"name\":\"Australia\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Faustralia-covid-cases.html\",\"slug\":\"world\u002Faustralia-covid-cases\",\"rel\":\"\"},{\"name\":\"Brazil\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fbrazil-covid-cases.html\",\"slug\":\"world\u002Fbrazil-covid-cases\",\"rel\":\"\"},{\"name\":\"Canada\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fcanada-covid-cases.html\",\"slug\":\"world\u002Fcanada-covid-cases\",\"rel\":\"\"},{\"name\":\"France\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Ffrance-covid-cases.html\",\"slug\":\"world\u002Ffrance-covid-cases\",\"rel\":\"\"},{\"name\":\"Germany\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fgermany-covid-cases.html\",\"slug\":\"world\u002Fgermany-covid-cases\",\"rel\":\"\"},{\"name\":\"India\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Findia-covid-cases.html\",\"slug\":\"world\u002Findia-covid-cases\",\"rel\":\"\"},{\"name\":\"Italy\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fitaly-covid-cases.html\",\"slug\":\"world\u002Fitaly-covid-cases\",\"rel\":\"\"},{\"name\":\"Japan\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fjapan-covid-cases.html\",\"slug\":\"world\u002Fjapan-covid-cases\",\"rel\":\"\"},{\"name\":\"Mexico\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fmexico-covid-cases.html\",\"slug\":\"world\u002Fmexico-covid-cases\",\"rel\":\"\"},{\"name\":\"Spain\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Fspain-covid-cases.html\",\"slug\":\"world\u002Fspain-covid-cases\",\"rel\":\"\"},{\"name\":\"U.K.\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fworld\u002Funited-kingdom-covid-cases.html\",\"slug\":\"world\u002Funited-kingdom-covid-cases\",\"rel\":\"\"}]},{\"icon\":\"images\u002Fhealth-icon.png\",\"section\":\"health\",\"primary\":[{\"name\":\"Vaccine Development\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fscience\u002Fcoronavirus-vaccine-tracker.html\",\"rel\":\"external\"},{\"name\":\"Coronavirus Variants\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fhealth\u002Fcoronavirus-variant-tracker.html\",\"rel\":\"external\"},{\"name\":\"Treatments\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fscience\u002Fcoronavirus-drugs-treatments.html\",\"rel\":\"external\"},{\"name\":\"Answers to Your Covid-19 Questions\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fworld\u002Fcoronavirus-tips-advice.html\",\"rel\":\"external\"},{\"name\":\"How the Covid-19 Vaccines Work\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2021\u002Fhealth\u002Fhow-covid-19-vaccines-work.html\",\"rel\":\"external\"},{\"name\":\"Symptoms of Covid-19\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002F08\u002F05\u002Fwell\u002Fcovid-19-symptoms.html\",\"rel\":\"external\"},{\"name\":\"What Happens in an Infection\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002F10\u002F02\u002Fscience\u002Fcharting-a-coronavirus-infection.html\",\"rel\":\"external\"},{\"name\":\"How Masks Work\",\"url\":\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002F10\u002F30\u002Fscience\u002Fwear-mask-covid-particles-ul.html\",\"rel\":\"external\"}],\"secondary\":[]}]}"}</script>
		
              </div>
              

<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>




     

    </div>
    <!-- If just "top" place header outside of div -->
    <div class="g-header-container"></div>
  


  
  <script id="nytg-dynamic-script_top">
  	(function() {
  		// move header to new location
  		var container = document.querySelector(".g-header-container");
  		var header = document.querySelector(".interactive-header");
      if ( container && header ) {
        container.appendChild(header);
        document.querySelector("#app").classList.add("has-top-cover");
      }
  	})(); 
  </script>
  

  


 

<!-- LINKS -->



<!-- story-body -->

<div class="g-story g-freebird g-max-limit " data-preview-slug="2020-09-10-coronavirus-vaccine-tracker">
    <!-- data preprocessed in process/process-data.js -->
    <!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic"  style="max-width: 800px">

<!-- Intro elements -->








<div role="img" aria-label="Graphic showing how many vaccines are in each phase of the approval process.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.113.0 - 2022-08-26 08:56 -->
<!-- ai file: phases.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-phases-box ,
	#g-phases-box .g-artboard {
		margin:0 auto;
	}
	#g-phases-box p {
		margin:0;
	}
	#g-phases-box .g-aiAbs {
		position:absolute;
	}
	#g-phases-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-phases-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-phases-box .g-aiPointText p { white-space: nowrap; }
	#g-phases-750 {
		position:relative;
		overflow:hidden;
	}
	#g-phases-750 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0.05em;
		font-size:14px;
		text-align:left;
		color:rgb(51,51,51);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-phases-750 .g-pstyle0 {
		height:17px;
		text-align:center;
		position:relative;
	}
	#g-phases-750 .g-pstyle1 {
		height:17px;
		letter-spacing:0.04em;
		text-align:center;
		position:relative;
	}
	#g-phases-750 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:400;
		line-height:72px;
		height:72px;
		letter-spacing:0em;
		font-size:60px;
		text-align:center;
		color:rgb(255,255,255);
	}
	#g-phases-750 .g-pstyle3 {
		font-weight:500;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(115,144,166);
		top:1.2px;
		position:relative;
	}
	#g-phases-750 .g-pstyle4 {
		font-weight:500;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(84,125,158);
		top:1.2px;
		position:relative;
	}
	#g-phases-750 .g-pstyle5 {
		font-weight:500;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(0,99,148);
		top:1.2px;
		position:relative;
	}
	#g-phases-750 .g-pstyle6 {
		font-weight:500;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(77,128,117);
		top:1.2px;
		position:relative;
	}
	#g-phases-750 .g-pstyle7 {
		font-weight:500;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(61,102,93);
		top:1.2px;
		position:relative;
	}
	#g-phases-750 .g-pstyle8 {
		font-weight:500;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(169,50,50);
		top:1.2px;
		position:relative;
	}
	#g-phases-750 .g-pstyle9 {
		font-style:italic;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(100,135,162);
		top:1.2px;
		position:relative;
	}
	#g-phases-750 .g-pstyle10 {
		font-style:italic;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(42,112,153);
		top:1.2px;
		position:relative;
	}
	#g-phases-600 {
		position:relative;
		overflow:hidden;
	}
	#g-phases-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:500;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,99,148);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-phases-600 .g-pstyle0 {
		font-weight:300;
		line-height:17px;
		height:17px;
		letter-spacing:0.07em;
		font-size:14px;
		text-align:center;
		color:rgb(51,51,51);
		top:1.1px;
		position:relative;
	}
	#g-phases-600 .g-pstyle1 {
		font-weight:300;
		line-height:17px;
		height:17px;
		letter-spacing:0.06em;
		font-size:14px;
		text-align:center;
		color:rgb(51,51,51);
		top:1.1px;
		position:relative;
	}
	#g-phases-600 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:400;
		line-height:72px;
		height:72px;
		font-size:60px;
		text-align:center;
		color:rgb(255,255,255);
	}
	#g-phases-600 .g-pstyle3 {
		height:18px;
		text-align:center;
		color:rgb(115,144,166);
		position:relative;
	}
	#g-phases-600 .g-pstyle4 {
		height:18px;
		text-align:center;
		color:rgb(84,125,158);
		position:relative;
	}
	#g-phases-600 .g-pstyle5 {
		height:18px;
		text-align:center;
		position:relative;
	}
	#g-phases-600 .g-pstyle6 {
		height:18px;
		text-align:center;
		color:rgb(77,128,117);
		position:relative;
	}
	#g-phases-600 .g-pstyle7 {
		height:18px;
		text-align:center;
		color:rgb(61,102,93);
		position:relative;
	}
	#g-phases-600 .g-pstyle8 {
		height:18px;
		text-align:center;
		color:rgb(169,50,50);
		position:relative;
	}
	#g-phases-335 {
		position:relative;
		overflow:hidden;
	}
	#g-phases-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0.05em;
		font-size:14px;
		text-align:left;
		color:rgb(51,51,51);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-phases-335 .g-pstyle0 {
		height:17px;
		text-align:center;
		position:relative;
	}
	#g-phases-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:400;
		line-height:64px;
		height:64px;
		letter-spacing:0em;
		font-size:53px;
		text-align:center;
		color:rgb(255,255,255);
	}
	#g-phases-335 .g-pstyle2 {
		font-weight:500;
		height:17px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(115,144,166);
		top:1.2px;
		position:relative;
	}
	#g-phases-335 .g-pstyle3 {
		font-weight:500;
		height:17px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(84,125,158);
		top:1.2px;
		position:relative;
	}
	#g-phases-335 .g-pstyle4 {
		font-weight:500;
		height:17px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(0,99,148);
		top:1.2px;
		position:relative;
	}
	#g-phases-335 .g-pstyle5 {
		font-weight:500;
		height:17px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(77,128,117);
		top:1.2px;
		position:relative;
	}
	#g-phases-335 .g-pstyle6 {
		font-weight:500;
		height:17px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(61,102,93);
		top:1.2px;
		position:relative;
	}
	#g-phases-335 .g-pstyle7 {
		font-weight:500;
		height:17px;
		letter-spacing:0em;
		font-size:15px;
		text-align:center;
		color:rgb(169,50,50);
		top:1.2px;
		position:relative;
	}
	#g-phases-300 {
		position:relative;
		overflow:hidden;
	}
	#g-phases-300 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0.05em;
		font-size:14px;
		text-align:left;
		color:rgb(51,51,51);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-phases-300 .g-pstyle0 {
		height:17px;
		text-align:center;
		position:relative;
	}
	#g-phases-300 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:400;
		line-height:64px;
		height:64px;
		letter-spacing:0em;
		font-size:53px;
		text-align:center;
		color:rgb(255,255,255);
	}
	#g-phases-300 .g-pstyle2 {
		font-weight:500;
		line-height:15px;
		height:15px;
		letter-spacing:0em;
		font-size:13px;
		text-align:center;
		color:rgb(115,144,166);
		top:1px;
		position:relative;
	}
	#g-phases-300 .g-pstyle3 {
		font-weight:500;
		line-height:15px;
		height:15px;
		letter-spacing:0em;
		font-size:13px;
		text-align:center;
		color:rgb(84,125,158);
		top:1px;
		position:relative;
	}
	#g-phases-300 .g-pstyle4 {
		font-weight:500;
		line-height:15px;
		height:15px;
		letter-spacing:0em;
		font-size:13px;
		text-align:center;
		color:rgb(0,99,148);
		top:1px;
		position:relative;
	}
	#g-phases-300 .g-pstyle5 {
		font-weight:500;
		line-height:15px;
		height:15px;
		letter-spacing:0em;
		font-size:13px;
		text-align:center;
		color:rgb(77,128,117);
		top:1px;
		position:relative;
	}
	#g-phases-300 .g-pstyle6 {
		font-weight:500;
		line-height:15px;
		height:15px;
		letter-spacing:0em;
		font-size:13px;
		text-align:center;
		color:rgb(61,102,93);
		top:1px;
		position:relative;
	}
	#g-phases-300 .g-pstyle7 {
		font-weight:500;
		line-height:15px;
		height:15px;
		letter-spacing:0em;
		font-size:13px;
		text-align:center;
		color:rgb(169,50,50);
		top:1px;
		position:relative;
	}

</style>

<div id="g-phases-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 750 -->
	<div id="g-phases-750" class="g-artboard" style="width:750px; height:172px;" data-aspect-ratio="4.36" data-min-width="750">
<div style=""></div>
		<img id="g-phases-750-img" class="g-phases-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/phases-750.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-phases_copy g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:6.6263%;margin-left:-40px;width:80px;">
			<p class="g-pstyle0">PHASE 1</p>
		</div>
		<div id="g-ai0-2" class="g-phases_copy g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:18.936%;margin-left:-48px;width:96px;">
			<p class="g-pstyle0">PHASE 1/2</p>
		</div>
		<div id="g-ai0-3" class="g-phases_copy g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:32.1737%;margin-left:-40px;width:80px;">
			<p class="g-pstyle0">PHASE 2</p>
		</div>
		<div id="g-ai0-4" class="g-phases_copy g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:44.6077%;margin-left:-48px;width:96px;">
			<p class="g-pstyle0">PHASE 2/3</p>
		</div>
		<div id="g-ai0-5" class="g-phases_copy g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:57.8454%;margin-left:-40px;width:80px;">
			<p class="g-pstyle0">PHASE 3</p>
		</div>
		<div id="g-ai0-6" class="g-phases_copy g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:69.7653%;margin-left:-53.5px;width:107px;">
			<p class="g-pstyle1">AUTHORIZED</p>
		</div>
		<div id="g-ai0-7" class="g-phases_copy g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:82.1296%;margin-left:-47px;width:94px;">
			<p class="g-pstyle1">APPROVED</p>
		</div>
		<div id="g-ai0-8" class="g-phases_copy g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:94.3364%;margin-left:-53px;width:106px;">
			<p class="g-pstyle1">ABANDONED</p>
		</div>
		<div id="g-ai0-9" class="g-phases_copy g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:6.6526%;margin-left:-42px;width:84px;">
			<p class="g-pstyle2">36</p>
		</div>
		<div id="g-ai0-10" class="g-phases_copy g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:19.6943%;margin-left:-37.5px;width:75px;">
			<p class="g-pstyle2">18</p>
		</div>
		<div id="g-ai0-11" class="g-phases_copy g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:32.562%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle2">17</p>
		</div>
		<div id="g-ai0-12" class="g-phases_copy g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:45.4115%;margin-left:-39.5px;width:79px;">
			<p class="g-pstyle2">10</p>
		</div>
		<div id="g-ai0-13" class="g-phases_copy g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:58.1831%;margin-left:-40.5px;width:81px;">
			<p class="g-pstyle2">42</p>
		</div>
		<div id="g-ai0-14" class="g-phases_copy g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:70.4624%;margin-left:-37px;width:74px;">
			<p class="g-pstyle2">21</p>
		</div>
		<div id="g-ai0-15" class="g-phases_copy g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:82.1806%;margin-left:-37px;width:74px;">
			<p class="g-pstyle2">12</p>
		</div>
		<div id="g-ai0-16" class="g-phases_copy g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:94.2714%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle2">17</p>
		</div>
		<div id="g-ai0-17" class="g-phases_copy g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:6.6481%;margin-left:-53.5px;width:107px;">
			<p class="g-pstyle3">Vaccines</p>
			<p class="g-pstyle3">testing safety</p>
			<p class="g-pstyle3">and dosage</p>
		</div>
		<div id="g-ai0-18" class="g-phases_copy g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:32.167%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle4">Vaccines</p>
			<p class="g-pstyle4">in expanded</p>
			<p class="g-pstyle4">safety trials</p>
		</div>
		<div id="g-ai0-19" class="g-phases_copy g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:57.8379%;margin-left:-53.5px;width:107px;">
			<p class="g-pstyle5">Vaccines</p>
			<p class="g-pstyle5">in large-scale</p>
			<p class="g-pstyle5">efficacy tests</p>
		</div>
		<div id="g-ai0-20" class="g-phases_copy g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:70.2829%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle6">Vaccines</p>
			<p class="g-pstyle6">in early or </p>
			<p class="g-pstyle6">limited use</p>
		</div>
		<div id="g-ai0-21" class="g-phases_copy g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:82.124%;margin-left:-44px;width:88px;">
			<p class="g-pstyle7">Vaccines</p>
			<p class="g-pstyle7">approved</p>
			<p class="g-pstyle7">for full use</p>
		</div>
		<div id="g-ai0-22" class="g-phases_copy g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:94.243%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle8">Vaccines</p>
			<p class="g-pstyle8">abandoned</p>
			<p class="g-pstyle8">after trials</p>
		</div>
		<div id="g-ai0-23" class="g-phases_copy g-aiAbs g-aiPointText" style="top:80.3765%;margin-top:-18.2px;left:19.3749%;margin-left:-42.5px;width:85px;">
			<p class="g-pstyle9">Combined</p>
			<p class="g-pstyle9">trials</p>
		</div>
		<div id="g-ai0-24" class="g-phases_copy g-aiAbs g-aiPointText" style="top:80.3765%;margin-top:-18.2px;left:44.9846%;margin-left:-42.5px;width:85px;">
			<p class="g-pstyle10">Combined</p>
			<p class="g-pstyle10">trials</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-phases-600" class="g-artboard" style="width:600px; height:172px;" data-aspect-ratio="3.488" data-min-width="600" data-max-width="749">
<div style=""></div>
		<img id="g-phases-600-img" class="g-phases-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/phases-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-phases g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:8.9355%;margin-left:-41px;width:82px;">
			<p class="g-pstyle0">PHASE 1</p>
		</div>
		<div id="g-ai1-2" class="g-phases g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:26.0352%;margin-left:-41px;width:82px;">
			<p class="g-pstyle0">PHASE 2</p>
		</div>
		<div id="g-ai1-3" class="g-phases g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:43.3021%;margin-left:-41px;width:82px;">
			<p class="g-pstyle0">PHASE 3</p>
		</div>
		<div id="g-ai1-4" class="g-phases g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:59.3576%;margin-left:-55px;width:110px;">
			<p class="g-pstyle1">AUTHORIZED</p>
		</div>
		<div id="g-ai1-5" class="g-phases g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:75.9544%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">APPROVED</p>
		</div>
		<div id="g-ai1-6" class="g-phases g-aiAbs g-aiPointText" style="top:5.6778%;margin-top:-8.8px;left:92.4395%;margin-left:-54.5px;width:109px;">
			<p class="g-pstyle1">ABANDONED</p>
		</div>
		<div id="g-ai1-7" class="g-phases g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:8.9318%;margin-left:-41px;width:82px;">
			<p class="g-pstyle2">54</p>
		</div>
		<div id="g-ai1-8" class="g-phases g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:26.466%;margin-left:-41px;width:82px;">
			<p class="g-pstyle2">45</p>
		</div>
		<div id="g-ai1-9" class="g-phases g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:43.805%;margin-left:-40.5px;width:81px;">
			<p class="g-pstyle2">52</p>
		</div>
		<div id="g-ai1-10" class="g-phases g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:60.255%;margin-left:-37px;width:74px;">
			<p class="g-pstyle2">21</p>
		</div>
		<div id="g-ai1-11" class="g-phases g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:76.0216%;margin-left:-37px;width:74px;">
			<p class="g-pstyle2">12</p>
		</div>
		<div id="g-ai1-12" class="g-phases g-aiAbs g-aiPointText" style="top:37.5522%;margin-top:-37.6px;left:92.2891%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle2">17</p>
		</div>
		<div id="g-ai1-13" class="g-phases g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:8.9427%;margin-left:-53.5px;width:107px;">
			<p class="g-pstyle3">Vaccines</p>
			<p class="g-pstyle3">testing safety</p>
			<p class="g-pstyle3">and dosage</p>
		</div>
		<div id="g-ai1-14" class="g-phases g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:26.0068%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle4">Vaccines</p>
			<p class="g-pstyle4">in expanded</p>
			<p class="g-pstyle4">safety trials</p>
		</div>
		<div id="g-ai1-15" class="g-phases g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:43.2729%;margin-left:-53.5px;width:107px;">
			<p class="g-pstyle5">Vaccines</p>
			<p class="g-pstyle5">in large-scale</p>
			<p class="g-pstyle5">efficacy tests</p>
		</div>
		<div id="g-ai1-16" class="g-phases g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:60.0187%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle6">Vaccines</p>
			<p class="g-pstyle6">in early or </p>
			<p class="g-pstyle6">limited use</p>
		</div>
		<div id="g-ai1-17" class="g-phases g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:75.9508%;margin-left:-44px;width:88px;">
			<p class="g-pstyle7">Vaccines</p>
			<p class="g-pstyle7">approved</p>
			<p class="g-pstyle7">for full use</p>
		</div>
		<div id="g-ai1-18" class="g-phases g-aiAbs g-aiPointText" style="top:80.3982%;margin-top:-27.3px;left:92.2536%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle8">Vaccines</p>
			<p class="g-pstyle8">abandoned</p>
			<p class="g-pstyle8">after trials</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-phases-335" class="g-artboard" style="width:335px; height:300px;" data-aspect-ratio="1.117" data-min-width="335" data-max-width="599">
<div style=""></div>
		<img id="g-phases-335-img" class="g-phases-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/phases-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-phases g-aiAbs g-aiPointText" style="top:2.922%;margin-top:-8.8px;left:16.8657%;margin-left:-40px;width:80px;">
			<p class="g-pstyle0">PHASE 1</p>
		</div>
		<div id="g-ai2-2" class="g-phases g-aiAbs g-aiPointText" style="top:2.922%;margin-top:-8.8px;left:50.0437%;margin-left:-40px;width:80px;">
			<p class="g-pstyle0">PHASE 2</p>
		</div>
		<div id="g-ai2-3" class="g-phases g-aiAbs g-aiPointText" style="top:2.922%;margin-top:-8.8px;left:83.1343%;margin-left:-40px;width:80px;">
			<p class="g-pstyle0">PHASE 3</p>
		</div>
		<div id="g-ai2-4" class="g-phases g-aiAbs g-aiPointText" style="top:18.1348%;margin-top:-33.4px;left:16.8374%;margin-left:-37.5px;width:75px;">
			<p class="g-pstyle1">54</p>
		</div>
		<div id="g-ai2-5" class="g-phases g-aiAbs g-aiPointText" style="top:18.1348%;margin-top:-33.4px;left:50.5096%;margin-left:-37.5px;width:75px;">
			<p class="g-pstyle1">45</p>
		</div>
		<div id="g-ai2-6" class="g-phases g-aiAbs g-aiPointText" style="top:18.1348%;margin-top:-33.4px;left:83.3981%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">52</p>
		</div>
		<div id="g-ai2-7" class="g-phases g-aiAbs g-aiPointText" style="top:38.9283%;margin-top:-25.8px;left:16.8601%;margin-left:-53.5px;width:107px;">
			<p class="g-pstyle2">Vaccines</p>
			<p class="g-pstyle2">testing safety</p>
			<p class="g-pstyle2">and dosage</p>
		</div>
		<div id="g-ai2-8" class="g-phases g-aiAbs g-aiPointText" style="top:38.9283%;margin-top:-25.8px;left:49.9746%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle3">Vaccines</p>
			<p class="g-pstyle3">in expanded</p>
			<p class="g-pstyle3">safety trials</p>
		</div>
		<div id="g-ai2-9" class="g-phases g-aiAbs g-aiPointText" style="top:38.9283%;margin-top:-25.8px;left:83.0641%;margin-left:-53.5px;width:107px;">
			<p class="g-pstyle4">Vaccines</p>
			<p class="g-pstyle4">in large-scale</p>
			<p class="g-pstyle4">efficacy tests</p>
		</div>
		<div id="g-ai2-10" class="g-phases g-aiAbs g-aiPointText" style="top:55.922%;margin-top:-8.8px;left:16.5747%;margin-left:-54.5px;width:109px;">
			<p class="g-pstyle0">AUTHORIZED</p>
		</div>
		<div id="g-ai2-11" class="g-phases g-aiAbs g-aiPointText" style="top:55.922%;margin-top:-8.8px;left:50.0029%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle0">APPROVED</p>
		</div>
		<div id="g-ai2-12" class="g-phases g-aiAbs g-aiPointText" style="top:55.922%;margin-top:-8.8px;left:83.0416%;margin-left:-53.5px;width:107px;">
			<p class="g-pstyle0">ABANDONED</p>
		</div>
		<div id="g-ai2-13" class="g-phases g-aiAbs g-aiPointText" style="top:71.1348%;margin-top:-33.4px;left:17.1831%;margin-left:-34px;width:68px;">
			<p class="g-pstyle1">21</p>
		</div>
		<div id="g-ai2-14" class="g-phases g-aiAbs g-aiPointText" style="top:71.1348%;margin-top:-33.4px;left:50.0624%;margin-left:-34px;width:68px;">
			<p class="g-pstyle1">12</p>
		</div>
		<div id="g-ai2-15" class="g-phases g-aiAbs g-aiPointText" style="top:71.1348%;margin-top:-33.4px;left:83.1087%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">17</p>
		</div>
		<div id="g-ai2-16" class="g-phases g-aiAbs g-aiPointText" style="top:91.9283%;margin-top:-25.8px;left:16.7581%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle5">Vaccines</p>
			<p class="g-pstyle5">in early or </p>
			<p class="g-pstyle5">limited use</p>
		</div>
		<div id="g-ai2-17" class="g-phases g-aiAbs g-aiPointText" style="top:91.9283%;margin-top:-25.8px;left:49.9335%;margin-left:-44px;width:88px;">
			<p class="g-pstyle6">Vaccines</p>
			<p class="g-pstyle6">approved</p>
			<p class="g-pstyle6">for full use</p>
		</div>
		<div id="g-ai2-18" class="g-phases g-aiAbs g-aiPointText" style="top:91.9283%;margin-top:-25.8px;left:83.0967%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle7">Vaccines</p>
			<p class="g-pstyle7">abandoned</p>
			<p class="g-pstyle7">after trials</p>
		</div>
	</div>

	<!-- Artboard: 300 -->
	<div id="g-phases-300" class="g-artboard" style="max-width: 300px;max-height: 290px" data-aspect-ratio="1.034" data-min-width="0" data-max-width="334">
<div style="padding: 0 0 96.6667% 0;"></div>
		<img id="g-phases-300-img" class="g-phases-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/phases-300.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-phases g-aiAbs g-aiPointText" style="top:3.0227%;margin-top:-8.8px;left:16.8333%;margin-left:-40px;width:80px;">
			<p class="g-pstyle0">PHASE 1</p>
		</div>
		<div id="g-ai3-2" class="g-phases g-aiAbs g-aiPointText" style="top:3.0227%;margin-top:-8.8px;left:50.0488%;margin-left:-40px;width:80px;">
			<p class="g-pstyle0">PHASE 2</p>
		</div>
		<div id="g-ai3-3" class="g-phases g-aiAbs g-aiPointText" style="top:3.0227%;margin-top:-8.8px;left:83.1667%;margin-left:-40px;width:80px;">
			<p class="g-pstyle0">PHASE 3</p>
		</div>
		<div id="g-ai3-4" class="g-phases g-aiAbs g-aiPointText" style="top:18.7601%;margin-top:-33.4px;left:16.8018%;margin-left:-37.5px;width:75px;">
			<p class="g-pstyle1">54</p>
		</div>
		<div id="g-ai3-5" class="g-phases g-aiAbs g-aiPointText" style="top:18.7601%;margin-top:-33.4px;left:50.569%;margin-left:-37.5px;width:75px;">
			<p class="g-pstyle1">45</p>
		</div>
		<div id="g-ai3-6" class="g-phases g-aiAbs g-aiPointText" style="top:18.7601%;margin-top:-33.4px;left:83.4613%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">52</p>
		</div>
		<div id="g-ai3-7" class="g-phases g-aiAbs g-aiPointText" style="top:39.223%;margin-top:-22.7px;left:16.7093%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle2">Vaccines</p>
			<p class="g-pstyle2">testing safety</p>
			<p class="g-pstyle2">and dosage</p>
		</div>
		<div id="g-ai3-8" class="g-phases g-aiAbs g-aiPointText" style="top:39.223%;margin-top:-22.7px;left:50.0186%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle3">Vaccines</p>
			<p class="g-pstyle3">in expanded</p>
			<p class="g-pstyle3">safety trials</p>
		</div>
		<div id="g-ai3-9" class="g-phases g-aiAbs g-aiPointText" style="top:39.223%;margin-top:-22.7px;left:83.1465%;margin-left:-48px;width:96px;">
			<p class="g-pstyle4">Vaccines</p>
			<p class="g-pstyle4">in large-scale</p>
			<p class="g-pstyle4">efficacy tests</p>
		</div>
		<div id="g-ai3-10" class="g-phases g-aiAbs g-aiPointText" style="top:55.7813%;margin-top:-8.8px;left:16.1751%;margin-left:-54.5px;width:109px;">
			<p class="g-pstyle0">AUTHORIZED</p>
		</div>
		<div id="g-ai3-11" class="g-phases g-aiAbs g-aiPointText" style="top:55.7813%;margin-top:-8.8px;left:50.0033%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle0">APPROVED</p>
		</div>
		<div id="g-ai3-12" class="g-phases g-aiAbs g-aiPointText" style="top:55.7813%;margin-top:-8.8px;left:83.0632%;margin-left:-53.5px;width:107px;">
			<p class="g-pstyle0">ABANDONED</p>
		</div>
		<div id="g-ai3-13" class="g-phases g-aiAbs g-aiPointText" style="top:71.5187%;margin-top:-33.4px;left:17.1878%;margin-left:-34px;width:68px;">
			<p class="g-pstyle1">21</p>
		</div>
		<div id="g-ai3-14" class="g-phases g-aiAbs g-aiPointText" style="top:71.5187%;margin-top:-33.4px;left:50.0697%;margin-left:-34px;width:68px;">
			<p class="g-pstyle1">12</p>
		</div>
		<div id="g-ai3-15" class="g-phases g-aiAbs g-aiPointText" style="top:71.5187%;margin-top:-33.4px;left:83.138%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">17</p>
		</div>
		<div id="g-ai3-16" class="g-phases g-aiAbs g-aiPointText" style="top:91.9817%;margin-top:-22.7px;left:16.7549%;margin-left:-41px;width:82px;">
			<p class="g-pstyle5">Vaccines</p>
			<p class="g-pstyle5">in early or </p>
			<p class="g-pstyle5">limited use</p>
		</div>
		<div id="g-ai3-17" class="g-phases g-aiAbs g-aiPointText" style="top:91.9817%;margin-top:-22.7px;left:50.0677%;margin-left:-40px;width:80px;">
			<p class="g-pstyle6">Vaccines</p>
			<p class="g-pstyle6">approved</p>
			<p class="g-pstyle6">for full use</p>
		</div>
		<div id="g-ai3-18" class="g-phases g-aiAbs g-aiPointText" style="top:91.9817%;margin-top:-22.7px;left:83.0335%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle7">Vaccines</p>
			<p class="g-pstyle7">abandoned</p>
			<p class="g-pstyle7">after trials</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-phases-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-08-26 08:56 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>

<p class="g-body g-alert" >
	This tracker is no longer being updated. It followed the development of Covid vaccines from early 2020 through August 2022. More than 120 clinical trials were underway at that time.<br><br>The Centers for Disease Control and Prevention maintains a list of <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html">Covid vaccines</a> that are authorized or approved in the United States.
</p>
<p class="g-body " >
	Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time.
</p>

<!-- ======= LEADING VACCINES ======= -->

<div class="g-asset g-table"><div><table class="g-vaccine-table"><tbody>

<tr>
<th class="g-table-text g-table-heading g-hed g-news" style="color: #bc3c40" colspan="5">Leading vaccines</th>
</tr>

<tr>
<th class="g-table-text g-table-heading g-small" colspan="2">Developer</th>
<th class="g-table-text g-table-heading g-small">How It Works</th>
<th class="g-table-text g-table-heading g-small" style="text-align: center;">Phase</th>
<th class="g-table-text g-table-heading g-small g-last">Status</th>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-usa.png" width="15px" height="11px" alt="U.S.A." title="U.S.A." class="g-flag1"><br><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-germany.png" width="15px" height="11px" alt="Germany" title="Germany" class="g-flag2"></td>
<td><a href="#pfizer">Pfizer-BioNTech</a></td>
<td class="g-small"><a href="https://www.nytimes.com/interactive/2020/health/pfizer-biontech-covid-19-vaccine.html">mRNA</a></td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in U.S., other countries.<br>Emergency use in many countries.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-china.png" width="15px" height="11px" alt="China" title="China"></td>
<td><a href="#sinopharm">Sinopharm</a></td>
<td class="g-small"><a href="https://www.nytimes.com/interactive/2020/health/sinopharm-covid-19-vaccine.html">Inactivated</a></td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in China, Bahrain.<br>Emergency use in many countries.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-uk.png" width="15px" height="11px" alt="U.K." title="U.K." class="g-flag1"><br><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-sweden.png" width="15px" height="11px" alt="Sweden" title="Sweden" class="g-flag2"></td>
<td><a href="#astrazeneca">Oxford-AstraZeneca</a></td>
<td class="g-small"><a href="https://www.nytimes.com/interactive/2020/health/oxford-astrazeneca-covid-19-vaccine.html">ChAdOx1</a></td>
<td class="g-small g-center"><span class="g-2">2</span><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in Brazil, India.<br>Emergency use in many countries.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-china.png" width="15px" height="11px" alt="China" title="China"></td>
<td><a href="#sinovac">Sinovac</a></td>
<td class="g-small"><a href="https://www.nytimes.com/interactive/2020/health/sinovac-covid-19-vaccine.html">Inactivated</a></td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small">Approved in China.<br>Emergency use in many countries.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-usa.png" width="15px" height="11px" alt="U.S.A." title="U.S.A."></td>
<td><a href="#moderna">Moderna</a></td>
<td class="g-small"><a href="https://www.nytimes.com/interactive/2020/health/moderna-covid-19-vaccine.html">mRNA</a></td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in U.S., Canada, Switzerland.<br>Emergency use in many countries.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-usa.png" width="15px" height="11px" alt="U.S.A." title="U.S.A."></td>
<td><a href="#novavax">Novavax</a></td>
<td class="g-small"><a href="https://www.nytimes.com/interactive/2020/health/novavax-covid-19-vaccine.html">Protein</a></td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in Canada, South Korea.<br>Emergency use in several countries.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-india.png" width="15px" height="11px" alt="India" title="India"></td>
<td><a href="#bharat">Bharat Biotech</a></td>
<td class="g-small"><a href="https://www.nytimes.com/interactive/2021/health/bharat-biotech-covid-19-vaccine.html">Inactivated</a></td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in India.<br>Emergency use in other countries.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-usa.png" width="15px" height="11px" alt="U.S.A." title="U.S.A." class="g-flag1"><br><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-belgium.png" width="15px" height="11px" alt="Belgium" title="Belgium" class="g-flag2"></td>
<td><a href="#jnj">Johnson & Johnson</a></td>
<td class="g-small"><a href="https://www.nytimes.com/interactive/2020/health/johnson-johnson-covid-19-vaccine.html">Ad26</a></td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in Canada. Limited in U.S.<br>Emergency use in many countries.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-usa.png" width="15px" height="11px" alt="U.S.A." title="U.S.A." class="g-flag1"><br><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-india.png" width="15px" height="11px" alt="India" title="India" class="g-flag2"></td>
<td><a href="#baylor">Baylor-Biological&nbsp;E</a></td>
<td class="g-small">Protein</td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Emergency use in India, Botswana.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-russia.png" width="15px" height="11px" alt="Russia" title="Russia"></td>
<td><a href="#gamaleya">Gamaleya</a></td>
<td class="g-small"><a href="https://www.nytimes.com/interactive/2021/health/gamaleya-covid-19-vaccine.html">Ad26, Ad5</a></td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in Russia.<br>Emergency use in many countries.</td>
</tr>

<!-- <tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-china.png" width="15px" height="11px" alt="China" title="China"></td>
<td><a href="#cansino">CanSino</a></td>
<td class="g-small">Ad5</td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in China.<br> Emergency use in other countries.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-russia.png" width="15px" height="11px" alt="Russia" title="Russia"></td>
<td><a href="#vector">Vector Institute</a></td>
<td class="g-small">Protein</td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in Turkmenistan.<br>Early use in Russia.</td>
</tr>

<tr>
<td class="g-flag-bullet"><img src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/flag-china.png" width="15px" height="11px" alt="China" title="China"></td>
<td><a href="#wuhan">Sinopharm-Wuhan</a></td>
<td class="g-small">Inactivated</td>
<td class="g-small g-center"><span class="g-3">3</span></td>
<td class="g-small g-last">Approved in China.<br>Limited use in U.A.E.</td>
</tr> -->

</tbody></table></div></div><p class="g-body " >
	Below is a list of all vaccines that have reached trials in humans.  For an explanation of virus variants and mutations, see our <a href="https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html">Coronavirus Variant Tracker</a>. For treatments for Covid-19, see our <a href="https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html">Coronavirus Drug and Treatment Tracker</a>. For an explanation of leading vaccines, see <a href="https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html">How Nine Covid-19 Vaccines Work</a>.
</p>
<h2 class="g-subhed g-optimize-type " id="">
	<span class="g-balancer" data-id="1"><strong>The Vaccine Testing Process</strong></span>
</h2>
<p class="g-body g-description g-optimize-type " id="">
	<span class="g-xbalancer" data-id="2"><em>The development cycle of a vaccine, from lab to clinic.</em></span>
</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic"  style="max-width: 600px">

<!-- Intro elements -->








<div role="region">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.100.0 - 2020-09-10 08:31 -->
<!-- ai file: types.ai -->
<!-- preview: undefined -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-types-box ,
	#g-types-box .g-artboard {
		margin:0 auto;
	}
	#g-types-box p {
		margin:0;
	}
	#g-types-box .g-aiAbs {
		position:absolute;
	}
	#g-types-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-types-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-types-box .g-aiPointText p { white-space: nowrap; }
	#g-types-600 {
		position:relative;
		overflow:hidden;
	}
	#g-types-450 {
		position:relative;
		overflow:hidden;
	}
	#g-types-335 {
		position:relative;
		overflow:hidden;
	}

</style>

<div id="g-types-box" class="ai2html">

	<!-- Artboard: 600 -->
	<div id="g-types-600" class="g-artboard" style="width:600px; height:250px;" data-aspect-ratio="2.4" data-min-width="600">
<div style=""></div>
		<img id="g-types-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/types-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
	</div>

	<!-- Artboard: 450 -->
	<div id="g-types-450" class="g-artboard" style="width:450px; height:250px;" data-aspect-ratio="1.8" data-min-width="450" data-max-width="599">
<div style=""></div>
		<img id="g-types-450-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/types-450.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-types-335" class="g-artboard" style="max-width: 335px;max-height: 250px" data-aspect-ratio="1.34" data-min-width="0" data-max-width="449">
<div style="padding: 0 0 74.6269% 0;"></div>
		<img id="g-types-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/types-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-types-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2020-09-10 08:31 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>

<div class="g-container  g-process" id="">
<p class="g-body " >
	<br><span class="g-phase0">PRECLINICAL TESTING</span>: Scientists test a new vaccine on cells and then give it to <strong>animals</strong> such as mice or monkeys to see if it produces an immune response.
</p>
<p class="g-body " >
	<span class="g-phase1">PHASE 1 SAFETY TRIALS</span>: Scientists give the vaccine to a <strong>small number of people</strong> to test safety and dosage, as well as to confirm that it stimulates the immune system.
</p>
<p class="g-body " >
	<span class="g-phase2">PHASE 2 EXPANDED TRIALS</span>: Scientists give the vaccine to <strong>hundreds of people</strong> split into groups, such as children and the elderly, to see if the vaccine acts differently in them. These trials further test the vaccine’s safety.
</p>
<p class="g-body " >
	<span class="g-phase3">PHASE 3 EFFICACY TRIALS</span>: Scientists give the vaccine to <strong>thousands of people</strong> and wait to see how many become infected, compared with volunteers who received a placebo. These trials can determine if the vaccine protects against the coronavirus, measuring what’s known as the <a href="https://www.nytimes.com/2020/11/20/health/covid-vaccine-95-effective.html">efficacy rate</a>. Phase 3 trials are also large enough to reveal evidence of relatively rare side effects.
</p>
<p class="g-body " >
	<span class="g-limited">EARLY OR LIMITED APPROVAL</span>: Many countries have procedures for providing emergency authorizations for vaccines, based on preliminary evidence that they are safe and effective. In addition, some countries such as <a href="#cansino">China</a> and <a href="#gamaleya">Russia</a> began administering vaccines before detailed Phase 3 trial data was made public. Experts have warned of <a href="https://www.nytimes.com/2020/08/11/health/russia-covid-19-vaccine-safety.html">serious risks</a> from jumping ahead of these results.
</p>
<p class="g-body " >
	<span class="g-approval">APPROVAL</span>: Regulators review the complete trial results and plans for a vaccine’s manufacturing, and decide whether to give it full approval.
</p>
<p class="g-body " >
	<span class="g-combined">COMBINED PHASES</span>: One  way to <a href="https://www.nytimes.com/interactive/2020/04/30/opinion/coronavirus-covid-vaccine.html">accelerate vaccine development</a> is to combine phases. Some vaccines are now in Phase 1/2 trials, for example, which this tracker would count as both Phase 1 and Phase 2.
</p>
<p class="g-body " >
	<span class="g-paused">PAUSED</span> or <span class="g-abandoned">ABANDONED</span>: If investigators observe worrying symptoms in volunteers, they can <a href="https://www.nytimes.com/2020/10/14/health/covid-clinical-trials.html">pause</a> the trial. After an investigation, the trial may resume or be <a href="https://www.nytimes.com/2020/12/11/world/australia/uq-coronavirus-vaccine-false-positive.html">abandoned</a>. Trials may also be abandoned if they indicate a vaccine isn’t effective against Covid-19.
</p>
</div>
<p class="g-body " >
	<!-- FILTER -->
</p>
<!-- ASSET : START -->




<div class="g-asset g-svelte"  style="max-width: 650px">

<!-- Intro elements -->








<div role="region">


          <div class="g-svelte" data-component="3">
            



<div style="text-align: center;"><span class="button-header svelte-i2owh7">Filter the list of vaccines:</span><br>

<button class="all svelte-i2owh7 active">All vaccines</button>



<button class="phase1 svelte-i2owh7">Phase 1</button>

<button class="phase2 svelte-i2owh7">2</button>

<button class="phase3 svelte-i2owh7">3</button>

<button class="approved svelte-i2owh7">Authorized</button>

<button class="abandoned svelte-i2owh7">Abandoned</button>

</div>
          </div>

          
          <script>
            (function(target, url, props) {
              
              let component;

              // TODO capture props. requires compilation in dev mode
              NYTG.watch(url, (mod) => {
                const Component = mod.default;

                try {
                  if (component) component.$destroy();
                  console.log('destroyed component 3');
                } catch (err) {
                  console.error(err);
                  target.innerHTML = '';
                }

                component = new Component({
                  target,
                  hydrate: !component,
                  props
                });
              });
            }(
              document.querySelector('[data-component="3"]'),
              NYTG.ASSETS + '/build/js/filter.js',
              {"amp":false,"color":"none"}
            ));
          </script>
<!-- ASSET : END -->

</div>



</div>

<h2 class="g-subhed g-optimize-type g-sub-hidden g-sub-phase0" id="">
	<span class="g-balancer" data-id="4"><strong>Preclinical Vaccines</strong></span>
</h2>
<h2 class="g-subhed g-optimize-type g-sub-hidden g-sub-phase1" id="">
	<span class="g-balancer" data-id="5"><strong>Phase 1 Vaccines</strong></span>
</h2>
<h2 class="g-subhed g-optimize-type g-sub-hidden g-sub-phase2" id="">
	<span class="g-balancer" data-id="6"><strong>Phase 2 Vaccines</strong></span>
</h2>
<h2 class="g-subhed g-optimize-type g-sub-hidden g-sub-phase3" id="">
	<span class="g-balancer" data-id="7"><strong>Phase 3 Vaccines</strong></span>
</h2>
<h2 class="g-subhed g-optimize-type g-sub-hidden g-sub-approved" id="">
	<span class="g-balancer" data-id="8"><strong>Authorized or Approved Vaccines</strong></span>
</h2>
<h2 class="g-subhed g-optimize-type g-sub-hidden g-sub-abandoned" id="">
	<span class="g-balancer" data-id="9"><strong>Abandoned Vaccines</strong></span>
</h2>
<h2 class="g-subhed g-optimize-type g-filtered" id="">
	<span class="g-balancer" data-id="10"><strong>Genetic Vaccines</strong></span>
</h2>
<p class="g-body g-description g-optimize-type g-filtered" id="">
	<span class="g-xbalancer" data-id="11"><em>Vaccines that deliver one or more of the coronavirus’s own </em><em><a href="https://www.nytimes.com/interactive/2020/04/03/science/coronavirus-genome-bad-news-wrapped-in-protein.html">genes</a></em><em> into our cells to provoke an immune response.</em></span>
</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filtered"  style="max-width: 600px">

<!-- Intro elements -->








<div role="img" aria-label="RNA and DNA vaccines">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.101.0 - 2021-01-07 10:27 -->
<!-- ai file: genetic.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-genetic-box ,
	#g-genetic-box .g-artboard {
		margin:0 auto;
	}
	#g-genetic-box p {
		margin:0;
	}
	#g-genetic-box .g-aiAbs {
		position:absolute;
	}
	#g-genetic-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-genetic-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-genetic-box .g-aiPointText p { white-space: nowrap; }
	#g-genetic-600 {
		position:relative;
		overflow:hidden;
	}
	#g-genetic-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(51,51,51);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-genetic-600 .g-pstyle0 {
		height:17px;
		text-align:right;
		position:relative;
	}
	#g-genetic-600 .g-pstyle1 {
		height:17px;
		position:relative;
	}
	#g-genetic-450 {
		position:relative;
		overflow:hidden;
	}
	#g-genetic-450 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(51,51,51);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-genetic-450 .g-pstyle0 {
		height:17px;
		position:relative;
	}
	#g-genetic-450 .g-pstyle1 {
		height:17px;
		text-align:right;
		position:relative;
	}
	#g-genetic-335 {
		position:relative;
		overflow:hidden;
	}
	#g-genetic-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(51,51,51);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-genetic-335 .g-pstyle0 {
		height:17px;
		position:relative;
	}
	#g-genetic-335 .g-pstyle1 {
		height:17px;
		text-align:right;
		position:relative;
	}

</style>

<div id="g-genetic-box" class="ai2html">

	<!-- Artboard: 600 -->
	<div id="g-genetic-600" class="g-artboard" style="width:600px; height:250px;" data-aspect-ratio="2.4" data-min-width="600">
<div style=""></div>
		<img id="g-genetic-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/genetic-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-450 g-aiAbs g-aiPointText" style="top:87.9063%;margin-top:-8.8px;right:81.4262%;width:96px;">
			<p class="g-pstyle0">RNA vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-450 g-aiAbs g-aiPointText" style="top:87.9063%;margin-top:-8.8px;left:81.1345%;width:97px;">
			<p class="g-pstyle1">DNA vaccine</p>
		</div>
	</div>

	<!-- Artboard: 450 -->
	<div id="g-genetic-450" class="g-artboard" style="width:450px; height:250px;" data-aspect-ratio="1.8" data-min-width="450" data-max-width="599">
<div style=""></div>
		<img id="g-genetic-450-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/genetic-450.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-450 g-aiAbs g-aiPointText" style="top:96.7063%;margin-top:-8.8px;left:0%;width:96px;">
			<p class="g-pstyle0">RNA vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-450 g-aiAbs g-aiPointText" style="top:96.7063%;margin-top:-8.8px;right:0.0329%;width:97px;">
			<p class="g-pstyle1">DNA vaccine</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-genetic-335" class="g-artboard" style="max-width: 335px;max-height: 250px" data-aspect-ratio="1.34" data-min-width="0" data-max-width="449">
<div style="padding: 0 0 74.6269% 0;"></div>
		<img id="g-genetic-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/genetic-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-450 g-aiAbs g-aiPointText" style="top:96.7063%;margin-top:-8.8px;left:-0.0002%;width:96px;">
			<p class="g-pstyle0">RNA vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-450 g-aiAbs g-aiPointText" style="top:96.7063%;margin-top:-8.8px;right:-0.0018%;width:97px;">
			<p class="g-pstyle1">DNA vaccine</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-genetic-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-01-07 10:27 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="pfizer"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN U.S., ELSEWHERE</span>


<span class="g-limited">EMERGENCY USE IN MANY COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/pfizer-800.png" class="g-vlogo" 
    style="width: 70px; height: 41px; margin-right: 20px;" alt="Pfizer logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/biontech-800.png" class="g-vlogo" 
    style="width: 200px; height: 33px;" alt="BioNTech logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> <a href="https://www.ema.europa.eu/en/medicines/human/summaries-opinion/comirnaty">Comirnaty</a> (also known as <a href="https://www.fiercepharma.com/marketing/pfizer-biontech-select-comirnaty-as-brand-name-for-covid-19-vaccine">tozinameran</a> or <a href="https://www.nytimes.com/interactive/2020/health/pfizer-biontech-covid-19-vaccine.html">BNT162b2</a>)<br>
<span class="g-info">Efficacy:</span> <a href="https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1">91%</a><br>
<span class="g-info">Dose:</span> 2 doses, 3 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Freezer storage only at –13°F to 5°F (–25°C to –15°C)<br>
<br>
</span>

<!-- description -->
On Nov. 9, 2020, New York-based <strong>Pfizer </strong>and the German company <strong>BioNTech </strong>made history by announcing that  their coronavirus vaccine had an efficacy rate of <a href="https://www.nytimes.com/2020/11/09/health/covid-vaccine-pfizer.html?smid=tw-share">over 90 percent</a>, far surpassing expectations.  It was the first time anyone had found such evidence. Just over a month later, on Dec. 11, the Food and Drug Administration granted the vaccine, known as Comirnaty, the first <a href="https://www.nytimes.com/2020/12/11/health/pfizer-vaccine-authorized.html">emergency use authorization</a> ever given by the United States to a coronavirus vaccine. On Aug. 23, 2021, the F.D.A. granted <a href="https://www.nytimes.com/live/2021/08/23/world/covid-delta-variant-vaccine#fda-approval-pfizer-vaccine">full approval</a> to Comirnaty for people 16 and older, and it now has an emergency authorization for children <a href="https://www.nytimes.com/2022/06/17/us/politics/pfizer-moderna-vaccines-kids-fda.html?smid=url-share">as young as six months</a>. Comrinaty received <a href="https://www.pfizer.com/news/announcements/pfizer-and-biontech-announce-us-fda-approval-their-covid-19-vaccine-comirnatyr">full approval</a> for adolescents 12 and older on July 8, 2022.<br><br>As of July 3, 2022, Pfizer had delivered more than 3.6 billion doses of Comirnaty to 180 countries and territories.<br><br> <subhed>VACCINE DEVELOPMENT</subhed>The work on Comirnaty began in January 2020,  when BioNTech researchers started fashioning a genetic molecule called messenger RNA (mRNA). They created the <a href="https://www.nytimes.com/interactive/2021/health/pfizer-coronavirus-vaccine.html">genetic instructions</a> for building a coronavirus protein, known as spike. When the mRNA enters cells, the vaccine causes them to make spike proteins, which then get released into the body and provoke a response from the immune system. In March 2020, BioNTech partnered with Pfizer to scale up the research, launching a clinical trial in May.<br><br> <subhed>TRIAL RESULTS</subhed>The Phase 1 trials <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2027906">showed</a> that Comirnaty caused volunteers to produce antibodies against SARS-CoV-2, as well as immune cells called T cells that respond to the virus. On July 27, the companies announced the <a href="https://www.nytimes.com/2020/07/27/health/moderna-vaccine-covid.html">launch</a> of a Phase 2/3 trial with 30,000 volunteers. On Sept. 12, Pfizer and BioNTech <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19">announced</a> that they would seek to expand the trial to 44,000 participants.<br><br>Through the summer and into the fall, the world closely followed  the Pfizer-BioNTech trial. In September, Dr. Albert Bourla, the chief executive of Pfizer, <a href="https://www.nytimes.com/2020/09/30/health/pfizer-covid-vaccine.html">said</a> that as soon as October the Phase 3 trial would deliver enough results to show if the vaccine worked or not. President Trump touted their progress, hinting that a vaccine would be available before the election. But on Oct. 27, Dr. Bourla <a href="https://www.nytimes.com/2020/10/27/health/pfizer-covid-19-vaccine.html">announced</a> that the volunteers in the trial had yet to experience enough cases of Covid-19 to determine if the vaccines work. Finally, on Nov. 9, Pfizer and BioNTech released their preliminary analysis of the first 94 cases of Covid-19 in their volunteers.<br><br>Over the next month, Pfizer and BioNTech released more data on more cases. On Dec. 8 the FDA released <a href="https://www.nytimes.com/2020/12/08/health/covid-vaccine-pfizer.html">their independent analysis</a> of the clinical trials. They determined that Comirnaty has an efficacy rate of 95 percent. While Comirnaty caused no serious side effects, it frequently caused short-lived fatigue, fever, and muscle aches.<br><br>In Israel, which took the lead in mass vaccination, researchers found that the vaccine was <a href="https://www.nytimes.com/2021/02/24/world/pfizer-vaccine-effective-israel.html">as effective in the real world</a> as the trials had indicated. A study published by the Centers for Disease Control in March <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious">found that</a> the vaccine is 91.3% effective after the second dose. <br><br>Subsequent trials showed that the Pfizer-BioNTech vaccine was safe and effective for children as young as five. But in children aged 2 to 5, <a href="https://www.nytimes.com/live/2021/12/17/world/covid-omicron-vaccines/in-a-trial-pfizer-biontechs-low-dose-shot-did-not-provoke-an-adequate-immune-response-in-2-to-5-year-olds">the dosage did not produce high levels of antibodies</a>, and so Pfizer <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-ongoing-studies-covid-19">announced</a> on Dec. 17, 2021, that it would try again in a trial using three doses instead of two. In May 2022, Pfizer <a href="https://www.nytimes.com/2022/05/23/us/politics/pfizer-vaccine-kids.html">announced</a> that the extra dose produced favorable responses.<br><br> <subhed>AUTHORIZATION</subhed>On Dec. 2, 2020, the United Kingdom became the first country to give Comirnaty <a href="https://nyti.ms/3qj8Mue">emergency authorization</a>, followed by many more countries. On Dec. 31, the World Health Organization gave the vaccine an <a href="https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access">Emergency Use Listing</a>, which sped up its authorization across the world. The F.D.A. <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use-0">expanded its authorization</a> for adolescents 12 through 15 on Jan. 3, 2022. On Feb. 1, 2022, Pfizer began the process of applying for an <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-emergency">expansion of its authorization for children younger than five</a>, after the F.D.A. made the <a href="https://endpts.com/fda-takes-a-rare-step-and-asks-pfizer-to-submit-a-covid-19-vaccine-eua-for-the-youngest-children/">unusual step of requesting it</a>. An advisory panel to the F.D.A. <a href="https://www.nytimes.com/live/2022/06/15/world/covid-19-mandates-vaccine-cases/covid-vaccine-kids-fda?smid=url-share">voted to recommend</a> Comirnaty for that age group on June 15, and emergency authorization came two days later.<br><br> <subhed>DISTRIBUTION</subhed>As their clinical trials progressed, Pfizer and BioNTech also scaled up factories to produce Comirnaty. To secure a supply in advance, the Trump administration <a href="https://www.nytimes.com/2020/07/22/us/politics/pfizer-coronavirus-vaccine.html">awarded</a> Pfizer and BioNTech a $1.9 billion contract in July 2020 for 100 million doses. By July 2021, the companies had reached agreements with the United States government for a total of <a href="https://www.businesswire.com/news/home/20210723005094/en/Pfizer-and-BioNTech-to-Provide-U.S.-Government-with-an-Additional-200-Million-Doses-of-COVID-19-Vaccine-to-Help-Meet-Continued-Need-for-Vaccine-Supply-in-the-U.S.">a billion doses</a>: half for domestic use and half for donations to other countries. In April 2021, the European Union <a href="https://www.nytimes.com/2021/04/14/world/europe/EU-Pfizer-AstraZeneca-Covid.html?searchResultPosition=1">negotiated an option to purchase</a> 1.8 billion doses, which they <a href="https://www.reuters.com/world/europe/eu-place-order-with-pfizer-covid-shots-adapted-omicron-2021-12-17/?rpc=401&">exercised</a> in December in response to the Omicron variant.<br><br>In June 2022, Pfizer reached an <a href="https://www.businesswire.com/news/home/20220629005833/en/Pfizer-and-BioNTech-Announce-New-Agreement-with-U.S.-Government-to-Provide-Additional-Doses-of-COVID-19-Vaccine">agreement</a> with the United States for a new delivery of vaccines in preparation for an anticipated winter surge. The U.S. government agreed to pay $3.2 billion for 105 million doses.<br><br>While Comirnaty has proven highly effective, it was initially a challenging vaccine to distribute because it had to be kept frozen at –94°F (–70°C).  On Feb. 19, 2021, Pfizer and BioNTech <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-covid-19-vaccine-stability-data">announced</a> that they could keep the vaccine stable at –25°C to –15°C (–13°F to 5°F).<br><br> <subhed>VARIANTS</subhed>In January 2021, scientists grew concerned about <a href="https://www.nytimes.com/2021/01/20/health/coronavirus-variants-immunity.html?smid=tw-share">the emergence of fast-spreading variants</a> that might be able to evade antibodies. <a href="https://www.nytimes.com/2021/05/05/health/coronavirus-pfizer-vaccine-variants.html?action=click&module=RelatedLinks&pgtype=Article">A study published in May</a> demonstrated that Comirnaty was somewhat less effective against some variants, but still provided strong protection. A British study showed that  Comirnaty had an effectiveness of 88 percent against infection with <a href="https://www.nejm.org/doi/full/10.1056/NEJMe2110605?query=recirc_curatedRelated_article">Delta</a>, the variant first identified in India. Its effectiveness against hospitalization from Delta was <a href="https://www.gov.uk/government/news/vaccines-highly-effective-against-hospitalisation-from-delta-variant">96 percent</a>.<br><br>On Dec. 8, Pfizer and BioNTech <a href="https://www.nytimes.com/live/2021/12/08/world/omicron-variant-covid/pfizer-says-blood-samples-showed-a-third-dose-of-its-vaccine-provides-significant-protection-against-omicron">announced</a> that the Omicron variant greatly reduced the ability of vaccine antibodies to neutralize the coronavirus. However, results from <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-publish-data-two-laboratory-studies">two lab studies</a>, released on Jan. 24, 2022, suggested that three doses of the vaccine were able to generate antibodies against Omicron. And epidemiological studies show that three doses of Comirnaty are <a href="https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x">highly effective</a> at preventing serious Covid from Omicron infections. Pfizer and BioNTech <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-evaluate-omicron-based">launched</a> a trial of an Omicron-specific vaccine on Jan. 25, but <a href="https://news.yahoo.com/pfizer-biontech-omicron-targeted-vaccine-194709756.html">delays</a> have kept the companies from deploying the vaccine, they said on Feb. 16. Results from trials suggest that the vaccine is effective at protecting adults from Omicron, the companies <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19">said</a> on June 25. They <a href="https://www.pfizer.com/news/announcements/pfizer-and-biontech-advance-covid-19-vaccine-strategy-study-start-next">launched</a> a Phase 2 trial of the Omicron-specific vaccine on July 27.<br><br>On June 15, the companies <a href="https://www.pfizer.com/news/announcements/pfizer-and-biontech-provide-update-rolling-submission-european-medicines-agency">said</a> that the European Medicines Agency had launched its review of a version of its vaccine adapted against variants. Pfizer and BioNTech <a href="https://www.businesswire.com/news/home/20220822005376/en/Pfizer-and-BioNTech-Submit-Application-to-U.S.-FDA-for-Emergency-Use-Authorization-of-Omicron-BA.4BA.5-Adapted-Bivalent-COVID-19-Vaccine">applied</a> to the F.D.A. for emergency use authorization of the vaccine on Aug. 22.<br><br> <subhed>BOOSTERS</subhed>In April 2021, Dr. Bourla, the chief executive, said people would “likely” need an <a href="https://www.cnbc.com/2021/04/15/pfizer-ceo-says-third-covid-vaccine-dose-likely-needed-within-12-months.html?__source=sharebar%7Ctwitter&par=sharebar">additional shot of its vaccine</a> within a year of receiving two doses. Over the summer, evidence began to emerge that Comirnaty’s effectiveness against infection was waning. Researchers in Israel, which got an early start on mass vaccination in January, observed that the vaccine was also becoming less effective in people over 65 at preventing hospitalization. A Phase 3 trial on 10,000 volunteers found that a Pfizer-BioNTech booster has an efficacy of 95.6 percent against disease, at a time when the Delta variant was dominant.<br><br>As the Delta variant fueled a new surge of cases in Israel, the country began providing a third dose of Comirnaty as a booster. Other countries followed suit. An Israeli <a href="https://www.nejm.org/doi/full/10.1056/NEJMc2202542?query=featured_home">study</a> published on March 16, 2022, found that a fourth dose lifted antibody levels once again, but it may only offer marginal benefits for young adults compared to getting just three shots.<br><br>The F.D.A. <a href="https://nymag.com/intelligencer/2021/08/fda-approves-third-covid-vaccine-dose-for-immunocompromised.html">expanded</a> its emergency authorization to include a third dose of Comirnaty in certain immunocompromised adults on Aug. 13. In November 2021, the F.D.A. authorized the Comirnaty booster for all adults 18 and older. Health officials <a href="https://www.nytimes.com/live/2021/12/09/world/omicron-variant-covid/the-fda-authorizes-pfizer-biontech-boosters-for-16-and-17-year-olds">expanded</a> that authorization to 16- and 17-year olds the following month, and then to children <a href="https://www.cdc.gov/media/releases/2022/s0105-Booster-Shot.html">12 and older</a> in January 2022. In May it further expanded its booster authorization to children <a href="https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-fda-expands-eligibility-for-pfizer-biontech-covid-19-vaccine-booster-dose-to-children-5-through-11-years-301549235.html">as young as five</a>.<br><br>On March 29, the F.D.A. <a href="https://www.nytimes.com/live/2022/03/29/world/covid-19-mandates-cases-vaccine/the-fda-authorizes-second-covid-booster-shots-for-those-50-and-older">authorized</a> a fourth dose of Comirnaty in those aged 50 and older and certain immunocompromised people to protect against emerging variants.<br><br>Results from a trial in children aged 5 through 11, <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-data-demonstrating-high-immune">released</a> on April 14, 2022, suggest that a third dose of the vaccine produced substantial antibodies against the Omicron variant. Pfizer has <a href="https://www.npr.org/sections/health-shots/2022/04/26/1094679811/pfizer-asks-fda-to-authorize-booster-shots-for-kids-ages-5-through-11">asked</a> the F.D.A. to expand the emergency use authorization for boosters down to age 5. On Aug. 31, 2022, the F.D.A. <a href="https://www.nytimes.com/2022/08/31/us/politics/covid-booster-shots-variants.html">authorized Pfizer’s latest booster</a>, a combination of RNA for the original coronavirus and BA.5.<br><br>For more details, see <strong><a href="https://www.nytimes.com/interactive/2020/health/pfizer-biontech-covid-19-vaccine.html">How the Pfizer-BioNTech Vaccine Works</a></strong> and <strong><a href="https://www.nytimes.com/interactive/2021/health/pfizer-coronavirus-vaccine.html">How Pfizer Makes Its Covid-19 Vaccine</a></strong>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175">Bahrain</a>, <a href="https://www.reuters.com/article/health-coronavirus-brazil/update-2-brazil-approves-pfizers-covid-19-shot-but-has-none-to-use-idUSL1N2KT0XI">Brazil</a>, <a href="https://globalnews.ca/news/8195443/covid-coronavirus-vaccine-12-kids-pfizer-moderna/">Canada</a>, <a href="http://www.xinhuanet.com/english/2021-02/03/c_139717615.htm">New Zealand</a>, <a href="https://www.arabnews.com/node/1775896/saudi-arabia">Saudi Arabia</a>, <a href="https://www.bag.admin.ch/bag/en/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/impfen.html">Switzerland</a>, <a href="https://www.nytimes.com/live/2021/08/23/world/covid-delta-variant-vaccine#fda-approval-pfizer-vaccine">United States</a>.<br>


<span class="g-info">Emergency use in:</span> <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Albania</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Algeria</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Andorra</a>, <a href="https://antiguaobserver.com/pfizer-to-remain-in-demand-for-use-in-children-as-other-manufacturers-take-their-time/">Antigua and Barbuda</a>, <a href="https://riotimesonline.com/brazil-news/mercosur/argentine-extends-emergency-approval-to-the-pfizer-vaccine/">Argentina</a>, <a href="https://am.usembassy.gov/u-s-citizen-services/covid-19-information/">Armenia</a>, <a href="https://www.pm.gov.au/media/pfizer-vaccine-approved">Australia</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Azerbaijan</a>, <a href="https://www.bahamas.gov.bs/wps/portal/public/gov/government/news/bahamas%20gets%2057330%20doses%20of%20pfizer%20vaccine%20to%20boost%20its%20covid-19%20vaccination%20programme/!ut/p/b1/vZbJjqNIFEW_JT_ARRDMy8CMZp6HDWKwndgMtgGD-fpySim1srsra1Nl3grphk7EgfcUWIrFWNrl9_qYj3Xf5c3He0pnBJANhEjWYCUaATUgJILSECE7OBZhsZ4wvDCoR1F0s9RjObHhC4_kNu4NJro3hwFXyzs_XuhHLAN2PftefmKy21SOxC1gN5XnzvtTZzWxMPgtlRrrXoZOnhOzRKk8uozvolZFh-1u64TR9agLe_2csNv5PCMFigIXkKLQJXXeC2haQ7Ue6XutxhfY2myQW0U1xsepdfVLBTux8Rc9zsRh2p9gQUfXre0cwo5e4kPARTDqeslh-BNt8qPiR4-CmmJiPXlN__YUkTxFgF88CHz1ZEGfAyq-xWktoAAr0J_rvwn81nP6NSJTgH5GbB3ZjAItEnwGvtvi95skseQZYH4dYDAfiwGZeafHRV3Pq3taHWD4oWr6yYqvwTyc18j0RcIcc9wXEhwUwWwEAzBWgxhX1_Qrxa5CN-CRYAvHx_Q90NPJ1wJZn341kHgxkACvBsJXA6kXA3ev_kuJP9-HOyyti_bHXLY_wA8K4DgkcJaCBEMzEAt35ZHa9mgWRcEd8HeDBsuokbUJxaSovbRX-XFRbQUWY5zZvEMq5WNBjq5ZVdVWhyBSJH7BLxwynEC6bF39flVl2O86xu26Yr6eEH-Ti7bJ-HVnn7kDW_YcvNF9sbum8Yre3jBT6dv9v63IfgieVgByPdwBLPM_VrzZFEx1WHkNrMEyiqfn0aXdWG3xQXBwEADgB8NirpXq665qVvqnFYQjU-1_M51k4m8DZcpinyOe8W1EwecEp18NpP4WULYMZ_uh1Oc_lBKKgmidsET81cA__w2_thKJUxSHQ46GDGRwBgvHJOOLo7oIz8vSkpalmp-d6yTId3czU4lW3nZ7szFcl5Gp_s5Q7uIcwNw2crIZL8uZgSUejenGMmiGuPdsxsxmS7qAkk7aZKYbsw1N_-4NiaSfLxJziG3bdK2lDffFkJWTUAPJ7a2A3G3jHEGxl-Q6RPI8WZrsxNMF6QrH2vxcLlt0W1C8V22zOs7v0lFtDHGtgVreSJmwrGzvD-wtn5wHVJZ7K9hp9iAulBZNuJjbjzNYhAPx0JJcQw8bRo0Sx96sw00juZUNy8NZQh2-6Z1nb1_au6bTrrLG_6m9fG__qecg-Ak3BHZV/dl4/d5/L2dBISEvZ0FBIS9nQSEh/">Bahamas</a>, <a href="https://www.dhakatribune.com/bangladesh/2021/05/27/bangladesh-approves-pfizer-covid-19-vaccine-for-emergency-use">Bangladesh</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Barbados</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Belize</a>, <a href="https://www.gov.bm/sites/default/files/COVID-19%20Vaccine%20Information%20and%20Consent%20Form.pdf">Bermuda</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Bhutan</a>, <a href="https://www.swissinfo.ch/spa/coronavirus-bolivia_adolescentes-se-vacunar%C3%A1n-en-bolivia-contra-la-covid-con-autorizaci%C3%B3n-paterna/47008358">Bolivia</a>, Bonaire, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Bosnia and Herzegovina</a>, <a href="http://www.xinhuanet.com/english/africa/2021-02/27/c_139771113.htm">Botswana</a>, <a href="https://thescoop.co/2021/04/02/covid-19-brunei-to-begin-mass-vaccination-on-april-3/">Brunei</a>, <a href="https://www.eris.cv/index.php/noticias/194-celebrar-a-saude-atribuicoes-e-atuacao-da-eris-no-setor-farmaceutico">Cabo Verde</a>, <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/pfizer-biontech/authorization.html">Canada</a>, <a href="https://elpais.com/sociedad/2020-12-16/chile-y-ecuador-se-adelantan-en-sudamerica-y-autorizan-la-vacuna-de-pfizer.html">Chile</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-colombia-vaccine/colombia-regulator-approves-pfizer-biontech-vaccine-for-emergency-use-idUSKBN29B02M">Colombia</a>, <a href="https://ticotimes.net/2020/12/16/costa-rica-authorizes-pfizer-biontech-coronavirus-vaccine">Costa Rica</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Côte d’Ivoire</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Curaçao</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Dominican Republic</a>, <a href="https://elpais.com/sociedad/2020-12-16/chile-y-ecuador-se-adelantan-en-sudamerica-y-autorizan-la-vacuna-de-pfizer.html">Ecuador</a>, <a href="https://www.reuters.com/world/africa/egypt-authorizes-pfizers-covid-19-vaccine-12-15-year-olds-2021-11-28/">Egypt</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">El Salvador</a>, <a href="https://www.nytimes.com/live/2020/12/21/world/covid-19-coronavirus#eu-regulators-approve-the-pfizer-biontech-vaccine-clearing-the-way-for-distribution">European Union</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Faroe Islands</a>, <a href="https://fj.usembassy.gov/u-s-citizen-services/covid-19-information/">French Polynesia</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Gabon</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Georgia</a>, <a href="http://www.xinhuanet.com/english/africa/2021-07/29/c_1310092883.htm">Ghana</a>, <a href="https://www.rcinet.ca/eye-on-the-arctic/2021/01/04/greenland-launches-covid-19-vaccination-campaign-1/">Greenland</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Guadeloupe</a>, <a href="https://gt.usembassy.gov/alert-covid-19-2/">Guatemala</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Guyana</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Honduras</a>, <a href="https://www.chp.gov.hk/files/pdf/consensus_on_the_use_of_bnt162b2_among_frail_elderly_in_hk_as_of_8_feb_2021.pdf">Hong Kong</a>, <a href="https://www.icelandreview.com/news/covid-19-in-iceland-iceland-medicines-agency-approves-pfizer-vaccine/">Iceland</a>, <a href="http://www.xinhuanet.com/english/2021-07/15/c_1310063615.htm">Indonesia</a>, <a href="https://www.arabnews.com/node/1783516/middle-east">Iraq</a>, <a href="https://www.nytimes.com/2021/01/25/world/middleeast/israels-vaccine-data.html">Israel</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Jamaica</a>, <a href="https://www.japantimes.co.jp/news/2021/02/15/national/science-health/pfizer-vaccine-approval-japan/">Japan</a>, <a href="https://en.royanews.tv/news/24726/2021-01-10">Jordan</a>, <a href="https://astanatimes.com/2021/11/first-batch-of-pfizer-vaccine-delivered-to-kazakhstan/">Kazakhstan</a>, <a href="https://www.bloomberg.com/news/articles/2021-08-02/kenya-approves-j-j-pfizer-covid-19-vaccines-as-cases-surge">Kenya</a>, <a href="https://xk.usembassy.gov/coronavirus/">Kosovo</a>, <a href="https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175">Kuwait</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Kyrgyzstan</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Laos</a>, <a href="https://www.moph.gov.lb/userfiles/files/Prevention/COVID-19%20Vaccine/Lebanon%20NDVP-%20Feb%2016%202021.pdf">Lebanon</a>, <a href="https://reliefweb.int/sites/reliefweb.int/files/resources/libya_covid_update_25_final.pdf">Libya</a>, Liechtenstein, <a href="https://www.facebook.com/malawimoh/posts/4098884300167054">Malawi</a>, <a href="https://www.lowyat.net/2021/241888/cansino-johnson-and-johnson-vaccines-get-conditional-approval-malaysian-children-to-get-stabbed-with-pfizer/">Malaysia</a>, <a href="https://timesofaddu.com/2021/03/15/breaking-sinopharm-pfizer-approved-for-use-in-maldives/">Maldives</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Malta</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Martinique</a>, <a href="https://www.nytimes.com/live/2020/12/11/world/covid-19-coronavirus/mexico-approves-pfizer-vaccine-for-emergency-use-and-other-news-around-the-world">Mexico</a>, <a href="https://news.trust.org/item/20210227162136-o0jx5/">Moldova</a>, <a href="https://covid19.mc/en/mesures/tout-sur-les-vaccins/">Monaco</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Montenegro</a>, <a href="https://news.mn/en/795048/">Mongolia</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Nepal</a>, <a href="https://fj.usembassy.gov/u-s-citizen-services/covid-19-information/">New Caledonia</a>, <a href="https://nica-biz.com/2021/07/29/pfizer-and-astrazeneca-vaccines-on-their-way-to-nicaragua/?utm_source=rss&utm_medium=rss&utm_campaign=pfizer-and-astrazeneca-vaccines-on-their-way-to-nicaragua">Nicaragua</a>, <a href="https://guardian.ng/news/nafdac-approves-pfizer-biotech-vaccine-for-emergency-use-authorisation/">Nigeria</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Niue</a>, <a href="https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/development-of-covid-19-vaccine/">Norway</a>, <a href="https://kovid19vakcinacija.mk/za-vakcinite/">North Macedonia</a>, Oman, <a href="https://www.geo.tv/latest/352816-drap-gives-emergency-approval-for-pfizers-coronavirus-vaccine">Pakistan</a>, <a href="https://www.telemetro.com/nacionales/2020/12/16/panama-aprueba-vacuna-pfizer-biontech/3559342.html">Panama</a>, <a href="https://covid19.info.gov.pg/vaccination-is-not-compulsory-prime-minister-tells-parliament/">Papua New Guinea</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Paraguay</a>, <a href="https://www.reuters.com/article/idUSKBN2A22F1">Peru</a>, <a href="https://www.pna.gov.ph/articles/1127336">Philippines</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-vaccine-qatar/qatar-oman-to-receive-pfizer-biontech-covid-19-vaccine-this-week-idUSKBN28U0VE">Qatar</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Republic of Congo</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Rwanda</a>, <a href="http://health.gov.vc/health/images/stories/PDF/SRO-Public_Health_Emergency_Authorisation_of_Covid-19_Vaccine.pdf">Saint Vincent and the Grenadines</a>, Serbia, <a href="https://www.hsa.gov.sg/announcements/press-release/interimauth-firstcovid19vaccine">Singapore</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/sri-lanka-approves-pfizer-covid-vaccine-emergency-use-2021-05-08/">Sri Lanka</a>, <a href="https://www.reuters.com/article/health-coronavirus-safrica/update-1-south-africa-approves-pfizer-biontech-covid-vaccine-for-emergency-use-idUSL8N2LE52I">South Africa</a>, <a href="http://m.koreaherald.com/amp/view.php?ud=20210203001122">South Korea</a>, <a href="http://www.sintmaartengov.org/government/VSA/Health-Updates/NOVELCORONAVIRUS/Pages/Vaccine.aspx">St. Maarten</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Sudan</a>, <a href="https://www.cdc.gov.tw/En/Bulletin/Detail/Kk0E6h8N0ei4y1Tw0XZPLQ?typeid=158">Taiwan</a>, <a href="https://www.reuters.com/world/asia-pacific/thailand-approves-pfizer-biontech-vaccine-emergency-use-2021-06-24/">Thailand</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Timor-Leste</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Togo</a>,  <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Tokelau</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Tonga</a>, <a href="https://m.facebook.com/MinistryofHealthTT/photos/a.153051404724676/4635809886448783/?type=3&source=48">Trinidad and Tobago</a>, <a href="http://www.santetunisie.rns.tn/images/strategie-vaccination-covid-19.pdf">Tunisia</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-turkey/turkey-begins-administering-pfizer-biontech-covid-19-shots-idUSKBN2BP0VN">Turkey</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Turks and Caicos</a>, <a href="https://www.kmu.gov.ua/en/news/intervyu-premyer-ministra-ukrayini-denisa-shmigalya-nimeckij-gazeti-bild-vid-19-bereznya-2021-roku">Ukraine</a>, <a href="https://www.reuters.com/world/middle-east/uae-allows-pfizer-covid-19-dose-emergency-use-12-15-year-olds-2021-05-13/#:~:text=DUBAI%2C%20May%2013%20(Reuters),for%2016%20years%20and%20above.">United Arab Emirates</a>, <a href="https://www.nytimes.com/2020/12/02/world/europe/pfizer-coronavirus-vaccine-approved-uk.html">United Kingdom</a>, <a href="https://www.nytimes.com/2020/12/11/health/pfizer-vaccine-authorized.html">United States</a>, <a href="https://en.mercopress.com/2021/01/23/uruguay-acquired-pfizer-and-sinovac-vaccines-details-will-be-announced-saturday">Uruguay</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Vatican</a>, <a href="https://www.reuters.com/world/asia-pacific/vietnam-approves-pfizerbiontech-covid-19-vaccine-emergency-use-2021-06-12/">Vietnam</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">West Bank</a>, <a href="https://covid-19pharmacovigilance.paho.org/pfizer-biontech#col-0">Zambia</a>. Emergency use validation from the <a href="https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access">World Health Organization</a>. Recommended for emergency use by the <a href="https://www.carpha.org/Portals/0/Documents/COVID-19%20Vaccine%20Updates/CARPHA%20COVID-19%20Vaccine%20Update%20012%20March%2029,%202021.pdf">Caribbean Regulatory System</a>.<br>



</span>

<span class="g-updated">Updated Aug. 31, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.106.0 - 2022-03-02 11:54 -->
<!-- ai file: map-pfizer.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-pfizer-box ,
	#g-map-pfizer-box .g-artboard {
		margin:0 auto;
	}
	#g-map-pfizer-box p {
		margin:0;
	}
	#g-map-pfizer-box .g-aiAbs {
		position:absolute;
	}
	#g-map-pfizer-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-pfizer-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-pfizer-box .g-aiPointText p { white-space: nowrap; }
	#g-map-pfizer-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-pfizer-900 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-pfizer-900 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-pfizer-900 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-pfizer-900 .g-pstyle2 {
		height:13px;
	}
	#g-map-pfizer-900 .g-pstyle3 {
		height:13px;
		text-align:right;
	}
	#g-map-pfizer-900 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-pfizer-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-pfizer-720 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-pfizer-720 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-pfizer-720 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-pfizer-720 .g-pstyle2 {
		height:13px;
	}
	#g-map-pfizer-720 .g-pstyle3 {
		height:13px;
		text-align:right;
	}
	#g-map-pfizer-720 .g-pstyle4 {
		height:13px;
		letter-spacing:0.05em;
		text-align:center;
	}
	#g-map-pfizer-720 .g-pstyle5 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-pfizer-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-pfizer-600 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-pfizer-600 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-pfizer-600 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-pfizer-600 .g-pstyle2 {
		height:13px;
	}
	#g-map-pfizer-600 .g-pstyle3 {
		height:13px;
		text-align:right;
	}
	#g-map-pfizer-600 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-pfizer-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-pfizer-335 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-pfizer-335 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-pfizer-335 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-pfizer-335 .g-pstyle2 {
		height:13px;
		text-align:right;
	}
	#g-map-pfizer-335 .g-pstyle3 {
		height:13px;
	}
	#g-map-pfizer-335 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}

</style>

<div id="g-map-pfizer-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-pfizer-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-pfizer-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-pfizer-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:126px;">
			<p class="g-pstyle0">Pfizer-BioNTech</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:12.4659%;margin-top:-13.4px;left:61.9444%;margin-left:-51px;width:102px;">
			<p class="g-pstyle1">BRITAIN AND</p>
			<p class="g-pstyle1">THE E.U.</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:21.0027%;margin-top:-6.8px;left:66.8999%;width:112px;">
			<p class="g-pstyle2">SWITZERLAND</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:22.6876%;margin-top:-6.8px;left:26.7859%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:23.53%;margin-top:-6.8px;left:87.6107%;width:62px;">
			<p class="g-pstyle2">JAPAN</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:26.619%;margin-top:-6.8px;left:76.2289%;width:90px;">
			<p class="g-pstyle2">MONGOLIA</p>
		</div>
		<div id="g-ai0-7" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:28.3039%;margin-top:-6.8px;right:36.8917%;width:76px;">
			<p class="g-pstyle3">ALGERIA</p>
		</div>
		<div id="g-ai0-8" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:35.3243%;margin-top:-6.8px;left:27.0314%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai0-9" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:36.4476%;margin-top:-6.8px;left:87.364%;width:99px;">
			<p class="g-pstyle2">PHILIPPINES</p>
		</div>
		<div id="g-ai0-10" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:36.7284%;margin-top:-6.8px;left:68.2553%;width:53px;">
			<p class="g-pstyle2">IRAQ</p>
		</div>
		<div id="g-ai0-11" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:40.0982%;margin-top:-6.8px;left:71.2122%;width:79px;">
			<p class="g-pstyle2">BAHRAIN</p>
		</div>
		<div id="g-ai0-12" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:42.6255%;margin-top:-6.8px;right:41.5111%;width:73px;">
			<p class="g-pstyle3">NIGERIA</p>
		</div>
		<div id="g-ai0-13" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:47.5679%;margin-top:-13.4px;left:69.6209%;margin-left:-34.5px;width:69px;">
			<p class="g-pstyle1">SAUDI</p>
			<p class="g-pstyle1">ARABIA</p>
		</div>
		<div id="g-ai0-14" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:47.6802%;margin-top:-6.8px;left:21.1426%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai0-15" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:51.3308%;margin-top:-6.8px;left:39.004%;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai0-16" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:56.1047%;margin-top:-6.8px;right:66.6175%;width:82px;">
			<p class="g-pstyle3">ECUADOR</p>
		</div>
		<div id="g-ai0-17" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:56.6664%;margin-top:-6.8px;left:53.2617%;width:93px;">
			<p class="g-pstyle2">BOTSWANA</p>
		</div>
		<div id="g-ai0-18" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:57.228%;margin-top:-6.8px;left:84.6811%;margin-left:-47px;width:94px;">
			<p class="g-pstyle1">SINGAPORE</p>
		</div>
		<div id="g-ai0-19" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:58.3513%;margin-top:-6.8px;left:95.471%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai0-20" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:64.2484%;margin-top:-6.8px;right:63.0998%;width:55px;">
			<p class="g-pstyle3">PERU</p>
		</div>
		<div id="g-ai0-21" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:71.4373%;margin-top:-13.4px;left:5.166%;margin-left:-40.5px;width:81px;">
			<p class="g-pstyle1">NEW</p>
			<p class="g-pstyle1">ZEALAND</p>
		</div>
		<div id="g-ai0-22" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:74.2455%;margin-top:-13.4px;left:58.9876%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">AFRICA</p>
		</div>
		<div id="g-ai0-23" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:72.9537%;margin-top:-6.8px;left:44.055%;width:95px;">
			<p class="g-pstyle2">ARGENTINA</p>
		</div>
		<div id="g-ai0-24" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:78.2892%;margin-top:-6.8px;right:58.8593%;width:59px;">
			<p class="g-pstyle3">CHILE</p>
		</div>
		<div id="g-ai0-25" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai0-26" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle4">Early, limited or</p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-pfizer-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-pfizer-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-pfizer-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:119px;">
			<p class="g-pstyle0">Pfizer-BioNTech</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:11.4002%;margin-top:-13.4px;left:60.9184%;margin-left:-51px;width:102px;">
			<p class="g-pstyle1">BRITAIN AND</p>
			<p class="g-pstyle1">THE E.U.</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:22.4513%;margin-top:-6.8px;left:26.913%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:23.5071%;margin-top:-6.8px;left:75.6108%;width:90px;">
			<p class="g-pstyle2">MONGOLIA</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:25.2669%;margin-top:-6.8px;left:87.6573%;width:62px;">
			<p class="g-pstyle2">JAPAN</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:33.7136%;margin-top:-6.8px;right:33.1643%;width:58px;">
			<p class="g-pstyle3">LIBYA</p>
		</div>
		<div id="g-ai1-7" class="g-type_copy g-aiAbs g-aiPointText" style="top:35.1214%;margin-top:-6.8px;left:27.1625%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai1-8" class="g-type_copy g-aiAbs g-aiPointText" style="top:35.1214%;margin-top:-6.8px;left:67.9746%;width:53px;">
			<p class="g-pstyle2">IRAQ</p>
		</div>
		<div id="g-ai1-9" class="g-type_copy g-aiAbs g-aiPointText" style="top:36.1772%;margin-top:-6.8px;left:87.2263%;width:99px;">
			<p class="g-pstyle2">PHILIPPINES</p>
		</div>
		<div id="g-ai1-10" class="g-type_copy g-aiAbs g-aiPointText" style="top:39.6967%;margin-top:-6.8px;left:71.0531%;width:79px;">
			<p class="g-pstyle2">BAHRAIN</p>
		</div>
		<div id="g-ai1-11" class="g-type_copy g-aiAbs g-aiPointText" style="top:42.8642%;margin-top:-6.8px;left:51.201%;width:73px;">
			<p class="g-pstyle2">NIGERIA</p>
		</div>
		<div id="g-ai1-12" class="g-type_copy g-aiAbs g-aiPointText" style="top:48.7066%;margin-top:-13.4px;left:69.1909%;margin-left:-34.5px;width:69px;">
			<p class="g-pstyle1">SAUDI</p>
			<p class="g-pstyle1">ARABIA</p>
		</div>
		<div id="g-ai1-13" class="g-type_copy g-aiAbs g-aiPointText" style="top:47.7915%;margin-top:-6.8px;right:76.0971%;width:71px;">
			<p class="g-pstyle3">MEXICO</p>
		</div>
		<div id="g-ai1-14" class="g-type_copy g-aiAbs g-aiPointText" style="top:51.311%;margin-top:-6.8px;left:38.4153%;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai1-15" class="g-type_copy g-aiAbs g-aiPointText" style="top:55.8863%;margin-top:-6.8px;left:50.5178%;width:93px;">
			<p class="g-pstyle2">BOTSWANA</p>
		</div>
		<div id="g-ai1-16" class="g-type_copy g-aiAbs g-aiPointText" style="top:57.646%;margin-top:-6.8px;left:84.6305%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle4">SINGAPORE</p>
		</div>
		<div id="g-ai1-17" class="g-type_copy g-aiAbs g-aiPointText" style="top:60.4616%;margin-top:-6.8px;left:94.1439%;margin-left:-43.5px;width:87px;">
			<p class="g-pstyle4">AUSTRALIA</p>
		</div>
		<div id="g-ai1-18" class="g-type_copy g-aiAbs g-aiPointText" style="top:63.9811%;margin-top:-6.8px;right:63.0456%;width:55px;">
			<p class="g-pstyle3">PERU</p>
		</div>
		<div id="g-ai1-19" class="g-type_copy g-aiAbs g-aiPointText" style="top:70.5274%;margin-top:-13.4px;left:6.5137%;margin-left:-40.5px;width:81px;">
			<p class="g-pstyle1">NEW</p>
			<p class="g-pstyle1">ZEALAND</p>
		</div>
		<div id="g-ai1-20" class="g-type_copy g-aiAbs g-aiPointText" style="top:72.4279%;margin-top:-6.8px;left:43.9747%;width:95px;">
			<p class="g-pstyle2">ARGENTINA</p>
		</div>
		<div id="g-ai1-21" class="g-type_copy g-aiAbs g-aiPointText" style="top:75.8066%;margin-top:-13.4px;left:60.0411%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">AFRICA</p>
		</div>
		<div id="g-ai1-22" class="g-type_copy g-aiAbs g-aiPointText" style="top:79.1149%;margin-top:-6.8px;right:58.8996%;width:59px;">
			<p class="g-pstyle3">CHILE</p>
		</div>
		<div id="g-ai1-23" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle5">Approved</p>
		</div>
		<div id="g-ai1-24" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle5">Early, limited or </p>
			<p class="g-pstyle5">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-pfizer-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-pfizer-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-pfizer-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:112px;">
			<p class="g-pstyle0">Pfizer-BioNTech</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:11.9796%;margin-top:-13.4px;left:59.9188%;margin-left:-51px;width:102px;">
			<p class="g-pstyle1">BRITAIN AND</p>
			<p class="g-pstyle1">THE E.U.</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:22.2749%;margin-top:-6.8px;left:26.9877%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:25.2285%;margin-top:-6.8px;left:87.6982%;width:62px;">
			<p class="g-pstyle2">JAPAN</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:29.026%;margin-top:-6.8px;right:36.4459%;width:76px;">
			<p class="g-pstyle3">ALGERIA</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:35.3551%;margin-top:-6.8px;left:27.0816%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai2-7" class="g-type g-aiAbs g-aiPointText" style="top:36.1989%;margin-top:-6.8px;left:87.1071%;width:99px;">
			<p class="g-pstyle2">PHILIPPINES</p>
		</div>
		<div id="g-ai2-8" class="g-type g-aiAbs g-aiPointText" style="top:40.8403%;margin-top:-6.8px;left:71.7136%;width:79px;">
			<p class="g-pstyle2">BAHRAIN</p>
		</div>
		<div id="g-ai2-9" class="g-type g-aiAbs g-aiPointText" style="top:47.1694%;margin-top:-6.8px;right:76.1257%;width:71px;">
			<p class="g-pstyle3">MEXICO</p>
		</div>
		<div id="g-ai2-10" class="g-type g-aiAbs g-aiPointText" style="top:49.9543%;margin-top:-13.4px;left:69.359%;margin-left:-34.5px;width:69px;">
			<p class="g-pstyle1">SAUDI</p>
			<p class="g-pstyle1">ARABIA</p>
		</div>
		<div id="g-ai2-11" class="g-type g-aiAbs g-aiPointText" style="top:52.2327%;margin-top:-6.8px;left:37.5397%;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai2-12" class="g-type g-aiAbs g-aiPointText" style="top:55.1863%;margin-top:-6.8px;left:49.5396%;width:93px;">
			<p class="g-pstyle2">BOTSWANA</p>
		</div>
		<div id="g-ai2-13" class="g-type g-aiAbs g-aiPointText" style="top:57.7179%;margin-top:-6.8px;left:84.7684%;margin-left:-47px;width:94px;">
			<p class="g-pstyle1">SINGAPORE</p>
		</div>
		<div id="g-ai2-14" class="g-type g-aiAbs g-aiPointText" style="top:65.7348%;margin-top:-6.8px;right:62.0988%;width:55px;">
			<p class="g-pstyle3">PERU</p>
		</div>
		<div id="g-ai2-15" class="g-type g-aiAbs g-aiPointText" style="top:71.4732%;margin-top:-13.4px;left:7.2262%;margin-left:-40.5px;width:81px;">
			<p class="g-pstyle1">NEW</p>
			<p class="g-pstyle1">ZEALAND</p>
		</div>
		<div id="g-ai2-16" class="g-type g-aiAbs g-aiPointText" style="top:71.642%;margin-top:-6.8px;left:93.8013%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai2-17" class="g-type g-aiAbs g-aiPointText" style="top:75.6927%;margin-top:-13.4px;left:63.338%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">AFRICA</p>
		</div>
		<div id="g-ai2-18" class="g-type g-aiAbs g-aiPointText" style="top:73.7517%;margin-top:-6.8px;left:44.0078%;width:95px;">
			<p class="g-pstyle2">ARGENTINA</p>
		</div>
		<div id="g-ai2-19" class="g-type g-aiAbs g-aiPointText" style="top:78.815%;margin-top:-6.8px;right:58.9156%;width:59px;">
			<p class="g-pstyle3">CHILE</p>
		</div>
		<div id="g-ai2-20" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai2-21" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle4">Early, limited or</p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-pfizer-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-pfizer-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-pfizer-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:112px;">
			<p class="g-pstyle0">Pfizer-BioNTech</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:12.3497%;margin-top:-6.8px;left:53.7847%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:19.7017%;margin-top:-6.8px;left:53.9197%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:26.2136%;margin-top:-6.8px;right:51.626%;width:71px;">
			<p class="g-pstyle2">MEXICO</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:28.7343%;margin-top:-6.8px;left:75.7265%;width:67px;">
			<p class="g-pstyle3">BRAZIL</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:36.0863%;margin-top:-6.8px;right:26.8508%;width:55px;">
			<p class="g-pstyle2">PERU</p>
		</div>
		<div id="g-ai3-7" class="g-type g-aiAbs g-aiPointText" style="top:38.8171%;margin-top:-6.8px;left:87.8778%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai3-8" class="g-type g-aiAbs g-aiPointText" style="top:40.4136%;margin-top:-13.4px;left:12.3812%;margin-left:-40.5px;width:81px;">
			<p class="g-pstyle1">NEW</p>
			<p class="g-pstyle1">ZEALAND</p>
		</div>
		<div id="g-ai3-9" class="g-type g-aiAbs g-aiPointText" style="top:43.6484%;margin-top:-6.8px;right:18.3709%;width:59px;">
			<p class="g-pstyle2">CHILE</p>
		</div>
		<div id="g-ai3-10" class="g-type g-aiAbs g-aiPointText" style="top:51.1266%;margin-top:-13.4px;left:21.3432%;margin-left:-51px;width:102px;">
			<p class="g-pstyle1">BRITAIN AND</p>
			<p class="g-pstyle1">THE E.U.</p>
		</div>
		<div id="g-ai3-11" class="g-type g-aiAbs g-aiPointText" style="top:56.6721%;margin-top:-6.8px;left:50.5763%;width:90px;">
			<p class="g-pstyle3">MONGOLIA</p>
		</div>
		<div id="g-ai3-12" class="g-type g-aiAbs g-aiPointText" style="top:57.5123%;margin-top:-6.8px;left:75.408%;width:62px;">
			<p class="g-pstyle3">JAPAN</p>
		</div>
		<div id="g-ai3-13" class="g-type g-aiAbs g-aiPointText" style="top:61.0833%;margin-top:-6.8px;right:72.8835%;width:76px;">
			<p class="g-pstyle2">ALGERIA</p>
		</div>
		<div id="g-ai3-14" class="g-type g-aiAbs g-aiPointText" style="top:64.4443%;margin-top:-6.8px;left:74.8123%;width:99px;">
			<p class="g-pstyle3">PHILIPPINES</p>
		</div>
		<div id="g-ai3-15" class="g-type g-aiAbs g-aiPointText" style="top:67.175%;margin-top:-6.8px;left:43.2706%;width:79px;">
			<p class="g-pstyle3">BAHRAIN</p>
		</div>
		<div id="g-ai3-16" class="g-type g-aiAbs g-aiPointText" style="top:69.1916%;margin-top:-13.4px;left:33.353%;margin-left:-34.5px;width:69px;">
			<p class="g-pstyle1">SAUDI</p>
			<p class="g-pstyle1">ARABIA</p>
		</div>
		<div id="g-ai3-17" class="g-type g-aiAbs g-aiPointText" style="top:75.3673%;margin-top:-6.8px;left:1.9359%;width:93px;">
			<p class="g-pstyle3">BOTSWANA</p>
		</div>
		<div id="g-ai3-18" class="g-type g-aiAbs g-aiPointText" style="top:76.2076%;margin-top:-6.8px;left:69.5794%;margin-left:-47px;width:94px;">
			<p class="g-pstyle1">SINGAPORE</p>
		</div>
		<div id="g-ai3-19" class="g-type g-aiAbs g-aiPointText" style="top:84.1898%;margin-top:-6.8px;left:88.2384%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai3-20" class="g-type g-aiAbs g-aiPointText" style="top:86.2064%;margin-top:-13.4px;left:17.9906%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">AFRICA</p>
		</div>
		<div id="g-ai3-21" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai3-22" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle4">Early, limited or </p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-pfizer-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-03-02 11:54 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="moderna"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN U.S., ELSEWHERE</span>


<span class="g-limited">EMERGENCY USE IN MANY COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/moderna-800.png" class="g-vlogo" 
    style="width: 200px; height: 47px; margin-right: 20px;" alt="Moderna logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/nih-800.png" class="g-vlogo" 
    style="width: 270px; height: 42px;" alt="National Institutes of Health logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> <a href="https://www.nytimes.com/interactive/2020/health/moderna-covid-19-vaccine.html">mRNA-1273</a> or <a href="https://www.fiercepharma.com/marketing/moderna-secures-spikevax-name-europe-joins-pfizer-s-comirnaty-awaiting-official-name-and">Spikevax</a><br>
<span class="g-info">Efficacy:</span> Preventing Covid-19 illness: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2113017">93.2%</a>. Preventing severe disease: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2113017">98.2%</a>.<br>
<span class="g-info">Dose:</span> 2 doses, 4 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> 30 days with refrigeration, 6 months at –4°F (–20°C)<br>
<br>
</span>

<!-- description -->
On Dec. 18, 2020, the F.D.A. gave <a href="https://www.nytimes.com/2020/12/18/health/covid-vaccine-fda-moderna.html">emergency use authorization</a> for a vaccine made by the Boston-based company <strong>Moderna</strong>. The Moderna vaccine, known as Spikevax or mRNA-1273, was the second to be authorized for adults 18 and older by the F.D.A., coming a week after Comirnaty, the vaccine made by Pfizer and BioNTech. In 2021, Moderna shipped <a href="https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Advances-Across-Its-Industry-Leading-mRNA-Pipeline-and-Provides-Business-Update/default.aspx">over 800 million doses</a> worldwide. The F.D.A. gave full <a href="https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax/default.aspx">approval</a> to Spikevax on Jan. 31, 2022, and it is now authorized for children <a href="https://www.nytimes.com/2022/06/17/us/politics/pfizer-moderna-vaccines-kids-fda.html?smid=url-share">as young as six months</a>.<br><br> <subhed>VACCINE DEVELOPMENT</subhed>Like Pfizer and BioNTech, Moderna makes its vaccine from mRNA. In recent years, the company had tested mRNA vaccines for a number of diseases, but they had yet to bring one to market. In January 2020, they began developing a vaccine for the coronavirus.<br><br>The United States government bankrolled Moderna’s efforts, providing nearly $1 billion in support. In partnership with the <strong>National Institutes of Health</strong>, they found that Spikevax  <a href="https://www.nytimes.com/2020/07/28/health/coronavirus-moderna-vaccine-monkeys.html">protects monkeys</a> from the coronavirus.<br><br> <subhed>TRIAL RESULTS</subhed>In March 2020, Moderna launched  <a href="https://www.nytimes.com/2020/03/16/health/coronavirus-vaccine.html">the first clinical trial of a Covid-19 vaccine</a>. After those studies yielded <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2022483">promising results</a>, Phase 3 testing on 30,000 volunteers <a href="https://www.nytimes.com/2020/07/27/health/moderna-vaccine-covid.html">began</a> on July 27.<br><br>On Nov. 16, Moderna <a href="https://nyti.ms/2Uy7YmA">announced</a> that the first preliminary data demonstrated that the vaccine provided strong protection against Covid-19. In a <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2113017">paper</a> published in September 2021, researchers reported that the efficacy of the vaccine at preventing Covid-19 illness was 93.2 percent. The efficacy of the vaccine in preventing severe disease was 98.2 percent.<br><br>On May 25, 2021, Moderna <a href="https://www.nytimes.com/2021/05/25/science/moderna-vaccine-teens-efficacy.html">announced</a> that the vaccine safely provided strong protection to children as young as 12. On Sept. 22, an NYU <a href="https://www.sciencedirect.com/science/article/pii/S2589933321001762?via%3Dihub">study</a> suggested that Pfizer and Moderna vaccine doses which were administered to pregnant women later brought about a high amount of antibodies in their newborns. And on Oct. 25, Moderna said that the vaccine produced a <a href="https://www.nytimes.com/2021/10/25/health/moderna-covid-vaccine-children.html?searchResultPosition=1">powerful immune response</a> in children aged 6 through 11. <a href="https://www.biospace.com/article/clinical-catch-up-march-21-25/">Positive results</a> pushed Moderna to <a href="https://www.nytimes.com/live/2022/03/23/world/covid-19-mandates-cases-vaccine">announce</a> that it would apply for emergency use authorization in children younger than six on March 23, 2022.<br><br> <subhed>AUTHORIZATION</subhed>The United States currently authorizes the use of Spikevax for people six months and older. In June 2021, after the F.D.A. authorized the use of the vaccine in adults, Moderna <a href="https://investors.modernatx.com/news-releases/news-release-details/moderna-files-emergency-use-authorization-its-covid-19-vaccine">applied</a> to expand the authorization to children as young as 12. The Europe Medicines Agency <a href="https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu">authorized</a> giving Spikevax to adolescents in July and <a href="http://www.xinhuanet.com/english/europe/20220304/d985cd1b36ca4b739cf21b2d46fb5888/c.html">expanded its authorization</a> on March 3, 2022, to include children aged 6 to 11. On April 28, 2022, Moderna <a href="https://www.nytimes.com/live/2022/04/28/world/covid-19-mandates-vaccine-cases#moderna-fda-vaccine-children-under-6">asked</a> the F.D.A. to authorize its vaccine for children younger than 6. An advisory panel to the F.D.A. <a href="https://www.nytimes.com/live/2022/06/15/world/covid-19-mandates-vaccine-cases/covid-vaccine-kids-fda?smid=url-share">voted to recommend</a> Spikevax for that age group on June 15, and emergency authorization came two days later.<br><br> <subhed>DISTRIBUTION</subhed>While Moderna’s clinical trials were still underway in the summer of 2020, the company entered deals with several countries to supply the vaccine pending its approval. On Aug. 11, the United States government <a href="https://www.businesswire.com/news/home/20200811005852/en/Moderna-Announces-Supply-Agreement-U.S.-Government-Initial">awarded</a> the company $1.5 billion in exchange for 100 million doses if the vaccine proves safe and effective. Additional negotiations have increased the agreement to <a href="https://www.nytimes.com/2021/06/16/us/politics/moderna-covid-vaccine-booster-shots.html">500 million doses</a>. The <a href="https://investors.modernatx.com/news-releases/news-release-details/european-commission-purchases-additional-150-million-doses">European Commission</a> secured 460 million doses. Moderna has made similar deals with other countries including <a href="https://investors.modernatx.com/news-releases/news-release-details/canada-exercises-increased-option-20-million-doses-mrna-vaccine">Canada</a>, <a href="https://investors.modernatx.com/news-releases/news-release-details/moderna-partners-takeda-and-government-japan-supply-50-million">Japan</a>, <a href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-supply-agreement-ministry-public-health-supply">Qatar</a> and <a href="https://investors.modernatx.com/news-releases/news-release-details/moderna-confirms-40-million-covid-19-vaccine-dose-supply">South Korea</a>. The company has also pledged <a href="https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Additional-20-Million-Doses-of-COVID-19-Vaccine-to-COVAX-for-Supply-in-2021-and-New-Additional-Supply-Agreement-for-2022/default.aspx">650 million doses to COVAX</a>, a global vaccine initiative, to supply vaccines to low-income countries. On April 29, Moderna <a href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-additional-investments-increase-global-supply">announced</a> they would produce 800 million to 1 billion doses in 2021, and planned to manufacture 3 billion doses in 2022.<br><br> <subhed>VARIANTS</subhed>Initially, Moderna’s vaccine proved highly effective against variants such as Beta and Delta that emerged in 2021. The Omicron variant proved able to evade some of the immunity provided by the vaccine, making the vaccine less effective at protecting against infection. However, the vaccine remained effective at reducing the risk of hospitalization and death.<br><br> <subhed>BOOSTERS</subhed>When variants emerged in early 2021, Moderna initially tested boosters tailored to their particular molecular structure. In March 2021, Moderna began a <a href="https://clinicaltrials.gov/ct2/show/NCT04785144?term=covid-19+vaccine&draw=2&rank=95">Phase 1 trial</a> of a new mRNA vaccine made specifically for the <a href="https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html#B1351">Beta variant</a>, which yielded <a href="https://endpts.com/moderna-says-covid-19-vaccine-booster-increased-immune-response-against-variants-of-concern/">positive results</a> in humans and mice.<br><br>However, the first Moderna boosters to go into use were simply a third dose of the original vaccine. Results from a trial of a third Moderna shot in adults who received an organ transplant <a href="https://www.nejm.org/doi/full/10.1056/NEJMc2111462">suggested</a> that the booster improved their immune response — a finding that led the F.D.A. to authorize the booster shot in that population. The company then ran a trial on <a href="https://www.nytimes.com/2021/08/05/world/moderna-vaccine-efficacy.html">healthy volunteers</a> and found that a booster of the original strain raised their production of antibodies against all major variants.<br><br>On Oct. 20, the F.D.A. <a href="https://www.nytimes.com/2021/10/20/us/politics/fda-mix-match-covid-booster-shots.html">authorized</a> Moderna boosters for people over the age of 65 and those with weakened immune systems or greater risk of infection due to their work. In November 2021, the F.D.A. authorized the Moderna booster for all adults 18 and older. Moderna asked the F.D.A. for authorization for a <a href="https://www.nytimes.com/live/2022/03/17/world/covid-19-mandates-cases-vaccine/second-booster-covid-moderna">fourth dose</a> in adults 18 and older in March 2022. On March 29, the F.D.A. <a href="https://www.nytimes.com/live/2022/03/29/world/covid-19-mandates-cases-vaccine">authorized</a> the fourth dose in those 50 and older and certain immunocompromised people.<br><br>Meanwhile Moderna continued to experiment with variant-specific boosters. On June 8, 2022, they <a href="https://www.nytimes.com/2022/06/08/us/politics/moderna-vaccine-omicron-variant.html">announced</a> that an Omicron-specific booster produced a strong increase in antibodies against the variant. The company <a href="https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Bivalent-Booster-mRNA-1273.214-Demonstrates-Potent-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA.4-And-BA.5/default.aspx">said</a> on June 22 that the booster also works against newly evolved forms of the Omicron variant called BA.4 and BA.5. On July 29, Moderna <a href="https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-New-Supply-Contract-With-The-U.S.-Government-For-An-Initial-66-Million-Doses-Of-A-Moderna-Bivalent-Covid-19-Booster-Vaccine-With-Options-For-U.S.-Government-To-Purchase-Up-To-An-Additional-234-Million-Doses/default.aspx">announced</a> a deal with the United States government to provide 66 million booster shots, containing RNA for the original spike protein, as well as one shared by BA.4 and BA.5.<br><br>Moderna’s Omicron booster won <a href="https://investors.modernatx.com/news/news-details/2022/Medicines-and-Healthcare-Products-Regulatory-Agency-MHRA-Authorizes-Modernas-Omicron-Containing-Bivalent-Booster-in-the-UK/default.aspx">conditional approval</a> from the United Kingdom  on Aug. 15, 2022. The company said in an Aug. 23 statement that it had <a href="https://investors.modernatx.com/news/news-details/2022/Moderna-Completes-Application-To-U.S.-Food-And-Drug-Administration-For-Emergency-Use-Authorization-Of-Omicron-Targeting-Bivalent-Covid-19-Booster-Vaccine-mRNA-1273.222/default.aspx">completed</a> its application to the F.D.A. for approval. On Aug. 31, 2022, the F.D.A. <a href="https://www.nytimes.com/2022/08/31/us/politics/covid-booster-shots-variants.html">authorized Moderna’s latest booster</a>, a combination of RNA for the original coronavirus and BA.5.<br><br>For more details, see <strong><a href="https://www.nytimes.com/interactive/2020/health/moderna-covid-19-vaccine.html">How Moderna’s Vaccine Works</a></strong>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax/default.aspx">United States</a>, <a href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-health-canada-approves-its-covid-19-vaccine">Canada</a>, <a href="https://www.swissinfo.ch/eng/moderna-covid-vaccine-approved-for-use-in-switzerland/46280118">Switzerland</a>.<br>


<span class="g-info">Emergency use in:</span> <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Andorra</a>, <a href="https://www.saludneuquen.gob.ar/campana-de-vacunacion-contra-el-coronavirus/">Argentina</a>, <a href="https://www.aljazeera.com/news/2021/8/9/australian-pm-approves-use-of-moderna-vaccine">Australia</a>, <a href="https://www.aa.com.tr/en/latest-on-coronavirus-outbreak/moderna-vaccine-gets-approval-in-bangladesh/2289614">Bangladesh</a>, <a href="https://kuenselonline.com/dra-approves-emergency-use-of-moderna-vaccine-for-children-aged-12-17/">Bhutan</a>, <a href="https://www.businesswire.com/news/home/20210603005629/en/Moderna-Announces-Agreement-to-Supply-the-Republic-of-Botswana-with-its-COVID-19-Vaccine">Botswana</a>, <a href="http://www.xinhuanet.com/english/asiapacific/2021-06/20/c_1310018624.htm">Brunei</a>, <a href="https://www.canada.ca/en/health-canada/news/2020/12/health-canada-authorizes-moderna-covid-19-vaccine.html">Canada</a>, <a href="https://www.ispch.cl/noticia/el-isp-valida-el-uso-de-emergencia-de-la-vacuna-contra-covid-19-del-laboratorio-moderna/">Chile</a>, <a href="https://www.invima.gov.co/en/web/guest/invima-otorgo-autorizacion-sanitaria-de-uso-de-emergencia-a-la-vacuna-desarrollada-por-la-farmaceutica-moderna-switzerland-gmbh?redirect=%2Fen%2Fweb%2Fguest%2Fnoticias">Colombia</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Curacao</a>, <a href="https://dailynewsegypt.com/2021/10/31/egypt-receives-784280-doses-of-modernas-covid-19-vaccine/">Egypt</a>, <a href="https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu">European Union</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Faroe Islands</a>, <a href="https://www.health.gov.fj/fiji-to-receive-moderna-covid-19-vaccines-pregnant-women-also-to-be-vaccinated/">Fiji</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Ghana</a>, Greenland, <a href="https://gt.usembassy.gov/alert-covid-19-2/">Guatemala</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Guyana</a>, <a href="https://ht.usembassy.gov/covid-19-information/">Haiti</a>, <a href="https://hn.usembassy.gov/covid-19-information/">Honduras</a>, <a href="https://www.icelandreview.com/sci-tech/moderna-vaccine-granted-conditional-marketing-authorisation-in-iceland/">Iceland</a>, <a href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-emergency-use-authorization-its-covid-19">India</a>, <a href="http://www.xinhuanet.com/english/asiapacific/2021-07/02/c_1310040037.htm">Indonesia</a>, <a href="https://investors.modernatx.com/news-releases/news-release-details/israeli-ministry-health-authorizes-covid-19-vaccine-moderna-use">Israel</a>, <a href="https://www.japantimes.co.jp/news/2021/05/21/national/moderna-astrazeneca-formal-ok/">Japan</a>, <a href="https://www.bloomberg.com/news/articles/2021-08-19/kenya-approves-moderna-sinopharm-vaccines-amid-fourth-wave">Kenya</a>, <a href="https://gulfnews.com/world/gulf/kuwait/covid-19-kuwait-unlikely-to-import-sputnik-v-1.78388637">Kuwait</a>, <a href="https://reliefweb.int/sites/reliefweb.int/files/resources/libya_covid_update_25_final.pdf">Libya</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Liechtenstein</a>, <a href="https://www.facebook.com/malawimoh/posts/4098884300167054">Malawi</a>, <a href="https://www.reuters.com/article/health-coronavirus-malaysia/malaysia-grants-conditional-approval-for-moderna-covid-19-vaccine-idUSK7N2K400Z">Malaysia</a>, <a href="http://health.gov.mv/Uploads/Downloads//Informations/Informations(382).pdf">Maldives</a>, <a href="https://www.reuters.com/world/americas/mexico-health-regulator-approves-emergency-use-moderna-vaccine-2021-08-18/">Mexico</a>, <a href="https://gov.fm/index.php/component/content/article/35-pio-articles/news-and-updates/518-57-of-fsm-adults-fully-vaccinated-fda-approved-pfizer-vaccine-arrives-in-fsm-suitable-for-adolescents-multiple-repatriation-flights-scheduled-for-august-september?Itemid=177">Micronesia</a>, <a href="https://msmps.gov.md/comunicare/comunicate/membrii-nitag-au-venit-cu-recomandari-privind-utilizarea-vaccinurilor-impotriva-covid-19-in-republica-moldova/">Moldova</a>, <a href="https://news.mn/en/795048/">Mongolia</a>, <a href="http://www.dda.gov.np/events/moderna-covid-19-mrna-%E0%A4%96-%E0%A4%AA%E0%A4%95-%E0%A4%86%E0%A4%AA%E0%A4%A4%E0%A4%95-%E0%A4%B2-%E0%A4%A8-%E0%A4%AA-%E0%A4%B0%E0%A4%AF-%E0%A4%97-%E0%A4%85%E0%A4%A8-%E0%A4%AE%E0%A4%A4-%E0%A4%AA-%E0%A4%B0%E0%A4%A6-%E0%A4%A8-%E0%A4%97%E0%A4%B0-%E0%A4%8F%E0%A4%95-%E0%A4%B8%E0%A4%AE-%E0%A4%AC%E0%A4%A8-%E0%A4%A7%E0%A4%AE">Nepal</a>, <a href="https://guardian.ng/news/nigeria/nafdac-approves-emergency-use-of-three-additional-covid-19-vaccines-for-nigeria/">Nigeria</a>, <a href="https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/development-of-covid-19-vaccine/">Norway</a>, <a href="https://en.dailypakistan.com.pk/01-Jul-2021/pakistan-approves-emergency-use-of-moderna-s-covid-vaccine">Pakistan</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Palestinian Authority</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Paraguay</a>, <a href="https://www.digemid.minsa.gob.pe/covid-19/productos-covid-19">Peru</a>, <a href="https://www.reuters.com/world/asia-pacific/philippines-approves-emergency-use-modernas-covid-19-vaccine-2021-05-05/">Philippines</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Puerto Rico</a>, <a href="https://investors.modernatx.com/news-releases/news-release-details/qatar-ministry-public-health-issues-emergency-use-authorization">Qatar</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Republic of Congo</a>, <a href="https://www.rbc.gov.rw/index.php?id=777">Rwanda</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Saba</a>, <a href="http://health.gov.vc/health/images/stories/PDF/SRO-Public_Health_Emergency_Authorisation_of_Covid-19_Vaccine.pdf">Saint Vincent and the Grenadines</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Saint Martin</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/saudi-arabia-approves-modernas-covid-vaccine-state-news-agency-2021-07-09/">Saudi Arabia</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Seychelles</a>, <a href="https://www.straitstimes.com/singapore/health/spore-approves-modernas-covid-19-vaccine-first-shipment-to-arrive-around-march">Singapore</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">Sint Eustatius</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/skorea-approves-modernas-covid-19-vaccine-2021-05-21/">South Korea</a>, <a href="https://www.ft.lk/news/Approval-given-for-AstraZeneca-Pfizer-and-Moderna-vaccine-combination/56-719769">Sri Lanka</a>, <a href="https://www.taiwannews.com.tw/en/news/4196247">Taiwan</a>, <a href="https://news.trust.org/item/20210513105421-emnx4/">Thailand</a>, <a href="https://m.facebook.com/MinistryofHealthTT/photos/a.153051404724676/4635809886448783/?type=3&source=48">Trinidad and Tobago</a>, <a href="https://ua.usembassy.gov/covid-19-information/">Ukraine</a>, <a href="https://www.reuters.com/world/middle-east/uae-approves-moderna-covid-19-vaccine-emergency-use-2021-07-04/">United Arab Emirates</a>, <a href="https://investors.modernatx.com/news-releases/news-release-details/united-kingdom-medicines-and-healthcare-products-regulatory">United Kingdom</a>, <a href="https://tass.com/society/1260545">Vietnam</a>, <a href="https://covid-19pharmacovigilance.paho.org/moderna#col-0">West Bank</a>. Emergency use validation from the <a href="https://www.who.int/news/item/30-04-2021-who-lists-moderna-vaccine-for-emergency-use">World Health Organization</a>.<br>



</span>

<span class="g-updated">Updated Aug. 31, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-04-21 14:28 -->
<!-- ai file: map-moderna.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-moderna-box ,
	#g-map-moderna-box .g-artboard {
		margin:0 auto;
	}
	#g-map-moderna-box p {
		margin:0;
	}
	#g-map-moderna-box .g-aiAbs {
		position:absolute;
	}
	#g-map-moderna-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-moderna-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-moderna-box .g-aiPointText p { white-space: nowrap; }
	#g-map-moderna-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-moderna-900 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-moderna-900 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-moderna-900 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-moderna-900 .g-pstyle2 {
		height:13px;
	}
	#g-map-moderna-900 .g-pstyle3 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-moderna-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-moderna-720 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-moderna-720 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-moderna-720 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-moderna-720 .g-pstyle2 {
		height:13px;
	}
	#g-map-moderna-720 .g-pstyle3 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-moderna-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-moderna-600 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-moderna-600 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-moderna-600 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-moderna-600 .g-pstyle2 {
		height:13px;
	}
	#g-map-moderna-600 .g-pstyle3 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-moderna-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-moderna-335 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-moderna-335 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-moderna-335 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-moderna-335 .g-pstyle2 {
		height:13px;
	}
	#g-map-moderna-335 .g-pstyle3 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}

</style>

<div id="g-map-moderna-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-moderna-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-moderna-900-img" class="g-map-moderna-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-moderna-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:0%;width:132px;">
			<p class="g-pstyle0">Moderna vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-900 g-aiAbs g-aiPointText" style="top:13.0275%;margin-top:-13.4px;left:61.2398%;margin-left:-51px;width:102px;">
			<p class="g-pstyle1">BRITAIN AND</p>
			<p class="g-pstyle1">THE E.U.</p>
		</div>
		<div id="g-ai0-3" class="g-900 g-aiAbs g-aiPointText" style="top:22.6876%;margin-top:-6.8px;left:66.7314%;width:112px;">
			<p class="g-pstyle2">SWITZERLAND</p>
		</div>
		<div id="g-ai0-4" class="g-900 g-aiAbs g-aiPointText" style="top:22.9684%;margin-top:-6.8px;left:26.8132%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai0-5" class="g-900 g-aiAbs g-aiPointText" style="top:25.7766%;margin-top:-6.8px;left:87.443%;width:62px;">
			<p class="g-pstyle2">JAPAN</p>
		</div>
		<div id="g-ai0-6" class="g-900 g-aiAbs g-aiPointText" style="top:32.5162%;margin-top:-6.8px;left:76.1537%;width:90px;">
			<p class="g-pstyle2">MONGOLIA</p>
		</div>
		<div id="g-ai0-7" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:34.7627%;margin-top:-6.8px;left:27.074%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai0-8" class="g-900 g-aiAbs g-aiPointText" style="top:37.0092%;margin-top:-6.8px;left:66.5661%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">EGYPT</p>
		</div>
		<div id="g-ai0-9" class="g-900 g-aiAbs g-aiPointText" style="top:42.3447%;margin-top:-6.8px;left:55.384%;margin-left:-36.5px;width:73px;">
			<p class="g-pstyle1">NIGERIA</p>
		</div>
		<div id="g-ai0-10" class="g-900 g-aiAbs g-aiPointText" style="top:46.557%;margin-top:-6.8px;left:81.2994%;width:80px;">
			<p class="g-pstyle2">VIETNAM</p>
		</div>
		<div id="g-ai0-11" class="g-900 g-aiAbs g-aiPointText" style="top:46.8378%;margin-top:-6.8px;left:27.0812%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai0-12" class="g-900 g-aiAbs g-aiPointText" style="top:47.6802%;margin-top:-6.8px;left:76.9751%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai0-13" class="g-900 g-aiAbs g-aiPointText" style="top:57.5088%;margin-top:-6.8px;left:84.7621%;margin-left:-47px;width:94px;">
			<p class="g-pstyle1">SINGAPORE</p>
		</div>
		<div id="g-ai0-14" class="g-900 g-aiAbs g-aiPointText" style="top:58.3513%;margin-top:-6.8px;left:94.5156%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai0-15" class="g-900 g-aiAbs g-aiPointText" style="top:61.1594%;margin-top:-6.8px;left:53.9512%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle1">BOTSWANA</p>
		</div>
		<div id="g-ai0-16" class="g-900 g-aiAbs g-aiPointText" style="top:64.81%;margin-top:-6.8px;left:36.0793%;margin-left:-27.5px;width:55px;">
			<p class="g-pstyle1">PERU</p>
		</div>
		<div id="g-ai0-17" class="g-900 g-aiAbs g-aiPointText" style="top:73.5153%;margin-top:-6.8px;left:47.6583%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai0-18" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai0-19" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle3">Early, limited or</p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-moderna-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-moderna-720-img" class="g-map-moderna-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-moderna-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0153%;width:125px;">
			<p class="g-pstyle0">Moderna vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-720 g-aiAbs g-aiPointText" style="top:11.7521%;margin-top:-13.4px;left:61.2706%;margin-left:-51px;width:102px;">
			<p class="g-pstyle1">BRITAIN AND</p>
			<p class="g-pstyle1">THE E.U.</p>
		</div>
		<div id="g-ai1-3" class="g-720 g-aiAbs g-aiPointText" style="top:21.3954%;margin-top:-6.8px;left:66.7442%;width:112px;">
			<p class="g-pstyle2">SWITZERLAND</p>
		</div>
		<div id="g-ai1-4" class="g-720 g-aiAbs g-aiPointText" style="top:22.0993%;margin-top:-6.8px;left:26.6543%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai1-5" class="g-720 g-aiAbs g-aiPointText" style="top:32.6578%;margin-top:-6.8px;left:77.506%;width:90px;">
			<p class="g-pstyle2">MONGOLIA</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:35.1214%;margin-top:-6.8px;left:27.2062%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai1-7" class="g-720 g-aiAbs g-aiPointText" style="top:37.2331%;margin-top:-6.8px;left:66.7122%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">EGYPT</p>
		</div>
		<div id="g-ai1-8" class="g-720 g-aiAbs g-aiPointText" style="top:42.8642%;margin-top:-6.8px;left:54.8415%;margin-left:-36.5px;width:73px;">
			<p class="g-pstyle1">NIGERIA</p>
		</div>
		<div id="g-ai1-9" class="g-720 g-aiAbs g-aiPointText" style="top:46.3837%;margin-top:-6.8px;left:26.5589%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai1-10" class="g-720 g-aiAbs g-aiPointText" style="top:46.3837%;margin-top:-6.8px;left:80.7705%;width:80px;">
			<p class="g-pstyle2">VIETNAM</p>
		</div>
		<div id="g-ai1-11" class="g-720 g-aiAbs g-aiPointText" style="top:48.4954%;margin-top:-6.8px;left:76.9609%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai1-12" class="g-720 g-aiAbs g-aiPointText" style="top:58.7019%;margin-top:-6.8px;left:94.3329%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai1-13" class="g-720 g-aiAbs g-aiPointText" style="top:58.7019%;margin-top:-6.8px;left:53.589%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle1">BOTSWANA</p>
		</div>
		<div id="g-ai1-14" class="g-720 g-aiAbs g-aiPointText" style="top:65.7408%;margin-top:-6.8px;left:35.9998%;margin-left:-27.5px;width:55px;">
			<p class="g-pstyle1">PERU</p>
		</div>
		<div id="g-ai1-15" class="g-720 g-aiAbs g-aiPointText" style="top:72.4279%;margin-top:-6.8px;left:48.9957%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai1-16" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai1-17" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle3">Early, limited or </p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-moderna-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-moderna-600-img" class="g-map-moderna-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-moderna-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:72px;">
			<p class="g-pstyle0">Moderna</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-600 g-aiAbs g-aiPointText" style="top:11.1357%;margin-top:-13.4px;left:60.5966%;margin-left:-51px;width:102px;">
			<p class="g-pstyle1">BRITAIN AND</p>
			<p class="g-pstyle1">THE E.U.</p>
		</div>
		<div id="g-ai2-3" class="g-600 g-aiAbs g-aiPointText" style="top:19.3213%;margin-top:-6.8px;left:66.9721%;width:112px;">
			<p class="g-pstyle2">SWITZERLAND</p>
		</div>
		<div id="g-ai2-4" class="g-600 g-aiAbs g-aiPointText" style="top:21.431%;margin-top:-6.8px;left:26.8989%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai2-5" class="g-600 g-aiAbs g-aiPointText" style="top:32.8234%;margin-top:-6.8px;left:77.2808%;width:90px;">
			<p class="g-pstyle2">MONGOLIA</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:35.3551%;margin-top:-6.8px;left:27.1039%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai2-7" class="g-600 g-aiAbs g-aiPointText" style="top:37.0428%;margin-top:-6.8px;left:66.5553%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">EGYPT</p>
		</div>
		<div id="g-ai2-8" class="g-600 g-aiAbs g-aiPointText" style="top:46.7475%;margin-top:-6.8px;left:27.3583%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai2-9" class="g-600 g-aiAbs g-aiPointText" style="top:48.8572%;margin-top:-6.8px;left:77.052%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai2-10" class="g-600 g-aiAbs g-aiPointText" style="top:55.6082%;margin-top:-6.8px;left:58.0535%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle1">BOTSWANA</p>
		</div>
		<div id="g-ai2-11" class="g-600 g-aiAbs g-aiPointText" style="top:60.2496%;margin-top:-6.8px;left:93.6216%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai2-12" class="g-600 g-aiAbs g-aiPointText" style="top:66.1568%;margin-top:-6.8px;left:35.9782%;margin-left:-27.5px;width:55px;">
			<p class="g-pstyle1">PERU</p>
		</div>
		<div id="g-ai2-13" class="g-600 g-aiAbs g-aiPointText" style="top:72.9078%;margin-top:-6.8px;left:50.1322%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai2-14" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai2-15" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle3">Early, limited or</p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-moderna-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-moderna-335-img" class="g-map-moderna-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-moderna-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:72px;">
			<p class="g-pstyle0">Moderna</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-335 g-aiAbs g-aiPointText" style="top:12.3497%;margin-top:-6.8px;left:53.4933%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:19.4917%;margin-top:-6.8px;left:54.0165%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai3-4" class="g-335 g-aiAbs g-aiPointText" style="top:26.6337%;margin-top:-6.8px;left:53.0615%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai3-5" class="g-335 g-aiAbs g-aiPointText" style="top:40.0774%;margin-top:-6.8px;left:85.1415%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai3-6" class="g-335 g-aiAbs g-aiPointText" style="top:50.9165%;margin-top:-13.4px;left:23.0176%;margin-left:-51px;width:102px;">
			<p class="g-pstyle1">BRITAIN AND</p>
			<p class="g-pstyle1">THE E.U.</p>
		</div>
		<div id="g-ai3-7" class="g-335 g-aiAbs g-aiPointText" style="top:55.6218%;margin-top:-6.8px;left:34.2392%;width:112px;">
			<p class="g-pstyle2">SWITZERLAND</p>
		</div>
		<div id="g-ai3-8" class="g-335 g-aiAbs g-aiPointText" style="top:62.7638%;margin-top:-6.8px;left:55.8791%;width:90px;">
			<p class="g-pstyle2">MONGOLIA</p>
		</div>
		<div id="g-ai3-9" class="g-335 g-aiAbs g-aiPointText" style="top:65.0744%;margin-top:-6.8px;left:33.7815%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">EGYPT</p>
		</div>
		<div id="g-ai3-10" class="g-335 g-aiAbs g-aiPointText" style="top:71.1662%;margin-top:-6.8px;left:54.3329%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai3-11" class="g-335 g-aiAbs g-aiPointText" style="top:74.9472%;margin-top:-6.8px;left:13.5068%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle1">BOTSWANA</p>
		</div>
		<div id="g-ai3-12" class="g-335 g-aiAbs g-aiPointText" style="top:77.4679%;margin-top:-6.8px;left:88.3572%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai3-13" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai3-14" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle3">Early, limited or </p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-moderna-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-04-21 14:28 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="zydus"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN INDIA</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/zyduslife-800.png" class="g-vlogo" 
    style="width: 118px; height: 65px; margin-right: 20px;" alt="Zydus Lifesciences logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> ZyCoV-D<br>
<span class="g-info">Efficacy:</span> <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2822%2900151-9/fulltext">66.6%</a><br>
<span class="g-info">Dose:</span> <a href="https://www.indiainfoline.com/article/news-top-story/dcgi-approves-emergency-use-of-zycov-d-as-a-two-dose-vaccine-122042700214_1.html">2 or 3 doses</a>, 4 weeks apart<br>
<span class="g-info">Type:</span> Skin injection<br>
<span class="g-info">Storage:</span> <a href="https://www.business-standard.com/article/current-affairs/zycov-d-shot-can-remain-stable-at-room-temperature-zydus-cadila-chairman-120121200544_1.html">Stable at room temperature</a> for three months<br>
<br>
</span>

<!-- description -->
In July 2020, the Indian vaccine-maker <strong>Zydus Lifesciences </strong>(then known as Zydus Cadila) began <a href="https://twitter.com/ZydusUniverse/status/1278997989382483968">testing</a> a DNA-based vaccine delivered by a skin patch. After getting <a href="https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00300-X/fulltext">promising results</a> in their Phase 1 trial, they launched a <a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306&EncHid=&userName=vaccine">Phase 2 trial</a> on ZyCoV-D on Aug. 6. On Jan. 3, 2021 the Indian government gave Zydus Lifesciences <a href="https://timesofindia.indiatimes.com/city/ahmedabad/cdsco-recommends-nod-for-zydus-cadilas-phase-3-vaccine-trials/articleshow/80077209.cms">permission</a> to advance to a <a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=51254&EncHid=&userName=Novel%20Corona%20Virus-2019-nCov%20vaccine%20by">Phase 3 trial </a>with 30,000 volunteers.<br><br>The company announced on July 1 that the vaccine had an <a href="https://www.thehindubusinessline.com/companies/phase-iii-trials-of-zycov-d-find-vaccine-to-be-efficacious-safe-and-immunogenic/article65280711.ece">efficacy of 66.6%</a> and that none of the vaccinated volunteers in the trial developed severe disease or died, making ZyCoV-D the first DNA-based vaccine shown to work against Covid-19. The results were <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2822%2900151-9/fulltext">published</a> in April 2022.<br><br>Zydus Lifesciences received <a href="https://www.bloombergquint.com/coronavirus-outbreak/india-grants-emergency-use-approval-to-zydus-cadilas-covid-19-vaccine-for-12-years-and-above">emergency authorization</a> from the Indian government on Aug. 20, 2021. The authorization was later <a href="https://www.newindianexpress.com/states/andhra-pradesh/2021/dec/22/zycov-d-vax-gets-nod-to-use-among-12-plus-2398323.html">expanded</a> to include adolescents 12 and older. On Feb. 3, 2022, Zydus Lifesciences <a href="https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/zydus-cadila-first-consignment-covid-vaccine-zycov-d-government-1907593-2022-02-02">announced</a> it had delivered its first shipment of vaccines to the Indian government. Zydus Lifesciences received authorization from Indian health officials to administer ZyCoV-D in a <a href="https://www.indiainfoline.com/article/news-top-story/dcgi-approves-emergency-use-of-zycov-d-as-a-two-dose-vaccine-122042700214_1.html">two-dose regimen</a> on April 27.<br><br> But in May 2022 the Hindu Business Line <a href="https://www.thehindubusinessline.com/companies/zydus-sees-no-significant-business-from-zycov-d-with-negligible-demand/article65454061.ece">reported</a> that there had been negligible demand for ZyCoV-D, with no commercial opportunity for the rest of the year.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/india-approves-zydus-cadilas-covid-19-vaccine-emergency-use-2021-08-20/">India</a>.<br>



</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.102.0 - 2021-08-20 18:25 -->
<!-- ai file: map-zydus.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-zydus-box ,
	#g-map-zydus-box .g-artboard {
		margin:0 auto;
	}
	#g-map-zydus-box p {
		margin:0;
	}
	#g-map-zydus-box .g-aiAbs {
		position:absolute;
	}
	#g-map-zydus-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-zydus-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-zydus-box .g-aiPointText p { white-space: nowrap; }
	#g-map-zydus-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-zydus-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-zydus-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-zydus-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-zydus-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-zydus-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-zydus-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-zydus-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-zydus-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-zydus-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-zydus-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-zydus-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-zydus-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-zydus-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-zydus-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-zydus-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-zydus-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-zydus-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-zydus-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-zydus-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-zydus-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-zydus-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-zydus-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-zydus-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:104px;">
			<p class="g-pstyle0">Zydus Cadila</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:47.3994%;margin-top:-6.8px;left:76.9064%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-zydus-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-zydus-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-zydus-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:98px;">
			<p class="g-pstyle0">Zydus Cadila</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:47.4396%;margin-top:-6.8px;left:76.8956%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-zydus-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-zydus-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-zydus-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:93px;">
			<p class="g-pstyle0">Zydus Cadila</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:46.7475%;margin-top:-6.8px;left:77.057%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-zydus-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-zydus-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-zydus-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:93px;">
			<p class="g-pstyle0">Zydus Cadila</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:70.536%;margin-top:-6.8px;left:54.5337%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-zydus-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-08-20 18:25 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="gennova"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN INDIA</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/gennova-800.png" class="g-vlogo" 
    style="width: 180px; height: 42px; margin-right: 20px;" alt="Gennova Biopharmaceuticals logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/hdtbio-800.png" class="g-vlogo" 
    style="width: 120px; height: 46px;" alt="HDT Bio logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
On June 28, 2022, India <a href="https://indianexpress.com/article/india/dcgi-indigenous-mrna-covid-jab-emergency-use-covovax-7997142/">authorized</a> GEMCOVAC-19, a Covid-19 vaccine that contains self-amplifying RNA. It became the third RNA-based vaccine to get the green light. And unlike RNA vaccines from Moderna and Pfizer-BioNTech, which have to be frozen, GEMCOVAC-19 only needs to be refrigerated.<br><br>Seattle-based <strong>HDT Bio </strong>developed the original technology behind GEMCOVAC-19. Their prototype vaccine, known as <a href="https://gennova.bio/mrna-vaccines/">HGC019</a>, safely provoked animals to make antibodies to the coronavirus. In July 2020, HDT Bio teamed up with <strong>Gennova Biopharmaceuticals</strong> to launch clinical trials in India. <a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=54697">Phase 1/2 trials</a> started in December 2020.<br><br>In March 2022, HDT Bio <a href="https://www.fiercebiotech.com/biotech/nih-backed-hdt-bio-sues-indian-partner-950m-alleging-it-willfully-and-maliciously-stole">sued</a> Gennova’s parent company, Emcore. In its court filing, HDT Bio accused the Indian company of stealing trade secrets for the vaccine and claiming it as their own. In May, Emcore sought to have the lawsuit <a href="https://endpts.com/indian-drugmaker-seeks-to-toss-bloated-billion-dollar-lawsuit-over-covid-vaccine-candidate/">dismissed</a>. A decision was still pending as of June.<br><br>Gennova has yet to publish the results of its Phase 3 study. The company <a href="https://indianexpress.com/article/explained/india-mrna-covid-vaccine-gennova-biopharmaceuticals-gemcovac-7998264/">told</a> the Indian Express that it had submitted data to the Indian government showing that GEMCOVAC’s immune response was as good or better than Covishield, the Indian version of the AstraZeneca vaccine.<br><br>Meanwhile, HDT Bio has partnered with Quratis to launch a trial in <a href="https://www.hdt.bio/news-blog/hdt-bio-partner-quratis-doses-first-healthy-volunteers-in-phase-1-trial-of-hdt-bios-rna-covid-19-vaccine-in-south-korea">South Korea</a>, with SENAI CIMATEC in <a href="https://www.hdt.bio/news-blog/brazils-senai-cimatec-doses-first-healthy-volunteers-in-phase-1-trial-of-hdt-bios-rna-covid-19-vaccine">Brazil</a> and with <a href="https://www.businesswire.com/news/home/20220405005060/en/HDT-Bio-Demonstrates-RNA-Vaccines-Matched-to-SARS-CoV2-Variants-Protect-Against-Infection-of-Upper-Airways-Important-for-Preventing-Transmission">another company in China</a>. HDT Bio is also reportedly creating a version of the RNA vaccine tailored for the Omicron variant.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://indianexpress.com/article/india/dcgi-indigenous-mrna-covid-jab-emergency-use-covovax-7997142/">India</a>.<br>



</span>

<span class="g-updated">Updated June 29, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.111.0 - 2022-06-29 11:36 -->
<!-- ai file: map-gennova.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-gennova-box ,
	#g-map-gennova-box .g-artboard {
		margin:0 auto;
	}
	#g-map-gennova-box p {
		margin:0;
	}
	#g-map-gennova-box .g-aiAbs {
		position:absolute;
	}
	#g-map-gennova-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-gennova-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-gennova-box .g-aiPointText p { white-space: nowrap; }
	#g-map-gennova-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-gennova-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-gennova-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-gennova-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-gennova-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-gennova-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-gennova-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-gennova-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-gennova-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-gennova-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-gennova-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-gennova-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-gennova-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-gennova-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-gennova-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-gennova-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-gennova-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-gennova-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-gennova-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-gennova-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-gennova-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-gennova-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-gennova-900-img" class="g-map-gennova-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-gennova-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:79px;">
			<p class="g-pstyle0">Gennova</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:47.3994%;margin-top:-6.8px;left:76.9064%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-gennova-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-gennova-720-img" class="g-map-gennova-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-gennova-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:75px;">
			<p class="g-pstyle0">Gennova</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:47.4396%;margin-top:-6.8px;left:76.8956%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-gennova-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-gennova-600-img" class="g-map-gennova-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-gennova-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:71px;">
			<p class="g-pstyle0">Gennova</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:46.7475%;margin-top:-6.8px;left:77.057%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-gennova-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-gennova-335-img" class="g-map-gennova-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-gennova-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:71px;">
			<p class="g-pstyle0">Gennova</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:70.536%;margin-top:-6.8px;left:54.5337%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-gennova-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-06-29 11:36 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="ams"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/ams-800.png" class="g-vlogo" 
    style="width: 55px; height: 55px; margin-right: 20px;" alt="Academy of Military Medical Sciences logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/abogen-800.png" class="g-vlogo" 
    style="width: 200px; height: 52px; margin-right: 20px;" alt="Suzhou Abogen Biosciences logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/walvax-800.png" class="g-vlogo" 
    style="width: 200px; height: 29px;" alt="Walvax Biotechnology logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In the spring of 2022, the Omicron variant created a <a href="https://www.nytimes.com/2022/05/26/world/asia/china-economy-zero-covid.html">crippling surge</a> of Covid cases in China. Calls came for China to switch from inactivated-virus vaccines to more effective ones made from mRNA. Rather than import these vaccines from Moderna or Pfizer-BioNTech, the government reportedly <a href="https://apnews.com/article/covid-science-technology-health-00e7e5ebf9460bad115b491009b58bef">chose to wait</a> for the development of a Chinese mRNA vaccine, called AWcorna. But even though research on AWcorna began early in the pandemic, Phase 3 clinical trial results had yet to emerge as of June 2022.<br><br>In July 2020, Chinese researchers at the <strong>Academy of Military Medical Sciences</strong>, <strong>Suzhou Abogen Biosciences</strong> and <strong>Walvax Biotechnology</strong> <a href="https://doi.org/10.1016/j.cell.2020.07.024">published</a> a paper describing how they created AWcorna (originally known as ARCoV). While authorized mRNA vaccines from Pfizer-BioNTech and Moderna encode the entire spike protein, AWcorna only encodes the tip of the protein, called the receptor binding domain.<br><br>A Phase 1 trial carried out in the summer of 2020 demonstrated that the vaccine was safe and produced modest amounts of antibodies, as the researchers described in a paper they  <a href="https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00280-9/fulltext">published</a> in January 2022.<br><br>The <a href="http://www.chictr.org.cn/showprojen.aspx?proj=119719">Phase 2 trial</a> of AWcorna commenced  in January 2021, followed by a <a href="https://clinicaltrials.gov/ct2/show/NCT04847102?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 3 trial</a> in July. In January 2022, Reuters <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-walvax-says-has-most-participants-large-mrna-covid-vaccine-trial-2022-01-27/">reported</a> that the trial had progressed in China, Indonesia, and Mexico. Reuters <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-mrna-covid-vaccine-candidates-2022-02-28/">reported</a> in February 2022 that Walvax had a capacity to make 400 million doses and planned to increase their production. But in April Bloomberg <a href="https://www.bloomberg.com/news/articles/2022-04-26/china-covid-situation-worsened-by-lack-of-local-mrna-vaccine">reported</a> that disappointing preliminary results might delay the introduction of the vaccine in China till the end of 2022.<br><br>On Nov. 24, 2021, researchers also registered a separate <a href="http://www.chictr.org.cn/showproj.aspx?proj=140886">Phase 3 trial</a> to assess the vaccine as a booster. In a <a href="https://www.nature.com/articles/s41422-022-00626-w">paper</a> published in February 2022, researchers reported that a third dose of AWcorna was potent against Omicron in vaccinated mice. That study was followed by a clinical trial in which researchers compared AWcorna as a booster against the inactivated virus vaccines Sinopharm and Sinovac. Researchers <a href="https://www.nature.com/articles/s41422-022-00681-3">found</a> that AWcorna produced higher levels of antibodies that neutralize the coronavirus. But it is still not clear how AWcorna compares against other mRNA vaccines, either as a primary vaccination or a booster.<br><br>In December 2021, the U.S. government put the military academy on <a href="https://www.washingtonpost.com/business/2021/12/16/china-entity-list-military-institute-added/">an export blacklist</a> over concerns their research on biometrics and other technologists might become a threat to national security. It’s not clear how that move will affect the development of AWcorna.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 29, 2022</span>

</p>

<a name="inovio"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/inovio-800.png" class="g-vlogo" 
    style="width: 180px; height: 55px; margin-right: 20px;" alt="Inovio logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> INO-4800<br>
<span class="g-info">Efficacy:</span> Unknown<br>
<span class="g-info">Dose:</span> To be determined<br>
<span class="g-info">Type:</span> Skin injection<br>
<span class="g-info">Storage:</span> Over a year at room temperature<br>
<br>
</span>

<!-- description -->
The Pennsylvania-based company <strong>Inovio </strong><a href="https://www.nytimes.com/2020/08/09/business/coronavirus-vaccine-inovio.html">gained attention</a> early in the pandemic.  At a March 2020 White House meeting, Inovio’s chief executive, J. Joseph Kim, described the company as a leader in the race to make a Covid vaccine. But two years later, Inovio had yet to demonstrate that their vaccine is effective<br><br>Before the pandemic, the company developed DNA-based vaccines that are delivered into the skin with electric pulses from a hand-held device. At the start of the pandemic, Inovio created a DNA vaccine against the spike protein on the coronavirus. A Phase 1 trial, <a href="https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30433-8/fulltext">published in December 2020</a>, did not uncover any  serious adverse effects, and measured an immune response in all 38 volunteers.<br><br>But Inovio soon experienced a number of setbacks. The company became <a href="https://www.nytimes.com/2020/08/09/business/coronavirus-vaccine-inovio.html">embroiled</a> in several lawsuits with stockholders and a company partner. On Sept. 28, 2020, the F.D.A. put the vaccine on a <a href="http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Reports-FDA-Partial-Clinical-Hold-for-Planned-Phase-2--3-Trial-of-COVID-19-Vaccine-Candidate-INO-4800/default.aspx">partial hold</a> due to questions about the delivery device. The pause was <a href="http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Initiation-of-Phase-2-Segment-of-its-Phase-23-Clinical-Trial-for-its-COVID-19-DNA-Vaccine-Candidate-INO-4800-Trial-Will-Be-Funded-by-the-U.S.-Department-of-Defense/default.aspx">lifted</a> in November.<br><br>In November 2020, Inovio started <a href="https://www.medrxiv.org/content/10.1101/2021.05.07.21256652v1">Phase 2 trials</a> in the <a href="https://clinicaltrials.gov/ct2/show/NCT04642638">United States</a> as well as in <a href="http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Publication-of-Phase-1-Data-from-its-COVID-19-DNA-Vaccine-Candidate-INO-4800-in-The-Lancets-EClinicalMedicine/default.aspx">China and South Korea</a>. But by the time Inovio began preparing for a Phase 3 trial of their vaccine, other vaccines had already been authorized and being deployed on a wide scale. As a result, the U.S. government decided in April 2021 to <a href="https://www.prnewswire.com/news-releases/inovio-planning-for-ex-us-global-phase-3-trial-for-ino-4800-301275657.html">stop supporting Inovio’s trial</a>.<br><br>On Aug. 26, 2021, Inovio <a href="https://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-Receives-Authorization-to-Conduct-Phase-3-Efficacy-Trial-of-its-COVID-19-DNA-Vaccine-Candidate-INO-4800/default.aspx">announced</a> that Brazilian regulators authorized their Phase 3 trial, and in September they <a href="https://twitter.com/InovioPharma/status/1435937330506915840">announced</a> that they had received approval for another Phase 3 trial in the Philippines and in <a href="https://www.prnewswire.com/news-releases/inovio-receives-regulatory-authorization-to-conduct-phase-3-efficacy-trial-of-its-covid-19-dna-vaccine-candidate-ino-4800-in-mexico-301382333.html">Mexico</a>. The F.D.A. <a href="https://www.prnewswire.com/news-releases/inovio-receives-us-fda-authorization-to-proceed-with-innovate-phase-3-segment-for-its-covid-19-vaccine-candidate-ino-4800-in-the-us-301419117.html">authorized</a> a Phase 3 trial in the U.S. on Nov. 9, 2021. However, these trials have yet to move forward.<br><br>More disappointment came in February 2022, when the company <a href="https://ir.inovio.com/news-releases/news-releases-details/2022/INOVIO-Reports-Fourth-Quarter-2021-and-Year-End-Financial-Results/default.aspx">reported</a> that the vaccine was proving less potent against the Omicron variant. As a result, Inovio paused the trial to change its design. They will be measuring the vaccine’s efficacy only against severe disease, rather than against any symptomatic cases of Covid.<br><br>On May 10, 2022, Inovio said that it would <a href="https://www.prnewswire.com/news-releases/inovio-reports-first-quarter-2022-financial-results-and-program-developments-301544326.html">discontinue its Phase 3 trial</a> and focus attention on testing the vaccine as a booster. Their booster trial is currently in <a href="https://www.inovio.com/dna-medicines-pipeline/">Phase 2</a>.<br><br>The World Health Organization selected Inovio’s vaccine as one its first candidates in the <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-of-covid-19-vaccines">Solidarity Trial Vaccine study</a>. In an August 2022 corporate presentation, Inovio said that this Phase 3 trial had begun.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 12, 2022</span>

</p>

<a name="arcturus"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-phase3 ">

<!-- phases -->








<span class="g-phase2">PHASE 2</span> <span class="g-phase3">PHASE 3</span> <span class="g-combined">COMBINED PHASES</span>

<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/arcturus-800.png" class="g-vlogo" 
    style="width: 165px; height: 62px; margin-right: 20px;" alt="Arcturus logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/dukenus-800.png" class="g-vlogo" 
    style="width: 215px; height: 48px;" alt="Duke-NUS Medical School logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> ARCT-154<br>
<span class="g-info">Efficacy:</span> 55% against infection, 95.3% against severe disease. (Trial conducted when Delta and Omicron were dominant.)<br>



<br>
</span>

<!-- description -->
The California-based company <strong>Arcturus Therapeutics</strong> and <strong>Duke-NUS Medical School</strong> in Singapore have developed a  vaccine called ARCT-154 that delivers mRNA that can self-replicate inside cells. As a result, the vaccine requires a lower dose to produce the viral proteins required for an immune response. <a href="https://www.biorxiv.org/content/10.1101/2020.09.03.280446v1">Tests on animals</a> showed that it protected them against infection.<br><br>Starting in August 2020, Arcturus <a href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-it-has-initiated-dosing-its">launched</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT04668339">series</a> of <a href="https://clinicaltrials.gov/ct2/show/NCT04668339">clinical</a> <a href="https://clinicaltrials.gov/ct2/show/NCT05012943?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">trials</a> on two different versions of the vaccine. <a href="https://www.businesswire.com/news/home/20220124005288/en/Arcturus-Therapeutics-Updates-Data-from-ARCT-154-and-ARCT-165-Booster-Clinical-Trial-Demonstrating-Robust-Neutralizing-Antibody-Responses-to-SARS-CoV-2-and-Several-Variants">Results</a> from the trials suggest that both candidates stimulate the production of antibodies against several variants, including <a href="https://www.businesswire.com/news/home/20220125005602/en/Arcturus-Therapeutics-Reports-New-Data-Demonstrating-Neutralizing-Antibody-Immune-Response-to-the-SARS-CoV-2-Omicron-Variant-from-ARCT-154-and-ARCT-165-Booster-Clinical-Trial">Omicron</a>.<br><br>On April 20, 2022, Arcturus <a href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-announces-self-amplifying-covid-19-mrna-vaccine">announced</a> that ARCT-154 had an efficacy of 55 percent against infection, and 95.3 percent against severe disease, including death. While the efficacy of the vaccine was lower than mRNA vaccines from Moderna and Pfizer-BioNTech, the company noted that its volunteers were exposed to the Delta and Omicron variants, instead of the original strain of the coronavirus. In May 2022, Arcturus <a href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-first-quarter-2022-financial">reported</a> that ARCT-154 performed well as a booster for people vaccinated with Comirnaty and later reported that it <a href="https://www.businesswire.com/news/home/20220809006007/en/Arcturus-Therapeutics-Announces-Second-Quarter-2022-Financial-Update-and-Pipeline-Progress">raised antibodies</a> against the Omicron variant and <a href="https://www.businesswire.com/news/home/20220818005266/en/Arcturus-Reports-Durability-Data-Against-Omicron-Variants-Including-BA.5-at-Six-Month-Timepoint-Following-Booster-with-ARCT-154-COVID-19-Vaccine">its subvariants</a>.<br><br>On February 28, 2022, Arcturus <a href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-fourth-quarter-and-full-year-0">announced</a> it had applied for emergency use authorization in Vietnam for ARCT-154. In an August 2022 company <a href="https://www.bloomberg.com/press-releases/2022-08-09/arcturus-therapeutics-announces-second-quarter-2022-financial-update-and-pipeline-progress">report</a>, it said that a government reorganization delayed the vaccine’s review. Arcturus said it expected authorization in the fourth quarter of 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>

<a name="daiichi"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-phase3 ">

<!-- phases -->








<span class="g-phase2">PHASE 2</span> <span class="g-phase3">PHASE 3</span> <span class="g-combined">COMBINED PHASES</span>

<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/daiichi-800.png" class="g-vlogo" 
    style="width: 200px; height: 35px; margin-right: 20px;" alt="Daiichi Sankyo logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/utokyo-800.png" class="g-vlogo" 
    style="width: 210px; height: 54px;" alt="University of Tokyo logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Japan-based researchers at <strong>Daiichi Sankyo</strong> have developed an mRNA vaccine against the coronavirus in collaboration with the <strong>University of Tokyo</strong>. They <a href="https://www.daiichisankyo.com/files/news/pressrelease/pdf/202103/20210322_E1.pdf">launched</a> a Phase 1/2 trial of the vaccine, named DS-5670, on March 22, 2021. In an Oct. 21 <a href="https://www.daiichisankyo.com/files/news/pressrelease/pdf/202110/20211021_E.pdf">press release</a>, Daiichi Sankyo said that the vaccine produced no relevant safety concerns in the trial. The company began <a href="https://www.daiichisankyo.com/files/news/pressrelease/pdf/202111/20211117_E.pdf">Phase 2 trials</a> on Nov. 17, and reported positive results  in a May 26, 2022 <a href="https://www.daiichisankyo.com/files/news/pressrelease/pdf/202205/20220526_E.pdf">press release</a>.<br><br>In January 2022, the company <a href="https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202201/20220131_J.pdf">started</a>  a <a href="https://jrct.niph.go.jp/latest-detail/jRCT2071210106">Phase 2/3 trial</a> of the vaccine as a booster. On May 26, 2022, Daiichi Sankyo <a href="https://www.daiichisankyo.com/files/news/pressrelease/pdf/202205/20220526_E.pdf">announced</a> that the level of antibodies produced by a DS-5670 booster were comparable or higher than authorized mRNA vaccines. The company said it was going to launch a trial on 4,500 volunteers to compare the performance of their booster to one that has already been approved. In June, Biospectrum <a href="https://www.biospectrumasia.com/news/25/20434/japans-daiichi-sankyo-to-commercialise-mrna-vaccine-against-covid-19-in-2022.html">reported</a> that Daiichi Sankyo planned to commercialize the vaccine by the end of 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 18, 2022</span>

</p>

<a name="providence"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/providence-800.png" class="g-vlogo" 
    style="width: 110px; height: 100px; margin-right: 20px;" alt="Providence Therapeutics logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Canada’s <strong>Providence Therapeutics</strong> specializes in messenger RNA vaccines to treat cancer. In response to the pandemic, they developed an mRNA vaccine against the coronavirus. They launched a <a href="https://clinicaltrials.gov/ct2/show/NCT04765436">Phase 1 study</a> of an RNA vaccine in late January 2021, and in May 2022 they <a href="https://www.medrxiv.org/content/10.1101/2022.05.06.22274690v1">published</a> results of the trial, showing that the vaccine  <a href="https://www.providencetherapeutics.com/providence-therapeutics-announces-very-favorable-interim-phase-1-trial-data-for-ptx-covid19-b-its-mrna-vaccine-against-covid-19">appeared</a> safe and produced promising levels of antibodies. In August 2021, Providence Therapeutics launched a <a href="https://clinicaltrials.gov/ct2/show/NCT05175742?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 2 trial</a> comparing the vaccine to Comirnaty.<br><br>In June 2021, the company reached an <a href="https://www.biologicale.com/news.html">agreement</a> with the Indian vaccine maker Biological E to carry out further trials in India. Biological E agreed to purchase up to 30 million doses and planned to scale their production of the vaccine to as many as a billion doses in 2022. In September, Providence also <a href="https://health.economictimes.indiatimes.com/news/pharma/everest-to-bring-canadian-biotechs-potential-covid-shots-to-china-other-markets/86166310">reached</a> an agreement with Everest Medicines to produce and market the vaccine in China.<br><br>In December 2021, Providence Therapeutics <a href="https://providencetherapeutics.com/press-details/providence-therapeutics-and-everest-medicines-announces-that-ptx-covid19-b-a-mrna-vaccine-for-covid-19-has-received-approval-for-inclusion-in-who-solidarity-trial-vaccines-stv-program.html">announced</a> that the World Health Organization had chosen its vaccine as one of the candidates it will test in its <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-of-covid-19-vaccines">Solidarity Trial Vaccine study</a>.<br><br>In an Aug. 24, 2022, update, Everest <a href="https://www.prnewswire.com/news-releases/everest-medicines-announces-interim-results-for-first-half-of-2022-301611629.html">said</a> that it and Providence expect to launch a Phase 3 trial for the booster vaccine this year. The two companies predict that its vaccine will be approved and marketed globally in 2023.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>

<a name="chula"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/chula-800.png" class="g-vlogo" 
    style="width: 148px; height: 54px; margin-right: 20px;" alt="Chulalongkorn University logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/chulavrc-800.png" class="g-vlogo" 
    style="width: 280px; height: 57px;" alt="Chula Vaccine Research Center logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at Thailand’s <strong>Chulalongkorn University</strong> developed several potential vaccines for the coronavirus. The furthest along is an mRNA-based vaccine known as ChulaCov19. In September 2020, the <strong>Chula Vaccine Research Center</strong> registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04566276">Phase 1 trial</a> to test it in humans. Delays in funding and manufacturing slowed the study’s launch until <a href="http://www.xinhuanet.com/english/asiapacific/2021-06/15/c_1310009011.htm">June 2021</a>. In May 2022, Chula researchers issued a <a href="https://www.medrxiv.org/content/10.1101/2022.05.12.22274989v1">report</a> showing that the Phase 1 volunteers produced higher antibodies than people who received Comirnaty.<br><br>In an <a href="https://www.bangkokpost.com/business/1993579/covid-19-spurs-thailands-rise-as-global-medical-hub">interview</a> with the Bangkok Post, the leader of the project said that up to 30 million doses might be produced for Thailand and six other Asian countries if the vaccine proved to be safe and effective. Citing positive preliminary results, the researchers <a href="https://www.chula.ac.th/en/news/49950/">said</a> in August that the vaccine would soon advance to the next phase of clinical trials.<br><br>At a November 2021 conference at Chulalongkorn University, the scientists behind the vaccine said that <a href="https://www.chula.ac.th/en/news/55782/">Phase 2 trials were completed</a> with satisfactory results, and that the Thai government had approved Phase 3 trials. But a Phase 3 trial is not yet registered.<br><br>In May 2022, the Bangkok Post <a href="https://www.bangkokpost.com/thailand/general/2306270/first-lot-of-local-covid-vaccine-produced">reported</a> that a factory in Thailand was beginning to produce the vaccine, and it could be authorized by the end of 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 3, 2022</span>

</p>

<a name="aim"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/aim-800.png" class="g-vlogo" 
    style="width: 180px; height: 29px; margin-right: 20px;" alt="AIM Vaccine logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Chinese researchers from <strong>AIM Vaccine</strong> and <strong>Liverna Therapeutics </strong>have developed an mRNA vaccine against the coronavirus. They registered a <a href="http://www.chictr.org.cn/showproj.aspx?proj=131000">Phase 1 trial</a> in China on July 31, 2021, and reported <a href="https://www.asahi.com/and/pressrelease/413535692/">positive results</a> in January 2022. On April 29, 2022, they registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05352867?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 2 trial</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 29, 2022</span>

</p>

<a name="cspc"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/cspc-800.png" class="g-vlogo" 
    style="width: 237px; height: 30px; margin-right: 20px;" alt="CSPC Pharmaceutical Group logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>CSPC Pharmaceutical Group</strong> is working on an mRNA vaccine against the coronavirus, called SYS6006. After <a href="https://www.scmp.com/business/china-business/article/3172972/china-approves-cspc-cansino-mrna-vaccines-clinical-trial">promising results</a> from preclinical studies, CSPC said on April 3, 2022, that it had <a href="https://www.chinadaily.com.cn/a/202204/05/WS624b7c15a310fd2b29e550e6.html">received approval</a> to begin <a href="https://clinicaltrials.gov/ct2/show/NCT05354089?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">clinical</a> <a href="https://clinicaltrials.gov/ct2/show/NCT05354063?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">trials</a> in China. The researchers moved to <a href="https://clinicaltrials.gov/ct2/show/NCT05439824?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 2 trials</a> on June 30.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 1, 2022</span>

</p>

<a name="anges"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/anges-800.png" class="g-vlogo" 
    style="width: 81px; height: 50px; margin-right: 20px;" alt="AnGes logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/osaka-u-800.png" class="g-vlogo" 
    style="width: 193px; height: 50px; margin-right: 20px;" alt="Osaka University logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/takara-800.png" class="g-vlogo" 
    style="width: 148px; height: 50px;" alt="Takara Bio logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> AG0302-COVID19<br>
<span class="g-info">Efficacy:</span> Unknown<br>
<span class="g-info">Dose:</span> 2 doses, 2 weeks apart<br>
<span class="g-info">Type:</span> Skin injection<br>
<span class="g-info">Storage:</span> Over a year at room temperature<br>
<br>
</span>

<!-- description -->
On June 30, 2020, the Japanese biotechnology company <strong>AnGes</strong> <a href="https://www.japantimes.co.jp/news/2020/06/30/national/science-health/japan-first-coronavirus-vaccine-clinical-test-starts/">launched</a> a Phase 1 trial to test a DNA-based vaccine, developed in partnership with <strong>Osaka University</strong> and <strong>Takara Bio</strong>. The company moved on to a <a href="https://clinicaltrials.gov/ct2/show/NCT04655625?">Phase 2/3 trial</a> in December. Preliminary results <a href="https://www.anges.co.jp/blog/detail.php?p=100352">suggested</a> the dose was too low to produce a strong immune response, and so the researchers registered a new <a href="https://clinicaltrials.gov/ct2/show/NCT04993586?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">Phase 1/2 trial</a> of the vaccine at a higher dose on Augs. 6, 2021. On Nov. 25, AnGes <a href="https://www.anges.co.jp/blog/detail.php?p=100420&page_now=2">released a statement</a> rebutting  reports that it had abandoned progress on the vaccine. Even though the candidate’s ability to generate antibodies has been disappointing, it said, the trials would continue. AnGes <a href="https://www.anges.co.jp/blog/detail.php?p=100486">said</a> on Feb. 15, 2022, that the trial was experiencing delays and that the final results still need to be analyzed before moving to Phase 3 trials.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 3, 2022</span>

</p>

<a name="geneone"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/geneone-800.png" class="g-vlogo" 
    style="width: 230px; height: 49px; margin-right: 20px;" alt="GeneOne Life Science logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>GeneOne Life Science</strong>, a South Korean biotech company, developed a DNA-based vaccine that encodes two proteins from the coronavirus. In December 2020, they launched a <a href="https://clinicaltrials.gov/ct2/show/NCT04673149">Phase 1/2 trial</a> with 345 participants. After receiving positive interim results from the trial, GeneOne <a href="http://www.koreaherald.com/view.php?ud=20210708000805">announced</a> on July 8, 2021 that it would begin Phase 2.<br><br>GeneOne is also experimenting with different vaccine delivery techniques. On Oct. 20, the company registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05085639?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2">Phase 1 trial</a> to gauge how well their candidate works when injected into a patient’s arm and delivered as a nasal spray. In the study, the researchers will also see if a skin suction device will improve outcomes. In January 2022, GeneOne <a href="https://clinicaltrials.gov/ct2/show/NCT05182567">registered</a> a new trial to test their vaccine as a booster. The trial began on May 23, 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 3, 2022</span>

</p>

<a name="takis"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/takis-800.png" class="g-vlogo" 
    style="width: 170px; height: 68px; margin-right: 20px;" alt="Takis Biotech logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/rottapharm-800.png" class="g-vlogo" 
    style="width: 250px; height: 64px;" alt="Rottapharm Biotech logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>Takis Biotech</strong> and <strong>Rottapharm Biotech, </strong>two vaccine companies in Italy, developed a vaccine called COVID-eVax. A special device uses a tiny electric pulse to deliver DNA through the skin. The DNA enters cells, which use the genetic instructions to make spike protein fragments. In February 2021, Takis and Rottapharm <a href="https://clinicaltrials.gov/ct2/show/NCT04788459?term=covid-19+vaccine&draw=3">launched a Phase 1/2 trial</a> in Italy. COVID-eVax can remain stable at room temperature. In September, the companies issued a <a href="https://www.rottapharmbiotech.com/07-september-2021-press-release/">press release</a> stating that the Phase 1 trial delivered promising results. But they were not yet able to proceed to a Phase 2 trial because the vaccination rate in Italy had climbed so high that recruiting volunteers would be difficult.<br><br>In November 2021, Takis and Rottapharm announced they had created an <a href="https://www.rottapharmbiotech.com/29-november-2021-press-release/">Omicron-specific version</a> of COVID-eVax. But they acknowledged that they still lacked funding for additional clinical studies. By then, Italy’s vaccination rate had climbed so far that the companies said it would be difficult to recruit enough volunteers to move to the Phase 2 trial. They have not issued any further statements about the status of the vaccine.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 29, 2022</span>

</p>

<a name="elixirgen"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/elixirgen-800.png" class="g-vlogo" 
    style="width: 180px; height: 46px; margin-right: 20px;" alt="Elixirgen Therapeutics logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at Baltimore-based <strong>Elixirgen Therapeutics</strong> have created an RNA vaccine, named EXG-5003, that targets a small part of the coronavirus spike protein. In May 2021 they <a href="https://www.prnewswire.com/news-releases/elixirgen-therapeutics-announces-dosing-of-first-and-second-participants-in-its-covid-19-vaccine-phase-12-clinical-trial-at-fujita-health-university-301298735.html">launched</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT04863131?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=4">Phase 1/2 trial</a> of the vaccine in Japan. On Oct. 8, Elixirgen <a href="https://www.prnewswire.com/news-releases/elixirgen-therapeutics-announces-licensing-agreement-for-its-novel-covid-19-vaccine-301396136.html">announced</a> that it has licensed its vaccine to an undisclosed company for worldwide marketing, excluding Japan.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Oct. 8, 2021</span>

</p>

<a name="eyegene"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/eyegene-800.png" class="g-vlogo" 
    style="width: 200px; height: 42px; margin-right: 20px;" alt="Eyegene logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at Korean biotechnology company <strong>Eyegene </strong>have developed an mRNA vaccine that uses a delivery system slightly different from other genetic vaccines. Instead of using a lipid nanoparticle, their vaccine uses liposomes — tiny fat bubbles — to bring the genetic material to the cell. Korean regulators <a href="https://www.koreabiomed.com/news/articleView.html?idxno=12040">approved</a> a Phase 1/2 trial in August 2021 for the vaccine, called EG-COVID. Eyegene’s C.E.O., Wonil Yoo, <a href="https://www.wowtv.co.kr/NewsCenter/News/Read?articleId=A202109220067&t=NNv">told</a> a Korean television station that the trial began in September. But in December, Eyegene <a href="https://www.koreabiomed.com/news/articleView.html?idxno=12720">said</a> that it will receive help from the Korean government in recruiting patients for the trial, after experiencing difficulties finding enough eligible participants. In January 2022, Eyegene <a href="https://clinicaltrials.gov/ct2/show/NCT05188469?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">registered</a> the trial in Australia. Eyegene <a href="http://www.koreabiomed.com/news/articleView.html?idxno=13172">received approval</a> to conduct a Phase 1/2 booster trial of EG-COVID in Australia on Feb. 21, 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Feb. 21, 2022</span>

</p>

<a name="stemirna"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/stemirna-800.png" class="g-vlogo" 
    style="width: 179px; height: 36px; margin-right: 20px;" alt="Stemirna Therapeutics logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/shanghaieast-800.png" class="g-vlogo" 
    style="width: 60px; height: 64px;" alt="Shanghai East Hospital logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Chinese researchers at <strong>Stemirna Therapeutics</strong> have developed an mRNA vaccine in collaboration with <strong>Shanghai East Hospital</strong>. They registered a <a href="http://www.chictr.org.cn/showprojen.aspx?proj=126046">Phase 1 trial</a> on May 1, 2021. The scientists registered another <a href="https://clinicaltrials.gov/ct2/show/NCT05144139?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1/2 trial</a> on Dec. 3 and an <a href="https://www.chictr.org.cn/showprojen.aspx?proj=170605">additional Phase 1 trial</a> on May 12, 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>

<a name="nykode"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/nykode-800.png" class="g-vlogo" 
    style="width: 127px; height: 61px; margin-right: 20px;" alt="Nykode logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Norwegian biopharmaceutical company <strong>Nykode Therapeutics </strong>have developed <a href="https://www.vaccibody.com/wp-content/uploads/2021/06/210629_PR_Vaccibody-CoV-2-FINAL.pdf">two DNA vaccine candidates</a> to protect against coronavirus variants. On Oct. 6, 2021, the researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05069623?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">Phase 1/2 trial</a>. They will test the two vaccines head-to-head in the first part of the study and then select one for further trials. Formerly called <strong>Vaccibody</strong>, the company <a href="https://www.biospace.com/article/vaccibody-changes-name-to-nykode-and-teams-up-with-regeneron/">changed</a> its name on Nov. 23. Nykode and needle-free injection technology company <strong>PharmaJet </strong>announced a new <a href="https://www.businesswire.com/news/home/20211214005014/en/PharmaJet-Partner-Nykode-Therapeutics-Announces-Phase-12-Clinical-Trial-With-Next-Generation-DNA-Based-COVID-19-Vaccine-Candidates">Phase 1/2 trial</a> to address variants on Dec. 14.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Dec. 16, 2021</span>

</p>

<a name="immunitybio2"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/immunitybio-800.png" class="g-vlogo" 
    style="width: 200px; height: 67px; margin-right: 20px;" alt="ImmunityBio logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In addition to its adenovirus-based vaccine, <strong>ImmunityBio</strong> has developed two additional vaccines that use <a href="https://www.biorxiv.org/content/10.1101/2022.03.22.485230v1">self-amplifying RNA</a> to stimulate the body’s T cells. Researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05370040?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1/2 trial</a> to compare the two as boosters in May 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated May 23, 2022</span>

</p>

<a name="entos"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/entos-800.png" class="g-vlogo" 
    style="width: 190px; height: 49px; margin-right: 20px;" alt="entos logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
The Canadian company <strong><a href="https://www.entospharma.com/">Entos Pharmaceuticals</a></strong> has created a DNA vaccine for the coronavirus. Most other genetic vaccines carry the gene for the spike protein on the surface of the virus. Entos instead chose the gene for a protein called nucleocapsid that sits inside the virus’s membrane. The company is betting it can offer long-lasting immunity.<br><br>In October 2020, Entos <a href="https://clinicaltrials.gov/ct2/show/NCT04591184">launched</a> a Phase 1 trial in Canada for their vaccine, called Covigenix VAX-001. They <a href="https://www.entospharma.com/news/phase-i-trial-of-entos-covid-19-dna-vaccine-began-today-with-first-recruits">began</a> dosing participants on April 15. Entos C.E.O. John Lewis <a href="https://edmonton.ctvnews.ca/edmonton-made-vaccine-prepares-for-next-phase-of-clinical-trials-1.5535230">told</a> Canadian media on Aug. 4 that the vaccine produced a sufficient immune response without adverse reactions. Lewis later told the Owen Sound Sun Times in December 2021 that a <a href="https://www.owensoundsuntimes.com/news/local-news/owen-sound-natives-firm-to-begin-phase-2-trial-of-covid-19-dna-vaccine">Phase 2 trial would begin</a> in South Africa in early 2022, but the company had not yet announced the trial as of August 2022. Entos is also one of four vaccine makers that received a portion of an <a href="https://globalnews.ca/news/8417576/alberta-government-funding-develop-manufacture-vaccines/">$81.2 million commitment</a> from the Alberta government to develop their candidates.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 12, 2022</span>

</p>

<a name="symvivo"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/symvivo-800.png" class="g-vlogo" 
    style="width: 200px; height: 41px; margin-right: 20px;" alt="symvivo logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
On Nov. 2, 2020, the Canadian company <strong>Symvivo</strong> <a href="https://www.businesswire.com/news/home/20201102005496/en/First-Healthy-Volunteer-Dosed-in-Symvivo%E2%80%99s-Phase-1-Clinical-Trial-of-bacTRL-Spike%E2%84%A2-an-Oral-COVID-19-Vaccine-Candidate">announced</a> they had administered a DNA vaccine to their first volunteer in a <a href="https://clinicaltrials.gov/ct2/show/NCT04334980">Phase 1 trial</a>. The DNA is inserted into <a href="https://www.symvivo.com/covid-19">harmless bacteria</a>, which volunteers swallow in a frozen liquid (the company is working on putting the bacteria into a pill). When the bacteria reach the intestines, the DNA slips into cells in the gut lining, which then make viral proteins. Symvivo <a href="https://www.newswire.ca/news-releases/symvivo-corporation-receives-funding-for-covid-19-vaccine-program-809774563.html">announced</a> on July 19, 2021 that it received nearly $5 million in funding from the National Research Council of Canada’s Industrial Research Assistance Program to continue developing its vaccine.<br><br>In its <a href="https://clinicaltrials.gov/ct2/show/NCT04334980">trial registry</a>, Symvivo said that it expected results from the Phase 1 study in February 2022. The company has yet to release any data from the trial. And on May 3, Symvivo <a href="https://clinicaltrials.gov/ct2/history/NCT04334980?A=10&B=11&C=merged#StudyPageTop">pushed</a> the study completion date to September 2022 in the trial registry.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>

<a name="bionetasia"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/bionetasia-800.png" class="g-vlogo" 
    style="width: 119px; height: 53px; margin-right: 20px;" alt="BioNet-Asia logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/technovalia-800.png" class="g-vlogo" 
    style="width: 163px; height: 70px;" alt="Technovalia logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Using a delivery system from <a href="https://pharmajet.com/needle-free-technology/">PharmaJet</a>, researchers at <strong>BioNet-Asia </strong>and Australia-based <strong>Technovalia </strong>have developed a DNA vaccine called COVIGEN that can be pushed through the skin without a needle. Instead, the dose is loaded into a handheld device and shot directly into cell tissue through a jet spray of fluid. Vaccines for the flu already use the device, which PharmaJet says is a <a href="https://pharmajet.com/needle-free-technology/">safer alternative</a> to needle injections.<br><br>The University of Sydney <a href="https://clinicaltrials.gov/ct2/show/NCT04742842?term=vaccine+SARS-CoV-2&draw=4&rank=207">registered a Phase 1 trial</a> of COVIGEN in Australia on Feb. 8, 2021. In January 2022, Technovalia <a href="https://www.technovalia.com/media-releases/covalia-study-update-interim-safety-results-from-needle-free-sars-cov2-dna-vaccine-phase-1-trial">announced</a> that an interim study found no safety issues with the vaccine. The company said that the trial would shift to testing COVIGEN as a booster on people who are already vaccinated.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 3, 2022</span>

</p>

<a name="scancell"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/scancell-800.png" class="g-vlogo" 
    style="width: 190px; height: 48px; margin-right: 20px;" alt="Scancell logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>Scancell</strong>, a British company that develops treatments for cancer, has created two DNA vaccine candidates against the coronavirus. Their first vaccine, called SCOV1, targets the original virus and its early variants. SCOV2 is intended to act as a booster shot. Scancell is using a <a href="https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/scancell-selects-pharmajet%E2%80%99s-clinically-proven-needle-free-systems-for-covid-19-vaccine-trial-final-17.08.21.pdf">needle-free injection technology</a> made by Colorado-based PharmaJet to administer the vaccines into the skin through a concentrated jet of fluid. On Jan. 31, 2022, the company <a href="https://www.scancell.co.uk/update-on-covidity-phase-1-clinical-trial-in-south-africa-">announced</a> that it had dosed the first volunteer in its <a href="https://clinicaltrials.gov/ct2/show/NCT05047445?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">Phase 1 clinical trial</a> in South Africa. Scancell <a href="https://www.proactiveinvestors.com/companies/news/978064/scancell-says-south-african-authorities-have-signed-off-a-broadening-of-its-covid-study-978064.html">broadened</a> the trial to include individuals with prior infection or other vaccines in March. In May, Scancell <a href="https://clinicaltrials.gov/ct2/history/NCT05047445?A=2&B=3&C=merged#StudyPageTop">pushed</a> the study completion date to December 2022 in their trial registry.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>

<a name="gritstonerna"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/gritstone-800.png" class="g-vlogo" 
    style="width: 200px; height: 49px; margin-right: 20px;" alt="Gritstone bio logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/niaid-800.png" class="g-vlogo" 
    style="width: 200px; height: 49px;" alt=" logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>Gritstone bio </strong>has developed experimental vaccines in recent years that teach the immune system to attack tumors. The company has created vaccines for Covid-19 based on RNA molecules that can make copies of themselves, increasing the production of viral proteins from each cell. While most RNA-based vaccines produce spike proteins, Gritstone bio includes RNA molecules to produce parts of other viral proteins. T cells can use those additional proteins to recognize infected cells and kill them. Experiments on monkeys, <a href="https://www.nature.com/articles/s41467-022-31005-z">published</a> in June 2022, showed that the vaccine produced high levels of antibodies and protected the animals from disease.<br><br>On Sept. 20, 2021, Gritstone <a href="https://www.nasdaq.com/articles/gritstone-bio-doses-first-volunteer-in-phase-1-trial-of-grt-r910-as-covid-19-vaccine">dosed</a> the first volunteer in a Phase 1 trial to gauge the effectiveness of the mRNA vaccine as a booster shot in older adults who have already received the Astrazeneca vaccine. In January 2022, the company <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-announces-positive-clinical-results-first-cohort-phase">announced</a> promising initial results from the trial.<br><br>In a financial report in August 2022, Gritstone bio <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-reports-second-quarter-2022-financial-results-and">announced</a> that three additional Phase 1 trials were underway, <a href="https://clinicaltrials.gov/ct2/show/NCT05435027?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">including</a> volunteers with immune systems compromised by HIV and B cell deficiencies.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 12, 2022</span>

</p>

<a name="hku"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/hku-800.png" class="g-vlogo" 
    style="width: 280px; height: 54px; margin-right: 20px;" alt="University of Hong Kong logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at the <strong>University of Hong Kong </strong>developed a DNA vaccine against the coronavirus. In a Phase 1 trial, which was <a href="https://clinicaltrials.gov/ct2/show/NCT05102643?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">registered</a> on Nov. 1, 2021, the researchers injected the vaccine into the muscles of volunteers, followed by electric shocks to induce cells into receiving the vaccine. They wrote in the trial record that this strategy could improve vaccine uptake.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 3, 2022</span>

</p>

<a name="vlpjapan"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/vlpjapan-800.png" class="g-vlogo" 
    style="width: 200px; height: 50px; margin-right: 20px;" alt="VLP Therapeutics Japan logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>VLP Therapeutics Japan</strong>, a subsidiary of Maryland-based company VLP Therapeutics, <a href="https://vlptherapeutics.com/press-release/13232/">won funding</a> in August 2020 from the Japanese government to develop a self-amplifying RNA vaccine against the coronavirus. In October 2020, it <a href="https://vlptherapeutics.com/press-release/13235/">announced</a> a partnership with FUJIFILM to help manufacture their candidate, called VLPCOV-01. The researchers registered a <a href="https://jrct.niph.go.jp/latest-detail/jRCT2071210067">Phase 1 clinical trial</a> in Japan a year later. On Feb. 1, 2022, they launched a <a href="https://jrct.niph.go.jp/latest-detail/jRCT2051210164">Phase 1 trial</a> for the vaccine as a booster.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Feb. 7, 2022</span>

</p>

<a name="diosynvax"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/diosynvax-800.png" class="g-vlogo" 
    style="width: 75px; height: 47px; margin-right: 20px;" alt="DIOSynVax logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/ucambridge-800.png" class="g-vlogo" 
    style="width: 228px; height: 47px;" alt="University of Cambridge logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at <strong>DIOSynVax</strong>, led by a professor at the <strong>University of Cambridge</strong>, have developed a genetic vaccine that targets <a href="https://www.cam.ac.uk/stories/DIOSCoVax_safetytrial">specific parts</a> of the coronavirus that they say are common across all known variants. They have partnered with <strong><a href="https://www.businesswire.com/news/home/20220118005182/en/University-of-Cambridge-Begins-COVID-19-Clinical-Trial-Using-PharmaJet%E2%80%99s-Needle-free-System">PharmaJet</a></strong> to administer the vaccine, called DIOS-CoVax, through the skin without using needles. On Dec. 14, the BBC reported that a <a href="https://www.bbc.com/news/uk-england-59642182">Phase 1 trial</a> began in the United Kingdom to assess DIOS-CoVax’s effectiveness as a booster in participants who have already received two doses of another vaccine. On March 8, 2022, the Coalition for Epidemic Preparedness Innovations <a href="https://cepi.net/news_cepi/cepi-and-diosynvax-partner-in-quest-to-develop-broadly-protective-betacoronavirus-vaccine/">announced</a> that it would give up to $42 million  to DIOSynVax to develop a vaccine against a range of coronaviruses.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated March 11, 2022</span>

</p>

<a name="curevac2"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/curevac-800.png" class="g-vlogo" 
    style="width: 200px; height: 54px; margin-right: 20px;" alt="CureVac logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/gsk-800.png" class="g-vlogo" 
    style="width: 55px; height: 47px;" alt="GSK logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> CV2nCoV<br>

<span class="g-info">Dose:</span> 2 doses, 4 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Stable at least 3 months at 36–46°F (2–8°C)<br>
<br>
</span>

<!-- description -->
In March 2022, the German company <strong>CureVac, </strong>in partnership with <strong>GSK</strong>, launched <a href="https://clinicaltrials.gov/ct2/show/NCT05260437">Phase 1 clinical trial</a> for an mRNA vaccine called CV2nCoV. The vaccine is an improved version of CureVac’s initial Covid vaccine, <a href="#curevac">CVnCoV</a>, which delivered disappointing results in clinical trials in 2021 .<br><br>After abandoning the CVnCoV trial, CureVac retooled the vaccine to create CV2nCoV. The new version triggers the production of more spike proteins in cells, leading to a stronger immune response. In November 2021, researchers at Harvard published a <a href="https://www.nature.com/articles/s41586-021-04231-6">study</a> in the journal Nature showing that monkeys given CV2CoV produced antibodies to the coronavirus at a level comparable to the Comirnaty vaccine from Pfizer and BioNTech. In the Phase 1 clinical trial, researchers will evaluate  CV2CoV as a booster shot. The researchers <a href="https://www.curevac.com/en/2022/03/30/curevac-and-gsk-start-clinical-development-of-second-generation-covid-19-vaccine-candidate-cv2cov/">dosed</a> the first participant on March 30, 2022. <a href="https://www.curevac.com/en/curevac-and-gsks-bivalent-second-generation-mrna-vaccine-candidate-shown-to-be-highly-effective-against-sars-cov-2-variants-in-preclinical-study/">Preclinical studies</a> suggest that the vaccine is effective against emerging variants, the companies said in April 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug 26, 2022</span>

</p>

<a name="melbournemrna"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/melbourne-800.png" class="g-vlogo" 
    style="width: 115px; height: 116px; margin-right: 20px;" alt="University of Melbourne logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at the University of Melbourne are testing an mRNA vaccine in a <a href="https://clinicaltrials.gov/ct2/show/NCT05272605?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2">Phase 1 trial</a>. In the trial, which was registered on March 9, 2022, the researchers plan to measure antibody levels produced in volunteers who have already received two doses and a booster shot of widely used vaccines. The university is also testing a <a href="#melbourneprotein">protein-based vaccine</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated March 11, 2022</span>

</p>

<a name="cansinomrna"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/cansino-new-800.png" class="g-vlogo" 
    style="width: 200px; height: 37px; margin-right: 20px;" alt="CanSino Biologics logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Chinese researchers at <strong>CanSino Biologics </strong>have also developed an mRNA vaccine against the coronavirus. <a href="https://www.biospectrumasia.com/news/37/20005/china-approves-clinical-trial-for-cansinobios-covid-19-mrna-vaccine-.html">Preclinical studies</a> have shown that the vaccine stimulates antibody production against emerging variants. On April 4, 2022, CanSino <a href="https://www.chinadaily.com.cn/a/202204/05/WS624b7c15a310fd2b29e550e6.html">announced</a> that it had received approval from the Chinese government to begin clinical trials.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 8, 2022</span>

</p>

<a name="jiangsurecbio"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/recbio-800.png" class="g-vlogo" 
    style="width: 190px; height: 46px; margin-right: 20px;" alt="Jiangsu Rec-Biotechnology logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>Jiangsu Rec-Biotechnology</strong>, a Chinese biotechnology company, registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05351450">Phase 1 trial</a> for an mRNA vaccine called RH109 on April 28, 2022. They will test the vaccine as a booster on 24 participants.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 29, 2022</span>

</p>

<a name="rnacure"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/rnacure-800.png" class="g-vlogo" 
    style="width: 180px; height: 39px; margin-right: 20px;" alt="RNACure logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>Shanghai RNACure Biopharma</strong>, a Chinese biotechnology company, registered a two-part Phase 1 clinical trial on May 31, 2022. The company has developed a number of mRNA molecules as potential vaccines for Covid. Some coax cells to make virus-like particles. Others only encode the spike protein on the surface of the coronavirus. For their clinical trials, RNACure is collaborating with Walvax to test a spike-producing vaccine called RQ3013. The spike protein produced by RQ3013 gives animals immunity <a href="https://www.biorxiv.org/content/10.1101/2022.05.10.491301v1.full">to a range of variants</a>. In the clinical trial, RNACure will test <a href="https://clinicaltrials.gov/ct2/show/NCT05394012">two doses of the vaccine</a> on volunteers who have not been vaccinated before and will also give it to vaccinated volunteers as a <a href="https://clinicaltrials.gov/ct2/show/NCT05396573">booster</a>. They will compare RQ3013 to the Comirnaty vaccine from Pfizer and BioNTech.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 3, 2022</span>

</p>

<a name="adelaide"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/adelaide-800.png" class="g-vlogo" 
    style="width: 200px; height: 62px; margin-right: 20px;" alt="University of Adelaide logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at the <strong>University of Adelaide </strong>are developing a DNA-based booster vaccine to fight against the Omicron variant. The creators say that using DNA allows them to <a href="https://www.adelaide.edu.au/newsroom/news/list/2022/06/17/south-australian-omicron-covid-19-booster-vaccine-starting-human-trials">quickly configure</a> the vaccine for future variants. On Aug. 16, 2022, <strong>PharmaJet</strong> said that its needle-free delivery technology is being used in <a href="https://www.businesswire.com/news/home/20220816005002/en/University-of-Adelaide-Begins-Human-Trial-of-Omicron-COVID-Vaccine-Booster-Using-PharmaJet-Needle-free-System">ongoing human trials</a> for the Adelaide vaccine.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>

<a name="curevac3"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/curevac-800.png" class="g-vlogo" 
    style="width: 200px; height: 54px; margin-right: 20px;" alt="CureVac logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/gsk-800.png" class="g-vlogo" 
    style="width: 55px; height: 47px;" alt="GSK logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> CV0501<br>




<br>
</span>

<!-- description -->
After its initial vaccine failed in trials, CureVac and GSK started a new trial of a version they called CV2nCoV in early 2022. But the companies went on to make a second round of updates, producing a new vaccine called CV0501. On Aug. 18, 2022, they  <a href="https://www.curevac.com/en/curevac-starts-phase-1-clinical-study-of-modified-omicron-targeting-covid-19-vaccine-candidate/">announced</a> that they were launching a Phase 1 trial of CV0501 as a booster.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>

<a name="genexine"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/genexine-800.png" class="g-vlogo" 
    style="width: 179px; height: 32px; margin-right: 20px;" alt="Genexine logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
The South Korean company <strong>Genexine</strong> started testing the safety of a DNA-based vaccine early in the pandemic, but a series of disappointments soon put them  behind other developers. In December 2020, the Korea Biomedical Review <a href="http://www.koreabiomed.com/news/articleView.html?idxno=9932">reported</a> that Genexine got disappointing results from their initial formulation and decided to restart their trials with a modified vaccine.<br><br>On Jan. 20, 2021, the company <a href="https://clinicaltrials.gov/ct2/show/NCT04715997">registered</a> a Phase 1/2 trial, and in June they registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04915989?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 1 trial</a> specifically for elderly volunteers. The Indonesian pharmaceutical company Kalbe Farma <a href="https://www.koreabiomed.com/news/articleView.html?idxno=11024">pledged</a> in April to buy 10 million doses of Genexine’s vaccine if it was proven to be safe and effective. In July, Indonesian regulators gave <a href="http://www.koreabiomed.com/news/articleView.html?idxno=11582">the green light</a> for a late-stage clinical trial. Genexine registered <a href="https://clinicaltrials.gov/ct2/show/NCT05067946?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">a Phase 2/3 clinical trial</a> in October to test their vaccine as a booster for other vaccines.<br><br>But their clinical trials proved disappointing once more. <a href="https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00358-X/fulltext#seccestitle150">Results</a> from the Phase 1/2 trial suggested that the vaccine, called GX-19N, would need improvement to be competitive with other vaccines. By March 2022, the company decided that it could not justify continuing its trials when authorized Covid vaccines were already so accessible in many countries. Genexine <a href="http://www.koreabiomed.com/news/articleView.html?idxno=13283">announced</a> on March 11 that it was abandoning further development of GX-19N.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 3, 2022</span>

</p>

<a name="imperialcollege"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/imperialcollege-800.png" class="g-vlogo" 
    style="width: 200px; height: 54px; margin-right: 20px;" alt="Imperial College logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/morningside-800.png" class="g-vlogo" 
    style="width: 220px; height: 30px;" alt="Morningside logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In early 2020, <strong>Imperial College London</strong> researchers developed a <a href="https://www.nytimes.com/2020/06/07/world/europe/imperial-college-uk-vaccine-coronavirus.html">“self-amplifying” RNA vaccine</a> for Covid-19, which boosted production of a viral protein to stimulate the immune system. They began Phase 1/2 trials on June 15, partnering with <strong>Morningside Ventures</strong> to manufacture and distribute the vaccine through a new company called VacEquity Global Health. On Dec. 18, the researchers <a href="https://www.prnewswire.com/news-releases/enesi-pharma-and-imperial-college-london-collaborate-to-develop-thermostable-rna-vaccines-with-potential-to-eliminate-cold-chain-and-transform-global-vaccination-logistics-for-covid-19-301195362.html">announced</a> a collaboration with Enesi Pharma to formulate a solid version of the vaccine that can be implanted in the skin without a needle.<br><br>On Jan. 27, 2021, Robin Shattuck, the leader of the project, <a href="https://www.imperial.ac.uk/news/213313/imperial-vaccine-tech-target-covid-mutations/">announced</a> that “it is not the right time to start a new efficacy trial for a further vaccine in the U.K.” Instead of competing with authorized vaccines, they turned their efforts to making candidates that will work well against emerging variants of the coronavirus.<br><br>A year later, the researchers <a href="https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00543-5/fulltext">published</a> the final results from the trial. They found that the self-amplifying RNA platform was safe and promising, but the vaccine couldn’t generate a promising  immune response.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 3, 2022</span>

</p>

<a name="sanofi"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/sanofi-800.png" class="g-vlogo" 
    style="width: 200px; height: 50px; margin-right: 20px;" alt="Sanofi logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/translatebio-800.png" class="g-vlogo" 
    style="width: 230px; height: 25px;" alt="Translate Bio logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
The French pharmaceutical company <strong>Sanofi </strong>collaborated with Massachusetts-based <strong>Translate Bio </strong>to develop an mRNA vaccine for Covid-19. In 2020, they reported that the vaccine, MRT5500, produced <a href="https://investors.translate.bio/news-releases/news-release-details/sanofi-and-translate-bio-mrna-covid-19-vaccine-candidate-induced">a strong antibody response</a> in mice and monkeys, and <a href="https://www.nature.com/articles/s41541-021-00324-5">protected hamsters</a> against coronavirus infections. They followed up on that research with a Phase 1/2 trial in March 2021. Over the summer, Sanofi acquired Translate Bio for $3 billion. On Sept. 28, the company <a href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-09-28-08-00-00-2304069">announced</a> that the clinical trial had yielded encouraging early results. By then, however, Pfizer-BioNTech and Moderna vaccines were widely available, and so Sanofi decided to <a href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-09-28-18-44-47-2304800">pull the plug</a> on its own mRNA Covid-19 vaccine program. Meanwhile, it continued a Phase 3 trial on a protein-based vaccine that may serve as a booster against Covid-19.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 3, 2022</span>

</p>

<a name="curevac"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/curevac-800.png" class="g-vlogo" 
    style="width: 200px; height: 54px; margin-right: 20px;" alt="CureVac logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> CVnCoV<br>
<span class="g-info">Efficacy:</span> <a href="https://www.curevac.com/en/2021/06/30/curevac-final-data-from-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov-demonstrates-protection-in-age-group-of-18-to-60/">48%</a><br>
<span class="g-info">Dose:</span> 2 doses, 4 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Stable at least 3 months at 36–46°F (2–8°C)<br>
<br>
</span>

<!-- description -->
The German company <strong>CureVac </strong>generated a lot of hope for its mRNA vaccine for Covid-19 in 2020, only to see it deliver disappointing results in clinical trials the following year.<br><br>The company, founded in 2001, had years of experience developing experimental mRNA vaccines for a host of diseases. In early 2020, they began work on a Covid-19 vaccine, called CVnCoV.  In March, the Trump administration unsuccessfully tried to entice <strong>CureVac</strong> to <a href="https://www.nytimes.com/2020/03/15/world/europe/cornonavirus-vaccine-us-germany.html">move its research</a> on their mRNA vaccine from Germany to the United States.<br><br>The company <a href="https://www.nytimes.com/2021/05/05/health/covid-vaccine-curevac.html">plowed ahead</a> with its work in Germany, seeing responses to the vaccine <a href="https://www.curevac.com/en/2020/10/23/curevac-reports-positive-preclinical-data-for-its-covid-19-vaccine-candidate-cvncov/">in mice</a> and <a href="https://www.biorxiv.org/content/10.1101/2020.12.23.424138v1">monkeys</a> before launching clinical trials in July. CVnCoV showed promise in several respects: it could remain stable in a refrigerator rather than a freezer, and preliminary studies suggested it would work well at a low dose, reducing its cost.<br><br><a href="https://www.curevac.com/en/2020/12/14/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov/">In December</a>, CureVac launched <a href="https://clinicaltrials.gov/ct2/show/NCT04652102">a Phase 3 trial</a>, recruiting up to 36,500 volunteers in Germany. The European Union began a <a href="https://www.curevac.com/en/2021/02/12/curevac-initiates-rolling-submission-with-european-medicines-agency-for-covid-19-vaccine-candidate-cvncov/">rolling review</a> in February, intended to speed up approval if the Phase 3 trial delivers positive results. <br><br>Meanwhile, CureVac prepared for mass production of the vaccine.  The company negotiated a deal to provide the European Union with <a href="https://www.nytimes.com/2021/05/05/health/covid-vaccine-curevac.html">up to 400 million doses</a> of their vaccine. They projected manufacturing <a href="https://www.curevac.com/en/2020/11/17/curevac-establishes-european-based-network-to-ramp-up-manufacturing-of-its-covid-19-vaccine-candidate-cvncov/">up to 300 million doses in 2021</a> and up to <a href="https://www.webcast-eqs.com/curevac20210205/en">a billion doses</a> the following year. Starting in January 2021, CureVac forged a series of partnerships with pharmaceutical giants <a href="https://www.curevac.com/en/2021/01/07/curevac-and-bayer-join-forces-on-covid-19-vaccine-candidate-cvncov/">Bayer</a>, <a href="https://www.pharmaceutical-technology.com/news/curevac-celonic-partner-vaccine/">Celonic</a>, <a href="https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/">GSK</a>, and <a href="https://www.curevac.com/en/2021/03/04/curevac-and-novartis-sign-initial-agreement-on-manufacturing-of-covid-19-vaccine-candidate-cvncov/">Novartis</a>, to support the production of their vaccine and develop new ones against <a href="https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html">coronavirus variants</a>.<br><br>In June 2021, CureVac reported <a href="https://www.nytimes.com/2021/06/30/science/curevac-vaccine-results.html">disappointing results</a> from their Phase 3 trial. <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3911826">Overall</a>, CVnCoV  had an efficacy of just 48 percent against Covid-19. It proved somewhat better for younger volunteers: For those between the ages of 18 and 60, the efficacy rose to 53 percent. In that group, the researchers also found the vaccine provided 100 percent protection against hospitalization and death. Researchers later <a href="https://www.medrxiv.org/content/10.1101/2021.06.29.21259504v1">pointed</a> to the vaccine dosage along with the rise of new variants as potential reasons for the low efficacy. On Sept. 14, CureVac <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/curevac-slashes-covid-19-vaccine-production-plans-2021-09-14/">announced</a> that it had canceled its manufacturing deals with Celonic and German company Wacker, citing a decline in demand for CVnCoV. <br><br>Despite the disappointing results, the company moved ahead with preparing an application to  the European Union for emergency authorization for the use of the vaccine in people 60 and under. But European regulators gave no indication they would continue speeding along their review. As a result, on Oct. 12, CureVac <a href="https://www.nytimes.com/2021/10/12/health/curevac-has-withdrawn-its-covid-vaccine-application-to-european-regulators.html">announced</a> that it would withdraw CVnCoV from the regulatory approval process. The company is now testing a new version of their vaccine, called <a href="#curevac2">CV2CoV</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated March 4, 2022</span>

</p>

<a name="oncosec"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/oncosec-800.png" class="g-vlogo" 
    style="width: 195px; height: 45px; margin-right: 20px;" alt="OncoSec Immunotherapies logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
New Jersey-based <strong>OncoSec Immunotherapies</strong> has developed experimental cancer treatments that deliver genes into tumors. There, the injected genes produce a natural signaling molecule called IL-12, which attracts the attention of immune cells that attack the cancer. In the spring of 2020, OncoSec began adapting their technology to make a vaccine for the coronavirus. The vaccine, called CORVax12, consisted of a loop of DNA that encodes both the spike protein and IL-12. OncoSec researchers hoped that by causing  the body to make extra IL-12, the vaccine would enhance the immune system’s ability to make antibodies to the spike protein. On Jan. 27, 2021, the company <a href="https://www.prnewswire.com/news-releases/oncosec-announces-first-subjects-dosed-in-phase-1-trial-of-corvax12-oncosecs-covid-19-vaccine-candidate-combining-interleukin-12-il-12-with-an-enhanced-sars-cov-2-spike-protein-301216247.html">began</a> dosing participants in its <a href="https://clinicaltrials.gov/ct2/show/NCT04627675">Phase 1 trial</a> to test the safety of CORVax12. In November, a spokeswoman said that OncoSec was no longer investigating the vaccine.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 3, 2022</span>

</p>
<h2 class="g-subhed g-optimize-type g-filtered" id="">
	<span class="g-balancer" data-id="12"><strong>Viral Vector Vaccines</strong></span>
</h2>
<p class="g-body g-description g-optimize-type g-filtered" id="">
	<span class="g-xbalancer" data-id="13"><em>Vaccines that contain viruses engineered to carry coronavirus genes. Some viral vector vaccines enter cells and cause them to make viral proteins. Other viral vectors slowly replicate, carrying coronavirus proteins on their surface. </em></span>
</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filtered"  style="max-width: 600px">

<!-- Intro elements -->








<div role="region">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.100.0 - 2020-09-10 08:31 -->
<!-- ai file: viral.ai -->
<!-- preview: undefined -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-viral-box ,
	#g-viral-box .g-artboard {
		margin:0 auto;
	}
	#g-viral-box p {
		margin:0;
	}
	#g-viral-box .g-aiAbs {
		position:absolute;
	}
	#g-viral-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-viral-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-viral-box .g-aiPointText p { white-space: nowrap; }
	#g-viral-600 {
		position:relative;
		overflow:hidden;
	}
	#g-viral-450 {
		position:relative;
		overflow:hidden;
	}
	#g-viral-335 {
		position:relative;
		overflow:hidden;
	}

</style>

<div id="g-viral-box" class="ai2html">

	<!-- Artboard: 600 -->
	<div id="g-viral-600" class="g-artboard" style="width:600px; height:310px;" data-aspect-ratio="1.935" data-min-width="600">
<div style=""></div>
		<img id="g-viral-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/viral-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
	</div>

	<!-- Artboard: 450 -->
	<div id="g-viral-450" class="g-artboard" style="width:450px; height:310px;" data-aspect-ratio="1.452" data-min-width="450" data-max-width="599">
<div style=""></div>
		<img id="g-viral-450-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/viral-450.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-viral-335" class="g-artboard" style="max-width: 335px;max-height: 310px" data-aspect-ratio="1.081" data-min-width="0" data-max-width="449">
<div style="padding: 0 0 92.5373% 0;"></div>
		<img id="g-viral-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/viral-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-viral-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2020-09-10 08:31 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="gamaleya"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN RUSSIA</span>


<span class="g-limited">EMERGENCY USE IN MANY COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/russiahealth-800.png" class="g-vlogo" 
    style="width: 265px; height: 54px; margin-right: 20px;" alt="Gamaleya Research Institute logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Sputnik V (also known as Gam-Covid-Vac)<br>
<span class="g-info">Efficacy:</span> <a href="https://www.nytimes.com/2021/02/02/world/europe/russia-vaccine-safe-effective.html">91.6%</a> against Alpha Variant, <a href="https://rdif.ru/Eng_fullNews/7282/">75%</a> against Omicron.<br>
<span class="g-info">Dose:</span> 2 doses, 3 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Freezer storage. Developing an alternative formulation that can be refrigerated.<br>
<br>
</span>

<!-- description -->
The <strong>Gamaleya Research Institute</strong>, part of Russia’s Ministry of Health, has created a vaccine with <a href="https://www.nytimes.com/2021/02/02/world/europe/russia-vaccine-safe-effective.html">an efficacy rate of 91.6 percent</a>. Russia began distributing the vaccine, known as Sputnik V, in fall 2020, and it is now widely used around the world. On Feb. 4, 2022, Sputnik V received<a href="https://rdif.ru/Eng_fullNews/7287/"> </a><a href="https://rdif.ru/Eng_fullNews/7287/">full approval</a> from the Russian government. Tass <a href="https://tass.com/world/1492239">reported</a> in August 2022 that 400 million doses had been distributed to 71 countries. <br><br> <subhed>VACCINE DEVELOPMENT</subhed>Gamaleya produced the vaccine, initially called Gam-Covid-Vac, from a combination of two adenoviruses called Ad5 and Ad26. Both kinds have been tested as vaccines over a number of years. By combining them, the Russian researchers hoped to prevent the immune system from recognizing one of the adenoviruses from the first dose and destroy it in the second dose. <br><br> <subhed>TRIAL RESULTS</subhed>The researchers launched clinical trials in June 2020. Within a few months, the trial became bogged down in controversy. On Aug. 11, President Vladimir V. Putin <a href="https://www.nytimes.com/2020/08/11/world/coronavirus-covid-19.html#link-b092b4d">announced</a> that a Russian health care regulator had <a href="https://www.nytimes.com/2020/08/11/world/europe/russia-coronavirus-vaccine.html">approved the vaccine</a>, renamed Sputnik V, despite the fact that the Phase 3 trials had not even begun. Vaccine experts <a href="https://www.nytimes.com/2020/08/11/health/russia-covid-19-vaccine-safety.html">decried</a> the move as risky, and Russia later <a href="https://abcnews.go.com/International/russia-announces-expanded-trials-coronavirus-vaccine-approved-10/story?id=72497297">walked back</a> the announcement, saying that the approval was a “conditional registration certificate,” which would depend on positive results from Phase 3 trials.<br><br>On Nov. 11, 2020, the Russian Direct Investment Fund <a href="https://www.nytimes.com/live/2020/11/11/world/covid-19-coronavirus-live-updates/russias-vaccine-proves-effective-in-early-trial-data-company-says">announced</a> the first preliminary evidence from their Phase 3 trial indicating that the vaccine was effective. Based on 20 cases of Covid-19 among the trial participants, Russian scientists estimated that the vaccine demonstrated 92 percent efficacy.<br><br>By December, the trial had reached its final total of 78 cases. The creators of the vaccine <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext">published the results of their Phase 3 trial</a> on Feb. 2, 2021 in the Lancet.<br><br>When other countries began using Sputnik V, they ran studies of their own to measure the effectiveness of the vaccine. On Nov. 1, 2021, a team of researchers in Argentina published a <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785597">paper</a> showing that the vaccine reduces infection by 88.1 percent and Covid-19-related deaths by 98.3 percent in people over 60.<br><br>In January 2021, Gamaleya researchers started a trial in which they gave people only the first dose of Ad26 adenoviruses, the same adenovirus in Johnson & Johnson’s single-dose vaccine. They dubbed this one-dose version “<a href="https://clinicaltrials.gov/ct2/show/NCT04713488">Sputnik Light</a>.” A Phase 1/2 trial showed that a single dose produced antibodies and was safe; the details were eventually <a href="https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00227-1/fulltext">published</a> in the Lancet in Nov. 2021.<br><br>Russia announced on May 6 that Sputnik Light provided <a href="https://www.nytimes.com/2021/05/06/world/sputnik-dose-virus.html">an efficacy of 79.4 percent</a> but did not publish the details of the study or say how long the efficacy would last. After the single-dose version of the vaccine was rolled out in Argentina, a <a href="https://rdif.ru/Eng_fullNews/6863/">study</a> found that its effectiveness there was between 78.6 and 83.7 percent.<br><br><a href="https://tass.com/society/1377801">Phase 2 human trials</a> for an intranasal version of Sputnik V have <a href="https://tass.com/society/1403405">begun</a>, Tass reported on Feb. 15, 2022.<br><br>Russian researchers are also working on modifying the vaccine for use in teenagers. Called “<a href="https://tass.com/science/1363667">Sputnik M</a>,” the candidate is a fractional dose of Sputnik V. They have recruited <a href="https://tass.com/science/1363667">3,000 adolescents</a> for the ongoing clinical trials. On June 14, 2022, 14 children between 9 and 11 <a href="https://tass.com/society/1464881">received</a> one-tenth of an adult dose as part of a clinical trial.<br><br> <subhed>AUTHORIZATION</subhed>In November 2020, the Russian government began offering Sputnik V within Russia in a mass vaccination campaign. But worry that the vaccine was rushed to approval led to <a href="https://www.nytimes.com/2020/12/07/world/europe/russia-coronavirus-vaccine.html">widespread hesitancy</a>. Sputnik Light received authorization for use in Russia on May 6, 2021.<br><br>On Dec. 22, 2020, Belarus became <a href="https://rdif.ru/Eng_fullNews/6216/">the first country outside of Russia</a> to register Sputnik V, and since then a number of other countries have followed suit. But as of August 2022, neither the <a href="https://www.reuters.com/world/europe/exclusive-eu-decision-russias-sputnik-v-shot-impossible-this-year-source-2021-10-21/">European Medicines Agency</a> and the <a href="https://www.nature.com/articles/d41591-022-00042-y">World Health Organization</a> had yet to accept Russia’s application for an emergency authorization. In June 2022, Tass <a href="https://tass.com/world/1465449">reported</a> that Sputnik had not been produced for months.<br><br> <subhed>VARIANTS</subhed>The Gamaleya Institute <a href="https://rdif.ru/Eng_fullNews/7123/">announced</a> on Oct. 13, 2021, that Sputnik Light demonstrated a <a href="https://www.medrxiv.org/content/10.1101/2021.10.08.21264715v1">70 percent efficacy</a> against the Delta variant. Tass <a href="https://tass.com/science/1389635">reported</a> on Jan. 18, 2022 that the Gamelaya Institute director said Sputnik V demonstrates around <a href="https://rdif.ru/Eng_fullNews/7282/">75 percent efficacy</a> against the Omicron variant, but the data supporting this conclusion have not yet been released. On July 26, Tass <a href="https://tass.com/society/1484369">reported</a> that the Gamelaya Institute director said Sputnik V can protect against B.A.2.75, though no data has been released yet, either. Tass said on Aug. 23 that researchers have made <a href="https://tass.com/society/1497079">another version</a> of Sputnik V to fight against the Delta and Omicron variants.<br><br>For more details, see <strong><a href="https://www.nytimes.com/interactive/2021/health/gamaleya-covid-19-vaccine.html">How Gamaleya’s Vaccine Works</a></strong>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://www.prnewswire.com/in/news-releases/sputnik-v-vaccine-granted-full-permanent-approval-in-russia-879907727.html">Russia</a>.<br>


<span class="g-info">Emergency use in:</span> <a href="https://rdif.ru/Eng_fullNews/6761/">Albania</a>, <a href="https://www.elkhabar.com/press/article/179814/%D8%B1%D8%B3%D9%85%D9%8A%D8%A7-%D8%A7%D9%84%D8%AC%D8%B2%D8%A7%D8%A6%D8%B1-%D8%AA%D9%85%D9%86%D8%AD-%D8%AA%D8%B3%D8%AC%D9%8A%D9%84-%D9%84%D9%82%D8%A7%D8%AD-%D8%B3%D8%A8%D9%88%D8%AA%D9%86%D9%8A%D9%83-v/">Algeria</a>, <a href="https://rdif.ru/Eng_fullNews/6493/">Angola</a>, <a href="https://rdif.ru/Eng_fullNews/6549/">Antigua and Barbuda</a>, <a href="https://twitter.com/msalnacion/status/1341824231726862336">Argentina</a> (including <a href="https://www.prnewswire.com/in/news-releases/the-one-shot-sputnik-light-vaccine-authorized-in-argentina-as-a-standalone-vaccine-and-a-booster-shot-823250204.html">Sputnik Light</a>), <a href="https://sputnikvaccine.com/newsroom/pressreleases/sputnik-v-vaccine-authorized-in-armenia/">Armenia</a> (including <a href="https://rdif.ru/Eng_fullNews/7072/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6524/">Azerbaijan</a>, <a href="https://sputnikvaccine.com/newsroom/pressreleases/sputnik-v-authorized-in-the-kingdom-of-bahrain/">Bahrain</a>, <a href="https://rdif.ru/Eng_fullNews/6755/">Bangladesh</a>, <a href="https://rdif.ru/Eng_fullNews/6216/">Belarus</a> (including <a href="https://tass.com/society/1298035">Sputnik Light</a>), Benin (<a href="https://tass.com/world/1388289">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6274/">Bolivia</a>, <a href="https://tass.com/world/1253307">Bosnian Serb Republic</a>, <a href="https://rdif.ru/Eng_fullNews/6876/">Brazil</a>, <a href="https://rdif.ru/Eng_fullNews/7138/">Cambodia</a> (including <a href="https://rdif.ru/Eng_fullNews/7138/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6533/">Cameroon</a>, <a href="https://rdif.ru/Eng_fullNews/7007/">Chile</a>, <a href="https://rdif.ru/Eng_fullNews/6493/">Congo Republic</a> (including <a href="https://rdif.ru/Eng_fullNews/6878/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6493/">Djibouti</a>, <a href="https://rdif.ru/Eng_fullNews/6843/">Ecuador</a>, <a href="https://rdif.ru/Eng_fullNews/6462/">Egypt</a> (including <a href="https://rdif.ru/Eng_fullNews/7109/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6464/">Honduras</a>, <a href="https://rdif.ru/Eng_fullNews/6445/">Gabon</a>, <a href="https://covid-19pharmacovigilance.paho.org/gamaleya-sputnik-v-sputnik-light#col-0">Gambia</a>, <a href="https://rdif.ru/Eng_fullNews/6454/">Ghana</a>, <a href="https://rdif.ru/Eng_fullNews/6466/">Guatemala</a>, <a href="https://rdif.ru/Eng_fullNews/6341/">Guinea</a>, <a href="https://rdif.ru/Eng_fullNews/6458/">Guyana</a>, <a href="https://rdif.ru/Eng_fullNews/6322/">Hungary</a>, <a href="https://rdif.ru/Eng_fullNews/6708/">India</a>, Indonesia, <a href="https://en.irna.ir/news/84200274/FM-Zarif-Russia-s-Sputnik-V-COVID-19-vaccine-registered-in-Iran">Iran</a> (including <a href="https://rdif.ru/Eng_fullNews/7082/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6501/">Iraq</a>, <a href="https://rdif.ru/Eng_fullNews/6518/">Jordan</a>, <a href="https://medicalxpress.com/news/2021-02-kazakhstan-russian-vaccine-coronavirus.html">Kazakhstan</a> (including <a href="https://rdif.ru/Eng_fullNews/6936/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6514/">Kenya</a>, <a href="https://rdif.ru/Eng_fullNews/6456/">Kyrgyzstan</a> (including <a href="https://rdif.ru/Eng_fullNews/6915/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6499/">Laos</a> (including <a href="https://rdif.ru/Eng_fullNews/7173/">Sputnik Light</a>), <a href="https://tass.com/world/1253257">Lebanon</a>, <a href="https://covid-19pharmacovigilance.paho.org/gamaleya-sputnik-v-sputnik-light#col-0">Libya</a>, <a href="https://rdif.ru/Eng_fullNews/6837/">Maldives</a>, <a href="https://rdif.ru/Eng_fullNews/6679/">Mali</a>, <a href="https://rdif.ru/Eng_fullNews/6539/">Mauritius</a> (including <a href="https://rdif.ru/Eng_fullNews/6861/">Sputnik Light</a>), <a href="https://sputnikvaccine.com/newsroom/pressreleases/mexico-becomes-the-first-country-of-north-america-to-register-sputnik-v-vaccine-/">Mexico</a>, <a href="https://news.trust.org/item/20210227162136-o0jx5/">Moldova</a>, <a href="https://sputnikvaccine.com/newsroom/pressreleases/mongolia-approves-the-use-of-sputnik-v/">Mongolia</a> (including <a href="https://rdif.ru/Eng_fullNews/6907/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6440/">Montenegro</a>, <a href="https://rdif.ru/Eng_fullNews/6516/">Morocco</a>, <a href="https://tass.com/world/1253415">Myanmar</a>, <a href="https://rdif.ru/Eng_fullNews/6520/">Namibia</a>, <a href="https://www.reuters.com/article/health-coronavirus-nepal-idINL4N2MD3KU">Nepal</a>, <a href="https://rdif.ru/Eng_fullNews/6351/">Nicaragua</a> (including <a href="https://rdif.ru/Eng_fullNews/6846/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6938/">Nigeria</a>, <a href="https://rdif.ru/Eng_fullNews/6503/">North Macedonia</a>, <a href="https://gulfnews.com/world/gulf/oman/covid-19-oman-approves-use-of-sinovac-and-sputnik-vaccines-1.80173049">Oman</a>, <a href="https://www.dawn.com/news/1603273">Pakistan</a>, <a href="https://rdif.ru/Eng_fullNews/6279/">Palestinian Authority</a> (including <a href="https://rdif.ru/Eng_fullNews/6859/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6685/">Panama</a>, <a href="https://rdif.ru/Eng_fullNews/6299/">Paraguay</a>, <a href="https://rdif.ru/Eng_fullNews/6529/">Philippines</a> (including <a href="https://rdif.ru/Eng_fullNews/7057/">Sputnik Light</a>), <a href="https://www.nytimes.com/2020/08/11/world/europe/russia-coronavirus-vaccine-approval.html">Russia</a> (including <a href="https://rdif.ru/Eng_fullNews/6763/">Sputnik Light</a> and <a href="https://tass.com/society/1365751">Sputnik M</a>), <a href="https://www.rbc.gov.rw/index.php?id=777">Rwanda</a>, <a href="https://rdif.ru/Eng_fullNews/6451/">San Marino</a> (including <a href="https://rdif.ru/Eng_fullNews/7171/">Sputnik Light</a>), <a href="https://www.prnewswire.co.uk/news-releases/rdif-to-supply-2-million-doses-of-sputnik-v-vaccine-to-serbia-830021530.html">Serbia</a>, <a href="https://rdif.ru/Eng_fullNews/6535/">Seychelles</a>, <a href="https://tass.com/world/1294251">Slovakia</a>, <a href="https://rdif.ru/Eng_fullNews/6497/">Sri Lanka</a>, <a href="https://rdif.ru/Eng_fullNews/6440/">Saint Vincent and the Grenadines</a>, <a href="https://www.arabnews.com/node/1813751/middle-east">Syria</a>, <a href="https://rdif.ru/Eng_fullNews/6343/">Tunisia</a> (including <a href="https://rdif.ru/Eng_fullNews/7262/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6759/">Turkey</a>, <a href="https://rdif.ru/Eng_fullNews/6309/">Turkmenistan</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-emirates-russia/uae-approves-russias-sputnik-v-covid-19-vaccine-for-emergency-use-idUSKBN29Q17L">United Arab Emirates</a> (including <a href="https://rdif.ru/Eng_fullNews/7120/">Sputnik Light</a>), <a href="https://rdif.ru/Eng_fullNews/6443/">Uzbekistan</a>, <a href="https://rdif.ru/Eng_fullNews/6297/">Venezuela</a> (including <a href="https://rdif.ru/Eng_fullNews/6840/">Sputnik Light</a>), <a href="https://tass.com/society/1260545">Vietnam</a>, <a href="https://covid-19pharmacovigilance.paho.org/gamaleya-sputnik-v-sputnik-light#col-0">West Bank</a>, <a href="https://www.reuters.com/article/uk-health-coronavirus-zimbabwe-vaccine/zimbabwe-authorises-sputnik-v-sinovac-coronavirus-vaccines-for-emergency-use-idUSKBN2B20K3">Zimbabwe</a>.<br>



</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.103.0 - 2022-02-08 10:29 -->
<!-- ai file: map-gamaleya.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-gamaleya-box ,
	#g-map-gamaleya-box .g-artboard {
		margin:0 auto;
	}
	#g-map-gamaleya-box p {
		margin:0;
	}
	#g-map-gamaleya-box .g-aiAbs {
		position:absolute;
	}
	#g-map-gamaleya-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-gamaleya-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-gamaleya-box .g-aiPointText p { white-space: nowrap; }
	#g-map-gamaleya-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-gamaleya-900 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-gamaleya-900 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-gamaleya-900 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-gamaleya-900 .g-pstyle2 {
		height:13px;
		text-align:right;
	}
	#g-map-gamaleya-900 .g-pstyle3 {
		height:13px;
	}
	#g-map-gamaleya-900 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-gamaleya-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-gamaleya-720 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-gamaleya-720 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-gamaleya-720 .g-pstyle1 {
		height:13px;
		text-align:right;
	}
	#g-map-gamaleya-720 .g-pstyle2 {
		height:13px;
		text-align:center;
	}
	#g-map-gamaleya-720 .g-pstyle3 {
		height:13px;
	}
	#g-map-gamaleya-720 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-gamaleya-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-gamaleya-600 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-gamaleya-600 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-gamaleya-600 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-gamaleya-600 .g-pstyle2 {
		height:13px;
		text-align:right;
	}
	#g-map-gamaleya-600 .g-pstyle3 {
		height:13px;
	}
	#g-map-gamaleya-600 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-gamaleya-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-gamaleya-335 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-gamaleya-335 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-gamaleya-335 .g-pstyle1 {
		height:13px;
		text-align:right;
	}
	#g-map-gamaleya-335 .g-pstyle2 {
		height:13px;
	}
	#g-map-gamaleya-335 .g-pstyle3 {
		height:13px;
		text-align:center;
	}
	#g-map-gamaleya-335 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}

</style>

<div id="g-map-gamaleya-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-gamaleya-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-gamaleya-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-gamaleya-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:7.0941%;margin-top:-27.3px;left:0%;width:95px;">
			<p class="g-pstyle0">Gamaleya&rsquo;s</p>
			<p class="g-pstyle0">Sputnik V</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:17.9137%;margin-top:-6.8px;left:78.2803%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">RUSSIA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:19.8794%;margin-top:-6.8px;right:32.3605%;width:84px;">
			<p class="g-pstyle2">HUNGARY</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:26.8998%;margin-top:-6.8px;left:60.9069%;margin-left:-38px;width:76px;">
			<p class="g-pstyle1">ALGERIA</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:27.1806%;margin-top:-6.8px;left:76.4082%;width:90px;">
			<p class="g-pstyle3">MONGOLIA</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:30.2696%;margin-top:-6.8px;left:52.233%;margin-left:-35px;width:70px;">
			<p class="g-pstyle1">GUINEA</p>
		</div>
		<div id="g-ai0-7" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:32.797%;margin-top:-6.8px;left:58.5022%;margin-left:-27px;width:54px;">
			<p class="g-pstyle1">MALI</p>
		</div>
		<div id="g-ai0-8" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:37.29%;margin-top:-6.8px;left:70.1635%;width:53px;">
			<p class="g-pstyle3">IRAN</p>
		</div>
		<div id="g-ai0-9" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:41.5023%;margin-top:-6.8px;left:72.0294%;width:83px;">
			<p class="g-pstyle3">PAKISTAN</p>
		</div>
		<div id="g-ai0-10" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:42.6255%;margin-top:-6.8px;right:29.8177%;width:79px;">
			<p class="g-pstyle2">BAHRAIN</p>
		</div>
		<div id="g-ai0-11" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:45.9953%;margin-top:-6.8px;left:55.5491%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">GABON</p>
		</div>
		<div id="g-ai0-12" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:47.3994%;margin-top:-6.8px;left:69.8497%;width:58px;">
			<p class="g-pstyle3">U.A.E.</p>
		</div>
		<div id="g-ai0-13" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:48.5227%;margin-top:-6.8px;right:75.1744%;width:71px;">
			<p class="g-pstyle2">MEXICO</p>
		</div>
		<div id="g-ai0-14" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:49.646%;margin-top:-6.8px;left:75.01%;width:57px;">
			<p class="g-pstyle3">INDIA</p>
		</div>
		<div id="g-ai0-15" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:51.6117%;margin-top:-6.8px;left:54.8711%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">ANGOLA</p>
		</div>
		<div id="g-ai0-16" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:51.6117%;margin-top:-6.8px;left:39.1817%;width:67px;">
			<p class="g-pstyle3">BRAZIL</p>
		</div>
		<div id="g-ai0-17" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:51.8925%;margin-top:-6.8px;left:87.807%;width:91px;">
			<p class="g-pstyle3">INDONESIA</p>
		</div>
		<div id="g-ai0-18" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:56.6664%;margin-top:-6.8px;left:66.8565%;width:63px;">
			<p class="g-pstyle3">KENYA</p>
		</div>
		<div id="g-ai0-19" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:60.8786%;margin-top:-6.8px;left:43.3937%;width:89px;">
			<p class="g-pstyle3">PARAGUAY</p>
		</div>
		<div id="g-ai0-20" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:72.1113%;margin-top:-6.8px;left:44.085%;width:95px;">
			<p class="g-pstyle3">ARGENTINA</p>
		</div>
		<div id="g-ai0-21" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai0-22" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle4">Early, limited or</p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-gamaleya-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-gamaleya-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-gamaleya-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:8.2866%;margin-top:-25.5px;left:0.0153%;width:90px;">
			<p class="g-pstyle0">Gamaleya&rsquo;s</p>
			<p class="g-pstyle0">Sputnik V</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:18.9318%;margin-top:-6.8px;right:32.2673%;width:84px;">
			<p class="g-pstyle1">HUNGARY</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:19.2837%;margin-top:-6.8px;left:76.5941%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">RUSSIA</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:26.6746%;margin-top:-6.8px;left:59.7356%;margin-left:-38px;width:76px;">
			<p class="g-pstyle2">ALGERIA</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:27.0266%;margin-top:-6.8px;left:75.4221%;width:90px;">
			<p class="g-pstyle3">MONGOLIA</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:31.25%;margin-top:-6.8px;left:51.3723%;margin-left:-35px;width:70px;">
			<p class="g-pstyle2">GUINEA</p>
		</div>
		<div id="g-ai1-7" class="g-type_copy g-aiAbs g-aiPointText" style="top:38.6409%;margin-top:-6.8px;left:74.9967%;width:83px;">
			<p class="g-pstyle3">PAKISTAN</p>
		</div>
		<div id="g-ai1-8" class="g-type_copy g-aiAbs g-aiPointText" style="top:38.9928%;margin-top:-6.8px;left:69.8094%;width:53px;">
			<p class="g-pstyle3">IRAN</p>
		</div>
		<div id="g-ai1-9" class="g-type_copy g-aiAbs g-aiPointText" style="top:44.272%;margin-top:-6.8px;right:29.6946%;width:79px;">
			<p class="g-pstyle1">BAHRAIN</p>
		</div>
		<div id="g-ai1-10" class="g-type_copy g-aiAbs g-aiPointText" style="top:45.3279%;margin-top:-6.8px;left:54.9177%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">GABON</p>
		</div>
		<div id="g-ai1-11" class="g-type_copy g-aiAbs g-aiPointText" style="top:47.7915%;margin-top:-6.8px;right:75.6234%;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai1-12" class="g-type_copy g-aiAbs g-aiPointText" style="top:48.1435%;margin-top:-6.8px;left:74.5676%;width:57px;">
			<p class="g-pstyle3">INDIA</p>
		</div>
		<div id="g-ai1-13" class="g-type_copy g-aiAbs g-aiPointText" style="top:49.5512%;margin-top:-6.8px;left:69.364%;width:58px;">
			<p class="g-pstyle3">U.A.E.</p>
		</div>
		<div id="g-ai1-14" class="g-type_copy g-aiAbs g-aiPointText" style="top:51.311%;margin-top:-6.8px;left:38.3198%;width:67px;">
			<p class="g-pstyle3">BRAZIL</p>
		</div>
		<div id="g-ai1-15" class="g-type_copy g-aiAbs g-aiPointText" style="top:52.0149%;margin-top:-6.8px;left:53.9309%;margin-left:-37px;width:74px;">
			<p class="g-pstyle2">ANGOLA</p>
		</div>
		<div id="g-ai1-16" class="g-type_copy g-aiAbs g-aiPointText" style="top:56.5902%;margin-top:-6.8px;left:66.8214%;width:63px;">
			<p class="g-pstyle3">KENYA</p>
		</div>
		<div id="g-ai1-17" class="g-type_copy g-aiAbs g-aiPointText" style="top:62.2214%;margin-top:-6.8px;left:43.3537%;width:89px;">
			<p class="g-pstyle3">PARAGUAY</p>
		</div>
		<div id="g-ai1-18" class="g-type_copy g-aiAbs g-aiPointText" style="top:72.7798%;margin-top:-6.8px;left:44.0482%;width:95px;">
			<p class="g-pstyle3">ARGENTINA</p>
		</div>
		<div id="g-ai1-19" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai1-20" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle4">Early, limited or </p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-gamaleya-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-gamaleya-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-gamaleya-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:9.2099%;margin-top:-23.8px;left:-0.067%;width:85px;">
			<p class="g-pstyle0">Gamaleya&rsquo;s</p>
			<p class="g-pstyle0">Sputnik V</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:18.4774%;margin-top:-6.8px;left:76.3964%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">RUSSIA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:18.4774%;margin-top:-6.8px;right:31.8699%;width:84px;">
			<p class="g-pstyle2">HUNGARY</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:26.4943%;margin-top:-6.8px;left:74.5749%;width:90px;">
			<p class="g-pstyle3">MONGOLIA</p>
		</div>
		<div id="g-ai2-5" class="g-600 g-aiAbs g-aiPointText" style="top:26.9162%;margin-top:-6.8px;right:37.4513%;width:76px;">
			<p class="g-pstyle2">ALGERIA</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:38.7306%;margin-top:-6.8px;left:69.0237%;width:53px;">
			<p class="g-pstyle3">IRAN</p>
		</div>
		<div id="g-ai2-7" class="g-type g-aiAbs g-aiPointText" style="top:39.9964%;margin-top:-6.8px;left:75.158%;width:83px;">
			<p class="g-pstyle3">PAKISTAN</p>
		</div>
		<div id="g-ai2-8" class="g-600 g-aiAbs g-aiPointText" style="top:46.7475%;margin-top:-6.8px;right:41.7811%;width:67px;">
			<p class="g-pstyle2">GABON</p>
		</div>
		<div id="g-ai2-9" class="g-600 g-aiAbs g-aiPointText" style="top:47.5914%;margin-top:-6.8px;right:75.7537%;width:71px;">
			<p class="g-pstyle2">MEXICO</p>
		</div>
		<div id="g-ai2-10" class="g-type g-aiAbs g-aiPointText" style="top:48.8572%;margin-top:-6.8px;left:74.1589%;width:57px;">
			<p class="g-pstyle3">INDIA</p>
		</div>
		<div id="g-ai2-11" class="g-type g-aiAbs g-aiPointText" style="top:51.8108%;margin-top:-6.8px;left:37.7055%;width:67px;">
			<p class="g-pstyle3">BRAZIL</p>
		</div>
		<div id="g-ai2-12" class="g-type g-aiAbs g-aiPointText" style="top:56.8741%;margin-top:-6.8px;left:67.0666%;width:63px;">
			<p class="g-pstyle3">KENYA</p>
		</div>
		<div id="g-ai2-13" class="g-type g-aiAbs g-aiPointText" style="top:61.0935%;margin-top:-6.8px;left:43.4546%;width:89px;">
			<p class="g-pstyle3">PARAGUAY</p>
		</div>
		<div id="g-ai2-14" class="g-type g-aiAbs g-aiPointText" style="top:72.9078%;margin-top:-6.8px;left:44.141%;width:95px;">
			<p class="g-pstyle3">ARGENTINA</p>
		</div>
		<div id="g-ai2-15" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai2-16" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle4">Early, limited or</p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-gamaleya-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-gamaleya-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-gamaleya-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:4.585%;margin-top:-23.8px;left:0.2695%;width:85px;">
			<p class="g-pstyle0">Gamaleya&rsquo;s</p>
			<p class="g-pstyle0">Sputnik V</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-335 g-aiAbs g-aiPointText" style="top:26.6337%;margin-top:-6.8px;right:50.7269%;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai3-3" class="g-335 g-aiAbs g-aiPointText" style="top:28.5242%;margin-top:-6.8px;left:75.8136%;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai3-4" class="g-335 g-aiAbs g-aiPointText" style="top:34.4059%;margin-top:-6.8px;right:19.9049%;width:89px;">
			<p class="g-pstyle1">PARAGUAY</p>
		</div>
		<div id="g-ai3-5" class="g-335 g-aiAbs g-aiPointText" style="top:40.2875%;margin-top:-6.8px;right:18.6004%;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:54.7816%;margin-top:-6.8px;left:53.8539%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle3">RUSSIA</p>
		</div>
		<div id="g-ai3-7" class="g-335 g-aiAbs g-aiPointText" style="top:55.2017%;margin-top:-6.8px;right:63.2438%;width:84px;">
			<p class="g-pstyle1">HUNGARY</p>
		</div>
		<div id="g-ai3-8" class="g-335 g-aiAbs g-aiPointText" style="top:58.7727%;margin-top:-6.8px;right:73.5013%;width:76px;">
			<p class="g-pstyle1">ALGERIA</p>
		</div>
		<div id="g-ai3-9" class="g-335 g-aiAbs g-aiPointText" style="top:58.9827%;margin-top:-6.8px;left:50.2548%;width:90px;">
			<p class="g-pstyle2">MONGOLIA</p>
		</div>
		<div id="g-ai3-10" class="g-335 g-aiAbs g-aiPointText" style="top:65.2845%;margin-top:-6.8px;left:49.8073%;width:83px;">
			<p class="g-pstyle2">PAKISTAN</p>
		</div>
		<div id="g-ai3-11" class="g-335 g-aiAbs g-aiPointText" style="top:65.9147%;margin-top:-6.8px;left:38.9047%;width:53px;">
			<p class="g-pstyle2">IRAN</p>
		</div>
		<div id="g-ai3-12" class="g-335 g-aiAbs g-aiPointText" style="top:68.8555%;margin-top:-6.8px;right:59.3228%;width:79px;">
			<p class="g-pstyle1">BAHRAIN</p>
		</div>
		<div id="g-ai3-13" class="g-335 g-aiAbs g-aiPointText" style="top:69.9058%;margin-top:-6.8px;right:83.5888%;width:67px;">
			<p class="g-pstyle1">GABON</p>
		</div>
		<div id="g-ai3-14" class="g-335 g-aiAbs g-aiPointText" style="top:71.5863%;margin-top:-6.8px;left:48.6924%;width:57px;">
			<p class="g-pstyle2">INDIA</p>
		</div>
		<div id="g-ai3-15" class="g-335 g-aiAbs g-aiPointText" style="top:73.6869%;margin-top:-6.8px;right:83.0364%;width:74px;">
			<p class="g-pstyle1">ANGOLA</p>
		</div>
		<div id="g-ai3-16" class="g-335 g-aiAbs g-aiPointText" style="top:75.5774%;margin-top:-6.8px;left:34.1233%;width:63px;">
			<p class="g-pstyle2">KENYA</p>
		</div>
		<div id="g-ai3-17" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai3-18" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle4">Early, limited or </p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-gamaleya-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-02-08 10:29 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="astrazeneca"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-phase3 g-filter-approved ">

<!-- phases -->








<span class="g-phase2">PHASE 2</span> <span class="g-phase3">PHASE 3</span> <span class="g-combined">COMBINED PHASES</span>

<!-- approvals -->
<br><span class="g-approval">APPROVED IN BRAZIL, INDIA</span>


<span class="g-limited">EMERGENCY USE IN E.U., ELSEWHERE</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/uoxford-800.png" class="g-vlogo" 
    style="width: 150px; height: 45px; margin-right: 20px;" alt="University of Oxford logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/astrazeneca-800.png" class="g-vlogo" 
    style="width: 150px; height: 42px;" alt="AstraZeneca logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Vaxzevria (also known as AZD1222, or Covishield in India)<br>
<span class="g-info">Efficacy:</span> <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2105290?query=featured_coronavirus">74%</a> against symptomatic Covid19; <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2105290?query=featured_coronavirus">100%</a> against severe or critical Covid-19.<br>
<span class="g-info">Dose:</span> 2 doses<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Stable in refrigerator for at least 6 months<br>
<br>
</span>

<!-- description -->
A vaccine designed by <strong>the University of Oxford </strong>and produced by the British-Swedish company <strong>AstraZeneca</strong> emerged as a key element in the effort to meet the global demand for Covid-19 vaccines. With an efficacy of 76 percent, the vaccine — now known as <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca">Vaxzevria</a> —was produced in vast quantities at a <a href="https://www.theguardian.com/global-development/2020/nov/23/oxford-astrazeneca-results-covid-vaccine-developing-countries">low price</a>. Because it only needs to be refrigerated rather than frozen, it can be used far more widely than mRNA vaccines. But Vaxzevria’s journey has been turbulent, jolted by confusing messages from AstraZeneca, high-profile worries about safety, and difficulties with manufacturing.<br><br>Over the course of 2021, <a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/full-year-2021-and-q4-results.html">2.5 billion doses</a> of Vaxzevria were distributed worldwide. An independent study <a href="https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html">estimated</a> that the vaccine saved six million lives through December 2021. But in 2022, as supplies of other vaccines grew, the demand for Vaxzevria fell, leading some manufacturers to halt production.<br><br> <subhed>VACCINE DEVELOPMENT</subhed>Vaxzevria was based on a vaccine platform that Oxford researchers had been developing for years for other diseases. They began with an adenovirus that normally infects chimpanzees and genetically engineered it to carry viral genes. In early 2020, the scientists  <a href="https://www.nytimes.com/2020/04/27/world/europe/coronavirus-vaccine-update-oxford.html">developed</a> Vaxzevria by endowing the adenovirus with the spike gene from the coronavirus. When they gave the vaccine to monkeys, they found that it <a href="https://www.nytimes.com/2020/07/30/health/covid-19-vaccine-monkeys.html">protected the animals from the disease</a>.<br><br> <subhed>TRIAL RESULTS</subhed>The United States <a href="https://public3.pagefreezer.com/browse/HHS%20%E2%80%93%C2%A0About%20News/20-01-2021T12:29/https://www.hhs.gov/about/news/2020/05/21/trump-administration-accelerates-astrazeneca-covid-19-vaccine-to-be-available-beginning-in-october.html">supported</a> the development of Vaxzevria in May 2020, with $1.2 billion <a href="https://www.nytimes.com/2020/12/08/business/covid-vaccine-oxford-astrazeneca.html">provided</a> as part of Operation Warp Speed. The money helped AstraZeneca and Oxford embark on large late-stage trials in the United States, United Kingdom, South Africa, and elsewhere. But the researchers ran the trials independently, making it difficult to combine their results into a single clear picture of how well the vaccine worked. Making matters murkier, they gave different amounts of the vaccine to different people and also waited anywhere from four to twelve weeks to deliver the second dose.<br><br>On Dec. 8, 2020, AstraZeneca and Oxford published <a href="https://doi.org/10.1016/S0140-6736(20)32661-1">the first scientific paper</a> on a Phase 3 clinical trial of a coronavirus vaccine. The trial demonstrated that the vaccine can protect people from Covid-19, but it <a href="https://www.nytimes.com/2020/12/08/business/covid-vaccine-oxford-astrazeneca.html?searchResultPosition=1">left many questions unresolved</a> about the results. Nevertheless, the vaccine’s low cost and ease of storage made it attractive to countries looking for a way out of the pandemic.<br><br>On Feb. 14, 2021, AstraZeneca <a href="https://www.ox.ac.uk/news/2021-02-12-oxford-university-extends-covid-19-vaccine-study-children">announced</a> they would start trials on children as young as six. Researchers at Oxford <a href="https://www.nytimes.com/2021/06/28/health/mixing-pfizer-astrazeneca-results.html">reported</a> preliminary results suggesting that a combination of AstraZeneca’s vaccine followed by Comirnaty produces strong levels of antibodies. AstraZeneca also <a href="https://www.nytimes.com/live/2020/12/11/world/covid-19-coronavirus/british-and-russian-vaccine-makers-are-set-to-begin-clinical-trials-combining-two-vaccines">launched</a> a similar trial with Russia’s Sputnik V vaccine. Results from that study <a href="https://rdif.ru/Eng_fullNews/7111/">suggest</a> that the combination yielded at least a four-fold increase in antibodies in 85 percent of participants. In September 2021, Imperial College London launched a <a href="https://clinicaltrials.gov/ct2/show/NCT05007275">trial</a> of an inhaled form of the vaccine. Brazilian researchers <a href="https://clinicaltrials.gov/ct2/show/NCT05059106?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">registered</a> a Phase 2/3 trial on Sept. 28 to evaluate the effectiveness of a half dose of the AstraZeneca vaccine compared to the normal dosing scheme. A <a href="https://clinicaltrials.gov/ct2/show/NCT05231005?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">fourth dose of AstraZeneca</a> is being tested in Israel to gauge its effectiveness against the Omicron variant.<br><br> <subhed>AUTHORIZATION</subhed><a href="https://www.nytimes.com/2020/12/30/world/europe/uk-covid-19-vaccine-oxford-astrazeneca.html">The United Kingdom</a> and <a href="https://www.reuters.com/article/us-health-coronavirus-argentina-astrazen/argentine-regulator-approves-astrazeneca-oxford-covid-19-vaccine-astrazeneca-idUSKBN29421P">Argentina</a> were the first countries to give  the vaccine emergency authorization, on Dec. 30, 2020. On Jan. 3, <a href="https://www.nytimes.com/2021/01/03/world/asia/india-covid-19-vaccine.html">India</a> issued an emergency authorization to a version called Covishield, made by the Serum Institute of India. It granted Covishield <a href="https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/covaxin-covishield-granted-regular-market-approval-india-1905218-2022-01-27">full approval</a> just over a year later on Jan. 27, 2022 . On Feb. 16, 2021 the World Health Organization <a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-authorised-for-emergency-use-by-the-world-health-organization.html">recommended</a> Vaxzevria for emergency use in adults 18 or older. Brazil gave <a href="https://medicalxpress.com/news/2021-03-brazil-grants-full-oxford-vaccine.html">full approval</a> to the vaccine on March 13, 2021.<br><br>In the summer of 2020, Astrazeneca <a href="https://www.nytimes.com/2020/12/08/business/covid-vaccine-oxford-astrazeneca.html">promised</a> it would distribute Vaxzevria in the United States as soon as that October. But a concern about the health of a volunteer in the U.S. clinical trial stalled the study for seven weeks. AstraZeneca did not deliver the results of the trial until March 2021 — only to be rebuked by its expert advisors for <a href="https://www.nytimes.com/2021/03/23/business/astrazeneca-vaccine-questions.html">cherry-picking data</a>. These speed bumps slowed the company down, while other vaccines were getting authorized and meeting the demand in the United States. By spring 2022, AstraZeneca had <a href="https://www.statnews.com/2022/05/19/astrazeneca-white-house-contract-canceled/">abandoned</a> its plan to apply to the F.D.A.<br><br> <subhed>DISTRIBUTION</subhed>Vaxzevria promised at first to be a cheap, robust vaccine that would go a long way to meeting the world’s need for protection from Covid-19. But it has suffered a number of setbacks.<br><br>Even while it was running clinical trials in 2020, AstraZeneca reached agreements with a number of manufacturers in order to produce billions of doses of Vaxzevria. But in January 2021, it admitted that it would fall short of its promised delivery of vaccines to the European Union. Its shortfall grew only worse in March when India, facing an explosion of new cases, <a href="https://www.nytimes.com/2021/03/25/world/asia/india-covid-vaccine-astrazeneca.html?searchResultPosition=6">blocked export of the vaccine</a> from its factories. On April 26, the European Commission <a href="https://www.nytimes.com/2021/04/26/world/astrazeneca-eu-lawsuit.html">filed a lawsuit</a> against the company for breach of contract. The court <a href="https://www.dw.com/en/eu-astrazeneca-both-claim-win-in-vaccine-delivery-legal-dispute/a-57958063">ordered</a> AstraZeneca on June 18 to deliver 50 million additional doses of Vaxzevria, substantially less than the 90 million the European Commission had demanded. AstraZeneca <a href="https://newseu.cgtn.com/news/2021-07-26/AstraZeneca-meets-vaccine-deadline-but-battle-with-EU-far-from-over-12dz0d46GI0/index.html">met</a> the revised deadline on July 26. In September, AstraZeneca and the European Commission <a href="https://www.fiercepharma.com/pharma/astrazeneca-strikes-covid-19-vaccine-delivery-deal-europe-ending-month-s-long-legal-battle">settled their dispute</a>, with an agreement for the company to supply 200 million doses by March 2022.<br><br>In the spring of 2021, as other countries struggled with devastating new waves of Covid-19, the United States came under intense criticism for holding back raw materials India needed to make its own supply of Covishield. On April 25, the Biden administration <a href="https://www.nytimes.com/2021/04/25/world/us-vaccines-india-covid.html">announced</a> it would partially lift its ban. Later, it promised to distribute AstraZeneca vaccines to other countries. But due to concerns about the facility where the vaccines were made in Baltimore, the vaccines were <a href="https://endpts.com/it-looks-like-the-final-round-of-emergents-astrazeneca-covid-19-doses-have-been-released/">held back</a> for nearly one year, until the F.D.A. said in February 2022 that it had <a href="https://www.fda.gov/news-events/press-announcements/fda-roundup-february-18-2022">cleared them</a> for shipment.<br><br>In South Africa, a small trial failed to demonstrate that it protected people against <a href="https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html">the Beta variant</a>, which had become predominant in the country. On Feb. 7, 2021, South Africa <a href="https://www.nytimes.com/2021/02/07/world/africa/covid-vaccine-astrazeneca-south-africa.html">halted plans</a> for a rollout of 1 million doses of the AstraZeneca vaccine and switched to Johnson & Johnson. <br><br>In March 2021, <a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax.html">Covax</a> began delivering doses of the vaccine to low- and middle-income countries. But manufacturing bottlenecks have <a href="https://www.nytimes.com/2021/08/02/world/europe/covax-covid-vaccine-problems-africa.html">slowed</a> the pipeline. Declining demand for the vaccine pushed the Serum Institute of India to halve its production of new Vaxzevria shots, Reuters <a href="https://www.reuters.com/world/india/indias-sii-halve-output-astrazeneca-vaccine-demand-sinks-cnbc-tv18-2021-12-08/?rpc=401&">reported</a> on Dec. 8. The Serum Institute <a href="https://www.bloomberg.com/news/articles/2022-04-22/serum-stops-making-covid-vaccines-with-200-million-doses-spare">announced</a> that it would halt production on April 22, 2022.<br><br>On April 11, 2022, Japan <a href="https://www.reuters.com/world/asia-pacific/japan-cancels-third-contracted-astrazeneca-vaccine-purchase-2022-04-11/">announced</a> that it would not purchase 40 million of the 120 million doses it agreed to buy last year, citing lower demand.<br><br>Concerns over Vaxzevria’s short shelf life have also pushed some countries to <a href="https://www.fiercepharma.com/pharma/poor-countries-are-declining-covid-19-vaccines-astrazeneca-because-shorter-shelf-life">decline millions of doses</a> of the vaccine.<br><br> <subhed>VARIANTS</subhed>As variants emerged in 2021, Vaxzevria proved more vulnerable than vaccines from Moderna or Pfizer-BioNTech. A British <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2108891">study</a> found that the AstraZeneca vaccine provided 67 percent effectiveness against infection with the Delta variant. A Canadian study <a href="https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-is-highly-effective-after-one-dose-against-severe-disease-or-hospitalisation-caused-by-beta-and-delta-variants-of-concern.html">found</a> that it had an effectiveness of 87 percent against hospitalization and death from the variant. British researchers <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063023/Vaccine-surveillance-report-week-12.pdf">found</a> that Vaxzevria offered less protection against Omicron. Vaxzevria was only 4o percent effective against infection within three months of vaccination, and its effectiveness disappeared completely after six months.  <br><br>AstraZeneca and Oxford created a version of the vaccine <a href="https://www.ox.ac.uk/news/2021-02-07-chadox1-ncov-19-provides-minimal-protection-against-mild-moderate-covid-19-infection">tailored to the Beta variant</a> and launched a <a href="https://clinicaltrials.gov/ct2/show/NCT04973449?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 2/3 trial</a> to test it. But on Feb. 10, 2022, AstraZeneca announced that the Beta vaccine provided no greater efficacy against the Omicron variant, leading them to <a href="https://www.fiercebiotech.com/biotech/astrazeneca-dumps-late-phase-next-gen-covid-19-vaccine-calling-time-a-beta-player-omicron">abandon it</a>.<br><br> <subhed>BOOSTERS</subhed>In June, Oxford researchers <a href="https://www.nytimes.com/2021/06/28/world/astrazeneca-vaccine-booster-shot.html">reported</a> that a third booster of the AstraZeneca vaccine generated strong immune responses in volunteers. On Dec. 3, 2021, Bloomberg <a href="https://www.bloomberg.com/news/articles/2021-12-01/astra-to-scrap-plan-for-u-s-booster-study-participants-told?sref=XGjS8839">reported</a> that AstraZeneca was scrapping its plans for a booster trial in the United States, and encouraged trial participants to seek a different vaccine for their third shot.<br><br> <subhed>SIDE EFFECTS</subhed>In March 2021, European medical regulators became concerned about a small number of cases of blood clots in younger people who received Vaxzevria. The European Medicines Agency concluded that the vaccine had a very rare side effect in which people suffered blood clots in large veins combined with low platelets. The regulators emphasized that <a href="https://www.nytimes.com/2021/03/18/world/europe/astrazeneca-vaccine-europe.html">the vaccine is effective</a> and the benefits it provided outweighed the small risk of its side effects. In response <a href="https://www.nytimes.com/live/2021/04/09/world/covid-vaccine-coronavirus-cases?type=styln-live-updates&label=coronavirus%20updates&index=0&action=click&module=Spotlight&pgtype=Homepage#france-says-those-under-55-who-got-a-first-astrazeneca-shot-should-follow-up-with-a-different-vaccine">some countries</a> chose to minimize the risk by restricting the vaccine to older people. In May, <a href="https://www.bloomberg.com/news/articles/2021-05-12/norway-permanently-removes-astrazeneca-from-vaccine-program">Norway</a> permanently removed Vaxzevria from their vaccination program. In August, a team of British researchers reported that the risk of blood clots is <a href="https://www.medrxiv.org/content/10.1101/2021.07.29.21261348v1">far higher</a> from Covid-19 than from the Vaxzevria vaccine.<br><br>For more details, see <strong><a href="https://www.nytimes.com/interactive/2020/health/oxford-astrazeneca-covid-19-vaccine.html">How the Oxford-AstraZeneca Vaccine Works</a></strong>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://medicalxpress.com/news/2021-03-brazil-grants-full-oxford-vaccine.html">Brazil</a>, <a href="https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/covaxin-covishield-granted-regular-market-approval-india-1905218-2022-01-27">India</a>.<br>
<span class="g-info">Stopped use in:</span> <a href="https://www.nytimes.com/2021/04/14/world/europe/denmark-astrazeneca-vaccine.html">Denmark</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/norway-will-not-use-astrazeneca-covid-19-vaccine-says-daily-vg-2021-05-12/">Norway</a>.<br>

<span class="g-info">Emergency use in:</span> <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Albania</a>, <a href="http://elbilad.net/article/detail?id=113247">Algeria</a>, <a href="https://africa.cgtn.com/2021/05/14/angolas-president-lourenco-first-lady-take-covid-19-vaccines/">Angola</a>, <a href="https://bb.usembassy.gov/u-s-citizen-services/covid-19-information/">Anguilla</a>, <a href="https://vaccineantiguabarbuda.com/faq/">Antigua</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-argentina-astrazen/argentine-regulator-approves-astrazeneca-oxford-covid-19-vaccine-astrazeneca-idUSKBN29421P">Argentina</a>, <a href="https://am.usembassy.gov/u-s-citizen-services/covid-19-information/">Armenia</a>, <a href="https://www.tga.gov.au/media-release/tga-provisionally-approves-astrazenecas-covid-19-vaccine">Australia</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Azerbaijan</a>, <a href="https://opm.gov.bs/prime-minister-minnis-receives-first-batch-of-covid-19-vaccines/">Bahamas</a>, <a href="https://gulfbusiness.com/bahrain-approves-emergency-use-of-oxford-astrazeneca-covid-19-vaccine/">Bahrain</a>, Bangladesh, <a href="https://www.livemint.com/news/world/barbados-dominica-get-covishield-jaishankar-says-consolidating-carib-connect-11612932587299.html">Barbados</a>, <a href="https://bb.usembassy.gov/u-s-citizen-services/covid-19-information/">Barbuda</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Belize</a>, <a href="https://www.gov.bm/astrazeneca-vaccine">Bermuda</a>, Bhutan, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Bosnia and Herzegovina</a>, <a href="http://www.xinhuanet.com/english/africa/2021-02/27/c_139771113.htm">Botswana</a>, <a href="https://www.bbc.com/news/world-latin-america-55699535">Brazil</a>, <a href="https://thescoop.co/2021/04/02/covid-19-brunei-to-begin-mass-vaccination-on-april-3/">Brunei</a>, <a href="https://bf.usembassy.gov/u-s-citizen-services/covid-19-information/">Burkina Faso</a>, <a href="https://www.eris.cv/index.php/noticias/194-celebrar-a-saude-atribuicoes-e-atuacao-da-eris-no-setor-farmaceutico">Cabo Verde</a>, <a href="https://www.who.int/cambodia/news/detail/03-03-2021-cambodia-among-first-countries-to-receive-covid-19-vaccines-from-covax-facility">Cambodia</a>, <a href="https://www.nytimes.com/2021/02/26/world/canada-astrazeneca-vaccine.html">Canada</a>, <a href="https://www.ispch.cl/noticia/isp-aprueba-la-tercera-vacuna-para-combatir-covid-19/">Chile</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-colombia/colombia-approves-emergency-use-of-astrazeneca-coronavirus-vaccine-idUSKBN2AO01A">Colombia</a>, <a href="https://mg.usembassy.gov/u-s-citizen-services/security-and-travel-information/covid-19-information/">Comoros</a>, <a href="https://qcostarica.com/costa-rica-approves-use-of-astrazenecas-covid-19-vaccine/">Costa Rica</a>, <a href="https://www.pio.gov.cy/coronavirus/eng/categories/vaccines-en">Cyprus</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazenecask-bio-serum-institute-of-india#col-0">Democratic Republic of the Congo</a>, <a href="https://bb.usembassy.gov/u-s-citizen-services/covid-19-information/">Dominica</a>, Dominican Republic, <a href="https://www.controlsanitario.gob.ec/arcsa-autoriza-el-ingreso-a-ecuador-de-vacuna-astra-zeneca-oxford-para-covid-19/">Ecuador</a>, <a href="https://www.facebook.com/egyptiandrugauthority/posts/232521865257571">Egypt</a>, El Salvador, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazenecask-bio-serum-institute-of-india#col-0">Estonia</a>, <a href="https://www.afro.who.int/news/eswatini-launches-nationwide-covid-19-vaccination-campaign">Eswatini</a>, <a href="https://www.ena.et/en/?p=22615">Ethiopia</a>, <a href="https://www.nytimes.com/2021/01/29/world/europe/EU-AstraZeneca-vaccine-export.html">European Union</a>, <a href="http://www.health.gov.fj/covid-vaccine/vaccine-faqs/">Fiji</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Gambia</a>, <a href="https://www.moh.gov.ge/news/5767/">Georgia</a>, <a href="http://fdaghana.gov.gh/news-media.php?page=78">Ghana</a>, Greenland, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Grenada</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Guadeloupe</a>, <a href="https://gt.usembassy.gov/alert-covid-19-2/">Guatemala</a>, <a href="https://gw.usmission.gov/covid-19-information/">Guinea-Bissau</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Guyana</a>, <a href="https://www.miamiherald.com/news/nation-world/world/americas/haiti/article251531528.html">Haiti</a>, <a href="https://hn.usembassy.gov/covid-19-information/">Honduras</a>, <a href="https://www.euronews.com/2021/03/22/covid-19-vaccine-hungary-approves-two-more-jabs-not-authorised-by-eu-regulator">Hungary</a>, <a href="https://www.icelandreview.com/society/iceland-to-receive-13800-doses-of-astrazeneca-vaccine-in-february/">Iceland</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-indonesia/indonesia-approves-astrazeneca-vaccine-for-emergency-use-idUSKBN2B10BE">Indonesia</a>, <a href="https://en.irna.ir/news/84233593/Iran-issues-permit-for-emergency-use-for-three-other-COVID-19">Iran</a>, <a href="http://www.businessworld.in/article/Iraq-approves-Sinopharm-AstraZeneca-COVID-19-vaccines-for-emergency-use/19-01-2021-367325/">Iraq</a>, <a href="https://corona.health.gov.il/en/vaccine-for-covid/">Israel</a>, <a href="https://ci.usembassy.gov/covid-19-information/">Ivory Coast</a>, <a href="https://jis.gov.jm/health-official-says-astrazeneca-vaccine-has-gone-through-layers-of-approval/">Jamaica</a>, <a href="http://www.xinhuanet.com/english/2021-07/30/c_1310097096.htm">Japan</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Jordan</a>, <a href="https://www.theeastafrican.co.ke/tea/news/east-africa/rwanda-leads-region-in-covid-19-vaccination-3321500">Kenya</a>, <a href="https://fj.usembassy.gov/u-s-citizen-services/covid-19-information/">Kiribati</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Kosovo</a>, <a href="https://gulfbusiness.com/kuwait-authorises-emergency-use-of-oxford-astrazeneca-covid-19-vaccine/">Kuwait</a>, <a href="https://cabar.asia/en/covid-19-vaccination-in-kyrgyzstan-frequently-asked-questions">Kyrgyzstan</a>, <a href="https://www.moph.gov.lb/userfiles/files/Prevention/COVID-19%20Vaccine/COVID-19%20Vaccine%20FAQ%20-%20EN%20-22-3-%202021.pdf">Lebanon</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Lesotho</a>, <a href="https://www.afro.who.int/news/liberia-launches-vaccination-against-covid-19">Liberia</a>, <a href="https://reliefweb.int/sites/reliefweb.int/files/resources/libya_covid_update_25_final.pdf">Libya</a>, Liechtenstein, <a href="https://mg.usembassy.gov/u-s-citizen-services/security-and-travel-information/covid-19-information/">Madagascar</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Malawi</a>, <a href="https://www.channelnewsasia.com/news/asia/covid-19-malaysia-approves-sinovac-astrazeneca-vaccines-uk-china-14316202">Malaysia</a>, Maldives, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Mali</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Malta</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Mauritius</a>, <a href="https://www.nytimes.com/2021/01/04/world/mexico-oxford-astrazeneca-vaccine.html">Mexico</a>, <a href="https://news.trust.org/item/20210227162136-o0jx5/">Moldova</a>, <a href="https://news.mn/en/795048/">Mongolia</a>, <a href="https://www.gov.me/en/article/vaccination-with-astrazeneca-vaccine-begins">Montenegro</a>, <a href="https://bb.usembassy.gov/u-s-citizen-services/covid-19-information/">Montserrat</a>, Morocco, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Myanmar</a>, <a href="https://mhss.gov.na/documents/119527/775250/SKM_36721030413220.pdf/7a4534bb-022f-46e4-9113-571432290194">Namibia</a>, <a href="https://fj.usembassy.gov/u-s-citizen-services/covid-19-information/">Nauru</a>, Nepal, <a href="https://www.reuters.com/world/asia-pacific/new-zealand-gives-provisional-nod-astrazenecas-covid-19-vaccine-2021-07-28/">New Zealand</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Nicaragua</a>, <a href="https://ne.usembassy.gov/u-s-citizen-services/covid-19-information/">Niger</a>, <a href="https://www.nafdac.gov.ng/nafdac-approves-covid19-vaccine/">Nigeria</a>, <a href="https://kovid19vakcinacija.mk/za-vakcinite/">North Macedonia</a>, <a href="https://www.urdupoint.com/en/world/norway-recommends-astrazenecas-covid-vaccine-1159619.html">Norway</a>, <a href="https://omannews.gov.om/NewsDescription/ArtMID/392/ArticleID/34544/Health-Sector-in-Sultanate-Has-Become-%E2%80%9CExhausted%E2%80%9D-Health-Minister">Oman</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-pakistan-astrazene/pakistan-approves-astrazeneca-covid-19-vaccine-for-emergency-use-idUKKBN29L0DO">Pakistan</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazenecask-bio-serum-institute-of-india#col-0">Palestinian Authority</a>, <a href="http://minsa.b-cdn.net/sites/default/files/publicacion-general/aue_no_002dnfd_de_la_vacuna_covid19_astrazeneca.pdf">Panama</a>, <a href="https://www.rnz.co.nz/international/pacific-news/438009/png-approves-astrazeneca-covid-19-vaccine">Papua New Guinea</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Paraguay</a>, <a href="http://www.digemid.minsa.gob.pe/main.asp?Seccion=1065">Peru</a>, <a href="https://www.pharmaceutical-technology.com/news/astrazeneca-vaccine-eua-philippines/">Philippines</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Republic of Congo</a>, <a href="https://www.theeastafrican.co.ke/tea/science-health/rwanda-astrazeneca-jab-3326026">Rwanda</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Sao Tome and Principe</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">San Martin</a>, <a href="https://twitter.com/Saudi_fda_en/status/1362370882996490245">Saudi Arabia</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Senegal</a>, <a href="https://www.euronews.com/2021/02/24/which-vaccine-should-i-choose-serbia-gives-citizens-choice-of-four-coronavirus-jabs">Serbia</a>, <a href="https://www.thehindu.com/news/national/coronavirus-myanmar-mauritius-seychelles-receive-covishield-vaccine/article33638057.ece">Seychelles</a>, <a href="https://www.africanews.com/2021/03/16/sierra-leone-president-bio-and-government-get-first-covid-19-shots//">Sierra Leone</a>, <a href="https://solomons.gov.sb/solomon-islands-receive-24000-doses-of-covid-19-vaccines-through-the-covax-facility/">Solomon Islands</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Somalia</a>, <a href="https://www.gov.za/covid-19/vaccine">South Africa</a>, <a href="https://www.mfds.go.kr/eng/brd/m_64/view.do?seq=54&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1">South Korea</a>, <a href="https://www.livemint.com/news/world/sri-lanka-approves-oxford-astrazeneca-covid-19-vaccine-for-emergency-use-11611304254187.html">Sri Lanka</a>, <a href="http://health.gov.vc/health/images/stories/PDF/SRO-Public_Health_Emergency_Authorisation_of_Covid-19_Vaccine.pdf">Saint Vincent and the Grenadines</a>, <a href="https://www.sknis.gov.kn/2021/06/09/st-kitts-and-nevis-will-only-use-who-approved-covid-19-vaccines-assures-pm-harris/">St. Kitts and Nevis</a>, <a href="https://bb.usembassy.gov/u-s-citizen-services/covid-19-information/">St. Lucia</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazenecask-bio-serum-institute-of-india#col-0">South Sudan</a>, <a href="https://www.unicef.org/press-releases/sudan-receives-first-delivery-covid-19-vaccines-over-800000-doses">Sudan</a>, <a href="http://health.gov.sr/actueel/2021/india-doneert-50000-doses-astrazeneca-dinsdag-kickoff-vaccinatie">Suriname</a>, <a href="https://www.aljazeera.com/news/2021/3/18/taiwan-clears-astrazeneca-vaccine-shots-might-start-on-monday">Taiwan</a>, <a href="https://tj.usembassy.gov/covid-19-information/">Tajikistan</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-thailand-vaccine/thai-regulator-approves-astrazenca-vaccine-for-emergency-use-sources-idUSKBN29Q194">Thailand</a>, <a href="http://timor-leste.gov.tl/?p=28430&lang=pt">Timor-Leste</a>, <a href="http://www.xinhuanet.com/english/2021-03/08/c_139794633.htm">Togo</a>, <a href="https://fj.usembassy.gov/u-s-citizen-services/covid-19-information/">Tonga</a>, <a href="https://m.facebook.com/MinistryofHealthTT/photos/a.153051404724676/4635809886448783/?type=3&source=48">Trinidad and Tobago</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Tunisia</a>, <a href="https://fj.usembassy.gov/u-s-citizen-services/covid-19-information/">Tuvalu</a>, <a href="http://www.xinhuanet.com/english/2021-03/19/c_139820209.htm">Uganda</a>, <a href="https://www.ukrinform.net/rubric-society/3195736-ukraine-registers-oxfordastrazeneca-vaccine-for-emergency-use.html">Ukraine</a>, <a href="https://www.nytimes.com/2020/12/30/world/europe/uk-covid-19-vaccine-oxford-astrazeneca.html">United Kingdom</a>, <a href="https://www.gub.uy/ministerio-salud-publica/sites/ministerio-salud-publica/files/documentos/noticias/-1612033397.pdf">Uruguay</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Uzbekistan</a>, <a href="https://dailypost.vu/news/vanuatu-vaccine-deployment-plan-approved/article_7995c78e-7560-11eb-b794-bffccbab2f6d.html?fbclid=IwAR0QxnXAABx-zDb_B8Qn6mp0h_DDoFflcl73Me-2zYXUCxhFLzP55nkpSD8">Vanuatu</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-vietnam-idUSKBN29Z00Q">Vietnam</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Virgin Islands</a>, <a href="https://covid-19pharmacovigilance.paho.org/eu-nodes-astrazeneca-oxford-astrazeneca-sk-bio-serum-institute-of-india#col-0">Yemen</a>, <a href="https://zanis.com.zm/2021/03/27/covid-19-vaccine-roll-out-set-moh/">Zambia</a>. Emergency use validation from the <a href="https://www.who.int/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out">World Health Organization</a>. Endorsed by the <a href="https://africacdc.org/download/africa-regulatory-taskforce-has-endorsed-the-emergency-used-listing-for-two-versions-of-the-astrazeneca-oxford-vaccine-astrazeneca-skbio-in-south-korea-and-serum-institute-of-india/">Africa Regulatory Taskforce</a>. Recommended for emergency use by the <a href="https://www.carpha.org/More/Media/Articles/ArticleID/435/CARPHA-Issues-its-First-Emergency-Use-Recommendation-for-a-COVID-19-Vaccine">Caribbean Regulatory System</a>.<br>



</span>

<span class="g-updated">Updated Aug. 31, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase2 g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-05-23 13:05 -->
<!-- ai file: map-oxford.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-oxford-box ,
	#g-map-oxford-box .g-artboard {
		margin:0 auto;
	}
	#g-map-oxford-box p {
		margin:0;
	}
	#g-map-oxford-box .g-aiAbs {
		position:absolute;
	}
	#g-map-oxford-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-oxford-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-oxford-box .g-aiPointText p { white-space: nowrap; }
	#g-map-oxford-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-oxford-900 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-oxford-900 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-oxford-900 .g-pstyle1 {
		height:13px;
	}
	#g-map-oxford-900 .g-pstyle2 {
		height:13px;
		text-align:center;
	}
	#g-map-oxford-900 .g-pstyle3 {
		height:13px;
		text-align:right;
	}
	#g-map-oxford-900 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-oxford-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-oxford-720 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-oxford-720 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-oxford-720 .g-pstyle1 {
		height:13px;
	}
	#g-map-oxford-720 .g-pstyle2 {
		height:13px;
		text-align:center;
	}
	#g-map-oxford-720 .g-pstyle3 {
		height:13px;
		text-align:right;
	}
	#g-map-oxford-720 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-oxford-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-oxford-600 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-oxford-600 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-oxford-600 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-oxford-600 .g-pstyle2 {
		height:13px;
	}
	#g-map-oxford-600 .g-pstyle3 {
		height:13px;
		text-align:right;
	}
	#g-map-oxford-600 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-oxford-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-oxford-335 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-oxford-335 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-oxford-335 .g-pstyle1 {
		height:13px;
		text-align:right;
	}
	#g-map-oxford-335 .g-pstyle2 {
		height:13px;
	}
	#g-map-oxford-335 .g-pstyle3 {
		height:13px;
		text-align:center;
	}
	#g-map-oxford-335 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}

</style>

<div id="g-map-oxford-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-oxford-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-oxford-900-img" class="g-map-oxford-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-oxford-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:151px;">
			<p class="g-pstyle0">Oxford-AstraZeneca</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-900 g-aiAbs g-aiPointText" style="top:9.4892%;margin-top:-6.8px;left:68.4269%;width:77px;">
			<p class="g-pstyle1">NORWAY</p>
		</div>
		<div id="g-ai0-3" class="g-900 g-aiAbs g-aiPointText" style="top:12.7467%;margin-top:-13.4px;left:61.7231%;margin-left:-51px;width:102px;">
			<p class="g-pstyle2">BRITAIN AND</p>
			<p class="g-pstyle2">THE E.U.</p>
		</div>
		<div id="g-ai0-4" class="g-900 g-aiAbs g-aiPointText" style="top:20.441%;margin-top:-6.8px;right:39.8516%;width:86px;">
			<p class="g-pstyle3">MOROCCO</p>
		</div>
		<div id="g-ai0-5" class="g-900 g-aiAbs g-aiPointText" style="top:22.1259%;margin-top:-6.8px;left:26.7642%;margin-left:-37px;width:74px;">
			<p class="g-pstyle2">CANADA</p>
		</div>
		<div id="g-ai0-6" class="g-900 g-aiAbs g-aiPointText" style="top:23.53%;margin-top:-6.8px;left:76.294%;width:90px;">
			<p class="g-pstyle1">MONGOLIA</p>
		</div>
		<div id="g-ai0-7" class="g-900 g-aiAbs g-aiPointText" style="top:28.5847%;margin-top:-6.8px;left:85.432%;width:111px;">
			<p class="g-pstyle1">SOUTH KOREA</p>
		</div>
		<div id="g-ai0-8" class="g-900 g-aiAbs g-aiPointText" style="top:29.708%;margin-top:-6.8px;right:35.3735%;width:76px;">
			<p class="g-pstyle3">ALGERIA</p>
		</div>
		<div id="g-ai0-9" class="g-900 g-aiAbs g-aiPointText" style="top:37.0092%;margin-top:-6.8px;left:32.3946%;width:84px;">
			<p class="g-pstyle1">BAHAMAS</p>
		</div>
		<div id="g-ai0-10" class="g-900 g-aiAbs g-aiPointText" style="top:37.29%;margin-top:-6.8px;left:87.5381%;width:99px;">
			<p class="g-pstyle1">PHILIPPINES</p>
		</div>
		<div id="g-ai0-11" class="g-900 g-aiAbs g-aiPointText" style="top:37.5708%;margin-top:-6.8px;right:31.3856%;width:62px;">
			<p class="g-pstyle3">EGYPT</p>
		</div>
		<div id="g-ai0-12" class="g-900 g-aiAbs g-aiPointText" style="top:37.8517%;margin-top:-6.8px;left:70.8787%;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai0-13" class="g-900 g-aiAbs g-aiPointText" style="top:41.7831%;margin-top:-6.8px;right:20.9553%;width:83px;">
			<p class="g-pstyle3">PAKISTAN</p>
		</div>
		<div id="g-ai0-14" class="g-900 g-aiAbs g-aiPointText" style="top:42.3447%;margin-top:-6.8px;right:41.8403%;width:73px;">
			<p class="g-pstyle3">NIGERIA</p>
		</div>
		<div id="g-ai0-15" class="g-900 g-aiAbs g-aiPointText" style="top:47.3994%;margin-top:-6.8px;left:76.9981%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle2">INDIA</p>
		</div>
		<div id="g-ai0-16" class="g-900 g-aiAbs g-aiPointText" style="top:47.6802%;margin-top:-6.8px;right:75.3855%;width:71px;">
			<p class="g-pstyle3">MEXICO</p>
		</div>
		<div id="g-ai0-17" class="g-900 g-aiAbs g-aiPointText" style="top:51.3308%;margin-top:-6.8px;left:41.471%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai0-18" class="g-900 g-aiAbs g-aiPointText" style="top:52.7349%;margin-top:-6.8px;left:84.9704%;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai0-19" class="g-900 g-aiAbs g-aiPointText" style="top:54.7006%;margin-top:-6.8px;right:67.4415%;width:95px;">
			<p class="g-pstyle3">COSTA RICA</p>
		</div>
		<div id="g-ai0-20" class="g-900 g-aiAbs g-aiPointText" style="top:54.9815%;margin-top:-6.8px;left:65.7206%;margin-left:-31.5px;width:63px;">
			<p class="g-pstyle2">KENYA</p>
		</div>
		<div id="g-ai0-21" class="g-900 g-aiAbs g-aiPointText" style="top:58.6321%;margin-top:-6.8px;left:90.28%;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai0-22" class="g-900 g-aiAbs g-aiPointText" style="top:59.1937%;margin-top:-6.8px;right:43.2333%;width:76px;">
			<p class="g-pstyle3">NAMIBIA</p>
		</div>
		<div id="g-ai0-23" class="g-900 g-aiAbs g-aiPointText" style="top:59.7553%;margin-top:-6.8px;left:77.7468%;width:87px;">
			<p class="g-pstyle1">MALDIVES</p>
		</div>
		<div id="g-ai0-24" class="g-900 g-aiAbs g-aiPointText" style="top:65.0909%;margin-top:-6.8px;left:68.8052%;width:101px;">
			<p class="g-pstyle1">SEYCHELLES</p>
		</div>
		<div id="g-ai0-25" class="g-900 g-aiAbs g-aiPointText" style="top:70.4264%;margin-top:-6.8px;right:60.2932%;width:59px;">
			<p class="g-pstyle3">CHILE</p>
		</div>
		<div id="g-ai0-26" class="g-900 g-aiAbs g-aiPointText" style="top:73.9647%;margin-top:-13.4px;left:58.7542%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">SOUTH</p>
			<p class="g-pstyle2">AFRICA</p>
		</div>
		<div id="g-ai0-27" class="g-900 g-aiAbs g-aiPointText" style="top:72.6729%;margin-top:-6.8px;left:43.6507%;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai0-28" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai0-29" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:87.9755%;margin-top:-27.3px;left:72.1094%;width:121px;">
			<p class="g-pstyle4">Stopped use</p>
			<p class="g-pstyle4">in favor of other</p>
			<p class="g-pstyle4">vaccines</p>
		</div>
		<div id="g-ai0-30" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle4">Early, limited or</p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-oxford-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-oxford-720-img" class="g-map-oxford-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-oxford-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:8.2866%;margin-top:-25.5px;left:0.0094%;width:97px;">
			<p class="g-pstyle0">Oxford-</p>
			<p class="g-pstyle0">AstraZeneca</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-720 g-aiAbs g-aiPointText" style="top:9.4292%;margin-top:-6.8px;left:68.7758%;width:77px;">
			<p class="g-pstyle1">NORWAY</p>
		</div>
		<div id="g-ai1-3" class="g-720 g-aiAbs g-aiPointText" style="top:12.104%;margin-top:-13.4px;left:61.0236%;margin-left:-51px;width:102px;">
			<p class="g-pstyle2">BRITAIN AND</p>
			<p class="g-pstyle2">THE E.U.</p>
		</div>
		<div id="g-ai1-4" class="g-720 g-aiAbs g-aiPointText" style="top:21.7474%;margin-top:-6.8px;left:26.7849%;margin-left:-37px;width:74px;">
			<p class="g-pstyle2">CANADA</p>
		</div>
		<div id="g-ai1-5" class="g-720 g-aiAbs g-aiPointText" style="top:22.0993%;margin-top:-6.8px;right:40.6897%;width:86px;">
			<p class="g-pstyle3">MOROCCO</p>
		</div>
		<div id="g-ai1-6" class="g-720 g-aiAbs g-aiPointText" style="top:22.4513%;margin-top:-6.8px;left:75.1495%;width:90px;">
			<p class="g-pstyle1">MONGOLIA</p>
		</div>
		<div id="g-ai1-7" class="g-720 g-aiAbs g-aiPointText" style="top:28.7863%;margin-top:-6.8px;left:85.5873%;width:111px;">
			<p class="g-pstyle1">SOUTH KOREA</p>
		</div>
		<div id="g-ai1-8" class="g-720 g-aiAbs g-aiPointText" style="top:29.4902%;margin-top:-6.8px;right:34.408%;width:76px;">
			<p class="g-pstyle3">ALGERIA</p>
		</div>
		<div id="g-ai1-9" class="g-720 g-aiAbs g-aiPointText" style="top:35.8253%;margin-top:-6.8px;left:71.0171%;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai1-10" class="g-720 g-aiAbs g-aiPointText" style="top:36.5292%;margin-top:-6.8px;left:32.3609%;width:84px;">
			<p class="g-pstyle1">BAHAMAS</p>
		</div>
		<div id="g-ai1-11" class="g-720 g-aiAbs g-aiPointText" style="top:36.8811%;margin-top:-6.8px;left:87.427%;width:99px;">
			<p class="g-pstyle1">PHILIPPINES</p>
		</div>
		<div id="g-ai1-12" class="g-720 g-aiAbs g-aiPointText" style="top:36.8811%;margin-top:-6.8px;right:30.9852%;width:62px;">
			<p class="g-pstyle3">EGYPT</p>
		</div>
		<div id="g-ai1-13" class="g-720 g-aiAbs g-aiPointText" style="top:41.1045%;margin-top:-6.8px;right:19.5197%;width:83px;">
			<p class="g-pstyle3">PAKISTAN</p>
		</div>
		<div id="g-ai1-14" class="g-720 g-aiAbs g-aiPointText" style="top:43.2162%;margin-top:-6.8px;right:41.9988%;width:73px;">
			<p class="g-pstyle3">NIGERIA</p>
		</div>
		<div id="g-ai1-15" class="g-720 g-aiAbs g-aiPointText" style="top:46.7357%;margin-top:-6.8px;right:75.9703%;width:71px;">
			<p class="g-pstyle3">MEXICO</p>
		</div>
		<div id="g-ai1-16" class="g-720 g-aiAbs g-aiPointText" style="top:48.8474%;margin-top:-6.8px;left:76.9929%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle2">INDIA</p>
		</div>
		<div id="g-ai1-17" class="g-720 g-aiAbs g-aiPointText" style="top:51.6629%;margin-top:-6.8px;left:41.3816%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai1-18" class="g-720 g-aiAbs g-aiPointText" style="top:54.4785%;margin-top:-6.8px;left:65.6055%;margin-left:-31.5px;width:63px;">
			<p class="g-pstyle2">KENYA</p>
		</div>
		<div id="g-ai1-19" class="g-720 g-aiAbs g-aiPointText" style="top:55.1824%;margin-top:-6.8px;right:67.3414%;width:95px;">
			<p class="g-pstyle3">COSTA RICA</p>
		</div>
		<div id="g-ai1-20" class="g-720 g-aiAbs g-aiPointText" style="top:58.3499%;margin-top:-6.8px;left:89.5596%;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai1-21" class="g-720 g-aiAbs g-aiPointText" style="top:59.4058%;margin-top:-6.8px;right:43.4745%;width:76px;">
			<p class="g-pstyle3">NAMIBIA</p>
		</div>
		<div id="g-ai1-22" class="g-720 g-aiAbs g-aiPointText" style="top:60.1097%;margin-top:-6.8px;left:77.5057%;width:87px;">
			<p class="g-pstyle1">MALDIVES</p>
		</div>
		<div id="g-ai1-23" class="g-720 g-aiAbs g-aiPointText" style="top:65.7408%;margin-top:-6.8px;left:68.7924%;width:101px;">
			<p class="g-pstyle1">SEYCHELLES</p>
		</div>
		<div id="g-ai1-24" class="g-720 g-aiAbs g-aiPointText" style="top:70.3162%;margin-top:-6.8px;right:60.3963%;width:59px;">
			<p class="g-pstyle3">CHILE</p>
		</div>
		<div id="g-ai1-25" class="g-720 g-aiAbs g-aiPointText" style="top:72.0759%;margin-top:-6.8px;left:43.9152%;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai1-26" class="g-720 g-aiAbs g-aiPointText" style="top:74.7507%;margin-top:-13.4px;left:59.491%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">SOUTH</p>
			<p class="g-pstyle2">AFRICA</p>
		</div>
		<div id="g-ai1-27" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai1-28" class="g-type_copy g-aiAbs g-aiPointText" style="top:89.2419%;margin-top:-25.6px;left:71.0674%;width:114px;">
			<p class="g-pstyle4">Stopped use</p>
			<p class="g-pstyle4">in favor of other</p>
			<p class="g-pstyle4">vaccines</p>
		</div>
		<div id="g-ai1-29" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle4">Early, limited or </p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-oxford-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-oxford-600-img" class="g-map-oxford-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-oxford-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:9.2099%;margin-top:-23.8px;left:-0.0735%;width:92px;">
			<p class="g-pstyle0">Oxford-</p>
			<p class="g-pstyle0">AstraZeneca</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-600 g-aiAbs g-aiPointText" style="top:9.8699%;margin-top:-13.4px;left:58.9426%;margin-left:-51px;width:102px;">
			<p class="g-pstyle1">BRITAIN AND</p>
			<p class="g-pstyle1">THE E.U.</p>
		</div>
		<div id="g-ai2-3" class="g-600 g-aiAbs g-aiPointText" style="top:9.6167%;margin-top:-6.8px;left:69.0208%;width:77px;">
			<p class="g-pstyle2">NORWAY</p>
		</div>
		<div id="g-ai2-4" class="g-600 g-aiAbs g-aiPointText" style="top:21.431%;margin-top:-6.8px;left:74.4538%;width:90px;">
			<p class="g-pstyle2">MONGOLIA</p>
		</div>
		<div id="g-ai2-5" class="g-600 g-aiAbs g-aiPointText" style="top:21.853%;margin-top:-6.8px;left:27.0853%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai2-6" class="g-600 g-aiAbs g-aiPointText" style="top:24.3846%;margin-top:-6.8px;right:40.5819%;width:86px;">
			<p class="g-pstyle3">MOROCCO</p>
		</div>
		<div id="g-ai2-7" class="g-600 g-aiAbs g-aiPointText" style="top:29.8698%;margin-top:-6.8px;right:33.8384%;width:76px;">
			<p class="g-pstyle3">ALGERIA</p>
		</div>
		<div id="g-ai2-8" class="g-600 g-aiAbs g-aiPointText" style="top:30.7137%;margin-top:-6.8px;left:85.1737%;width:111px;">
			<p class="g-pstyle2">SOUTH KOREA</p>
		</div>
		<div id="g-ai2-9" class="g-600 g-aiAbs g-aiPointText" style="top:35.777%;margin-top:-6.8px;left:32.444%;width:84px;">
			<p class="g-pstyle2">BAHAMAS</p>
		</div>
		<div id="g-ai2-10" class="g-600 g-aiAbs g-aiPointText" style="top:36.6209%;margin-top:-6.8px;right:30.8286%;width:62px;">
			<p class="g-pstyle3">EGYPT</p>
		</div>
		<div id="g-ai2-11" class="g-600 g-aiAbs g-aiPointText" style="top:36.6209%;margin-top:-6.8px;left:87.3029%;width:99px;">
			<p class="g-pstyle2">PHILIPPINES</p>
		</div>
		<div id="g-ai2-12" class="g-600 g-aiAbs g-aiPointText" style="top:37.8867%;margin-top:-6.8px;left:70.7472%;width:53px;">
			<p class="g-pstyle2">IRAN</p>
		</div>
		<div id="g-ai2-13" class="g-600 g-aiAbs g-aiPointText" style="top:42.95%;margin-top:-6.8px;right:42.2079%;width:73px;">
			<p class="g-pstyle3">NIGERIA</p>
		</div>
		<div id="g-ai2-14" class="g-600 g-aiAbs g-aiPointText" style="top:46.7475%;margin-top:-6.8px;right:76.1963%;width:71px;">
			<p class="g-pstyle3">MEXICO</p>
		</div>
		<div id="g-ai2-15" class="g-600 g-aiAbs g-aiPointText" style="top:50.123%;margin-top:-6.8px;right:20.2361%;width:57px;">
			<p class="g-pstyle3">INDIA</p>
		</div>
		<div id="g-ai2-16" class="g-600 g-aiAbs g-aiPointText" style="top:51.8108%;margin-top:-6.8px;left:41.3295%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai2-17" class="g-600 g-aiAbs g-aiPointText" style="top:53.4985%;margin-top:-6.8px;left:65.7285%;margin-left:-31.5px;width:63px;">
			<p class="g-pstyle1">KENYA</p>
		</div>
		<div id="g-ai2-18" class="g-600 g-aiAbs g-aiPointText" style="top:54.7643%;margin-top:-6.8px;right:67.8346%;width:95px;">
			<p class="g-pstyle3">COSTA RICA</p>
		</div>
		<div id="g-ai2-19" class="g-600 g-aiAbs g-aiPointText" style="top:59.4057%;margin-top:-6.8px;right:42.8547%;width:76px;">
			<p class="g-pstyle3">NAMIBIA</p>
		</div>
		<div id="g-ai2-20" class="g-600 g-aiAbs g-aiPointText" style="top:59.8276%;margin-top:-6.8px;left:77.7054%;width:87px;">
			<p class="g-pstyle2">MALDIVES</p>
		</div>
		<div id="g-ai2-21" class="g-600 g-aiAbs g-aiPointText" style="top:67.0006%;margin-top:-6.8px;left:68.8298%;width:101px;">
			<p class="g-pstyle2">SEYCHELLES</p>
		</div>
		<div id="g-ai2-22" class="g-600 g-aiAbs g-aiPointText" style="top:71.22%;margin-top:-6.8px;left:41.8833%;width:95px;">
			<p class="g-pstyle2">ARGENTINA</p>
		</div>
		<div id="g-ai2-23" class="g-600 g-aiAbs g-aiPointText" style="top:73.3297%;margin-top:-6.8px;left:88.0716%;width:92px;">
			<p class="g-pstyle2">AUSTRALIA</p>
		</div>
		<div id="g-ai2-24" class="g-600 g-aiAbs g-aiPointText" style="top:76.1146%;margin-top:-13.4px;left:59.4975%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">AFRICA</p>
		</div>
		<div id="g-ai2-25" class="g-600 g-aiAbs g-aiPointText" style="top:75.8614%;margin-top:-6.8px;right:59.6879%;width:59px;">
			<p class="g-pstyle3">CHILE</p>
		</div>
		<div id="g-ai2-26" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai2-27" class="g-type g-aiAbs g-aiPointText" style="top:89.8088%;margin-top:-23.8px;left:70.9104%;width:108px;">
			<p class="g-pstyle4">Stopped use</p>
			<p class="g-pstyle4">in favor of other</p>
			<p class="g-pstyle4">vaccines</p>
		</div>
		<div id="g-ai2-28" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle4">Early, limited or</p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-oxford-335" class="g-artboard" style="max-width: 599px;max-height: 865px" data-aspect-ratio="0.692" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 144.489% 0;"></div>
		<img id="g-map-oxford-335-img" class="g-map-oxford-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-oxford-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:4.5094%;margin-top:-23.8px;left:0.2579%;width:92px;">
			<p class="g-pstyle0">Oxford-</p>
			<p class="g-pstyle0">AstraZeneca</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-335 g-aiAbs g-aiPointText" style="top:11.9395%;margin-top:-6.8px;right:38.9348%;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai3-3" class="g-335 g-aiAbs g-aiPointText" style="top:19.9967%;margin-top:-6.8px;left:64.8454%;width:84px;">
			<p class="g-pstyle2">BAHAMAS</p>
		</div>
		<div id="g-ai3-4" class="g-335 g-aiAbs g-aiPointText" style="top:25.7813%;margin-top:-6.8px;right:52.3157%;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai3-5" class="g-335 g-aiAbs g-aiPointText" style="top:28.2605%;margin-top:-6.8px;left:82.3796%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle3">BRAZIL</p>
		</div>
		<div id="g-ai3-6" class="g-335 g-aiAbs g-aiPointText" style="top:29.9132%;margin-top:-6.8px;right:35.2128%;width:95px;">
			<p class="g-pstyle1">COSTA RICA</p>
		</div>
		<div id="g-ai3-7" class="g-335 g-aiAbs g-aiPointText" style="top:36.9375%;margin-top:-6.8px;right:21.8552%;width:59px;">
			<p class="g-pstyle1">CHILE</p>
		</div>
		<div id="g-ai3-8" class="g-335 g-aiAbs g-aiPointText" style="top:41.4826%;margin-top:-6.8px;left:77.5889%;width:95px;">
			<p class="g-pstyle2">ARGENTINA</p>
		</div>
		<div id="g-ai3-9" class="g-335 g-aiAbs g-aiPointText" style="top:50.2836%;margin-top:-13.4px;left:22.0074%;margin-left:-51px;width:102px;">
			<p class="g-pstyle3">BRITAIN AND</p>
			<p class="g-pstyle3">THE E.U.</p>
		</div>
		<div id="g-ai3-10" class="g-335 g-aiAbs g-aiPointText" style="top:49.1266%;margin-top:-6.8px;left:38.1042%;width:77px;">
			<p class="g-pstyle2">NORWAY</p>
		</div>
		<div id="g-ai3-11" class="g-335 g-aiAbs g-aiPointText" style="top:55.7377%;margin-top:-6.8px;left:49.3859%;width:90px;">
			<p class="g-pstyle2">MONGOLIA</p>
		</div>
		<div id="g-ai3-12" class="g-335 g-aiAbs g-aiPointText" style="top:59.4564%;margin-top:-6.8px;right:68.9351%;width:76px;">
			<p class="g-pstyle1">ALGERIA</p>
		</div>
		<div id="g-ai3-13" class="g-335 g-aiAbs g-aiPointText" style="top:59.663%;margin-top:-6.8px;left:71.5624%;width:111px;">
			<p class="g-pstyle2">SOUTH KOREA</p>
		</div>
		<div id="g-ai3-14" class="g-335 g-aiAbs g-aiPointText" style="top:63.5883%;margin-top:-6.8px;right:61.4756%;width:62px;">
			<p class="g-pstyle1">EGYPT</p>
		</div>
		<div id="g-ai3-15" class="g-335 g-aiAbs g-aiPointText" style="top:63.7949%;margin-top:-6.8px;left:74.9857%;width:99px;">
			<p class="g-pstyle2">PHILIPPINES</p>
		</div>
		<div id="g-ai3-16" class="g-335 g-aiAbs g-aiPointText" style="top:64.6213%;margin-top:-6.8px;left:40.2173%;width:53px;">
			<p class="g-pstyle2">IRAN</p>
		</div>
		<div id="g-ai3-17" class="g-335 g-aiAbs g-aiPointText" style="top:69.5796%;margin-top:-6.8px;left:54.8748%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle3">INDIA</p>
		</div>
		<div id="g-ai3-18" class="g-335 g-aiAbs g-aiPointText" style="top:72.4719%;margin-top:-6.8px;right:81.9699%;width:76px;">
			<p class="g-pstyle1">NAMIBIA</p>
		</div>
		<div id="g-ai3-19" class="g-335 g-aiAbs g-aiPointText" style="top:73.0917%;margin-top:-6.8px;left:31.724%;margin-left:-31.5px;width:63px;">
			<p class="g-pstyle3">KENYA</p>
		</div>
		<div id="g-ai3-20" class="g-335 g-aiAbs g-aiPointText" style="top:76.3972%;margin-top:-6.8px;left:55.5641%;width:87px;">
			<p class="g-pstyle2">MALDIVES</p>
		</div>
		<div id="g-ai3-21" class="g-335 g-aiAbs g-aiPointText" style="top:79.7027%;margin-top:-6.8px;left:37.6671%;width:101px;">
			<p class="g-pstyle2">SEYCHELLES</p>
		</div>
		<div id="g-ai3-22" class="g-335 g-aiAbs g-aiPointText" style="top:83.2148%;margin-top:-6.8px;left:78.3788%;width:92px;">
			<p class="g-pstyle2">AUSTRALIA</p>
		</div>
		<div id="g-ai3-23" class="g-335 g-aiAbs g-aiPointText" style="top:84.785%;margin-top:-13.4px;left:17.6077%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle3">SOUTH</p>
			<p class="g-pstyle3">AFRICA</p>
		</div>
		<div id="g-ai3-24" class="g-type g-aiAbs g-aiPointText" style="top:88.4737%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai3-25" class="g-type g-aiAbs g-aiPointText" style="top:93.5974%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle4">Early, limited or </p>
			<p class="g-pstyle4">emergency use</p>
		</div>
		<div id="g-ai3-26" class="g-type g-aiAbs g-aiPointText" style="top:98.5969%;margin-top:-8.2px;left:42.1259%;width:91px;">
			<p class="g-pstyle4">Stopped use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-oxford-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-05-23 13:05 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="cansino"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN CHINA</span>


<span class="g-limited">EMERGENCY USE IN OTHER COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/cansino-new-800.png" class="g-vlogo" 
    style="width: 200px; height: 37px; margin-right: 20px;" alt="CanSino Biologics logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/ams-800.png" class="g-vlogo" 
    style="width: 55px; height: 55px;" alt="Academy of Military Medical Sciences logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Convidecia (also known as Ad5-nCoV)<br>
<span class="g-info">Efficacy:</span> <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02753-7/fulltext">57.5%</a> against symptomatic Covid​​, <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02753-7/fulltext">91.7%</a>​​ against severe disease.<br>
<span class="g-info">Dose:</span> Single dose<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Refrigerated<br>
<br>
</span>

<!-- description -->
Convidecia is a vaccine developed by the Chinese company <strong>CanSino Biologics</strong> in partnership with the Institute of Biology at the country’s <strong>Academy of Military Medical Sciences</strong>. The one-shot vaccine, based on an adenovirus called Ad5, was approved in China in February 2021. The World Health Organization <a href="https://www.who.int/news/item/19-05-2022-who-validates-11th-vaccine-for-covid-19">granted</a> Convidecia emergency use listing in May 2022.<br><br>CanSino researchers <a href="https://www.nytimes.com/2020/05/22/health/coronavirus-vaccine-china.html">published</a> promising results from a Phase 1 safety trial on Convidecia in May 2020, and in July they <a href="https://www.thelancet.com/lancet/article/s0140-6736(20)31605-6">reported</a> that their Phase 2 trials demonstrated the vaccine produced a strong immune response. In an unprecedented move, the Chinese military <a href="https://www.nytimes.com/2020/07/16/business/china-vaccine-coronavirus.html">approved</a> the vaccine on June 25 for a year as a “specially needed drug.” On Nov. 28, the Chief Executive of CanSino Biologics <a href="https://www.reuters.com/article/us-health-coronavirus-vaccine-cansinobio-idUSKBN28V1N8">said</a> in an interview that about 40,000 to 50,000 people had received Convidecia.<br><br>Starting in August 2020, CanSino began running <a href="https://clinicaltrials.gov/ct2/show/NCT04526990?term=Ad5-nCov&draw=2&rank=4">Phase 3 trials</a> in <a href="https://www.reuters.com/article/us-health-coronavirus-vaccine-cansinobio-idUSKBN28V1N8">a number of countries</a>, including Pakistan, Russia, Mexico and Chile. On Feb. 25, 2021, China <a href="https://www.nytimes.com/live/2021/02/25/world/covid-19-coronavirus/china-approves-two-more-covid-19-vaccines">announced</a> the approval of the CanSino vaccine for general use.<br><br>Results from the Phase 3 trial, <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02753-7/fulltext">published in The Lancet</a> in December  2021, showed that  Convidecia had an efficacy against Covid-19 of 57.5 percent. Against severe disease, its efficacy was 91.7 percent.<br><br>As time passed, it became clear that Convidecia’s effectiveness was waning, and researchers began testing boosters. In January 2022, Chinese researchers <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4000565">reported</a> that an inhaled booster of Convidecia was safe and produced very high levels of antibodies against the coronavirus when administered in individuals who originally received a different vaccine. In Argentina, researchers are <a href="https://clinicaltrials.gov/ct2/show/NCT05293223?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">evaluating</a> how well Convidecia works as a booster in individuals who have received Sputnik V.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://www.nytimes.com/2020/07/16/business/china-vaccine-coronavirus.html">China</a>.<br>


<span class="g-info">Emergency use in:</span> <a href="https://www.reuters.com/world/americas/argentina-issues-emergency-approval-chinas-single-dose-cansino-covid-19-vaccine-2021-06-11/">Argentina</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-chile-vaccines/chilean-health-regulator-approves-cansino-covid-19-vaccine-for-emergency-use-idUSKBN2BU3M3">Chile</a>, <a href="https://www.reuters.com/world/americas/ecuador-authorizes-use-chinas-cansino-vaccine-against-covid-19-2021-06-15/">Ecuador</a>, <a href="https://www.reuters.com/article/health-coronavirus-cansinobio-hungary/update-2-chinas-cansino-biologics-covid-19-vaccine-receives-emergency-use-approval-in-hungary-idUSL1N2LK00K">Hungary</a>, <a href="https://www.reuters.com/world/asia-pacific/indonesia-approves-jj-cansino-covid-19-vaccines-emergency-use-2021-09-07/">Indonesia</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/malaysia-grants-conditional-approval-cansino-jj-covid-19-vaccines-2021-06-15/">Malaysia</a>, <a href="https://www.reuters.com/article/health-coronavirus-mexico-cansino/update-1-chinas-cansinobio-says-mexico-approves-covid-19-vaccine-for-emergency-use-idUSL1N2KG0NO">Mexico</a>, <a href="https://msmps.gov.md/comunicare/comunicate/membrii-nitag-au-venit-cu-recomandari-privind-utilizarea-vaccinurilor-impotriva-covid-19-in-republica-moldova/">Moldova</a>, <a href="https://www.reuters.com/article/health-coronavirus-pakistan-vaccine/update-2-pakistan-approves-chinese-cansinobio-covid-vaccine-for-emergency-use-idUSL1N2KI0UD">Pakistan</a>, <a href="https://covid-19pharmacovigilance.paho.org/cansino#col-0">Paraguay</a>. Emergency use validation from the <a href="https://www.who.int/news/item/19-05-2022-who-validates-11th-vaccine-for-covid-19">World Health Organization</a>.<br>



</span>

<span class="g-updated">Updated May 23, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.103.0 - 2022-02-08 10:00 -->
<!-- ai file: map-cansino.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-cansino-box ,
	#g-map-cansino-box .g-artboard {
		margin:0 auto;
	}
	#g-map-cansino-box p {
		margin:0;
	}
	#g-map-cansino-box .g-aiAbs {
		position:absolute;
	}
	#g-map-cansino-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-cansino-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-cansino-box .g-aiPointText p { white-space: nowrap; }
	#g-map-cansino-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-cansino-900 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-cansino-900 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-cansino-900 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-cansino-900 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-cansino-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-cansino-720 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-cansino-720 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-cansino-720 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-cansino-720 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-cansino-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-cansino-600 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-cansino-600 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-cansino-600 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-cansino-600 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-cansino-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-cansino-335 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-cansino-335 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-cansino-335 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-cansino-335 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}

</style>

<div id="g-map-cansino-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-cansino-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-cansino-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-cansino-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:0%;width:128px;">
			<p class="g-pstyle0">CanSino vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:21.0027%;margin-top:-6.8px;left:71.3672%;margin-left:-42px;width:84px;">
			<p class="g-pstyle1">HUNGARY</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:34.7627%;margin-top:-6.8px;left:80.7651%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:42.6255%;margin-top:-6.8px;left:74.4957%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle1">PAKISTAN</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:45.9953%;margin-top:-6.8px;left:26.9615%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:56.6664%;margin-top:-6.8px;left:30.1075%;margin-left:-41px;width:82px;">
			<p class="g-pstyle1">ECUADOR</p>
		</div>
		<div id="g-ai0-7" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:59.7553%;margin-top:-6.8px;left:86.1934%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai0-8" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:71.5496%;margin-top:-6.8px;left:48.1032%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai0-9" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:78.57%;margin-top:-6.8px;left:39.081%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">CHILE</p>
		</div>
		<div id="g-ai0-10" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-11" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-cansino-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-cansino-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-cansino-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0153%;width:121px;">
			<p class="g-pstyle0">CanSino vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:19.9876%;margin-top:-6.8px;left:72.3588%;margin-left:-42px;width:84px;">
			<p class="g-pstyle1">HUNGARY</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:35.1214%;margin-top:-6.8px;left:80.827%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:42.1603%;margin-top:-6.8px;left:74.2373%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle1">PAKISTAN</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:45.6798%;margin-top:-6.8px;left:27.26%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:57.646%;margin-top:-6.8px;left:29.3963%;margin-left:-41px;width:82px;">
			<p class="g-pstyle1">ECUADOR</p>
		</div>
		<div id="g-ai1-7" class="g-type_copy g-aiAbs g-aiPointText" style="top:60.4616%;margin-top:-6.8px;left:86.6757%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai1-8" class="g-type_copy g-aiAbs g-aiPointText" style="top:71.724%;margin-top:-6.8px;left:49.2575%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai1-9" class="g-type_copy g-aiAbs g-aiPointText" style="top:78.7629%;margin-top:-6.8px;left:38.3021%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">CHILE</p>
		</div>
		<div id="g-ai1-10" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-11" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-cansino-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-cansino-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-cansino-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:2.6276%;margin-top:-8.2px;left:-0.067%;width:114px;">
			<p class="g-pstyle0">CanSino vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:21.431%;margin-top:-6.8px;left:73.6615%;margin-left:-42px;width:84px;">
			<p class="g-pstyle1">HUNGARY</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:34.9331%;margin-top:-6.8px;left:80.9395%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:41.6842%;margin-top:-6.8px;left:74.7498%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle1">PAKISTAN</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:45.9036%;margin-top:-6.8px;left:26.4509%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:57.296%;margin-top:-6.8px;left:28.5691%;margin-left:-41px;width:82px;">
			<p class="g-pstyle1">ECUADOR</p>
		</div>
		<div id="g-ai2-7" class="g-type g-aiAbs g-aiPointText" style="top:61.0935%;margin-top:-6.8px;left:87.209%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai2-8" class="g-type g-aiAbs g-aiPointText" style="top:70.3762%;margin-top:-6.8px;left:50.4058%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai2-9" class="g-type g-aiAbs g-aiPointText" style="top:77.9711%;margin-top:-6.8px;left:37.8702%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">CHILE</p>
		</div>
		<div id="g-ai2-10" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-11" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-cansino-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-cansino-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-cansino-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:1.3081%;margin-top:-8.2px;left:0.2694%;width:114px;">
			<p class="g-pstyle0">CanSino vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:25.7934%;margin-top:-6.8px;left:54.0612%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:32.0952%;margin-top:-6.8px;left:87.8287%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:32.3053%;margin-top:-6.8px;left:58.2514%;margin-left:-41px;width:82px;">
			<p class="g-pstyle1">ECUADOR</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:41.7579%;margin-top:-6.8px;left:75.0072%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">CHILE</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:55.6218%;margin-top:-6.8px;left:45.5696%;margin-left:-42px;width:84px;">
			<p class="g-pstyle1">HUNGARY</p>
		</div>
		<div id="g-ai3-7" class="g-type g-aiAbs g-aiPointText" style="top:63.604%;margin-top:-6.8px;left:61.2873%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai3-8" class="g-type g-aiAbs g-aiPointText" style="top:77.888%;margin-top:-6.8px;left:73.9136%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai3-9" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-10" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-cansino-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-02-08 10:00 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="jnj"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN CANADA</span>


<span class="g-limited">EMERGENCY USE IN U.S., OTHER COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/jnj-800.png" class="g-vlogo" 
    style="width: 200px; height: 42px; margin-right: 20px;" alt="Johnson & Johnson logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/bidmc-800.png" class="g-vlogo" 
    style="width: 240px; height: 51px; margin-right: 20px;" alt="Beth Israel Deaconess Medical Center logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/janssen-800.png" class="g-vlogo" 
    style="width: 114px; height: 48px;" alt="Janssen Pharmaceutica logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Ad26.COV2.S<br>
<span class="g-info">Efficacy:</span> 72% in United States, 68% in Brazil and 64% in South Africa<br>
<span class="g-info">Dose:</span> 1 dose<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Up to two years frozen at –4° F (–20° C), and up to <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-agrees-extend-jj-covid-19-vaccines-shelf-life-6-months-2021-07-28/">6 months</a> refrigerated at 36–46° F (2–8° C).<br>
<br>
</span>

<!-- description -->
On Feb. 27, 2021, the F.D.A. <a href="https://www.nytimes.com/2021/02/27/health/covid-vaccine-johnson-and-johnson.html">issued an emergency use authorization</a> for <strong>Johnson & Johnson</strong>’s vaccine, making it the third coronavirus vaccine available in the United States. It was also the first to be shown to be safe and effective with just one dose rather than two. But the vaccine has not lived up to its initial promise. The company was bedeviled by manufacturing problems, <a href="https://www.nytimes.com/2022/02/08/business/johnson-johnson-covid-vaccine.html">dashing</a> hopes that it could be widely used in poor and lower-income countries, especially in Africa. And over time, rare blood clotting led the F.D.A. to restrict its use in the United States. On May 5, 2022, the agency <a href="https://www.nytimes.com/live/2022/05/06/world/covid-19-mandates-vaccine-cases?name=styln-coronavirus&#174ion=TOP_BANNER&block=storyline_menu_recirc&action=click&pgtype=Interactive&variant=show&is_new=false#johnson-vaccine-fda-covid">announced</a> that the vaccine would be limited to adults who cannot or refuse to get the Pfizer-BioNTech or Moderna vaccines, citing safety concerns.<br><br> <subhed>VACCINE DEVELOPMENT</subhed>The work that led to the vaccine started a decade ago at <strong>Beth Israel Deaconess Medical Center</strong> in Boston, where researchers developed a method for making vaccines out of a virus called Adenovirus 26, or Ad26 for short. Johnson & Johnson used Ad26 to develop vaccines for Ebola and other diseases with Ad26. In January 2020, the company and Beth Israel researchers collaborated <a href="https://www.nytimes.com/2020/07/17/health/coronavirus-vaccine-johnson-janssen.html">on creating a coronavirus vaccine</a>. In March they received <a href="https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use">$456 million</a> from the United States government to support their move towards production. That spring, researchers found that  the vaccine provided protection in <a href="https://www.nytimes.com/2020/07/30/health/covid-19-vaccine-monkeys.html">experiments on monkeys</a>.<br><br><subhed>TRIAL RESULTS</subhed>Johnson & Johnson began Phase 1/2 <a href="https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1">trials</a> in July 2020. Based on promising results in these studies, Johnson & Johnson <a href="https://www.nytimes.com/2020/09/23/health/covid-19-vaccine-johnson-and-johnson.html">launched a Phase 3 trial</a> in September using just one dose rather than two. Although Johnson & Johnson initially set out to recruit 60,000 volunteers, it <a href="https://www.jnj.com/our-company/johnson-johnson-announces-its-first-phase-3-covid-19-vaccine-trial-ensemble-is-fully-enrolled">capped</a> the trial at 45,000 in December as cases rose.<br><br>On Jan. 29, 2021, Johnson & Johnson <a href="https://www.nytimes.com/2021/01/29/health/covid-vaccine-johnson-and-johnson-variants.html?action=click&module=Spotlight&pgtype=Homepage">announced</a> that the trial had proven that the vaccine was safe and effective, and the F.D.A. <a href="https://www.nytimes.com/2021/02/24/health/covid-vaccine-johnson-and-johnson.html?smid=tw-share">released</a> a similar analysis on Feb. 24. Johnson & Johnson published a <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2101544">paper</a> on the trial in the New England Journal of Medicine on April 21, 2021. With a single shot, the vaccine had an efficacy of 66 percent, although it varied from country to country, likely due to variants and other factors. Efficacy against severe disease was higher, at 76 percent.<br><br>Results from a trial in which the Johnson & Johnson vaccine was given six months after a two-dose regimen of Comirnaty showed that the mix-and-match approach significantly boosted immune responses.<br><br>In a <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2117608">final analysis of the Phase 3 trial</a>, published in the New England Journal of Medicine on Feb. 9, 2022, the researchers determined that the vaccine was 56.3 percent effective against moderate to severe disease, and that the effectiveness dropped to 52.9 percent after four weeks.<br><br>Later studies have also demonstrated that the vaccine’s effectiveness was waning. Results from a French trial among more than one million older adults,  <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789572?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=030222">published</a> on March 2, 2022, suggests that individuals who receive the Johnson & Johnson vaccine are five times more likely to be hospitalized from Covid-19 than those who receive Comirnaty.<br><br> <subhed>AUTHORIZATION</subhed>Bahrain became the first country to <a href="https://www.haaretz.com/middle-east-news/bahrain-becomes-1st-nation-to-grant-johnson-johnson-shot-emergency-use-1.9570191">authorize the vaccine</a> for emergency use on Feb. 25. Two days later, the United States followed suit. South Africa dropped plans to use AstraZeneca’s vaccine for their health care workers after a small trial failed to show it was effective against the Beta variant that had grown dominant across the country. <a href="https://www.nytimes.com/2021/02/07/world/africa/covid-vaccine-astrazeneca-south-africa.html?searchResultPosition=1">They began using Johnson & Johnson’s instead</a>. On Oct. 15, an F.D.A. panel <a href="https://www.nytimes.com/2021/10/15/health/johnson-johnson-vaccine-booster.html">unanimously voted to recommend</a> a second dose of the Johnson & Johnson vaccine for all adults who received a first dose, and authorization <a href="https://www.nytimes.com/2021/10/20/us/politics/fda-boosters-moderna-johnson-johnson.html">came</a> on Oct. 20. On Nov. 24, Canada became the first country to give full <a href="https://www.reuters.com/world/americas/canada-gives-full-approval-jjs-single-shot-covid-19-vaccine-2021-11-24/">approval</a> to the Johnson & Johnson vaccine for adults.<br><br> <subhed>DISTRIBUTION</subhed>In August 2020, the federal government <a href="https://www.jnj.com/johnson-johnson-announces-agreement-with-u-s-government-for-100-million-doses-of-investigational-covid-19-vaccine">agreed</a> to pay Johnson & Johnson $1 billion for 100 million doses if the vaccine was authorized. Most of the U.S. supply was supposed to be made by Baltimore-based Emergent Solutions. But the company struggled to get the vaccine’s complex manufacturing up and running.  In April 2021, the F.D.A. issued a scathing report about the company’s <a href="https://www.nytimes.com/2021/04/21/us/politics/emergent-johnson-johnson-covid-vaccine.html">lax standards</a>. At least 15 million doses of Johnson & Johnson’s vaccine were contaminated at the factory. As a result, the company only delivered <a href="https://www.nytimes.com/2021/02/27/health/covid-vaccine-johnson-and-johnson.html">4 million doses</a> to the United States after authorization, shipping them from its factory in the Netherlands. On June 11, the New York Times reported that the F.D.A. told the company <a href="https://www.nytimes.com/2021/06/11/us/politics/johnson-covid-vaccine-emergent.html">to throw out 60 million doses</a>.  The following month, Emergent <a href="https://www.wsj.com/articles/j-j-contractor-plans-to-resume-covid-19-vaccine-production-at-troubled-baltimore-plant-11627528043?mod=latest_headlines">announced</a> that it would resume production of the vaccines from its Baltimore plant after it receives  authorization from the F.D.A. On March 2, 2021, Merck <a href="https://www.nytimes.com/2021/03/10/world/biden-announces-his-intention-to-secure-another-100-million-doses-of-johnson-johnsons-vaccine.html">announced</a> it would assist Johnson & Johnson with manufacturing the vaccine, but it’s not clear how much that partnership helped in the production. By the time the F.D.A. limited the use of the Johnson & Johnson vaccine, only <a href="https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total">16.9 million people</a> in the United States had received it. Over ten times more people had received a vaccine from Pfizer or Moderna.<br><br>The <a href="https://www.jnj.com/johnson-johnson-announces-european-commission-approval-of-agreement-to-supply-200-million-doses-of-janssens-covid-19-vaccine-candidate">European Union</a> reached a deal on Oct. 8, 2020 for 200 million doses. But after concerns about rare blood clots emerged, <a href="https://www.reuters.com/article/us-health-coronovirus-eu-vaccines/eu-commission-to-end-astrazeneca-and-jj-vaccine-contracts-at-expiry-paper-idUSKBN2C10MU">reports</a> surfaced that the E.U. might not renew its contract with the company.<br><br>A coalition of African countries announced on March 29, 2021, that it had secured <a href="https://www.jnj.com/johnson-johnson-announces-advance-purchase-agreement-with-the-african-vaccine-acquisition-trust-for-the-companys-covid-19-vaccine-candidate">up to 400 million doses</a> of the Johnson & Johnson vaccine through 2022. COVAX, an international collaboration to deliver the vaccine equitably across the world, announced a separate deal for <a href="https://cepi.net/news_cepi/covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021/">500 million doses</a>. But manufacturing problems slowed these deliveries. By September, COVAX <a href="https://www.nytimes.com/2021/09/08/health/covax-global-covid-vaccine-boosters.html">had lowered</a> its 2021 forecast of Johnson & Johnson vaccines to only 180 million doses. On Nov. 30, South African company Aspen Pharmacare <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/safricas-aspen-signs-non-binding-agreement-with-jj-covid-vaccine-license-2021-11-30/?rpc=401&">said</a> that it was finalizing a deal with Johnson & Johnson to market and distribute the vaccine in Africa. In March 2022, the South African company Aspen Pharmacare <a href="https://www.fiercepharma.com/pharma/johnson-johnson-locks-vaccine-licensing-deal-aspen-teeing-africas-first-local-covid-19-shot">announced</a> that it had signed the agreement with Johnson & Johnson to distribute the vaccine, dubbed Aspenovax, throughout Africa. But the following month the company <a href="https://www.devex.com/news/lack-of-orders-could-halt-covid-19-vaccine-production-in-south-africa-103052">said</a> it might have to shut down its Aspenovax factory because it had yet to receive any orders for Aspenovax from African nationals.<br><br> <subhed>VARIANTS</subhed>Johnson & Johnson found that its vaccine only had an efficacy of 52 percent in South Africa, where the Beta variant was dominant during the trial.  As the Delta variant emerged in the summer of 2021, Johnson & Johnson released <a href="https://www.biorxiv.org/content/10.1101/2021.07.01.450707v1">results</a> of experiments indicating that their vaccine provided <a href="https://www.nytimes.com/live/2021/07/01/world/covid-19-vaccine-coronavirus-updates/johnson-johnson-says-its-vaccine-protects-against-the-delta-variant">durable protection</a> against it. But <a href="https://www.nytimes.com/2021/07/20/health/coronavirus-johnson-vaccine-delta.html">another study</a> from outside scientists suggested that the vaccine only weakly protects against Delta. Preliminary experiments found that Johnson & Johnson’s vaccine does not produce neutralizing antibodies against the Omicron variant.<br><br><subhed>BOOSTERS</subhed>On Oct. 5,  Johnson & Johnson <a href="https://www.nytimes.com/2021/10/05/world/johnson-covid-vaccine-booster-fda.html">applied</a> for emergency authorization for a booster. Over the following few weeks, the F.D.A. reviewed the results of two studies that suggest a second dose of the vaccine might provide an effective boost to immunity.<br><br>In one study, the company gave 17 trial volunteers a booster shot six months after their initial vaccination. On Aug. 25, the company <a href="https://www.nytimes.com/2021/08/25/health/johnson-booster-shot.html">announced</a> that the boosters lifted levels of antibodies against the coronavirus nine times higher than their initial peak. Later, those levels rose twelvefold.<br><br>In a second study, Johnson & Johnson ran a Phase 3 trial in which 32,000 volunteers received either a placebo or two doses of the vaccine, separated by eight weeks. On Sept. 21, the company <a href="https://www.nytimes.com/live/2021/09/21/world/covid-delta-variant-vaccine/an-extra-j-j-shot-substantially-boosts-protection-against-covid-the-company-reports">reported</a> that the pair of shots provided much higher efficacy than just one. In the United States, efficacy against mild to severe Covid-19 rose from 74 percent to 94 percent. Efficacy against severe disease worldwide rose to 100 percent. On Oct. 20, the F.D.A. <a href="https://www.nytimes.com/2021/10/20/us/politics/fda-mix-match-covid-booster-shots.html">authorized</a> Johnson & Johnson boosters.<br><br><subhed>SIDE EFFECTS</subhed>On April 13, 2021, the U.S. government recommended a pause in using the vaccine while it investigated reports of rare blood clots. <a href="https://www.nytimes.com/2021/04/23/health/johnson-vaccine-resume.html">Ten days later</a>, C.D.C. researchers reported 15 cases of the unusual clots in nearly 8 million people who received the vaccine. The government decided to lift the pause and add a warning to the vaccine that younger women may run a slight risk of the severe side effect. But as cases continued to accrue, the C.D.C.’s advisory committee voted on Dec. 16., 2021, to recommend that other vaccines be preferred over Johnson & Johnson’s. In May 2022, the F.D.A. reported nine deaths due to blood clotting and limited the vaccine’s use.<br><br>For more details, see <strong><a href="https://www.nytimes.com/interactive/2020/health/johnson-johnson-covid-19-vaccine.html">How the Johnson & Johnson Vaccine Works</a></strong>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://www.jnj.com/johnson-johnson-covid-19-vaccine-fully-approved-by-health-canada-to-prevent-covid-19-in-individuals-18-years-and-older">Canada</a>.<br>
<span class="g-info">Stopped use in:</span> <a href="https://www.sst.dk/en/english/news/2021/the-danish-covid-19-vaccine-rollout-continues-without-the-covid-19-vaccine-from-johnson-johnson">Denmark</a>, <a href="https://www.bloomberg.com/news/articles/2021-05-18/finland-to-exclude-johnson-johnson-from-covid-vaccine-program">Finland</a>, <a href="https://www.newsweek.com/death-covid-vaccinated-20-year-old-prompts-slovenia-halt-use-jj-shot-1634011">Slovenia</a>.<br>

<span class="g-info">Emergency use in:</span> <a href="https://covid-19pharmacovigilance.paho.org/janssen#col-0">Andorra</a>, <a href="https://www.tga.gov.au/media-release/tga-grants-third-provisional-approval-covid-19-vaccine-janssen">Australia</a>, <a href="https://covid-19pharmacovigilance.paho.org/janssen#col-0">Bahamas</a>, <a href="https://www.haaretz.com/middle-east-news/bahrain-becomes-1st-nation-to-grant-johnson-johnson-shot-emergency-use-1.9570191">Bahrain</a>, <a href="http://www.newagebd.net/article/140817/belgian-janssen-covid-vaccine-gets-emergency-approval-in-bangladesh">Bangladesh</a>, <a href="https://www.bomra.co.bw/index.php/news-updates/177-covid-19-vaccines-approved-by-bomra">Botswana</a>, <a href="https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/anvisa-aprova-uso-emergencial-da-vacina-da-janssen">Brazil</a>, <a href="https://covid-19pharmacovigilance.paho.org/janssen#col-0">Burkina Faso</a>, <a href="https://www.crtv.cm/2021/04/covd-19-four-vaccines-on-cameroons-vaccination-plan/">Cameroon</a>, <a href="https://www.nytimes.com/2021/03/05/world/canada-approves-the-johnson-johnson-vaccine-giving-it-a-fourth-option.html">Canada</a>, <a href="https://www.ispch.cl/noticia/isp-valida-uso-de-emergencia-de-la-vacuna-janssen-de-johnson-johnson-a-traves-de-mecanismo-covax/">Chile</a>, <a href="https://medicaldialogues.in/news/industry/pharma/johnson-and-johnson-covid-19-vaccine-gets-emergency-use-authorization-in-colombia-75971">Colombia</a>, <a href="https://www.egypttoday.com/Article/1/107547/Egypt-receives-2nd-batch-of-Johnson-Johnson-vaccine">Egypt</a>, <a href="https://www.nytimes.com/live/2021/03/11/world/covid-19-coronavirus#astrazeneca-vaccine-denmark">European Union</a>, <a href="https://www.graphic.com.gh/news/general-news/johnson-johnson-covid-19-vaccine-to-be-available-in-ghana-by-august.html">Ghana</a>, <a href="https://www.gabonreview.com/gabon-covid19-la-vaccination-desormais-possible-dans-les-structures-sanitaires-de-la-cnss/">Gabon</a>, Greenland, Iceland, <a href="https://www.theguardian.com/world/2021/aug/07/india-approves-johnson-johnson-covid-vaccine-for-emergency-use">India</a>, <a href="https://www.reuters.com/world/asia-pacific/indonesia-approves-jj-cansino-covid-19-vaccines-emergency-use-2021-09-07/">Indonesia</a>, <a href="https://www.reuters.com/world/middle-east/iran-approves-us-jj-covid-shot-fifth-wave-spreads-2021-09-16/">Iran</a>, <a href="https://covid-19pharmacovigilance.paho.org/janssen#col-0">Jamaica</a>, <a href="https://www.bloomberg.com/news/articles/2021-08-02/kenya-approves-j-j-pfizer-covid-19-vaccines-as-cases-surge">Kenya</a>, <a href="https://www.kuna.net.kw/ArticleDetails.aspx?id=2980741&language=en">Kuwait</a>, <a href="https://reliefweb.int/sites/reliefweb.int/files/resources/libya_covid_update_25_final.pdf">Libya</a>, Liechtenstein, <a href="https://documents1.worldbank.org/curated/en/978101625729383050/pdf/Madagascar-Support-to-COVID-19-Vaccine-Purchase-and-Health-System-Strengthening-Project.pdf">Madagascar</a>, <a href="https://www.facebook.com/malawimoh/posts/4098884300167054">Malawi</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/malaysia-grants-conditional-approval-cansino-jj-covid-19-vaccines-2021-06-15/">Malaysia</a>, <a href="http://health.gov.mv/Uploads/Downloads//Informations/Informations(381).pdf">Maldives</a>, <a href="https://www.gob.mx/cofepris/articulos/cofepris-emite-autorizacion-para-uso-de-emergencia-a-vacuna-contra-covid-19-ad26-cov2-s-de-janssen-johnson-johnson?idiom=es">Mexico</a>, <a href="https://gov.fm/index.php/component/content/article/35-pio-articles/news-and-updates/518-57-of-fsm-adults-fully-vaccinated-fda-approved-pfizer-vaccine-arrives-in-fsm-suitable-for-adolescents-multiple-repatriation-flights-scheduled-for-august-september?Itemid=177">Micronesia</a>, <a href="https://msmps.gov.md/comunicare/comunicate/membrii-nitag-au-venit-cu-recomandari-privind-utilizarea-vaccinurilor-impotriva-covid-19-in-republica-moldova/">Moldova</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/new-zealand-health-regulator-approves-use-janssen-covid-19-vaccine-2021-07-07/">New Zealand</a>, <a href="https://allafrica.com/stories/202105180601.html">Nigeria</a>, Norway, <a href="https://covid19.info.gov.pg/vaccination-is-not-compulsory-prime-minister-tells-parliament/">Papua New Guinea</a>, <a href="https://www.gob.pe/institucion/minsa/noticias/505162-el-ministerio-de-salud-autorizo-el-registro-sanitario-condicional-de-la-vacuna-contra-la-covid-19-de-la-farmaceutica-johnson-johnson">Peru</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/philippines-approves-emergency-use-jj-bharat-biotechcovid-19-vaccines-2021-04-19/">Philippines</a>, <a href="https://www.rbc.gov.rw/index.php?id=777">Rwanda</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-safrica-johnson-jo/jj-says-south-african-health-regulator-registers-its-covid-19-vaccine-idUSKBN2BO5FM">South Africa</a>, <a href="https://www.usnews.com/news/health-news/articles/2021-04-07/south-korea-grants-conditional-approval-to-johnson-johnson-coronavirus-vaccine">South Korea</a>, <a href="http://health.gov.vc/health/images/stories/PDF/SRO-Public_Health_Emergency_Authorisation_of_Covid-19_Vaccine.pdf">Saint Vincent and the Grenadines</a>, <a href="https://saudigazette.com.sa/article/610193">Saudi Arabia</a>, <a href="https://www.medrxiv.org/content/10.1101/2021.10.06.21264664v1.full.pdf">Senegal</a>, <a href="https://www.unicef.org/sudan/press-releases/united-states-donates-more-600000-single-dose-johnson-johnson-covid-19-vaccines-help">Sudan</a>, <a href="https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/dritten-impfstoff-gegen-covid-19-erkrankung.html">Switzerland</a>, <a href="https://covid-19pharmacovigilance.paho.org/janssen#col-0">Syria</a>, <a href="https://allafrica.com/stories/202107270065.html">Tanzania</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-thailand/thailand-approves-johnson-johnsons-covid-19-vaccine-idUSKBN2BH1L7">Thailand</a>, <a href="https://m.facebook.com/MinistryofHealthTT/photos/a.153051404724676/4635809886448783/?type=3&source=48">Trinidad and Tobago</a>, <a href="https://www.reuters.com/article/uk-health-coronavirus-tunisia/tunisia-approve-johnson-johnson-covid-19-vaccine-idUSKBN2BV1SQ">Tunisia</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/ukraine-approves-johnson-johnson-covid-19-vaccine-2021-07-05/">Ukraine</a>, <a href="https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-janssen">United Kingdom</a>, <a href="https://www.nytimes.com/live/2021/02/27/world/covid-19-coronavirus#fda-clears-johnson-johnsons-shot-the-third-vaccine-for-us">United States</a>, <a href="https://www.reuters.com/article/health-coronavirus-vietnam-vaccine/vietnam-approves-johnson-johnsons-covid-19-vaccine-idUSL4N2OR2SJ">Vietnam</a>, <a href="https://zanis.com.zm/2021/03/27/covid-19-vaccine-roll-out-set-moh/">Zambia</a>, <a href="https://www.reuters.com/article/health-coronavirus-zimbabwe/zimbabwe-approves-jj-covid-19-vaccine-for-emergency-use-idUSL8N2P43WX">Zimbabwe</a>. Emergency use validation from the <a href="https://www.who.int/news/item/12-03-2021-who-adds-janssen-vaccine-to-list-of-safe-and-effective-emergency-tools-against-covid-19">World Health Organization</a>. Endorsed by the <a href="https://africacdc.org/news-item/update-statement-to-member-states-regarding-thromboembolic-events-after-vaccination-with-janssen-covid-19-vaccine-johnson-johnson/">Africa Regulatory Taskforce</a>.<br>



</span>

<span class="g-updated">Updated May 6, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-04-15 12:41 -->
<!-- ai file: map-jnj.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-jnj-box ,
	#g-map-jnj-box .g-artboard {
		margin:0 auto;
	}
	#g-map-jnj-box p {
		margin:0;
	}
	#g-map-jnj-box .g-aiAbs {
		position:absolute;
	}
	#g-map-jnj-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-jnj-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-jnj-box .g-aiPointText p { white-space: nowrap; }
	#g-map-jnj-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-jnj-900 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-jnj-900 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-jnj-900 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-jnj-900 .g-pstyle2 {
		height:13px;
	}
	#g-map-jnj-900 .g-pstyle3 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-jnj-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-jnj-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-jnj-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-jnj-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-jnj-720 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-jnj-720 .g-pstyle3 {
		height:17px;
		position:relative;
	}
	#g-map-jnj-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-jnj-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-jnj-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-jnj-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-jnj-600 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-jnj-600 .g-pstyle3 {
		height:16px;
		position:relative;
	}
	#g-map-jnj-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-jnj-335 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-jnj-335 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-jnj-335 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-jnj-335 .g-pstyle2 {
		height:13px;
	}
	#g-map-jnj-335 .g-pstyle3 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}

</style>

<div id="g-map-jnj-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-jnj-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-jnj-900-img" class="g-map-jnj-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-jnj-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:145px;">
			<p class="g-pstyle0">Johnson & Johnson</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:12.7467%;margin-top:-13.4px;left:61.3435%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">EUROPEAN</p>
			<p class="g-pstyle1">UNION</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:16.2288%;margin-top:-6.8px;left:71.4467%;width:77px;">
			<p class="g-pstyle2">FINLAND</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:22.6876%;margin-top:-6.8px;left:26.8595%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:31.8422%;margin-top:-13.4px;left:89.018%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:34.7627%;margin-top:-6.8px;left:27.0694%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai0-7" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:35.0435%;margin-top:-6.8px;left:64.8279%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">LIBYA</p>
		</div>
		<div id="g-ai0-8" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:40.0982%;margin-top:-6.8px;left:71.2861%;width:79px;">
			<p class="g-pstyle2">BAHRAIN</p>
		</div>
		<div id="g-ai0-9" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:46.557%;margin-top:-6.8px;left:26.6596%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai0-10" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:46.557%;margin-top:-6.8px;left:75.0303%;width:57px;">
			<p class="g-pstyle2">INDIA</p>
		</div>
		<div id="g-ai0-11" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:51.6117%;margin-top:-6.8px;left:41.2949%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai0-12" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:53.2966%;margin-top:-6.8px;left:59.3147%;width:70px;">
			<p class="g-pstyle2">ZAMBIA</p>
		</div>
		<div id="g-ai0-13" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:58.6321%;margin-top:-6.8px;left:94.8721%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai0-14" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:73.6839%;margin-top:-13.4px;left:58.5559%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">AFRICA</p>
		</div>
		<div id="g-ai0-15" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:73.2345%;margin-top:-6.8px;left:38.385%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">CHILE</p>
		</div>
		<div id="g-ai0-16" class="g-900 g-aiAbs g-aiPointText" style="top:87.9755%;margin-top:-27.3px;left:72.0686%;width:121px;">
			<p class="g-pstyle3">Stopped use</p>
			<p class="g-pstyle3">in favor of other</p>
			<p class="g-pstyle3">vaccines</p>
		</div>
		<div id="g-ai0-17" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai0-18" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle3">Early, limited or</p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-jnj-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-jnj-720-img" class="g-map-jnj-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-jnj-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:137px;">
			<p class="g-pstyle0">Johnson & Johnson</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:11.7521%;margin-top:-13.4px;left:60.9826%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">EUROPEAN</p>
			<p class="g-pstyle1">UNION</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:17.1721%;margin-top:-6.8px;left:71.2778%;width:77px;">
			<p class="g-pstyle2">FINLAND</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:22.0993%;margin-top:-6.8px;left:26.8836%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:31.8131%;margin-top:-13.4px;left:89.9219%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:34.7694%;margin-top:-6.8px;left:64.7376%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">LIBYA</p>
		</div>
		<div id="g-ai1-7" class="g-type_copy g-aiAbs g-aiPointText" style="top:35.1214%;margin-top:-6.8px;left:27.2383%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai1-8" class="g-type_copy g-aiAbs g-aiPointText" style="top:39.3448%;margin-top:-6.8px;left:71.2385%;width:79px;">
			<p class="g-pstyle2">BAHRAIN</p>
		</div>
		<div id="g-ai1-9" class="g-type_copy g-aiAbs g-aiPointText" style="top:40.0487%;margin-top:-6.8px;left:55.9499%;width:73px;">
			<p class="g-pstyle2">NIGERIA</p>
		</div>
		<div id="g-ai1-10" class="g-type_copy g-aiAbs g-aiPointText" style="top:47.0876%;margin-top:-6.8px;left:26.3548%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai1-11" class="g-type_copy g-aiAbs g-aiPointText" style="top:47.4396%;margin-top:-6.8px;left:74.4721%;width:57px;">
			<p class="g-pstyle2">INDIA</p>
		</div>
		<div id="g-ai1-12" class="g-type_copy g-aiAbs g-aiPointText" style="top:51.6629%;margin-top:-6.8px;left:41.3095%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai1-13" class="g-type_copy g-aiAbs g-aiPointText" style="top:56.2383%;margin-top:-6.8px;left:63.6639%;width:70px;">
			<p class="g-pstyle2">ZAMBIA</p>
		</div>
		<div id="g-ai1-14" class="g-type_copy g-aiAbs g-aiPointText" style="top:58.3499%;margin-top:-6.8px;left:89.6377%;width:92px;">
			<p class="g-pstyle2">AUSTRALIA</p>
		</div>
		<div id="g-ai1-15" class="g-type_copy g-aiAbs g-aiPointText" style="top:74.7507%;margin-top:-13.4px;left:57.8832%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">AFRICA</p>
		</div>
		<div id="g-ai1-16" class="g-type_copy g-aiAbs g-aiPointText" style="top:73.4837%;margin-top:-6.8px;left:37.6882%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">CHILE</p>
		</div>
		<div id="g-ai1-17" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai1-18" class="g-720 g-aiAbs g-aiPointText" style="top:89.5939%;margin-top:-25.6px;left:71.063%;width:114px;">
			<p class="g-pstyle3">Stopped use</p>
			<p class="g-pstyle3">in favor of other</p>
			<p class="g-pstyle3">vaccines</p>
		</div>
		<div id="g-ai1-19" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle3">Early, limited or </p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-jnj-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-jnj-600-img" class="g-map-jnj-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-jnj-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:9.2099%;margin-top:-23.8px;left:-0.067%;width:83px;">
			<p class="g-pstyle0">Johnson & </p>
			<p class="g-pstyle0">Johnson</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:11.9796%;margin-top:-13.4px;left:59.6266%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">EUROPEAN</p>
			<p class="g-pstyle1">UNION</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:17.6335%;margin-top:-6.8px;left:71.3745%;width:77px;">
			<p class="g-pstyle2">FINLAND</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:22.6968%;margin-top:-6.8px;left:26.7998%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:31.8108%;margin-top:-13.4px;left:90.5999%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:34.0892%;margin-top:-6.8px;left:64.797%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">LIBYA</p>
		</div>
		<div id="g-ai2-7" class="g-type g-aiAbs g-aiPointText" style="top:34.5112%;margin-top:-6.8px;left:27.1704%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai2-8" class="g-type g-aiAbs g-aiPointText" style="top:40.4184%;margin-top:-6.8px;left:55.4194%;width:73px;">
			<p class="g-pstyle2">NIGERIA</p>
		</div>
		<div id="g-ai2-9" class="g-type g-aiAbs g-aiPointText" style="top:46.7475%;margin-top:-6.8px;left:25.6138%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai2-10" class="g-type g-aiAbs g-aiPointText" style="top:48.0133%;margin-top:-6.8px;left:74.2799%;width:57px;">
			<p class="g-pstyle2">INDIA</p>
		</div>
		<div id="g-ai2-11" class="g-type g-aiAbs g-aiPointText" style="top:52.2327%;margin-top:-6.8px;left:41.2288%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai2-12" class="g-type g-aiAbs g-aiPointText" style="top:56.8741%;margin-top:-6.8px;left:64.1217%;width:70px;">
			<p class="g-pstyle2">ZAMBIA</p>
		</div>
		<div id="g-ai2-13" class="g-type g-aiAbs g-aiPointText" style="top:58.5618%;margin-top:-6.8px;left:88.1961%;width:92px;">
			<p class="g-pstyle2">AUSTRALIA</p>
		</div>
		<div id="g-ai2-14" class="g-type g-aiAbs g-aiPointText" style="top:75.6927%;margin-top:-13.4px;left:58.2524%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">AFRICA</p>
		</div>
		<div id="g-ai2-15" class="g-type g-aiAbs g-aiPointText" style="top:74.1736%;margin-top:-6.8px;left:37.1411%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">CHILE</p>
		</div>
		<div id="g-ai2-16" class="g-600 g-aiAbs g-aiPointText" style="top:89.8088%;margin-top:-23.8px;left:70.9838%;width:108px;">
			<p class="g-pstyle3">Stopped use</p>
			<p class="g-pstyle3">in favor of other</p>
			<p class="g-pstyle3">vaccines</p>
		</div>
		<div id="g-ai2-17" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai2-18" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle3">Early, limited or</p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-jnj-335" class="g-artboard" style="max-width: 599px;max-height: 867px" data-aspect-ratio="0.691" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 144.7761% 0;"></div>
		<img id="g-map-jnj-335-img" class="g-map-jnj-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-jnj-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.8922%;margin-top:-16px;left:0.2695%;width:129px;">
			<p class="g-pstyle0">Johnson & Johnson</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:12.3281%;margin-top:-6.8px;left:53.457%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:19.1323%;margin-top:-6.8px;left:53.9223%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:25.7302%;margin-top:-6.8px;left:50.7372%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:28.2044%;margin-top:-6.8px;left:82.2132%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:39.957%;margin-top:-6.8px;left:74.4951%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">CHILE</p>
		</div>
		<div id="g-ai3-7" class="g-type g-aiAbs g-aiPointText" style="top:49.7715%;margin-top:-13.4px;left:22.5149%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">EUROPEAN</p>
			<p class="g-pstyle1">UNION</p>
		</div>
		<div id="g-ai3-8" class="g-type g-aiAbs g-aiPointText" style="top:53.1529%;margin-top:-6.8px;left:42.8111%;width:77px;">
			<p class="g-pstyle2">FINLAND</p>
		</div>
		<div id="g-ai3-9" class="g-type g-aiAbs g-aiPointText" style="top:60.9055%;margin-top:-13.4px;left:73.2622%;width:65px;">
			<p class="g-pstyle2">SOUTH</p>
			<p class="g-pstyle2">KOREA</p>
		</div>
		<div id="g-ai3-10" class="g-type g-aiAbs g-aiPointText" style="top:62.2251%;margin-top:-6.8px;left:29.7913%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">LIBYA</p>
		</div>
		<div id="g-ai3-11" class="g-type g-aiAbs g-aiPointText" style="top:64.6993%;margin-top:-6.8px;left:42.4764%;width:79px;">
			<p class="g-pstyle2">BAHRAIN</p>
		</div>
		<div id="g-ai3-12" class="g-type g-aiAbs g-aiPointText" style="top:65.1117%;margin-top:-6.8px;left:12.039%;width:73px;">
			<p class="g-pstyle2">NIGERIA</p>
		</div>
		<div id="g-ai3-13" class="g-type g-aiAbs g-aiPointText" style="top:69.2355%;margin-top:-6.8px;left:49.0632%;width:57px;">
			<p class="g-pstyle2">INDIA</p>
		</div>
		<div id="g-ai3-14" class="g-type g-aiAbs g-aiPointText" style="top:73.7714%;margin-top:-6.8px;left:27.2887%;width:70px;">
			<p class="g-pstyle2">ZAMBIA</p>
		</div>
		<div id="g-ai3-15" class="g-type g-aiAbs g-aiPointText" style="top:75.2146%;margin-top:-6.8px;left:78.0835%;width:92px;">
			<p class="g-pstyle2">AUSTRALIA</p>
		</div>
		<div id="g-ai3-16" class="g-type g-aiAbs g-aiPointText" style="top:84.823%;margin-top:-13.4px;left:16.8448%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">AFRICA</p>
		</div>
		<div id="g-ai3-17" class="g-type g-aiAbs g-aiPointText" style="top:88.2983%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai3-18" class="g-type g-aiAbs g-aiPointText" style="top:93.4117%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle3">Early, limited or </p>
			<p class="g-pstyle3">emergency use</p>
		</div>
		<div id="g-ai3-19" class="g-335 g-aiAbs g-aiPointText" style="top:98.4015%;margin-top:-8.2px;left:42.1259%;width:91px;">
			<p class="g-pstyle3">Stopped use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-jnj-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-04-15 12:41 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="hkuxiamen"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/hku-800.png" class="g-vlogo" 
    style="width: 280px; height: 54px; margin-right: 20px;" alt="University of Hong Kong logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/xiamen-800.png" class="g-vlogo" 
    style="width: 190px; height: 58px; margin-right: 20px;" alt="Xiamen University logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/wantai-800.png" class="g-vlogo" 
    style="width: 190px; height: 52px;" alt="Wantai Biopharmaceutical logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In 2019, researchers at the <strong>University of Hong Kong</strong> and <strong>Xiamen University</strong> <a href="https://mbio.asm.org/content/10/5/e02180-19">created</a> a nasal-spray vaccine for the flu based on a genetically weakened form of the influenza virus. In early 2020, they engineered the vaccine to produce part of the coronavirus spike protein as well. On Sept. 9, they received <a href="https://www.hku.hk/press/news_detail_21583.html">approval</a> to start clinical trials in partnership with <strong>Beijing Wantai Biological Pharmacy</strong>. They  <a href="https://clinicaltrials.gov/ct2/show/NCT04809389">registered</a> a Phase 1 trial on March 22, 2021. At a June 11 press conference, a researcher for the Chinese Center for Disease Control and Prevention said that this vaccine has <a href="http://www.xinhuanet.com/english/2021-06/11/c_1310003298.htm">completed Phase 2 trials</a>. And on Sept. 22, the researchers registered a <a href="https://www.chictr.org.cn/showprojen.aspx?proj=133897">Phase 3 trial</a>. In January 2022, the University of Hong Kong registered a new trial to test the vaccine <a href="https://clinicaltrials.gov/ct2/show/NCT05200741">as a booster</a>. The researchers are receiving <a href="https://cepi.net/news_cepi/cepi-and-university-of-hong-kong-expand-partnership-to-develop-intranasal-covid-19-vaccine-candidate/">$5.4 million in support</a> from CEPI, the Coalition for Epidemic Preparedness Innovations.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Jan. 26, 2022</span>

</p>

<a name="ndv"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/icahn-800.png" class="g-vlogo" 
    style="width: 290px; height: 41px; margin-right: 20px;" alt="Icahn School of Medicine at Mount Sinai logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/mahidol-800.png" class="g-vlogo" 
    style="width: 230px; height: 58px; margin-right: 20px;" alt="Mahidol University logo"><br><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/gpo-800.png" class="g-vlogo" 
    style="width: 135px; height: 51px; margin-right: 20px;" alt="Government Pharmaceutical Organization logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/avimex-800.png" class="g-vlogo" 
    style="width: 175px; height: 34px;" alt="Avi-Mex logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In 2020, researchers at the <strong>Icahn School of Medicine at Mount Sinai</strong> in New York developed a <a href="https://www.nytimes.com/2021/04/05/health/hexapro-mclellan-vaccine.html?smid=tw-share">Covid-19 vaccine based on a virus called Newcastle Disease Virus</a>, or NDV for short. NDV is a bird pathogen and does not cause symptoms in humans. The researchers engineered NDV to carry the gene for a modified version of the coronavirus spike protein called <a href="https://science.sciencemag.org/content/369/6510/1501">HexaPro</a>, developed at the University of Texas. They  then grew the modified virus in chicken eggs. The researchers inactivated the NDVs with chemicals and combined them with immune-boosting chemicals called adjuvants.  The researchers found that the vaccine, called NDV-HXP-S, produced high levels of coronavirus antibodies in mice and hamsters.  They <a href="https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30508-9/fulltext">published</a> the results of their experiments in November.<br><br>NDV-HXP-S could potentially help low- to middle-income countries secure their own supplies of Covid-19 vaccines. The Newcastle Disease Virus can be safely grown in large quantities in chicken eggs, the same way influenza vaccines have been produced since the 1950s. As a result, the vaccine could be very cheap to make. Those advantages attracted interest from four countries, all of which licensed the vaccine and launched trials. But as of August 2022, the trials had either been abandoned or had yet to deliver final results.<br><br>In Thailand, <strong>Mahidol University </strong>and the <strong>Government Pharmaceutical Organization</strong>, a state-run drug manufacturer <a href="https://www.bangkokpost.com/thailand/general/2066063/thai-made-vaccine-ready-by-next-year">licensed the vaccine</a> and <a href="https://clinicaltrials.gov/ct2/show/NCT04764422">launched</a> clinical trials in February 2021. The <a href="https://www.medrxiv.org/content/10.1101/2021.09.17.21263758v1.full">Phase 1 trial results</a> showed that the vaccine showed an acceptable safety profile and produced promising levels of antibodies. A <a href="https://www.gpo.or.th/view/480">Phase 2 trial</a> started in August.<br><br><strong><a href="https://www.reuters.com/article/us-health-coronavirus-mexico/mexican-made-covid-19-vaccine-could-be-ready-this-year-idUSKBN2C01L5">Avi-Mex</a></strong> in Mexico also licensed NDV-HXP-S under the name Patria, which the company delivers as a <a href="https://journals.asm.org/doi/10.1128/mBio.01908-21">nasal spray</a>, Preliminary results from the Phase 1 trial, <a href="https://www.parisbeacon.com/45573/">released</a> in February 2022, suggest that the vaccine is safe. The company registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05205746?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 2 trial</a> in January 2022, with a primary completion date of April 2022. As of August 2022, however, the company had not reported the results of the trial, nor had they registered a Phase 3 trial.<br><br>In June, Brazil’s Butantan Institute <a href="https://www.reuters.com/world/americas/brazil-oks-clinical-tests-homegrown-covid-vaccine-butanvac-2021-06-09/">launched</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT04993209?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1 trial</a> of the vaccine, known there as Butanvac. On April 29, 2022, the institute <a href="https://clinicaltrials.gov/ct2/show/NCT05354024">registered</a> a Phase 2/3 trial. But in July 2022, Globo <a href="https://g1.globo.com/sp/sao-paulo/noticia/2022/07/13/um-ano-apos-iniciar-fase-1-da-butanvac-butantan-ainda-tenta-autorizacao-para-continuar-estudo.ghtml">reported</a> that the trial had not yet been authorized to proceed.<br><br>Meanwhile, the <a href="https://clinicaltrials.gov/ct2/show/NCT04830800">Institute of Vaccines and Medical Biologicals</a> in Vietnam launched trials of its own, dubbing the vaccine Covivac. In August they advanced to <a href="http://en.ivac.com.vn/tin-tuc/2/44/vietnam-made-covid-19-vaccine-moves-to-phase-2-following-positive-phase-1-results/vien-vac-xin.html">Phase 2 trials</a>. In January 2022, the institute <a href="https://ivac.com.vn/tin-tuc/2/391/ket-qua-giua-ky-giai-doan-2-thu-nghiem-lam-sang-vac-xin-covivac-do-ivac-san-xuat/vien-vac-xin.html">announced</a> that the vaccine was safe and produced better antibody levels than the AstraZeneca vaccine. Some of the results of the trial were <a href="https://www.sciencedirect.com/science/article/pii/S0264410X22005266">published</a> in June 2022. But the Institute has <a href="https://tiasang.com.vn/-tin-tuc/Vaccine-COVIVAC-Sinh-khang-the-trung-hoa-cao-hon-AstraZeneca-29824">decided against</a> advancing Covivac to Phase 3.<br><br>In March 2022, researchers at Mt. Sinai <a href="https://www.mountsinai.org/about/newsroom/2022/mount-sinai-launches-phase-one-us-trial-of-ndvhxps-an-egg-based-investigational-covid-vaccine-in-healthy-adults-previously-immunized-against-covid">launched</a> a Phase 1 trial to study NDV-HXP-S as a booster for people vaccinated with other vaccines.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 12, 2022</span>

</p>

<a name="reithera"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-phase3 ">

<!-- phases -->








<span class="g-phase2">PHASE 2</span> <span class="g-phase3">PHASE 3</span> <span class="g-combined">COMBINED PHASES</span>

<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/reithera-800.png" class="g-vlogo" 
    style="width: 200px; height: 63px; margin-right: 20px;" alt="ReiThera logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/spallanzani-800.png" class="g-vlogo" 
    style="width: 270px; height: 60px;" alt="Lazzaro Spallanzani National Institute for Infectious Disease logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
The Italian biotechnology company <strong>ReiThera</strong> has developed a Covid-19 vaccine, called GRAd-COV2, that is based on an adenovirus that infects gorillas. Working in collaboration with the <strong>Lazzaro Spallanzani National Institute for Infectious Diseases</strong> in Rome, they found that it produced strong levels of antibodies in <a href="https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(21)00210-0">mice and monkeys</a>. In July 2020, they launched a <a href="https://clinicaltrials.gov/ct2/show/NCT04528641">Phase 1 clinical trial</a>. In November, they <a href="https://www.prnewswire.com/news-releases/reithera-announces-its-grad-cov2-covid-19-vaccine-candidate-is-well-tolerated-and-induces-clear-immune-responses-in-healthy-subjects-aged-18-55-years-301179423.html">announced</a> that the vaccine was well tolerated and produced antibodies, and <a href="https://www.science.org/doi/10.1126/scitranslmed.abj1996">released a report</a> on the trial.<br><br>In March 2021, researchers launched a <a href="https://clinicaltrials.gov/ct2/show/NCT04791423">Phase 2 trial</a> of the vaccine, which delivered <a href="https://www.prnewswire.com/news-releases/reithera-announces-preliminary-phase-2-data-from-its-covid-19-vaccine-candidate-301331316.html">encouraging results</a> in July. But it remained unclear if ReiThera would be able to advance to a final Phase 3 trial.<br><br>In May, Reuters reported, a court in Italy <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/exclusive-italy-audit-court-rejects-public-funding-reithera-covid-19-vaccine-2021-05-14/">struck down</a> the government’s plan to fund the Phase 3 trial. The government later said it was <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/italy-govt-ready-fund-reithera-covid-19-vaccine-project-minister-says-2021-05-21/">ready</a> to support the vaccine trial, but has yet to offer up the funds. In November 2021, the Bill & Melinda Gates Foundation <a href="https://www.prnewswire.com/news-releases/reithera-awarded-grant-to-develop-next-generation-vaccines-301414294.html">awarded</a> ReiThera a grant of $1.4 million to continue to develop the vaccine.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Dec. 3, 2021</span>

</p>

<a name="bbv154"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-phase3 ">

<!-- phases -->








<span class="g-phase2">PHASE 2</span> <span class="g-phase3">PHASE 3</span> <span class="g-combined">COMBINED PHASES</span>

<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/wustl-800.png" class="g-vlogo" 
    style="width: 150px; height: 59px; margin-right: 20px;" alt="Washington University logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/bharat-800.png" class="g-vlogo" 
    style="width: 151px; height: 70px;" alt="Bharat Biotech logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at <strong>Washington University </strong>designed a nasal spray vaccine that can produce high levels of coronavirus antibodies in mice <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437481/">with just a single dose</a>. It contains a chimpanzee adenovirus engineered to carry the spike protein gene. The Indian drug maker <strong>Bharat Biotech </strong>licensed the technology, and in February 2021 they won <a href="https://timesofindia.indiatimes.com/city/hyderabad/sec-okays-bbil-nasal-vaccine-phase-i-trials/articleshow/80801077.cms">approval</a> to launch a <a href="https://clinicaltrials.gov/ct2/show/NCT04751682">Phase 1 trial </a>of a vaccine, which they named BBV154. The company started a Phase 2 trial in September 2021. On Jan. 28, 2022, it <a href="https://twitter.com/BharatBiotech/status/1487036533211164672">announced</a> that it had received approval from India’s Drugs Controller General to conduct a Phase 3 trial for BBV154 as a booster; the trial <a href="https://medicaldialogues.in/news/industry/pharma/bharat-biotechs-intranasal-booster-vaccine-may-be-potential-game-changer-say-expert-89838">began</a> in March 2022. On Aug. 15, 2022, Bharat <a href="https://twitter.com/BharatBiotech/status/1559097724053897218">announced</a> that it had completed the clinical development of BBV154 and had submitted its data to Indian regulators for authorization.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 31, 2022</span>

</p>

<a name="geovax"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/geovax-800.png" class="g-vlogo" 
    style="width: 155px; height: 42px; margin-right: 20px;" alt="GeoVax logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/cityofhope-800.png" class="g-vlogo" 
    style="width: 130px; height: 54px;" alt="City of Hope logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at <strong>City of Hope</strong>, a California biomedical research institute, created a <a href="https://www.nature.com/articles/s41467-020-19819-1">vaccine</a> based on a weakened form of a virus called Modified Vaccinia Ankara, or MVA for short. They added two coronavirus genes to the MVA virus — one for the spike protein, and one for another protein called nucleocapsid. They are testing the vaccine, called COH04S1, specifically for people with immune systems impaired by cancer and other disorders. Many of them do not produce a strong immune response to authorized vaccines based on mRNA. The City of Hope researchers reasoned that  COH04S1 might work better.<br><br>City of Hope launched a <a href="https://clinicaltrials.gov/ct2/show/NCT04639466">Phase 1 trial</a> in November 2020, giving the vaccine to healthy volunteers. They <a href="https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(22)00027-1/fulltext">found</a> that COH04S1 was safe and produced a promising level of antibodies. The researchers moved on to a <a href="https://clinicaltrials.gov/ct2/show/NCT04977024">Phase 2 trial</a> in September 2021, giving the vaccine to immunocompromised volunteers.<br><br>On Nov. 9, 2021, <strong>GeoVax</strong> <a href="https://www.cityofhope.org/news/geovax-and-city-of-hope">announced</a> that it has been granted exclusive rights to develop COH04S1, and market it worldwide. GeoVax <a href="https://www.clinicaltrialsarena.com/news/geovax-commences-dosing-booster/">dosed</a> the first participant in a Phase 2 booster trial in December 2021.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated March 18, 2022</span>

</p>

<a name="vaxart"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/vaxart-800.png" class="g-vlogo" 
    style="width: 220px; height: 54px; margin-right: 20px;" alt="Vaxart logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
While many vaccines are given as injections, some vaccines can be taken as a pill. Oral vaccines have been <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132247/">approved</a> for diseases including polio, cholera, and typhoid fever. The small San Francisco company <strong>Vaxart </strong>specializes in developing oral vaccines. They have created and tested pills for <a href="https://doi.org/10.1016/S1473-3099(19)30584-5">influenza</a> and other diseases. Last spring Vaxart began work on an oral vaccine for Covid-19. It contains an adenovirus called Ad5 (the same viral vector in CanSinoBio’s vaccine and in Russia’s Sputnik V).<br><br>When Vaxart gave the pill to <a href="https://www.biorxiv.org/content/10.1101/2020.09.04.283853v1">mice</a>, they produced antibodies against the coronavirus. Mice don’t suffer symptoms of Covid-19, however, so the researchers then switched to hamsters, which do. They <a href="https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab561/6425228">found</a> that the vaccine pill not only <a href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-additional-data-hamster-challenge-study-its">dramatically reduced</a> the amount of coronavirus in sick <a href="https://www.science.org/doi/10.1126/scitranslmed.abn6868">hamsters</a>, but also protected them from two important symptoms of the disease: weight loss and swollen lungs. More studies on monkeys <a href="https://investors.vaxart.com/news-releases/news-release-details/vaxarts-s-only-covid-19-vaccine-candidate-produces-strong-cross">released</a> in February 2022 showed that the vaccine produced antibodies against a range of variants.<br><br>The company’s stock price increased 3,600 percent in the first half of 2020. In June, The New York Times <a href="https://www.nytimes.com/2020/07/25/business/coronavirus-vaccine-profits-vaxart.html">reported</a>, a hedge fund that partly controlled the company sold off most of its shares, netting over $200 million in profits. In the wake of that reporting, the Department of Justice began <a href="https://www.nytimes.com/2020/10/15/business/vaxart-covid-coronavirus-vaccine.html">investigating</a> the company, while a number of shareholder lawsuits were brought against Vaxart, its executives and its board.<br><br>In October 2020, the company began giving the pill to volunteers in a <a href="https://clinicaltrials.gov/ct2/show/NCT04563702">Phase 1 clinical trial</a>. On Feb. 3, 2021, Vaxart <a href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-preliminary-data-phase-1-clinical">announced</a> that the trial revealed no serious safety concerns. While the pill produced a response from T cells, it didn’t produce encouraging neutralizing antibodies. Its stock price <a href="https://www.cnbc.com/2021/02/03/covid-vaccine-vaxart-says-its-oral-vaccine-got-promising-results.html">plunged</a> 60 percent on the news. <br><br>On Feb. 25, 2021, the company <a href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-provides-business-update-and-reports-fourth-quarter-and">announced</a> it would advance to a Phase 2 trial in the second quarter of 2021, but manufacturing problems forced them to <a href="https://www.prnewswire.com/news-releases/fda-clears-vaxarts-ind-application-for-s-only-oral-tablet-covid-19-vaccine-candidate-301345771.html">delay the launch</a>.<br><br>On Oct. 5, Vaxart registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05067933?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 2 trial.</a> In the new study, the company is <a href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-begins-recruiting-global-phase-ii-covid-19-oral-tablet">testing</a> its pill as a primary vaccine on unvaccinated volunteers, and as a booster for people who have already received an authorized vaccine. The researchers <a href="https://www.prnewswire.com/news-releases/vaxart-doses-first-subject-in-phase-ii-covid-19-oral-tablet-vaccine-clinical-trial-301408386.html">dosed</a> their first participant on Oct. 26. In May 2022, the company <a href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-provides-business-update-and-reports-first-quarter-2022">said</a> they expected results in the third quarter of 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated May 15, 2022</span>

</p>

<a name="immunitybio"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/immunitybio-800.png" class="g-vlogo" 
    style="width: 200px; height: 67px; margin-right: 20px;" alt="ImmunityBio logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
The California-based company <strong>ImmunityBio</strong> created a vaccine using  the Ad5 adenovirus, the same one used by CanSinoBio and the Gamaleya Institute in Russia. ImmunityBio <a href="https://www.biorxiv.org/content/10.1101/2020.07.29.227595v1">engineered</a> the Ad5 virus to carry genes for two genes from the coronavirus. In addition to the spike protein, it also carries the gene for a protein called nucleocapsid. The company hopes that this combination will provoke a strong immune response. <br><br> The company found  that the vaccine protects monkeys from the coronavirus. ImmunityBio launched a <a href="https://clinicaltrials.gov/ct2/show/NCT04591717">Phase 1 trial</a> of a Covid-19 vaccine in October 2020 in the United States and <a href="https://clinicaltrials.gov/ct2/show/NCT04710303">another</a> in South Africa in January. In February 2021, the company <a href="https://clinicaltrials.gov/ct2/show/NCT04732468">registered</a> a Phase 1 trial of an <a href="https://immunitybio.com/immunitybio-and-nantkwest-announce-fda-authorization-to-study-had5-t-cell-covid-19-vaccine-for-combination-of-subcutaneous-oral-and-sublingual-boost-to-induce-t-cell-mucosal-and-antibody-immunity/">oral version</a> of the vaccine.<br><br>On May 25, the company <a href="https://www.businesswire.com/news/home/20210525005370/en/ImmunityBio-Expands-Trials-of-T-Cell-Based-COVID-19-Vaccine-Candidate-as-a-%E2%80%98Universal-Boost%E2%80%99-in-Vaccinated-Subjects-and-Receives-Approval-to-Test-Intranasal-Spray-in-South-Africa">announced</a> that it would study how well their candidate works as a booster shot for those who already received other vaccines. It said on Dec. 20 that <a href="https://immunitybio.com/immunitybio-announces-completion-of-470-million-post-merger-financing-to-fund-late-stage-cancer-clinical-trials-phase-3-of-covid-t-cell-universal-boost-vaccine-trial-and-provides-update-on-bladder/">Phase 2 trials</a> of the booster are ongoing, and serious adverse effects have not been reported. Phase 3 trials could begin in early 2022. Researchers are also testing a nasal spray version.<br><br>The chairman, C.E.O. and Global Chief Scientific and Medical Officer of ImmunityBio is billionaire <a href="https://www.businesswire.com/news/home/20210816005236/en/ImmunityBio-Appoints-Dr.-Patrick-Soon-Shiong-to-Global-Chief-Scientific-and-Medical-Officer-Newly-Created-Role-Will-Lead-Company%E2%80%99s-Scientific-Strategy-and-Global-Expansion">Patrick Soon-Shiong</a>, the owner of the Los Angeles Times.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Dec. 22, 2021</span>

</p>

<a name="cellid"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/cellid-800.png" class="g-vlogo" 
    style="width: 124px; height: 30px; margin-right: 20px;" alt="Cellid logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/lgchem-800.png" class="g-vlogo" 
    style="width: 180px; height: 38px;" alt="LG Chem logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In April 2020, the South Korean biotech company <strong>Cellid</strong> began to <a href="http://www.koreabiomed.com/news/articleView.html?idxno=9876">develop</a> a vaccine for Covid-19. The vaccine, called AdCLD-CoV19, was based on a combination of two strains of adenoviruses, called Ad5 and Ad35. After <a href="https://innovation.lgchem.com/newsroom/view.do">testing</a> the vaccine on monkeys, Cellid entered into a <a href="https://www.en24news.com/covid-19/en/2020/12/celid-corona-19-vaccine-production-consortium-including-lg-chem.html">partnership</a> with the South Korean chemical manufacturer <strong>LG Chem</strong> to manufacture the vaccine.<br><br>In December 2020, Cellid  registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04666012">Phase 1 trial</a> for AdCLD-CoV19, and a Phase 2 trial launched in June 2021. But the <a href="https://www.koreabiomed.com/news/articleView.html?idxno=12064">results</a> were disappointing, leading the company to reformulate <a href="http://www.koreabiomed.com/news/articleView.html?idxno=12223">a new version</a> of the vaccine, called AdCLD-CoV19-1.<br><br>Cellid <a href="http://www.koreabiomed.com/news/articleView.html?idxno=12064">finished</a> administering the updated vaccine to Phase 1 volunteers in October 2021 and applied to run a Phase 2/3 trial the following month. At the time, a Cellid official <a href="http://www.koreabiomed.com/news/articleView.html?idxno=12580">told</a> the Korean Biomedical Review that the company would compare the impacts of one and  doses in the Phase 2 portion of the trial before moving to Phase 3. Cellid said on Aug. 8 that it decided to <a href="http://www.koreabiomed.com/news/articleView.html?idxno=14349">move</a> the Phase 2 trial in Kenya and Tanzania after having difficulty finding eligible participants in Korea.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 12, 2022</span>

</p>

<a name="biocad"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/biocad-800.png" class="g-vlogo" 
    style="width: 150px; height: 29px; margin-right: 20px;" alt="BIOCAD logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Russian biotechnology company <strong>BIOCAD</strong> has developed a vaccine that uses a type of virus known as an adenovirus-associated virus as a vector. The virus, called AAV-5, carries a gene encoding part of the spike protein from the coronavirus.  They <a href="https://clinicaltrials.gov/ct2/show/NCT05037188?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">registered</a> a Phase 1/2 trial for the vaccine, called BCD-250, on Sept. 8, 2021.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Sept. 13, 2021</span>

</p>

<a name="dzif"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/dzif-800.png" class="g-vlogo" 
    style="width: 110px; height: 74px; margin-right: 20px;" alt="German Center for Infection Research logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Three decades ago, the <strong>German Center for Infection Research</strong> developed a smallpox vaccine from a harmless virus called Modified Vaccinia Ankara, or MVA for short. In recent years, they adapted it to create a vaccine for MERS, a disease caused by another coronavirus.<br><br>In the spring of 2020, they made an MVA-based vaccine for SARS-CoV-2, the coronavirus that is causing the Covid-19 pandemic. It carries the gene for the spike protein, which is produced inside cells that it invades. On Sept. 29, 2020, the center and a consortium of German universities registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04569383">Phase 1 trial</a>. In January 2021, the center <a href="https://www.dzif.de/en/node/2894">announced</a> that their initial formulation provided disappointing results and had postponed the trial until they updated it. They said that they <a href="https://www.dzif.de/en/study-optimized-vector-vaccine-mva-sars-2-s-resumed">resumed</a> the trial with an updated version of the vaccine on July 16, 2021, and completed the trial that August.<br><br>The researchers announced in November that they are evaluating an MVA-based vaccine in <a href="https://www.dzif.de/en/study-booster-vaccination-mva-sars-2-st-vector-vaccine-starting-uke">Phase 1 trials</a> as a booster and in unvaccinated individuals. They <a href="https://clinicaltrials.gov/ct2/show/NCT05226390?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2">registered the trial</a> on Feb. 7, 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Feb. 8, 2022</span>

</p>

<a name="gritstone"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/gritstone-800.png" class="g-vlogo" 
    style="width: 200px; height: 49px; margin-right: 20px;" alt="Gritstone bio logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/niaid-800.png" class="g-vlogo" 
    style="width: 200px; height: 49px;" alt="National Institute of Allergy and Infectious Diseases logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>Gritstone bio </strong>has developed experimental vaccines in recent years that teach the immune system to attack tumors. In 2020, they constructed a vaccine for Covid-19 that presents a number of targets in the coronavirus for the immune system to attack.<br><br>The researchers constructed a piece of DNA that encodes the entire spike protein of the coronavirus. In addition, it encodes instructions for building small pieces of other viral proteins called nucleocapsid and ORF3a. They then inserted this cassette into the genes of a chimpanzee adenovirus. The spike protein provokes the body to make antibodies, while the pieces of other proteins train the immune system to recognize infected cells and kill them.<br><br>In addition, the researchers created an RNA molecule with the same genetic instructions, which they put in a shell. Once the shell slips into a cell, the RNA molecule can make copies of itself, and the cell then makes proteins from those copies.<br><br>In a <a href="https://clinicaltrials.gov/ct2/show/NCT04776317">Phase 1 trial</a> launched in March 2021, the <strong>National Institute of Allergy and Infectious Diseases</strong> is testing how well these two vaccines work together, with the chimpanzee adenovirus serving as the first dose and the self-amplifying mRNA as the second. The researchers hope that this combination will produce a better immune response than two doses of either vaccine. In a May 2022 company <a href="https://ir.gritstonebio.com/news-releases/news-release-details/correction-gritstone-reports-first-quarter-2022-financial">update</a>, Gritstone bio said that its vaccine program was continuing.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 3, 2022</span>

</p>

<a name="meissa"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/meissa-800.png" class="g-vlogo" 
    style="width: 101px; height: 70px; margin-right: 20px;" alt="Meissa Vaccines logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>Meissa Vaccines</strong> has developed a vaccine that can be delivered as a spray or drops into the nose. To make the vaccine, researchers started off with another virus, called respiratory syncytial virus (RSV for short). The researchers introduced mutations into the RSV virus’s genes so that it replicated too slowly to cause disease. Then they added a gene for the coronavirus spike protein, so that the weakened RSV viruses could present it to the immune system. <a href="https://www.biorxiv.org/content/10.1101/2021.07.16.452733v2">A study on monkeys</a> released in July 2021 showed that the vaccine could produce antibodies in the noses of the animals and protect them from Covid-19. The initial data from <a href="https://clinicaltrials.gov/ct2/show/NCT04798001?term=covid-19+vaccine&draw=2&rank=76">a Phase 1 trial</a>, announced <a href="https://www.businesswire.com/news/home/20211028005281/en/Meissa-Announces-Positive-Preliminary-Clinical-Data-on-Safety-and-Immunogenicity-of-Intranasal-COVID-19-Vaccine">Oct. 28</a>, indicate that the vaccine can also produce high levels of antibodies against the coronavirus in people’s noses. The full results of the trial will be released in 2022. Meissa <a href="https://www.bloomberg.com/news/features/2022-04-25/can-nasal-sprays-work-on-covid-meissa-vaccines-thinks-so">told Bloomberg News</a> in April 2022 that it is testing the vaccine as a booster and plans to begin a trial in children. A representative from Meissa <a href="https://www.businesswire.com/news/home/20220726006074/en/Meissa-Vaccines-Presented-at-The-White-House-Summit-on-the-Future-of-COVID-19-Vaccines">described</a> the ongoing Phase 1 trial at a July 2022 White House vaccine summit.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 29, 2022</span>

</p>

<a name="tetherex"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/tetherex-800.png" class="g-vlogo" 
    style="width: 170px; height: 42px; margin-right: 20px;" alt="Tetherex Pharmaceuticals logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at Oklahoma-based <strong>Tetherex Pharmaceuticals</strong> have created a vaccine that uses genetically engineered viruses to develop immunity. They registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04839042">Phase 1 trial</a> in Australia on April 9, 2021. Mayo Clinic <a href="https://www.prnewswire.com/news-releases/tetherex-pharmaceuticals-signs-exclusive-worldwide-license-with-mayo-clinic-for-development-and-commercialization-of-a-novel-single-cycle-adenovirus-vaccine-platform-301325739.html">announced</a> a deal to develop and market the vaccine technology worldwide on July 6. A spokesperson for Tetherex said on Jan. 18, 2022, that the trial remains ongoing. A change to the trial record from April 2022 shows that the researchers expect the study to end in August.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated May 6, 2022</span>

</p>

<a name="cyanvac"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/cyanvac-800.png" class="g-vlogo" 
    style="width: 83px; height: 70px; margin-right: 20px;" alt="CyanVac logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Scientists at the <strong>University of Georgia</strong> and the <strong>University of Iowa </strong>have developed a vaccine based on canine parainfluenza virus, which has never been found to cause disease in humans. They engineered it to carry proteins from the coronavirus. The vaccine, called CVXGA1, is administered as a nasal spray. In July 2021, the researchers published a <a href="https://advances.sciencemag.org/content/7/27/eabi5246">study</a> showing that a single dose of the vaccine could protect mice and ferrets against Covid-19.  A spin-off company called <strong>CyanVac </strong>took the intranasal vaccine, called CVXGA1, to <a href="https://clinicaltrials.gov/ct2/show/NCT04954287?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=5">Phase 1 trials</a> the same month, and <a href="https://www.prnewswire.com/news-releases/cyanvac-and-blue-lake-biotechnology-announce-first-participant-dosed-in-a-phase-1-clinical-trial-to-evaluate-its-cvxga1-intranasal-covid-19-vaccine-301385485.html">enrolled</a> the first participant in late September. In a February 2022 update to the trial registry, the researchers opened the study to adults who had previously received other vaccines. In July 2022, CyanVac’s founder <a href="https://www.prnewswire.com/news-releases/cyanvac-ceo-speaks-at-white-house-summit-on-the-future-of-covid-19-vaccines-301594133.html">described</a> the ongoing Phase 1 trial at a vaccine summit at the White House.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 29, 2022</span>

</p>

<a name="engeneic"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/engeneic-800.png" class="g-vlogo" 
    style="width: 180px; height: 68px; margin-right: 20px;" alt="EnGeneIC logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at Australian biotechnology company <strong>EnGeneIC </strong>have modified their cancer treatment platform to carry a molecular payload that targets the coronavirus. They are producing the vaccine, known as COVID-19-EDV, primarily for people with compromised immune systems. On Sept. 7, 2021, EnGeneIC <a href="https://www.globenewswire.com/news-release/2021/09/08/2293003/0/en/Australian-biotech-EnGeneIC-develops-world-first-nanocellular-anti-COVID-19-vaccine-that-defeats-mutant-viruses-and-stimulates-a-broad-anti-viral-response.html">announced</a> that it had begun a Phase 1 trial in Australia. EnGeneIC <a href="https://www.globenewswire.com/en/news-release/2021/11/30/2342890/0/en/Australian-Biotech-EnGeneIC-Strikes-Landmark-Deal-with-Major-US-Biotech-ImmunityBio-for-COVID-19-Vaccine-and-Cancer-Treatment.html">signed an agreement</a> with ImmunityBio in November 2021 to develop and manufacture its vaccine worldwide. EnGeneIC <a href="https://www.globenewswire.com/en/news-release/2022/06/28/2470195/0/en/EnGeneIC-s-second-generation-COVID-19-vaccine-protects-against-all-variants.html">said</a> on June 28, 2022, that the vaccine stimulates the creation of antibodies against “all” variants.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 31, 2022</span>

</p>

<a name="mcmaster"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/mcmaster-800.png" class="g-vlogo" 
    style="width: 145px; height: 80px; margin-right: 20px;" alt="McMaster University logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Canadian researchers at <strong>McMaster University </strong>are testing the effectiveness of two viral vector vaccines as a booster in adults who have already received three doses of an mRNA vaccine. They plan to administer the candidates into the lungs using a nebulizer. On Oct. 26, 2021 the researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05094609">Phase 1 trial</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 29, 2022</span>

</p>

<a name="iibr"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/iibr-800.png" class="g-vlogo" 
    style="width: 240px; height: 58px; margin-right: 20px;" alt="Israel Institute for Biological Research logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In the spring of 2020, the <strong><a href="https://iibr.gov.il/Pages/Who-We-are.aspx">Israel Institute for Biological Research</a></strong> started <a href="https://www.biorxiv.org/content/10.1101/2020.06.18.160655v1">work</a> on a coronavirus vaccine based on vesicular stomatitis viruses. They engineered the viruses to carry the gene for the coronavirus spike protein. On Oct. 25, the Israeli government <a href="https://www.jpost.com/health-science/israel-to-kick-off-human-trials-of-covid-19-vaccine-candidate-on-nov-1-646904">announced</a> that the vaccine, called <a href="https://www.jpost.com/israel-news/israel-names-its-vaccine-candidate-brilife-646254">Brilife</a>, would be going into a Phase 1 trial. In January 2021, the vaccine moved on to a  <a href="https://www.jpost.com/health-science/israel-launches-phase-ii-trial-of-its-coronavirus-vaccine-candidate-654350">Phase 2 trial</a>. In July, Israel formed a <a href="https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-partnership-with-the-israel-institute-for-biological-research-to-complete-development-and-commercialization-of-brilife-covid-vaccine-301331618.html">partnership</a> with the American company NRx Pharmaceuticals to advance research on Brilife in studies to be conducted in Israel, Georgia, and the Ukraine. <br><br>NRx registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04990466">Phase 2/3 trial</a> in August 2021. The trial was originally planned for 550 volunteers, but the company increased the number to 20,000 after a month. It was slated to end by February 2022, but results have yet to be made public. In an <a href="https://www.nrxpharma.com/nrx-reports-remarks-by-israel-institute-for-biological-research-on-the-future-of-the-brilife-covid-19-investigational-vaccine/">interview</a>, the director of the Israel Institute for Biological Research said that the results would come in the next several months.<br><br>On March 31, 2022, NRx <a href="https://www.nrxpharma.com/nrx-pharmaceuticals-provides-business-update-and-reports-full-year-2021-financial-results/">announced</a> that it would no longer pursue developing Brilife.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 4, 2022</span>

</p>

<a name="merck"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/merck-800.png" class="g-vlogo" 
    style="width: 150px; height: 49px; margin-right: 20px;" alt="Merck logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/themis-800.png" class="g-vlogo" 
    style="width: 60px; height: 60px; margin-right: 20px;" alt="Themis logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/pasteur-800.png" class="g-vlogo" 
    style="width: 180px; height: 49px;" alt="Institut Pasteur logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
The American company <strong>Merck</strong> acquired the Austrian firm <strong>Themis Bioscience </strong>in June 2020 to develop their vaccine, which had been originally developed at <strong>Institut Pasteur</strong>. The vaccine used a weakened measles virus that carries a gene for the coronavirus spike protein. Researchers <a href="https://clinicaltrials.gov/ct2/show/NCT04497298">launched</a> a Phase 1 trial in August 2020. On Jan. 25, 2021, Merck <a href="https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/">announced</a> it was abandoning the effort, because the vaccine provoked a response that was <a href="https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00605-8/fulltext#%20">weaker</a> than a natural infection. In March they entered into a partnership with Johnson & Johnson to help produce their vaccine instead.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated March 4, 2022</span>

</p>

<a name="iavi"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/merck-800.png" class="g-vlogo" 
    style="width: 150px; height: 49px; margin-right: 20px;" alt="Merck logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/iavi-800.png" class="g-vlogo" 
    style="width: 60px; height: 54px;" alt="International AIDS Vaccine Initiative logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In addition to its project with Themis, <strong>Merck</strong> partnered with <strong>IAVI</strong> on a second viral vector vaccine. It was based on vesicular stomatitis viruses, the same approach Merck successfully used to produce the <a href="https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health">first approved vaccine for Ebola</a>. They designed their coronavirus vaccine as a pill, which could have made  it easier to distribute than syringes for injections. Merck and IAVI received <a href="https://medicalcountermeasures.gov/newsroom/2020/merck-iavi/">$38 million</a> from the United States government to support their research, and on September 30, 2020, they registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04569786">Phase 1 trial</a>. But on Jan. 25, 2021, they <a href="https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/">announced</a> they were abandoning the effort because the vaccine failed to trigger an immune system comparable to what happens in a natural infection of Covid-19.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Jan. 25, 2021</span>

</p>

<a name="altimmune"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/altimmune-800.png" class="g-vlogo" 
    style="width: 210px; height: 38px; margin-right: 20px;" alt="Altimmune logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> AdCOVID<br>
<span class="g-info">Efficacy:</span> Unknown<br>
<span class="g-info">Dose:</span> 1 dose<br>
<span class="g-info">Type:</span> Nasal spray<br>
<span class="g-info">Storage:</span> Refrigerated<br>
<br>
</span>

<!-- description -->
Maryland-based <strong>Altimmune</strong> is a biopharmaceutical company that focuses on developing vaccines delivered by nasal spray. They developed a nasal spray vaccine for Covid-19, delivering the Ad5 adenovirus to the airway. Studies on the immune system suggests that a nasal spray <a href="https://www.nytimes.com/2020/07/14/health/coronavirus-nasal-vaccines.html">could be more effective</a> for blocking the transmission of the virus than vaccines given by injection. In a study on mice, Altimmune researchers found that a single dose of the vaccine gave <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-new-preclinical-data-adcovidtm-demonstrating">complete protection</a> from a lethal infection of coronaviruses. On Dec. 22, 2020, the company <a href="https://clinicaltrials.gov/ct2/show/NCT04679909">registered</a> a Phase 1 clinical trial of a single dose of the vaccine.<br><br>But on June 29, 2021, Altimmune <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-update-adcovidtm-phase-1-clinical-trial">announced</a> they were abandoning their Covid-19 vaccine. In their Phase 1 trial, they gave the spray to 80 volunteers and found that they produced substantially lower levels of antibodies than produced by Covid-19 vaccines that have already been authorized.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 30, 2021</span>

</p>
<h2 class="g-subhed g-optimize-type g-filtered" id="">
	<span class="g-balancer" data-id="14"><strong>Protein-Based Vaccines</strong></span>
</h2>
<p class="g-body g-description g-optimize-type g-filtered" id="">
	<span class="g-xbalancer" data-id="15"><em>Vaccines that contain coronavirus proteins but no genetic material. Some vaccines contain whole proteins, and some contain fragments of them. Some pack many of these molecules on nanoparticles.</em></span>
</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filtered"  style="max-width: 600px">

<!-- Intro elements -->








<div role="region">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.100.0 - 2020-09-10 08:32 -->
<!-- ai file: protein.ai -->
<!-- preview: undefined -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-protein-box ,
	#g-protein-box .g-artboard {
		margin:0 auto;
	}
	#g-protein-box p {
		margin:0;
	}
	#g-protein-box .g-aiAbs {
		position:absolute;
	}
	#g-protein-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-protein-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-protein-box .g-aiPointText p { white-space: nowrap; }
	#g-protein-600 {
		position:relative;
		overflow:hidden;
	}
	#g-protein-450 {
		position:relative;
		overflow:hidden;
	}
	#g-protein-335 {
		position:relative;
		overflow:hidden;
	}

</style>

<div id="g-protein-box" class="ai2html">

	<!-- Artboard: 600 -->
	<div id="g-protein-600" class="g-artboard" style="width:600px; height:260px;" data-aspect-ratio="2.308" data-min-width="600">
<div style=""></div>
		<img id="g-protein-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/protein-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
	</div>

	<!-- Artboard: 450 -->
	<div id="g-protein-450" class="g-artboard" style="width:450px; height:260px;" data-aspect-ratio="1.731" data-min-width="450" data-max-width="599">
<div style=""></div>
		<img id="g-protein-450-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/protein-450.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-protein-335" class="g-artboard" style="max-width: 335px;max-height: 260px" data-aspect-ratio="1.288" data-min-width="0" data-max-width="449">
<div style="padding: 0 0 77.6119% 0;"></div>
		<img id="g-protein-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/protein-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-protein-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2020-09-10 08:32 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="novavax"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN CANADA, SOUTH KOREA</span>


<span class="g-limited">EMERGENCY USE IN U.S., OTHER COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/novavax-800.png" class="g-vlogo" 
    style="width: 200px; height: 50px; margin-right: 20px;" alt="Novavax logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> NVX-CoV2373 (also known as Covovax or Nuvaxovid)<br>
<span class="g-info">Efficacy:</span> <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2116185">90.4</a>%<br>
<span class="g-info">Dose:</span> 2 doses, 3 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Stable in refrigerator<br>
<br>
</span>

<!-- description -->
With massive support from the U.S. government, Maryland-based <strong>Novavax</strong> developed a highly effective protein-based vaccine in 2020. But manufacturing woes  drastically slowed its rollout. It wasn’t until November 2021 that the company began gaining emergency authorizations, including from <a href="https://ir.novavax.com/2021-12-28-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-India">India</a>, <a href="https://ir.novavax.com/2022-01-10-Novavax-and-Serum-Institute-of-India-File-for-Emergency-Use-Authorization-of-Novavax-COVID-19-Vaccine-in-South-Africa">South Africa</a>, <a href="https://www.gov.uk/government/news/novavax-covid-19-vaccine-nuvaxovid-approved-by-mhra">the United Kingdom</a>, the <a href="https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu">European Union</a> and the <a href="https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries">World Health Organization</a>. The F.D.A. <a href="https://www.nytimes.com/2022/07/13/health/novavax-covid-vaccine-fda.html">authorized</a> the vaccine on July 13, 2022.<br><br> <subhed>VACCINE DEVELOPMENT</subhed> Before the pandemic, Novavax developed a number of vaccines for diseases by attaching viral proteins to microscopic particles. In 2019, the company’s flu vaccine finished Phase 3 clinical trials, but at the start of the Covid pandemic, Novavax had yet to deliver a single vaccine to market.<br><br>In May 2020, the company launched trials for a Covid-19 vaccine, which they named NVX-CoV2373. The Coalition for Epidemic Preparedness Innovations invested $384 million to support the research. In July, the U.S. government awarded Novavax another <a href="https://www.nytimes.com/2020/07/07/health/novavax-coronavirus-vaccine-warp-speed.html">$1.75 billion</a> to support the vaccine’s clinical trials and manufacturing.<br><br> <subhed>TRIAL RESULTS</subhed> After getting <a href="https://www.nytimes.com/2020/08/04/health/covid-19-vaccine-novavax.html">promising results</a> from <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494251/">preliminary studies</a> in monkeys and humans, Novavax launched a Phase 2 <a href="https://clinicaltrials.gov/ct2/show/NCT04533399">trial</a> on 2,900 people in South Africa in August 2020, and the next month it <a href="https://www.nytimes.com/2020/09/24/health/covid-19-vaccine-novavax.html">launched</a> a Phase 3 <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004123-16/GB">trial</a> with up to 15,000 volunteers in the United Kingdom.  <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-provides-phase-3-covid-19-vaccine-clinical-development">The Phase 3 trial in the United States</a> was delayed because of problems with manufacturing the doses required for the study. It finally <a href="https://www.nytimes.com/live/2020/12/28/world/covid-19-coronavirus-updates/novavax-is-starting-the-final-stage-of-testing-for-its-covid-vaccine">launched</a> on Dec. 28, 2020.<br><br>On March 11, 2021, Novavax <a href="https://www.reuters.com/article/us-health-coronavirus-vaccines-novavax/novavax-vaccine-96-effective-against-original-coronavirus-86-vs-british-variant-in-uk-trial-idUSKBN2B32ZO">reported</a> that its United Kingdom trial determined an efficacy rate of <a href="https://www.nytimes.com/live/2021/03/12/world/covid-19-coronavirus#novavax-reports-strong-trial-results-in-britain-and-weaker-ones-in-south-africa">96 percent against the original coronavirus</a>, and an efficacy of 86 percent against the Alpha variant. In a study on nearly 30,000 volunteers in the United States in Mexico, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2116185">the vaccine’s efficacy was 90.4 percent</a>. Results from a <a href="https://www.prnewswire.com/news-releases/novavax-announces-positive-results-of-covid-19-vaccine-in-pediatric-population-of-prevent-19-phase-3-clinical-trial-301480238.html">pediatric study</a> suggest that the vaccine’s efficacy was 82 percent against the Delta variant.<br><br>On Feb. 28, 2022, Novavax <a href="https://www.prnewswire.com/news-releases/novavax-announces-extended-durability-of-protection-against-infection-and-disease-in-united-kingdom-covid-19-vaccine-phase-3-clinical-trial-301491818.html">released</a> results from a six-month follow up on its Phase 3 clinical trial in the United Kingdom. The vaccine’s efficacy against Covid waned slightly to 82.7  percent. But its efficacy against severe disease remained at 100 percent.<br><br> <subhed>AUTHORIZATION</subhed> Despite the strong performance of NVX-CoV2373 in clinical trials, Novavax’s path to authorization has been long and difficult.  The company has been <a href="https://www.nytimes.com/2021/05/11/health/covid-vaccine-novavax-delays.html">dogged by delays</a> in manufacturing and has struggled to develop reliable tests of its vaccines’ quality. In August 2021, the United States government <a href="https://www.nytimes.com/2021/08/05/us/politics/novavax-coronavirus-vaccine.html">said</a> that it would not fund further production of Novavax’s vaccine until the company resolved concerns of regulators about its work. <br><br><a href="https://www.politico.com/news/2021/10/19/novavax-vaccine-rush-process-global-campaign-516298">Politico</a> reported on Oct. 19, 2021, that Novavax was still struggling to manufacture enough doses to meet its targets, causing the company’s stock to <a href="https://www.politico.com/news/2021/10/20/novavax-expresses-fresh-confidence-in-its-vaccine-516319">drop 24 percent</a>. In March 2022, the Wall Street Journal <a href="https://www.wsj.com/articles/novavaxs-covid-19-vaccine-moves-closer-to-fda-authorization-decision-11646562601">reported</a> that the company had resolved its manufacturing problems.<br><br> On March 22, 2022, India <a href="https://www.prnewswire.com/news-releases/novavax-and-serum-institute-of-india-announce-first-emergency-use-authorization-of-novavax-covid-19-vaccine-in-adolescents-12-to-18-in-india-301508279.html">authorized</a> the vaccine for use in adolescents, Novavax’s first approval in that age group. European health officials <a href="https://ir.novavax.com/2022-07-05-Novavax-Nuvaxovid-TM-COVID-19-Vaccine-Conditionally-Authorized-in-the-European-Union-for-Adolescents-Aged-12-Through-17">extended its authorization</a> to adolescents on July 5, followed by <a href="https://ir.novavax.com/2022-07-26-Novavax-Nuvaxovid-TM-COVID-19-Vaccine-Granted-Provisional-Registration-in-Australia-for-Use-in-Adolescents-Aged-12-Through-17">Australia</a> and <a href="https://ir.novavax.com/2022-07-26-Novavax-Announces-Expanded-Approval-of-Nuvaxovid-TM-COVID-19-Vaccine-for-Adolescents-Aged-12-through-17-in-Japan">Japan</a> later that month.<br><br>After the United States authorized the vaccine for adults in July 2022, it <a href="https://ir.novavax.com/U-S-Centers-for-Disease-Control-and-Prevention-Expands-Recommendation-for-Novavax-COVID-19-Vaccine,-Adjuvanted-to-Adolescents-Aged-12-Through-17">expanded</a> the authorization to adolescents the following month.<br><br> <subhed>DISTRIBUTION</subhed> Novavax reached an <a href="https://www.reuters.com/article/health-coronavirus-novavax-idUSKBN2661PI">agreement</a> in September 2020 with the Serum Institute of India, a major vaccine manufacturer. It now has an agreement with other countries, including <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-and-uk-government-announce-collaboration-and-purchase">the United Kingdom</a>, <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-and-government-canada-finalize-advance-purchase">Canada</a>, <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-finalizes-agreement-commonwealth-australia-51-million">Australia</a>, <a href="https://www.prnewswire.com/news-releases/novavax-and-israel-announce-advance-purchase-agreement-for-supply-of-covid-19-vaccine-301470553.html">Israel</a> and <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-announces-expanded-collaboration-and-license-agreement">South Korea</a>. Novavax began <a href="https://ir.novavax.com/2022-02-23-Novavax-Announces-Shipments-of-its-COVID-19-Vaccine-to-European-Union-Member-States">distributing</a> the vaccines to European Union member states on Feb. 23, 2022. But actual vaccine uptake has been slow, Reuters <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/novavaxs-covid-vaccine-rollout-eu-off-slow-start-data-2022-03-14/">reported</a> on March 14, as European Union member states have administered an “underwhelming” number of doses of the vaccine. On July 11, Novavax announced that the the United States <a href="https://ir.novavax.com/2022-07-11-U-S-Government-Secures-3-2-Million-Doses-of-Novavax-COVID-19-Vaccine">agreed</a> to purchase 3.2 million doses. But in its first month after authorization, <a href="https://twitter.com/carlzimmer/status/1560628760080154624">only 11,990 doses</a> of Novavax were administered in the United States.<br><br> <subhed>VARIANTS</subhed>Because Novavax was slow to reach clinical trials, it was one of the first companies to measure the efficacy of its vaccines against variants that emerged starting in early 2021. In a small clinical trial in South Africa, Novavax found that the Beta variant <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2103055">drastically reduced</a> the efficacy of the vaccine to less than 50 percent. That efficacy may have been unusually low because some of the volunteers in the study had H.I.V. and thus had weakened immune systems. Novavax estimated that the efficacy of the vaccine against Beta was 60 percent in people without H.I.V. On Dec. 22, Novavax <a href="https://www.prnewswire.com/news-releases/novavax-announces-initial-omicron-cross-reactivity-data-from-covid-19-vaccine-booster-and-adolescent-studies-301450099.html">announced</a> that its vaccine also lost some of its potency against the Omicron variant, but a booster shot restored much of its protection.<br><br> <subhed>BOOSTERS</subhed>On Dec. 21, 2021, Novavax <a href="https://ir.novavax.com/2021-12-21-Novavax-Announces-Initiation-of-PREVENT-19-COVID-19-Vaccine-Phase-3-Trial-Booster-Study">announced</a> that it was extending its Phase 3 clinical trial into a booster trial. They gave  volunteers a third shot of NVX-CoV2373 to observe its safety and efficacy. In a separate trial, British researchers tested Novavax’s vaccine in a “mix-and-match” trial, in which volunteers switched from one vaccine to another for a booster. The researchers <a href="https://www.nytimes.com/2021/12/02/health/covid-booster-shots-mix-and-match.html">found</a> that NVX-CoV2373 raised coronavirus antibodies to high levels.<br><br>On June 28, 2022, Novavax <a href="https://ir.novavax.com/2022-06-28-Novavax-COVID-19-Data-Presented-at-FDA-VRBPAC-Meeting-Demonstrates-Broad-Antibody-Responses-to-Both-Prototype-and-Omicron-Specific-Variants">presented</a> new data at an FDA advisory meeting on updating Covid vaccines for the winter. Both Novavax’s prototype vaccine and a Omicron-specific vaccine produced antibodies against new Omicron subvariants.<br><br>Novavax <a href="https://ir.novavax.com/2022-07-19-Novavax-Announces-Expanded-Agreement-with-SK-bioscience-to-Manufacture-COVID-19-Vaccine-Containing-Omicron-Variant-and-Manufacture-the-Novavax-COVID-19-Vaccine-in-Prefilled-Syringes">announced</a> on July 19 that it was working with SK bioscience to manufacture the Omicron-specific vaccine in pre-filled syringes as early as 2023.<br><br>On Aug. 15, 2022, Novavax <a href="https://ir.novavax.com/2022-08-15-Novavax-Submits-Application-to-the-U-S-FDA-for-Emergency-Use-Authorization-for-Novavax-COVID-19-Vaccine,-Adjuvanted-as-a-Booster-in-Adults-Aged-18-and-Older">applied</a> to the F.D.A. for authorization of its vaccine as a booster in adults.<br><br>For more details, see <strong><a href="https://www.nytimes.com/interactive/2020/health/novavax-covid-19-vaccine.html">How the Novavax Vaccine Works</a></strong>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://ir.novavax.com/2022-02-17-Health-Canada-Authorizes-Novavax-COVID-19-Vaccine">Canada</a>, <a href="https://ir.novavax.com/2022-01-12-South-Korea-Ministry-of-Food-and-Drug-Safety-Approves-Novavax-COVID-19-Vaccine">South Korea</a>.<br>


<span class="g-info">Emergency use in:</span> <a href="https://ir.novavax.com/2022-07-26-Novavax-Nuvaxovid-TM-COVID-19-Vaccine-Granted-Provisional-Registration-in-Australia-for-Use-in-Adolescents-Aged-12-Through-17">Australia</a>, <a href="https://ir.novavax.com/Novavax-Fourth-Quarter-2021-Financial-Results">Bangladesh</a>, <a href="https://covid-19pharmacovigilance.paho.org/novavax-serum-institute-of-india-sii#col-0">Iceland</a>, <a href="https://ir.novavax.com/2021-12-28-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-India">India</a>, <a href="https://ir.novavax.com/2021-11-01-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-Indonesia">Indonesia</a>, <a href="https://ir.novavax.com/2022-07-26-Novavax-Announces-Expanded-Approval-of-Nuvaxovid-TM-COVID-19-Vaccine-for-Adolescents-Aged-12-through-17-in-Japan">Japan</a>, <a href="https://covid-19pharmacovigilance.paho.org/novavax-serum-institute-of-india-sii#col-0">Mexico</a>, <a href="http://www.xinhuanet.com/english/asiapacific/20220301/b624036d1f3f4e9db27c8185b9ac3af7/c.html">New Zealand</a>, <a href="https://covid-19pharmacovigilance.paho.org/novavax-serum-institute-of-india-sii#col-0">Norway</a>, <a href="https://www.prnewswire.com/in/news-releases/novavax-and-serum-institute-of-india-receive-emergency-use-authorization-for-covid-19-vaccine-in-the-philippines-828887786.html">Philippines</a>, <a href="https://ir.novavax.com/2022-02-14-Singapore-Health-Sciences-Authority-Issues-Interim-Authorization-for-Novavax-COVID-19-Vaccine">Singapore</a>, <a href="https://ir.novavax.com/2022-04-13-Swissmedic-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine">Switzerland</a>, <a href="https://ir.novavax.com/2022-06-23-Novavax-Nuvaxovid-TM-COVID-19-Vaccine-Receives-Emergency-Use-Authorization-in-Taiwan-for-Use-in-Individuals-Aged-18-and-Over">Taiwan</a>, <a href="https://ir.novavax.com/2022-04-08-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-Novavax-COVID-19-Vaccine-in-Thailand">Thailand</a>, <a href="https://ir.novavax.com/Novavax-Fourth-Quarter-2021-Financial-Results">United Arab Emirates</a>, United Kingdom, <a href="https://www.nytimes.com/2022/07/13/health/novavax-covid-vaccine-fda-authorization.html">United States</a>. Conditional authorization in the <a href="https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu">European Union</a>. Emergency use validation from the <a href="https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries">World Health Organization</a>.<br>



</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.111.0 - 2022-07-18 11:57 -->
<!-- ai file: map-novavax.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-novavax-box ,
	#g-map-novavax-box .g-artboard {
		margin:0 auto;
	}
	#g-map-novavax-box p {
		margin:0;
	}
	#g-map-novavax-box .g-aiAbs {
		position:absolute;
	}
	#g-map-novavax-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-novavax-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-novavax-box .g-aiPointText p { white-space: nowrap; }
	#g-map-novavax-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-novavax-900 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-novavax-900 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-novavax-900 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-novavax-900 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-novavax-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-novavax-720 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-novavax-720 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-novavax-720 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-novavax-720 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-novavax-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-novavax-600 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-novavax-600 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-novavax-600 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-novavax-600 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-novavax-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-novavax-335 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-novavax-335 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-novavax-335 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-novavax-335 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}

</style>

<div id="g-map-novavax-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-novavax-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-novavax-900-img" class="g-map-novavax-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-novavax-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:0%;width:129px;">
			<p class="g-pstyle0">Novavax vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:12.7467%;margin-top:-13.4px;left:61.3435%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">EUROPEAN</p>
			<p class="g-pstyle1">UNION</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:23.1369%;margin-top:-13.4px;left:81.7046%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:22.4068%;margin-top:-6.8px;left:26.8541%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:34.7627%;margin-top:-6.8px;left:27.0393%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:35.8859%;margin-top:-6.8px;left:91.0387%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle1">PHILIPPINES</p>
		</div>
		<div id="g-ai0-7" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:47.1186%;margin-top:-6.8px;left:90.1282%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai0-8" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:47.3994%;margin-top:-6.8px;left:26.5807%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai0-9" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:48.8035%;margin-top:-6.8px;left:77.1909%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai0-10" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:58.9129%;margin-top:-6.8px;left:94.2007%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai0-11" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-12" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-novavax-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-novavax-720-img" class="g-map-novavax-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-novavax-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0153%;width:122px;">
			<p class="g-pstyle0">Novavax vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:11.7521%;margin-top:-13.4px;left:60.9825%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">EUROPEAN</p>
			<p class="g-pstyle1">UNION</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:21.9586%;margin-top:-13.4px;left:81.2618%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:22.0993%;margin-top:-6.8px;left:26.8319%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:34.7694%;margin-top:-6.8px;left:26.9403%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:35.8253%;margin-top:-6.8px;left:92.2834%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle1">PHILIPPINES</p>
		</div>
		<div id="g-ai1-7" class="g-type_copy g-aiAbs g-aiPointText" style="top:47.0876%;margin-top:-6.8px;left:26.0284%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai1-8" class="g-type_copy g-aiAbs g-aiPointText" style="top:47.4396%;margin-top:-6.8px;left:89.8829%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai1-9" class="g-type_copy g-aiAbs g-aiPointText" style="top:48.4954%;margin-top:-6.8px;left:76.8491%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai1-10" class="g-type_copy g-aiAbs g-aiPointText" style="top:58.7019%;margin-top:-6.8px;left:94.3446%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai1-11" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-12" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-novavax-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-novavax-600-img" class="g-map-novavax-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-novavax-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:2.6276%;margin-top:-8.2px;left:-0.067%;width:115px;">
			<p class="g-pstyle0">Novavax vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:11.9796%;margin-top:-13.4px;left:59.6265%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">EUROPEAN</p>
			<p class="g-pstyle1">UNION</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:21.2623%;margin-top:-13.4px;left:80.4644%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:21.853%;margin-top:-6.8px;left:27.1735%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:34.5112%;margin-top:-6.8px;left:27.1007%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:34.9331%;margin-top:-6.8px;left:93.3203%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle1">PHILIPPINES</p>
		</div>
		<div id="g-ai2-7" class="g-type g-aiAbs g-aiPointText" style="top:46.7475%;margin-top:-6.8px;left:25.1007%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai2-8" class="g-type g-aiAbs g-aiPointText" style="top:48.0133%;margin-top:-6.8px;left:89.4227%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai2-9" class="g-type g-aiAbs g-aiPointText" style="top:48.8572%;margin-top:-6.8px;left:77.2002%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai2-10" class="g-type g-aiAbs g-aiPointText" style="top:58.9838%;margin-top:-6.8px;left:93.9259%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai2-11" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-12" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-novavax-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-novavax-335-img" class="g-map-novavax-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-novavax-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:1.3081%;margin-top:-8.2px;left:0.2695%;width:115px;">
			<p class="g-pstyle0">Novavax vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:12.7698%;margin-top:-6.8px;left:53.9326%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:19.2816%;margin-top:-6.8px;left:53.9009%;margin-left:-22.5px;width:45px;">
			<p class="g-pstyle1">U.S.</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:25.5834%;margin-top:-6.8px;left:51.2127%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai3-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:50.7064%;margin-top:-13.4px;left:22.5147%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">EUROPEAN</p>
			<p class="g-pstyle1">UNION</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:56.7982%;margin-top:-13.4px;left:61.6608%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai3-7" class="g-type g-aiAbs g-aiPointText" style="top:63.8141%;margin-top:-6.8px;left:86.2086%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle1">PHILIPPINES</p>
		</div>
		<div id="g-ai3-8" class="g-type g-aiAbs g-aiPointText" style="top:70.746%;margin-top:-6.8px;left:79.56%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai3-9" class="g-type g-aiAbs g-aiPointText" style="top:71.1662%;margin-top:-6.8px;left:53.8308%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai3-10" class="g-type g-aiAbs g-aiPointText" style="top:77.258%;margin-top:-6.8px;left:88.417%;margin-left:-46px;width:92px;">
			<p class="g-pstyle1">AUSTRALIA</p>
		</div>
		<div id="g-ai3-11" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-12" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-novavax-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-07-18 11:57 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="vector"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN TURKMENISTAN</span>

<span class="g-limited">EARLY USE IN RUSSIA</span>

    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/vector-800.png" class="g-vlogo" 
    style="width: 200px; height: 29px; margin-right: 20px;" alt="Vector Institute logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> EpiVacCorona, Aurora-CoV<br>
<span class="g-info">Efficacy:</span> <a href="https://www.researchsquare.com/article/rs-1709300/v1">Not effective</a><br>
<span class="g-info">Dose:</span> 2 doses, 3 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Stable in refrigerator for up to two years<!-- +2 to +8 degrees Celsius --><br>
<br>
</span>

<!-- description -->
EpiVacCorona, also known as Aurora-CoV, was approved in Russia even before Phase 3 trials were launched. A total of <a href="https://www.themoscowtimes.com/2022/01/25/russia-halts-orders-for-2nd-covid-vaccine-vedomosti-a76137">13 million doses</a> of EpiVacCorona were produced in 2021. Even now, however, the results of the Phase 3 trial remain unpublished. Meanwhile, many critics have <a href="https://meduza.io/en/feature/2022/02/09/worse-than-ineffective">questioned</a> whether the vaccine actually works. In a study released in May 2022, the vaccine <a href="https://www.researchsquare.com/article/rs-1709300/v1">failed</a> to show any effectiveness at protecting people from lung injury due to Covid-19.<br><br>EpiVacCorona was created by  the <strong>Vector Institute</strong>, a Russian biological research center. The vaccine contains small portions of viral proteins, known as peptides. The institute <a href="https://clinicaltrials.gov/ct2/show/NCT04527575">registered</a> a Phase 1/2 trial for EpiVacCorona in August 2020, the results of which were <a href="https://www.iimmun.ru/iimm/article/view/1699#">published</a> in an obscure Russian journal in late March 2021. But outside experts pointed out <a href="https://meduza.io/en/feature/2021/03/27/sputnik-v-s-ugly-cousin">serious flaws in the study</a>. <br><br>Less than two months after the launch of the Phase 1/2 trial, <a href="https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html">on Oct. 14</a>, 2021, Vladimir Putin announced that Russia has granted regulatory approval to the vaccine, making it the second one to receive that designation after the Gamaleya Institute’s Sputnik V vaccine. The following month, a Phase 3 trial <a href="https://www.interfax.ru/russia/737432">began</a>. In January 2021, without any results yet from the trial,  Russia <a href="https://tass.com/russia/1245871">launched</a> a mass vaccination campaign that included EpiVacCorona. Critics in Russia asked the government there to <a href="https://en.newizv.ru/news/science/29-07-2021/independent-experts-ask-the-authorities-for-the-third-time-to-interrupt-the-vaccination-with-epivaccorona">stop administering the vaccine</a> until the Phase 3 trial results are published, to no avail. On July 5, 2021, Tass <a href="https://tass.com/coronavirus-outbreak-in-china/1310653">reported</a> that the Vector Institute is registering the vaccine under the name Aurora-CoV.<br><br>In February 2021, Tass reported that the immune response from EpiVacCorona lasted <a href="https://tass.com/science/1252725">“for </a><a href="https://tass.com/science/1252725">approximately</a><a href="https://tass.com/science/1252725"> a year,”</a> but the vaccine’s creators did not publish the scientific details behind this claim.<br><br>On March 3, 2021, the Vector Institute <a href="https://clinicaltrials.gov/ct2/show/NCT04780035">registered</a> their Phase 3 trial on an international registry. The entry now indicates that the trial ended in December 2021. But the Vector Institute has yet to publish the results.<br><br>In January 2022, the Moscow Times reported that Russia had <a href="https://www.themoscowtimes.com/2022/01/25/russia-halts-orders-for-2nd-covid-vaccine-vedomosti-a76137">halted</a> orders for EpiVacCorona. But the following month, Tass reported that the vaccine’s  manufacturers agreed to produce <a href="https://tass.com/economy/1395949">more than 50 million doses</a> of the vaccine for foreign companies.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://covid-19pharmacovigilance.paho.org/vector-institute#col-0">Cambodia</a>,<br>

<span class="g-info">Early use in:</span> <a href="https://tass.com/russia/1245871">Russia</a>.<br>




</span>

<span class="g-updated">Updated June 3, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.103.0 - 2022-02-08 10:05 -->
<!-- ai file: map-vector.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-vector-box ,
	#g-map-vector-box .g-artboard {
		margin:0 auto;
	}
	#g-map-vector-box p {
		margin:0;
	}
	#g-map-vector-box .g-aiAbs {
		position:absolute;
	}
	#g-map-vector-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-vector-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-vector-box .g-aiPointText p { white-space: nowrap; }
	#g-map-vector-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-vector-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-vector-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-vector-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-vector-900 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-vector-900 .g-pstyle3 {
		height:18px;
		position:relative;
	}
	#g-map-vector-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-vector-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-vector-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-vector-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-vector-720 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-vector-720 .g-pstyle3 {
		height:17px;
		position:relative;
	}
	#g-map-vector-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-vector-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-vector-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-vector-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-vector-600 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-vector-600 .g-pstyle3 {
		height:16px;
		position:relative;
	}
	#g-map-vector-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-vector-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-vector-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-vector-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-vector-335 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-vector-335 .g-pstyle3 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-vector-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-vector-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-vector-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-vector-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:-0.005%;width:121px;">
			<p class="g-pstyle0">Vector Institute</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:19.8794%;margin-top:-6.8px;left:76.7491%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">RUSSIA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:36.1668%;margin-top:-6.8px;left:74.5508%;width:120px;">
			<p class="g-pstyle2">TURKMENISTAN</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:53.2966%;margin-top:-6.8px;left:36.6784%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">VENEZUELA</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle3">Early, limited or</p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-vector-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-vector-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-vector-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0094%;width:115px;">
			<p class="g-pstyle0">Vector Institute</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:19.6357%;margin-top:-6.8px;left:76.9155%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">RUSSIA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:33.0097%;margin-top:-6.8px;left:74.1142%;width:120px;">
			<p class="g-pstyle2">TURKMENISTAN</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:53.4227%;margin-top:-6.8px;left:36.5571%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">VENEZUELA</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle3">Early, limited or </p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-vector-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-vector-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-vector-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.0735%;width:108px;">
			<p class="g-pstyle0">Vector Institute</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:19.7433%;margin-top:-6.8px;left:76.4298%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">RUSSIA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:34.0892%;margin-top:-6.8px;left:74.286%;width:120px;">
			<p class="g-pstyle2">TURKMENISTAN</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:54.3424%;margin-top:-6.8px;left:36.3869%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">VENEZUELA</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle3">Early, limited or</p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-vector-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-vector-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-vector-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2579%;width:108px;">
			<p class="g-pstyle0">Vector Institute</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:30.4147%;margin-top:-6.8px;left:73.8121%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">VENEZUELA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:55.4117%;margin-top:-6.8px;left:53.4104%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">RUSSIA</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:63.394%;margin-top:-6.8px;left:49.6855%;width:120px;">
			<p class="g-pstyle2">TURKMENISTAN</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle3">Early, limited or </p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-vector-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-02-08 10:05 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="zfsw"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN SEVERAL COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/zfsw-800.png" class="g-vlogo" 
    style="width: 144px; height: 42px; margin-right: 20px;" alt="Anhui Zhifei Longcom logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/imb-800.png" class="g-vlogo" 
    style="width: 280px; height: 41px;" alt="Institute of Medical Biology at the Chinese Academy of Medical Sciences logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> ZF2001, Zifivax<br>
<span class="g-info">Efficacy:</span> <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2202261">75.7% against symptomatic Covid-19, 87.6% against severe to critical disease</a><br>
<span class="g-info">Dose:</span> 3 doses, 4 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>

<br>
</span>

<!-- description -->
The Chinese company <strong>Anhui Zhifei Longcom </strong>and the <strong>Institute of Medical Biology at the Chinese Academy of Medical Sciences </strong>partnered to make a vaccine. Their candidate is composed of an adjuvant, along with a section of the spike protein called the receptor-binding domain.  They launched Phase 2 trials in July 2020, followed by a <a href="https://clinicaltrials.gov/ct2/show/NCT04646590?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 3 trial</a> with 29,000 volunteers in December. In March 2021, Indonesia became the first country to authorize  the vaccine, called <a href="http://www.xinhuanet.com/english/asiapacific/2021-10/07/c_1310230685.htm">Zifivax</a>, for emergency use. Anhui Zhifei received a <a href="http://www.xinhuanet.com/english/20220302/7b7c242710034972b3bbad2989fa30b0/c.html">conditional authorization</a> for the vaccine from China on March 2, 2022.<br><br>The company <a href="https://www.reuters.com/world/china/chinas-zhifei-units-covid-19-shot-shows-8176-efficacy-late-stage-trial-2021-08-27/">announced</a> on Aug. 27, 2021, that their vaccine had an efficacy rate of 82 percent against Covid-19 of any severity. In the <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2202261">final results</a> of their Phase 3 trial, published on May 5, 2022, Zifivax proved to be 75.7 percent against symptomatic Covid-19, 87.6 percent against severe to critical disease. In a follow-up trial, researchers found that a <a href="https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003953">Zifivax booster</a> produced a strong immune response from people who were initially vaccinated with a shot of CanSino’s Convidecia vaccine.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://www.reuters.com/article/health-coronavirus-china-vaccine/china-imcass-covid-19-vaccine-obtained-emergency-use-approval-in-china-idUSL4N2LD3BZ">China</a>, <a href="https://www.elespectador.com/salud/colombia-aprueba-otra-vacuna-para-el-coronavirus-zifivax-desarrollada-en-china/">Colombia</a>, <a href="https://www.reuters.com/world/asia-pacific/indonesia-approves-covid-19-vaccine-chinas-zhifei-unit-2021-10-07/">Indonesia</a>, <a href="http://en.ce.cn/Insight/202111/08/t20211108_37068436.shtml">Pakistan</a>, <a href="https://www.reuters.com/article/uzbekistan-china-coronavirus-vaccine/uzbekistan-approves-chinese-developed-covid-19-vaccine-idUSS0N2IK00P">Uzbekistan</a>.<br>



</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-04-15 12:16 -->
<!-- ai file: map-imcas.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-imcas-box ,
	#g-map-imcas-box .g-artboard {
		margin:0 auto;
	}
	#g-map-imcas-box p {
		margin:0;
	}
	#g-map-imcas-box .g-aiAbs {
		position:absolute;
	}
	#g-map-imcas-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-imcas-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-imcas-box .g-aiPointText p { white-space: nowrap; }
	#g-map-imcas-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-imcas-900 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-imcas-900 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-imcas-900 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-imcas-900 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-imcas-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-imcas-720 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-imcas-720 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-imcas-720 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-imcas-720 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-imcas-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-imcas-600 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-imcas-600 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-imcas-600 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-imcas-600 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-imcas-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-imcas-335 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-imcas-335 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-imcas-335 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-imcas-335 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}

</style>

<div id="g-map-imcas-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-imcas-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-imcas-900-img" class="g-map-imcas-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-imcas-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:-0.005%;width:162px;">
			<p class="g-pstyle0">Anhui Zhifei Longcom</p>
			<p class="g-pstyle0">and IMCAS vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:28.3039%;margin-top:-6.8px;left:71.8516%;margin-left:-50px;width:100px;">
			<p class="g-pstyle1">UZBEKISTAN</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:34.7627%;margin-top:-6.8px;left:80.9868%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:48.2419%;margin-top:-6.8px;left:74.0154%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle1">PAKISTAN</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:56.9472%;margin-top:-6.8px;left:34.9999%;margin-left:-44px;width:88px;">
			<p class="g-pstyle1">COLOMBIA</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:60.0362%;margin-top:-6.8px;left:86.1378%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai0-7" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-8" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-imcas-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-imcas-720-img" class="g-map-imcas-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-imcas-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:8.2866%;margin-top:-25.5px;left:0.0094%;width:153px;">
			<p class="g-pstyle0">Anhui Zhifei Longcom</p>
			<p class="g-pstyle0">and IMCAS</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:26.6746%;margin-top:-6.8px;left:70.3625%;margin-left:-50px;width:100px;">
			<p class="g-pstyle1">UZBEKISTAN</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:34.7694%;margin-top:-6.8px;left:80.827%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:49.1993%;margin-top:-6.8px;left:73.4059%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle1">PAKISTAN</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:57.998%;margin-top:-6.8px;left:35.2903%;margin-left:-44px;width:88px;">
			<p class="g-pstyle1">COLOMBIA</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:60.8136%;margin-top:-6.8px;left:86.3882%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai1-7" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-8" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-imcas-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-imcas-600-img" class="g-map-imcas-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-imcas-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:9.2099%;margin-top:-23.8px;left:-0.0735%;width:98px;">
			<p class="g-pstyle0">Anhui Zhifei</p>
			<p class="g-pstyle0">Longcom and</p>
			<p class="g-pstyle0">IMCAS</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:26.0724%;margin-top:-6.8px;left:69.5452%;margin-left:-50px;width:100px;">
			<p class="g-pstyle1">UZBEKISTAN</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:34.5112%;margin-top:-6.8px;left:80.957%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:50.123%;margin-top:-6.8px;left:73.3819%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle1">PAKISTAN</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:58.5618%;margin-top:-6.8px;left:35.1808%;margin-left:-44px;width:88px;">
			<p class="g-pstyle1">COLOMBIA</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:61.0935%;margin-top:-6.8px;left:86.9663%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai2-7" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-8" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-imcas-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-imcas-335-img" class="g-map-imcas-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-imcas-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:4.585%;margin-top:-23.8px;left:0.2579%;width:143px;">
			<p class="g-pstyle0">Anhui Zhifei Longcom</p>
			<p class="g-pstyle0">and IMCAS</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:32.0952%;margin-top:-6.8px;left:69.566%;margin-left:-44px;width:88px;">
			<p class="g-pstyle1">COLOMBIA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:59.4029%;margin-top:-6.8px;left:40.1203%;margin-left:-50px;width:100px;">
			<p class="g-pstyle1">UZBEKISTAN</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:63.394%;margin-top:-6.8px;left:61.8169%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:71.7963%;margin-top:-6.8px;left:47.1906%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle1">PAKISTAN</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:78.3082%;margin-top:-6.8px;left:72.9768%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai3-7" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-8" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-imcas-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-04-15 12:16 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="soberana2"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN SEVERAL COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/finlay-800.png" class="g-vlogo" 
    style="width: 195px; height: 58px; margin-right: 20px;" alt="Finlay Vaccine Institute logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Soberana 2, or PastoCoVac (in Iran)<br>
<span class="g-info">Efficacy:</span> <a href="https://www.medrxiv.org/content/10.1101/2021.10.31.21265703v1">71% with two doses</a><a href="https://www.medrxiv.org/content/10.1101/2021.10.31.21265703v1">, 92.4 % with Soberana Plus booster</a><br>



<br>
</span>

<!-- description -->
Cuba’s <strong>Finlay Vaccine Institute</strong> developed a vaccine known as <a href="https://rpcec.sld.cu/ensayos/RPCEC00000340-Sp">Soberana 2</a>. It contains a part of the coronavirus spike protein, <a href="https://twitter.com/FinlayInstituto/status/1321131664156905476">fused</a> to a standard tetanus vaccine to make it stable. Soberana 2 also contains aluminum hydroxide as an adjuvant to boost the immune system.<br><br>After <a href="https://www.biorxiv.org/content/10.1101/2021.02.08.430146v1">testing Soberana 2 in animals</a>, Finlay researchers started a Phase 1 trial in October 2020, followed by a <a href="https://rpcec.sld.cu/ensayos/RPCEC00000347-Sp">Phase 2 trial</a> in December. On March 3, 2021, the Finlay Vaccine Institute registered a <a href="https://rpcec.sld.cu/ensayos/RPCEC00000354-Sp">Phase 3 trial</a> for Soberana 2, with plans to recruit 44,010 participants in Havana. Researchers <a href="https://www.tehrantimes.com/news/460275/Iran-Cuba-vaccine-enters-phase-three-clinical-trials">began dosing trial participants</a> in Iran on April 26. The trial <a href="https://www.medrxiv.org/content/10.1101/2021.10.31.21265703v1">showed</a> that two doses of Soberana 2 have an efficacy of 71 percent against symptomatic Covid-19.<br><br>Before the Phase 3 trial delivered its results, however, the Cuban government began rolling out Soberana 2 on May 12 <a href="https://www.nytimes.com/2021/05/12/world/cuba-vaccine.html?searchResultPosition=1">in a mass vaccination campaign</a>. The government announced plans to make <a href="https://www.prensa-latina.cu/index.php?o=rn&id=425008&SEO=cuba-alista-100-millones-de-dosis-de-vacuna-anticovid-19">100 million doses</a> of Soberana 2 in order to <a href="https://www.euronews.com/2021/01/21/cuba-aims-to-immunise-its-population-this-year-with-its-own-coronavirus-vaccine">vaccinate its entire population</a>, <a href="https://www.nytimes.com/2021/02/17/world/americas/coronavirus-cuba-vaccine.html">pinning hopes</a> on the vaccine as a source of economic benefit to the island. On Dec. 13, Cuban authorities <a href="https://www.prensa-latina.cu/2021/12/13/cuba-sera-primer-pais-latinoamericano-vacunado-contra-covid-19">predicted</a> that the island nation will be the first in Latin America to completely vaccinate its population, which it expects will happen by June 2022.<br><br>Cuban scientists <a href="http://www.cubadebate.cu/noticias/2021/04/28/informan-sobre-escalado-productivo-de-candidatos-vacunales-cubanos/#anexo-1537271">also tested</a> a combination of Soberana 2 and a boost of another Cuba-made vaccine called <a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00100-X/fulltext">Soberana Plus</a>. It <a href="https://www.medrxiv.org/content/10.1101/2021.10.31.21265703v1">lifts</a> the efficacy of the vaccine to 92.4 percent, and 100 percent against severe Covid-19. The Finlay Vaccine Institute announced on June 10 that it had <a href="https://www.finlay.edu.cu/blog/soberana-pediatria-se-aprueba-inicio-de-ensayo-clinico-pediatrico/">received approval</a> to begin a trial of the combined vaccines in children. Preliminary results from the pediatric trial <a href="https://twitter.com/leticiadeCuba/status/1428009481523372040">suggest</a> the combination may be more effective in children than adults. Later results showed that Soberana 2 and Soberana Plus had an efficacy of <a href="https://twitter.com/FinlayInstituto/status/1547204230351671297">90.1 percent</a> against the Omicron variant in children.<br><br> Cuba <a href="https://associatestimes.com/cuba-begins-to-vaccinate-children-between-ages-of-2-and-18-with-soberana-2/">expanded</a> its Soberana 2 vaccination campaign to <a href="https://www.aljazeera.com/news/2021/9/17/cuba-begins-vaccinating-children-as-young-as-two-against-covid-19">include children</a> in September.<br><br>On June 29, 2021, Iran’s health minister announced that Soberana 2 has received emergency use approval. The  <strong>Pasteur Institute of Iran</strong> is marketing the vaccine in the country as <a href="https://en.irna.ir/news/84463924/Iran-Cuba-COVID-19-vaccine-proven-suitable-for-children">PastoCoVac</a>. In May 2022, Iran <a href="https://en.granma.cu/mundo/2022-05-23/iran-will-be-the-first-country-to-produce-cuban-anti-covid-vaccine-abroad">opened</a> a factory to manufacture Soberana 2 in-country.<br><br>On Aug. 20, 2021, the Cuban government <a href="https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-vacunas-cubanas-soberana-02-soberana-plus">announced</a> the <a href="https://www.cecmed.cu/covid-19/aprobaciones/soberana-02-0">emergency authorization</a> of both Soberana 2 and Soberana Plus. Just two weeks later, on September 2, Cuba authorized Soberana 2 <a href="https://www.cecmed.cu/noticias/aprueba-cecmed-autorizacion-uso-emergencia-vacuna-cubana-soberanar-02-poblacion-pediatrica">for children</a> between the age of 2 and 18. In their announcement, Cuban regulators said that the immune response in children was similar to adults who received Soberana 2. The researchers <a href="https://twitter.com/FinlayInstituto/status/1514368747120775174">said</a> in April 2022 that they will begin a study for the vaccine in infants.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-vacunas-cubanas-soberana-02-soberana-plus">Cuba</a>, <a href="https://www.finlay.edu.cu/blog/autorizo-de-emergencia-soberana-02-en-iran/">Iran</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/nicaragua-authorises-two-covid-19-vaccines-cuba-cuban-firm-says-2021-10-02/">Nicaragua</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/venezuela-begins-vaccinating-2-year-old-children-with-cuban-doses-vice-president-2021-11-08/">Venezuela</a>.<br>



</span>

<span class="g-updated">Updated July 29, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.113.0 - 2022-07-29 12:59 -->
<!-- ai file: map-soberana2.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-soberana2-box ,
	#g-map-soberana2-box .g-artboard {
		margin:0 auto;
	}
	#g-map-soberana2-box p {
		margin:0;
	}
	#g-map-soberana2-box .g-aiAbs {
		position:absolute;
	}
	#g-map-soberana2-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-soberana2-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-soberana2-box .g-aiPointText p { white-space: nowrap; }
	#g-map-soberana2-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-soberana2-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-soberana2-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-soberana2-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-soberana2-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-soberana2-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-soberana2-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-soberana2-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-soberana2-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-soberana2-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-soberana2-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-soberana2-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-soberana2-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-soberana2-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-soberana2-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-soberana2-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-soberana2-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-soberana2-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-soberana2-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-soberana2-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-soberana2-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-soberana2-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-soberana2-900-img" class="g-map-soberana2-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-soberana2-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:96px;">
			<p class="g-pstyle0">Soberana 2</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:38.1325%;margin-top:-6.8px;left:34.4262%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:39.5366%;margin-top:-6.8px;left:71.8843%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:54.139%;margin-top:-6.8px;left:31.406%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-soberana2-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-soberana2-720-img" class="g-map-soberana2-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-soberana2-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:91px;">
			<p class="g-pstyle0">Soberana 2</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:37.937%;margin-top:-6.8px;left:34.8251%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:39.3448%;margin-top:-6.8px;left:72.0354%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:54.8305%;margin-top:-6.8px;left:31.4086%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-soberana2-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-soberana2-600-img" class="g-map-soberana2-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-soberana2-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:86px;">
			<p class="g-pstyle0">Soberana 2</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:37.4648%;margin-top:-6.8px;left:35.382%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:39.5745%;margin-top:-6.8px;left:71.8481%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:55.6082%;margin-top:-6.8px;left:31.5118%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-soberana2-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-soberana2-335-img" class="g-map-soberana2-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-soberana2-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:86px;">
			<p class="g-pstyle0">Soberana 2</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:20.9621%;margin-top:-6.8px;left:69.9349%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:30.6248%;margin-top:-6.8px;left:62.7141%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:66.1247%;margin-top:-6.8px;left:44.1127%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-soberana2-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-07-29 12:59 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="abdala"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN CUBA</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/cigb-800.png" class="g-vlogo" 
    style="width: 240px; height: 41px; margin-right: 20px;" alt="Centro de Ingeniería Genética y Biotecnología de Cuba logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Abdala<br>
<span class="g-info">Efficacy:</span> <a href="https://www.nytimes.com/2021/06/22/world/americas/cuba-vaccine-abdala.html">92.28%</a><br>



<br>
</span>

<!-- description -->
In November 2020, the <strong>Center for Genetic Engineering and Biotechnology of Cuba</strong> <a href="https://www.facebook.com/CIGBCubaCuba/posts/3382131015238089">launched</a> a <a href="https://rpcec.sld.cu/ensayos/RPCEC00000346-Sp">trial</a> on a coronavirus vaccine called Abdala. The name is from a poem by the nineteenth-century poet José Marti. The Abdala vaccine consists of a piece of the coronavirus spike protein called the receptor binding domain, and is delivered in three doses. On Feb. 1, 2021, the center held a press conference <a href="http://www.cubadebate.cu/noticias/2021/02/01/inicia-en-santiago-de-cuba-ensayo-clinico-fase-ii-del-candidato-vacunal-abdala/">to announce</a> the start of a Phase 2 trial. <a href="https://rpcec.sld.cu/ensayos/RPCEC00000359-Sp">A Phase 3 trial</a> involving up to 48,000 participants was <a href="https://www.cecmed.cu/noticias/aprueba-cecmed-ensayo-clinico-fase-iii-candidato-vacunal-abdala">launched</a> on March 18. On May 12, while the Phase 3 trial was still underway, the Cuban government began rolling out Abdala <a href="https://www.nytimes.com/2021/05/12/world/cuba-vaccine.html?searchResultPosition=1">in a mass vaccination campaign</a><a href="https://www.nytimes.com/2021/05/12/world/cuba-vaccine.html?searchResultPosition=1">, in the hopes of reining in a surge of cases.</a> Venezuela began <a href="https://www.bloomberg.com/news/articles/2021-07-02/venezuela-deploys-cuban-homemade-vaccines-as-who-urges-caution">using</a> the vaccine in late June.<br><br>On June 21, 2021, Cuban officials <a href="https://www.nytimes.com/2021/06/22/world/americas/cuba-vaccine-abdala.html">reported</a> that Abdala had an efficacy of 92.28 percent. In a <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4072478">follow-up study</a> released in April 2022, Cuban researchers estimated that the Abdala vaccine has an effectiveness of about 94 percent against severe disease and death. The Cuban government granted <a href="https://www.urdupoint.com/en/world/cuban-drug-regulator-approves-homegrown-covid-1298945.html">emergency use authorization</a> for the vaccine on July 9, 2021. In September, Cuba agreed to sell 10 million doses of Abdala <a href="https://www.straitstimes.com/asia/se-asia/vietnam-to-buy-10-million-cuban-coronavirus-vaccine-doses">to Vietnam</a>, which has granted the vaccine emergency authorization. In Venezuela, meanwhile, the National Academy of Medicine <a href="https://www.nbcnews.com/news/latino/venezuela-deep-concern-use-cubas-covid-vaccine-rcna2324">expressed concern</a> over the lack of published scientific research on Abdala’s safety and efficacy.<br><br>Cuban researchers <a href="https://twitter.com/FinlayInstituto/status/1486173140053106689">announced</a> on Jan. 25, 2022, that dosing individuals with Abdala and Soberana 1 could generate an immune response against the Omicron variant. BioCubaFarma is <a href="http://en.escambray.cu/2022/cuba-has-abdala-vaccine-dossier-ready-for-who/">preparing</a> to send data from its Abdala trials to the World Health Organization to consider for an emergency use listing.<br><br>The researchers <a href="https://www.plenglish.com/news/2022/04/13/cuban-scientists-propose-new-trials-in-covid-19-vaccination-strategy/">said</a> in April 2022 that they will use Abdala and Soberana 2 in a new trial in infants.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://www.reuters.com/world/americas/cuban-drug-regulator-gives-emergency-approval-abdala-covid-19-vaccine-2021-07-09/">Cuba</a>, <a href="https://twitter.com/BioCubaFarma/status/1476302626505609218">Mexico</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/nicaragua-authorises-two-covid-19-vaccines-cuba-cuban-firm-says-2021-10-02/">Nicaragua</a>, <a href="https://www.politicallore.com/st-vincent-the-grenadines-to-use-cubas-abdala-vaccine/27626">Saint Vincent and the Grenadines</a>, <a href="https://newsinamerica.com/en/othernews/2022/cuba-donates-abdala-vaccines-against-covid-19-to-syria/">Syria</a>, <a href="https://ve.usembassy.gov/covid-19-information/">Venezuela</a>, Vietnam.<br>



</span>

<span class="g-updated">Updated April 15, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-04-15 12:19 -->
<!-- ai file: map-abdala.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-abdala-box ,
	#g-map-abdala-box .g-artboard {
		margin:0 auto;
	}
	#g-map-abdala-box p {
		margin:0;
	}
	#g-map-abdala-box .g-aiAbs {
		position:absolute;
	}
	#g-map-abdala-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-abdala-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-abdala-box .g-aiPointText p { white-space: nowrap; }
	#g-map-abdala-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-abdala-900 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-abdala-900 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-abdala-900 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-abdala-900 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-abdala-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-abdala-720 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-abdala-720 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-abdala-720 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-abdala-720 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:17px;
		height:17px;
		letter-spacing:0em;
		font-size:14px;
		top:1.1px;
		position:relative;
	}
	#g-map-abdala-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-abdala-600 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-abdala-600 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-abdala-600 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-abdala-600 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-abdala-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-abdala-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-abdala-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-abdala-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-abdala-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-abdala-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-abdala-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-abdala-900-img" class="g-map-abdala-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-abdala-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:-0.005%;width:119px;">
			<p class="g-pstyle0">Abdala vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:37.8517%;margin-top:-6.8px;left:69.1248%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">SYRIA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:38.4133%;margin-top:-6.8px;left:34.3433%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:46.557%;margin-top:-6.8px;left:24.8688%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:50.2076%;margin-top:-6.8px;left:42.0483%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">VENEZUELA</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:51.3308%;margin-top:-6.8px;left:84.1124%;margin-left:-40px;width:80px;">
			<p class="g-pstyle1">VIETNAM</p>
		</div>
		<div id="g-ai0-7" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:54.139%;margin-top:-6.8px;left:31.666%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai0-8" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-9" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-abdala-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-abdala-720-img" class="g-map-abdala-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-abdala-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0094%;width:112px;">
			<p class="g-pstyle0">Abdala vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:37.585%;margin-top:-6.8px;left:34.9013%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:39.3448%;margin-top:-6.8px;left:69.2181%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">SYRIA</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:46.0318%;margin-top:-6.8px;left:24.0413%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:50.2551%;margin-top:-6.8px;left:43.3009%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">VENEZUELA</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:52.0149%;margin-top:-6.8px;left:84.3338%;margin-left:-40px;width:80px;">
			<p class="g-pstyle1">VIETNAM</p>
		</div>
		<div id="g-ai1-7" class="g-type_copy g-aiAbs g-aiPointText" style="top:55.1824%;margin-top:-6.8px;left:31.7556%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai1-8" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-9" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-abdala-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-abdala-600-img" class="g-map-abdala-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-abdala-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:2.6276%;margin-top:-8.2px;left:0.0235%;width:106px;">
			<p class="g-pstyle0">Abdala vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:37.0428%;margin-top:-6.8px;left:35.7117%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:39.9964%;margin-top:-6.8px;left:69.1687%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">SYRIA</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:45.9036%;margin-top:-6.8px;left:23.0885%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:50.9669%;margin-top:-6.8px;left:44.5349%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">VENEZUELA</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:53.4985%;margin-top:-6.8px;left:84.4631%;margin-left:-40px;width:80px;">
			<p class="g-pstyle1">VIETNAM</p>
		</div>
		<div id="g-ai2-7" class="g-type g-aiAbs g-aiPointText" style="top:56.0302%;margin-top:-6.8px;left:31.5108%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai2-8" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-9" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-abdala-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-abdala-335-img" class="g-map-abdala-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-abdala-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:1.3081%;margin-top:-8.2px;left:0.0592%;width:106px;">
			<p class="g-pstyle0">Abdala vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:20.752%;margin-top:-6.8px;left:70.414%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:25.3733%;margin-top:-6.8px;left:45.8848%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:28.3141%;margin-top:-6.8px;left:86.4815%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">VENEZUELA</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:31.0449%;margin-top:-6.8px;left:62.7563%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:66.1247%;margin-top:-6.8px;left:38.6167%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle1">SYRIA</p>
		</div>
		<div id="g-ai3-7" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-8" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-abdala-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-04-15 12:19 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="vaxine"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN IRAN</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/vaxine-800.png" class="g-vlogo" 
    style="width: 130px; height: 71px; margin-right: 20px;" alt="Vaxine logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Covax-19, Spikogen<br>

<span class="g-info">Dose:</span> 2 doses, 3 weeks apart<br>


<br>
</span>

<!-- description -->
Flinders University endocrinologist Professor Nikolai Petrovsky developed a vaccine that combines viral proteins with an adjuvant that stimulates the immune system. Dr. Petrovsky founded the company <strong>Vaxine</strong> to develop the vaccine, called Covax-19 or Spikogen. After promising <a href="https://www.sciencedirect.com/science/article/pii/S0264410X21009920">animal studies</a>, the company launched a <a href="https://clinicaltrials.gov/ct2/show/NCT04453852?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2">Phase 1 trial</a> in June 2020. In May 2021, Vaxine <a href="https://web.archive.org/web/20210525012806/https://vaxine.net/early-promising-data-from-the-phase-1-clinical-trial-of-the-vaxines-covid-19-vaccine/">claimed</a> to have gotten promising preliminary results from that trial, but the company failed to get funds for further clinical trials in Australia. Instead, they <a href="https://vaxine.net/start-of-the-phase-2-clinical-study-of-the-vaxine-originated-covid-19-vaccine-in-iran/">followed up</a> with a <a href="https://clinicaltrials.gov/ct2/show/NCT04944368?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 2</a> trial in Iran, the results of which were <a href="https://www.clinicalmicrobiologyandinfection.com/action/showPdf?pii=S1198-743X%2822%2900207-5">published</a> in April 2022. A <a href="https://clinicaltrials.gov/ct2/show/NCT05005559?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 3</a><a href="https://clinicaltrials.gov/ct2/show/NCT05005559?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2"> trial was also carried out </a>in Iran, but those results have yet to be released.<br><br>Despite this lack of public data,  Iran issued an <a href="https://en.mehrnews.com/news/179432/Iran-issues-emergency-permit-for-new-local-Covid-19-vaccine">emergency authorization</a> for Spikogen in October 2021, to be <a href="https://vaxine.net/vaxine-cinnagen-collaboration-covid-19-vaccine-technology-under-the-tradename-spikogen-in-iran/">produced</a> by the Iranian company CinnaGen, and <a href="https://www.tasnimnews.com/fa/news/1400/10/23/2643585/%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D8%A7%D8%B3%D9%BE%D8%A7%DB%8C%DA%A9%D9%88%DA%98%D9%86-%D8%A8%D8%B1%D8%A7%DB%8C-%D8%AA%D8%B2%D8%B1%DB%8C%D9%82-%D8%A8%D9%87-%D8%B9%D9%86%D9%88%D8%A7%D9%86-%D8%AF%D9%88%D8%B2-%D8%B3%D9%88%D9%85-%D8%AA%D8%A3%DB%8C%DB%8C%D8%AF-%D8%B4%D8%AF">expanded the authorization</a> in January 2022 to include Spikogen as a booster shot. In January 2022, Dr. Petrovsky <a href="https://www.news.com.au/lifestyle/health/health-problems/australians-raise-almost-1-million-for-covax19-vaccine-but-they-may-be-better-off-getting-novavax/news-story/f24b172c37524cb508533efc00d71152">told</a> the Australian news service News.com.au that the Phase 3 trials in Iran showed Spikogen was 60 to 65 percent effective against the Delta variant. He has not published those results, however.<br><br>In late 2021, Vaxine revived its efforts to test Spikogen in Australia, but ran into <a href="https://www.spectator.com.au/2021/11/the-petrovsky-affair/">trouble</a> with regulators. Vaccine experts <a href="https://www.theguardian.com/world/2021/dec/28/questions-over-data-transparency-around-australian-doctors-1m-gofundme-covid-19-vaccine">questioned</a> the effort, since the company had yet to release detailed clinical data showing the safety and efficacy of Spikogen. Vaxine took the unprecedented move of starting a <a href="https://www.gofundme.com/f/bringing-covax19-back-to-australia?qid=b1491ff267047c9520eb1155a6323f90">crowdfunding campaign</a> in October 2021 to raise funds for their efforts. By February 2022 they had raised over $1 million. The Australian government gave Vaxine permission to submit clinical data for assessment in December 2021, and the researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05175625?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 3 trial</a> for a booster shot of Spikogen on Jan. 4, 2022. Vaxine <a href="https://www.gofundme.com/f/bringing-covax19-back-to-australia">announced</a> on Feb. 27 that they received approval to begin trials for Spikogen in Australia.<br><br>But controversy again arose on March 11, 2022, when The Australian <a href="https://www.theaustralian.com.au/nation/no-evidence-aussies-covid-vaccine-works/news-story/1557cfba472f1abf2503b12cc6ec3cef">reported</a> that the vaccine produced “no scientific evidence of efficacy” in its Phase 1 trial, according to an investigative committee. The newspaper also said that a research ethics team warned participants in November 2021 of a “low likelihood of its effectiveness.” On March 24, the Australian government <a href="https://www.tga.gov.au/media-release/vaxine-pty-ltd-fined-13320-alleged-unlawful-advertising-unapproved-covid-19-vaccine">fined</a> Vaxine for alleged unlawful advertising of an unapproved COVID-19 vaccine. On March 30, Vaxine ended the crowdfunding campaign, citing “repeated attacks from the media.” The company announced in August 2022 that it had created a version of their vaccine for animals that would be used in <a href="https://www.zooaquarium.org.au/Public/News/Articles/Veterinary-COVID-19-vaccine-available-for-zoo-animals-in-Australia.aspx">Australian zoos</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://en.mehrnews.com/news/179432/Iran-issues-emergency-permit-for-new-local-Covid-19-vaccine">Iran</a>.<br>



</span>

<span class="g-updated">Updated Aug. 31, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.102.0 - 2021-10-12 12:02 -->
<!-- ai file: map-vaxine.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-vaxine-box ,
	#g-map-vaxine-box .g-artboard {
		margin:0 auto;
	}
	#g-map-vaxine-box p {
		margin:0;
	}
	#g-map-vaxine-box .g-aiAbs {
		position:absolute;
	}
	#g-map-vaxine-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-vaxine-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-vaxine-box .g-aiPointText p { white-space: nowrap; }
	#g-map-vaxine-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-vaxine-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-vaxine-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-vaxine-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-vaxine-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-vaxine-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-vaxine-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-vaxine-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-vaxine-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-vaxine-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-vaxine-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-vaxine-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-vaxine-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-vaxine-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-vaxine-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-vaxine-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-vaxine-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-vaxine-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-vaxine-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-vaxine-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-vaxine-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-vaxine-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-vaxine-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-vaxine-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:-0.005%;width:117px;">
			<p class="g-pstyle0">Vaxine vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:39.5366%;margin-top:-6.8px;left:71.8843%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-vaxine-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-vaxine-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-vaxine-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0094%;width:111px;">
			<p class="g-pstyle0">Vaxine vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:39.3448%;margin-top:-6.8px;left:72.0354%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-vaxine-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-vaxine-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-vaxine-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:2.6276%;margin-top:-8.2px;left:-0.0735%;width:105px;">
			<p class="g-pstyle0">Vaxine vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:39.5745%;margin-top:-6.8px;left:71.8481%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-vaxine-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-vaxine-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-vaxine-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:1.3081%;margin-top:-8.2px;left:0.2579%;width:105px;">
			<p class="g-pstyle0">Vaxine vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:66.1247%;margin-top:-6.8px;left:44.1127%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-vaxine-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-10-12 12:02 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="medigen"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN TAIWAN</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/medigen-800.png" class="g-vlogo" 
    style="width: 240px; height: 49px; margin-right: 20px;" alt="Medigen logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/dynavax-800.png" class="g-vlogo" 
    style="width: 180px; height: 46px;" alt="Dynavax logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Taiwan-based vaccine maker <strong>Medigen</strong> created a vaccine containing a combination of spike proteins and an adjuvant from <strong>Dynavax</strong>. After a series of promising experiments on animals, they began injecting volunteers for a <a href="https://clinicaltrials.gov/ct2/show/NCT04487210">Phase 1 trial</a> in <a href="https://www.prnewswire.com/news-releases/medigens-covid-19-vaccine-combined-with-dynavaxs-cpg-1018-adjuvant-receives-taiwan-government-subsidy-with-first-participant-dosed-in-early-october-301150814.html">early October 2020</a>, which showed that the vaccine <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233066/">provoked</a> strong immune responses. On Dec. 30, Medigen <a href="https://focustaiwan.tw/society/202012300016">announced</a> that it had received permission to commence a <a href="https://clinicaltrials.gov/ct2/show/NCT04822025?term=vaccine&type=Intr&cond=Covid19&draw=2&rank=6">Phase 2 trial</a>. The first volunteers in the trial <a href="https://investors.dynavax.com/news-releases/news-release-details/medigen-vaccine-biologics-covid-19-vaccine-adjuvanted-dynavaxs">were injected</a> in late January 2021. In July, Medigen started another Phase 2 trial on <a href="https://clinicaltrials.gov/ct2/show/NCT04951388">children between 12 and 18 years old</a>. Medigen received <a href="https://www.taipeitimes.com/News/taiwan/archives/2021/08/01/2003761826">permission</a> to begin a <a href="https://clinicaltrials.gov/ct2/show/NCT05011526?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=4">Phase 3 trial</a> in Paraguay on July 20, 2021. The World Health Organization selected Medigen’s vaccine as one its first candidates in the <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-of-covid-19-vaccines">Solidarity Trial Vaccine study</a>.<br><br>On Oct. 15, 2021, Medigen <a href="https://clinicaltrials.gov/ct2/show/NCT05079633?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">registered a trial</a> to assess the vaccine’s effectiveness as a booster for those who have received one dose of the Moderna shot. They <a href="https://clinicaltrials.gov/ct2/show/NCT05097053?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">registered a similar trial</a> on Oct. 27 for adults with two doses of the AstraZeneca vaccine. The Coalition for Epidemic Preparedness <a href="https://cepi.net/news_cepi/cepi-and-mvc-co-fund-mix-and-match-booster-trial-of-covid-19-vaccines/">announced</a> on Dec. 2 that it pledged up to $2.3 million to help fund a mix-and-match study in which volunteers will get Medigen’s vaccine after a primary vaccination with other  Covid-19 shots. On Jan. 31, 2022, Medigen registered <a href="https://clinicaltrials.gov/ct2/show/NCT05216601">a Phase 2 trial</a> of a booster based on the Beta variant. <a href="https://www.taipeitimes.com/News/biz/archives/2021/10/04/2003765464">Animal studies</a> suggest that it might provide a broad protection against many coronavirus variants.<br><br>Taiwan granted <a href="https://www.reuters.com/world/asia-pacific/taiwan-approves-production-medigens-covid-19-vaccine-candidate-2021-07-19/">emergency use authorization</a> to the vaccine on July 19, 2021, based on Phase 2 trial results that <a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00402-1/fulltext">suggested</a> that volunteers were producing strong levels of antibodies and did not have serious adverse reactions. Taiwan <a href="https://www.nytimes.com/2021/08/23/world/asia/taiwan-homegrown-covid-vaccine.html">started administering</a> Medigen’s vaccine on Aug. 23. By Oct. 22, Medigen <a href="https://www.who.int/news-room/events/detail/2021/10/25/default-calendar/who-consultation-on-covid-19-vaccines-research-emerging-evidence-on-safety-and-the-need-for-additional-doses-of-covid-19-vaccines">said</a> that 1,362,524 doses had been administered. The company <a href="https://www.taipeitimes.com/News/biz/archives/2022/03/02/2003774006">said</a> in March 2022 that it planned to make 100 million doses this year.<br><br>In July 2022, Medigen released a <a href="https://www.medrxiv.org/content/10.1101/2022.07.14.22277617v1.full-text">report</a> on its Phase 3 trial in Paraguay. In people who had not previously had Covid, the Medigen produced significantly higher antibody levels than AstraZeneca’s vaccines. But the difference was much smaller in people who had already been infected. Additionally, the researchers found that antibodies produced by Medigen were much poorer at neutralizing the Omicron variant.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://www.scmp.com/news/china/politics/article/3167129/coronavirus-taiwans-home-grown-vaccine-approved-emergency-use">Paraguay</a>, <a href="https://www.taiwannews.com.tw/en/news/4252111">Taiwan</a>.<br>



</span>

<span class="g-updated">Updated July 23, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-04-21 14:30 -->
<!-- ai file: map-medigen.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-medigen-box ,
	#g-map-medigen-box .g-artboard {
		margin:0 auto;
	}
	#g-map-medigen-box p {
		margin:0;
	}
	#g-map-medigen-box .g-aiAbs {
		position:absolute;
	}
	#g-map-medigen-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-medigen-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-medigen-box .g-aiPointText p { white-space: nowrap; }
	#g-map-medigen-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-medigen-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-medigen-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-medigen-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-medigen-900 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-medigen-900 .g-pstyle3 {
		height:18px;
		position:relative;
	}
	#g-map-medigen-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-medigen-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-medigen-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-medigen-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-medigen-720 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-medigen-720 .g-pstyle3 {
		height:17px;
		position:relative;
	}
	#g-map-medigen-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-medigen-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-medigen-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-medigen-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-medigen-600 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-medigen-600 .g-pstyle3 {
		height:16px;
		position:relative;
	}
	#g-map-medigen-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-medigen-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-medigen-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-medigen-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-medigen-335 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-medigen-335 .g-pstyle3 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-medigen-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-medigen-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-medigen-900-img" class="g-map-medigen-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-medigen-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:78px;">
			<p class="g-pstyle0">Medigen</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:35.3243%;margin-top:-6.8px;left:86.2943%;width:72px;">
			<p class="g-pstyle1">TAIWAN</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:65.9333%;margin-top:-6.8px;left:41.8162%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle2">PARAGUAY</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle3">Early, limited or</p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-medigen-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-medigen-720-img" class="g-map-medigen-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-medigen-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:74px;">
			<p class="g-pstyle0">Medigen</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:35.1214%;margin-top:-6.8px;left:86.3067%;width:72px;">
			<p class="g-pstyle1">TAIWAN</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:66.7967%;margin-top:-6.8px;left:42.0251%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle2">PARAGUAY</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle3">Early, limited or </p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-medigen-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-medigen-600-img" class="g-map-medigen-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-medigen-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:71px;">
			<p class="g-pstyle0">Medigen</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:33.6673%;margin-top:-6.8px;left:86.1471%;width:72px;">
			<p class="g-pstyle1">TAIWAN</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:68.2665%;margin-top:-6.8px;left:41.932%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle2">PARAGUAY</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle3">Early, limited or</p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-medigen-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-medigen-335-img" class="g-map-medigen-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-medigen-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:71px;">
			<p class="g-pstyle0">Medigen</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:37.5567%;margin-top:-6.8px;left:83.543%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle1">PARAGUAY</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:63.1839%;margin-top:-6.8px;left:72.3037%;width:72px;">
			<p class="g-pstyle2">TAIWAN</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle3">Approved</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle3">Early, limited or </p>
			<p class="g-pstyle3">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-medigen-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-04-21 14:30 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="rvsr"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN IRAN</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/rvsr-800.png" class="g-vlogo" 
    style="width: 140px; height: 75px; margin-right: 20px;" alt="Razi Vaccine and Serum Research Institute logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
On Feb. 7, 2021, Iran <a href="https://www.voanews.com/covid-19-pandemic/who-urges-measures-stop-spread-covid-19-amid-vaccinations">announced</a> that it was launching <a href="https://www.irct.ir/trial/52975">a clinical trial</a> of a second vaccine, known as Cov-Pars Razi and developed by the <strong>Razi Vaccine and Serum Research Institute</strong>. The vaccine contains fragments of coronavirus spike proteins and is delivered in three doses: two injections and one nasal spray. The researchers <a href="https://www.tehrantimes.com/news/461417/Razi-Cov-Pars-enters-second-clinical-trial-phase">began dosing participants</a> for their <a href="https://en.irct.ir/trial/55238">Phase 2 trial</a> on May 28. In July Razi officials promised that they would be able to produce at least <a href="https://www.tehrantimes.com/news/463427/Cov-Pars-to-produce-1m-doses-of-vaccine-monthly">one million doses</a> of the vaccine every month. At the end of August, Iran <a href="https://www.tehrantimes.com/news/464365/COVID-19-vaccine-Razi-Cov-Pars-starts-third-clinical-trial-phase">rolled out</a> a <a href="https://en.irct.ir/trial/57980">Phase 3 trial</a>. The Tehran Times <a href="https://www.tehrantimes.com/news/465937/Nasal-dose-of-COV-Pars-reduces-virus-transmission-by-90">reported</a> on Oct. 12 that a nasal dose of the vaccine reduces the transmission of the virus by as much as 90 percent. And on Nov. 14, scientists <a href="https://www.tehrantimes.com/news/467035/Cov-Pars-causes-9-12-months-immunity-to-COVID-19">reported</a> that the vaccine stimulates immunity for up to one year. Iranian health officials granted <a href="https://www.tehrantimes.com/news/466570/Two-homegrown-vaccines-receive-emergency-use-license">emergency use authorization</a> for the vaccine on Nov. 1. Tasnim News Agency, an Iranian media outlet, <a href="https://www.tasnimnews.com/fa/news/1400/09/09/2617639/%D9%85%D8%B7%D8%A7%D9%84%D8%B9%D9%87-%D8%AF%D9%88%D8%B2-%DB%8C%D8%A7%D8%AF%D8%A2%D9%88%D8%B1-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D8%B1%D8%A7%D8%B2%DB%8C-%D8%A2%D8%BA%D8%A7%D8%B2-%D8%B4%D8%AF">reported</a> on Nov. 30 that the researchers began a booster trial comparing the vaccine against the Sinopharm shot. Tasnim later reported that Cov-Pars Razi is <a href="https://www.tasnimnews.com/fa/news/1400/11/20/2659676/%D8%A7%D8%AB%D8%B1%D8%A8%D8%AE%D8%B4%DB%8C-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D8%B1%D8%A7%D8%B2%DB%8C-3-%D8%A8%D8%B1%D8%A7%D8%A8%D8%B1-%D8%B3%DB%8C%D9%86%D9%88%D9%81%D8%A7%D8%B1%D9%85-%D8%A7%D8%B3%D8%AA-%D8%A7%D9%85%DA%A9%D8%A7%D9%86-%D8%A7%D8%B3%D8%AA%D9%81%D8%A7%D8%AF%D9%87-%D8%A7%D8%B2-%D8%AF%D9%88%D8%B2-%D8%A7%D8%B3%D8%AA%D9%86%D8%B4%D8%A7%D9%82%DB%8C-%D8%A8%D9%87-%D8%B9%D9%86%D9%88%D8%A7%D9%86-%D8%AF%D9%88%D8%B2-%D8%B3%D9%88%D9%85-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D9%87%D8%A7%DB%8C-%DA%A9%D8%B1%D9%88%D9%86%D8%A7">three times more effective</a> than the Sinopharm vaccine. The researchers <a href="https://www.tehrantimes.com/news/470305/Cov-Pars-begins-clinical-trial-on-adolescents">received approval</a> to launch a clinical trial on adolescents in February 2022. But millions of doses remain in the organization’s warehouses as it awaits payment from Iran, Tasnim News Agency <a href="https://www.tasnimnews.com/fa/news/1401/04/15/2739858/%D9%88%D8%B2%D8%A7%D8%B1%D8%AA-%D8%A8%D9%87%D8%AF%D8%A7%D8%B4%D8%AA-%D8%A8%D8%AF%D9%87%DB%8C-%D8%AE%D9%88%D8%AF-%D8%A8%D9%87-%D9%85%D8%A4%D8%B3%D8%B3%D9%87-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D8%B3%D8%A7%D8%B2%DB%8C-%D8%B1%D8%A7%D8%B2%DB%8C-%D8%B1%D8%A7-%D9%BE%D8%B1%D8%AF%D8%A7%D8%AE%D8%AA-%D9%86%DA%A9%D8%B1%D8%AF%D9%87-%D8%A7%D8%B3%D8%AA">reported</a> in July.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://www.tehrantimes.com/news/466570/Two-homegrown-vaccines-receive-emergency-use-license">Iran</a>.<br>



</span>

<span class="g-updated">Updated July 18, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.102.1 - 2021-11-26 12:08 -->
<!-- ai file: map-rvsr.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-rvsr-box ,
	#g-map-rvsr-box .g-artboard {
		margin:0 auto;
	}
	#g-map-rvsr-box p {
		margin:0;
	}
	#g-map-rvsr-box .g-aiAbs {
		position:absolute;
	}
	#g-map-rvsr-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-rvsr-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-rvsr-box .g-aiPointText p { white-space: nowrap; }
	#g-map-rvsr-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-rvsr-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-rvsr-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-rvsr-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-rvsr-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-rvsr-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-rvsr-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-rvsr-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-rvsr-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-rvsr-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-rvsr-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-rvsr-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-rvsr-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-rvsr-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-rvsr-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-rvsr-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-rvsr-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-rvsr-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-rvsr-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-rvsr-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-rvsr-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-rvsr-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-rvsr-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-rvsr-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:0%;width:102px;">
			<p class="g-pstyle0">Razi vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:39.5366%;margin-top:-6.8px;left:71.8843%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-rvsr-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-rvsr-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-rvsr-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0153%;width:96px;">
			<p class="g-pstyle0">Razi vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:39.3448%;margin-top:-6.8px;left:72.0354%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-rvsr-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-rvsr-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-rvsr-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:2.6276%;margin-top:-8.2px;left:-0.067%;width:91px;">
			<p class="g-pstyle0">Razi vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:39.5745%;margin-top:-6.8px;left:71.8481%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-rvsr-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-rvsr-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-rvsr-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:1.3081%;margin-top:-8.2px;left:0.2695%;width:91px;">
			<p class="g-pstyle0">Razi vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:66.1247%;margin-top:-6.8px;left:44.1127%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-rvsr-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-11-26 12:08 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="baylor"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN INDIA, BOTSWANA</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/baylor-800.png" class="g-vlogo" 
    style="width: 100px; height: 100px; margin-right: 20px;" alt="Baylor College of Medicine logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/texaschildrens-800.png" class="g-vlogo" 
    style="width: 140px; height: 92px; margin-right: 20px;" alt="Texas Children’s Hospital Center for Vaccine Development logo"><br><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/biologicale-800.png" class="g-vlogo" 
    style="width: 220px; height: 40px; margin-right: 20px;" alt="Biological E logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/dynavax-800.png" class="g-vlogo" 
    style="width: 180px; height: 46px;" alt="Dynavax logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Corbevax<br>
<span class="g-info">Efficacy:</span> <a href="https://www.prnewswire.com/news-releases/texas-childrens-hospital-and-baylor-college-of-medicine-covid-19-vaccine-technology-secures-emergency-use-authorization-in-india-301451215.html">Over 90%</a><br>



<br>
</span>

<!-- description -->
Corbevax is a protein-based vaccine initially <a href="https://www.biologicale.com/news.html">authorized</a> in India in December 2021, and then as a booster in June 2022. That authorization was later expanded to children as young as 5. Corbevax was also authorized in <a href="https://www.voanews.com/a/botswana-approves-texas-made-covid-vaccine-manufacturing-plant/6506456.html">Botswana</a> in March 2022.<br><br>The research that led to Corbevax was already underway years before the Covid-19 pandemic. After the SARS epidemic in 2002, <strong>Baylor College of Medicine</strong> researchers began developing a vaccine that could prevent a new outbreak. Despite promising early results, support for the research disappeared. Because the coronaviruses that cause SARS and Covid-19 are very similar, the researchers revived the project in 2020, working in partnership with the <strong>Texas Children’s Hospital</strong>.<br><br>After the Texas researchers demonstrated the promise of the vaccine in preclinical studies, the Indian company <strong>Biological E</strong> <a href="http://www.biologicale.com/news.html">licensed it</a> in August 2020, <a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329&EncHid=&userName=covid-19%20vaccine">launching</a> a Phase 1/2 trial in November, combining the viral proteins with an <a href="https://www.prnewswire.com/news-releases/biological-e-limited-starts-phase-iii-clinical-trial-of-its-covid-19-vaccine-candidate-301173314.html">adjuvant</a> made by <strong>Dynavax</strong>. On Dec. 29, Biological E and the Coalition for Epidemic Preparedness Innovations <a href="https://cepi.net/news_cepi/cepi-partners-with-biological-e-limited-to-advance-development-and-manufacture-of-covid-19-vaccine-candidate/">announced</a> a partnership to advance the development and manufacturing of the vaccine with CEPI initially contributing $5 million to the effort. The United States <a href="https://www.biologicale.com/news.html">agreed</a> to give $50 million to expand the company’s production capacity on Oct. 25.<br><br>On April 24, 2021, Biological E <a href="http://www.biologicale.com/news.html">announced</a> it was starting a Phase 3 trial of the vaccine. Biological E <a href="https://www.jagranjosh.com/current-affairs/corbevax-covid-vaccine-biological-e-vaccine-gets-dgci-approval-to-conduct-phase-23-trials-on-children-1630575934-1">received approval</a> for a Phase 2/3 trial of Corbevax on children on Sept. 2.<br><br>On Dec. 28, Biological E <a href="https://www.prnewswire.com/news-releases/texas-childrens-hospital-and-baylor-college-of-medicine-covid-19-vaccine-technology-secures-emergency-use-authorization-in-india-301451215.html">reported</a> that it performed better than Covishield, the Indian version of AstraZeneca’s vaccine, while causing half the reported side effects. Based on the level of antibodies produced by people vaccinated with Corbevax, the company <a href="https://www.medrxiv.org/content/10.1101/2022.03.08.22271822v2">estimated</a> its efficacy to be over 90 percent against the original version of the variant. <br><br>Corbevax uses standard protein-vaccination technology that’s widely available around the world, making it relatively cheap and easy to produce. Biological E said that it planned to deliver 300 million doses to the Indian government in early 2022, and deliver a billion additional doses worldwide.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://www.bnnbloomberg.ca/botswana-approves-corbevax-covid-vaccine-plans-local-output-1.1743985">Botswana</a>, <a href="https://www.prnewswire.com/news-releases/texas-childrens-hospital-and-baylor-college-of-medicine-covid-19-vaccine-technology-secures-emergency-use-authorization-in-india-301451215.html">India</a>.<br>



</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-04-15 12:34 -->
<!-- ai file: map-baylor.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-baylor-box ,
	#g-map-baylor-box .g-artboard {
		margin:0 auto;
	}
	#g-map-baylor-box p {
		margin:0;
	}
	#g-map-baylor-box .g-aiAbs {
		position:absolute;
	}
	#g-map-baylor-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-baylor-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-baylor-box .g-aiPointText p { white-space: nowrap; }
	#g-map-baylor-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-baylor-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-baylor-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-baylor-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-baylor-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-baylor-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-baylor-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-baylor-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-baylor-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-baylor-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-baylor-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-baylor-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-baylor-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-baylor-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-baylor-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-baylor-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-baylor-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-baylor-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-baylor-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-baylor-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-baylor-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-baylor-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-baylor-900-img" class="g-map-baylor-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-baylor-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:83px;">
			<p class="g-pstyle0">Corbevax</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:47.3994%;margin-top:-6.8px;left:76.9064%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:66.7757%;margin-top:-6.8px;left:59.2931%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle1">BOTSWANA</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-baylor-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-baylor-720-img" class="g-map-baylor-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-baylor-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:79px;">
			<p class="g-pstyle0">Corbevax</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:47.4396%;margin-top:-6.8px;left:76.8956%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:67.8525%;margin-top:-6.8px;left:59.4362%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle1">BOTSWANA</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-baylor-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-baylor-600-img" class="g-map-baylor-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-baylor-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:75px;">
			<p class="g-pstyle0">Corbevax</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:46.7475%;margin-top:-6.8px;left:77.057%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:68.6884%;margin-top:-6.8px;left:59.4308%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle1">BOTSWANA</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-baylor-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-baylor-335-img" class="g-map-baylor-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-baylor-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:75px;">
			<p class="g-pstyle0">Corbevax</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:70.536%;margin-top:-6.8px;left:54.5337%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:82.0892%;margin-top:-6.8px;left:19.0925%;margin-left:-46.5px;width:93px;">
			<p class="g-pstyle1">BOTSWANA</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-baylor-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-04-15 12:34 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="medicago"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN CANADA</span>



    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/medicago-800.png" class="g-vlogo" 
    style="width: 188px; height: 43px; margin-right: 20px;" alt="Medicago logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/gsk-800.png" class="g-vlogo" 
    style="width: 55px; height: 47px;" alt="GSK logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> CoVLP (brand name Covifenz)<br>
<span class="g-info">Efficacy:</span> 69.5% against symptomatic Covid-19, 78.8% against moderate-to-severe disease<br>
<span class="g-info">Dose:</span> 2 doses, 3 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Stable in refrigerator<br>
<br>
</span>

<!-- description -->
Canada-based <strong>Medicago</strong>, partly funded by the cigarette maker Philip Morris, developed a Covid-19 vaccine that can be grown in a plant called Nicotiana benthamiana, a wild species related to tobacco. They deliver coronavirus genes into leaves, and the plant cells then create protein shells that mimic the viruses. Canada <a href="https://medicago.com/en/press-release/covifenz/">authorized</a> Medicago’s vaccine, called Cofivenz, on Feb. 24, 2022.<br><br>Medicago <a href="https://www.medicago.com/en/newsroom/medicago-begins-phase-i-clinical-trials-for-its-covid-19-vaccine-candidate/">launched</a> a Phase 1 trial for Cofivenz in July 2020. In that <a href="https://www.nature.com/articles/s41591-021-01370-1">study</a>, they found that their plant-based vaccine, combined with an adjuvant made by GSK, produced promising levels of antibodies in volunteers. A Phase 2 trial also provided <a href="https://www.medrxiv.org/content/10.1101/2021.05.14.21257248v1">encouraging results</a>, followed by the launch of a <a href="https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/">24,000-person Phase 3 trial</a> on March 16, 2021. On Dec. 7, Medicago announced that Cofivenz had an <a href="https://medicago.com/en/press-release/medicago-and-gsk-announce-positive-phase-3-efficacy-and-safety-results-for-adjuvanted-plant-based-covid-19-vaccine-candidate/">efficacy of 75.3%</a> against the Delta variant. No one who got the vaccine was hospitalized or died from Covid-19, but it was not possible to estimate its efficacy against severe disease because there were relatively few cases among volunteers who received the placebo. On May 5, 2022, the final results of the Phase 3 trial were <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2201300?query=featured_home">published</a> in the New England Journal of Medicine, showing that Cofivenz had an efficacy of 69.5 percent against symptomatic Covid-19 and 78.8 percent against moderate-to-severe disease.  <br><br>Medicago said in October 2020 that it had reached <a href="https://www.medicago.com/en/newsroom/medicago-signs-agreements-with-the-government-of-canada-to-supply-up-to-76-million-doses-of-its-recombinant-plant-derived-covid-19-vaccine/">an agreement</a> with the government of Canada to supply 76 million doses. In April 2021, the Canadian government <a href="https://www.medicago.com/en/media-room/health-canada-initiates-the-review-of-the-rolling-submission-for-the-first-canadian-based-covid-19-vaccine-candidate/">announced</a> a rolling review of the company’s vaccine. After the Phase 3 results were unveiled, Medicago <a href="https://medicago.com/en/press-release/medicago-submits-phase-3-data-to-health-canada-for-its-plant-based-covid-19-vaccine-candidate/">submitted them</a> to Canadian health officials for authorization on Dec. 16, and it was authorized two months later. The company has said it also plans to seek authorization <a href="https://www.medicago.com/en/media-room/medicago-to-launch-clinical-trials-for-covid-19-vaccine-candidate-with-gsku2019s-pandemic-adjuvant-in-japan/">in Japan</a> in March 2022.<br><br>Medicago also launched an application to the World Health Organization for an emergency use listing. But on March 2, 2022, the W.H.O. rejected its request for pre-qualification, casting doubt on its ultimate success. Bloomberg <a href="https://www.bloomberg.com/news/articles/2022-03-16/medicago-covid-shot-faces-rejection-by-who-over-tobacco-links?srnd=prognosis&sref=XGjS8839">reported</a> that W.H.O. was concerned about the fact that Medicago is partly funded by a tobacco company. Medicago later <a href="https://www.who.int/teams/regulation-prequalification/eul/covid-19">withdrew</a> its application. In July 2022, CTV News <a href="https://www.ctvnews.ca/mobile/health/coronavirus/canada-not-paying-for-tobacco-company-stake-in-vaccine-maker-medicago-minister-1.5979158">reported</a> that the Canadian government was seeking a solution so that it could donate its purchased doses to low-income countries.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://www.canada.ca/en/health-canada/news/2022/02/health-canada-authorizes-medicago-covid-19-vaccine-for-adults-18-to-64-years-of-age.html">Canada</a> (for ages 18–64).<br>






</span>

<span class="g-updated">Updated July 23, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.108.0 - 2022-03-25 13:38 -->
<!-- ai file: map-medicago.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-medicago-box ,
	#g-map-medicago-box .g-artboard {
		margin:0 auto;
	}
	#g-map-medicago-box p {
		margin:0;
	}
	#g-map-medicago-box .g-aiAbs {
		position:absolute;
	}
	#g-map-medicago-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-medicago-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-medicago-box .g-aiPointText p { white-space: nowrap; }
	#g-map-medicago-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-medicago-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-medicago-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-medicago-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-medicago-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-medicago-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-medicago-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-medicago-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-medicago-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-medicago-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-medicago-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-medicago-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-medicago-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-medicago-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-medicago-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-medicago-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-medicago-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-medicago-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-medicago-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-medicago-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-medicago-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-medicago-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-medicago-900-img" class="g-map-medicago-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-medicago-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:0%;width:138px;">
			<p class="g-pstyle0">Medicago vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:22.4068%;margin-top:-6.8px;left:26.8541%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-medicago-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-medicago-720-img" class="g-map-medicago-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-medicago-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0153%;width:130px;">
			<p class="g-pstyle0">Medicago vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:22.0993%;margin-top:-6.8px;left:26.8319%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-medicago-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-medicago-600-img" class="g-map-medicago-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-medicago-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:2.6276%;margin-top:-8.2px;left:-0.067%;width:122px;">
			<p class="g-pstyle0">Medicago vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:21.853%;margin-top:-6.8px;left:27.0068%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-medicago-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-medicago-335-img" class="g-map-medicago-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-medicago-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:77px;">
			<p class="g-pstyle0">Medicago</p>
			<p class="g-pstyle0"> vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:12.7698%;margin-top:-6.8px;left:53.9326%;margin-left:-37px;width:74px;">
			<p class="g-pstyle1">CANADA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-medicago-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-03-25 13:38 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="uw"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN SOUTH KOREA</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/uw-800.png" class="g-vlogo" 
    style="width: 280px; height: 57px; margin-right: 20px;" alt="University of Washington logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/skbioscience-800.png" class="g-vlogo" 
    style="width: 161px; height: 50px; margin-right: 20px;" alt="SK Bioscience logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/gsk-800.png" class="g-vlogo" 
    style="width: 55px; height: 47px;" alt="GSK logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> SKYCovione (GBP510)<br>
<span class="g-info">Efficacy:</span> <a href="https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=123&">Stronger immune response</a> than AstraZeneca’s vaccine in a Phase 3 trial.<br>



<br>
</span>

<!-- description -->
On June 29, 2022, South Korea <a href="https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=132&">authorized</a> SKYCovione, a protein-based vaccine originally <a href="https://www.nytimes.com/2020/08/27/health/covid-19-vaccines.html">developed</a> by researchers at the <strong>University of Washington.</strong> SKYCovione is a nanoparticle studded with pieces of the coronavirus spike protein.<br><br><a href="https://www.cell.com/cell/fulltext/S0092-8674(20)31450-1">Experiments on mice</a> showed that it could produce a strong immune response. The South Korean vaccine company <strong>SK Bioscience </strong><a href="https://newsroom.uw.edu/news/ultrapotent-covid-19-vaccine-candidate-designed-computer">licensed</a> the vaccine and <a href="https://www.skbioscience.co.kr/kr/news/news_01_01?mode=view&id=40&">partnered with GSK</a>, to launch a <a href="https://clinicaltrials.gov/ct2/show/NCT04742738">Phase 1/2 trial </a>of the vaccine in February 2021. Genetic Engineering and Biotechnology News <a href="https://www.genengnews.com/virology/coronavirus/six-up-and-coming-covid-19-vaccines/">reported</a> that people who received the vaccines made five to eight times more antibodies than people who recovered from Covid-19. SK Bioscience received <a href="https://cepi.net/news_cepi/cepi-and-sk-bioscience-expand-partnership-to-advance-multiple-covid-19-variant-vaccines-and-scale-up-manufacturing/">$210.1 million</a> from the Coalition for Epidemic Preparedness Innovations for the development of SKYCovione. In August 2021, the <a href="https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=88&">company</a> launched <a href="https://clinicaltrials.gov/ct2/show/NCT05007951?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=5">a Phase 3 trial</a>, <a href="https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94344?xid=nl_covidupdate_2021-09-03&eun=g1270317d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=DailyUpdate_090321&utm_term=NL_Gen_Int_Daily_News_Update_active">comparing</a> the vaccine to AstraZeneca’s Vaxzevria vaccine.<br><br>In January 2022, the Korean Biomedical Review <a href="http://www.koreabiomed.com/news/articleView.html?idxno=12979">reported</a> that SK Bioscience was preparing to supply GBP51o to South Korea and the COVAX facility. The company <a href="http://www.koreabiomed.com/news/articleView.html?idxno=13299">applied</a> for emergency use authorization in <a href="http://www.koreabiomed.com/news/articleView.html?idxno=14281">the United Kingdom</a> in March 2022. <br><br>On April 25, 2022, SK Bioscience <a href="https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=123&">announced</a> the results of its Phase 3 trial. They found that volunteers who received the vaccine produced a stronger immune response than people who received the AstraZeneca vaccine. In older people, the results were also promising. SKYCovione produced antibodies against the coronavirus in <a href="https://www.gsk.com/en-gb/media/press-releases/sk-bioscience-and-gsk-s-adjuvanted-covid-19-vaccine-candidate-meets-coprimary-objectives-in-a-phase-iii-study/">95 percent</a> of volunteers 65 or older. The AstraZeneca vaccine only produced antibodies in 79 percent.<br><br>With SKYCovione going into use, SK Bioscience <a href="https://clinicaltrials.gov/ct2/show/NCT05501522">launched</a> a Phase 3 trial of the vaccine as a booster on August 15, 2022. It is also developing a “variant-proof” vaccine based on the same nanoparticle design, with a <a href="https://cepi.net/news_cepi/cepi-expands-partnership-with-sk-bioscience-to-develop-a-variant-proof-vaccine-against-sars-cov-and-sars-cov-2-variants/">$50 million grant</a> from CEPI.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug 26, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.111.0 - 2022-07-01 10:44 -->
<!-- ai file: map-uw.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-uw-box ,
	#g-map-uw-box .g-artboard {
		margin:0 auto;
	}
	#g-map-uw-box p {
		margin:0;
	}
	#g-map-uw-box .g-aiAbs {
		position:absolute;
	}
	#g-map-uw-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-uw-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-uw-box .g-aiPointText p { white-space: nowrap; }
	#g-map-uw-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-uw-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-uw-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-uw-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-uw-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-uw-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-uw-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-uw-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-uw-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-uw-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-uw-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-uw-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-uw-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-uw-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-uw-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-uw-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-uw-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-uw-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-uw-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-uw-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-uw-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-uw-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-uw-900-img" class="g-map-uw-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-uw-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:100px;">
			<p class="g-pstyle0">SKYCovione</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:30.9998%;margin-top:-13.4px;left:88.2081%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-uw-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-uw-720-img" class="g-map-uw-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-uw-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:95px;">
			<p class="g-pstyle0">SKYCovione</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:30.4053%;margin-top:-13.4px;left:88.9444%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-uw-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-uw-600-img" class="g-map-uw-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-uw-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:90px;">
			<p class="g-pstyle0">SKYCovione</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:30.9669%;margin-top:-13.4px;left:89.6865%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-uw-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-uw-335-img" class="g-map-uw-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-uw-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:90px;">
			<p class="g-pstyle0">SKYCovione</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:61.8396%;margin-top:-13.4px;left:79.2383%;margin-left:-32.5px;width:65px;">
			<p class="g-pstyle1">SOUTH</p>
			<p class="g-pstyle1">KOREA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-uw-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-07-01 10:44 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="sanofi2"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/sanofi-800.png" class="g-vlogo" 
    style="width: 200px; height: 50px; margin-right: 20px;" alt="Sanofi logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/gsk-800.png" class="g-vlogo" 
    style="width: 55px; height: 47px;" alt="GSK logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Vidprevtyn<br>
<span class="g-info">Efficacy:</span> 57.9% against symptomatic Covid-19 (in a trial dominated by variants of concern). 75% efficacy against moderate or severe Covid-19. <a href="https://www.nytimes.com/live/2022/02/23/world/covid-19-tests-cases-vaccine/a-new-covid-vaccine-shows-100-percent-efficacy-against-severe-disease-and-hospitalizations-its-makers-say">100% against severe disease and hospitalization</a>.<br>
<span class="g-info">Dose:</span> 2 doses, 3 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Stable in refrigerator at 36–46°F (2–8°C)<br>
<br>
</span>

<!-- description -->
In early 2020, <strong>Sanofi</strong> developed a Covid-19 vaccine based on viral proteins they produced with engineered viruses that grow inside insect cells. <strong>GSK</strong> supplemented these proteins with adjuvants that stimulate the immune system. The vaccine, called Vidprevtyn, is based on the same design Sanofi used to create <a href="https://sanofiflu.com/flublok-quadrivalent-influenza-vaccine.html">Flublok</a>, an approved vaccine for influenza. On Feb. 23, 2022, Sanofi announced that it would s<a href="https://www.sanofi.com/en/media-room/press-releases/2022/2022-02-23-11-15-00-2390091">eek regulatory approval</a> after trials showed it can protect against Covid-19 and produces a strong response as a booster.<br><br>The companies <a href="https://www.sanofi.com/en/media-room/press-releases/2020/2020-09-03-07-00-00">launched</a> a Phase 1/2 clinical trial on Vidprevtyn in September 2020.  At the time, the vaccine was widely expected to play a major role in tackling the pandemic. In the United States, Operation Warp Speed selected it as one of six vaccines to secure in large quantities, reaching a <a href="https://www.nytimes.com/2020/07/31/health/covid-19-vaccine-sanofi-gsk.html">$2.1 billion agreement </a><a href="https://www.nytimes.com/2020/07/31/health/covid-19-vaccine-sanofi-gsk.html">for</a> 100 million doses. On Sept. 18 Sanofi closed another deal <a href="https://www.sanofi.com/en/media-room/press-releases/2020/2020-09-18-12-52-46">with the European Union for 300 million doses</a> for an unspecified amount, and later reached <a href="https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-sign-agreements-with-the-government-of-canada-to-supply-up-to-72-million-doses-of-adjuvanted-covid-19-vaccine/">an agreement</a> with Canada for up to 72 million doses. In addition, Sanofi agreed to provide <a href="https://www.sanofi.com/en/media-room/press-releases/2020/2020-10-28-07-00-00">200 million doses</a> to COVAX, an international collaboration to deliver the vaccine equitably across the world. The company expected to move to a Phase 3 trial in December and potentially seek emergency use authorization for Vidprevtyn in the United States by spring 2021. Sanofi announced plans to make up to one billion doses in 2021.<br><br>But on Dec. 11, 2020, Sanofi and GSK <a href="https://www.nytimes.com/live/2020/12/10/world/covid-19-coronavirus/sanofi-and-glaxosmithkline-delay-plans-for-a-trial-after-experimental-vaccine-fails-in-some-older-patients">announced</a> that Vidprevtyn was proving disappointing. While it provided promising levels of antibodies in people under 50, older people did not respond as strongly as they had hoped. The company halted the trial. In January 2021, Sanofi <a href="https://www.fiercepharma.com/pharma/sanofi-after-r-d-setback-lends-a-hand-to-vaccine-rival-pfizer-for-coronavirus-shot">decided</a> to help Pfizer and BioNTech make 100 million doses of their vaccine, and they reached <a href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-22-11-40-00-2179318">a similar agreement</a> with Johnson & Johnson in February.<br><br>Meanwhile, Sanofi developed a stronger formulation of Vidprevtyn. On Feb. 22, 2021, the company <a href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-22-11-40-00">launched</a> a new <a href="https://clinicaltrials.gov/ct2/show/NCT04762680">Phase 2 trial</a>, which <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00764-7/fulltext">showed</a> that the new version <a href="https://www.nytimes.com/2021/05/17/business/sanofi-glaxosmithkline-vaccine-trial.html">produced</a> strong immune responses. They began <a href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-05-27-07-30-00-2236989">enrolling participants</a> for their <a href="https://clinicaltrials.gov/ct2/show/study/NCT04904549">Phase 3 trial</a> on May 27. On July 20, 2021, the European Medicines Agency started a <a href="https://www.ema.europa.eu/en/news/ema-starts-rolling-review-covid-19-vaccine-vidprevtyn">rolling review</a> of Vidprevtyn in advance of their application for authorization. In an earnings report on Oct. 28, Sanofi <a href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-10-28-07-30-00-2322319">said</a> it expected results from its new Phase 3 trial by the end of 2021, but on Dec. 15, the company announced  the trial would <a href="https://www.nytimes.com/live/2021/12/14/world/covid-omicron-vaccines#sanofis-long-delayed-vaccine-showed-promise-as-a-booster">continue into early 2022</a> because too few participants have gotten sick with Covid-19.<br><br>Finally, in February 2022, Sanofi had results to share. They found that Vidprevtyn had an efficacy of 57.9 percent against symptomatic Covid-19. This relatively low result may have been the result of the trial taking place after variants of concerns were widespread. The vaccine offered stronger  protection against developing a serious case of Covid-19; it had an efficacy of 100 percent versus severe Covid-19 and hospitalizations.<br><br>Sanofi has also developed a version of Vidprevtyn that is based on the Beta variant of the coronavirus. After giving the vaccine as a booster to volunteers, they <a href="https://www.sanofi.com/en/media-room/press-releases/2022/2022-06-13-05-30-00-2460833">found</a> that it could provoke strong antibodies to other variants, including Omicron. Preliminary data from the tral  <a href="https://www.gsk.com/en-gb/media/press-releases/sanofi-gsk-first-to-report/">demonstrated an efficacy</a> of 64.7 percent against symptomatic Covid-19 and 72 percent against Omicron. In June 2022, the company registered a Phase 3 <a href="https://clinicaltrials.gov/ct2/show/NCT05405283">trial</a> of the Beta booster.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 29, 2022</span>

</p>

<a name="sichuan"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/sichuan-800.png" class="g-vlogo" 
    style="width: 290px; height: 58px; margin-right: 20px;" alt="West China Hospital of Sichuan University logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In July 2020, researchers at <strong>West China Hospital of Sichuan University</strong> published a <a href="https://www.nature.com/articles/s41586-020-2599-8">study</a> in Nature describing a vaccine made from the RBD region of the spike protein that could protect mice and monkeys from the coronavirus. To make the vaccine, researchers encoded the RBD region in a gene, which they inserted into a virus. They then infected insect cells with the virus, causing them to make the molecule in huge amounts. On Aug. 24, they <a href="http://en.nhc.gov.cn/2020-08/26/c_81483.htm">launched</a> a Phase 1 trial, and on Nov. 16 they moved to <a href="http://www.chictr.org.cn/showprojen.aspx?proj=64449">Phase 2</a> with a study on 960 volunteers. On Jan. 22, 2021, the researchers  registered <a href="https://clinicaltrials.gov/ct2/show/NCT04718467">another Phase 2 trial</a> with 4,000 volunteers. A <a href="https://clinicaltrials.gov/ct2/show/NCT04887207">Phase 3 trial</a> began on June 1.<br><br> The researchers <a href="https://clinicaltrials.gov/ct2/show/NCT05463354?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">registered</a> a Phase 2 trial for the vaccine as a booster on July 19.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 23, 2022</span>

</p>

<a name="nanogen"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/nanogen-800.png" class="g-vlogo" 
    style="width: 160px; height: 44px; margin-right: 20px;" alt="Nanogen Biopharmaceutical logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Nanocovax<br>
<span class="g-info">Efficacy:</span> 51% against symptomatic Covid from the Delta variant, 93.9 percent against severe illness and death<br>



<br>
</span>

<!-- description -->
On Dec. 10, 2020, <strong>Nanogen Biopharmaceutical</strong> in Vietnam <a href="https://nanogenpharma.com/tin-tuc/viet-nam-chinh-thuc-thu-nghiem-vaccine-covid19-tu-1012-147.html">began</a> recruiting 60 volunteers for a <a href="https://clinicaltrials.gov/ct2/show/NCT04683484">Phase 1 trial</a> of their protein-based vaccine Nanocovax. Vietnam news agencies <a href="https://en.vietnamplus.vn/many-elderly-people-join-2nd-stage-of-nano-covax-vaccine-trials/197139.vnp">announced</a> that Nanocovax entered a Phase 2 trial in February 2021. Nanogen researchers <a href="https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(22)00089-X/fulltext">reported</a> that in these early studies, the vaccine did not cause any dangerous side effects and promising levels of antibodies. In June, Nanogen <a href="https://en.vietnamplus.vn/homegrown-nano-covax-vaccine-enters-thirdphase-trial/202932.vnp">launched</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT04922788">Phase 3 trial</a>. <a href="http://www.koreabiomed.com/news/articleView.html?idxno=12808">Promising preliminary results</a> from the trial have pushed the company to accelerate the process for emergency use authorization in Vietnam. The <a href="https://www.medrxiv.org/content/10.1101/2022.03.22.22272739v1">full analysis</a> of the Phase 3 trial, published on March 23, 2022, found that Nanocovax has an efficacy rate of 93.3 percent against severe illness and death, and an efficacy against symptoms amid the Delta variant of 51.5 percent. In August Vietnam’s Dan Tri news <a href="https://dantri.com.vn/suc-khoe/vaccine-covid-19-noi-nanocovax-va-4-ung-vien-khac-hien-nhu-the-nao-20220812053854158.htm">reported</a> that regulators there were still reviewing the vaccine.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 12, 2022</span>

</p>

<a name="livzon"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/livzon-800.png" class="g-vlogo" 
    style="width: 140px; height: 46px; margin-right: 20px;" alt="Livzon Pharmaceutical Group logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/biophysics-800.png" class="g-vlogo" 
    style="width: 240px; height: 45px;" alt="Institute of Biophysics logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> V-01<br>
<span class="g-info">Efficacy:</span> <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4066508">47%</a> against disease, as a booster<br>



<br>
</span>

<!-- description -->
A subsidiary of Chinese company <strong>Livzon Pharmaceutical Group</strong> has developed a protein vaccine in collaboration with the <strong>Institute of Biophysics</strong> at the Chinese Academy of Sciences. Called V-01, the vaccine completed Phase 1 and 2 trials earlier in 2021. A <a href="https://clinicaltrials.gov/ct2/show/NCT05096845?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 3 trial</a> began in <a href="https://www.thestar.com.my/aseanplus/aseanplus-news/2021/08/30/chinese-covid-19-vaccine-v-01-enters-phase-iii-trials-in-philippines">the Philippines</a> on Aug. 25 and <a href="https://tass.com/society/1358867">expanded to Russia</a> in November.<br><br>Livzon also  <a href="https://clinicaltrials.gov/ct2/show/NCT05050474?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">registered</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT05239832?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">series</a> of <a href="https://clinicaltrials.gov/ct2/show/NCT05273528?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">booster studies. </a>In June 2022, the company released <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4066508">results</a> of one of these trials, which found that their booster had an efficacy of 47 percent.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>

<a name="lanzhou"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/lanzhou-800.png" class="g-vlogo" 
    style="width: 300px; height: 49px; margin-right: 20px;" alt="Lanzhou Institute of Biological Products logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/zhengzhou-800.png" class="g-vlogo" 
    style="width: 180px; height: 48px;" alt="Zhengzhou University logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at the <strong>Lanzhou Institute of Biological Products</strong>, <strong>Beijing Zhong Sheng Heng Yi Pharmaceutical Technology </strong>and <strong>Zhengzhou University </strong>are testing a vaccine that is grown in Chinese hamster ovary cells. They registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04869592?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 1/2 trial</a> on May 3, 2021. In October 2021 they <a href="https://clinicaltrials.gov/ct2/show/NCT05069129?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=14">registered</a> a Phase 3 trial to test their vaccine as a booster for an inactivated virus vaccine.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Oct. 19, 2021</span>

</p>

<a name="shionogi"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/shionogi-800.png" class="g-vlogo" 
    style="width: 185px; height: 34px; margin-right: 20px;" alt="Shionogi logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/niid-800.png" class="g-vlogo" 
    style="width: 240px; height: 37px; margin-right: 20px;" alt="National Institute of Infectious Diseases logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/kyushu-800.png" class="g-vlogo" 
    style="width: 170px; height: 52px;" alt="Kyushu University logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>Shionogi</strong>, a Japanese pharmaceutical giant, <a href="https://www.shionogi.com/global/en/news/2020/12/201216.html">launched</a> a Phase 1/2 trial of a coronavirus vaccine on Dec. 16, 2020. The company developed it in collaboration with the <strong>National Institute of Infectious Diseases</strong> and <strong>Kyushu University</strong>. The vaccine is based on a coronavirus protein which is produced in insect cells by genetically altered viruses. They combined the protein with an adjuvant to stimulate the immune system.<br><br>For months, the trial <a href="https://www.japantimes.co.jp/news/2021/03/17/national/shionogi-vaccine/">advanced slowly</a> and ultimately delivered disappointing results. In the summer, Shionogi <a href="https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/presentation/2021/e_20210802_final.pdf">switched</a> to a new adjuvant and started a new Phase 1/2 trial in August 2021. Results from the trial, <a href="https://www.shionogi.com/jp/ja/news/2021/12/211207.html">released</a> on Dec. 7, proved more encouraging, showing  that the vaccine produced levels of antibodies on par with those in people who recovered from Covid-19. On Oct. 21, the company <a href="https://www.shionogi.com/global/en/news/2021/10/e-211021.html">announced</a> that it had moved to a Phase 2/3 trial. In May 2022, it <a href="https://www.shionogi.com/global/en/news/2022/05/e-20220516.html">expanded</a> the trial to include volunteers as young as 12.<br><br>In December 2021, Shionogi also started trials of their vaccine as a <a href="https://www.shionogi.com/jp/ja/news/2021/12/211203.html">booster</a>. On March 4, 2022, the company <a href="https://www.shionogi.com/global/en/news/2022/03/e20220304.html">announced</a> that one of the trials <a href="https://www.medrxiv.org/content/10.1101/2022.03.03.22271827v1">demonstrated</a> that people who get the Shionogi vaccine produced antibody levels on par with a Pfizer-BioNTech booster.<br><br>Shionogi President Isao Teshirogi <a href="https://asia.nikkei.com/Spotlight/Coronavirus/COVID-vaccines/Shionogi-to-file-as-soon-as-June-for-COVID-shot-green-light">said</a> in May 2022 that the company could send data to the Japanese government for authorization as early as June, but that month passed without any further developments.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 23, 2022</span>

</p>

<a name="noora"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN IRAN</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/baqiyatallah-800.png" class="g-vlogo" 
    style="width: 190px; height: 82px; margin-right: 20px;" alt="Baqiyatallah University of Medical Sciences logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Iranian researchers at the <strong>Baqiyatallah University of Medical Sciences</strong> developed a protein-based vaccine against the coronavirus. On June 27, 2021, the Islamic Revolutionary Guard Corps <a href="https://www.tehrantimes.com/news/462470/IRGC-starts-clinical-trial-of-Noora-coronavirus-vaccine">announced</a> that the vaccine, called Noora, had entered Phase 1 trials. The researchers registered a <a href="https://en.irct.ir/trial/59156">Phase 2 trial</a> on Oct. 11. The head of Baqiyatallah University of Medical Sciences said in December that <a href="https://www.tasnimnews.com/fa/news/1400/09/17/2622286/5-%D9%85%DB%8C%D9%84%DB%8C%D9%88%D9%86-%D8%AF%D9%88%D8%B2-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D9%86%D9%88%D8%B1%D8%A7-%D8%AA%D9%88%D9%84%DB%8C%D8%AF-%D8%B4%D8%AF">5 million doses</a> of the vaccine have been produced. Noora entered <a href="https://www.tehrantimes.com/news/468703/IRGC-s-Noora-vaccine-begins-third-phase-of-human-trial">Phase 3 trials</a> on Jan. 2. <a href="https://www.tasnimnews.com/fa/news/1400/10/12/2636826/%D9%81%DB%8C%D9%84%D9%85-%D8%AC%D8%B2%D8%A6%DB%8C%D8%A7%D8%AA-%D9%81%D8%A7%D8%B2-%D8%B3%D9%88%D9%85-%D8%AA%D8%B3%D8%AA-%D8%A7%D9%86%D8%B3%D8%A7%D9%86%DB%8C-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D9%86%D9%88%D8%B1%D8%A7">dosing</a> a commander of the Islamic Revolutionary Guard Corps as the first participant. After <a href="https://www.tehrantimes.com/news/469983/IRGC-s-Noora-vaccine-awaiting-emergency-use-license">completing</a> Phase 3 trials, Noora received <a href="https://www.tehrantimes.com/news/470601/Noora-vaccine-receives-emergency-use-license">emergency use authorization</a> from the Iranian government, the Tehran Times reported on March 1, 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://www.tehrantimes.com/news/470601/Noora-vaccine-receives-emergency-use-license">Iran</a>.<br>



</span>

<span class="g-updated">Updated March 1, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.106.0 - 2022-03-02 11:17 -->
<!-- ai file: map-noora.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-noora-box ,
	#g-map-noora-box .g-artboard {
		margin:0 auto;
	}
	#g-map-noora-box p {
		margin:0;
	}
	#g-map-noora-box .g-aiAbs {
		position:absolute;
	}
	#g-map-noora-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-noora-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-noora-box .g-aiPointText p { white-space: nowrap; }
	#g-map-noora-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-noora-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-noora-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-noora-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-noora-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-noora-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-noora-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-noora-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-noora-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-noora-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-noora-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-noora-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-noora-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-noora-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-noora-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-noora-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-noora-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-noora-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-noora-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-noora-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-noora-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-noora-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-noora-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-noora-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:0%;width:114px;">
			<p class="g-pstyle0">Noora vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:39.5366%;margin-top:-6.8px;left:71.8843%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-noora-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-noora-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-noora-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0153%;width:107px;">
			<p class="g-pstyle0">Noora vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:39.3448%;margin-top:-6.8px;left:72.0354%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-noora-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-noora-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-noora-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:2.6276%;margin-top:-8.2px;left:-0.067%;width:101px;">
			<p class="g-pstyle0">Noora vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:39.5745%;margin-top:-6.8px;left:71.8481%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-noora-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-noora-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-noora-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:1.3081%;margin-top:-8.2px;left:0.2695%;width:101px;">
			<p class="g-pstyle0">Noora vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:66.1247%;margin-top:-6.8px;left:44.1127%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-noora-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-03-02 11:17 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="vaxxinity"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/vaxxinity-800.png" class="g-vlogo" 
    style="width: 240px; height: 60px; margin-right: 20px;" alt="Vaxxinity logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Dallas-based <strong>Vaxxinity</strong> is testing a vaccine called UB-612 containing parts of several viral proteins. (Vaxxinity <a href="https://vaxxinity.com/news_media/covaxx-and-united-neuroscience-are-now-vaxxinity/">formed</a> in April 2021 when the companies COVAXX and United Neuroscience combined.)<br><br>On Sept. 11, 2020, COVAXX <a href="https://clinicaltrials.gov/ct2/show/NCT04545749">registered</a> a Phase 1 trial in Taiwan which <a href="https://www.businesswire.com/news/home/20210208005198/en/COVAXX%E2%80%99s-COVID-19-Vaccine-UB-612-Induced-Neutralizing-Antibodies-in-100-of-Participants-During-Phase-1-Clinical-Trial">led to</a> 100 percent of volunteers producing antibodies without any serious side effects. In February 2021, COVAXX launched a <a href="https://www.prnewswire.com/news-releases/covaxx-announces-initiation-of-phase-2-clinical-trials-in-taiwan-of-ub-612-vaccine-candidate-against-covid-19-301220506.html">Phase 2 trial</a>, also in Taiwan, as well as a <a href="https://clinicaltrials.gov/ct2/show/NCT04683224">Phase 2/3 trial</a> in Brazil, India and other countries. On Nov. 25, 2021, Covaxx <a href="https://www.businesswire.com/news/home/20201125005466/en/COVAXX-Announces-2.8-Billion-Advance-Purchase-Commitments">announced</a> agreements with countries including Brazil, Ecuador, and Peru to deliver more than 140 million doses for $2.8 billion. In a <a href="https://www.businesswire.com/news/home/20210621005250/en/Vaxxinity-Signs-Purchase-Order-with-the-Government-of-Paraguay-for-1-Million-Doses-of-Vaxxinity%E2%80%99s-UB-612-COVID-19-Vaccine">June 21, 2021 press release</a>, Vaxxinity said it expected to deliver the vaccine by the end of the summer, but in August, Taiwan regulators <a href="https://www.reuters.com/world/asia-pacific/taiwan-denies-approval-ubis-covid-19-vaccine-candidate-2021-08-16/">rejected</a> their application for emergency authorization. In Vaxxinity’s October 2021 <a href="https://www.sec.gov/Archives/edgar/data/0001851657/000119312521295612/d142511ds1.htm">filing</a> for an initial public offering, the company said it was appealing the decision.<br><br>On February 11, 2022, Vaxxinity announced that antibodies taken from volunteers in their Phase 1 and 2 trials were potent <a href="https://ir.vaxxinity.com/news-releases/news-release-details/vaxxinitys-covid-19-vaccine-candidate-ub-612-produces-high">against the Omicron variant</a>. In the announcement the company said it was planning a Phase 3 trial for later in 2022. In an <a href="https://www.prnewswire.com/news-releases/united-biomedical-asia-ubi-asia-announces-phase-12-and-phase-1-extension-trial-results-of-multitope-sars-cov-2-vaccine-published-in-the-journal-of-clinical-investigation-301518318.html">April announcement</a> the company presented further evidence demonstrating that the vaccine can  protect against variants.<br><br>The company <a href="https://clinicaltrials.gov/ct2/show/NCT05293665?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">registered</a> a Phase 3 trial on March 24, 2022 comparing a booster dose of UB-612 with vaccines from Sinopharm, AstraZeneca and Pfizer and BioNTech, and <a href="https://finance.yahoo.com/news/vaxxinity-announces-first-participant-dosed-120000973.html">began dosing participants</a> on March 28. The Coalition for Epidemic Preparedness Innovations said on April 7 that it would <a href="https://finance.yahoo.com/news/cepi-co-fund-vaxxinity-pivotal-204300289.html">help fund trials</a> for UB-612, pledging up to $9.25 million.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 8, 2022</span>

</p>

<a name="hipra"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/hipra-800.png" class="g-vlogo" 
    style="width: 150px; height: 24px; margin-right: 20px;" alt=" logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at Spanish animal health company <strong>HIPRA</strong> have created a recombinant protein vaccine against the coronavirus in humans. They registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05007509?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=7">Phase 1/2 trial</a> for their candidate on Aug. 16, 2021, followed by a <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005226-26">Phase 2/3 trial</a> on Nov. 15. On Feb. 1, 2022, Spanish health authorities <a href="https://whtc.com/2022/02/01/spanish-regulator-authorises-phase-iii-trials-of-hipras-covid-vaccine/">authorized</a> HIPRA researchers to move to Phase 3.<br><br> They are also testing the vaccine in children, adolescents and immunocompromised individuals, according to a <a href="https://www.irsicaixa.es/es/actualidad/el-proyecto-europeo-rbdcov-estudiara-la-vacuna-de-hipra-contra-la-covid-19-en-ninos">press release</a> from January 2022.<br><br>The researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05246137?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 3 booster trial</a> on Feb. 18, 2022. On July 6, 2022, HIPRA released a <a href="https://www.medrxiv.org/content/10.1101/2022.07.05.22277210v2">study</a> measuring the levels of antibodies its booster produced against different variants. They found that those levels were as high or higher than those of a Comirnaty booster.<br><br>On Aug. 2, the European Commission inked a deal with HIPRA for its member states to buy <a href="https://medicalxpress.com/news/2022-08-eu-spanish-covid-vaccine.html">as many as 250 million doses</a> of the vaccine, pending authorization, for use as a booster.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 6, 2022</span>

</p>

<a name="clover"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-phase3 ">

<!-- phases -->








<span class="g-phase2">PHASE 2</span> <span class="g-phase3">PHASE 3</span> <span class="g-combined">COMBINED PHASES</span>

<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/clover-800.png" class="g-vlogo" 
    style="width: 220px; height: 52px; margin-right: 20px;" alt="Clover Biopharmaceuticals logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/dynavax-800.png" class="g-vlogo" 
    style="width: 180px; height: 46px;" alt="Dynavax logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> SCB-2019<br>
<span class="g-info">Efficacy:</span> 79% against disease from the Delta variant, 100% against hospitalization<br>
<span class="g-info">Dose:</span> 2 doses, 3 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Stable at 2-8 degrees C for 6 months, room temperature for one month<br>
<br>
</span>

<!-- description -->
<strong>Clover Biopharmaceuticals</strong> developed a vaccine containing the spike protein from coronaviruses. To further stimulate the immune system, the company combined the proteins with so-called adjuvants made by British drugmaker <strong>GSK</strong> and the American company <strong>Dynavax</strong>. Clover’s formulation looks to be especially durable; the vaccine can sit out at room temperature for a month and remain viable. <a href="https://cepi.net/news_cepi/cepi-extends-partnership-with-clover-to-fund-covid-19-vaccine-candidate-through-global-phase-2-3-study-to-licensure/">Investments from the Coalition for Epidemic Preparedness</a> supported the development of manufacturing that could lead to the production of a billion doses a year. On June 30, 2021, Clover <a href="https://www.cloverbiopharma.com/news/75.html">announced</a> an agreement to provide 400 million doses to COVAX, the initiative to deliver vaccines to low- and middle-income countries. CEPI <a href="https://cepi.net/news_cepi/cepi-and-clover-expand-partnership-for-covid-19-vaccine-to-include-evaluation-as-a-booster/">pledged</a> an additional $36.9 million toward the development of the vaccine on Nov. 18.<br><br>Clover launched a Phase 1 trial in June 2020, and in December the company <a href="http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=53">announced</a> that the vaccine triggered <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00241-5/fulltext">a high level of antibodies</a>. It registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04672395">Phase 2/3 trial</a> with the GSK adjuvant, but in February 2021 the company <a href="https://www.prnewswire.com/news-releases/clover-and-dynavax-announce-planned-global-phase-23-efficacy-trial-of-adjuvanted-covid-19-vaccine-candidate-301218633.html">announced</a> it was <a href="https://www.reuters.com/article/health-coronavirus-clover-gsk/chinas-clover-ends-covid-19-vaccine-partnership-with-gsk-idUSL1N2K70OA">canceling</a> the study. Instead, it <a href="https://investors.dynavax.com/news-releases/news-release-details/clover-biopharmaceuticals-and-dynavax-announce-first">moved forward</a> with a trial with the Dynavax adjuvant. On Sept. 22, Clover announced that the trial showed their vaccine has an efficacy of <a href="https://www.prnewswire.com/news-releases/clovers-covid-19-vaccine-candidate-demonstrates-79-efficacy-against-delta-in-global-phase-23-spectra-trial-dominated-by-variants-of-concern-and-interest-301382628.html?tc=eml_cleartime">79 percent</a> against disease from Delta variant, and a 100 percent efficacy against hospitalization. The results were <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00055-1/fulltext">published</a> in the Lancet in January 2022. Clover continued to follow its trial volunteers and <a href="https://ir.cloverbiopharma.com/news-releases/news-release-details/clovers-covid-19-vaccine-candidate-demonstrates-durable-high">reported</a> that five months after the second dose, the vaccine’s efficacy was little changed. On Aug. 25, 2022, the company <a href="https://ir.cloverbiopharma.com/news-releases/news-release-details/clover-announces-positive-phase-23-results-adolescents-its-covid">announced</a> that the vaccine produced twice as many antibodies in adolescents than in young adults, which may translate into a greater protection against the coronavirus. <br><br>In February 2022, Clover announced that in 2022 it plans to seek authorization from the World Health Organization, the European Medicines Agency, and other regulators to use their vaccine as a <a href="https://ir.cloverbiopharma.com/news-releases/news-release-details/clover-provides-corporate-update-and-2022-priorities">universal booster</a>. The company reported that its booster produced three times the antibodies as an AstraZeneca booster. Later, on June 27, Clover said that the vaccine provided <a href="https://www.biospace.com/article/releases/clover-s-covid-19-vaccine-candidate-demonstrates-strong-cross-neutralization-against-omicron-as-a-homologous-booster/?keywords=COVID+19+vaccine">a boost of antibodies</a> against the Omicron variant when used as a third dose in individuals who have already received two doses.<br><br>Clover has created several updated versions of its vaccine that may offer better <a href="https://ir.cloverbiopharma.com/news-releases/news-release-details/clovers-bivalent-covid-19-vaccine-candidate-demonstrates-broad">protection</a> against new variants of the coronavirus. On May 31, 2022, the company <a href="https://ir.cloverbiopharma.com/news-releases/news-release-details/clover-doses-first-participants-phase-1-trial-scb-2020s">announced</a> that one of these new vaccines had entered a Phase 1 trial.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>

<a name="jiangsu"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-phase3 ">

<!-- phases -->








<span class="g-phase2">PHASE 2</span> <span class="g-phase3">PHASE 3</span> <span class="g-combined">COMBINED PHASES</span>

<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/recbio-800.png" class="g-vlogo" 
    style="width: 190px; height: 46px; margin-right: 20px;" alt="Jiangsu Rec-Biotechnology logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Scientists at <strong>Jiangsu Rec-Biotechnology </strong>have developed a vaccine, called ReCOV, that is made of viral proteins that are grown in Chinese hamster ovary cells. They registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04818801">Phase 1 trial</a> in New Zealand on March 26, 2021. Preliminary results from the trial <a href="https://www.prnewswire.com/news-releases/recbio-announces-promising-preliminary-results-from-first-in-human-study-of-a-covid-19-vaccine-candidate-with-novel-adjuvant-bfa03-301422205.html">suggest</a> that the vaccine was effective at generating immunity. On Sept. 29, Jiangsu <a href="https://www.prnewswire.com/news-releases/recbio-and-rhegen-signed-an-mrna-vaccine-cooperation-agreement-301387683.html">announced</a> that it would merge with Shenzhen Rhegen Biotechnology to become a new company called Wuhan Rhecogen Biotechnology. The company  registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05084989?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2">Phase 2/3 trial</a> in late 2021, and in January 2022 it <a href="https://www.prnewswire.com/news-releases/the-philippines-has-approved-recov-for-phase-iiiii-cinical-trial-301461886.html">announced</a> that the trial had been approved to start in the Philippines. It <a href="https://www.prnewswire.com/news-releases/receipt-of-approval-from-the-uae-for-phase-iiiii-clinical-trial-of-sequential-booster-vaccination-for-recov-301524546.html">received approval</a> to expand the trial to the U.A.E. in April and to <a href="https://www.prnewswire.com/news-releases/clinical-trial-approval-for-recov-in-the-prc-and-the-overseas-clinical-trial-progress-of-recov-301540351.html">China</a> in May.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>

<a name="akston"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-phase3 ">

<!-- phases -->








<span class="g-phase2">PHASE 2</span> <span class="g-phase3">PHASE 3</span> <span class="g-combined">COMBINED PHASES</span>

<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/akston-800.png" class="g-vlogo" 
    style="width: 230px; height: 41px; margin-right: 20px;" alt="Akston Biosciences logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Massachusetts-based <strong>Akston Biosciences</strong> has developed a vaccine that targets a part of the coronavirus spike protein called the receptor-binding domain. Researchers at Akston say that focusing on this section is an efficient way to boost immunity against new variants. They began a Phase 1/2 trial of their vaccine, known as AKS-452, on April 12. After <a href="https://www.businesswire.com/news/home/20210708005267/en/Akston-Biosciences-Announces-Positive-Phase-I-Data-for-Second-Generation-COVID-19-Vaccine-Candidate">positive results</a> from the Phase 1 trial, Akston <a href="https://www.businesswire.com/news/home/20210805005859/en/Akston-Biosciences-Doses-First-Subjects-in-Phase-II-Clinical-Trial-of-Second-Generation-Protein-Subunit-COVID-19-Vaccine">announced</a> that it began dosing participants in its Phase 2 trial on Aug. 5. On Nov. 20, the company said that it had dosed the first 100 patients in another <a href="https://www.akstonbio.com/press-release-11-19-2021/">Phase 2 trial in India</a>. <a href="https://www.clinicaltrialsarena.com/news/akston-covid-vaccine-trial/">Positive results</a> from the trial, released on Dec. 22, suggested that the vaccine could produce a significant immune response without adverse reactions. They <a href="https://www.businesswire.com/news/home/20220329005811/en/Akston-Biosciences-Receives-Regulatory-Approval-for-Phase-II-Clinical-Trial-for-Shelf-Stable-COVID-19-Vaccine-Booster">expanded</a> the study into a Phase 2/3 trial with 1,500 volunteers in 2022, <a href="https://www.akstonbio.com/press-release-04-07-22/">dosing the first participants</a> in India on April 7, 2022. <a href="https://www.businesswire.com/news/home/20220624005219/en/Biolexis-and-Akston-Biosciences-Announce-Encouraging-Top-Line-Results-from-Phase-IIIII-Trial-of-their-Thermostable-2nd-Gen-COVID-19-Vaccine">Results</a> from the trial suggest that the vaccine could safely help produce antibodies against variants of concern.. Akston <a href="https://www.marketscreener.com/quote/stock/STRIDES-PHARMA-SCIENCE-LI-9743222/news/Akston-Biosciences-and-Biolexis-Collaborate-to-Launch-a-Room-Temperature-Stable-2nd-Generation-COVID-39791108/">announced</a> on March 17 that it had signed a licensing agreement with Biolexis to produce and market the vaccine across the world under the name AmbiVax-C.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 29, 2022</span>

</p>

<a name="yisheng"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-phase3 ">

<!-- phases -->








<span class="g-phase2">PHASE 2</span> <span class="g-phase3">PHASE 3</span> <span class="g-combined">COMBINED PHASES</span>

<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/yishengbio-800.png" class="g-vlogo" 
    style="width: 190px; height: 48px; margin-right: 20px;" alt="Yisheng Biopharma logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at Chinese company <strong>Yisheng Biopharma </strong>have combined their adjuvant technology with proteins grown from Chinese hamster ovary cells to build a vaccine that targets the coronavirus. Yisheng’s C.E.O. told the <a href="https://www.scmp.com/news/china/science/article/3147760/chinese-covid-19-vaccine-gets-uae-nod-therapeutic-use-trial">South China Morning Post</a> that the vaccine only requires one week between doses. The company <a href="https://www.prnewswire.com/news-releases/yishengbio-announces-pika-recombinant-covid-19-vaccine-received-phase-i-clinical-trial-ind-clearance-from-the-uae-301336132.html">received clearance</a> to begin a Phase 1 trial in the U.A.E. in July 2021. And in August, they <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382358&isReview=true">registered a Phase 1 trial</a> in New Zealand. The South China Morning Post <a href="https://www.scmp.com/news/china/science/article/3147760/chinese-covid-19-vaccine-gets-uae-nod-therapeutic-use-trial">also reported</a> in September that the U.A.E. has authorized <a href="https://clinicaltrials.gov/ct2/show/NCT05305300?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">a trial for the vaccine</a> to be used in those who are already infected with Covid-19 or have received other vaccines.<br><br>In July 2022, Yisheng <a href="https://clinicaltrials.gov/ct2/show/NCT05463419">registered</a> a Phase 2/3 trial to start the following month.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 23, 2022</span>

</p>

<a name="soberanaplus"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-approved ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN CUBA</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/finlay-800.png" class="g-vlogo" 
    style="width: 195px; height: 58px; margin-right: 20px;" alt="Finlay Vaccine Institute logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Cuban researchers at <strong>Finlay Vaccine Institute </strong>have also developed a single-dose vaccine called Soberana Plus. Like its other candidates, Soberana Plus targets the part of the coronavirus known as the RBD and contains an adjuvant. But Finlay researchers are <a href="https://twitter.com/DagmarGarciaCub/status/1380689602336452608">specifically tailoring this vaccine</a> to people who have already had Covid-19 — <a href="https://as.com/diarioas/2021/04/12/actualidad/1618218667_899707.html">a first of its kind</a>. They say that such a strategy can help prevent reinfection and limit the spread of new variants. After positive <a href="https://www.sciencedirect.com/science/article/pii/S2667193X21000752">results</a> from a Phase 1 trial, Finlay received approval to begin a <a href="https://rpcec.sld.cu/trials/RPCEC00000366-En">Phase 2 trial</a> among Covid-19 survivors on April 9. Cuban regulators <a href="https://twitter.com/FinlayInstituto/status/1442990809041801218">allowed</a> Finlay to expand the trial to include children on Sept. 28. Researchers are also <a href="https://rpcec.sld.cu/trials/RPCEC00000397-En">conducting the Phase 2 trial</a> in Italy and plan to compare the results to those in Cuba. Results from that Phase 2 trial, <a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00100-X/fulltext">released</a> on June 9, 2022, showed that the vaccine significantly boosted the immunity that the participants already had.<br><br>Scientists <a href="http://www.cubadebate.cu/noticias/2021/04/28/informan-sobre-escalado-productivo-de-candidatos-vacunales-cubanos/#anexo-1537271">have reported</a> that combining two doses of Soberana 2 with one dose of Soberana Plus has yielded solid results in adults and in <a href="https://www.medrxiv.org/content/10.1101/2022.03.03.22271313v1">children</a>.<br><br>On Aug. 20, 2021, the Cuban government <a href="https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-vacunas-cubanas-soberana-02-soberana-plus">announced</a> the <a href="https://www.cecmed.cu/covid-19/aprobaciones/soberana-02-0">emergency authorization</a> of both Soberana 2 and Soberana Plus. Reuters <a href="https://www.reuters.com/world/americas/cuba-deploy-chinas-sinopharm-alongside-homegrown-vaccines-2021-08-28/">reported</a> later that month that Cuba would begin importing Sinopharm vaccines to make up for their lagging vaccination campaign, combining it with a Soberana Plus booster. Cuban regulators gave <a href="https://twitter.com/BioCubaFarma/status/1441190670731984896">emergency authorization</a> for the use of Soberana Plus in Covid-19 survivors on Sept. 23. On Dec. 7, health officials <a href="http://www.cubadebate.cu/noticias/2021/12/07/cecmed-aprueba-autorizo-de-uso-en-emergencia-de-soberana-plus-para-poblacion-pediatrica-mayor-de-dos-anos-convaleciente-de-covid-19/">expanded</a> the authorization to include child survivors older than two.<br><br>On July 27, 2022, Belarus <a href="https://twitter.com/FinlayInstituto/status/1552263580308889602">gave</a> emergency use authorization to the vaccine, becoming the first country in Europe to do so.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://twitter.com/FinlayInstituto/status/1552263580308889602">Belarus</a>, <a href="https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-vacunas-cubanas-soberana-02-soberana-plus">Cuba</a>, <a href="https://twitter.com/FinlayInstituto/status/1479143877227515908">Nicaragua</a>.<br>



</span>

<span class="g-updated">Updated July 29, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase2 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.113.0 - 2022-07-29 12:58 -->
<!-- ai file: map-soberanaplus.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-soberanaplus-box ,
	#g-map-soberanaplus-box .g-artboard {
		margin:0 auto;
	}
	#g-map-soberanaplus-box p {
		margin:0;
	}
	#g-map-soberanaplus-box .g-aiAbs {
		position:absolute;
	}
	#g-map-soberanaplus-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-soberanaplus-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-soberanaplus-box .g-aiPointText p { white-space: nowrap; }
	#g-map-soberanaplus-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-soberanaplus-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-soberanaplus-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-soberanaplus-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-soberanaplus-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-soberanaplus-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-soberanaplus-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-soberanaplus-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-soberanaplus-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-soberanaplus-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-soberanaplus-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-soberanaplus-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-soberanaplus-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-soberanaplus-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-soberanaplus-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-soberanaplus-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-soberanaplus-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-soberanaplus-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-soberanaplus-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-soberanaplus-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-soberanaplus-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-soberanaplus-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-soberanaplus-900-img" class="g-map-soberanaplus-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-soberanaplus-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:115px;">
			<p class="g-pstyle0">Soberana Plus</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-900 g-aiAbs g-aiPointText" style="top:25.4957%;margin-top:-6.8px;left:69.6175%;margin-left:-39.5px;width:79px;">
			<p class="g-pstyle1">BELARUS</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:38.1325%;margin-top:-6.8px;left:34.4262%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:54.139%;margin-top:-6.8px;left:31.5811%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-soberanaplus-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-soberanaplus-720-img" class="g-map-soberanaplus-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-soberanaplus-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:109px;">
			<p class="g-pstyle0">Soberana Plus</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-720 g-aiAbs g-aiPointText" style="top:26.3227%;margin-top:-6.8px;left:69.4328%;margin-left:-39.5px;width:79px;">
			<p class="g-pstyle1">BELARUS</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:37.937%;margin-top:-6.8px;left:34.8251%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:54.8305%;margin-top:-6.8px;left:31.5788%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-soberanaplus-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-soberanaplus-600-img" class="g-map-soberanaplus-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-soberanaplus-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:103px;">
			<p class="g-pstyle0">Soberana Plus</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-600 g-aiAbs g-aiPointText" style="top:26.4943%;margin-top:-6.8px;left:69.7236%;margin-left:-39.5px;width:79px;">
			<p class="g-pstyle1">BELARUS</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:37.4648%;margin-top:-6.8px;left:35.382%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:55.1863%;margin-top:-6.8px;left:32.0444%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-soberanaplus-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-soberanaplus-335-img" class="g-map-soberanaplus-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-soberanaplus-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:103px;">
			<p class="g-pstyle0">Soberana Plus</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:20.9621%;margin-top:-6.8px;left:69.9349%;margin-left:-28px;width:56px;">
			<p class="g-pstyle1">CUBA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:30.8349%;margin-top:-6.8px;left:62.2912%;margin-left:-48px;width:96px;">
			<p class="g-pstyle1">NICARAGUA</p>
		</div>
		<div id="g-ai3-4" class="g-335 g-aiAbs g-aiPointText" style="top:59.1928%;margin-top:-6.8px;left:39.0487%;margin-left:-39.5px;width:79px;">
			<p class="g-pstyle1">BELARUS</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-soberanaplus-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-07-29 12:58 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="tubitak"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/metu-800.png" class="g-vlogo" 
    style="width: 290px; height: 34px; margin-right: 20px;" alt="Middle East Technical University logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/bilkent-800.png" class="g-vlogo" 
    style="width: 210px; height: 45px; margin-right: 20px;" alt="Bilkent University logo"><br><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/tubitak-800.png" class="g-vlogo" 
    style="width: 50px; height: 67px; margin-right: 20px;" alt="TUBITAK logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/nobel-800.png" class="g-vlogo" 
    style="width: 46px; height: 67px;" alt="Nobel İlaç logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
A team of Turkish researchers at <strong>Middle East Technical University </strong>and <strong>Bilkent University</strong> have <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653174/">developed</a> a vaccine that is made up of virus-like particles. Each particle carries four of the coronavirus proteins. On March 26, 2021, they registered a small <a href="https://clinicaltrials.gov/ct2/show/NCT04818281?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1 trial</a> sponsored by TUBITAK, the <strong>Scientific and Technological Research Council of Turkey</strong>. The researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04962893?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 2 trial</a> of the vaccine on July 15.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 3, 2022</span>

</p>

<a name="zerunbio"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/zerun-800.png" class="g-vlogo" 
    style="width: 221px; height: 28px; margin-right: 20px;" alt="Shanghai Zerun Biotechnology logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/walvax-800.png" class="g-vlogo" 
    style="width: 200px; height: 29px;" alt="Walvax Biotechnology logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Chinese researchers at <strong>Shanghai Zerun Biotechnology </strong>and <strong>Walvax Biotechnology </strong>have modified the structure of the coronavirus spike protein to better stimulate an immune response from their vaccine. They registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04982068?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1 trial</a> for their prototype vaccine, called ZR-202-CoV, in China on July 29. On Aug. 4, they registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04990544?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 2 trial</a>. ZerunBio and Walvax announced on July 21 that they are also <a href="https://cepi.net/news_cepi/cepi-partners-with-shanghai-zerun-biotech-to-develop-covid-19-variant-vaccine/">partnering</a> with <strong>CEPI</strong>, the Coalition for Epidemic Preparedness Innovations, to support the development of ZR-202-CoV and to create a variant vaccine using the same technology. CEPI <a href="https://cepi.net/news_cepi/cepi-shanghai-zerun-biotech-and-walvax-biotech-expand-collaboration-to-develop-covid-19-multi-variant-vaccine/">expanded its partnership</a> with the two companies on Feb. 8, 2022, to support another Phase 1/2 trial in Africa for a multi-variant vaccine.<br><br>The researchers started a <a href="https://clinicaltrials.gov/ct2/show/NCT05313022?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1/2 trial</a> for the vaccine in adults 60 and older on Jan. 18, 2022. On Aug. 5, another <a href="https://clinicaltrials.gov/ct2/show/NCT05490108?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1/2 trial</a> began, comparing ZR-202-CoV and a booster vaccine called ZR-202a-CoV to Comirnaty.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>

<a name="bavarian"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/bavarian-800.png" class="g-vlogo" 
    style="width: 150px; height: 76px; margin-right: 20px;" alt="Bavarian Nordic logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
As part of the European Union-funded <strong>PREVENT-nCoV</strong> consortium, a team of biotechnology companies and research laboratories developed a vaccine against Covid-19. It contains a coronavirus protein called nucleocapsid. The vaccine, called ABNCoV2, uses technology from consortium members AdaptVac and ExpreS<sup style="font-size: 50%; line-height: 100%; vertical-align: super;">2</sup>ion, among others. After promising preclinical results in primates, <strong>Bavarian Nordic </strong><a href="https://www.bavarian-nordic.com/investor/news/news.aspx?news=6178">launched</a> a Phase 1/2 trial of the vaccine in the Netherlands. <a href="https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-updates-on-its-pipeline-outlook--including-for-covid-19-and-her2-breast-cancer-projects,c3306811">The first volunteers</a> received doses of the vaccine on March 15, 2021. On Aug. 9, the researchers said that the trial showed ABNCoV2 <a href="https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_9ba81a232e644e6cb7137629d24584d8.pdf">produced high levels of antibodies without dangerous side effects</a>.<br><br>Later that month, Bavarian Nordic <a href="https://view.news.eu.nasdaq.com/view?id=b2990620f9697f3fecb6a816bdbc726c9&lang=en">launched</a> <a href="https://clinicaltrials.gov/ct2/show/NCT05077267?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=4">Phase 2 trials</a> of the vaccine, both as an initial protection against Covid-19 and as a booster for other vaccines. Positive results from the trial, <a href="https://www.bavarian-nordic.com/investor/news/news.aspx?news=6440">released</a> Dec. 5 and <a href="https://www.marketscreener.com/quote/stock/EXPRES2ION-BIOTECH-HOLDIN-61747258/news/Additional-positive-Phase-II-COVID-19-results-presented-for-the-ABNCoV2-vaccine-39605603/">bolstered with more data</a> on Feb. 28, 2022, suggest that the vaccine is effective as a booster. In June, Bavarian Nordic <a href="https://www.marketscreener.com/quote/stock/EXPRES2ION-BIOTECH-HOLDIN-61747258/news/Updated-Phase-III-trial-for-the-ABNCoV2-COVID-19-vaccine-to-include-a-licensed-mRNA-vaccine-40742142/">announced</a> its upcoming Phase 3 trial would compare its vaccine as a booster against Pfizer-BioNTech’s Comirnaty vaccine. The trial will start in August 2022, and Bavarian Nordic <a href="https://endpts.com/bavarian-nordic-to-test-its-covid-19-booster-against-pfizer-biontech-shot-in-pivotal-study/">anticipates</a> gaining approval for the vaccine as early as 2023.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 29, 2022</span>

</p>

<a name="tubingen"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/tubingen-800.png" class="g-vlogo" 
    style="width: 220px; height: 57px; margin-right: 20px;" alt="University of Tübingen logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In early 2020, researchers at the <strong>University of Tübingen</strong> in Germany <a href="https://www.researchgate.net/publication/341298976_Designing_a_therapeutic_SARS-CoV-2_T-cell-inducing_vaccine_for_high-risk_patient_groups">created</a> a vaccine made of eight parts of two viral proteins, along with an immune-stimulating adjuvant. Most Covid-19 vaccines are designed to make the immune system produce strong antibodies. By contrast, the Tübingen team crafted their vaccine, called CoVac-1, to stimulate the production of T cells, which can attack infected cells. The researchers created CoVac-1 to help people with a deficiency in antibody-producing B cells. On Nov. 23, 2021, they published a <a href="https://www.nature.com/articles/s41586-021-04232-5">paper</a> in Nature demonstrating that their Phase 1 trial produced strong T cell responses that last for at least three months. The vaccine is <a href="https://www.medizin.uni-tuebingen.de/de/das-klinikum/pressemeldungen/452">currently</a> in a Phase 2 trial. On April 13, 2022, Indian news outlet Financial Express <a href="https://www.financialexpress.com/lifestyle/health/new-covid-19-vaccine-covac-1-offers-better-protection-to-immunocompromised-patients-study-reveals/2490617/">reported</a> that the researchers are preparing to move to Phase 3 trials. The researchers <a href="https://www.medizin.uni-tuebingen.de/de/das-klinikum/pressemeldungen/492?press_str=">said</a> in June that they are also looking for immunocompromised adults for a future study.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>

<a name="mambisa"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/cigb-800.png" class="g-vlogo" 
    style="width: 240px; height: 41px; margin-right: 20px;" alt="Centro de Ingeniería Genética y Biotecnología de Cuba logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In addition to their Abdala vaccine, the <strong>Center for Genetic Engineering and Biotechnology of Cuba</strong> <a href="https://www.facebook.com/CIGBCubaCuba/posts/3382131015238089">announced</a> on Nov. 26, 2020 that it was beginning a <a href="https://rpcec.sld.cu/ensayos/RPCEC00000345-Sp">Phase 1 trial</a> of a second vaccine, this one delivered as a nasal spray. Known as Mambisa, the vaccine contains a piece of the coronavirus spike protein called the receptor-binding domain, along with a protein from the hepatitis B virus that stimulates the immune system.  The name refers to women who fought in Cuba’s nineteenth-century wars of independence. Mambisa is one of two Cuban vaccines tested in a <a href="https://www.plenglish.com/index.php?o=rn&id=69737&SEO=second-clinical-trial-in-convalescents-of-covid-19-begins-in-cuba">Phase 1/2 clinical trial</a> to assess their ability to increase immunity in those who have already had Covid-19. That trial <a href="https://www.plenglish.com/news/2021/11/03/phase-ii-of-anti-covid-19-trial-for-convalescents-began-in-cuba/">moved to Phase 2</a> in November. After releasing <a href="https://twitter.com/BioCubaFarma/status/1484967029102759941">promising results</a> from the trial, the researchers <a href="http://www.correodelorinoco.gob.ve/avanzan-en-cuba-ensayos-del-candidato-vacunal-anticovid-mambisa/">announced</a> in January 2022 that they would continue evaluating the vaccine in human trials. Cuban health authorities <a href="https://twitter.com/CIGBCuba/status/1462092428442230794?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1462092428442230794%7Ctwgr%5E%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Foncubanews.com%2Fen%2Fcuba%2Fcuba-clinical-trial-for-booster-dose-with-mambisa-vaccine-candidate-approved%2F">approved</a> a trial for Mambisa as a booster dose on Nov. 20. Cuban news outlets <a href="https://www.laprensalatina.com/cuba-conducts-clinical-trials-of-nasal-covid-19-vaccine/">reported</a> on March 30 that the developers could apply for authorization for Mambisa’s use as a booster in the coming weeks.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 3, 2022</span>

</p>

<a name="baiya"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/baiya-800.png" class="g-vlogo" 
    style="width: 160px; height: 64px; margin-right: 20px;" alt="Baiya Phytopharm logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Scientists at Thai startup <strong>Baiya Phytopharm</strong> have created a vaccine that uses plant-based technology to develop immunity. They <a href="https://clinicaltrials.gov/ct2/show/NCT04953078?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=4">registered</a> a Phase 1 trial on July 7, 2021, and started the study in September. In November, the researchers said that <a href="https://www.chula.ac.th/en/news/55782/">Phase 2 trials were underway</a>.<br><br>Baiya is also working on a<a href="https://www.chula.ac.th/en/news/55782/"> second-generation version of its plant-based vaccine</a> to address variants.In August 2022, the company <a href="https://baiyaphytopharm.com/announces-preliminary-results-of-the-phase-1/">announced</a> Phase 1 results suggested the vaccine is safe.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>

<a name="vido"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/vido-800.png" class="g-vlogo" 
    style="width: 170px; height: 39px; margin-right: 20px;" alt="Vaccine and Infectious Disease Organization logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> COVAC<br>
<span class="g-info">Efficacy:</span> Unknown<br>
<span class="g-info">Dose:</span> 2 doses, 4 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>

<br>
</span>

<!-- description -->
The <strong>Vaccine and Infectious Disease Organization</strong> at the University of Saskatchewan has developed two vaccine candidates which use pieces of viral proteins to develop immunity against the coronavirus. VIDO registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04702178">Phase 1 trial</a> for COVAC-2 on Jan. 8, 2021. But as approved vaccines became easier to get in Canada, some volunteers began <a href="https://saskatoon.ctvnews.ca/with-more-shots-available-clinical-trial-for-saskatchewan-made-covid-19-vaccine-sheds-volunteers-1.5424915">dropping out</a> of the trial, Saskatoon’s CTV News reported. Still, on Sept. 15, VIDO director Volker Gerdts <a href="https://globalnews.ca/news/8193401/vido-covid-19-vaccine-saskatoon-phase-2/">told</a> Global News Morning that it was moving to a Phase 2 trial after getting promising preliminary results. He also said that VIDO is working with the Institut Pasteur in Senegal to market the vaccine in Africa. On Nov. 4, CEPI <a href="https://cepi.net/news_cepi/cepi-announces-first-funding-awards-in-quest-to-develop-variant-proof-covid-19-vaccines/">announced</a> that it pledged $5 million to support the development of the vaccine. VIDO registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05209009?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 2 trial</a> for COVAC-2 in January 2022. VIDO registered another <a href="https://clinicaltrials.gov/ct2/show/NCT05155982?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2">Phase 1 trial </a>in Canada and Brazil for its other vaccine candidate, COVAC-1, on Dec. 14. Those trials should have begun in June 2022, according to what the researchers wrote in the trial record.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 23, 2022</span>

</p>

<a name="sinocelltech"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/sinocelltech-800.png" class="g-vlogo" 
    style="width: 180px; height: 51px; margin-right: 20px;" alt="Sinocelltech logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Chinese company <strong>Sinocelltech </strong>has developed two protein vaccines, called SCTV01C and SCTV01E, against the coronavirus. In February 2022, the researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05239806?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">series</a> of Phase 2 <a href="https://clinicaltrials.gov/ct2/show/NCT05238441?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2">booster</a> <a href="https://clinicaltrials.gov/ct2/show/NCT05239975?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">studies</a> to evaluate their ability to generate immunity in adults and adolescents who have already received other vaccines. The researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05308576?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 3 trial</a> for SCTV01E on April 4.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Feb. 16, 2022</span>

</p>

<a name="soberana1"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/finlay-800.png" class="g-vlogo" 
    style="width: 195px; height: 58px; margin-right: 20px;" alt="Finlay Vaccine Institute logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
On Aug. 18, 2020, the head of epidemiology at Cuba’s public health ministry <a href="https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364">announced</a> the country’s first trial of a vaccine of Covid-19. The <strong><a href="https://www.finlay.edu.cu/en/">Finlay Vaccine Institute</a></strong> in Havana began testing a vaccine called <a href="https://rpcec.sld.cu/ensayos/RPCEC00000332-Sp">Soberana 1</a>. It contains a part of the spike protein, called RBD, along with two extra ingredients: proteins from a bacteria and aluminum hydroxide. These ingredients, known as adjuvants, boost the immune system’s response to the coronavirus RBD. On July 26, Cuban media outlets <a href="http://www.5septiembre.cu/en-cienfuegos-fase-ii-de-ensayo-clinico-de-soberana-01/">reported</a> that Soberana 1 had entered Phase 2 trials. In November, Cuban health officials <a href="https://www.granma.cu/cuba/2021-11-16/aprobado-estudio-clinico-con-soberana-01-como-dosis-de-refuerzo-anti-covid-19-16-11-2021-00-11-32">approved</a> a clinical trial for the use of Soberana 1 as a booster dose. <a href="https://pubs.rsc.org/en/content/articlelanding/2022/CB/D1CB00200G">Results</a> from the Phase 1 trial suggest that Soberana 1 could safely generate immunity, and, when combined with Abdala, <a href="https://twitter.com/FinlayInstituto/status/1486173140053106689">could fight</a> against the Omicron variant.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Jan. 26, 2022</span>

</p>

<a name="spybiotech"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/spybiotech-800.png" class="g-vlogo" 
    style="width: 230px; height: 39px; margin-right: 20px;" alt="spybiotech logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>SpyBiotech</strong>, a company spun off from the University of Oxford, produced a vaccine from a mixture of proteins. Some of the proteins, from <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921968/">hepatitis B viruses</a>, form hollow shells. The researchers decorated these shells with part of the coronavirus spike protein. The vaccine is relatively easy to manufacture because the proteins can be produced by fermenting yeast. Once purified, the proteins then self-assemble into shells.<br><br>Injected into <a href="https://www.biorxiv.org/content/10.1101/2021.07.13.452251v1">monkeys</a> the vaccine produced promising levels of immune responses. In September 2020, SpyBiotech <a href="https://www.spybiotech.com/news/-/">announced</a> that the first volunteers in an Australian <a href="http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380145&isReview=true">Phase 1/2 trial</a> were receiving their Covid-19 vaccine. The Serum Institute of India, which licensed the technology from SpyBiotech, is running the trials. But the trial record, which has not been updated since September 2020, shows that the researchers have only recruited nine volunteers of an expected 280.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 20, 2021</span>

</p>

<a name="eubiologics"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/eubiologics-800.png" class="g-vlogo" 
    style="width: 195px; height: 40px; margin-right: 20px;" alt="EuBiologics logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
South Korean vaccine producer <strong>EuBiologics</strong> <a href="http://www.eubiologics.com/en/info/press_view.php?idx=13&page_number=1&mode=&cat=&search_gubun=all&search_keyword=">launched</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT04783311">Phase 1</a> of a protein-based vaccine in late January 2021. Known as EuCorVac-19, the vaccine combines the spike protein with an adjuvant that stimulates the immune system. EuBiologics <a href="http://eubiologics.com/kor/sub4_1_view.php?idx=92&page_number=1&mode=&search_gubun=all&search_keyword=">announced</a> on June 10, 2021, that it had successfully completed Phase 1. On Sept. 17, they <a href="http://www.koreabiomed.com/news/articleView.html?idxno=12223">finished</a> administering the vaccine to Phase 2 volunteers and made plans for a Phase 3 trial in which they would compare it against the AstraZeneca vaccine, Vaxzevria. But the Korean Biomedical Review <a href="https://www.koreabiomed.com/news/articleView.html?idxno=12342">reported</a> that AstraZeneca would not be supplying the vaccine, raising doubts about the trial’s prospects. Still, on Jan. 28, 2022, EuBiologics <a href="https://www.businesswire.com/news/home/20220203005421/en/">announced</a> that it received approval from the South Korean government to proceed with Phase 3 trials.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Feb. 7, 2022</span>

</p>

<a name="vbi"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/vbi-800.png" class="g-vlogo" 
    style="width: 140px; height: 55px; margin-right: 20px;" alt="VBI Vaccines logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
The Massachusetts-based company <strong>VBI Vaccines</strong> developed a coronavirus vaccine that is based on hollow, virus-like protein shells. The company added pieces of coronavirus proteins to the shells, selected for their potential both to produce antibodies and to train T cells to attack infected cells. In February 2021, VBI registered a placebo-controlled <a href="https://clinicaltrials.gov/ct2/show/NCT04773665">Phase 1/2 trial</a> in Canada on 780 volunteers, comparing the effects from using one or two doses. The vaccine, called VBI-2902a, uses aluminum phosphate as an adjuvant. On June 29, VBI released <a href="https://www.vbivaccines.com/press-releases/covid-19-vaccine-phase-1-data/">preliminary results</a> from the trial, showing that volunteers produced high levels of antibodies without any serious side effects. VBI <a href="https://www.businesswire.com/news/home/20210929005307/en/VBI-Vaccines-Announces-New-Preclinical-Data-and-Initiation-of-VBI-2905-Clinical-Study-Targeting-Broadened-Immunity-Against-COVID-19-and-Variants-of-Concern">announced</a> on Sept. 29 that it had dosed the first participants in another Phase 1 trial for a vaccine meant to protect against emerging variants. Results from these trials were encouraging, VBI <a href="https://www.businesswire.com/news/home/20220405005385/en/VBI-Vaccines-Announces-New-Data-and-Progress-of-VBI-2900-VBI%E2%80%99s-eVLP-Coronavirus-Program">said</a> on April 5, 2022.<br><br>VBI Vaccines is also <a href="https://www.biorxiv.org/content/10.1101/2021.09.28.462109v1">experimenting</a> with vaccines that combine proteins from the three coronaviruses that cause severe disease in humans: Covid-19, SARS, and MERS. They are exploring the possibility that such a vaccine could someday protect against a wide swath of coronaviruses, including <a href="https://www.nytimes.com/2021/02/09/health/universal-coronavirus-vaccine.html">ones that have yet to spill over from animal hosts</a>. VBI’s pan-coronavirus vaccine, called VBI-2901, is <a href="https://www.vbivaccines.com/press-releases/q2-2022/">scheduled</a> to enter  clinical trials in the third quarter of 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 12, 2022</span>

</p>

<a name="sinopharm3"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 g-filter-approved ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN U.A.E.</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/sinopharm-800.png" class="g-vlogo" 
    style="width: 65px; height: 81px; margin-right: 20px;" alt="Sinopharm logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> NVSI-06-07<br>




<br>
</span>

<!-- description -->
Researchers at China’s <strong>Sinopharm</strong> have created a <a href="https://mp.weixin.qq.com/s?__biz=MzA5MzYyMjg3Nw==&mid=2650284158&idx=1&sn=68c84b1ec5b5ea92a991be8e0ff6262a&chksm=8857874cbf200e5aeb6d22afba5edd510e5b40a6cba5b0248632ed43f9819f5eec629853f60a&mpshare=1&scene=1&srcid=0410lrJV1t61hJ5324zZ7Jlj&sharer_sharetime=1618026351063&sharer_shareid=02c69e528c9b6ba22233f1b6b35b9516&exportkey=Ab%2FesaQuvrmCRQy3ZzKmNAM%3D&pass_ticket=0yEduwjhOAerRi0IpclEv7TC%2BP7qTcUV%2BDGNj0u21gBOIK8k3UHlHedSJZJTB2RT&wx_header=0#rd">protein-based vaccine</a> called NVSI-06-07 that uses a genetically engineered spike protein to help the body produce antibodies. Sinopharm’s two other vaccine candidates, one developed with the <a href="#sinopharm">Beijing Institute</a> and one developed with the <a href="#wuhan">Wuhan Institute</a>, use <a href="https://www.nytimes.com/interactive/2020/health/sinopharm-covid-19-vaccine.html">inactivated coronaviruses to develop immunity</a>. Sinopharm <a href="http://www.xinhuanet.com/english/2021-04/25/c_139904898.htm">started</a> a Phase 1/2 trial of NVSI-06-07 on April 24. The U.A.E. provided <a href="https://www.usnews.com/news/world/articles/2021-12-28/uae-approves-sinopharms-protein-based-vaccine">emergency use authorization</a> for the vaccine as a booster dose in late December, Reuters reported. In January 2022, a team of scientists from China and the U.A.E. released a <a href="https://www.medrxiv.org/content/10.1101/2021.12.29.21268499v1">report</a> showing that the booster produced a stronger dose of antibodies against the Omicron variant than a third dose of Sinopharm’s inactivated virus vaccine.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://www.usnews.com/news/world/articles/2021-12-28/uae-approves-sinopharms-protein-based-vaccine">United Arab Emirates</a>.<br>



</span>

<span class="g-updated">Updated Jan. 12, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase1 g-filter-phase2 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.102.1 - 2021-12-29 09:48 -->
<!-- ai file: map-sinopharm3.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-sinopharm3-box ,
	#g-map-sinopharm3-box .g-artboard {
		margin:0 auto;
	}
	#g-map-sinopharm3-box p {
		margin:0;
	}
	#g-map-sinopharm3-box .g-aiAbs {
		position:absolute;
	}
	#g-map-sinopharm3-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-sinopharm3-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-sinopharm3-box .g-aiPointText p { white-space: nowrap; }
	#g-map-sinopharm3-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm3-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm3-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-sinopharm3-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm3-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-sinopharm3-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm3-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm3-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-sinopharm3-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm3-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-sinopharm3-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm3-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm3-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-sinopharm3-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm3-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-sinopharm3-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm3-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm3-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-sinopharm3-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm3-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-sinopharm3-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-sinopharm3-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-sinopharm3-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm3-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:7.0941%;margin-top:-27.3px;left:0%;width:112px;">
			<p class="g-pstyle0">Sinopharm</p>
			<p class="g-pstyle0">protein-based</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:40.6598%;margin-top:-6.8px;left:71.3631%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">U.A.E.</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-sinopharm3-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-sinopharm3-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm3-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:8.2866%;margin-top:-25.5px;left:0.0153%;width:106px;">
			<p class="g-pstyle0">Sinopharm</p>
			<p class="g-pstyle0">protein-based</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:39.6967%;margin-top:-6.8px;left:71.4762%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">U.A.E.</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-sinopharm3-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-sinopharm3-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm3-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:9.2099%;margin-top:-23.8px;left:-0.067%;width:100px;">
			<p class="g-pstyle0">Sinopharm</p>
			<p class="g-pstyle0">protein-based</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:39.5745%;margin-top:-6.8px;left:71.5656%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">U.A.E.</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-sinopharm3-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-sinopharm3-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm3-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:4.585%;margin-top:-23.8px;left:0.2695%;width:100px;">
			<p class="g-pstyle0">Sinopharm</p>
			<p class="g-pstyle0">protein-based</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:66.3348%;margin-top:-6.8px;left:43.3079%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">U.A.E.</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-sinopharm3-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-12-29 09:48 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="petersburg"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/russia-800.png" class="g-vlogo" 
    style="width: 73px; height: 80px; margin-right: 20px;" alt="St. Petersburg Scientific Research Institute of Vaccines and Sera logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Russian researchers at the <strong>St. Petersburg Scientific Research Institute of Vaccines and Sera</strong> at the <strong>Federal Medical Biological Agency</strong> developed a protein subunit vaccine against the coronavirus. They launched a <a href="https://clinicaltrials.gov/ct2/show/NCT05156723?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1/2 trial</a> on the vaccine, known as Convacell, on July 19, 2021. Results from the preclinical trial suggest that the vaccine is safe and effective, Federal Medical Biological Agency leader Veronika Skvortsova <a href="https://tass.com/society/1343875">said</a> on Sept. 29. In April 2022, the institute <a href="https://interfax.com/newsroom/top-stories/77823/">announced</a> that Convacell was going into production. TASS <a href="https://tass.com/society/1467869">reported</a> in June that the vaccine “may” go into Phase 3 trials in late summer 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 29, 2022</span>

</p>

<a name="stemcells"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/stemcells-800.png" class="g-vlogo" 
    style="width: 119px; height: 69px; margin-right: 20px;" alt=" logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
The <strong>Human Stem Cells Institute</strong>, a private Russian biotechnology company, has developed a recombinant vaccine against the coronavirus called Betuvax-CoV-2. After <a href="https://tass.com/world/1342867">receiving government approval</a> in September 2021, the researchers began a <a href="https://clinicaltrials.gov/ct2/show/NCT05270954?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">Phase 1/2 trial</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated March 11, 2022</span>

</p>

<a name="adimmune"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/adimmune-800.png" class="g-vlogo" 
    style="width: 80px; height: 68px; margin-right: 20px;" alt="AdImmune logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Taiwan-based vaccine manufacturer <strong>Adimmune</strong> got permission to <a href="https://focustaiwan.tw/sci-tech/202008200011">launch a Phase 1 trial</a> on Aug. 20, 2020. The vaccine contains the RBD section of the virus’s spike protein. In December, the Taiwan press <a href="https://focustaiwan.tw/society/202012300016">reported</a> that Adimmune failed to find the right dose of their vaccine and needed to try a new formulation. Adimmune <a href="https://focustaiwan.tw/sci-tech/202102170021">announced</a> in February 2021 that it would shift vaccine research to target new variants. In September, the company <a href="https://www.taipeitimes.com/News/biz/archives/2021/09/14/2003764312">received permission</a> to launch a new <a href="https://clinicaltrials.gov/ct2/show/NCT05104489?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">Phase 1/2 trial</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Jan. 3, 2022</span>

</p>

<a name="airlangga"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 g-filter-phase2 ">

<!-- phases -->







<span class="g-phase1">PHASE 1</span> <span class="g-phase2">PHASE 2</span> <span class="g-combined">COMBINED PHASES</span>


<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/airlangga-800.png" class="g-vlogo" 
    style="width: 200px; height: 62px; margin-right: 20px;" alt="Airlangga University logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Indonesian researchers at <strong>Airlangga University </strong>have developed a vaccine that uses a coronavirus protein to develop immunity. After <a href="https://qs-gen.com/phase-1-pre-clinical-trial-of-unair-led-merah-putih-vaccine-shows-promising-result/">positive preclinical results</a>, Airlangga registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05226429?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1/2 trial</a> on Feb. 7, 2022, comparing the vaccine with CoronaVac. The researchers moved to <a href="https://clinicaltrials.gov/ct2/show/NCT05508477?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 3</a> on Aug. 19.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>

<a name="kbp"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/kbp-800.png" class="g-vlogo" 
    style="width: 140px; height: 67px; margin-right: 20px;" alt="KBio logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
A second plant-based vaccine is in development at <strong>KBio</strong>. Like Medicago, KBio engineers a wild relative of tobacco called Nicotiana benthamiana to make viral proteins. The company previously used this technique to make a drug called Zmapp for Ebola. A <a href="https://clinicaltrials.gov/ct2/show/NCT04473690">Phase 1 trial</a> launched <a href="https://www.bat-science.com/groupms/sites/BAT_B9JBW3.nsf/vwPagesWebLive/DOBWBEAH?opendocument">in December 2020</a>. British American Tobacco announced on Jan. 10, 2022, that it would peel off its vaccine subsidiary, formerly called Kentucky BioProcessing, into a <a href="https://bioprocessintl.com/bioprocess-insider/global-markets/british-american-tobacco-launches-plant-based-biotech-kbio/">new company called KBio</a>. Well over a year after the start of the Phase 1 trial, the results have yet to be made public.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 3, 2022</span>

</p>

<a name="wrair"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/wrair-800.png" class="g-vlogo" 
    style="width: 150px; height: 77px; margin-right: 20px;" alt="Walter Reed Army Institute of Research logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Scientists at the <strong>Walter Reed Army Institute of Research</strong> have designed a vaccine from a nanoparticle decorated with the coronavirus’s spike protein. <a href="https://www.biorxiv.org/content/10.1101/2021.03.24.436523v1">Experiments on monkeys</a> showed that the two-dose vaccine delivered extremely high levels of antibodies. <a href="https://eidresearch.org/news/news/phase-1-clinical-trial-wrair-developed-covid-19-vaccine-set-begin">On April 5, 2021</a>, the army launched a <a href="https://clinicaltrials.gov/ct2/show/NCT04784767">Phase 1 trial</a>. The vaccine designers hope to create a new version of the vaccine with proteins from other coronaviruses to offer <a href="https://www.nytimes.com/2021/02/09/health/universal-coronavirus-vaccine.html">protection that extends beyond Covid-19</a>. In December, DefenseOne reported that the researchers had <a href="https://www.defenseone.com/technology/2021/12/us-army-creates-single-vaccine-effective-against-all-covid-sars-variants/360089/">completed the Phase</a><a href="https://www.defenseone.com/technology/2021/12/us-army-creates-single-vaccine-effective-against-all-covid-sars-variants/360089/"> 1 trial</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Dec. 22, 2021</span>

</p>

<a name="vaxform"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/vaxform-800.png" class="g-vlogo" 
    style="width: 165px; height: 45px; margin-right: 20px;" alt="VaxForm logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/ussf-800.png" class="g-vlogo" 
    style="width: 160px; height: 72px; margin-right: 20px;" alt="US Specialty Formulations logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/syneos-800.png" class="g-vlogo" 
    style="width: 145px; height: 65px;" alt="Syneos Health logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at Pennsylvania-based <strong>VaxForm </strong>have created a vaccine that can be taken by mouth as a liquid. The scientists say that their candidate, called CoV2-OGEN1, has an advantage over injected vaccines because it’s stable at room temperature and it doesn’t require a medical professional to be administered. <strong>Syneos Health </strong>and <strong>US Specialty Formulations </strong>registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04893512">Phase 1 trial</a> in New Zealand on May 19, 2021.<br><br>In December, USSF reported that the trial showed the vaccine was safe and triggered a strong immune response in all the volunteers. Plans are now underway for a Phase 2/3 trial, USSF C.E.O. Kyle Flanigan said on April 18, 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 21, 2022</span>

</p>

<a name="oravax"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/oravax-800.png" class="g-vlogo" 
    style="width: 170px; height: 85px; margin-right: 20px;" alt="Oravax Medical logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Israel-based <strong><a href="https://ora-vax.com/">Oravax Medical</a></strong>, a subsidiary of <strong>Oramed Pharmaceuticals</strong>, developed a Covid-19 vaccine pill. The vaccine contains virus-like particles that are studded with three proteins from the coronavirus. Oravax Medical <a href="https://www.jpost.com/health-science/israel-to-become-first-in-world-to-test-oral-covid-19-vaccine-674563">began work</a> on the vaccine in March 2021, finding promising antibody responses from animals. On Oct. 29, 2021, the company <a href="https://www.prnewswire.com/news-releases/oramed-announces-oravaxs-oral-covid-19-vaccine-has-received-south-african-approval-to-initiate-phase-1-trial-301411568.html">announced</a> it had won approval from the South African government to start a Phase 1 trial. Oravax Medical has also <a href="https://www.jpost.com/health-and-wellness/coronavirus/israels-oral-covid-vaccine-gets-greenlight-for-trial-in-south-africa-683469">applied to Israel</a> to run another trial there. Oravax dosed <a href="https://www.prnewswire.com/news-releases/oramed-subsidiary-oravax-announces-first-participant-enrolled-in-phase-1-oral-covid-19-vaccine-trial-in-south-africa-301444095.html">its first volunteer</a> in South Africa on Dec. 14. On Dec. 29, Oravax agreed to supply Vietnamese company Tan Thanh Holdings with at least <a href="https://www.businesswire.com/news/home/20211229005200/en/MyMD-Pharmaceuticals-Investment-Company-Oravax-Medical-Signs-Cooperation-and-Purchase-Agreement-for-Initial-Pre-Purchase-of-10-Million-Doses-of-Oral-COVID-19-Vaccine-to-be-Commercialized-in-Southeast-Asia">10 million doses</a> of its vaccine for marketing and distribution across Southeast Asia. In a <a href="https://www.prnewswire.com/news-releases/oramed-issues-annual-message-to-shareholders-301459442.html">message to shareholders</a> on Jan. 12, 2022, Oramed said it expected to launch Phase 2/3 trials in the second half of the year.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 18, 2022</span>

</p>

<a name="emergex"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/emergex-800.png" class="g-vlogo" 
    style="width: 180px; height: 48px; margin-right: 20px;" alt="Emergex Vacines logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
The British company <strong>Emergex Vaccines</strong> has created a  vaccine that contains gold nanoparticles carrying pieces of coronavirus proteins, called peptides. Emergex hopes to use the vaccine to prime the immune system to attack infected cells <a href="https://emergexvaccines.com/technology/advantages-over-traditional-vaccines/">without relying on antibodies</a>. The researchers <a href="https://clinicaltrials.gov/ct2/show/NCT05113862?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">registered</a> a Phase 1 trial in Switzerland on Nov. 9, and <a href="https://newsinfo.inquirer.net/1542714/swiss-researchers-launch-trial-for-covid-patch-vaccine">began dosing participants</a> in January 2022. Emergex said it is administering the vaccine through <a href="https://newsinfo.inquirer.net/1542714/swiss-researchers-launch-trial-for-covid-patch-vaccine">arm patches</a> created by <a href="https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-nanopasss-intradermal-delivery-platform-used-in-emergexs-next-generation-covid-19-vaccination-study-20220126140050.html">Nanopass</a> and <a href="https://emergexvaccines.com/emergex-vaccines-announces-the-successful-coating-of-its-novel-cd8-t-cell-adaptive-covid-19-vaccine-onto-zosano-pharmas-micro-needle-patch/">Zosano</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>

<a name="inno"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/inno-800.png" class="g-vlogo" 
    style="width: 125px; height: 31px; margin-right: 20px;" alt="HK inno.N logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Seoul-based biotechnology company <strong>HK inno.N </strong>has developed a recombinant protein vaccine against the coronavirus. After <a href="http://www.inno-n.com/company/publicity_center/report_data/view.asp?crd_seq=728&pg=3&schTxt=&schFld=whle#%EB%B3%B4%EB%8F%84%EC%9E%90%EB%A3%8C">positive results</a> from preclinical trials in primates, the company began a <a href="https://clinicaltrials.gov/ct2/show/NCT05113849?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 1 trial</a> on Sept. 16, 2021.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Nov. 10, 2021</span>

</p>

<a name="dreamtec"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/dreamtec-800.png" class="g-vlogo" 
    style="width: 121px; height: 42px; margin-right: 20px;" alt="Dreamtec Limited logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at the Hong Kong biotechnology company <strong>DreamTec Limited </strong>have made a Covid-19 vaccine by <a href="https://www.mdpi.com/2076-393X/10/1/2">adding genes to harmless bacteria spores</a>. Volunteers in a <a href="http://www.chictr.org.cn/showproj.aspx?proj=137299">Phase 1 clinical trial</a> that began in Hong Kong on Nov. 28, 2021 swallow a pill containing the spores. Once the pill reaches the gut, the spores start to grow and produce parts of coronavirus proteins.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Dec. 28, 2021</span>

</p>

<a name="yantai"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/luye-800.png" class="g-vlogo" 
    style="width: 200px; height: 62px; margin-right: 20px;" alt="Luye Life Sciences Group logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> LYB001<br>

<span class="g-info">Dose:</span> 3 doses, 4 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>

<br>
</span>

<!-- description -->
The Chinese biotechnology company <strong>Yantai Patronus</strong>, a subsidiary of <strong>Luye Life Sciences Group</strong>, has created a vaccine that houses pieces of the coronavirus in a virus-like shell. The researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05125926">Phase 1 trial</a> on Nov. 18, 2021. They also <a href="https://clinicaltrials.gov/ct2/show/NCT05137444">registered</a> a Phase 2/3 trial, but have not yet begun recruiting volunteers.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 3, 2022</span>

</p>

<a name="melbourneprotein"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/melbourne-800.png" class="g-vlogo" 
    style="width: 115px; height: 116px; margin-right: 20px;" alt="University of Melbourne logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> DoCo-Pro-RBD-1<br>


<span class="g-info">Type:</span> Muscle injection<br>

<br>
</span>

<!-- description -->
Australian researchers at the <strong>University of Melbourne</strong> are testing a vaccine that uses a protein similar to a section of a coronavirus protein called the receptor binding domain. They registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05272605?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2">Phase 1 trial</a> on March 9, 2022. The researchers plan to test their candidate in individuals who have already received two full doses and a booster of widely used vaccines. The university is also testing an <a href="#melbournemrna">mRNA vaccine</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated March 11, 2022</span>

</p>

<a name="acmbio"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/acmbio-800.png" class="g-vlogo" 
    style="width: 120px; height: 52px; margin-right: 20px;" alt="ACM Biolabs logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> ACM-001<br>


<span class="g-info">Type:</span> Intranasal spray<br>

<br>
</span>

<!-- description -->
<strong>ACM Biolabs</strong>, a Singapore-based biotechnology company, created a vaccine for Covid-19 called ACM-001. It contains spike proteins along with an immunity-boosting adjuvant. ACM-001 can be delivered as an intranasal spray. In March 2022, the company <a href="https://acmbiolabs.com/acm-biolabs-intranasal-covid-vaccine-presents-excellent-preclinical-results-with-broad-protection-against-variants-of-concerns-including-omicron/">announced</a> that <a href="https://www.biorxiv.org/content/10.1101/2022.02.12.480188v1">studies</a> on hamsters indicated the vaccine produced strong immunity against a range of variants. ACB Biolabs followed up on those results with a <a href="https://clinicaltrials.gov/ct2/show/NCT05385991">Phase 1 trial</a> of ACM-001 as a booster. The company <a href="https://www.prnewswire.com/news-releases/as-part-of-operation-nasal-vaccine-to-counter-covid-19-spread-acm-001-booster-vaccine-administered-to-first-subject-in-phase-1-safety-and-immunogenicity-trial-301595985.html">announced</a> they dosed their first volunteer on July 29, 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 29, 2022</span>

</p>

<a name="icosavax"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/icosavax-800.png" class="g-vlogo" 
    style="width: 190px; height: 54px; margin-right: 20px;" alt="Icosavax logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/seqirus-800.png" class="g-vlogo" 
    style="width: 132px; height: 60px;" alt="Seqirus logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In spring 2021, researchers at the University of Washington developed a nanoparticle vaccine for Covid-19. Each nanoparticle carries numerous copies of a protein fragment called RBD, from the spike protein of the coronavirus. Seattle-based <strong>Icosavax </strong>purchased a license to test and market the vaccine, called IVX-411. On June 8, the company <a href="https://icosavax.com/news/icosavax-initiates-phase-1-2-trial-of-covid-19-vlp-vaccine-candidate/">announced</a> that it had begun a Phase 1/2 trial in Australia. In the trial, funded by the Bill and Melinda Gates Foundation, some of the volunteers received the vaccine along with an adjuvant from <strong>Seqirus</strong>. Icosavax is also giving IVX-411 to people who are already vaccinated and observing how it works as a booster.<br><br>On March 25, 2022, Icosavax <a href="https://www.globenewswire.com/news-release/2022/03/25/2410205/0/en/Icosavax-Announces-Topline-Interim-Phase-1-2-Results-for-IVX-411-Against-SARS-CoV-2.html">announced</a> that its Phase 1/2 trial was a disappointment. The vaccine did not deliver a stronger immune response than natural infection. On July 28, Icosovax <a href="https://investors.icosavax.com/news-releases/news-release-details/icosavax-announces-results-ivx-411-drug-product-investigation">reported</a> that the protein fragment turned out to be unstable. The company said it would turn its efforts to making a new vaccine with two different protein fragments.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 12, 2022</span>

</p>

<a name="zhongyianke"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/zhongyianke-800.png" class="g-vlogo" 
    style="width: 240px; height: 31px; margin-right: 20px;" alt="Zhongyianke Biotech logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/ams-800.png" class="g-vlogo" 
    style="width: 55px; height: 55px;" alt="Academy of Military Medical Sciences logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at <strong>Zhongyianke Biotech</strong>, <strong>Liaoning Maokangyuan</strong><strong> Biotech </strong>and the <strong>Academy of Military Medical Sciences</strong> are using Chinese hamster ovary cells to help create immunity in humans. They registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04636333?term=covid-19+vaccine&draw=2">Phase 1 trial</a> in China in  November 2020. On March 24, 2021, they <a href="https://clinicaltrials.gov/ct2/show/NCT04813562?term=covid-19+vaccine+cho&draw=2&rank=1">advanced the vaccine</a> to Phase 2. The researchers registered a <a href="https://www.chictr.org.cn/showprojen.aspx?proj=133228">Phase 3 trial</a> on Sept. 5, 2021, but the registry was <a href="https://web.archive.org/web/2021*/https://www.chictr.org.cn/showprojen.aspx?proj=133228">later removed</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 29, 2022</span>

</p>

<a name="ose"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/ose-800.png" class="g-vlogo" 
    style="width: 240px; height: 46px; margin-right: 20px;" alt="OSE Immunotherapeutics logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
On April 1, 2021, French researchers at <strong>OSE Immunotherapeutics </strong><a href="https://www.biospace.com/article/releases/ose-immunotherapeutics-receives-authorization-for-phase-1-clinical-trial-of-its-multi-target-multi-variant-covid-19-vaccine/">announced</a> they had received approval to launch a <a href="https://clinicaltrials.gov/ct2/show/NCT04885361?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 1 trial</a> of a vaccine, called CoVepiT, in Belgium. Their vaccine can teach the body to develop an immune response against 11 different proteins of the coronavirus. The researchers picked these proteins because they have a low chance of mutating — a feature, they say, that makes the vaccine “variant-proof.” They began <a href="https://www.businesswire.com/news/home/20210525005962/en/OSE-Immunotherapeutics-Announces-Dosing-of-the-First-Healthy-Volunteer-in-Phase-1-Clinical-Trial-of-its-Multi-Variant-Second-Generation-COVID-19-Vaccine">dosing participants</a> on May 26. But on July 19, OSE announced that it would <a href="https://www.businesswire.com/news/home/20210719005625/en/OSE-Immunotherapeutics-Announces-Voluntary-Pause-of-Enrollment-in-the-CoVepiT-Phase-1-Study">voluntarily pause</a> its trial after receiving preliminary news of adverse reactions to the vaccine. In October, the company <a href="https://www.businesswire.com/news/home/20211019005615/en/OSE-Immunotherapeutics-to-Present-New-Preclinical-Data-at-Upcoming-Bispecific-Antibody-and-Immunology-Conferences">said</a> the trial was still paused. OSE said on Nov. 30 that <a href="https://www.biospace.com/article/releases/ose-immunotherapeutics-provides-an-update-on-the-first-positive-results-and-clinical-development-of-covepit-its-multi-target-t-cell-anti-covid-vaccine/">early results from the trial</a> show that the vaccine was effective at generating an immune response.<br><br>In March 2022, OSE <a href="https://www.globenewswire.com/news-release/2022/03/16/2404720/0/en/OSE-Immunotherapeutics-Provides-Positive-Long-Term-Memory-Responses-with-CoVepiT-its-T-Lymphocyte-Multi-Target-Anti-COVID-Vaccine.html">said</a> that pursuing further development of CoVepiT would be “difficult,” as other therapeutics and vaccines have already proven successful in patients. The company now plans to use its vaccine platform for future pandemics.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 8, 2022</span>

</p>

<a name="kazakhstan2"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/ribsp-800.png" class="g-vlogo" 
    style="width: 210px; height: 74px; margin-right: 20px;" alt="Kazakhstan’s Research Institute for Biological Safety Problems logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Kazakhstani scientists at the <strong>Research Institute for Biological Safety Problems</strong> developed a second vaccine against Covid-19, called QazCoVac-P. Unlike their first vaccine, which is made from inactivated coronaviruses, QazCoVac-P  uses proteins from the virus to boost immunity. Kazakhstani researchers <a href="https://www.biosafety.kz/uncategorized/%d0%bd%d0%b0%d1%87%d0%b0%d1%82%d1%8b-%d0%ba%d0%bb%d0%b8%d0%bd%d0%b8%d1%87%d0%b5%d1%81%d0%ba%d0%b8%d0%b5-%d0%b8%d1%81%d1%81%d0%bb%d0%b5%d0%b4%d0%be%d0%b2%d0%b0%d0%bd%d0%b8%d1%8f-%d1%81%d1%83%d0%b1/">commenced</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT04930003?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1/2 trial</a> of the vaccine on June 15, 2021. But the trial record, which indicated the study would conclude in December 2021, has not been updated since July 2021. As of February 2022, there was <a href="https://www.inform.kz/en/what-vaccines-against-covid-19-used-in-kazakhstan_a3899051">no evidence</a> of QazCoVac-P in use in Kazakhstan. And on April 28, Kazakhstani health officials said that production of more vaccines would not be necessary, since there were <a href="https://www.inform.kz/en/karaganda-plant-no-longer-produces-anti-covid-vaccines-chief-sanitary-officer_a3927925">enough QazVac doses</a> to cover the population.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated April 29, 2022</span>

</p>

<a name="skbioscience"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/skbioscience-800.png" class="g-vlogo" 
    style="width: 161px; height: 50px; margin-right: 20px;" alt="SK Bioscience logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>SK Bioscience, </strong>a South Korean vaccine maker, <a href="https://www.koreabiomed.com/news/articleView.html?idxno=9722">won approval</a> on Nov. 23, 2020 from the country’s Ministry of Food and Drug Safety for a vaccine called NBP2001. The vaccine contained fragments of the spike protein. In a <a href="https://clinicaltrials.gov/ct2/show/NCT04760743">Phase 1 trial</a>, researchers tested the vaccine on 50 volunteers. In the trial’s registry, it was scheduled to end in April 2021. On SK BioScience’s website, the company <a href="https://www.skbioscience.co.kr/en/tech/rnd_01">says</a> that the trial is complete, without the launch of a Phase 2 trial to carry the research further. Meanwhile, SK Bioscience is actively pushing another vaccine, called GBP510, through a Phase 3 trial.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Feb. 23, 2022</span>

</p>

<a name="uqueensland"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/uqueensland-800.png" class="g-vlogo" 
    style="width: 190px; height: 53px; margin-right: 20px;" alt="University of Queensland logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/csl-800.png" class="g-vlogo" 
    style="width: 75px; height: 38px;" alt="CSL logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
On Dec. 10, 2020, a vaccine from Australia’s <strong>University of Queensland</strong> was the first <a href="https://www.smh.com.au/politics/federal/australian-covid-vaccine-terminated-due-to-hiv-false-positives-20201210-p56mju.html">to be abandoned</a> after entering a clinical trial. <a href="https://nyti.ms/37XNg5Q">Cancelling the vaccine</a> meant the collapse of a $1 billion deal with the Australian government for <a href="https://www.uq.edu.au/news/article/2020/09/csl-signs-agreement-australian-government-uq-vaccine-supply">51 million doses</a>.<br><br>The vaccine studies offered great promise at first. <a href="https://www.uq.edu.au/news/article/2020/08/uq-vaccine-scientists-report-positive-results-pre-clinical-testing">Experiments on hamsters</a> showed that the vaccine protected them from the coronavirus. The university launched a Phase 1 trial in July, combining coronavirus spike proteins with an adjuvant made by <strong>CSL</strong>. The trial delivered <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3769210">encouraging results</a>: volunteers produced a high level of antibodies with no evidence of harmful side effects.<br><br>But then the researchers made an unwelcome discovery: some volunteers were getting positive tests for HIV, even though they were not actually infected with that virus. In a <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3769210">report</a> released in February 2021, the researchers explained the false positives came about due to the way the researchers designed the vaccine.<br><br>To ensure that spike proteins can stimulate a strong immune response, the researchers had to prevent the molecules from unfolding and changing their shape. The researchers held the proteins in place with a molecular clamp, which was based on a segment of an HIV protein.<br><br>HIV tests use antibodies to probe for the presence of the virus’s proteins in people’s blood. The researchers thought that the antibodies would not grab the clamp. That assumption turned out to be wrong. Worried that false positive HIV test results would fuel hesitancy over getting Covid-19 vaccines, the Australian government decided to halt the trial.<br><br>“It will no longer feature in Australia’s vaccine plan,” said Prime Minister Scott Morrison at a press conference to announce the cancellation.<br><br>But Queensland researchers have still found promise in their vaccine platform. In April 2021, they published the <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00200-0/fulltext">full results</a> from their abandoned Phase 1 trial, which suggested that the candidate could still be effective against Covid-19. The researchers are now <a href="https://www.abc.net.au/news/health/2021-04-26/university-queensland-covid-19-vaccine-research-molecular-clamp/100050240">working to re-engineer their vaccine</a> with different proteins that will not generate false positives for HIV. They have yet to provide a timeline for the development of an updated vaccine.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated May 18, 2021</span>

</p>
<h2 class="g-subhed g-optimize-type g-filtered" id="">
	<span class="g-balancer" data-id="16"><strong>Inactivated or Attenuated Coronavirus Vaccines</strong></span>
</h2>
<p class="g-body g-description g-optimize-type g-filtered" id="">
	<span class="g-xbalancer" data-id="17"><em>Vaccines created from weakened coronaviruses or coronaviruses that have been killed with chemicals.</em></span>
</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filtered"  style="max-width: 600px">

<!-- Intro elements -->








<div role="region">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.100.0 - 2020-09-10 08:31 -->
<!-- ai file: whole.ai -->
<!-- preview: undefined -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-whole-box ,
	#g-whole-box .g-artboard {
		margin:0 auto;
	}
	#g-whole-box p {
		margin:0;
	}
	#g-whole-box .g-aiAbs {
		position:absolute;
	}
	#g-whole-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-whole-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-whole-box .g-aiPointText p { white-space: nowrap; }
	#g-whole-600 {
		position:relative;
		overflow:hidden;
	}
	#g-whole-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(51,51,51);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-whole-600 .g-pstyle0 {
		height:17px;
		text-align:center;
		position:relative;
	}
	#g-whole-450 {
		position:relative;
		overflow:hidden;
	}
	#g-whole-450 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(51,51,51);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-whole-450 .g-pstyle0 {
		height:17px;
		text-align:center;
		position:relative;
	}
	#g-whole-335 {
		position:relative;
		overflow:hidden;
	}
	#g-whole-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(51,51,51);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-whole-335 .g-pstyle0 {
		height:17px;
		text-align:center;
		position:relative;
	}

</style>

<div id="g-whole-box" class="ai2html">

	<!-- Artboard: 600 -->
	<div id="g-whole-600" class="g-artboard" style="width:600px; height:280px;" data-aspect-ratio="2.143" data-min-width="600">
<div style=""></div>
		<img id="g-whole-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/whole-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-600 g-aiAbs g-aiPointText" style="top:51.1664%;margin-top:-17.3px;left:49.6252%;margin-left:-43.5px;width:87px;">
			<p class="g-pstyle0">Inactivated</p>
			<p class="g-pstyle0">virus</p>
		</div>
	</div>

	<!-- Artboard: 450 -->
	<div id="g-whole-450" class="g-artboard" style="width:450px; height:280px;" data-aspect-ratio="1.607" data-min-width="450" data-max-width="599">
<div style=""></div>
		<img id="g-whole-450-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/whole-450.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-450 g-aiAbs g-aiPointText" style="top:51.1664%;margin-top:-17.3px;left:49.5003%;margin-left:-43.5px;width:87px;">
			<p class="g-pstyle0">Inactivated</p>
			<p class="g-pstyle0">virus</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-whole-335" class="g-artboard" style="max-width: 335px;max-height: 280px" data-aspect-ratio="1.196" data-min-width="0" data-max-width="449">
<div style="padding: 0 0 83.5821% 0;"></div>
		<img id="g-whole-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/whole-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-335 g-aiAbs g-aiPointText" style="top:51.1664%;margin-top:-17.3px;left:49.5503%;margin-left:-43.5px;width:87px;">
			<p class="g-pstyle0">Inactivated</p>
			<p class="g-pstyle0">virus</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-whole-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2020-09-10 08:31 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="sinopharm"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN CHINA, BAHRAIN</span>


<span class="g-limited">EMERGENCY USE IN MANY COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/sinopharm-800.png" class="g-vlogo" 
    style="width: 65px; height: 81px; margin-right: 20px;" alt="Sinopharm logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> BBIBP-CorV<br>
<span class="g-info">Efficacy:</span> <a href="https://www.nytimes.com/2021/05/07/business/economy/china-sinopharm-vaccine-who.html?action=click&module=RelatedLinks&pgtype=Article">78.1% </a><br>
<span class="g-info">Dose:</span> 2 doses, 3 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>

<br>
</span>

<!-- description -->
BBIBP-CorV, a vaccine made by the <strong>Beijing Institute of Biological Products </strong>and  the state-owned Chinese company <strong>Sinopharm, </strong>has emerged as China’s leading Covid-19 vaccine, both within the country and abroad. In September 2021, the head of the company said in an <a href="https://www.chinadaily.com.cn/a/202109/27/WS61510727a310cdd39bc6baae.html">interview</a> with China Daily that Sinopharm had reached an annual production capacity of 7 billion doses.<br><br> <subhed>VACCINE DEVELOPMENT</subhed>Researchers at the institute produced BBIP-CorV by growing live coronaviruses in cells and then dousing them with chemicals to inactivate them. Injected into the body, these inactivated viruses cannot infect cells, but they can draw the attention of the immune system. In June 2020, the researchers <a href="https://www.cell.com/cell/fulltext/S0092-8674(20)30695-4">reported</a> that the vaccine produced promising results in monkeys.<br><br><subhed>TRIAL RESULTS</subhed>A <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30831-8/fulltext">Phase 1/2 trial</a> showed that the vaccine didn’t cause any serious side effects and enabled people to make antibodies against the coronavirus. A <a href="http://www.chictr.org.cn/showprojen.aspx?proj=56651">Phase 3 trial</a> began in the United Arab Emirates in July 2020, and in <a href="https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm/peru-morocco-to-test-china-sinopharms-covid-19-vaccine-in-phase-3-trial-idUSKCN25G0G9">Morocco</a> and <a href="https://clinicaltrials.gov/ct2/show/NCT04612972">Peru</a> the following month.<br><br>On Dec. 30, Sinopharm <a href="https://www.nytimes.com/2020/12/30/business/china-vaccine.html">announced</a> that the vaccine had an efficacy of 79.34 percent, leading the Chinese government to <a href="https://www.nytimes.com/2020/12/30/business/china-vaccine.html">give it approval</a>. On May 7, 2021, the World Health Organization put forward a similar efficacy estimate of <a href="https://www.nytimes.com/2021/05/07/business/economy/china-sinopharm-vaccine-who.html?action=click&module=RelatedLinks&pgtype=Article">78.1 percent</a> and gave the vaccine emergency use authorization. On Aug. 3, Bloomberg <a href="https://www.bloomberg.com/news/articles/2021-08-03/sinopharm-vaccine-falls-short-on-antibodies-in-budapest-study">reported</a> that results from a Hungarian study showed that the vaccine failed to produce enough antibodies in more than one quarter of elderly people. Results from a Peru trial suggest that the vaccine was <a href="https://www.reuters.com/world/americas/peru-study-finds-sinopharm-covid-vaccine-504-effective-against-infections-2021-08-13/">50.4 percent effective</a> in preventing infections among healthcare workers, Reuters reported on Aug. 13.<br><br>After the vaccine was authorized in the United Arab Emirates, researchers there kept track of people who received the vaccine. In June 2022, they published a <a href="https://www.nature.com/articles/s41467-022-30835-1">study</a> showing that Sinopharm’s vaccine had an effectiveness of 79.6 percent against hospitalization and 84 percent against death. The effectiveness waned six months after vaccination.<br><br> <subhed>AUTHORIZATION</subhed>In the summer of 2020, long before the Phase 3 trial was complete, the Chinese government gave Sinopharm <a href="https://www.nytimes.com/2020/11/17/business/china-coronavirus-vaccine-safety.html">emergency approval</a> in the summer 0f 2020. Government officials, health care workers, and other select groups began receiving BBIBP-CorV. On Sept. 14, the U.A.E. <a href="https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/uae-announces-emergency-approval-for-use-of-covid-19-vaccine-idUSKBN2652OM">gave</a> emergency approval for Sinopharm’s vaccine to use on health care workers, and soon <a href="https://www.aljazeera.com/news/2020/11/3/uae-pm-and-dubai-ruler-receives-coronavirus-vaccine">government officials</a> and others were also receiving it. Less than two months later, on Dec. 9, the U.A.E. gave <a href="https://www.nytimes.com/2020/12/09/business/china-coronavirus-vaccine-united-arab-emirates.html">full approval</a> to BBIBP-CorV. Since then a number of countries in the Near East have authorized it; on Jan. 29, <a href="https://www.euronews.com/2021/01/29/hungary-becomes-the-first-country-in-the-eu-to-approve-a-covid-19-vaccine-from-china">Hungary</a> authorized BBIBp-CorV, making the country the first European nation to use a Chinese vaccine.<br><br>The vaccine received <a href="http://www.ecns.cn/news/2021-07-20/detail-ihaphzwf8857844.shtml">approval for emergency use</a> in children and adolescents in China on July 20. The U.A.E. <a href="https://www.bloomberg.com/news/articles/2021-08-02/uae-approves-sinopharm-shot-for-children-aged-three-and-above?sref=XGjS8839">approved</a> the vaccine for use in those aged three and over on Aug. 2.<br><br> <subhed>VARIANTS</subhed>In February 2021, as concerns grew about new mutations in the coronavirus, Chinese researchers tested BBIBP-CorV against a variant called Beta.1.351, which was first found in South Africa. They reported that the antibody response created by the vaccine was only modestly weaker against Beta. B.1.351. The <a href="https://www.biorxiv.org/content/10.1101/2021.02.01.429069v1">study</a> has not yet been published in a medical journal. Another <a href="https://www.medrxiv.org/content/10.1101/2021.07.15.21260621v1">study</a> from Sri Lanka, released in July, found that BBIBP-CorV produced antibody responses to the Delta variant that were as strong as those produced by natural infection.<br><br> <subhed>BOOSTERS</subhed>The World Health Organization <a href="https://www.nature.com/articles/d41586-021-02796-w">recommends</a> that people over 60 who receive Sinopharm get a booster shot with the same or another vaccine.<br><br>In May 2021,  concerns over the vaccine’s effectiveness emerged in the U.A.E. In response, the government <a href="https://abcnews.go.com/Health/wireStory/uae-offer-booster-shot-recipients-sinopharm-vaccine-77756591">announced</a> that it would provide booster shots to those who have received two doses of BBIBP-CorV. Bahrain followed with a <a href="https://www.newsweek.com/bahrain-urges-some-immunized-chinas-sinopharm-covid-vaccine-get-second-shot-1597194">similar announcement</a> on June 3. On Aug. 29, the U.A.E. <a href="https://medicalxpress.com/news/2021-08-uae-capital-mandates-booster-shot.html">mandated</a> booster shots for all residents who received BBIBP-CorV. A representative from Sinopharm <a href="https://www.who.int/news-room/events/detail/2021/10/25/default-calendar/who-consultation-on-covid-19-vaccines-research-emerging-evidence-on-safety-and-the-need-for-additional-doses-of-covid-19-vaccines">reported</a> at a W.H.O. meeting in October that a booster tripled antibody levels over their peak after two doses. <br><br> For more details, see <strong><a href="https://www.nytimes.com/interactive/2020/health/sinopharm-covid-19-vaccine.html">How the Sinopharm Vaccine Works</a></strong>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://www.reuters.com/article/us-health-coronavirus-bahrain/bahrain-approves-registration-for-sinopharm-covid-19-vaccine-idUSKBN28N07Z">Bahrain</a>, <a href="https://www.nytimes.com/2020/12/30/business/china-vaccine.html">China</a>.<br>


<span class="g-info">Emergency use in:</span> <a href="https://apps.who.int/iris/bitstream/handle/10665/341252/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Algeria</a>, <a href="https://africa.cgtn.com/2021/05/14/angolas-president-lourenco-first-lady-take-covid-19-vaccines/">Angola</a>, <a href="https://antiguaobserver.com/health-official-advises-young-people-to-take-sinopharm-vaccine/">Antigua and Barbuda</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-argentina-vaccine/argentina-approves-sinopharm-covid-19-vaccine-for-emergency-use-idUSKBN2AL0P9">Argentina</a>, <a href="https://www.azatutyun.am/a/31417734.html">Armenia</a>, <a href="https://in.news.yahoo.com/bangladesh-allows-emergency-chinese-vaccine-123310528.html">Bangladesh</a>, <a href="https://eng.belta.by/society/view/airlifter-with-300000-doses-of-covid-19-vaccine-leaves-beijing-for-belarus-139950-2021/">Belarus</a>, <a href="https://www.pressoffice.gov.bz/sinopharm-vaccines-now-available-to-public/">Belize</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341252/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Bhutan</a>, <a href="https://bo.usembassy.gov/covid-19-information/">Bolivia</a>, <a href="https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/oms-aprova-a-entrada-da-vacina-da-sinopharm-no-consorcio-internacional-covax-facility">Brazil</a>, <a href="https://thescoop.co/2021/04/02/covid-19-brunei-to-begin-mass-vaccination-on-april-3/">Brunei</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharmbibp#col-0">Burkina Faso</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharmbibp#col-0">Burundi</a>, <a href="http://www.xinhuanet.com/english/2021-02/04/c_139721602.htm">Cambodia</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp">Cameroon</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp#col-0">Chad</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp">Comoros</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharmbibp#col-0">Côte d'Ivoire</a>, <a href="https://www.republicworld.com/world-news/rest-of-the-world-news/cuba-adds-sinopharm-to-its-vaccination-programme.html">Cuba</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp#col-0">Dominica</a>, <a href="https://www.arabnews.com/node/1786531/middle-east">Egypt</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp#col-0">Equatorial Guinea</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341252/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Ethiopia</a>, <a href="https://gabon24.ga/en/news/gabon-authorises-second-covid-19-vaccine-sinopharms-immunization-from-china/4671/">Gabon</a>, <a href="http://www.xinhuanet.com/english/2021-06/18/c_1310014124.htm">Gambia</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp#col-0">Georgia</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341252/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Guinea</a>, <a href="https://www.youtube.com/watch?v=2ANBxmg1SfA">Guyana</a>, <a href="https://apnews.com/article/europe-coronavirus-pandemic-china-coronavirus-vaccine-hungary-a598b6170a1ca9eb120ac4b87e73636c">Hungary</a>, <a href="http://www.xinhuanet.com/english/2021-04/30/c_139916901.htm">Indonesia</a>, <a href="https://ifdana.fda.gov.ir/fa/News/18083">Iran</a>, <a href="http://www.businessworld.in/article/Iraq-approves-Sinopharm-AstraZeneca-COVID-19-vaccines-for-emergency-use/19-01-2021-367325/">Iraq</a>, <a href="https://english.alarabiya.net/en/coronavirus/2021/01/10/Coronavirus-Jordan-approves-China-s-Sinopharm-COVID-19-vaccine">Jordan</a>, <a href="https://astanatimes.com/2021/09/sinopharm-vaccine-vero-cell-arrives-in-kazakhstan/">Kazakhstan</a>, <a href="http://www.xinhuanet.com/english/africa/2021-08/19/c_1310136850.htm">Kenya</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp">Kyrgyzstan</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp">Laos</a>, <a href="https://www.moph.gov.lb/en/Pages/127/47199/the-ministry-of-public-health-allows-the-emergency-use-of-sinopharm-vaccine">Lebanon</a>, <a href="https://www.humanitarianresponse.info/sites/www.humanitarianresponse.info/files/documents/files/who_libya_covid-19_update_30_april_2021.pdf">Libya</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341252/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Macao</a>, <a href="https://www.facebook.com/malawimoh/posts/4098884300167054">Malawi</a>, <a href="https://www.reuters.com/article/health-coronavirus-malaysia-vaccine/malaysia-approves-chinas-sinopharm-vaccine-for-emergency-use-idUSL4N2OS18D">Malaysia</a>, <a href="https://timesofaddu.com/2021/03/15/breaking-sinopharm-pfizer-approved-for-use-in-maldives/">Maldives</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp#col-0">Mauritania</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp#col-0">Mauritius</a>, <a href="https://www.reuters.com/article/health-coronavirus-mexico-sinopharm/mexico-grants-emergency-use-approval-to-chinas-sinopharm-covid-19-vaccine-idUSE1N2NR02D">Mexico</a>, <a href="https://msmps.gov.md/comunicare/comunicate/membrii-nitag-au-venit-cu-recomandari-privind-utilizarea-vaccinurilor-impotriva-covid-19-in-republica-moldova/">Moldova</a>, <a href="https://mn.usembassy.gov/covid-19-information/">Mongolia</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp">Montenegro</a>, <a href="https://www.wam.ae/en/details/1395302903753">Morocco</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp">Mozambique</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341252/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Myanmar</a>, <a href="https://mhss.gov.na/documents/119527/775250/SKM_36721030413220.pdf/7a4534bb-022f-46e4-9113-571432290194">Namibia</a>, <a href="http://www.ecns.cn/news/2021-02-18/detail-ihahrtqt2712371.shtml">Nepal</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp">Niger</a>, <a href="https://www.nasdaq.com/articles/nigeria-approves-sinopharm-covid-vaccine-expects-7.7-mln-doses-2021-08-24-0">Nigeria</a>, <a href="https://kovid19vakcinacija.mk/za-vakcinite/">North Macedonia</a>, <a href="https://www.dra.gov.pk/docs/Pressnote_covid_vaccine_drap-edited%20tracked%20(1).pdf">Pakistan</a>, <a href="https://covid19.info.gov.pg/vaccination-is-not-compulsory-prime-minister-tells-parliament/">Papua New Guinea</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp#col-0">Paraguay</a>, <a href="http://www.digemid.minsa.gob.pe/main.asp?Seccion=1065">Peru</a>, <a href="https://www.rappler.com/nation/fda-grants-emergency-use-approval-sinopharm-covid-19-vaccines">Philippines</a> (including <a href="https://timesofindia.indiatimes.com/world/rest-of-world/philippines-approves-emergency-use-of-hayat-vax-vaccines/articleshow/85236353.cms">Hayat-Vax</a>), <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp">Republic of the Congo</a>, <a href="https://www.rbc.gov.rw/index.php?id=777">Rwanda</a>, <a href="https://gulfnews.com/world/gulf/saudi/saudi-arabia-approves-use-of-sinopharm-covid-19-vaccine-1.81350191">Saudi Arabia</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp">Senegal</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341252/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Serbia</a>, <a href="https://www.africanews.com/2021/03/16/sierra-leone-president-bio-and-government-get-first-covid-19-shots//">Sierra Leone</a>, <a href="https://solomons.gov.sb/solomon-islands-launches-roll-out-of-sinopharm-covid-19-vaccine/">Solomon Islands</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharm-bibp">Somalia</a>, South Africa, <a href="http://www.xinhuanet.com/english/2021-05/08/c_139932993.htm">Sri Lanka</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341252/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Sudan</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharmbibp#col-0">Tanzania</a>, <a href="https://thethaiger.com/coronavirus/sinopharm-wins-ok-from-fda-the-5th-approved-covid-19-vaccine">Thailand</a>, <a href="https://m.facebook.com/MinistryofHealthTT/photos/a.153051404724676/4635809886448783/?type=3&source=48">Trinidad and Tobago</a>, <a href="http://www.xinhuanet.com/english/africa/2021-07/13/c_1310057298.htm">Tunisia</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341252/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Turkmenistan</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharmbibp#col-0">United Arab Emirates</a>, <a href="http://www.xinhuanet.com/english/2021-06/04/c_139988757.htm">Vietnam</a> (including <a href="https://www.reuters.com/world/asia-pacific/vietnam-approves-hayat-vax-coronavirus-vaccine-emergency-use-2021-09-10/">Hayat-Vax</a>), <a href="https://www.reuters.com/article/us-health-coronavirus-venezuela-vaccine/venezuela-approves-use-of-chinas-sinopharm-coronavirus-vaccine-idUSKCN2AT3T2">Venezuela</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341252/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP-background-2021.1-eng.pdf?sequence=1&isAllowed=y">West Bank and Gaza Strip</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinopharmbibp#col-0">Vanuatu</a>, <a href="https://www.reuters.com/article/uk-health-coronavirus-zimbabwe-vaccine/zimbabwe-authorises-sputnik-v-sinovac-coronavirus-vaccines-for-emergency-use-idUSKBN2B20K3">Zimbabwe</a>. Emergency use validation from the <a href="https://www.nytimes.com/2021/05/07/business/economy/china-sinopharm-vaccine-who.html">World Health Organization</a>.<br>
<span class="g-info">Limited use in:</span> <a href="https://menafn.com/1101463608/Serbia-Health-minster-takes-Sinopharm-vaccine&source=30">Serbia</a>, <a href="https://www.reuters.com/article/uk-health-coronavirus-seychelles/seychelles-rolls-out-covid-19-vaccination-using-chinas-sinopharm-says-presidents-office-idUSKBN29G0J0">Seychelles</a>.<br>


</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-05-23 13:08 -->
<!-- ai file: map-sinopharm-beijing.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-sinopharm-beijing-box ,
	#g-map-sinopharm-beijing-box .g-artboard {
		margin:0 auto;
	}
	#g-map-sinopharm-beijing-box p {
		margin:0;
	}
	#g-map-sinopharm-beijing-box .g-aiAbs {
		position:absolute;
	}
	#g-map-sinopharm-beijing-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-sinopharm-beijing-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-sinopharm-beijing-box .g-aiPointText p { white-space: nowrap; }
	#g-map-sinopharm-beijing-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm-beijing-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm-beijing-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-sinopharm-beijing-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:right;
	}
	#g-map-sinopharm-beijing-900 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm-beijing-900 .g-pstyle3 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-sinopharm-beijing-900 .g-pstyle4 {
		height:18px;
		position:relative;
	}
	#g-map-sinopharm-beijing-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm-beijing-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm-beijing-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-sinopharm-beijing-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm-beijing-720 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-sinopharm-beijing-720 .g-pstyle3 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:right;
	}
	#g-map-sinopharm-beijing-720 .g-pstyle4 {
		height:17px;
		position:relative;
	}
	#g-map-sinopharm-beijing-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm-beijing-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm-beijing-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-sinopharm-beijing-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm-beijing-600 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:right;
	}
	#g-map-sinopharm-beijing-600 .g-pstyle3 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-sinopharm-beijing-600 .g-pstyle4 {
		height:16px;
		position:relative;
	}
	#g-map-sinopharm-beijing-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm-beijing-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm-beijing-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-sinopharm-beijing-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm-beijing-335 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-sinopharm-beijing-335 .g-pstyle3 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:right;
	}
	#g-map-sinopharm-beijing-335 .g-pstyle4 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-sinopharm-beijing-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-sinopharm-beijing-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-sinopharm-beijing-900-img" class="g-map-sinopharm-beijing-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm-beijing-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:7.0941%;margin-top:-27.3px;left:0%;width:124px;">
			<p class="g-pstyle0">Sinopharm and</p>
			<p class="g-pstyle0">Beijing Institute</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:34.201%;margin-top:-6.8px;right:36.5614%;width:61px;">
			<p class="g-pstyle1">NIGER</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:34.7627%;margin-top:-6.8px;left:80.7651%;margin-left:-31px;width:62px;">
			<p class="g-pstyle2">CHINA</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:37.5708%;margin-top:-6.8px;left:70.2642%;width:53px;">
			<p class="g-pstyle3">IRAN</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:38.4133%;margin-top:-6.8px;right:31.3179%;width:62px;">
			<p class="g-pstyle1">EGYPT</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:42.0639%;margin-top:-6.8px;left:72.1782%;width:83px;">
			<p class="g-pstyle3">PAKISTAN</p>
		</div>
		<div id="g-ai0-7" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:44.3104%;margin-top:-6.8px;right:29.8467%;width:79px;">
			<p class="g-pstyle1">BAHRAIN</p>
		</div>
		<div id="g-ai0-8" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:45.7145%;margin-top:-6.8px;right:41.9103%;width:67px;">
			<p class="g-pstyle1">GABON</p>
		</div>
		<div id="g-ai0-9" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:47.1186%;margin-top:-6.8px;left:27.2936%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle2">MEXICO</p>
		</div>
		<div id="g-ai0-10" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:51.05%;margin-top:-6.8px;left:41.7203%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai0-11" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:59.4745%;margin-top:-6.8px;right:43.0282%;width:76px;">
			<p class="g-pstyle1">NAMIBIA</p>
		</div>
		<div id="g-ai0-12" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:59.7553%;margin-top:-6.8px;left:86.0779%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle2">INDONESIA</p>
		</div>
		<div id="g-ai0-13" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:64.81%;margin-top:-6.8px;right:61.6895%;width:55px;">
			<p class="g-pstyle1">PERU</p>
		</div>
		<div id="g-ai0-14" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:65.3717%;margin-top:-6.8px;left:68.8341%;width:101px;">
			<p class="g-pstyle3">SEYCHELLES</p>
		</div>
		<div id="g-ai0-15" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:71.5496%;margin-top:-6.8px;left:42.1542%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle2">ARGENTINA</p>
		</div>
		<div id="g-ai0-16" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai0-17" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle4">Early, limited or</p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-sinopharm-beijing-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-sinopharm-beijing-720-img" class="g-map-sinopharm-beijing-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm-beijing-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:8.2866%;margin-top:-25.5px;left:0.0153%;width:118px;">
			<p class="g-pstyle0">Sinopharm and</p>
			<p class="g-pstyle0">Beijing Institute</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:35.1214%;margin-top:-6.8px;left:80.827%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:36.5292%;margin-top:-6.8px;left:70.8272%;width:53px;">
			<p class="g-pstyle2">IRAN</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:38.2889%;margin-top:-6.8px;right:31.1585%;width:62px;">
			<p class="g-pstyle3">EGYPT</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:42.1603%;margin-top:-6.8px;left:72.8021%;width:83px;">
			<p class="g-pstyle2">PAKISTAN</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:44.272%;margin-top:-6.8px;right:29.7504%;width:79px;">
			<p class="g-pstyle3">BAHRAIN</p>
		</div>
		<div id="g-ai1-7" class="g-type_copy g-aiAbs g-aiPointText" style="top:45.6798%;margin-top:-6.8px;right:41.9464%;width:67px;">
			<p class="g-pstyle3">GABON</p>
		</div>
		<div id="g-ai1-8" class="g-type_copy g-aiAbs g-aiPointText" style="top:46.7357%;margin-top:-6.8px;left:27.0822%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai1-9" class="g-type_copy g-aiAbs g-aiPointText" style="top:51.6629%;margin-top:-6.8px;left:41.359%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai1-10" class="g-type_copy g-aiAbs g-aiPointText" style="top:59.7577%;margin-top:-6.8px;right:43.281%;width:76px;">
			<p class="g-pstyle3">NAMIBIA</p>
		</div>
		<div id="g-ai1-11" class="g-type_copy g-aiAbs g-aiPointText" style="top:60.4616%;margin-top:-6.8px;left:82.8733%;width:91px;">
			<p class="g-pstyle2">INDONESIA</p>
		</div>
		<div id="g-ai1-12" class="g-type_copy g-aiAbs g-aiPointText" style="top:65.0369%;margin-top:-6.8px;right:61.6869%;width:55px;">
			<p class="g-pstyle3">PERU</p>
		</div>
		<div id="g-ai1-13" class="g-type_copy g-aiAbs g-aiPointText" style="top:66.0928%;margin-top:-6.8px;left:68.8285%;width:101px;">
			<p class="g-pstyle2">SEYCHELLES</p>
		</div>
		<div id="g-ai1-14" class="g-type_copy g-aiAbs g-aiPointText" style="top:72.7798%;margin-top:-6.8px;left:42.0093%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai1-15" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai1-16" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle4">Early, limited or </p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-sinopharm-beijing-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-sinopharm-beijing-600-img" class="g-map-sinopharm-beijing-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm-beijing-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:9.2099%;margin-top:-23.8px;left:-0.067%;width:107px;">
			<p class="g-pstyle0">Sinopharm and</p>
			<p class="g-pstyle0">Beijing Inst.</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:34.9331%;margin-top:-6.8px;left:80.9395%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:36.1989%;margin-top:-6.8px;right:30.2238%;width:62px;">
			<p class="g-pstyle2">EGYPT</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:37.0428%;margin-top:-6.8px;left:70.5963%;width:53px;">
			<p class="g-pstyle3">IRAN</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:43.3719%;margin-top:-6.8px;right:29.698%;width:79px;">
			<p class="g-pstyle2">BAHRAIN</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:44.6378%;margin-top:-6.8px;left:73.4068%;width:83px;">
			<p class="g-pstyle3">PAKISTAN</p>
		</div>
		<div id="g-ai2-7" class="g-type g-aiAbs g-aiPointText" style="top:45.9036%;margin-top:-6.8px;right:41.8125%;width:67px;">
			<p class="g-pstyle2">GABON</p>
		</div>
		<div id="g-ai2-8" class="g-type g-aiAbs g-aiPointText" style="top:46.7475%;margin-top:-6.8px;left:26.879%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai2-9" class="g-type g-aiAbs g-aiPointText" style="top:52.2327%;margin-top:-6.8px;left:41.255%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai2-10" class="g-type g-aiAbs g-aiPointText" style="top:61.0935%;margin-top:-6.8px;right:43.2297%;width:76px;">
			<p class="g-pstyle2">NAMIBIA</p>
		</div>
		<div id="g-ai2-11" class="g-type g-aiAbs g-aiPointText" style="top:61.0935%;margin-top:-6.8px;left:82.7253%;width:91px;">
			<p class="g-pstyle3">INDONESIA</p>
		</div>
		<div id="g-ai2-12" class="g-type g-aiAbs g-aiPointText" style="top:65.3129%;margin-top:-6.8px;left:35.6799%;margin-left:-27.5px;width:55px;">
			<p class="g-pstyle1">PERU</p>
		</div>
		<div id="g-ai2-13" class="g-type g-aiAbs g-aiPointText" style="top:67.0006%;margin-top:-6.8px;left:68.8731%;width:101px;">
			<p class="g-pstyle3">SEYCHELLES</p>
		</div>
		<div id="g-ai2-14" class="g-type g-aiAbs g-aiPointText" style="top:72.9078%;margin-top:-6.8px;left:42.2962%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai2-15" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai2-16" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle4">Early, limited or</p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-sinopharm-beijing-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-sinopharm-beijing-335-img" class="g-map-sinopharm-beijing-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm-beijing-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:4.585%;margin-top:-23.8px;left:0.2695%;width:107px;">
			<p class="g-pstyle0">Sinopharm and</p>
			<p class="g-pstyle0">Beijing Inst.</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:25.7934%;margin-top:-6.8px;left:53.4015%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:28.5242%;margin-top:-6.8px;left:82.7599%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:35.8763%;margin-top:-6.8px;left:69.8916%;margin-left:-27.5px;width:55px;">
			<p class="g-pstyle1">PERU</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:40.4976%;margin-top:-6.8px;left:83.7933%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:55.4117%;margin-top:-6.8px;left:36.0572%;width:84px;">
			<p class="g-pstyle2">HUNGARY</p>
		</div>
		<div id="g-ai3-7" class="g-type g-aiAbs g-aiPointText" style="top:63.604%;margin-top:-6.8px;left:62.0816%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai3-8" class="g-type g-aiAbs g-aiPointText" style="top:64.0242%;margin-top:-6.8px;left:41.6492%;width:53px;">
			<p class="g-pstyle2">IRAN</p>
		</div>
		<div id="g-ai3-9" class="g-type g-aiAbs g-aiPointText" style="top:64.8644%;margin-top:-6.8px;right:61.6243%;width:62px;">
			<p class="g-pstyle3">EGYPT</p>
		</div>
		<div id="g-ai3-10" class="g-type g-aiAbs g-aiPointText" style="top:67.8052%;margin-top:-6.8px;left:45.7298%;width:83px;">
			<p class="g-pstyle2">PAKISTAN</p>
		</div>
		<div id="g-ai3-11" class="g-type g-aiAbs g-aiPointText" style="top:68.4354%;margin-top:-6.8px;right:59.2929%;width:79px;">
			<p class="g-pstyle3">BAHRAIN</p>
		</div>
		<div id="g-ai3-12" class="g-type g-aiAbs g-aiPointText" style="top:73.6869%;margin-top:-6.8px;right:82.544%;width:74px;">
			<p class="g-pstyle3">ANGOLA</p>
		</div>
		<div id="g-ai3-13" class="g-type g-aiAbs g-aiPointText" style="top:78.0981%;margin-top:-6.8px;left:64.5221%;width:91px;">
			<p class="g-pstyle2">INDONESIA</p>
		</div>
		<div id="g-ai3-14" class="g-type g-aiAbs g-aiPointText" style="top:81.0389%;margin-top:-6.8px;left:37.7447%;width:101px;">
			<p class="g-pstyle2">SEYCHELLES</p>
		</div>
		<div id="g-ai3-15" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai3-16" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle4">Early, limited or </p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-sinopharm-beijing-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-05-23 13:08 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="sinovac"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN CHINA</span>


<span class="g-limited">EMERGENCY USE IN OTHER COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/sinovac-800.png" class="g-vlogo" 
    style="width: 200px; height: 34px; margin-right: 20px;" alt="Sinovac logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> CoronaVac (formerly PiCoVacc)<br>
<span class="g-info">Efficacy:</span> <a href="https://www.nytimes.com/2021/01/13/business/chinese-vaccine-brazil-sinovac.html">50.65%</a> in Brazil trial, <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01429-X/fulltext">83.5%</a> in Turkey trial<br>
<span class="g-info">Dose:</span> 2 doses, 2 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Refrigerated<br>
<br>
</span>

<!-- description -->
Coronavac, developed by the private Chinese company Sinovac, has emerged as one of China’s leading vaccines. As of April 2022, the company said that it had delivered <a href="https://www.businesswire.com/news/home/20220429005696/en/SINOVAC-Reports-Unaudited-Second-Half-of-2021-Financial-Results-and-Files-2021-Annual-Report-on-Form-20-F">over 2.8 billion doses</a> around the world. But concerns have arisen about its effectiveness and <a href="https://www.nytimes.com/2021/06/22/business/economy/china-vaccines-covid-outbreak.html">how long its protection lasts</a>.<br><br> <subhed>VACCINE DEVELOPMENT</subhed>In early 2020, Sinovac developed the Coronavac vaccine based on inactivated coronaviruses. They <a href="https://apps.who.int/iris/handle/10665/341455?search-result=true&query=&scope=&filtertype_0=mesh&filter_relational_operator_0=contains&filter_0=COVID-19&rpp=10&sort_by=dc.date.accessioned_dt&order=desc&page=3">found</a> in experiments on monkeys that the vaccine significantly lowered the amount of coronavirus that grew in the animals after an infection, and they recovered more quickly than unvaccinated monkeys.<br><br> <subhed>TRIAL RESULTS</subhed>After creating their vaccine last spring, Sinovac ran a Phase 1/2 trial on 743 volunteers that revealed <a href="https://www.medrxiv.org/content/10.1101/2020.07.31.20161216v1">no severe adverse effects</a>. Sinovac <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30843-4/fulltext">published</a> the details of the trial in November in a medical journal, showing a comparatively modest production of antibodies. In July, Sinovac <a href="http://www.sinovac.com/?optionid=754&auto_id=907">launched</a> a Phase 3 trial in Brazil, followed by others in <a href="https://www.reuters.com/article/us-health-coronavirus-indonesia-vaccine/sinovac-launches-phase-3-trial-for-covid-19-vaccine-in-indonesia-reports-phase-2-details-idUSKCN2570E9">Indonesia</a> and <a href="http://www.sinovac.com/?optionid=754&auto_id=911">Turkey</a>.<br><br>The trials in Brazil and Turkey demonstrated  that it could protect against Covid-19, but they delivered <a href="http://www.sinovac.com/?optionid=754&auto_id=927">strikingly different results</a> — in part because they designed the trials differently. <a href="https://www.nytimes.com/2021/01/13/business/chinese-vaccine-brazil-sinovac.html">In Brazil</a>, the efficacy against Covid-19 with or without symptoms was <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780">50 percent</a>. Against severe disease, its efficacy was 100 percent. The Turkish trial found that  the efficacy against Covid-19 with at least one symptom was <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01429-X/fulltext">83.5 percent</a>.<br><br>After CoronaVac was taken up in other countries, some of them conducted studies to measure its effectiveness. In Chile, researchers reviewed 10.5 million people who were vaccinated and estimated that the vaccine had an effectiveness of 67 percent against symptomatic Covid-19, and 85 percent protection against hospitalization.<br><br>Sinovac registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04884685?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 2 trial</a> of the vaccine in children and adolescents on May 13. They <a href="https://clinicaltrials.gov/ct2/show/NCT04992260?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">moved</a> to Phase 3 on Aug. 5. Preliminary results <a href="http://www.sinovac.com/news/shownews.php?id=1341">released</a> on Nov. 5, suggest that the vaccine demonstrated no serious adverse reactions, and that it was effective at stimulating the immune system.<br><br>On April 26, 2022, Sinovac announced that they had received approval to test a new version of Sinovac tailored for <a href="http://www.sinovac.com/news/shownews.php?id=1451">the Omicron variant</a>.<br><br> <subhed>AUTHORIZATION</subhed>China began giving CoronaVac to some of its citizens as early as the summer of 2020, long before its formal authorization. In October, authorities in the eastern Chinese city of Jiaxing announced they were <a href="https://www.nytimes.com/live/2020/10/16/world/covid-coronavirus/a-chinese-city-says-it-has-given-some-residents-a-vaccine-and-other-news-from-around-the-world">giving CoronaVac</a> to people in relatively high-risk jobs, including medical workers, port inspectors and public service personnel.<br><br>Indonesia gave the vaccine emergency authorization on Jan. 11, and two days later the president of Indonesia received an injection of CoronaVac on live television. Turkey <a href="https://apnews.com/article/turkey-china-coronavirus-pandemic-coronavirus-vaccine-ac68dcf62293e0cc70942a1c218681a8">authorized</a> the vaccine on Jan. 13, and its president <a href="https://www.reuters.com/article/us-health-coronavirus-turkey-vaccine-erd/turkeys-erdogan-receives-covid-19-vaccine-idUSKBN29J1WL">got vaccinated</a> the next day. <a href="https://www.bloomberg.com/news/articles/2021-01-17/brazil-poised-to-approve-emergency-use-of-first-covid-vaccines">Brazil</a> authorized CoronaVac on Jan. 17.<br><br>On Feb. 6, 2021,  Sinovac announced that China had given CoronaVac <a href="https://www.nytimes.com/live/2021/02/06/world/covid-19-coronavirus#china-approves-a-second-covid-19-vaccine-and-other-news-from-around-the-world">conditional approval</a>. China <a href="https://www.reuters.com/world/china/sinovacs-covid-19-vaccine-gains-china-approval-emergency-use-children-2021-06-05/">expanded its authorization</a> to include children and adolescents on June 4. Both authorizations came before Phase 3 data was made public. After reviewing clinical trial results, the <a href="https://www.scmp.com/news/china/science/article/3135677/who-approves-sinovac-biotechs-covid-19-vaccine-emergency-use">World Health Organization</a> gave emergency authorization to the vaccine on June 1, 2021.<br><br>On May 4, the European Medicines Agency said it was launching <a href="https://www.ema.europa.eu/en/news/ema-starts-rolling-review-covid-19-vaccine-vero-cell-inactivated">a rolling review of CoronaVac</a>, which will accelerate Sinovac’s marketing authorization if the company decides to apply for one. On April 14, 2022, Sinovac <a href="http://www.sinovac.com/news/shownews.php?id=1447">announced</a> that health officials in Hong Kong have authorized the use of an Omicron-specific version of CoronaVac. China <a href="http://www.sinovac.com/news/shownews.php?id=1451">followed</a> with an authorization two weeks later. Sinovac was authorized in Hong Kong for children <a href="http://www.sinovac.com/news/shownews.php?id=1500">as young as six months old</a> on Aug. 2.<br><br> <subhed>DISTRIBUTION</subhed>Sinovac has struck deals with at least 11 countries and regions to supply them with SinoVac. Sinovac reached an agreement <a href="https://www.businesswire.com/news/home/20210712005331/en/SINOVAC-Enters-Into-Agreement-to-Supply-CoronaVac%C2%AE-to-COVAX">announced</a> on July 12 to supply up to <a href="https://www.fiercepharma.com/pharma/china-s-sinovac-sinopharm-ink-covax-supply-deal-for-up-to-550m-doses-covid-19-vaccines">550 million doses</a> to COVAX, the initiative to distribute vaccines to low- and middle-income countries. On Dec. 31, 2021, the company <a href="http://www.sinovac.com.cn/news/shownews.php?id=1367&lang=en">announced</a> its sales surged to $11 billion in the first six months of the year. <br><br> <subhed>BOOSTERS</subhed>The World Health Organization <a href="https://www.nature.com/articles/d41586-021-02796-w">recommends</a> that people over 60 who receive Sinovac get a booster shot with the same or another vaccine. Sinovac registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05398926?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">trial</a> on June 1, 2022, to test the effectiveness of the vaccine as a booster in older adults.<br><br>Some of the earliest evidence that boosters might be needed came in the spring of 2021, when more than 350 doctors and health care workers in Indonesia came down with Covid-19 <a href="https://www.nytimes.com/2021/06/22/business/economy/china-vaccines-covid-outbreak.html">despite being fully vaccinated with Sinovac</a>. These alarming reports stirred concerns that CoronaVac’s protection was waning. In its June 2021 authorization of the vaccine, the World Health Organization <a href="https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations">noted</a> that they observed possible signs of waning immunity in the first three months of the clinical trial in Brazil. A <a href="https://www.medrxiv.org/content/10.1101/2021.07.23.21261026v1">study</a> released on July 25 found that six months after receiving two doses, healthy adults experienced a large drop in antibody levels.That same study showed that a booster of CoronaVac could restore high antibody levels.<br><br>In August, Chilean researchers <a href="https://clinicaltrials.gov/ct2/show/NCT04992182?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">registered</a> a Phase 2 trial to assess the effectiveness of giving a different vaccine as a booster to those who received the Sinovac shot. CoronaVac is also part of a <a href="https://medicalxpress.com/news/2021-08-china-mixed-vaccine-trial-delta.html">mixed-vaccine trial</a> with Inovio’s vaccine. Results from a <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/mixing-cansinobio-sinovac-covid-shots-induces-stronger-response-than-sinovac-2021-09-07/">Chinese study</a>, released on Sept. 7, suggested that getting a CanSino booster shot after the Sinovac vaccine produced a stronger antibody response compared to a third shot of the Sinovac vaccine.<br><br> For more details, see <strong><a href="https://www.nytimes.com/interactive/2020/health/sinovac-covid-19-vaccine.html">How the Sinovac Vaccine Works</a></strong>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://www.nytimes.com/live/2021/02/06/world/covid-19-coronavirus#china-approves-a-second-covid-19-vaccine-and-other-news-from-around-the-world">China</a>.<br>
<span class="g-info">Stopped use in:</span> <a href="https://www.reuters.com/world/asia-pacific/malaysia-stop-using-sinovac-vaccine-after-supply-ends-minister-2021-07-15/">Malaysia</a>.<br>

<span class="g-info">Emergency use in:</span> <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Albania</a>, <a href="http://www.sinovac.com/news/shownews.php?id=1310">Algeria</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/mixed-covid-vaccine-schedules-offer-stronger-boost-after-sinovac-regimen-study-2022-01-24/">Argentina</a>, <a href="https://am.usembassy.gov/u-s-citizen-services/covid-19-information/">Armenia</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-azerbaijan/azerbaijan-to-start-covid-19-inoculations-with-4-million-sinovac-shots-idUSKBN29L0BK">Azerbaijan</a>, <a href="http://www.xinhuanet.com/english/asiapacific/2021-06/06/c_139992410.htm">Bangladesh</a>, <a href="https://documents1.worldbank.org/curated/en/936011623022343506/pdf/Project-Information-Document-Benin-COVID-19-second-Vaccines-Additional-Financing-to-COVID-19-Preparedness-and-Response-Project-P176562.pdf">Benin</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Bolivia</a>,  <a href="https://www.bomra.co.bw/index.php/news-updates/177-covid-19-vaccines-approved-by-bomra">Botswana</a>, <a href="https://www.bloomberg.com/news/articles/2021-01-17/brazil-poised-to-approve-emergency-use-of-first-covid-vaccines">Brazil</a>, <a href="https://www.globaltimes.cn/page/202102/1215590.shtml">Cambodia</a>, <a href="https://www.reuters.com/article/health-coronavirus-chile-sinovac/update-1-chile-regulator-greenlights-sinovac-covid-19-vaccine-for-emergency-use-idUSL1N2JV1KB">Chile</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-vaccine-sinovac-idUSKBN2A60AY">Colombia</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341455/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Djibouti</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341455/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Dominica</a>, <a href="https://www.msp.gob.do/web/?p=11563">Dominican Republic</a>, <a href="https://www.salud.gob.ec/2-millones-de-vacunas-del-laboratorio-sinovac-llegaran-a-ecuador-entre-marzo-y-abril-de-2021/">Ecuador</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">El Salvador</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/egypt-approves-chinas-sinovac-coronavirus-vaccine-emergency-use-2021-04-26/">Egypt</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341455/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Gabon</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Georgia</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341455/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Guinea</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341455/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Guyana</a>, <a href="https://www.reuters.com/article/health-coronavirus-hongkong-idINKBN2AI0Q1">Hong Kong</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-indonesia/indonesia-approves-chinas-sinovac-vaccine-as-infections-surge-idUSKBN29G0RP">Indonesia</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Kazakhstan</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-vaccine-sinovac-idUSKBN2A60AY">Laos</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Libya</a>, <a href="https://www.facebook.com/malawimoh/posts/4098884300167054">Malawi</a>, <a href="http://www.xinhuanet.com/english/asiapacific/2021-03/02/c_139778599.htm">Malaysia</a>, <a href="https://timesofindia.indiatimes.com/world/rest-of-world/mexico-approves-chinas-cansino-and-sinovac-covid-19-vaccines/articleshow/80823868.cms">Mexico</a>, <a href="https://msmps.gov.md/comunicare/comunicate/membrii-nitag-au-venit-cu-recomandari-privind-utilizarea-vaccinurilor-impotriva-covid-19-in-republica-moldova/">Moldova</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341455/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Morocco</a>, <a href="https://apps.who.int/iris/bitstream/handle/10665/341455/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-background-2021.1-eng.pdf?sequence=1&isAllowed=y">Myanmar</a>, <a href="https://global.chinadaily.com.cn/a/202106/05/WS60bb2843a31024ad0bac3d4d.html">Nepal</a>, <a href="https://www.euronews.com/2021/08/20/eu-now-accepting-covid-passes-from-north-macedonia-turkey-and-ukraine">North Macedonia</a>, <a href="https://gulfnews.com/world/gulf/oman/covid-19-oman-approves-use-of-sinovac-and-sputnik-vaccines-1.80173049">Oman</a>, <a href="http://www.xinhuanet.com/english/2021-04/09/c_139869787.htm">Pakistan</a>, <a href="https://www.reuters.com/article/health-coronavirus-panama-vaccine/panama-approves-use-of-chinas-sinovac-vaccine-against-covid-19-idUSE1N2GV008">Panama</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Paraguay</a>, <a href="http://www.xinhuanet.com/english/asiapacific/2021-02/22/c_139758425.htm">Philippines</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Rwanda, Saint Vincent and the Grenadines</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">San Marino</a>, <a href="https://saudigazette.com.sa/article/610193">Saudi Arabia</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Serbia</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Seychelles</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Slovakia</a>, <a href="https://www.sanews.gov.za/south-africa/kubayi-lauds-sahpras-sinovac-use-approval">South Africa</a>, <a href="http://www.xinhuanet.com/english/2021-07/16/c_1310065935.htm">Sri Lanka</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Syria</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Tajikistan</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Tanzania</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-thailand/thailand-allows-emergency-use-of-sinovacs-covid-19-vaccine-idUSKBN2AM1BX">Thailand</a>, <a href="http://timor-leste.gov.tl/?p=28430&lang=pt">Timor-Leste</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Togo</a>, <a href="https://newsday.co.tt/2021/11/08/health-ministry-covaxin-vaccine-approved-use-in-trinidad-and-tobago/">Trinidad and Tobago</a>, <a href="http://www.xinhuanet.com/english/africa/2021-03/05/c_139784398.htm">Tunisia</a>, <a href="https://apnews.com/article/turkey-china-coronavirus-pandemic-coronavirus-vaccine-ac68dcf62293e0cc70942a1c218681a8">Turkey</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Turkmenistan</a>, <a href="https://twitter.com/minofhealthug/status/1420327273669005317?lang=en">Uganda</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-ukraine-vaccine/ukraine-approves-chinas-sinovac-covid-19-vaccine-idUSKBN2B11H6">Ukraine</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">United Arab Emirates</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-vaccine-sinovac-idUSKBN2A60AY">Uruguay</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Uzbekistan</a>, <a href="https://ve.usembassy.gov/covid-19-information/">Venezuela</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">Vietnam</a>, <a href="https://covid-19pharmacovigilance.paho.org/sinovac#col-0">West Bank</a>, <a href="https://www.reuters.com/article/uk-health-coronavirus-zimbabwe-vaccine/zimbabwe-authorises-sputnik-v-sinovac-coronavirus-vaccines-for-emergency-use-idUSKBN2B20K3">Zimbabwe</a>. Emergency use validation from the <a href="https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations">World Health Organization</a>.<br>



</span>

<span class="g-updated">Updated Aug. 6, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-05-23 13:20 -->
<!-- ai file: map-sinovac.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-sinovac-box ,
	#g-map-sinovac-box .g-artboard {
		margin:0 auto;
	}
	#g-map-sinovac-box p {
		margin:0;
	}
	#g-map-sinovac-box .g-aiAbs {
		position:absolute;
	}
	#g-map-sinovac-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-sinovac-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-sinovac-box .g-aiPointText p { white-space: nowrap; }
	#g-map-sinovac-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinovac-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinovac-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-sinovac-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-sinovac-900 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinovac-900 .g-pstyle3 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:right;
	}
	#g-map-sinovac-900 .g-pstyle4 {
		height:18px;
		position:relative;
	}
	#g-map-sinovac-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinovac-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinovac-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-sinovac-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-sinovac-720 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinovac-720 .g-pstyle3 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:right;
	}
	#g-map-sinovac-720 .g-pstyle4 {
		height:17px;
		position:relative;
	}
	#g-map-sinovac-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinovac-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinovac-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-sinovac-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-sinovac-600 .g-pstyle2 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinovac-600 .g-pstyle3 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:right;
	}
	#g-map-sinovac-600 .g-pstyle4 {
		height:16px;
		position:relative;
	}
	#g-map-sinovac-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinovac-335 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-sinovac-335 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-sinovac-335 .g-pstyle1 {
		height:13px;
		text-align:right;
	}
	#g-map-sinovac-335 .g-pstyle2 {
		height:13px;
		text-align:center;
	}
	#g-map-sinovac-335 .g-pstyle3 {
		height:13px;
	}
	#g-map-sinovac-335 .g-pstyle4 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}

</style>

<div id="g-map-sinovac-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-sinovac-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-sinovac-900-img" class="g-map-sinovac-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinovac-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:0%;width:125px;">
			<p class="g-pstyle0">Sinovac vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:22.9684%;margin-top:-6.8px;left:66.8596%;width:78px;">
			<p class="g-pstyle1">UKRAINE</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:29.4272%;margin-top:-6.8px;left:61.7463%;margin-left:-38px;width:76px;">
			<p class="g-pstyle2">ALGERIA</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:29.9888%;margin-top:-6.8px;left:68.7988%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle2">TURKEY</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:34.7627%;margin-top:-6.8px;left:80.7651%;margin-left:-31px;width:62px;">
			<p class="g-pstyle2">CHINA</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:40.9406%;margin-top:-6.8px;left:74.4343%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle2">PAKISTAN</p>
		</div>
		<div id="g-ai0-7" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:45.4337%;margin-top:-6.8px;right:76.0405%;width:71px;">
			<p class="g-pstyle3">MEXICO</p>
		</div>
		<div id="g-ai0-8" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:49.9268%;margin-top:-6.8px;right:11.4436%;width:86px;">
			<p class="g-pstyle3">MALAYSIA</p>
		</div>
		<div id="g-ai0-9" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:51.3308%;margin-top:-6.8px;left:41.5732%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai0-10" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:58.6321%;margin-top:-6.8px;right:41.3405%;width:93px;">
			<p class="g-pstyle3">BOTSWANA</p>
		</div>
		<div id="g-ai0-11" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:60.317%;margin-top:-6.8px;left:85.9161%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle2">INDONESIA</p>
		</div>
		<div id="g-ai0-12" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:73.6839%;margin-top:-13.4px;left:58.7043%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">SOUTH</p>
			<p class="g-pstyle2">AFRICA</p>
		</div>
		<div id="g-ai0-13" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:72.1113%;margin-top:-6.8px;left:43.755%;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai0-14" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:72.3921%;margin-top:-6.8px;left:38.0111%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle2">CHILE</p>
		</div>
		<div id="g-ai0-15" class="g-900 g-aiAbs g-aiPointText" style="top:87.9755%;margin-top:-27.3px;left:72.1419%;width:121px;">
			<p class="g-pstyle4">Stopped use</p>
			<p class="g-pstyle4">in favor of other</p>
			<p class="g-pstyle4">vaccines</p>
		</div>
		<div id="g-ai0-16" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai0-17" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle4">Early, limited or</p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-sinovac-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-sinovac-720-img" class="g-map-sinovac-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinovac-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0153%;width:118px;">
			<p class="g-pstyle0">Sinovac vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:21.0435%;margin-top:-6.8px;left:65.9104%;width:78px;">
			<p class="g-pstyle1">UKRAINE</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:28.0824%;margin-top:-6.8px;left:61.1099%;margin-left:-38px;width:76px;">
			<p class="g-pstyle2">ALGERIA</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:30.5461%;margin-top:-6.8px;left:68.8552%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle2">TURKEY</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:35.1214%;margin-top:-6.8px;left:80.827%;margin-left:-31px;width:62px;">
			<p class="g-pstyle2">CHINA</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:40.7526%;margin-top:-6.8px;left:73.6831%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle2">PAKISTAN</p>
		</div>
		<div id="g-ai1-7" class="g-type_copy g-aiAbs g-aiPointText" style="top:46.0318%;margin-top:-6.8px;right:75.7461%;width:71px;">
			<p class="g-pstyle3">MEXICO</p>
		</div>
		<div id="g-ai1-8" class="g-type_copy g-aiAbs g-aiPointText" style="top:49.5512%;margin-top:-6.8px;right:10.9497%;width:86px;">
			<p class="g-pstyle3">MALAYSIA</p>
		</div>
		<div id="g-ai1-9" class="g-type_copy g-aiAbs g-aiPointText" style="top:51.311%;margin-top:-6.8px;left:41.4903%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai1-10" class="g-type_copy g-aiAbs g-aiPointText" style="top:54.4785%;margin-top:-6.8px;right:66.7834%;width:88px;">
			<p class="g-pstyle3">COLOMBIA</p>
		</div>
		<div id="g-ai1-11" class="g-type_copy g-aiAbs g-aiPointText" style="top:57.646%;margin-top:-6.8px;right:41.5247%;width:93px;">
			<p class="g-pstyle3">BOTSWANA</p>
		</div>
		<div id="g-ai1-12" class="g-type_copy g-aiAbs g-aiPointText" style="top:61.1655%;margin-top:-6.8px;left:86.9656%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle2">INDONESIA</p>
		</div>
		<div id="g-ai1-13" class="g-type_copy g-aiAbs g-aiPointText" style="top:71.724%;margin-top:-6.8px;left:44.0095%;width:95px;">
			<p class="g-pstyle1">ARGENTINA</p>
		</div>
		<div id="g-ai1-14" class="g-type_copy g-aiAbs g-aiPointText" style="top:74.3988%;margin-top:-13.4px;left:58.5866%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">SOUTH</p>
			<p class="g-pstyle2">AFRICA</p>
		</div>
		<div id="g-ai1-15" class="g-type_copy g-aiAbs g-aiPointText" style="top:73.1317%;margin-top:-6.8px;left:37.4528%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle2">CHILE</p>
		</div>
		<div id="g-ai1-16" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai1-17" class="g-720 g-aiAbs g-aiPointText" style="top:89.5939%;margin-top:-25.6px;left:71.1546%;width:114px;">
			<p class="g-pstyle4">Stopped use</p>
			<p class="g-pstyle4">in favor of other</p>
			<p class="g-pstyle4">vaccines</p>
		</div>
		<div id="g-ai1-18" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle4">Early, limited or </p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-sinovac-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-sinovac-600-img" class="g-map-sinovac-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinovac-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:2.6276%;margin-top:-8.2px;left:-0.067%;width:111px;">
			<p class="g-pstyle0">Sinovac vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:21.431%;margin-top:-6.8px;left:65.2994%;width:78px;">
			<p class="g-pstyle1">UKRAINE</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:27.7601%;margin-top:-6.8px;left:60.916%;margin-left:-38px;width:76px;">
			<p class="g-pstyle2">ALGERIA</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:31.5576%;margin-top:-6.8px;left:69.4932%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle2">TURKEY</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:34.9331%;margin-top:-6.8px;left:80.9395%;margin-left:-31px;width:62px;">
			<p class="g-pstyle2">CHINA</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:42.1061%;margin-top:-6.8px;left:73.7518%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle2">PAKISTAN</p>
		</div>
		<div id="g-ai2-7" class="g-type g-aiAbs g-aiPointText" style="top:45.9036%;margin-top:-6.8px;right:76.0495%;width:71px;">
			<p class="g-pstyle3">MEXICO</p>
		</div>
		<div id="g-ai2-8" class="g-type g-aiAbs g-aiPointText" style="top:49.2791%;margin-top:-6.8px;right:10.4766%;width:86px;">
			<p class="g-pstyle3">MALAYSIA</p>
		</div>
		<div id="g-ai2-9" class="g-type g-aiAbs g-aiPointText" style="top:51.3888%;margin-top:-6.8px;left:41.402%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai2-10" class="g-type g-aiAbs g-aiPointText" style="top:55.1863%;margin-top:-6.8px;right:66.6799%;width:88px;">
			<p class="g-pstyle3">COLOMBIA</p>
		</div>
		<div id="g-ai2-11" class="g-type g-aiAbs g-aiPointText" style="top:61.5154%;margin-top:-6.8px;left:87.2528%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle2">INDONESIA</p>
		</div>
		<div id="g-ai2-12" class="g-type g-aiAbs g-aiPointText" style="top:76.1146%;margin-top:-13.4px;left:58.9342%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">SOUTH</p>
			<p class="g-pstyle2">AFRICA</p>
		</div>
		<div id="g-ai2-13" class="g-type g-aiAbs g-aiPointText" style="top:73.7517%;margin-top:-6.8px;left:36.871%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle2">CHILE</p>
		</div>
		<div id="g-ai2-14" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai2-15" class="g-600 g-aiAbs g-aiPointText" style="top:89.8088%;margin-top:-23.8px;left:71.0938%;width:108px;">
			<p class="g-pstyle4">Stopped use</p>
			<p class="g-pstyle4">in favor of other</p>
			<p class="g-pstyle4">vaccines</p>
		</div>
		<div id="g-ai2-16" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle4">Early, limited or</p>
			<p class="g-pstyle4">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-sinovac-335" class="g-artboard" style="max-width: 599px;max-height: 867px" data-aspect-ratio="0.691" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 144.7761% 0;"></div>
		<img id="g-map-sinovac-335-img" class="g-map-sinovac-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinovac-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:1.284%;margin-top:-8.2px;left:0.2695%;width:111px;">
			<p class="g-pstyle0">Sinovac vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:24.9055%;margin-top:-6.8px;right:52.5334%;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:28.2044%;margin-top:-6.8px;left:82.4614%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">BRAZIL</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:30.0601%;margin-top:-6.8px;right:33.2702%;width:88px;">
			<p class="g-pstyle1">COLOMBIA</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:38.7199%;margin-top:-6.8px;left:88.2294%;margin-left:-47.5px;width:95px;">
			<p class="g-pstyle2">ARGENTINA</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:42.4312%;margin-top:-6.8px;left:76.8278%;margin-left:-29.5px;width:59px;">
			<p class="g-pstyle2">CHILE</p>
		</div>
		<div id="g-ai3-7" class="g-type g-aiAbs g-aiPointText" style="top:55.0086%;margin-top:-6.8px;left:33.297%;width:78px;">
			<p class="g-pstyle3">UKRAINE</p>
		</div>
		<div id="g-ai3-8" class="g-type g-aiAbs g-aiPointText" style="top:58.9261%;margin-top:-6.8px;left:23.0373%;margin-left:-38px;width:76px;">
			<p class="g-pstyle2">ALGERIA</p>
		</div>
		<div id="g-ai3-9" class="g-type g-aiAbs g-aiPointText" style="top:60.7818%;margin-top:-6.8px;left:38.9834%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle2">TURKEY</p>
		</div>
		<div id="g-ai3-10" class="g-type g-aiAbs g-aiPointText" style="top:62.4312%;margin-top:-6.8px;left:62.0816%;margin-left:-31px;width:62px;">
			<p class="g-pstyle2">CHINA</p>
		</div>
		<div id="g-ai3-11" class="g-type g-aiAbs g-aiPointText" style="top:65.7302%;margin-top:-6.8px;left:47.5711%;margin-left:-41.5px;width:83px;">
			<p class="g-pstyle2">PAKISTAN</p>
		</div>
		<div id="g-ai3-12" class="g-type g-aiAbs g-aiPointText" style="top:70.0601%;margin-top:-6.8px;right:20.9723%;width:86px;">
			<p class="g-pstyle1">MALAYSIA</p>
		</div>
		<div id="g-ai3-13" class="g-type g-aiAbs g-aiPointText" style="top:76.4519%;margin-top:-6.8px;left:75.1758%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle2">INDONESIA</p>
		</div>
		<div id="g-ai3-14" class="g-type g-aiAbs g-aiPointText" style="top:84.4106%;margin-top:-13.4px;left:17.4066%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle2">SOUTH</p>
			<p class="g-pstyle2">AFRICA</p>
		</div>
		<div id="g-ai3-15" class="g-335 g-aiAbs g-aiPointText" style="top:88.2984%;margin-top:-8.2px;left:42.3228%;width:73px;">
			<p class="g-pstyle4">Approved</p>
		</div>
		<div id="g-ai3-16" class="g-335 g-aiAbs g-aiPointText" style="top:93.4117%;margin-top:-16px;left:42.3228%;width:109px;">
			<p class="g-pstyle4">Early, limited or </p>
			<p class="g-pstyle4">emergency use</p>
		</div>
		<div id="g-ai3-17" class="g-335 g-aiAbs g-aiPointText" style="top:98.4014%;margin-top:-8.2px;left:42.3228%;width:91px;">
			<p class="g-pstyle4">Stopped use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-sinovac-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-05-23 13:20 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="wuhan"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN CHINA</span>



    
<span class="g-limited">LIMITED USE IN U.A.E.</span>

<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/sinopharm-800.png" class="g-vlogo" 
    style="width: 65px; height: 81px; margin-right: 20px;" alt="Sinopharm logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/wuhan-800.png" class="g-vlogo" 
    style="width: 300px; height: 37px;" alt="Wuhan logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">

<span class="g-info">Efficacy:</span> <a href="https://www.reuters.com/article/us-health-coronavirus-sinopharm-vaccines/sinopharms-two-covid-19-shots-effective-study-says-idUSKCN2D80CT">72.8%</a><br>



<br>
</span>

<!-- description -->
Along with their Beijing Institute vaccine, <strong>Sinopharm</strong> also tested an inactivated virus vaccine developed by the <strong>Wuhan Institute of Biological Products</strong>. The Phase 1/2 trial, conducted in the spring of 2020, <a href="https://jamanetwork.com/journals/jama/fullarticle/2769612">showed</a> that the vaccine produced antibodies in volunteers, some of whom experienced fevers and other side effects. Sinopharm then launched a global Phase 3 trial of the Wuhan vaccine. In December 2020, Peru <a href="https://www.nytimes.com/live/2020/12/16/world/covid-19-coronavirus/the-clinical-trials-of-a-chinese-vaccine-resume-in-peru-after-a-volunteers-illness-is-deemed-unrelated">briefly paused</a> their  trial to investigate neurological problems that one volunteer experienced, but determined that it had nothing to do with the vaccines. On Feb. 25, 2021 China <a href="https://www.nytimes.com/live/2021/02/25/world/covid-19-coronavirus/china-approves-two-more-covid-19-vaccines">announced</a> the approval of the Wuhan vaccine for general use. In May, the vaccine researchers <a href="https://ja.ma/2Sy6ETh">published</a> the results of the Phase 3 trial, demonstrating that the vaccine has an efficacy of <a href="http://navirus-sinopharm-vaccines/sinopharms-two-covid-19-shots-effective-study-says-idUSKCN2D80CT">72.8 percent</a>. The researchers are also comparing a version of the vaccine to the Beijing Institute vaccine in a <a href="https://www.chictr.org.cn/showprojen.aspx?proj=170601">Phase 3 booster trial</a> against the Omicron variant.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://www.nytimes.com/live/2021/02/06/world/covid-19-coronavirus#china-approves-a-second-covid-19-vaccine-and-other-news-from-around-the-world">China</a>.<br>



<span class="g-info">Limited use in:</span> United Arab Emirates.<br>


</span>

<span class="g-updated">Updated June 29, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.101.0 - 2021-02-26 11:31 -->
<!-- ai file: map-sinopharm-wuhan.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-sinopharm-wuhan-box ,
	#g-map-sinopharm-wuhan-box .g-artboard {
		margin:0 auto;
	}
	#g-map-sinopharm-wuhan-box p {
		margin:0;
	}
	#g-map-sinopharm-wuhan-box .g-aiAbs {
		position:absolute;
	}
	#g-map-sinopharm-wuhan-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-sinopharm-wuhan-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-sinopharm-wuhan-box .g-aiPointText p { white-space: nowrap; }
	#g-map-sinopharm-wuhan-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm-wuhan-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm-wuhan-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-sinopharm-wuhan-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm-wuhan-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-sinopharm-wuhan-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm-wuhan-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm-wuhan-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-sinopharm-wuhan-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm-wuhan-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-sinopharm-wuhan-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm-wuhan-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm-wuhan-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-sinopharm-wuhan-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm-wuhan-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-sinopharm-wuhan-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-sinopharm-wuhan-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-sinopharm-wuhan-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-sinopharm-wuhan-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-sinopharm-wuhan-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-sinopharm-wuhan-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-sinopharm-wuhan-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-sinopharm-wuhan-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm-wuhan-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:7.0941%;margin-top:-27.3px;left:0%;width:125px;">
			<p class="g-pstyle0">Sinopharm and</p>
			<p class="g-pstyle0">Wuhan Institute</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:34.7627%;margin-top:-6.8px;left:80.7651%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:48.8035%;margin-top:-6.8px;left:71.6835%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">U.A.E.</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-sinopharm-wuhan-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-sinopharm-wuhan-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm-wuhan-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:8.2866%;margin-top:-25.5px;left:0.0153%;width:114px;">
			<p class="g-pstyle0">Sinopharm and</p>
			<p class="g-pstyle0">Wuhan Inst.</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:35.1214%;margin-top:-6.8px;left:80.827%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:49.1993%;margin-top:-6.8px;left:71.6497%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">U.A.E.</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-sinopharm-wuhan-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-sinopharm-wuhan-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm-wuhan-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:9.2099%;margin-top:-23.8px;left:-0.067%;width:107px;">
			<p class="g-pstyle0">Sinopharm and</p>
			<p class="g-pstyle0">Wuhan Inst.</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:34.9331%;margin-top:-6.8px;left:80.9395%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:49.2791%;margin-top:-6.8px;left:71.9756%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">U.A.E.</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-sinopharm-wuhan-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-sinopharm-wuhan-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-sinopharm-wuhan-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:4.585%;margin-top:-23.8px;left:0.2695%;width:107px;">
			<p class="g-pstyle0">Sinopharm and</p>
			<p class="g-pstyle0">Wuhan Inst.</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:63.604%;margin-top:-6.8px;left:62.0816%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:71.5863%;margin-top:-6.8px;left:43.6531%;margin-left:-29px;width:58px;">
			<p class="g-pstyle1">U.A.E.</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-sinopharm-wuhan-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-02-26 11:31 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="bharat"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->
<br><span class="g-approval">APPROVED IN INDIA</span>


<span class="g-limited">EMERGENCY USE IN OTHER COUNTRIES</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/bharat-800.png" class="g-vlogo" 
    style="width: 151px; height: 70px; margin-right: 20px;" alt="Bharat Biotech logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/icmr-800.png" class="g-vlogo" 
    style="width: 160px; height: 70px; margin-right: 20px;" alt="Indian Council of Medical Research logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/niv-800.png" class="g-vlogo" 
    style="width: 70px; height: 70px;" alt="National Institute of Virology logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Covaxin (also known as  BBV152)<br>
<span class="g-info">Efficacy:</span> <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02000-6/fulltext">77.8</a>%<br>
<span class="g-info">Dose:</span> 2 doses, 4 weeks apart<br>

<span class="g-info">Storage:</span> At least a week at room temperature<br>
<br>
</span>

<!-- description -->
Covaxin, produced by <strong>Bharat Biotech, </strong>was the first vaccine for Covid-19 developed in India to gain emergency use authorization. India approved it in April 2021, and the <a href="https://www.bbc.com/news/world-asia-india-58800168">World Health Organization</a> gave it emergency use listing on Nov. 3. As of February 2022, Bharat Biotech had distributed <a href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-us-fda-lifts-clinical-hold-submission-its">200 million doses</a>.<br><br> <subhed>VACCINE DEVELOPMENT</subhed>Researchers at  the <strong>Indian Council of Medical Research</strong> and the <strong>National Institute of Virology</strong>, designed Covaxin from inactivated coronaviruses. Studies carried out in the spring of 2021 on <a href="https://www.nature.com/articles/s41467-021-21639-w#disqus_thread">monkeys</a> and <a href="https://www.researchsquare.com/article/rs-76768/v1">hamsters</a> demonstrated that the vaccine provided the animals with protection against infection.<br><br> <subhed>TRIAL RESULTS</subhed>Bharat Biotech launched <a href="https://www.reuters.com/article/us-health-coronavirus-india-vaccine/indias-first-covid-19-vaccine-candidate-approved-for-human-trials-idUSKBN24108R"> clinical trials</a> in June 2020. The phase 1/2 trial <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext">showed</a> that the vaccine didn’t cause any serious side effects while <a href="https://www.sciencedirect.com/science/article/pii/S1473309921000700">producing antibodies</a> to the coronavirus. A <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00070-0/fulltext">follow-up study</a> confirmed these results. On Oct. 23, the company <a href="https://twitter.com/BharatBiotech/status/1319627204637028353">announced</a> they were initiating a <a href="http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=48057&EncHid=&userName=CTRI/2020/11/028976">Phase 3 trial</a>, eventually recruiting over 25,800 volunteers.<br><br>Bharat Biotech only <a href="https://www.nytimes.com/2021/03/04/world/asia/india-coronavirus-vaccine-covaxin.html?smid=tw-share">began releasing</a> results from the trial in March 2021, two months after the vaccine gained emergency authorization. The <a href="https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1">final results</a> were posted online on July 2 and <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02000-6/fulltext">appeared in the Lancet</a> on Nov. 11. The vaccine had an efficacy of 77.8 percent against symptomatic Covid-19, and its efficacy against severe Covid-19 was 93.4 percent. For asymptomatic disease, the vaccine had an efficacy of 63.6 percent, indicating that it can also slow transmission.<br><br>In June, Bharat Biotech registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04918797?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">trial</a> on children as young as 2. <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00307-3/fulltext">Results</a> from that trial suggested that Covaxin was more effective in children than in adults.<br><br> <subhed>AUTHORIZATION</subhed>On Jan. 3, 2021, the Indian government granted Covaxin <a href="https://www.nytimes.com/2021/01/03/world/asia/india-covid-19-vaccine.html">emergency authorization</a>. Just over a year later in January 2022, it granted <a href="https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/covaxin-covishield-granted-regular-market-approval-india-1905218-2022-01-27">full approval</a> for the vaccine. Indian health officials <a href="https://twitter.com/BharatBiotech/status/1518944327745302528">expanded their approval</a> to include children as young as six on April 26, 2022.<br><br> Other countries in Africa, Asia, and South America later authorized the vaccine. In Brazil, a controversy over <a href="https://www.thehindu.com/news/international/after-suspending-eua-request-brazil-now-shelves-import-authorisation-of-covaxin/article35600083.ece">corruption</a> led the government to suspend its authorization of Covaxin in July 2021.  On Nov. 3, 2021, Covaxin became the first Indian vaccine to receive <a href="https://www.cnbc.com/2021/11/03/indias-first-homegrown-covid-vaccine-wins-who-emergency-use-listing-.html">emergency use authorization</a> from the World Health Organization.<br><br>In June 2021, Bharat Biotech <a href="https://www.biospace.com/article/releases/ocugen-to-pursue-a-bla-path-in-the-us-for-its-covid-19-vaccine-candidate/">set out</a> to bring Covaxin to the United States. It formed a partnership with Pennsylvania-based Ocugen to seek a full approval for the vaccine, rather than an emergency use authorization. Ocugen and Bharat have suffered a series of setbacks in their efforts. The F.D.A. has <a href="https://www.fiercepharma.com/manufacturing/fda-slaps-another-clinical-hold-ocugen-and-bharats-covid-19-vaccine">twice</a> put their U.S. trial on hold. The latest pause, <a href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-provides-update-its-phase-23-study-covaxintm-bbv152">announced</a> on April 12, came after the World Health Organization raised concerns about Covaxin’s manufacturing. In May 2022, the F.D.A. <a href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-announces-fda-removes-clinical-hold-phase-23-clinical">allowed</a> Ocugen to <a href="https://www.fiercepharma.com/pharma/fda-lifts-hold-ocugens-covid-19-vaccine-trial-it-too-late-shot">resume</a> its trial.<br><br> <subhed>DISTRIBUTION</subhed>In May 2021, Bharat said it expected  to produce as many as one billion doses of Covaxin per year after <a href="https://twitter.com/SuchitraElla/status/1395395197501009921">expanding their manufacturing capacity</a>. But in April 2022, the company announced that it would <a href="https://twitter.com/BharatBiotech/status/1509927525966761996">slow its production</a> in light of lower foreseeable demand. <br><br><subhed>VARIANTS</subhed>Bharat ran its clinical trials in India just as the Delta variant was rising to dominance in the country. As a result, they were able to calculate the efficacy of Covaxin against Delta by looking at the relative risk volunteers had of contracting the variant. They estimated that its efficacy was <a href="https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1">65.2 percent</a>. On Jan. 12, 2022, Bharat announced that Covaxin <a href="https://twitter.com/BharatBiotech/status/1481236136672755715">works well as a booster</a> against prominent variants like Delta and Omicron.<br><br>For more details, see <strong><a href="https://www.nytimes.com/interactive/2021/health/bharat-biotech-covid-19-vaccine.html">How Bharat Biotech’s Vaccine Works</a></strong>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>
<span class="g-info">Approved for use in:</span> <a href="https://www.indiatoday.in/coronavirus-outbreak/vaccine-updates/story/covaxin-covishield-granted-regular-market-approval-india-1905218-2022-01-27">India</a>.<br>
<span class="g-info">Stopped use in:</span> <a href="https://www.reuters.com/world/india/brazil-suspends-import-permit-bharat-biotechs-covid-19-vaccine-2021-07-27/">Brazil</a> suspended import.<br>

<span class="g-info">Emergency use in:</span> <a href="https://www.bna.bh/en/BahrainauthorizesCOVAXINforemergencyuse.aspx?cms=q8FmFJgiscL2fwIzON1%2bDvdCpVGdtuusfPwcuTv4D1k%3d">Bahrain</a>, <a href="https://www.bharatbiotech.com/images/press/bharat-biotech-covaxin-capacity-expansion-to-worldwide.pdf">Botswana</a>, <a href="https://www.bharatbiotech.com/images/press/bharat-biotech-covaxin-capacity-expansion-to-worldwide.pdf">Guatemala</a>, <a href="https://www.bharatbiotech.com/images/press/bharat-biotech-covaxin-capacity-expansion-to-worldwide.pdf">Guyana</a>, <a href="https://www.livemint.com/news/india/covid19-vaccine-hong-kong-latest-to-approve-covaxin-for-emergency-use-11636531041255.html">Hong Kong</a>, <a href="https://en.irna.ir/news/84233593/Iran-issues-permit-for-emergency-use-for-three-other-COVID-19">Iran</a>, <a href="https://www.nst.com.my/news/nation/2022/02/770394/covaxin-given-conditional-approval-under-emergency-use-protocols">Malaysia</a>, <a href="https://besafemoris.mu/general_news/covid-19-covaxin-receives-approval-of-national-covid-19-vaccination-committee/">Mauritius</a>, <a href="https://www.reuters.com/article/us-health-coronavirus-mexico-india/mexico-authorizes-emergency-use-of-indian-covid-19-vaccine-idUSKBN2BU00H">Mexico</a>, <a href="https://www.reuters.com/article/healthcoronavirus-nepal-india/update-1-nepal-becomes-third-country-to-give-emergency-nod-to-indian-vaccine-covaxin-idUSL1N2LH10G">Nepal</a>, <a href="https://www.bharatbiotech.com/images/press/bharat-biotech-covaxin-capacity-expansion-to-worldwide.pdf">Nicaragua</a>, <a href="https://www.bharatbiotech.com/images/press/bharat-biotech-covaxin-capacity-expansion-to-worldwide.pdf">Paraguay</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/philippines-approves-emergency-use-jj-bharat-biotechcovid-19-vaccines-2021-04-19/">Philippines</a>, <a href="https://newsday.co.tt/2021/11/08/health-ministry-covaxin-vaccine-approved-use-in-trinidad-and-tobago/">Trinidad and Tobago</a>, <a href="https://covid-19pharmacovigilance.paho.org/bharat-biotech#col-0">Venezuela</a>, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/vietnam-approves-indias-covid-19-vaccine-covaxin-2021-11-10/">Vietnam</a>, <a href="http://www.xinhuanet.com/english/2021-03/04/c_139783893.htm">Zimbabwe</a>. Emergency use validation from the <a href="https://www.cnbc.com/2021/11/03/indias-first-homegrown-covid-vaccine-wins-who-emergency-use-listing-.html">World Health Organization</a>.<br>



</span>

<span class="g-updated">Updated June 29, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-04-15 12:40 -->
<!-- ai file: map-bharat.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-bharat-box ,
	#g-map-bharat-box .g-artboard {
		margin:0 auto;
	}
	#g-map-bharat-box p {
		margin:0;
	}
	#g-map-bharat-box .g-aiAbs {
		position:absolute;
	}
	#g-map-bharat-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-bharat-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-bharat-box .g-aiPointText p { white-space: nowrap; }
	#g-map-bharat-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-bharat-900 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-bharat-900 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-bharat-900 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-bharat-900 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:18px;
		height:18px;
		letter-spacing:0em;
		font-size:15px;
		top:1.2px;
		position:relative;
	}
	#g-map-bharat-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-bharat-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-bharat-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-bharat-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-bharat-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-bharat-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-bharat-600 p {
		font-family:nyt-cheltenham,georgia,serif;
		font-weight:300;
		line-height:13px;
		height:auto;
		opacity:1;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:left;
		color:rgb(0,0,0);
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
		position:static;
	}
	#g-map-bharat-600 .g-pstyle0 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:600;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-bharat-600 .g-pstyle1 {
		height:13px;
		text-align:center;
	}
	#g-map-bharat-600 .g-pstyle2 {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		line-height:16px;
		height:16px;
		letter-spacing:0em;
		font-size:13px;
		top:1px;
		position:relative;
	}
	#g-map-bharat-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-bharat-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-bharat-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-bharat-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-bharat-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-bharat-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-bharat-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-bharat-900-img" class="g-map-bharat-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-bharat-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:128px;">
			<p class="g-pstyle0">Bharat Biotech&rsquo;s</p>
			<p class="g-pstyle0">Covaxin vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-900 g-aiAbs g-aiPointText" style="top:37.29%;margin-top:-6.8px;left:91.9809%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle1">PHILIPPINES</p>
		</div>
		<div id="g-ai0-3" class="g-900 g-aiAbs g-aiPointText" style="top:38.4133%;margin-top:-6.8px;left:78.3633%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">NEPAL</p>
		</div>
		<div id="g-ai0-4" class="g-900 g-aiAbs g-aiPointText" style="top:39.5366%;margin-top:-6.8px;left:71.8235%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai0-5" class="g-900 g-aiAbs g-aiPointText" style="top:47.3994%;margin-top:-6.8px;left:76.9981%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai0-6" class="g-900 g-aiAbs g-aiPointText" style="top:48.5227%;margin-top:-6.8px;left:22.3009%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai0-7" class="g-900 g-aiAbs g-aiPointText" style="top:52.7349%;margin-top:-6.8px;left:48.5269%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai0-8" class="g-900 g-aiAbs g-aiPointText" style="top:58.0704%;margin-top:-6.8px;left:65.6488%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">ZIMBABWE</p>
		</div>
		<div id="g-ai0-9" class="g-900 g-aiAbs g-aiPointText" style="top:64.5292%;margin-top:-6.8px;left:37.795%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle1">PARAGUAY</p>
		</div>
		<div id="g-ai0-10" class="g-900 g-aiAbs g-aiPointText" style="top:85.4482%;margin-top:-18.3px;left:72.0688%;width:93px;">
			<p class="g-pstyle2">Suspended</p>
			<p class="g-pstyle2">import</p>
		</div>
		<div id="g-ai0-11" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-12" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-bharat-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-bharat-720-img" class="g-map-bharat-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-bharat-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:121px;">
			<p class="g-pstyle0">Bharat Biotech&rsquo;s</p>
			<p class="g-pstyle0">Covaxin vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-720 g-aiAbs g-aiPointText" style="top:36.5292%;margin-top:-6.8px;left:92.6731%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle1">PHILIPPINES</p>
		</div>
		<div id="g-ai1-3" class="g-720 g-aiAbs g-aiPointText" style="top:37.2331%;margin-top:-6.8px;left:78.5616%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">NEPAL</p>
		</div>
		<div id="g-ai1-4" class="g-720 g-aiAbs g-aiPointText" style="top:39.3448%;margin-top:-6.8px;left:71.915%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai1-5" class="g-720 g-aiAbs g-aiPointText" style="top:46.3837%;margin-top:-6.8px;left:76.9466%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai1-6" class="g-720 g-aiAbs g-aiPointText" style="top:48.8474%;margin-top:-6.8px;left:21.3225%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai1-7" class="g-720 g-aiAbs g-aiPointText" style="top:52.0149%;margin-top:-6.8px;left:49.0858%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai1-8" class="g-720 g-aiAbs g-aiPointText" style="top:57.2941%;margin-top:-6.8px;left:66.0853%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">ZIMBABWE</p>
		</div>
		<div id="g-ai1-9" class="g-720 g-aiAbs g-aiPointText" style="top:65.7408%;margin-top:-6.8px;left:37.1339%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle1">PARAGUAY</p>
		</div>
		<div id="g-ai1-10" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-11" class="g-720 g-aiAbs g-aiPointText" style="top:86.6375%;margin-top:-17.2px;left:71.0631%;width:88px;">
			<p class="g-pstyle2">Suspended</p>
			<p class="g-pstyle2">import</p>
		</div>
		<div id="g-ai1-12" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-bharat-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-bharat-600-img" class="g-map-bharat-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-bharat-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:9.2099%;margin-top:-23.8px;left:-0.067%;width:113px;">
			<p class="g-pstyle0">Bharat Biotech&rsquo;s</p>
			<p class="g-pstyle0">Covaxin</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-600 g-aiAbs g-aiPointText" style="top:34.5112%;margin-top:-6.8px;left:92.8953%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle1">PHILIPPINES</p>
		</div>
		<div id="g-ai2-3" class="g-600 g-aiAbs g-aiPointText" style="top:37.8867%;margin-top:-6.8px;left:79.4528%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">NEPAL</p>
		</div>
		<div id="g-ai2-4" class="g-600 g-aiAbs g-aiPointText" style="top:39.5745%;margin-top:-6.8px;left:72.0713%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai2-5" class="g-600 g-aiAbs g-aiPointText" style="top:47.1694%;margin-top:-6.8px;left:20.1321%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai2-6" class="g-600 g-aiAbs g-aiPointText" style="top:48.4352%;margin-top:-6.8px;left:77.1274%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai2-7" class="g-600 g-aiAbs g-aiPointText" style="top:52.2327%;margin-top:-6.8px;left:49.7896%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai2-8" class="g-600 g-aiAbs g-aiPointText" style="top:56.8741%;margin-top:-6.8px;left:67.4376%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">ZIMBABWE</p>
		</div>
		<div id="g-ai2-9" class="g-600 g-aiAbs g-aiPointText" style="top:66.1568%;margin-top:-6.8px;left:36.5204%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle1">PARAGUAY</p>
		</div>
		<div id="g-ai2-10" class="g-600 g-aiAbs g-aiPointText" style="top:86.5177%;margin-top:-16px;left:70.984%;width:84px;">
			<p class="g-pstyle2">Suspended</p>
			<p class="g-pstyle2">import</p>
		</div>
		<div id="g-ai2-11" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-12" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-bharat-335" class="g-artboard" style="max-width: 599px;max-height: 867px" data-aspect-ratio="0.691" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 144.7761% 0;"></div>
		<img id="g-map-bharat-335-img" class="g-map-bharat-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-bharat-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.8922%;margin-top:-16px;left:0.2695%;width:113px;">
			<p class="g-pstyle0">Bharat Biotech&rsquo;s</p>
			<p class="g-pstyle0">Covaxin vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-335 g-aiAbs g-aiPointText" style="top:26.3488%;margin-top:-6.8px;left:41.2671%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">MEXICO</p>
		</div>
		<div id="g-ai3-3" class="g-335 g-aiAbs g-aiPointText" style="top:28.4106%;margin-top:-6.8px;left:82.5048%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">BRAZIL</p>
		</div>
		<div id="g-ai3-4" class="g-335 g-aiAbs g-aiPointText" style="top:36.4519%;margin-top:-6.8px;left:73.6283%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle1">PARAGUAY</p>
		</div>
		<div id="g-ai3-5" class="g-335 g-aiAbs g-aiPointText" style="top:63.4622%;margin-top:-6.8px;left:86.5838%;margin-left:-49.5px;width:99px;">
			<p class="g-pstyle1">PHILIPPINES</p>
		</div>
		<div id="g-ai3-6" class="g-335 g-aiAbs g-aiPointText" style="top:64.4931%;margin-top:-6.8px;left:58.14%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">NEPAL</p>
		</div>
		<div id="g-ai3-7" class="g-335 g-aiAbs g-aiPointText" style="top:64.9055%;margin-top:-6.8px;left:44.1245%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai3-8" class="g-335 g-aiAbs g-aiPointText" style="top:69.6477%;margin-top:-6.8px;left:54.3721%;margin-left:-28.5px;width:57px;">
			<p class="g-pstyle1">INDIA</p>
		</div>
		<div id="g-ai3-9" class="g-335 g-aiAbs g-aiPointText" style="top:74.39%;margin-top:-6.8px;left:34.1781%;margin-left:-45px;width:90px;">
			<p class="g-pstyle1">ZIMBABWE</p>
		</div>
		<div id="g-ai3-10" class="g-335 g-aiAbs g-aiPointText" style="top:88.2983%;margin-top:-8.2px;left:42.1263%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-11" class="g-335 g-aiAbs g-aiPointText" style="top:93.4117%;margin-top:-16px;left:42.1263%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
		<div id="g-ai3-12" class="g-335 g-aiAbs g-aiPointText" style="top:98.4014%;margin-top:-8.2px;left:42.1263%;width:122px;">
			<p class="g-pstyle2">Suspended import</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-bharat-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-04-15 12:40 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="kazakhstan"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->


<span class="g-limited">EARLY USE IN TWO COUNTRIES</span>

    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/ribsp-800.png" class="g-vlogo" 
    style="width: 210px; height: 74px; margin-right: 20px;" alt="Kazakhstan’s Research Institute for Biological Safety Problems logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> QazVac<br>
<span class="g-info">Efficacy:</span> <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4016484">82%</a><br>



<br>
</span>

<!-- description -->
The central Asian nation of Kazakhstan <a href="https://astanatimes.com/2020/08/human-trials-for-kazakh-covid-19-vaccine-to-start-in-september/">began research</a> on a vaccine made from inactivated coronaviruses in the summer of 2020. On August 28, 2020, their <strong>Research Institute for Biological Safety Problems</strong> <a href="https://clinicaltrials.gov/ct2/show/NCT04530357?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">registered</a> a Phase 1 trial on the vaccine. On Dec. 19, Kazinform <a href="https://www.inform.kz/en/kazakhstan-to-vaccinate-3-000-volunteers-with-domestic-qazcovid-in_a3731631">reported</a> that researchers had completed the Phase 2 trial, finding that the vaccine was safe and produced a promising immune response. The researchers <a href="https://astanatimes.com/2020/12/kazakhstan-begins-vaccinating-3000-volunteers-with-self-made-qazcovid-in/">commenced</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT04691908">Phase 3 trial</a> in March 2021. Kazakhstan’s vice minister of education and science announced that the vaccine, known as QazVac, was <a href="https://www.inform.kz/en/vaccination-with-homegrown-qazvac-vaccine-likely-to-start-in-late-april_a3770566">expected</a> to be authorized in April, despite the lack of published results from the Phase 3 trial.<br><br>Kazakhstan began <a href="https://www.aa.com.tr/en/asia-pacific/kazakhstan-starts-using-indigenous-covid-19-vaccine/2220884">administering its vaccine </a>to the public in late April. On July 29, 2021, government officials <a href="https://astanatimes.com/2021/07/kazakhstan-delivers-25000-doses-of-its-own-vaccine-to-kyrgyzstan/">announced</a> that they would deliver 25,000 doses of the vaccine to neighboring country Kyrgyzstan.<br><br>Researchers at the institute released a <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4016484">report</a> on their Phase 3 trial in Jan. 2022. They found that the vaccine had an efficacy of 82 percent against infection. The trial was too small to determine efficacy against severe disease. After the vaccine was authorized in Kazakhstan, researchers tracked the vaccine’s performance from February to September 2021. In April 2022, they <a href="https://www.medrxiv.org/content/10.1101/2022.04.14.22273868v1">reported</a> that QazVac was 78 percent effective at preventing infection. Kazakhstani health officials said on April 28 that producing more doses of the vaccine would <a href="https://www.inform.kz/en/karaganda-plant-no-longer-produces-anti-covid-vaccines-chief-sanitary-officer_a3927925">no longer be necessary</a>, since there are already enough to cover the population.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>


<span class="g-info">Early use in:</span> <a href="https://www.aa.com.tr/en/asia-pacific/kazakhstan-starts-using-indigenous-covid-19-vaccine/2220884">Kazakhstan</a>, <a href="https://astanatimes.com/2021/07/kazakhstan-delivers-25000-doses-of-its-own-vaccine-to-kyrgyzstan/">Kyrgyzstan</a>.<br>




</span>

<span class="g-updated">Updated April 29, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.102.0 - 2021-10-05 11:31 -->
<!-- ai file: map-kazakhstan.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-kazakhstan-box ,
	#g-map-kazakhstan-box .g-artboard {
		margin:0 auto;
	}
	#g-map-kazakhstan-box p {
		margin:0;
	}
	#g-map-kazakhstan-box .g-aiAbs {
		position:absolute;
	}
	#g-map-kazakhstan-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-kazakhstan-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-kazakhstan-box .g-aiPointText p { white-space: nowrap; }
	#g-map-kazakhstan-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-kazakhstan-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-kazakhstan-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-kazakhstan-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-kazakhstan-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-kazakhstan-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-kazakhstan-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-kazakhstan-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-kazakhstan-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-kazakhstan-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-kazakhstan-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-kazakhstan-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-kazakhstan-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-kazakhstan-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-kazakhstan-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-kazakhstan-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-kazakhstan-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-kazakhstan-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-kazakhstan-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-kazakhstan-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-kazakhstan-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-kazakhstan-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-kazakhstan-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-kazakhstan-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:0%;width:122px;">
			<p class="g-pstyle0">QazVac vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:21.5643%;margin-top:-6.8px;left:70.0066%;width:106px;">
			<p class="g-pstyle1">KAZAKHSTAN</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:38.6941%;margin-top:-6.8px;left:71.447%;width:104px;">
			<p class="g-pstyle1">KYRGYZSTAN</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-kazakhstan-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-kazakhstan-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-kazakhstan-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0153%;width:115px;">
			<p class="g-pstyle0">QazVac vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:21.0435%;margin-top:-6.8px;left:69.0343%;width:106px;">
			<p class="g-pstyle1">KAZAKHSTAN</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:38.2889%;margin-top:-6.8px;left:70.1569%;width:104px;">
			<p class="g-pstyle1">KYRGYZSTAN</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-kazakhstan-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-kazakhstan-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-kazakhstan-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:2.6276%;margin-top:-8.2px;left:-0.067%;width:109px;">
			<p class="g-pstyle0">QazVac vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:21.431%;margin-top:-6.8px;left:66.7484%;width:106px;">
			<p class="g-pstyle1">KAZAKHSTAN</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:39.1525%;margin-top:-6.8px;left:68.9653%;width:104px;">
			<p class="g-pstyle1">KYRGYZSTAN</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-kazakhstan-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-kazakhstan-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-kazakhstan-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:1.3081%;margin-top:-8.2px;left:0.2695%;width:109px;">
			<p class="g-pstyle0">QazVac vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:56.0419%;margin-top:-6.8px;left:36.8803%;width:106px;">
			<p class="g-pstyle1">KAZAKHSTAN</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:66.1247%;margin-top:-6.8px;left:39.8258%;width:104px;">
			<p class="g-pstyle1">KYRGYZSTAN</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-kazakhstan-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-10-05 11:31 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="kangtai"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN CHINA, INDONESIA</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/kangtai-800.png" class="g-vlogo" 
    style="width: 205px; height: 57px; margin-right: 20px;" alt="Shenzhen Kangtai Biological Products logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong><a href="http://en.biokangtai.com/">Shenzhen Kangtai Biological Products</a></strong> is a Chinese company that makes vaccines for diseases such as hepatitis B and measles. In August 2020, AstraZeneca reached an <a href="https://www.reuters.com/article/health-coronavirus-astrazeneca-kangtai-b/astrazeneca-in-deal-with-kangtai-bio-to-supply-potential-covid-19-vaccine-in-china-idUSL4N2F82BI">agreement</a> with Shenzhen to supply China with their adenovirus  vaccine, despite <a href="https://www.nytimes.com/2020/12/07/business/china-vaccine-astrazeneca.html?searchResultPosition=1">the reports of corruption and scandals</a> that have plagued the company.<br><br>In October Shenzhen Kangtai <a href="http://www.chictr.org.cn/showprojen.aspx?proj=62350">launched</a> a Phase 1 trial on 180 volunteers of its own vaccine, based on inactivated coronaviruses, now known as <a href="https://www.prnewswire.com/news-releases/kangtai-adenovirus-vector-covid-19-vaccine-kconecavac-exported-for-the-first-time-301428966.html">KCONECAVAC</a>. In February 2021 the company ran a <a href="https://clinicaltrials.gov/ct2/show/NCT04756323">Phase 2 trial</a>, followed by a <a href="https://clinicaltrials.gov/ct2/show/NCT04852705?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 3 trial</a> launched in May. The first volunteers in the trial <a href="https://www.prnewswire.com/news-releases/phase-iii-clinical-trial-of-biokangtai-covid-19-vaccine-initiated-in-malaysia-301317445.html">received injections</a> on June 21 in Malaysia.<br><br>In May 2021, the company also <a href="https://news.cgtn.com/news/2021-05-15/Kangtai-s-COVID-19-vaccine-gets-emergency-use-approval-in-China-10hiaOB4jPG/index.html">announced</a> that the Chinese government had given it emergency use approval, even before the start of the  Phase 3 trial. In November 2021, Indonesia <a href="https://www.prnewswire.com/news-releases/biokangtais-adenovirus-vector-covid-19-vaccine-obtained-eua-in-indonesia-301415162.html">authorized</a> the Kangtai vaccine, and the company <a href="https://www.prnewswire.com/news-releases/biokangtais-adenovirus-vector-covid-19-vaccine-obtained-eua-in-indonesia-301415162.html">said</a> it was shipping 4 million doses there — despite the lack of public Phase 3 trial results.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://news.cgtn.com/news/2021-05-15/Kangtai-s-COVID-19-vaccine-gets-emergency-use-approval-in-China-10hiaOB4jPG/index.html">China</a>, <a href="https://www.prnewswire.com/news-releases/biokangtais-adenovirus-vector-covid-19-vaccine-obtained-eua-in-indonesia-301415162.html">Indonesia</a>.<br>



</span>

<span class="g-updated">Updated June 3, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.102.1 - 2021-11-26 12:15 -->
<!-- ai file: map-kangtai.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-kangtai-box ,
	#g-map-kangtai-box .g-artboard {
		margin:0 auto;
	}
	#g-map-kangtai-box p {
		margin:0;
	}
	#g-map-kangtai-box .g-aiAbs {
		position:absolute;
	}
	#g-map-kangtai-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-kangtai-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-kangtai-box .g-aiPointText p { white-space: nowrap; }
	#g-map-kangtai-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-kangtai-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-kangtai-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-kangtai-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-kangtai-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-kangtai-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-kangtai-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-kangtai-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-kangtai-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-kangtai-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-kangtai-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-kangtai-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-kangtai-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-kangtai-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-kangtai-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-kangtai-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-kangtai-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-kangtai-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-kangtai-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-kangtai-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-kangtai-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-kangtai-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-kangtai-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-kangtai-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:139px;">
			<p class="g-pstyle0">Shenzhen Kangtai</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:34.7627%;margin-top:-6.8px;left:80.9868%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:60.5978%;margin-top:-6.8px;left:86.8767%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-kangtai-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-kangtai-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-kangtai-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:132px;">
			<p class="g-pstyle0">Shenzhen Kangtai</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:34.7694%;margin-top:-6.8px;left:80.827%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:61.5175%;margin-top:-6.8px;left:86.8039%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-kangtai-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-kangtai-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-kangtai-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:9.2099%;margin-top:-23.8px;left:-0.067%;width:77px;">
			<p class="g-pstyle0">Shenzhen</p>
			<p class="g-pstyle0">Kangtai</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:34.5112%;margin-top:-6.8px;left:80.957%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:61.5154%;margin-top:-6.8px;left:87.5785%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-kangtai-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-kangtai-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-kangtai-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:4.585%;margin-top:-23.8px;left:0.2695%;width:77px;">
			<p class="g-pstyle0">Shenzhen</p>
			<p class="g-pstyle0">Kangtai</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:63.394%;margin-top:-6.8px;left:61.8169%;margin-left:-31px;width:62px;">
			<p class="g-pstyle1">CHINA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:78.3082%;margin-top:-6.8px;left:74.5644%;margin-left:-45.5px;width:91px;">
			<p class="g-pstyle1">INDONESIA</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-kangtai-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-11-26 12:15 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="iran"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN IRAN</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/shafa-800.png" class="g-vlogo" 
    style="width: 221px; height: 70px; margin-right: 20px;" alt="Shafa Pharmed Pars logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
<strong>Shafa Pharmed Pars</strong>, an Iranian pharmaceutical company, developed a vaccine made of inactivated coronaviruses. Results from preclinical trials <a href="https://www.biorxiv.org/content/10.1101/2021.06.10.447951v1.full.pdf">showed</a> that the vaccine was safe and effective in animals. Known as COVIran Barekat, it <a href="https://www.aljazeera.com/news/2020/12/29/iran-covid-vaccine-trials-start">entered</a> a Phase 1 trial at the end of December, becoming the first vaccine developed in Iran to go into clinical testing. The results of the Phase 1 and 2 trials were <a href="https://bmjopen.bmj.com/content/12/4/e056872">published</a> in April 2022.<br><br>COVIran Barekat <a href="https://en.irna.ir/news/84307984/Iran-begins-Phase-3-of-human-trial-of-Barekat-COVID-19-vaccine">began</a> a Phase 3 trial on April 25, 2021, and on June 14, the Iranian government announced it had <a href="https://apnews.com/article/joe-biden-germany-europe-g-7-summit-coronavirus-pandemic-4f651d5bd7a83606a4de0c321b8a037a">authorized</a> the vaccine, despite the fact that many volunteers in the Phase 3 trial had <a href="https://www.tehrantimes.com/news/461968/COVIRAN-vaccine-receives-public-use-license">not yet received their second dose</a>. On June 25, Ayatollah Khamenei <a href="https://twitter.com/farnazfassihi/status/1408423363610042370">received</a> the COVIran Barekat vaccine on television.<br><br>According to Iranian news reports, a study comparing COVIran Barekat as a booster with other vaccines found that the Iranian vaccine is roughly <a href="https://www.tasnimnews.com/fa/news/1400/11/04/2650356/%D9%86%D8%AA%D8%A7%DB%8C%D8%AC-%D8%A7%D8%AB%D8%B1%D8%A8%D8%AE%D8%B4%DB%8C-4-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%DA%A9%D8%B1%D9%88%D9%86%D8%A7-%D8%A7%D8%B9%D9%84%D8%A7%D9%85-%D8%B4%D8%AF-%D8%A7%D8%AB%D8%B1%D8%A8%D8%AE%D8%B4%DB%8C-87-%D8%AF%D8%B1%D8%B5%D8%AF%DB%8C-%D8%A8%D8%B1%DA%A9%D8%AA-%D8%AF%D8%B1-%D9%BE%DB%8C%D8%B4%DA%AF%DB%8C%D8%B1%DB%8C-%D8%A7%D8%B2-%D9%85%D8%B1%DA%AF">87-percent effective at preventing death</a>. The researchers are also producing a modified version of COVIran Barekat to address the Omicron variant after <a href="https://www.tasnimnews.com/fa/news/1400/11/27/2663508/%D8%B3%D8%A7%D8%AE%D8%AA-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D8%A8%D8%B1%DA%A9%D8%AA-%D8%A8%D8%A7-%D9%82%D8%A7%D8%A8%D9%84%DB%8C%D8%AA-%D8%B4%DA%A9%D8%B3%D8%AA-%D8%B3%D9%88%DB%8C%D9%87-%D8%A7%D9%88%D9%85%DB%8C%DA%A9%D8%B1%D9%88%D9%86">reportedly positive results</a> in animal tests. That version, called COVIran Plus, <a href="https://www.tehrantimes.com/news/470646/Iranian-made-vaccine-against-Omicron-begins-clinical-trial">began human trials</a> on March 2, 2022. Iranian officials are also <a href="https://www.tehrantimes.com/news/473934/Iran-exports-COVID-19-vaccines-to-Nicaragua">sending doses</a> of COVIran Barekat to Nicaragua.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://apnews.com/article/joe-biden-germany-europe-g-7-summit-coronavirus-pandemic-4f651d5bd7a83606a4de0c321b8a037a">Iran</a>.<br>



</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.102.0 - 2021-06-14 16:13 -->
<!-- ai file: map-iran.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-iran-box ,
	#g-map-iran-box .g-artboard {
		margin:0 auto;
	}
	#g-map-iran-box p {
		margin:0;
	}
	#g-map-iran-box .g-aiAbs {
		position:absolute;
	}
	#g-map-iran-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-iran-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-iran-box .g-aiPointText p { white-space: nowrap; }
	#g-map-iran-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-iran-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-iran-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-iran-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-iran-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-iran-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-iran-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-iran-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-iran-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-iran-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-iran-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-iran-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-iran-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-iran-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-iran-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-iran-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-iran-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-iran-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-iran-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-iran-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-iran-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-iran-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-iran-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-iran-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:154px;">
			<p class="g-pstyle0">Shafa Pharmed Pars</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:39.5366%;margin-top:-6.8px;left:71.8843%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-iran-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-iran-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-iran-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:145px;">
			<p class="g-pstyle0">Shafa Pharmed Pars</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:39.3448%;margin-top:-6.8px;left:72.0354%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-iran-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-iran-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-iran-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:108px;">
			<p class="g-pstyle0">Shafa Pharmed</p>
			<p class="g-pstyle0">Pars vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:39.5745%;margin-top:-6.8px;left:71.8481%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-iran-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-iran-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-iran-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:136px;">
			<p class="g-pstyle0">Shafa Pharmed Pars</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:66.1247%;margin-top:-6.8px;left:44.1127%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-iran-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-06-14 16:13 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="imb"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/imb-800.png" class="g-vlogo" 
    style="width: 280px; height: 41px; margin-right: 20px;" alt="Institute of Medical Biology at the Chinese Academy of Medical Sciences logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Researchers at the <strong>Institute of Medical Biology at the Chinese Academy of Medical Sciences</strong>, which has invented vaccines for polio and hepatitis A, created an inactivated coronavirus vaccine. In May 2020, they launched a Phase 1 trial on 192 volunteers which <a href="https://www.medrxiv.org/content/10.1101/2020.09.27.20189548v1">indicated</a> the vaccine was safe and produced an immune response. <a href="https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1703/5962856">A Phase 2 trial</a> followed on 750 volunteers, which led the researchers to select a two-week spacing between the two doses of the vaccine. In December the researchers launched a <a href="https://clinicaltrials.gov/ct2/show/NCT04659239">Phase 3 trial</a> on up to 34,020 volunteers in Brazil and Malaysia. On June 9, 2021, Chinese government newspaper Science and Technology Daily reported that the vaccine <a href="https://www.nytimes.com/2021/06/09/world/a-slow-reopening-continues-in-france-and-other-news-from-around-the-world.html">received</a> emergency use authorization.<!-- No name. Two doses separated by two weeks. --><br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 10, 2021</span>

</p>

<a name="valneva"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN BAHRAIN, E.U., U.K.</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/valneva-800.png" class="g-vlogo" 
    style="width: 220px; height: 31px; margin-right: 20px;" alt="Valneva logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/dynavax-800.png" class="g-vlogo" 
    style="width: 180px; height: 46px;" alt="Dynavax logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> VLA2001<br>
<span class="g-info">Efficacy:</span> Produces <a href="https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/">40 percent higher antibodies</a> than Vaxzevria from AstraZeneca.<br>
<span class="g-info">Dose:</span> 2 doses, 4 weeks apart<br>
<span class="g-info">Type:</span> Muscle injection<br>
<span class="g-info">Storage:</span> Refrigerated at 2 degrees to 8 degrees Celsius<br>
<br>
</span>

<!-- description -->
The French vaccine maker <strong>Valneva</strong> created a vaccine from chemically inactivated coronaviruses, using an adjuvant from <strong>Dynavax</strong>.  The vaccine, called VLA2001, <a href="https://valneva.com/press-release/valneva-receives-emergency-use-authorization-from-bahrain-for-its-inactivated-covid-19-vaccine-vla2001/">received</a> emergency authorization in Bahrain in March 2022, followed by the <a href="https://valneva.com/press-release/valneva-receives-conditional-marketing-authorization-from-uk-mhra-for-its-inactivated-covid-19-vaccine/">United Kingdom</a>, the <a href="https://valneva.com/press-release/valneva-receives-emergency-use-authorization-from-the-united-arab-emirates-for-its-inactivated-covid-19-vaccine/">United Arab Emirates</a>, the <a href="https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-inactivated-whole-virus-covid-19-vaccine-vla2001/">European Union</a>, and the <a href="https://valneva.com/press-release/valneva-confirms-who-recommendations-for-its-inactivated-covid-19-vaccine/">World Health Organization</a>. It thus became the first inactivated-virus Covid vaccine developed outside of Asia to win authorization.<br><br>Research on VLA2001 began in 2020, and on  Dec. 16, 2020 Valneva <a href="https://www.gov.uk/government/news/fifth-covid-19-vaccine-starts-uk-clinical-trials">launched</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT04671017">Phase 1/2 trial</a> in the United Kingdom. In April 2021, the company announced that the trial had delivered <a href="https://www.medrxiv.org/content/10.1101/2021.08.13.21262021v1">positive results</a> and <a href="https://valneva.com/press-release/valneva-initiates-phase-3-clinical-trial-for-its-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/">launched</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT04864561?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 3 trial</a> on 4,000 volunteers in the United Kingdom. The trial was different from the first wave of studies on Covid-19 vaccines, in which some volunteers got a vaccine and the others received a placebo. With a growing number of vaccines authorized for use in Britain, such randomized clinical trials were no longer ethical. Instead, Valneva gave VLA2001 to half of their volunteers, while the others received Vaxzevria, the vaccine made by AstraZeneca. Researchers then observed whether VLA2001 produced similar levels of antibodies to Vaxzevria.<br><br>On Oct. 18, 2021, Valneva <a href="https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/">announced</a> the top-line results of the trial. Compared to Vaxzevria, their VLA2001 vaccine produced 40 percent higher levels of antibodies that neutralized the coronavirus. It also produced fewer side effects.<br><br>Early in Valneva’s clinical trials, the British government agreed in February 2021 to purchase <a href="https://valneva.com/press-release/valneva-announces-uk-government-exercise-of-option-for-40-million-doses-of-its-inactivated-adjuvanted-covid-19-vaccine/">100 million doses</a> of the vaccine should it prove safe and effective, with an option to acquire a further 90 million — a deal potentially worth over $1 billion. But the deal <a href="https://valneva.com/press-release/valneva-receives-notice-of-termination-of-covid-19-vaccine-supply-agreement-by-uk-government/">collapsed</a> in September, when the United Kingdom claimed the company was in breach of its obligations, an accusation Valneva denied. The cancellation of the deal <a href="https://www.fiercepharma.com/pharma/latecomer-valneva-scores-approval-covid-19-vaccine-uk-can-shot-find-its-niche">raises questions</a> about the United Kingdom’s subsequent conditional approval of the vaccine seven months later. It’s not clear how available VLA2001 will be in the country. In the announcement of the conditional approval, Valneva’s president suggested the British people who were not comfortable with newer vaccine technologies might prefer VLA2001’s traditional design.<br><br>Despite Valneva’s troubles in the United Kingdom,  the company moved ahead with other negotiations with Bahrain as well as with the European Medicines Agency. But on April 25, Valneva said that the E.M.A. had <a href="https://valneva.com/press-release/valneva-provides-regulatory-update-on-its-inactivated-covid-19-vaccine-candidate/">more questions</a> about the vaccine, pushing a potential authorization to later in 2022. As the deliberations dragged on, the European Commission <a href="https://valneva.com/press-release/valneva-receives-notice-of-european-commissions-intent-to-terminate-covid-19-vaccine-purchase-agreement/">canceled</a> its advance purchase order for 60 million doses of VLA2001 in May 2022. In June 2022, the European Commission <a href="https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-inactivated-whole-virus-covid-19-vaccine-vla2001/">authorized</a> the vaccine. On July 20, the European Commission agreed to purchase <a href="https://valneva.com/press-release/european-commission-approves-purchase-agreement-amendment-for-valnevas-inactivated-covid-19-vaccine/">1.25 million doses, a tiny fraction of the order it had originally promised</a>.<br><br>After missing the initial wave of vaccine authorizations, Valneva positioned VLA2001 as a booster for other vaccines. Results from the United Kingdom’s COV-Boost trial, which compared the effectiveness of seven vaccines head-to-head as boosters for those who have received two doses of Comirnaty or Vaxzevria, showed that Valneva’s vaccine <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02717-3/fulltext#fig3">performed the least well</a> at generating an immune response. In a <a href="https://valneva.com/press-release/valneva-comments-on-cov-boost-clinical-trial-data/">Dec. 3 statement</a>, Valneva said the short interval between the second dose and the booster shot during the trial could be to blame for the disappointing results.<br><br>In its own booster trial, Valneva said that administering the vaccine <a href="https://valneva.com/press-release/valneva-announces-positive-homologous-booster-data-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/">seven to eight months</a> after two doses of VLA2001 significantly increased immunity. In May 2022, Valneva <a href="https://valneva.com/press-release/valneva-initiates-heterologous-booster-trial-of-inactivated-covid-19-vaccine-candidate/">launched</a> another booster trial, giving VLA2001 to people who had previously received mRNA vaccines.<br><br>In a May 2022 <a href="https://www.fool.com/earnings/call-transcripts/2022/05/05/valneva-se-valn-q1-2022-earnings-call-transcript/">earnings call</a>, the company said it was intending to apply to the F.D.A. in the second half of the year. It would apply for a standard approval, rather than an emergency authorization, which would take longer for the agency to review.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://valneva.com/press-release/valneva-receives-emergency-use-authorization-from-bahrain-for-its-inactivated-covid-19-vaccine-vla2001/">Bahrain</a>, <a href="https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-inactivated-whole-virus-covid-19-vaccine-vla2001/">European Union</a>, Iceland, Liechtenstein, Norway, <a href="https://valneva.com/press-release/valneva-receives-conditional-marketing-authorization-from-uk-mhra-for-its-inactivated-covid-19-vaccine/">United Kingdom</a>, <a href="https://valneva.com/press-release/valneva-confirms-who-recommendations-for-its-inactivated-covid-19-vaccine/">World Health Organization</a>.<br>



</span>

<span class="g-updated">Updated Aug. 26, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.111.0 - 2022-06-29 11:28 -->
<!-- ai file: map-valneva.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-valneva-box ,
	#g-map-valneva-box .g-artboard {
		margin:0 auto;
	}
	#g-map-valneva-box p {
		margin:0;
	}
	#g-map-valneva-box .g-aiAbs {
		position:absolute;
	}
	#g-map-valneva-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-valneva-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-valneva-box .g-aiPointText p { white-space: nowrap; }
	#g-map-valneva-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-valneva-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-valneva-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-valneva-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:right;
	}
	#g-map-valneva-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-valneva-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-valneva-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-valneva-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-valneva-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:right;
	}
	#g-map-valneva-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-valneva-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-valneva-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-valneva-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-valneva-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
	}
	#g-map-valneva-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-valneva-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-valneva-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-valneva-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-valneva-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:right;
	}
	#g-map-valneva-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-valneva-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-valneva-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-valneva-900-img" class="g-map-valneva-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-valneva-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:-0.005%;width:72px;">
			<p class="g-pstyle0">Valneva</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:9.77%;margin-top:-6.8px;right:33.5649%;width:72px;">
			<p class="g-pstyle1">BRITAIN</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:42.9064%;margin-top:-6.8px;right:29.9288%;width:79px;">
			<p class="g-pstyle1">BAHRAIN</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-valneva-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-valneva-720-img" class="g-map-valneva-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-valneva-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0094%;width:69px;">
			<p class="g-pstyle0">Valneva</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:10.1331%;margin-top:-6.8px;right:33.732%;width:72px;">
			<p class="g-pstyle1">BRITAIN</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:42.8642%;margin-top:-6.8px;right:29.9717%;width:79px;">
			<p class="g-pstyle1">BAHRAIN</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-valneva-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-valneva-600-img" class="g-map-valneva-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-valneva-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.0735%;width:66px;">
			<p class="g-pstyle0">Valneva</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:10.0386%;margin-top:-6.8px;left:57.7196%;width:72px;">
			<p class="g-pstyle1">BRITAIN</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:39.5745%;margin-top:-6.8px;left:71.3515%;width:79px;">
			<p class="g-pstyle1">BAHRAIN</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-valneva-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-valneva-335-img" class="g-map-valneva-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-valneva-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2579%;width:66px;">
			<p class="g-pstyle0">Valneva</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-335 g-aiAbs g-aiPointText" style="top:49.9502%;margin-top:-6.8px;right:67.7032%;width:72px;">
			<p class="g-pstyle1">BRITAIN</p>
		</div>
		<div id="g-ai3-3" class="g-335 g-aiAbs g-aiPointText" style="top:68.0153%;margin-top:-6.8px;right:59.5213%;width:79px;">
			<p class="g-pstyle1">BAHRAIN</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-valneva-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-06-29 11:28 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="erciyes"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN TURKEY</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/erciyes-800.png" class="g-vlogo" 
    style="width: 115px; height: 112px; margin-right: 20px;" alt="Erciyes University logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Turkovac<br>




<br>
</span>

<!-- description -->
On Nov. 5, Turkey’s <strong>Erciyes University</strong> <a href="https://www.aa.com.tr/en/health/turkish-university-tests-covid-19-vaccine-candidate/2033228">announced</a> they had begun injecting volunteers with an inactivated coronavirus vaccine initially called ERUCOV-VAC. It was the first clinical trial of a coronavirus vaccine developed in Turkey. On Dec. 14, 2020, the president of the university <a href="https://bianet.org/english/health/235998-turkey-completes-phase-1-studies-of-domestic-covid-19-vaccine">said</a> that the <a href="https://clinicaltrials.gov/ct2/show/NCT04691908">Phase 1 trial</a> was complete. Sabah Today <a href="https://www.dailysabah.com/turkey/turkey-aims-to-start-mass-vaccination-against-covid-19-by-friday/news">reported</a> the following month that <a href="https://clinicaltrials.gov/ct2/show/NCT04824391?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 2 trials</a> had begun. On June 23, 2021, Turkish president Recep Tayyip Erdoğan <a href="https://www.dailysabah.com/turkey/domestic-covid-19-jab-turkovac-begins-phase-3-trials-in-turkey/news">announced</a> that the vaccine, renamed Turkovac, has entered a <a href="https://clinicaltrials.gov/ct2/show/NCT04942405">Phase 3 trial</a>. In July, the researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT04979949?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">Phase 2 trial</a> to evaluate the vaccine as a booster shot, moving on to a <a href="https://clinicaltrials.gov/ct2/show/NCT05077176?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=3">Phase 3 trial</a> on Oct. 14. Turkovac is <a href="http://www.xinhuanet.com/english/20220124/93c7cafec5db416088339358bc1ef7a3/c.html">also being assessed</a> in a booster trial for individuals who received an mRNA vaccine. Researchers registered <a href="https://clinicaltrials.gov/ct2/show/NCT05210179?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">another booster trial</a> on Jan. 27, 2022, in which Turkovac will be used in participants who received Comirnaty. They also <a href="https://clinicaltrials.gov/ct2/show/NCT05230940?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">registered a trial</a> on Feb. 9, comparing the vaccine’s effectiveness in adolescents against CoronaVac. <br><br>On Dec. 23, 2021, Turkey announced that it was granting <a href="http://www.xinhuanet.com/english/20211223/50dddf11c0eb49768eb89b8da8039e4f/c.html">emergency use authorization</a> to Turkovac. <a href="http://www.xinhuanet.com/english/20211230/81dc8d0a85f6450e8902777b6b9df489/c.html">Appointments</a> for the shot opened on Dec. 30, and Turkey began giving Turkovac as a <a href="https://www.hurriyetdailynews.com/turkey-starts-giving-turkovac-as-booster-shot-to-biontech-recipients-171001">booster</a> in January 2022.<br><br>When Turkovac rolled out, Turkish medical associations <a href="https://ahvalnews.com/turkey-covid-19/turkey-start-mass-production-domestic-covid-19-vaccine-turkovac">requested</a> that the government make the results of the Phase 3 trial <a href="https://www.duvarenglish.com/turkeys-top-medical-association-asks-govt-to-share-scientific-reports-on-locally-made-vaccine-turkovac-news-60008">public. </a> <a href="https://www.duvarenglish.com/turkeys-top-medical-association-asks-govt-to-share-scientific-reports-on-locally-made-vaccine-turkovac-news-60008">It is not yet known</a> how safe and effective Turkovac is, but the leader of its development claimed in a conference on Jan. 25, 2022, that it <a href="https://www.hurriyetdailynews.com/turkovac-protects-against-alpha-delta-variants-expert-171050"> can protect against the Alpha and Delta variants</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="http://www.xinhuanet.com/english/20211223/50dddf11c0eb49768eb89b8da8039e4f/c.html">Turkey</a>.<br>



</span>

<span class="g-updated">Updated Feb. 9, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase3 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.102.1 - 2021-12-28 22:16 -->
<!-- ai file: map-erciyes.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-erciyes-box ,
	#g-map-erciyes-box .g-artboard {
		margin:0 auto;
	}
	#g-map-erciyes-box p {
		margin:0;
	}
	#g-map-erciyes-box .g-aiAbs {
		position:absolute;
	}
	#g-map-erciyes-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-erciyes-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-erciyes-box .g-aiPointText p { white-space: nowrap; }
	#g-map-erciyes-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-erciyes-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-erciyes-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-erciyes-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-erciyes-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-erciyes-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-erciyes-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-erciyes-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-erciyes-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-erciyes-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-erciyes-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-erciyes-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-erciyes-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-erciyes-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-erciyes-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-erciyes-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-erciyes-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-erciyes-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-erciyes-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-erciyes-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-erciyes-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-erciyes-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-erciyes-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-erciyes-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:80px;">
			<p class="g-pstyle0">Turkovac</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:36.4476%;margin-top:-6.8px;left:69.1513%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">TURKEY</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-erciyes-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-erciyes-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-erciyes-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:76px;">
			<p class="g-pstyle0">Turkovac</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:36.8811%;margin-top:-6.8px;left:69.1398%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">TURKEY</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-erciyes-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-erciyes-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-erciyes-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:73px;">
			<p class="g-pstyle0">Turkovac</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:37.4648%;margin-top:-6.8px;left:69.4243%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">TURKEY</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-erciyes-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-erciyes-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-erciyes-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:73px;">
			<p class="g-pstyle0">Turkovac</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:65.2845%;margin-top:-6.8px;left:39.1972%;margin-left:-35.5px;width:71px;">
			<p class="g-pstyle1">TURKEY</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-erciyes-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-12-28 22:16 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="chumakov"></a><p class="g-body g-list-item g-filter-item g-filter-phase3 g-filter-approved ">

<!-- phases -->





<span class="g-phase3">PHASE 3</span>




<!-- approvals -->


<span class="g-limited">EARLY USE IN RUSSIA</span>

    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/ras-800.png" class="g-vlogo" 
    style="width: 240px; height: 94px; margin-right: 20px;" alt="The Chumakov Center at the Russian Academy of Sciences logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
The <strong>Chumakov Center</strong> at the <strong>Russian Academy of Sciences </strong>developed an inactivated coronavirus vaccine called CoviVac. On Oct. 14, 2020, Tass <a href="https://tass.com/society/1212183">reported</a> that <a href="https://clinicaltrials.gov/ct2/show/NCT05046548?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">clinical trials</a> of the vaccine would begin in Kirov and St. Petersburg on Oct. 19. On Feb. 20, 2021, Russia <a href="https://www.rferl.org/a/russia-coronavirus-vaccine-covivac/31113697.html">approved</a> the vaccine for domestic use, despite the fact that the Chumakov Center only later began a Phase 3 trial. Belarus and Cambodia also gave emergency authorization to CoviVac.<br><br>On June 3, 2021, the director of the Chumakov Center <a href="https://tass.com/society/1297341">said</a> the trial was still underway and it was not yet possible to speak of the vaccine’s efficacy. He later said that the Chumakov Center could produce <a href="https://tass.com/economy/1373613">20 million doses</a> in 2022. The director <a href="https://tass.com/science/1347995">told Tass</a> in October that a trial for adults aged 60 and older could begin soon. Chumakov <a href="https://tass.com/society/1399121">received approval</a> to begin Phase 3 trials in children on Feb. 7, 2022.<br><br>Despite being in widespread use since early 2021, there is still little scientific information about CoviVac. In February 2022, Chumakov researchers <a href="https://www.medrxiv.org/content/10.1101/2022.02.08.22270658v1.full-text">reported</a> results of the Phase 1 / 2 trial. While volunteers produced antibodies against the coronavirus, the trial was too small to determine the efficacy of CoviVac against Covid-19.<br><br>In June 2022, the Chumakov Center created an <a href="https://clinicaltrials.gov/ct2/show/NCT05407142">entry</a> for the Phase 3 trial of CoviVac on a registry maintained by the U.S. National Institutes of Health. They indicated that the trial had begun in July 2021, and would be finished by the end of 2022.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>


<span class="g-info">Early use in:</span> Belarus, <a href="https://cambodianess.com/article/the-cambodian-health-authorities-authorize-russian-vaccines-for-emergency-use">Cambodia</a>, <a href="https://www.rferl.org/a/russia-coronavirus-vaccine-covivac/31113697.html">Russia</a>.<br>




</span>

<span class="g-updated">Updated June 13, 2022</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-phase1 g-filter-phase2 g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.110.0 - 2022-04-15 12:27 -->
<!-- ai file: map-chumakov.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-chumakov-box ,
	#g-map-chumakov-box .g-artboard {
		margin:0 auto;
	}
	#g-map-chumakov-box p {
		margin:0;
	}
	#g-map-chumakov-box .g-aiAbs {
		position:absolute;
	}
	#g-map-chumakov-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-chumakov-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-chumakov-box .g-aiPointText p { white-space: nowrap; }
	#g-map-chumakov-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-chumakov-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-chumakov-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-chumakov-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-chumakov-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-chumakov-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-chumakov-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-chumakov-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-chumakov-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-chumakov-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-chumakov-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-chumakov-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-chumakov-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-chumakov-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-chumakov-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-chumakov-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-chumakov-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-chumakov-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-chumakov-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-chumakov-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-chumakov-box" class="ai2html ai2html-responsive">

	<!-- Artboard: 900 -->
	<div id="g-map-chumakov-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-chumakov-900-img" class="g-map-chumakov-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-chumakov-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:4.5668%;margin-top:-18.3px;left:0%;width:137px;">
			<p class="g-pstyle0">Chumakov Center</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:19.8794%;margin-top:-6.8px;left:76.7491%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">RUSSIA</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:24.0917%;margin-top:-6.8px;left:66.2027%;margin-left:-39.5px;width:79px;">
			<p class="g-pstyle1">BELARUS</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:51.3308%;margin-top:-6.8px;left:83.7208%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle1">CAMBODIA</p>
		</div>
		<div id="g-ai0-5" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-6" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-chumakov-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-chumakov-720-img" class="g-map-chumakov-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-chumakov-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:5.3302%;margin-top:-17.1px;left:0.0153%;width:130px;">
			<p class="g-pstyle0">Chumakov Center</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:19.6357%;margin-top:-6.8px;left:76.9155%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">RUSSIA</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:24.211%;margin-top:-6.8px;left:65.0257%;margin-left:-39.5px;width:79px;">
			<p class="g-pstyle1">BELARUS</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:51.6629%;margin-top:-6.8px;left:83.875%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle1">CAMBODIA</p>
		</div>
		<div id="g-ai1-5" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-6" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-chumakov-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-chumakov-600-img" class="g-map-chumakov-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-chumakov-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:5.9187%;margin-top:-16px;left:-0.067%;width:122px;">
			<p class="g-pstyle0">Chumakov Center</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:19.7433%;margin-top:-6.8px;left:76.4298%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">RUSSIA</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:24.8065%;margin-top:-6.8px;left:64.4527%;margin-left:-39.5px;width:79px;">
			<p class="g-pstyle1">BELARUS</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:52.6546%;margin-top:-6.8px;left:83.8188%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle1">CAMBODIA</p>
		</div>
		<div id="g-ai2-5" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-6" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-chumakov-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-chumakov-335-img" class="g-map-chumakov-img g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-chumakov-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:2.9466%;margin-top:-16px;left:0.2695%;width:122px;">
			<p class="g-pstyle0">Chumakov Center</p>
			<p class="g-pstyle0">vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:55.4117%;margin-top:-6.8px;left:53.4104%;margin-left:-33.5px;width:67px;">
			<p class="g-pstyle1">RUSSIA</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:58.1425%;margin-top:-6.8px;left:29.4443%;margin-left:-39.5px;width:79px;">
			<p class="g-pstyle1">BELARUS</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:73.0567%;margin-top:-6.8px;left:67.2078%;margin-left:-44.5px;width:89px;">
			<p class="g-pstyle1">CAMBODIA</p>
		</div>
		<div id="g-ai3-5" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-6" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		var nameSpace = opts.namespace || '';
		var containers = findContainers(containerId);
		containers.forEach(resize);

		function resize(container) {
			var onResize = throttle(update, 200);
			var waiting = !!window.IntersectionObserver;
			var observer;
			update();

			document.addEventListener('DOMContentLoaded', update);
			window.addEventListener('resize', onResize);

			// NYT Scoop-specific code
			if (opts.setup) {
				opts.setup(container).on('cleanup', cleanup);
			}

			function cleanup() {
				document.removeEventListener('DOMContentLoaded', update);
				window.removeEventListener('resize', onResize);
				if (observer) observer.disconnect();
			}

			function update() {
				var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
						width = Math.round(container.getBoundingClientRect().width);

				// Set artboard visibility based on container width
				artboards.forEach(function(el) {
					var minwidth = el.getAttribute('data-min-width'),
							maxwidth = el.getAttribute('data-max-width');
					if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
						if (!waiting) {
							selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
						}
						el.style.display = 'block';
					} else {
						el.style.display = 'none';
					}
				});

				// Initialize lazy loading on first call
				if (waiting && !observer) {
					if (elementInView(container)) {
						waiting = false;
						update();
					} else {
						observer = new IntersectionObserver(onIntersectionChange, {});
						observer.observe(container);
					}
				}
			}

			function onIntersectionChange(entries) {
				// There may be multiple entries relating to the same container
				// (captured at different times)
				var isIntersecting = entries.reduce(function(memo, entry) {
					return memo || entry.isIntersecting;
				}, false);
				if (isIntersecting) {
					waiting = false;
					// update: don't remove -- we need the observer to trigger an update
					// when a hidden map becomes visible after user interaction
					// (e.g. when an accordion menu or tab opens)
					// observer.disconnect();
					// observer = null;
					update();
				}
			}
		}

		function findContainers(id) {
			// support duplicate ids on the page
			return selectChildren('.ai2html-responsive', document).filter(function(el) {
				if (el.getAttribute('id') != id) return false;
				if (el.classList.contains('ai2html-resizer')) return false;
				el.classList.add('ai2html-resizer');
				return true;
			});
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-chumakov-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2022-04-15 12:27 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>


<a name="kmb"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 g-filter-phase3 ">

<!-- phases -->








<span class="g-phase2">PHASE 2</span> <span class="g-phase3">PHASE 3</span> <span class="g-combined">COMBINED PHASES</span>

<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/kmb-800.png" class="g-vlogo" 
    style="width: 240px; height: 34px; margin-right: 20px;" alt="KM Biologics logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
On March 22, 2021, Japan’s <strong>KM Biologics</strong> <a href="https://www.reuters.com/article/us-health-coronavirus-japan-vaccine/japans-km-biologics-begins-clinical-trial-of-covid-19-vaccine-candidate-idUSKBN2BE0YY">launched</a> a <a href="https://jrct.niph.go.jp/en-latest-detail/jRCT2071200106">Phase 1/2 trial</a> of its inactivated vaccine candidate, called KD-414. Seven months later, the company  registered a <a href="https://jrct.niph.go.jp/latest-detail/jRCT2071210081">Phase 2/3 trial</a> in Japan for its vaccine on Oct. 22. In December, KM Biologics <a href="https://jrct.niph.go.jp/latest-detail/jRCT1031210517">began testing</a> the vaccine as a booster. The company <a href="https://jrct.niph.go.jp/latest-detail/jRCT2031210679">registered</a> a Phase 3 trial in March 2022 to compare KD-414 to Vaxzevria.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated June 29, 2022</span>

</p>

<a name="codagenix"></a><p class="g-body g-list-item g-filter-item g-filter-phase2 ">

<!-- phases -->




<span class="g-phase2">PHASE 2</span>





<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/codagenix-new-800.png" class="g-vlogo" 
    style="width: 200px; height: 42px; margin-right: 20px;" alt="Codagenix logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
New York-based <strong><a href="https://codagenix.com/">Codagenix</a></strong> develops vaccines based on live attenuated  viruses, but with a twist: they <a href="https://www.nytimes.com/2020/08/27/health/covid-19-vaccines.html">create the viruses from scratch</a>. The  Codagenix researchers begin by rewriting the genomes of the viruses they want to protect against, introducing hundreds of extra mutations that dramatically slow down the virus’s growth in infected cells. The researchers then produce the weakened viruses and package them in a nasal spray.<br><br>In 2020, Codagenix developed a vaccine for Covid-19 called CoviLiv. After <a href="https://www.pnas.org/content/118/29/e2102775118">successful experiments</a> in animals, a <a href="https://clinicaltrials.gov/ct2/show/NCT04619628?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1 trial</a> was <a href="https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-dosing-in-phase-1-trial-of-covi-vac-a-single-dose-intranasal-live-attenuated-vaccine-for-covid-19-301203130.html">launched</a> in the United Kingdom in January 2021.<br><br>In March 2022, Codagenix <a href="https://codagenix.com/codagenix-intranasal-covid-19-vaccine-shows-potent-cellular-immune-response-against-conserved-viral-proteins-indicating-potential-for-immunogenicity-against-omicron-and-future-variants-in-phase-1-dat/?pag=1">announced</a> that people who received CoviLiv produced a strong response from antibodies in the nose, which appears to block the spread of the virus. They also found that CoviLiv produced T cells that attack infected cells. Their studies suggest that these T cells will be able to fight different variants of the coronavirus.<br><br>In May 2022, the World Health Organization <a href="https://www.who.int/publications/m/item/solidarity-trial-vaccines-(stv)-presentation">announced</a> that they were testing CoviLiv in a Phase 2 trial, as part of their <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-of-covid-19-vaccines">Solidarity Trial</a>. In the same month, Codagenix  <a href="https://codagenix.com/codagenix-initiates-phase-1-evaluation-of-intranasal-vaccine-coviliv-for-use-as-covid-19-booster/?pag=1">launched</a> a <a href="https://clinicaltrials.gov/ct2/show/NCT05233826">Phase 1 trial</a> to test CoviLiv as a booster.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 23, 2022</span>

</p>

<a name="kocak"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/kocak-800.png" class="g-vlogo" 
    style="width: 200px; height: 28px; margin-right: 20px;" alt="Koçak Farma logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Turkish researchers at <strong>Koçak Farma </strong>have developed a vaccine made of inactivated coronaviruses. They began a <a href="https://clinicaltrials.gov/ct2/show/NCT04838080?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=4">Phase 1 trial</a> on April 8, 2021. The trial record indicates that the study was expected to end on Oct. 20, 2021, but no updates have since been recorded.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated March 11, 2022</span>

</p>

<a name="nrc"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/nrc-800.png" class="g-vlogo" 
    style="width: 52px; height: 85px; margin-right: 20px;" alt="National Research Centre, Egypt logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
Egypt’s <strong>National Research Centre </strong>has developed an inactivated coronavirus vaccine called Covi Vax. The researchers <a href="https://clinicaltrials.gov/ct2/show/NCT05128721?term=vaccine&recrs=adf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=2">registered</a> a Phase 1 trial on Nov. 22, 2021, in which they plan to test the vaccine’s effectiveness at different doses. But no updates have since been recorded.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 31, 2022</span>

</p>

<a name="eva"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/evapharma-800.png" class="g-vlogo" 
    style="width: 95px; height: 53px; margin-right: 20px;" alt="Eva Pharma logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/ministryhesc-800.png" class="g-vlogo" 
    style="width: 110px; height: 81px; margin-right: 20px;" alt="The Supreme Council of University Hospitals, Egypt logo"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/agresearch-800.png" class="g-vlogo" 
    style="width: 125px; height: 37px;" alt="Agriculture Research Center, Egypt logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
A <a href="https://cairoscene.com/Buzz/Studies-Underway-to-Produce-All-Egyptian-Vaccine-EgyVax">public-private partnership</a> between the Egyptian government and <strong>Eva Pharma </strong>has resulted in another inactivated coronavirus vaccine called EgyVax. On Feb. 1, 2022, the researchers registered a <a href="https://clinicaltrials.gov/ct2/show/NCT05218070?term=vaccine&recrs=abdf&cond=COVID-19&phase=0123&sort=nwst&draw=2&rank=1">Phase 1 trial</a>.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Feb. 7, 2022</span>

</p>

<a name="speransa"></a><p class="g-body g-list-item g-filter-item g-filter-phase1 ">

<!-- phases -->



<span class="g-phase1">PHASE 1</span>






<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/speransa-800.png" class="g-vlogo" 
    style="width: 200px; height: 43px; margin-right: 20px;" alt="Speransa Therapeutics logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">
<span class="g-info">Vaccine&nbsp;name:</span> Prime-2-CoV<br>


<span class="g-info">Type:</span> Injection<br>

<br>
</span>

<!-- description -->
<strong>Speransa Therapeutics</strong>, based in Germany, builds vaccines using attenuated viruses. Their <a href="https://www.speransatherapeutics.com/technology">platform</a> is a weakened version of the so-called Orf virus, which infects sheep. Speransa researchers engineered the virus to make two Covid proteins, spike and nucleocapsid. In June 2022, the company launched Phase 1 <a href="https://clinicaltrials.gov/ct2/show/NCT05367843">trials</a>, testing their Prime-2-CoV vaccine as a booster.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated July 18, 2022</span>

</p>

<a name="tubitak2"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->




    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/tubitak-800.png" class="g-vlogo" 
    style="width: 50px; height: 67px; margin-right: 20px;" alt="TUBITAK logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
In addition to its protein vaccine, the <strong>Scientific and Technological Research Council of Turkey </strong>has also developed a vaccine that uses inactivated coronaviruses. On April 29, 2021, they registered a <a href="https://www.clinicaltrials.gov/ct2/show/NCT04866069">Phase 1 trial</a> in Turkey. But the trial record shows that it has since been terminated, citing unsatisfactory antibody levels.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">








</span>

<span class="g-updated">Updated Aug. 12, 2022</span>

</p>

<a name="fakhravac"></a><p class="g-body g-list-item g-filter-item g-filter-abandoned g-filter-approved ">

<!-- phases -->
<span class="g-abandoned">ABANDONED</span>









<!-- approvals -->



<span class="g-limited">EMERGENCY USE IN IRAN</span>
    


<!-- paused -->


<br>




<!-- logos -->
<span class="g-vlogos"><img 
    src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/assets/images/iranmod-800.png" class="g-vlogo" 
    style="width: 140px; height: 103px; margin-right: 20px;" alt="Iran’s Ministry of Defence logo"></span><br>



<!-- vaccine info -->
<span class="g-vacinfo">






</span>

<!-- description -->
On March 16, 2021, <strong>Iran’s Ministry of Defence</strong> <a href="https://www.aljazeera.com/news/2021/3/16/iran-starts-human-trials-on-third-locally-developed-vaccine">announced</a> the launch of a vaccine made of inactivated coronaviruses. Known as Fakhravac, the vaccine was named after Mohsen Fakhrizadeh, Iran’s top nuclear scientist who was <a href="https://www.nytimes.com/2020/11/27/world/middleeast/iran-nuclear-scientist-killed.html">killed in November</a>. After the completion of a <a href="https://www.irct.ir/trial/54133">Phase 1 trial</a>, Fakhravac entered a <a href="https://en.irct.ir/trial/56027">Phase 2 trial</a> in June. In September it gained emergency use authorization before it was known how effective the vaccine was. But in October Iran <a href="https://www.nytimes.com/2021/10/20/world/iran-covid-vaccine-fakhravac.html">announced</a> it would abandon production of Fakhravac as Iranians turned to imported vaccines instead. Still, on Nov. 1, Tehran Times <a href="https://www.tehrantimes.com/news/466570/Two-homegrown-vaccines-receive-emergency-use-license">reported</a> that the vaccine received emergency use authorization in Iran.<br>

<!-- country lists -->
<span class="g-vacinfo g-vacinfocountrylist">
<br>



<span class="g-info">Emergency use in:</span> <a href="https://www.tehrantimes.com/news/466570/Two-homegrown-vaccines-receive-emergency-use-license">Iran</a>.<br>



</span>

<span class="g-updated">Updated Nov. 26, 2021</span>

</p>
<!-- data processed in process/freebird/process-graphic.js -->

<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-graphic g-filter-item g-filter-abandoned g-filter-approved"  style="max-width: 900px">

<!-- Intro elements -->








<div role="img" aria-label="Map of approving countries.">



<!-- inner graphic element -->
<!-- print .html file -->

  
<!-- Generated by ai2html v0.102.1 - 2021-11-26 12:20 -->
<!-- ai file: map-fakhravac.ai -->
<!-- preview: 2020-09-10-coronavirus-vaccine-tracker -->
<!-- scoop: coronavirus-vaccine-tracker -->
<style media="screen,print">
	#g-map-fakhravac-box ,
	#g-map-fakhravac-box .g-artboard {
		margin:0 auto;
	}
	#g-map-fakhravac-box p {
		margin:0;
	}
	#g-map-fakhravac-box .g-aiAbs {
		position:absolute;
	}
	#g-map-fakhravac-box .g-aiImg {
		position:absolute;
		top:0;
		display:block;
		width:100% !important;
	}
	#g-map-fakhravac-box .g-aiSymbol {
		position: absolute;
		box-sizing: border-box;
	}
	#g-map-fakhravac-box .g-aiPointText p { white-space: nowrap; }
	#g-map-fakhravac-900 {
		position:relative;
		overflow:hidden;
	}
	#g-map-fakhravac-900 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:18px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:15px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.2px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-fakhravac-900 .g-pstyle0 {
		font-weight:600;
		height:18px;
		position:relative;
	}
	#g-map-fakhravac-900 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-fakhravac-900 .g-pstyle2 {
		height:18px;
		position:relative;
	}
	#g-map-fakhravac-720 {
		position:relative;
		overflow:hidden;
	}
	#g-map-fakhravac-720 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:17px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:14px;
		text-align:left;
		color:rgb(0,0,0);
		top:1.1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-fakhravac-720 .g-pstyle0 {
		font-weight:600;
		height:17px;
		position:relative;
	}
	#g-map-fakhravac-720 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-fakhravac-720 .g-pstyle2 {
		height:17px;
		position:relative;
	}
	#g-map-fakhravac-600 {
		position:relative;
		overflow:hidden;
	}
	#g-map-fakhravac-600 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-fakhravac-600 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-fakhravac-600 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-fakhravac-600 .g-pstyle2 {
		height:16px;
		position:relative;
	}
	#g-map-fakhravac-335 {
		position:relative;
		overflow:hidden;
	}
	#g-map-fakhravac-335 p {
		font-family:nyt-franklin,arial,helvetica,sans-serif;
		font-weight:300;
		line-height:16px;
		height:auto;
		filter:alpha(opacity=100);
		-ms-filter:progid:DXImageTransform.Microsoft.Alpha(Opacity=100);
		opacity:1;
		letter-spacing:0em;
		font-size:13px;
		text-align:left;
		color:rgb(0,0,0);
		top:1px;
		position:static;
		text-transform:none;
		padding-bottom:0;
		padding-top:0;
		mix-blend-mode:normal;
		font-style:normal;
	}
	#g-map-fakhravac-335 .g-pstyle0 {
		font-weight:600;
		height:16px;
		position:relative;
	}
	#g-map-fakhravac-335 .g-pstyle1 {
		font-family:nyt-cheltenham,georgia,serif;
		line-height:13px;
		height:13px;
		letter-spacing:0.1em;
		font-size:11px;
		text-align:center;
	}
	#g-map-fakhravac-335 .g-pstyle2 {
		height:16px;
		position:relative;
	}

</style>

<div id="g-map-fakhravac-box" class="ai2html">

	<!-- Artboard: 900 -->
	<div id="g-map-fakhravac-900" class="g-artboard" style="min-width: 900px;" data-aspect-ratio="2.527" data-min-width="900">
<div style="padding: 0 0 39.5672% 0;"></div>
		<img id="g-map-fakhravac-900-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-fakhravac-900.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai0-1" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:2.0394%;margin-top:-9.3px;left:0%;width:140px;">
			<p class="g-pstyle0">Fakhravac vaccine</p>
		</div>
		<div id="g-ai0-2" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:39.5366%;margin-top:-6.8px;left:71.8843%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai0-3" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:82.9208%;margin-top:-9.3px;left:22.0066%;width:81px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai0-4" class="g-type_copy_2 g-aiAbs g-aiPointText" style="top:91.6261%;margin-top:-18.3px;left:22.0066%;width:119px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 720 -->
	<div id="g-map-fakhravac-720" class="g-artboard" style="min-width: 720px;max-width: 899px;max-height: 355px" data-aspect-ratio="2.534" data-min-width="720" data-max-width="899">
<div style="padding: 0 0 39.4629% 0;"></div>
		<img id="g-map-fakhravac-720-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-fakhravac-720.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai1-1" class="g-type_copy g-aiAbs g-aiPointText" style="top:2.3738%;margin-top:-8.7px;left:0.0153%;width:132px;">
			<p class="g-pstyle0">Fakhravac vaccine</p>
		</div>
		<div id="g-ai1-2" class="g-type_copy g-aiAbs g-aiPointText" style="top:39.3448%;margin-top:-6.8px;left:72.0354%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai1-3" class="g-type_copy g-aiAbs g-aiPointText" style="top:83.3292%;margin-top:-8.8px;left:21.4326%;width:77px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai1-4" class="g-type_copy g-aiAbs g-aiPointText" style="top:93.6764%;margin-top:-17.2px;left:21.4326%;width:116px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 600 -->
	<div id="g-map-fakhravac-600" class="g-artboard" style="min-width: 600px;max-width: 719px;max-height: 284px" data-aspect-ratio="2.532" data-min-width="600" data-max-width="719">
<div style="padding: 0 0 39.5% 0;"></div>
		<img id="g-map-fakhravac-600-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-fakhravac-600.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai2-1" class="g-type g-aiAbs g-aiPointText" style="top:2.6276%;margin-top:-8.2px;left:-0.067%;width:124px;">
			<p class="g-pstyle0">Fakhravac vaccine</p>
		</div>
		<div id="g-ai2-2" class="g-type g-aiAbs g-aiPointText" style="top:39.5745%;margin-top:-6.8px;left:71.8481%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai2-3" class="g-type g-aiAbs g-aiPointText" style="top:83.2265%;margin-top:-8.2px;left:21.1425%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai2-4" class="g-type g-aiAbs g-aiPointText" style="top:93.2687%;margin-top:-16px;left:21.1425%;width:106px;">
			<p class="g-pstyle2">Early, limited or</p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

	<!-- Artboard: 335 -->
	<div id="g-map-fakhravac-335" class="g-artboard" style="max-width: 599px;max-height: 851px" data-aspect-ratio="0.704" data-min-width="0" data-max-width="599">
<div style="padding: 0 0 142.1066% 0;"></div>
		<img id="g-map-fakhravac-335-img" class="g-aiImg" alt="" data-src="https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/map-fakhravac-335.png" src="data:image/gif;base64,R0lGODlhCgAKAIAAAB8fHwAAACH5BAEAAAAALAAAAAAKAAoAAAIIhI+py+0PYysAOw=="/>
		<div id="g-ai3-1" class="g-type g-aiAbs g-aiPointText" style="top:1.3081%;margin-top:-8.2px;left:0.2695%;width:124px;">
			<p class="g-pstyle0">Fakhravac vaccine</p>
		</div>
		<div id="g-ai3-2" class="g-type g-aiAbs g-aiPointText" style="top:66.1247%;margin-top:-6.8px;left:44.1127%;margin-left:-26.5px;width:53px;">
			<p class="g-pstyle1">IRAN</p>
		</div>
		<div id="g-ai3-3" class="g-type g-aiAbs g-aiPointText" style="top:89.957%;margin-top:-8.2px;left:42.1259%;width:73px;">
			<p class="g-pstyle2">Approved</p>
		</div>
		<div id="g-ai3-4" class="g-type g-aiAbs g-aiPointText" style="top:95.1665%;margin-top:-16px;left:42.1259%;width:109px;">
			<p class="g-pstyle2">Early, limited or </p>
			<p class="g-pstyle2">emergency use</p>
		</div>
	</div>

</div>

<script type="text/javascript">
	(function (containerId, opts) {
		if (!('querySelector' in document)) return;
		var container = document.getElementById(containerId);
		var nameSpace = opts.namespace || '';
		var onResize = throttle(update, 200);
		var waiting = !!window.IntersectionObserver;
		var observer;
		update();

		document.addEventListener('DOMContentLoaded', update);
		window.addEventListener('resize', onResize);

		// NYT Scoop-specific code
		if (opts.setup) {
			opts.setup(container).on('cleanup', cleanup);
		}

		function cleanup() {
			document.removeEventListener('DOMContentLoaded', update);
			window.removeEventListener('resize', onResize);
			if (observer) observer.disconnect();
		}

		function update() {
			var artboards = selectChildren('.' + nameSpace + 'artboard[data-min-width]', container),
					width = Math.round(container.getBoundingClientRect().width);

			// Set artboard visibility based on container width
			artboards.forEach(function(el) {
				var minwidth = el.getAttribute('data-min-width'),
						maxwidth = el.getAttribute('data-max-width');
				if (+minwidth <= width && (+maxwidth >= width || maxwidth === null)) {
					if (!waiting) {
						selectChildren('.' + nameSpace + 'aiImg', el).forEach(updateImgSrc);
					}
					el.style.display = 'block';
				} else {
					el.style.display = 'none';
				}
			});

			// Initialize lazy loading on first call
			if (waiting && !observer) {
				if (elementInView(container)) {
					waiting = false;
					update();
				} else {
					observer = new IntersectionObserver(onIntersectionChange, {});
					observer.observe(container);
				}
			}
		}

		function elementInView(el) {
			var bounds = el.getBoundingClientRect();
			return bounds.top < window.innerHeight && bounds.bottom > 0;
		}

		// Replace blank placeholder image with actual image
		function updateImgSrc(img) {
			var src = img.getAttribute('data-src');
			if (src && img.getAttribute('src') != src) {
				img.setAttribute('src', src);
			}
		}

		function onIntersectionChange(entries) {
			// There may be multiple entries relating to the same container
			// (captured at different times)
			var isIntersecting = entries.reduce(function(memo, entry) {
				return memo || entry.isIntersecting;
			}, false);
			if (isIntersecting) {
				waiting = false;
				// update: don't remove -- we need the observer to trigger an update
				// when a hidden map becomes visible after user interaction
				// (e.g. when an accordion menu or tab opens)
				// observer.disconnect();
				// observer = null;
				update();
			}
		}

		function selectChildren(selector, parent) {
			return parent ? Array.prototype.slice.call(parent.querySelectorAll(selector)) : [];
		}

		// based on underscore.js
		function throttle(func, wait) {
			var timeout = null, previous = 0;
			function run() {
					previous = Date.now();
					timeout = null;
					func();
			}
			return function() {
				var remaining = wait - (Date.now() - previous);
				if (remaining <= 0 || remaining > wait) {
					clearTimeout(timeout);
					run();
				} else if (!timeout) {
					timeout = setTimeout(run, remaining);
				}
			};
		}
	})("g-map-fakhravac-box", {namespace: "g-", setup: window.setupInteractive || window.getComponent});
</script>
<!-- End ai2html - 2021-11-26 12:20 -->



<!-- or print custom, pre-generated div with ID and classes -->


<!-- or print missing file warning -->




<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>

<h2 class="g-subhed g-optimize-type " id="">
	<span class="g-balancer" data-id="18">Tracking the Coronavirus</span>
</h2>
<!-- asset wrapper : start -->
<!-- ASSET : START -->




<div class="g-asset g-embed g-asset-width-full"  style="">

<!-- Intro elements -->








<div role="region">


<!-- data processed in process/freebird/process-image.js -->

<meta http-equiv="content-security-policy" content="">
	<link rel="stylesheet" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/pages/__layout.svelte-366a9710.css">
	<link rel="stylesheet" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/NewsletterSubscription.svelte_svelte_type_style_lang-7bb3bbb4.css">
	<link rel="stylesheet" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index-7857a851.css">
	<link rel="stylesheet" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index-c54d3c5d.css">
	<link rel="stylesheet" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index.svelte_svelte_type_style_lang-4351b175.css">
	<link rel="stylesheet" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index-395d65bb.css">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/start-474fa72e.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/index-4d5e6678.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/index-18d5c3da.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/paths-396f020f.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/preload-helper-8ee162e2.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/singletons-d1fb5791.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/pages/__layout.svelte-2c196e22.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/env-a8912701.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/index-1b5c1215.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/index-bc914825.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/yootils.es-5f329d3a.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/pages/embeds/footer-nav/index.html.svelte-5e593564.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/index-03c7422c.js">
	<link rel="modulepreload" href="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/chunks/index-0ae098e5.js">

<script type="text/plain" data-attr="nyt-asset-manifest">{"css":["https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/pages/__layout.svelte-366a9710.css","https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/NewsletterSubscription.svelte_svelte_type_style_lang-7bb3bbb4.css","https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index-7857a851.css","https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index-c54d3c5d.css","https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index.svelte_svelte_type_style_lang-4351b175.css","https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/assets/index-395d65bb.css"],"images":[]}</script>
<!-- publish_time: Wed Aug 31 2022 10:10:25 GMT+0000 (Coordinated Universal Time) -->

<div id="__covidtracker__" class="covid-tracker-wrapper">
  


<main class="covid-tracker" id="embeds/footer-nav"><div class="g-column"><div class="footer svelte-qjuty4">

	<nav class="svelte-qjuty4"><h3 class="svelte-qjuty4">United States</h3>
			<ul class="refers svelte-qjuty4"><li class="svelte-qjuty4"><a rel="" href="https://www.nytimes.com/interactive/2021/us/covid-cases.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/maps/USA/hotspots-state.png"></span>

							<div><h3>Latest Maps and Data</h3>
								<span class="svelte-qjuty4">Cases and deaths for every county</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/scoop/covid-19-vaccine-doses-promo-1608170893853-threeByTwoSmallAt2X-v528.png"></span>

							<div><h3>Vaccinations</h3>
								<span class="svelte-qjuty4">How many have been vaccinated, and who’s eligible</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="" href="https://www.nytimes.com/interactive/2021/us/covid-cases-deaths-tracker.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/personalized.png"></span>

							<div><h3>Your Places</h3>
								<span class="svelte-qjuty4">Build your own dashboard to track cases</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2020/us/covid-hospitals-near-you.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/scoop/covid-hospitals-near-you-promo-1608045359674-threeByTwoSmallAt2X-v5.jpg"></span>

							<div><h3>Hospitals Near You</h3>
								<span class="svelte-qjuty4">How many I.C.U. beds are occupied</span>
							</div></a>
					</li>
			</ul><h3 class="svelte-qjuty4">World</h3>
			<ul class="refers svelte-qjuty4"><li class="svelte-qjuty4"><a rel="" href="https://www.nytimes.com/interactive/2021/world/covid-cases.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/maps/NYT-World/hotspots.png"></span>

							<div><h3>Latest Maps and Data</h3>
								<span class="svelte-qjuty4">Cases and deaths for every country</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/maps/NYT-World/vaccinations.png"></span>

							<div><h3>Global Vaccinations</h3>
								<span class="svelte-qjuty4">How many have been vaccinated, by country</span>
							</div></a>
					</li>
			</ul><h3 class="svelte-qjuty4">Health</h3>
			<ul class="refers svelte-qjuty4"><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/vaccines.png"></span>

							<div><h3>Vaccines</h3>
								<span class="svelte-qjuty4">Track their development</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/treatments.png"></span>

							<div><h3>Treatments</h3>
								<span class="svelte-qjuty4">Rated by effectiveness and safety</span>
							</div></a>
					</li>
			</ul><h3 class="svelte-qjuty4">Previous Projects</h3>
			<ul class="refers svelte-qjuty4"><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2021/us/cdc-mask-guidance-states.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/08/02/mask-mandates/assets/promo-threeByTwoSmallAt2X.png"></span>

							<div><h3>Mask Mandates</h3>
								<span class="svelte-qjuty4">See state mask guidance for schools and indoors</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2021/us/covid-risk-map.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/county-risk-map.png"></span>

							<div><h3>Your County’s Risk</h3>
								<span class="svelte-qjuty4">See guidance for your local area</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2020/us/coronavirus-nursing-homes.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/nursing-homes.png"></span>

							<div><h3>Nursing Homes</h3>
								<span class="svelte-qjuty4">The hardest-hit states and facilities</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2021/us/college-covid-tracker.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/colleges-map.png"></span>

							<div><h3>Colleges and Universities</h3>
								<span class="svelte-qjuty4">Cases at more than 1,800 schools</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2021/01/14/us/covid-19-death-toll.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/deaths-us.jpg"></span>

							<div><h3>Deaths Above Normal</h3>
								<span class="svelte-qjuty4">The true toll of the pandemic in the U.S.</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2020/04/21/world/coronavirus-missing-deaths.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/deaths-world.jpg"></span>

							<div><h3>Deaths Above Normal</h3>
								<span class="svelte-qjuty4">The true toll of coronavirus around the world</span>
							</div></a>
					</li><li class="svelte-qjuty4"><a rel="" href="https://www.nytimes.com/interactive/2021/us/covid-case-outbreaks.html" class="svelte-qjuty4"><span class="thumb svelte-qjuty4" style="background-image: url(https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/images/outbreaks.png"></span>

							<div><h3>Early Coronavirus Outbreaks</h3>
								<span class="svelte-qjuty4">Cases in nursing homes, prisons and other places</span>
							</div></a>
					</li>
			</ul>

		<h3 class="svelte-qjuty4">Countries</h3>
		<ul class="locations svelte-qjuty4"><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/australia-covid-cases.html" class="svelte-qjuty4">Australia</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/brazil-covid-cases.html" class="svelte-qjuty4">Brazil</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/canada-covid-cases.html" class="svelte-qjuty4">Canada</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/china-covid-cases.html" class="svelte-qjuty4">China</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/france-covid-cases.html" class="svelte-qjuty4">France</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/germany-covid-cases.html" class="svelte-qjuty4">Germany</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/india-covid-cases.html" class="svelte-qjuty4">India</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/italy-covid-cases.html" class="svelte-qjuty4">Italy</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/japan-covid-cases.html" class="svelte-qjuty4">Japan</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/mexico-covid-cases.html" class="svelte-qjuty4">Mexico</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/south-africa-covid-cases.html" class="svelte-qjuty4">South Africa</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/spain-covid-cases.html" class="svelte-qjuty4">Spain</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html" class="svelte-qjuty4">United Kingdom</a></li><li class="svelte-qjuty4"><a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html" class="svelte-qjuty4">United States</a></li></ul>

		<h3 class="svelte-qjuty4">States, Territories and Cities</h3>
		<ul class="locations svelte-qjuty4"><li class="svelte-qjuty4"><a href="/interactive/2021/us/alabama-covid-cases.html" class="svelte-qjuty4">Alabama</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/alaska-covid-cases.html" class="svelte-qjuty4">Alaska</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/arizona-covid-cases.html" class="svelte-qjuty4">Arizona</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/arkansas-covid-cases.html" class="svelte-qjuty4">Arkansas</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/california-covid-cases.html" class="svelte-qjuty4">California</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/colorado-covid-cases.html" class="svelte-qjuty4">Colorado</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/connecticut-covid-cases.html" class="svelte-qjuty4">Connecticut</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/delaware-covid-cases.html" class="svelte-qjuty4">Delaware</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/florida-covid-cases.html" class="svelte-qjuty4">Florida</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/georgia-covid-cases.html" class="svelte-qjuty4">Georgia</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/guam-covid-cases.html" class="svelte-qjuty4">Guam</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/hawaii-covid-cases.html" class="svelte-qjuty4">Hawaii</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/idaho-covid-cases.html" class="svelte-qjuty4">Idaho</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/illinois-covid-cases.html" class="svelte-qjuty4">Illinois</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/indiana-covid-cases.html" class="svelte-qjuty4">Indiana</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/iowa-covid-cases.html" class="svelte-qjuty4">Iowa</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/kansas-covid-cases.html" class="svelte-qjuty4">Kansas</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/kentucky-covid-cases.html" class="svelte-qjuty4">Kentucky</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/louisiana-covid-cases.html" class="svelte-qjuty4">Louisiana</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/maine-covid-cases.html" class="svelte-qjuty4">Maine</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/maryland-covid-cases.html" class="svelte-qjuty4">Maryland</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/massachusetts-covid-cases.html" class="svelte-qjuty4">Massachusetts</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/michigan-covid-cases.html" class="svelte-qjuty4">Michigan</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/minnesota-covid-cases.html" class="svelte-qjuty4">Minnesota</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/mississippi-covid-cases.html" class="svelte-qjuty4">Mississippi</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/missouri-covid-cases.html" class="svelte-qjuty4">Missouri</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/montana-covid-cases.html" class="svelte-qjuty4">Montana</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/nebraska-covid-cases.html" class="svelte-qjuty4">Nebraska</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/nevada-covid-cases.html" class="svelte-qjuty4">Nevada</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/new-hampshire-covid-cases.html" class="svelte-qjuty4">New Hampshire</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/new-jersey-covid-cases.html" class="svelte-qjuty4">New Jersey</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/new-mexico-covid-cases.html" class="svelte-qjuty4">New Mexico</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/new-york-covid-cases.html" class="svelte-qjuty4">New York</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/north-carolina-covid-cases.html" class="svelte-qjuty4">North Carolina</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/north-dakota-covid-cases.html" class="svelte-qjuty4">North Dakota</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/northern-mariana-islands-covid-cases.html" class="svelte-qjuty4">Northern Mariana Islands</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/ohio-covid-cases.html" class="svelte-qjuty4">Ohio</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/oklahoma-covid-cases.html" class="svelte-qjuty4">Oklahoma</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/oregon-covid-cases.html" class="svelte-qjuty4">Oregon</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/pennsylvania-covid-cases.html" class="svelte-qjuty4">Pennsylvania</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/puerto-rico-covid-cases.html" class="svelte-qjuty4">Puerto Rico</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/rhode-island-covid-cases.html" class="svelte-qjuty4">Rhode Island</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/south-carolina-covid-cases.html" class="svelte-qjuty4">South Carolina</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/south-dakota-covid-cases.html" class="svelte-qjuty4">South Dakota</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/tennessee-covid-cases.html" class="svelte-qjuty4">Tennessee</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/texas-covid-cases.html" class="svelte-qjuty4">Texas</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/virgin-islands-covid-cases.html" class="svelte-qjuty4">U.S. Virgin Islands</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/utah-covid-cases.html" class="svelte-qjuty4">Utah</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/vermont-covid-cases.html" class="svelte-qjuty4">Vermont</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/virginia-covid-cases.html" class="svelte-qjuty4">Virginia</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/washington-covid-cases.html" class="svelte-qjuty4">Washington</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/washington-district-of-columbia-covid-cases.html" class="svelte-qjuty4">Washington, D.C.</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/west-virginia-covid-cases.html" class="svelte-qjuty4">West Virginia</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/wisconsin-covid-cases.html" class="svelte-qjuty4">Wisconsin</a></li><li class="svelte-qjuty4"><a href="/interactive/2021/us/wyoming-covid-cases.html" class="svelte-qjuty4">Wyoming</a></li></ul>

		<h3 class="svelte-qjuty4">Data</h3>
		<ul class="svelte-qjuty4"><li class="svelte-qjuty4"><a rel="external" href="https://www.nytimes.com/interactive/2020/us/about-coronavirus-data-maps.html" class="svelte-qjuty4">Frequently Asked Questions About the Covid Data</a></li><li class="svelte-qjuty4"><a rel="external" href="https://github.com/nytimes/covid-19-data" class="svelte-qjuty4">Access the Open Source Covid Data</a></li></ul></nav>
</div></div></main>




		<script type="module" data-hydrate="saexky">
		import { start } from "https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/start-474fa72e.js";
		start({
			target: document.querySelector('[data-hydrate="saexky"]').parentNode,
			paths: {"base":"/interactive/2021","assets":"https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking"},
			session: {embedded:true},
			route: false,
			spa: false,
			trailing_slash: "never",
			hydrate: {
				status: 200,
				error: null,
				nodes: [
					import("https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/pages/__layout.svelte-2c196e22.js"),
						import("https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/_app/pages/embeds/footer-nav/index.html.svelte-5e593564.js")
				],
				params: {},
				routeId: "embeds/footer-nav.html"
			}
		});
	</script><script type="application/json" sveltekit:data-type="data" sveltekit:data-url="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/page/navigation.json">{"status":200,"statusText":"","headers":{"content-type":"application/json"},"body":"{\"sections\":[{\"icon\":\"images/maps/USA/hotspots-state.png\",\"section\":\"usa\",\"primary\":[{\"name\":\"Latest Maps and Data\",\"url\":\"https://www.nytimes.com/interactive/2021/us/covid-cases.html\",\"rel\":\"\"},{\"name\":\"Vaccinations by State\",\"url\":\"https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html\",\"rel\":\"external\"},{\"name\":\"Your Places\",\"url\":\"https://www.nytimes.com/interactive/2021/us/covid-cases-deaths-tracker.html\",\"rel\":\"\"},{\"name\":\"Hospitals\",\"url\":\"https://www.nytimes.com/interactive/2020/us/covid-hospitals-near-you.html\",\"rel\":\"external\"}],\"secondary\":[{\"name\":\"Alabama\",\"url\":\"https://www.nytimes.com/interactive/2021/us/alabama-covid-cases.html\",\"slug\":\"us/alabama-covid-cases\",\"rel\":\"\"},{\"name\":\"Alaska\",\"url\":\"https://www.nytimes.com/interactive/2021/us/alaska-covid-cases.html\",\"slug\":\"us/alaska-covid-cases\",\"rel\":\"\"},{\"name\":\"Arizona\",\"url\":\"https://www.nytimes.com/interactive/2021/us/arizona-covid-cases.html\",\"slug\":\"us/arizona-covid-cases\",\"rel\":\"\"},{\"name\":\"Arkansas\",\"url\":\"https://www.nytimes.com/interactive/2021/us/arkansas-covid-cases.html\",\"slug\":\"us/arkansas-covid-cases\",\"rel\":\"\"},{\"name\":\"California\",\"url\":\"https://www.nytimes.com/interactive/2021/us/california-covid-cases.html\",\"slug\":\"us/california-covid-cases\",\"rel\":\"\"},{\"name\":\"Colorado\",\"url\":\"https://www.nytimes.com/interactive/2021/us/colorado-covid-cases.html\",\"slug\":\"us/colorado-covid-cases\",\"rel\":\"\"},{\"name\":\"Connecticut\",\"url\":\"https://www.nytimes.com/interactive/2021/us/connecticut-covid-cases.html\",\"slug\":\"us/connecticut-covid-cases\",\"rel\":\"\"},{\"name\":\"Delaware\",\"url\":\"https://www.nytimes.com/interactive/2021/us/delaware-covid-cases.html\",\"slug\":\"us/delaware-covid-cases\",\"rel\":\"\"},{\"name\":\"Florida\",\"url\":\"https://www.nytimes.com/interactive/2021/us/florida-covid-cases.html\",\"slug\":\"us/florida-covid-cases\",\"rel\":\"\"},{\"name\":\"Georgia\",\"url\":\"https://www.nytimes.com/interactive/2021/us/georgia-covid-cases.html\",\"slug\":\"us/georgia-covid-cases\",\"rel\":\"\"},{\"name\":\"Guam\",\"url\":\"https://www.nytimes.com/interactive/2021/us/guam-covid-cases.html\",\"slug\":\"us/guam-covid-cases\",\"rel\":\"\"},{\"name\":\"Hawaii\",\"url\":\"https://www.nytimes.com/interactive/2021/us/hawaii-covid-cases.html\",\"slug\":\"us/hawaii-covid-cases\",\"rel\":\"\"},{\"name\":\"Idaho\",\"url\":\"https://www.nytimes.com/interactive/2021/us/idaho-covid-cases.html\",\"slug\":\"us/idaho-covid-cases\",\"rel\":\"\"},{\"name\":\"Illinois\",\"url\":\"https://www.nytimes.com/interactive/2021/us/illinois-covid-cases.html\",\"slug\":\"us/illinois-covid-cases\",\"rel\":\"\"},{\"name\":\"Indiana\",\"url\":\"https://www.nytimes.com/interactive/2021/us/indiana-covid-cases.html\",\"slug\":\"us/indiana-covid-cases\",\"rel\":\"\"},{\"name\":\"Iowa\",\"url\":\"https://www.nytimes.com/interactive/2021/us/iowa-covid-cases.html\",\"slug\":\"us/iowa-covid-cases\",\"rel\":\"\"},{\"name\":\"Kansas\",\"url\":\"https://www.nytimes.com/interactive/2021/us/kansas-covid-cases.html\",\"slug\":\"us/kansas-covid-cases\",\"rel\":\"\"},{\"name\":\"Kentucky\",\"url\":\"https://www.nytimes.com/interactive/2021/us/kentucky-covid-cases.html\",\"slug\":\"us/kentucky-covid-cases\",\"rel\":\"\"},{\"name\":\"Louisiana\",\"url\":\"https://www.nytimes.com/interactive/2021/us/louisiana-covid-cases.html\",\"slug\":\"us/louisiana-covid-cases\",\"rel\":\"\"},{\"name\":\"Maine\",\"url\":\"https://www.nytimes.com/interactive/2021/us/maine-covid-cases.html\",\"slug\":\"us/maine-covid-cases\",\"rel\":\"\"},{\"name\":\"Maryland\",\"url\":\"https://www.nytimes.com/interactive/2021/us/maryland-covid-cases.html\",\"slug\":\"us/maryland-covid-cases\",\"rel\":\"\"},{\"name\":\"Massachusetts\",\"url\":\"https://www.nytimes.com/interactive/2021/us/massachusetts-covid-cases.html\",\"slug\":\"us/massachusetts-covid-cases\",\"rel\":\"\"},{\"name\":\"Michigan\",\"url\":\"https://www.nytimes.com/interactive/2021/us/michigan-covid-cases.html\",\"slug\":\"us/michigan-covid-cases\",\"rel\":\"\"},{\"name\":\"Minnesota\",\"url\":\"https://www.nytimes.com/interactive/2021/us/minnesota-covid-cases.html\",\"slug\":\"us/minnesota-covid-cases\",\"rel\":\"\"},{\"name\":\"Mississippi\",\"url\":\"https://www.nytimes.com/interactive/2021/us/mississippi-covid-cases.html\",\"slug\":\"us/mississippi-covid-cases\",\"rel\":\"\"},{\"name\":\"Missouri\",\"url\":\"https://www.nytimes.com/interactive/2021/us/missouri-covid-cases.html\",\"slug\":\"us/missouri-covid-cases\",\"rel\":\"\"},{\"name\":\"Montana\",\"url\":\"https://www.nytimes.com/interactive/2021/us/montana-covid-cases.html\",\"slug\":\"us/montana-covid-cases\",\"rel\":\"\"},{\"name\":\"Nebraska\",\"url\":\"https://www.nytimes.com/interactive/2021/us/nebraska-covid-cases.html\",\"slug\":\"us/nebraska-covid-cases\",\"rel\":\"\"},{\"name\":\"Nevada\",\"url\":\"https://www.nytimes.com/interactive/2021/us/nevada-covid-cases.html\",\"slug\":\"us/nevada-covid-cases\",\"rel\":\"\"},{\"name\":\"New Hampshire\",\"url\":\"https://www.nytimes.com/interactive/2021/us/new-hampshire-covid-cases.html\",\"slug\":\"us/new-hampshire-covid-cases\",\"rel\":\"\"},{\"name\":\"New Jersey\",\"url\":\"https://www.nytimes.com/interactive/2021/us/new-jersey-covid-cases.html\",\"slug\":\"us/new-jersey-covid-cases\",\"rel\":\"\"},{\"name\":\"New Mexico\",\"url\":\"https://www.nytimes.com/interactive/2021/us/new-mexico-covid-cases.html\",\"slug\":\"us/new-mexico-covid-cases\",\"rel\":\"\"},{\"name\":\"New York\",\"url\":\"https://www.nytimes.com/interactive/2021/us/new-york-covid-cases.html\",\"slug\":\"us/new-york-covid-cases\",\"rel\":\"\"},{\"name\":\"North Carolina\",\"url\":\"https://www.nytimes.com/interactive/2021/us/north-carolina-covid-cases.html\",\"slug\":\"us/north-carolina-covid-cases\",\"rel\":\"\"},{\"name\":\"North Dakota\",\"url\":\"https://www.nytimes.com/interactive/2021/us/north-dakota-covid-cases.html\",\"slug\":\"us/north-dakota-covid-cases\",\"rel\":\"\"},{\"name\":\"Northern Mariana Islands\",\"url\":\"https://www.nytimes.com/interactive/2021/us/northern-mariana-islands-covid-cases.html\",\"slug\":\"us/northern-mariana-islands-covid-cases\",\"rel\":\"\"},{\"name\":\"Ohio\",\"url\":\"https://www.nytimes.com/interactive/2021/us/ohio-covid-cases.html\",\"slug\":\"us/ohio-covid-cases\",\"rel\":\"\"},{\"name\":\"Oklahoma\",\"url\":\"https://www.nytimes.com/interactive/2021/us/oklahoma-covid-cases.html\",\"slug\":\"us/oklahoma-covid-cases\",\"rel\":\"\"},{\"name\":\"Oregon\",\"url\":\"https://www.nytimes.com/interactive/2021/us/oregon-covid-cases.html\",\"slug\":\"us/oregon-covid-cases\",\"rel\":\"\"},{\"name\":\"Pennsylvania\",\"url\":\"https://www.nytimes.com/interactive/2021/us/pennsylvania-covid-cases.html\",\"slug\":\"us/pennsylvania-covid-cases\",\"rel\":\"\"},{\"name\":\"Puerto Rico\",\"url\":\"https://www.nytimes.com/interactive/2021/us/puerto-rico-covid-cases.html\",\"slug\":\"us/puerto-rico-covid-cases\",\"rel\":\"\"},{\"name\":\"Rhode Island\",\"url\":\"https://www.nytimes.com/interactive/2021/us/rhode-island-covid-cases.html\",\"slug\":\"us/rhode-island-covid-cases\",\"rel\":\"\"},{\"name\":\"South Carolina\",\"url\":\"https://www.nytimes.com/interactive/2021/us/south-carolina-covid-cases.html\",\"slug\":\"us/south-carolina-covid-cases\",\"rel\":\"\"},{\"name\":\"South Dakota\",\"url\":\"https://www.nytimes.com/interactive/2021/us/south-dakota-covid-cases.html\",\"slug\":\"us/south-dakota-covid-cases\",\"rel\":\"\"},{\"name\":\"Tennessee\",\"url\":\"https://www.nytimes.com/interactive/2021/us/tennessee-covid-cases.html\",\"slug\":\"us/tennessee-covid-cases\",\"rel\":\"\"},{\"name\":\"Texas\",\"url\":\"https://www.nytimes.com/interactive/2021/us/texas-covid-cases.html\",\"slug\":\"us/texas-covid-cases\",\"rel\":\"\"},{\"name\":\"U.S. Virgin Islands\",\"url\":\"https://www.nytimes.com/interactive/2021/us/virgin-islands-covid-cases.html\",\"slug\":\"us/virgin-islands-covid-cases\",\"rel\":\"\"},{\"name\":\"Utah\",\"url\":\"https://www.nytimes.com/interactive/2021/us/utah-covid-cases.html\",\"slug\":\"us/utah-covid-cases\",\"rel\":\"\"},{\"name\":\"Vermont\",\"url\":\"https://www.nytimes.com/interactive/2021/us/vermont-covid-cases.html\",\"slug\":\"us/vermont-covid-cases\",\"rel\":\"\"},{\"name\":\"Virginia\",\"url\":\"https://www.nytimes.com/interactive/2021/us/virginia-covid-cases.html\",\"slug\":\"us/virginia-covid-cases\",\"rel\":\"\"},{\"name\":\"Washington\",\"url\":\"https://www.nytimes.com/interactive/2021/us/washington-covid-cases.html\",\"slug\":\"us/washington-covid-cases\",\"rel\":\"\"},{\"name\":\"Washington, D.C.\",\"url\":\"https://www.nytimes.com/interactive/2021/us/washington-district-of-columbia-covid-cases.html\",\"slug\":\"us/washington-district-of-columbia-covid-cases\",\"rel\":\"\"},{\"name\":\"West Virginia\",\"url\":\"https://www.nytimes.com/interactive/2021/us/west-virginia-covid-cases.html\",\"slug\":\"us/west-virginia-covid-cases\",\"rel\":\"\"},{\"name\":\"Wisconsin\",\"url\":\"https://www.nytimes.com/interactive/2021/us/wisconsin-covid-cases.html\",\"slug\":\"us/wisconsin-covid-cases\",\"rel\":\"\"},{\"name\":\"Wyoming\",\"url\":\"https://www.nytimes.com/interactive/2021/us/wyoming-covid-cases.html\",\"slug\":\"us/wyoming-covid-cases\",\"rel\":\"\"}]},{\"icon\":\"images/maps/NYT-World/hotspots.png\",\"section\":\"world\",\"primary\":[{\"name\":\"Latest Maps and Data\",\"url\":\"https://www.nytimes.com/interactive/2021/world/covid-cases.html\",\"rel\":\"\"},{\"name\":\"Vaccinations by Country\",\"url\":\"https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html\",\"rel\":\"external\"}],\"secondary\":[{\"name\":\"Australia\",\"url\":\"https://www.nytimes.com/interactive/2021/world/australia-covid-cases.html\",\"slug\":\"world/australia-covid-cases\",\"rel\":\"\"},{\"name\":\"Brazil\",\"url\":\"https://www.nytimes.com/interactive/2021/world/brazil-covid-cases.html\",\"slug\":\"world/brazil-covid-cases\",\"rel\":\"\"},{\"name\":\"Canada\",\"url\":\"https://www.nytimes.com/interactive/2021/world/canada-covid-cases.html\",\"slug\":\"world/canada-covid-cases\",\"rel\":\"\"},{\"name\":\"China\",\"url\":\"https://www.nytimes.com/interactive/2021/world/china-covid-cases.html\",\"slug\":\"world/china-covid-cases\",\"rel\":\"\"},{\"name\":\"France\",\"url\":\"https://www.nytimes.com/interactive/2021/world/france-covid-cases.html\",\"slug\":\"world/france-covid-cases\",\"rel\":\"\"},{\"name\":\"Germany\",\"url\":\"https://www.nytimes.com/interactive/2021/world/germany-covid-cases.html\",\"slug\":\"world/germany-covid-cases\",\"rel\":\"\"},{\"name\":\"India\",\"url\":\"https://www.nytimes.com/interactive/2021/world/india-covid-cases.html\",\"slug\":\"world/india-covid-cases\",\"rel\":\"\"},{\"name\":\"Italy\",\"url\":\"https://www.nytimes.com/interactive/2021/world/italy-covid-cases.html\",\"slug\":\"world/italy-covid-cases\",\"rel\":\"\"},{\"name\":\"Japan\",\"url\":\"https://www.nytimes.com/interactive/2021/world/japan-covid-cases.html\",\"slug\":\"world/japan-covid-cases\",\"rel\":\"\"},{\"name\":\"Mexico\",\"url\":\"https://www.nytimes.com/interactive/2021/world/mexico-covid-cases.html\",\"slug\":\"world/mexico-covid-cases\",\"rel\":\"\"},{\"name\":\"South Africa\",\"url\":\"https://www.nytimes.com/interactive/2021/world/south-africa-covid-cases.html\",\"slug\":\"world/south-africa-covid-cases\",\"rel\":\"\"},{\"name\":\"Spain\",\"url\":\"https://www.nytimes.com/interactive/2021/world/spain-covid-cases.html\",\"slug\":\"world/spain-covid-cases\",\"rel\":\"\"},{\"name\":\"United Kingdom\",\"url\":\"https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html\",\"slug\":\"world/united-kingdom-covid-cases\",\"rel\":\"\"}]},{\"icon\":\"images/health-icon.png\",\"section\":\"health\",\"primary\":[{\"name\":\"Vaccine Development\",\"url\":\"https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html\",\"rel\":\"external\"},{\"name\":\"Coronavirus Variants\",\"url\":\"https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html\",\"rel\":\"external\"},{\"name\":\"Treatments\",\"url\":\"https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html\",\"rel\":\"external\"},{\"name\":\"Answers to Your Covid-19 Questions\",\"url\":\"https://www.nytimes.com/interactive/2020/world/coronavirus-tips-advice.html\",\"rel\":\"external\"},{\"name\":\"How the Covid-19 Vaccines Work\",\"url\":\"https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html\",\"rel\":\"external\"},{\"name\":\"Symptoms of Covid-19\",\"url\":\"https://www.nytimes.com/interactive/2020/08/05/well/covid-19-symptoms.html\",\"rel\":\"external\"},{\"name\":\"What Happens in an Infection\",\"url\":\"https://www.nytimes.com/interactive/2020/10/02/science/charting-a-coronavirus-infection.html\",\"rel\":\"external\"},{\"name\":\"How Masks Work\",\"url\":\"https://www.nytimes.com/interactive/2020/10/30/science/wear-mask-covid-particles-ul.html\",\"rel\":\"external\"}],\"secondary\":[]}]}"}</script>
	<script type="application/json" sveltekit:data-type="data" sveltekit:data-url="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/data/text.json">{"status":200,"statusText":"","headers":{"content-type":"application/json"},"body":"{\"source_county_top_indicators\":\"Sources: State and local health agencies (cases, deaths); U.S. Department of Health and Human Services (hospitalizations, test positivity). Cases, deaths and test positivity charts show 7-day averages. Hospitalization data is a weekly average of Covid-19 patients in hospital service areas that intersect with LOCATION.\",\"source_state_top_indicators\":\"Sources: State and local health agencies (cases, deaths); U.S. Department of Health and Human Services (test positivity, hospitalizations, I.C.U. patients). Test positivity, hospitalizations, I.C.U.s and deaths show seven-day averages. Test positivity is based only on P.C.R. test results reported to the federal government. Test positivity, hospitalization and I.C.U. data may not yet be available for yesterday. Figures shown are the most recent data available.\",\"source_usa_top_indicators\":\"Sources: State and local health agencies (cases, deaths); U.S. Department of Health and Human Services (test positivity, hospitalizations, I.C.U. patients). Test positivity, hospitalizations, I.C.U.s and deaths show seven-day averages. Hospitalization data may not yet be available for yesterday. Test positivity is based only on P.C.R. test results reported to the federal government and is for the most recent seven days in which at least 40 states have reported testing data. 14-day change is hidden if not enough data is available to make a comparison. Figures shown are the most recent data available.\",\"source_country_top_indicators\":\"Source: Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Daily cases are the number of new cases reported each day. The seven-day average is the average of a day and the previous six days of data.\",\"source_custom_country_top_indicators\":\"Daily cases are the number of new cases reported each day. The seven-day average is the average of a day and the previous six days of data.\",\"note_county_cases\":\"Note: The 7-day average is the average of a day and the previous 6 days of data.\",\"note_county_deaths\":\"Note: The 7-day average is the average of a day and the previous 6 days of data.\",\"note_county_hospitalized\":\"Source: U.S. Department of Health and Human Services. Hospitalization data is a weekly average of Covid-19 patients in hospital service areas that intersect with LOCATION.\",\"note_vaccinations_map\":\"Sources: \u003Ca rel=\\\"external\\\" href=\\\"https://covid.cdc.gov/covid-data-tracker/#county-view\\\">Centers for Disease Control and Prevention\u003C/a> and state governments. Note: No C.D.C. data available for Hawaii and some counties. Some states were excluded because more than a quarter of data is missing.\",\"note_hotspots_map\":\"The hot spots map shows the share of population with a new reported case over the last week.\",\"mask_mandates_intro\":\"The New York Times is tracking mask policies at the state level, including current federal guidance by county and where leaders are rejecting such guidance or mandates. \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/interactive/2021/us/cdc-mask-guidance-states.html\\\">Read more here&nbsp;›\u003C/a>\",\"note_cases_map\":\"The map shows the known locations of coronavirus cases by county. Circles are sized by the number of people there who have tested positive or have a probable case of the virus, which may differ from where they contracted the illness.\",\"new_hospital_map_note\":\"\",\"note_hsa_map\":\"The map shows a seven-day average for the number of patients hospitalized with Covid-19. The \u003Ca rel=\\\"external\\\" href=\\\"https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/anag-cw7u\\\">data\u003C/a> is self-reported to the U.S. Department of Health and Human Services by individual hospitals. It excludes counts from hospitals operated by the U.S. Department of Veterans Affairs and the Indian Health Service. Numbers for hospitalized patients are based on inpatient beds and include I.C.U. beds. Hospitalized Covid-19 patients include both confirmed and suspected Covid-19 patients. \u003Ca rel=\\\"external\\\" href=\\\"https://healthdata.gov/dataset/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/6xf2-c3ie\\\">Data\u003C/a> for Puerto Rico is reported at the territory level instead of by hospital service area.\",\"note_hospitals_map\":\"The map shows the average I.C.U. occupancy at nearby hospitals in the most recent week with data reported. The \u003Ca rel=\\\"external\\\" href=\\\"https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/anag-cw7u\\\">data\u003C/a> is self-reported to the U.S. Department of Health and Human Services by individual hospitals. It excludes counts from hospitals operated by the U.S. Department of Veterans Affairs and the Indian Health Service. Numbers for hospitalized patients are based on inpatient beds and include I.C.U. beds. Hospitalized Covid-19 patients include both confirmed and suspected Covid-19 patients.\",\"note_cases_percap_map\":\"The map shows the known locations of cumulative coronavirus cases by share of the population in each county.\",\"note_deaths_percap_map\":\"The map shows the known locations of cumulative coronavirus deaths by share of the population in each county.\",\"note_deaths_map\":\"The map shows the known locations of coronavirus deaths by county. Circles are sized by the number of people there who have died from the virus, which may differ from where they contracted the illness.\",\"note_hospitalized_country_map\":\"\",\"note_hotspots_country_map\":\"The hot spots map shows the share of population with a new reported case over the last week.\",\"note_cases_country_map\":\"The map shows the known locations of cumulative reported coronavirus cases.\",\"note_deaths_country_map\":\"The map shows the known locations of cumulative reported coronavirus deaths.\",\"note_cases_percap_country_map\":\"The map shows the known locations of cumulative coronavirus cases by share of the population in each place.\",\"state_page_supertable_hed\":\"Reported cases, deaths and other trends by CHILDTYPE\",\"usa_page_supertable_hed\":\"Reported cases, deaths and other trends by CHILDTYPE\",\"country_page_supertable_hed\":\"Latest trends by CHILDTYPE\",\"world_page_supertable_hed\":\"Reported cases, deaths and vaccinations by country\",\"world_page_supertable_intro\":\"This table is sorted by places with the most cases per 100,000 residents in the last seven days. Charts show change in daily averages and are each on their own scale.\",\"state_page_supertable_intro\":\"This table is sorted by places with the most cases per 100,000 residents in the last seven days. Statewide data often updates more frequently than county-level data, and may not equal the sum of county-level figures. Charts show change in daily averages and are each on their own scale.\",\"country_page_supertable_intro\":\"This table is sorted by places with the most cases per 100,000 residents in the last seven days. Charts show change in daily averages and are each on their own scale.\",\"state_page_supertable_note\":\"Sources: State and local health agencies (cases, deaths); U.S. Department of Health and Human Services (hospitalizations); Centers for Disease Control and state governments (vaccinations); Census Bureau (population and demographic data). The daily average is calculated with data that was reported in the last seven days. Hospitalized for each county shows the average number of Covid-19 patients hospitalized per 100,000 residents within any hospital service areas that intersect with the county and is updated once a week. Vaccination data is not available for some counties. All-time charts show data from Jan. 21, 2020 to present.\",\"country_page_supertable_note\":\"Daily cases are the number of new cases reported each day. The seven-day average is the average of a day and the previous six days of data. All-time charts show data from Jan. 21, 2020 to present.\",\"world_page_supertable_note\":\"Daily cases are the number of new cases reported each day. Vaccination data provided by Our World in Data. Vaccination numbers marked with an asterisk * were last reported more than two weeks ago. The seven-day average is the average of a day and the previous six days of data. All-time charts show data from Jan. 21, 2020 to present.\",\"france_page_supertable_note\":\"Source: Public Health France. Daily hospitalizations are the number of new hospitalized Covid-19 patients reported each day, and death figures are the number of hospitalized Covid-19 patients who have died. The seven-day average is the average of a day and the previous six days of data. All-time charts show data from Jan. 21, 2020 to present.\",\"state_page_charts_hed\":\"How trends have changed in LOCATION\",\"county_page_charts_hed\":\"How trends have changed in LOCATION\",\"usa_page_charts_hed\":\"U.S. trends\",\"world_page_charts_hed\":\"How global trends have changed\",\"country_page_charts_hed\":\"How trends have changed in LOCATION_ARTICLE LOCATION\",\"embedded_state_chart_note\":\"Source: State and local health agencies. Daily cases are the number of new cases reported each day. The seven-day average is the average of the most recent seven days of data.\",\"embedded_state_hospitalized_chart_note\":\"Source: U.S. Department of Health and Human Services. The seven-day average is the average of a day and the previous six days of data. Currently hospitalized is the most recent number of patients with Covid-19 reported by hospitals in the state for the four days prior. Dips and spikes could be due to inconsistent reporting by hospitals. Hospitalization numbers early in the pandemic are undercounts due to incomplete reporting by hospitals to the federal government.\",\"embedded_world_chart_note\":\"Source: Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, U.S. state and local health agencies. Daily cases are the number of new cases reported each day. The seven-day average is the average of a day and the previous six days of data.\",\"embedded_charts_link\":\"LOCATION Coronavirus Cases\",\"embedded_charts_deaths_link\":\"LOCATION Coronavirus Deaths\",\"embedded_charts_hospitalized_link\":\"LOCATION Covid-19 Hospitalizations\",\"state_page_charts_note\":\"Sources: State and local health agencies (cases, deaths); U.S. Department of Health and Human Services (test positivty, hospitalizations, I.C.U. patients).  The seven-day average is the average of the most recent seven days of data. Cases and deaths data are assigned to dates based on when figures are publicly reported. Figures for Covid patients in hospitals and I.C.U.s are the most recent number of patients with Covid-19 who are hospitalized or in an intensive care unit on that day. Dips and spikes could be due to inconsistent reporting by hospitals. Hospitalization numbers early in the pandemic are undercounts due to incomplete reporting by hospitals to the federal government. Test positivity is based on P.C.R. viral test specimens tested by laboratories and state health departments and reported to the federal government. Hospitalizations and test positivity are reported based on dates assigned by the U.S. Department of Health and Human Services and are subject to historical revisions.\",\"usa_page_charts_note\":\"Sources: State and local health agencies (cases, deaths); U.S. Department of Health and Human Services (test positivity, hospitalizations, I.C.U. patients). The seven-day average is the average of the most recent seven days of data. Figures for Covid patients in hospitals and I.C.U.s are the most recent number of patients with Covid-19 who are hospitalized or in an intensive care unit on that day. Dips and spikes could be due to inconsistent reporting by hospitals. Hospitalization numbers early in the pandemic are undercounts due to incomplete reporting by hospitals to the federal government. Test positivity is based on P.C.R. viral test specimens tested by laboratories and state health departments and reported to the federal government by the 50 states, Washington D.C. and Puerto Rico. Hospitalizations and test positivity are reported based on dates assigned by the U.S. Department of Health and Human Services and are subject to historical revisions. Cases and deaths data are assigned to dates based on when figures are publicly reported. For case and death seven-day averages, if there are days within that range with no data reported, the period is extended to older days until at least seven days of data are included. Data from days following non-reporting days is averaged over that day and the non-reporting days that precede it. When calculating rolling averages, these days representing multiple day's worth of data are always included together, which means that in instances of irregularly timed reporting, the seven-day average may be an average over more than seven days. Certain days with anomalous total case or death reports are excluded from the average or have a portion of their cases and deaths which correspond to data backlogs removed from the average calculation. For the U.S. national case and death count averages, the average is the sum of the average number of cases and deaths in all states and territories each day. This average may not match the average when calculated from the U.S. case and death total in order to account for irregularly timed case and death reports at the state level.\",\"county_page_charts_note\":\"Sources: State and local health agencies (cases, deaths); U.S. Department of Health and Human Services (hospitalizations, test positivity). Cases, deaths and test positivity charts show 7-day averages. Hospitalization data is a weekly average of Covid-19 patients in hospital service areas that intersect with LOCATION.\",\"country_page_charts_note\":\"Source: Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. The daily average is calculated with data that was reported in the last seven days.\",\"custom_country_page_charts_note\":\"The daily average is calculated with data that was reported in the last seven days.\",\"clusters_page_hed\":\"Early Coronavirus Cases in Nursing Homes, Prisons and Other Locations\",\"clusters_page_intro\":\"In the first year of the pandemic, The Times tracked cases in places with some of the worst outbreaks, like \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/interactive/2020/us/coronavirus-nursing-homes.html\\\">nursing homes\u003C/a>, food processing plants and \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/interactive/2021/04/10/us/covid-prison-outbreak.html\\\">correctional facilities\u003C/a>. This list is an archive of that reporting and is no longer being updated.\",\"clusters_page_about_data\":\"Information on cases linked to these places comes from official releases by governments, companies and institutions directly. The Times is publishing lists of groupings of 50 or more cases related to a specific site, workplace or event. The clusters with the most reported cases in each category are shown here.\",\"vaccine_refer\":\"\u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html\\\">See more details&nbsp;›\u003C/a>\",\"vaccine_country_refer\":\"\u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html\\\">See more details&nbsp;›\u003C/a>\",\"county_vaccine_data_note\":\"Sources: Centers for Disease Control and Prevention, state governments, U.S. Census Bureau.\",\"vaccine_data_note\":\"Sources: Centers for Disease Control and Prevention, state governments, U.S. Census Bureau. The C.D.C. reported on Nov. 30 that booster doses are sometimes misclassified as first doses, which may overestimate first dose coverage among adults.\",\"global_vaccine_data_note\":\"Source: Vaccination data is based on government reports and is provided by the Our World in Data project at the University of Oxford. Data is based on reports at the time of publication.\",\"metros_vaccine_data_note\":\"The percentage vaccinated is based on the number of people reported vaccinated in each county in the metro area. A small share of the C.D.C.’s vaccination data for this area did not specify the person’s home county.\",\"no_vaccine_data_note\":\"County vaccination data is not comprehensive enough to provide a vaccinated share for this metro area.\",\"usa_page_state_supertable_hed\":\"State trends\",\"usa_page_state_supertable_intro\":\"This table is sorted by places with the most cases per 100,000 residents in the last seven days. Charts show change in daily averages and are each on their own scale. Select a table header to sort by another metric.\",\"usa_page_table_transition_note\":\"\",\"usa_page_state_table_note\":\"Sources: State and local health agencies (cases, deaths); U.S. Department of Health and Human Services (test positivity, hospitalizations); Centers for Disease Control and state governments (vaccinations); Census Bureau (population and demographic data). Test positivity data is based on viral P.C.R. test results only and is a seven day average. The daily average is calculated with data that was reported in the last seven days. \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html\\\">Vaccination data\u003C/a> is not available for some states. All-time charts show data from Jan. 21, 2020 to present.\",\"usa_page_county_supertable_hed\":\"County trends\",\"usa_page_county_supertable_intro\":\"This table is sorted by places with the most cases per 100,000 residents in the last seven days. Charts show change in daily averages and are each on their own scale. Select a table header to sort by another metric.\",\"usa_page_county_table_note\":\"Sources: State and local health agencies (cases, deaths); U.S. Department of Health and Human Services (test positivity, hospitalizations); Centers for Disease Control and state governments (vaccinations). The daily average is calculated with data that was reported in the last seven days. Counties with fewer than 10,000 residents are not shown. Test positivity data is based on viral P.C.R. test results only and is a seven day average. Hospitalized figures are updated once a week for each county and show the average number of Covid-19 patients hospitalized per 100,000 residents within any hospital service areas that intersect with the county, or in some cases, within any hospital referral regions that intersect with the county. Vaccination data is not available for some counties. All-time charts show data from Jan. 21, 2020 to present.\",\"table_no_rows_match_search\":\"There are no places that match your search.\",\"bullets_country_page_bra\":\"\",\"bullets_country_page_can\":\"\",\"bullets_country_page_fra\":\"See more Covid-19 data from the French government \u003Ca rel=\\\"external\\\" href=\\\"https://www.gouvernement.fr/info-coronavirus/carte-et-donnees\\\">here\u003C/a>.\",\"bullets_country_page_deu\":\"\",\"bullets_country_page_ind\":\"The official Covid-19 figures in India \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/interactive/2021/05/25/world/asia/india-covid-death-estimates.html\\\">grossly understate the true scale of the pandemic\u003C/a> in the country. Here’s what to know about \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/article/india-coronavirus-cases-deaths.html\\\">India’s coronavirus crisis\u003C/a>.\",\"bullets_country_page_ita\":\"\",\"bullets_country_page_jpn\":\"\",\"bullets_country_page_mex\":\"\",\"bullets_country_page_esp\":\"\",\"bullets_country_page_gbr\":\"\",\"bullets_country_page_chn\":[{\"type\":\"text\",\"value\":\"Under China’s “\u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/2022/01/21/world/asia/china-zero-covid-policy.html\\\">zero Covid\u003C/a>” policy, the country is deploying testing and quarantines on a massive scale to identify and isolate cases.\"},{\"type\":\"text\",\"value\":\"Early in the pandemic China is thought to have \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/2022/02/04/briefing/zero-covid-china-olympics.html\\\">drastically understated\u003C/a> the number of Covid cases and deaths in official figures.\"}],\"about_the_data_world_page\":\"Data for all countries except the United States comes from the Center for Systems Science and Engineering at Johns Hopkins University. United States data comes from state and local health officials and is \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/nytimes/covid-19-data\\\">collected by The New York Times\u003C/a>. Population data from the World Bank and U.S. Census Bureau. Data for some countries, like the United States, Denmark, France and the Netherlands, include counts for overseas territories. The New York Times has found that official tallies in \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/interactive/2020/04/21/world/coronavirus-missing-deaths.html\\\">more than thirty countries have undercounted deaths\u003C/a> during the coronavirus outbreak because of limited testing availability.\",\"about_the_data_country_page_aus\":\"Data for Australia comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/CSSEGISandData/COVID-19\\\">Center for Systems Science and Engineering at Johns Hopkins University\u003C/a>. Population data from the \u003Ca rel=\\\"external\\\" href=\\\"https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/latest-release\\\">Australia Bureau of Statistics\u003C/a>.\",\"about_the_data_country_page_bra\":\"Data for Brazil comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/CSSEGISandData/COVID-19\\\">Center for Systems Science and Engineering at Johns Hopkins University\u003C/a>. Population data from the \u003Ca rel=\\\"external\\\" href=\\\"https://www.ibge.gov.br/en/statistics/social/population/18176-population-projection.html?=&t=downloads\\\">Brazilian Institute of Geography and Statistics\u003C/a>.\",\"about_the_data_country_page_can\":\"Data for Canada comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/CSSEGISandData/COVID-19\\\">Center for Systems Science and Engineering at Johns Hopkins University\u003C/a>. Population data from Statistics Canada.\",\"about_the_data_country_page_fra\":\"Data for France comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/CSSEGISandData/COVID-19\\\">Center for Systems Science and Engineering at Johns Hopkins University\u003C/a>. Population data from the \u003Ca rel=\\\"external\\\" href=\\\"https://www.insee.fr/en/accueil\\\">French National Institute of Statistics and Economic Studies\u003C/a>.\",\"about_the_data_country_page_deu\":\"Data for Germany comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/CSSEGISandData/COVID-19\\\">Center for Systems Science and Engineering at Johns Hopkins University\u003C/a>. Population data from the \u003Ca rel=\\\"external\\\" href=\\\"https://www.destatis.de/EN/Themes/Society-Environment/Population/Current-Population/_node.html\\\">Federal Statistics Office of Germany\u003C/a>.\",\"about_the_data_country_page_ind\":\"Data for India comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/CSSEGISandData/COVID-19\\\">Center for Systems Science and Engineering at Johns Hopkins University\u003C/a>. Population data from \u003Ca rel=\\\"external\\\" href=\\\"https://hub.arcgis.com/datasets/esriindia1::india-districts-boundary\\\">ESRI\u003C/a>.\",\"about_the_data_country_page_ita\":\"Data for Italy comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/pcm-dpc/COVID-19\\\">Italian Department of Civil Protection\u003C/a>. Population data from the \u003Ca rel=\\\"external\\\" href=\\\"https://www.istat.it/en/population-and-households\\\">Italian National Institute of Statistics\u003C/a>.\",\"about_the_data_country_page_jpn\":\"Nationwide and regional data for Japan comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/CSSEGISandData/COVID-19\\\">Center for Systems Science and Engineering at Johns Hopkins University\u003C/a> and does not include cases or deaths connected to the 2020 Olympic games in Japan or aboard the Diamond Princess cruise ship, which experienced a Covid outbreak while docked in a Japanese port in 2020. Johns Hopkins reports data for Japanese prefectures starting in April 2021. Population data from the Statistics Bureau of Japan.\",\"about_the_data_country_page_mex\":\"Data for Mexico comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/CSSEGISandData/COVID-19\\\">Center for Systems Science and Engineering at Johns Hopkins University\u003C/a>. Population data from the \u003Ca rel=\\\"external\\\" href=\\\"https://web.archive.org/web/20151210230740/http://www.inegi.org.mx/est/contenidos/proyectos/encuestas/hogares/especiales/ei2015/doc/eic_2015_presentacion.pdf\\\">National Institute of Statistics, Geography and Informatics\u003C/a>.\",\"about_the_data_country_page_esp\":\"Data for Spain comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/CSSEGISandData/COVID-19\\\">Center for Systems Science and Engineering at Johns Hopkins University\u003C/a>. Population data from the \u003Ca rel=\\\"external\\\" href=\\\"https://www.ine.es/jaxiT3/Datos.htm?t=31304\\\">National Statistics Institute of Spain\u003C/a>.\",\"about_the_data_country_page_gbr\":\"Data for the United Kingdom comes from the Department for Health and Social Care, Public Health England, Public Health Scotland, Public Health Wales, Public Health Agency of Northern Ireland and the Chief Medical Officer Directorate. Population data from \u003Ca rel=\\\"external\\\" href=\\\"https://borders.ukdataservice.ac.uk/easy_download.html\\\">U.K. Data Service Census Support\u003C/a>. The \u003Ca rel=\\\"external\\\" href=\\\"https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases\\\">Office for National Statistics\u003C/a> also produces a weekly report on the number of deaths that mention Covid-19 on a death certificate. This figure, which includes deaths outside of hospitals, is many thousands of deaths higher than the reported daily death toll.\",\"about_the_data_country_page_zaf\":\"Data for South Africa comes from the \u003Ca rel=\\\"external\\\" href=\\\"https://github.com/CSSEGISandData/COVID-19\\\">Center for Systems Science and Engineering at Johns Hopkins University\u003C/a>. Population data from the World Bank.\",\"about_the_data_country_page_chn\":\"Data for China comes from the \u003Ca rel=\\\"external\\\" href=\\\"http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml\\\">National Health Commission of the People’s Republic of China\u003C/a> and includes all confirmed cases, including asymptomatic infections. Population data from the \u003Ca rel=\\\"external\\\" href=\\\"http://data.stats.gov.cn/english/easyquery.htm?cn=E0103\\\">National Bureau of Statistics of China\u003C/a>. Data does not include Hong Kong, Macau or Taiwan.\",\"usa_page_regional_chart_hed\":\"Cases by region\",\"usa_page_regional_chart_summary\":\"This chart shows how average daily cases per 100,000 people have changed in different parts of the country. The state with the highest recent average cases per 100,000 people is shown.\",\"usa_page_regional_chart_note\":\"Sources: State and local health agencies (cases); Census Bureau (population data).\",\"usa_page_regional_chart_location_comparison\":\"\",\"usa_page_state_grid_hed\":\"How cases, hospitalizations and deaths are trending\",\"usa_page_state_grid_summary\":\"Each chart shows how these three metrics compare to the corresponding peak level reached nationwide before Omicron became the dominant variant. For example, a state’s case line exceeds 100 percent on the chart when its number of cases per capita exceeds the highest number of U.S. cases per capita reached in January 2021.\",\"usa_page_state_grid_note\":\"Sources: State and local health agencies (cases, deaths); U.S. Department of Health and Human Services (hospitalizations).\",\"usa_and_state_page_trends_summary\":\"This chart shows how cases and hospitalizations per capita compare to the corresponding peak level reached nationwide before Omicron became the dominant variant. Sources: State and local health agencies (cases); U.S. Department of Health and Human Services (hospitalizations).\",\"world_page_regional_chart_hed\":\"Cases by region\",\"world_page_regional_chart_summary\":\"This chart shows how cases per capita have changed in different parts of the world.\",\"world_page_regional_chart_note\":\"Sources: Center for Systems Science and Engineering at Johns Hopkins University and state and local health agencies (cases); World Bank and U.S. Census Bureau (population data).\",\"world_page_regional_chart_location_comparison\":\"\",\"olympics_japan_chart_hed\":\"Reported cases at the 2020 Olympics\",\"olympics_japan_chart_summary\":\"More than 500 people with Olympic credentials, including more than 30 athletes, tested positive for the coronavirus in Japan. Others tested positive before their departure to the Games and are not included in the chart below.\",\"olympics_japan_chart_note\":\"Source: \u003Ca rel=\\\"external\\\" href=\\\"https://olympics.com/tokyo-2020/en/notices/covid-19-positive-case-list\\\">Tokyo 2020 organizing committee\u003C/a>. Data is shown by the date in Tokyo when a case was announced.\",\"olympics_china_chart_hed\":\"Reported cases at the 2022 Olympics\",\"olympics_china_chart_summary\":\"At least 509 people with Olympic credentials, including 185 athletes and team officials, tested positive for the coronavirus in China, either at the airport on arrival in China or within the \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/2021/09/29/sports/olympics/winter-olympics-beijing-restrictions.html\\\">Olympics “closed loop\u003C/a>.” Others tested positive before their departure to the Games and are not included in the chart below.\",\"olympics_china_chart_note\":\"Source: \u003Ca rel=\\\"external\\\" href=\\\"https://www.beijing2022.cn/en/press_centre/headlines.htm\\\">2022 Beijing Organizing Committee\u003C/a>.\",\"virgin_islands_map_note\":\"Note: Ocean areas were modified to bring St. Thomas and St. John closer to St. Croix in the maps on this page.\",\"credits\":\"By Jordan Allen, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/sarah-almukhtar\\\">Sarah Almukhtar\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/aliza-aufrichtig\\\">Aliza Aufrichtig\u003C/a>, Anne Barnard, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/matthew-bloch\\\">Matthew Bloch\u003C/a>, Sarah Cahalan, Weiyi Cai, Julia Calderone, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/keith-collins\\\">Keith Collins\u003C/a>, Matthew Conlen, Lindsey Cook, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/gabriel-gianordoli\\\">Gabriel Gianordoli\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/amy-harmon\\\">Amy Harmon\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/rich-harris\\\">Rich Harris\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/adeel-hassan\\\">Adeel Hassan\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/jon-huang\\\">Jon Huang\u003C/a>, Danya Issawi, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/danielle-ivory\\\">Danielle Ivory\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/kk-rebecca-lai\\\">K.K. Rebecca Lai\u003C/a>, Alex Lemonides, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/eleanor-lutz\\\">Eleanor Lutz\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/allison-mccann\\\">Allison McCann\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/richard-a-oppel-jr\\\">Richard A. Oppel Jr.\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/jugal-k-patel\\\">Jugal K. Patel\u003C/a>, Alison Saldanha, Kirk Semple, Shelly Seroussi, Julie Walton Shaver, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/amy-schoenfeld-walker\\\">Amy Schoenfeld Walker\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/anjali-singhvi\\\">Anjali Singhvi\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/charlie-smart\\\">Charlie Smart\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/mitch-smith\\\">Mitch Smith\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/albert-sun\\\">Albert Sun\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/rumsey-taylor\\\">Rumsey Taylor\u003C/a>, Lisa Waananen Jones, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/derek-watkins\\\">Derek Watkins\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/timothy-williams\\\">Timothy Williams\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/jin-wu\\\">Jin Wu\u003C/a> and \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/karen-yourish\\\">Karen Yourish\u003C/a>. &nbsp;&nbsp;·&nbsp;&nbsp; Reporting was contributed by Jeff Arnold, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/ian-austen\\\">Ian Austen\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/mike-baker\\\">Mike Baker\u003C/a>, Brillian Bao, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/ellen-barry\\\">Ellen Barry\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/shashank-bengali\\\">Shashank Bengali\u003C/a>, Samone Blair, Nicholas Bogel-Burroughs, Aurelien Breeden, Elisha Brown, Emma Bubola, Maddie Burakoff, Alyssa Burr, Christopher Calabrese, Julia Carmel, Zak Cassel, Robert Chiarito, Izzy Colón, Matt Craig, Yves De Jesus, Brendon Derr, Brandon Dupré, Melissa Eddy, John Eligon, Timmy Facciola, Bianca Fortis, Jake Frankenfield, Matt Furber, Robert Gebeloff, Thomas Gibbons-Neff, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/matthew-goldstein\\\">Matthew Goldstein\u003C/a>, Grace Gorenflo, Rebecca Griesbach, Benjamin Guggenheim, Barbara Harvey, Lauryn Higgins, Josh Holder, Jake Holland, Anna Joyce, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/john-keefe\\\">John Keefe\u003C/a>, Ann Hinga Klein, Jacob LaGesse, Alex Lim, Alex Matthews, Patricia Mazzei, Jesse McKinley, Miles McKinley, K.B. Mensah, Sarah Mervosh, Jacob Meschke, Lauren Messman, Andrea Michelson, Jaylynn Moffat-Mowatt, Steven Moity, Paul Moon, Derek M. Norman, Anahad O’Connor, Ashlyn O’Hara, Azi Paybarah, Elian Peltier, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/richard-perez-pena\\\">Richard Pérez-Peña\u003C/a>, Sean Plambeck, Laney Pope, Elisabetta Povoledo, Cierra S. Queen, Savannah Redl, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/scott-reinhard\\\">Scott Reinhard\u003C/a>, Chloe Reynolds, Thomas Rivas, Frances Robles, Natasha Rodriguez, Jess Ruderman, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/kai-schultz\\\">Kai Schultz\u003C/a>, Alex Schwartz, Emily Schwing, Libby Seline, Rachel Sherman, Sarena Snider, Brandon Thorp, Alex Traub, Maura Turcotte, Tracey Tully, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/jeremy-white\\\">Jeremy White\u003C/a>, Kristine White, Bonnie G. Wong, Tiffany Wong, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/sameer-yasir\\\">Sameer Yasir\u003C/a> and John Yoon. &nbsp;&nbsp;·&nbsp;&nbsp; Data acquisition and additional work contributed by Will Houp, Andrew Chavez, Michael Strickland, Tiff Fehr, Miles Watkins, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/josh-williams\\\">Josh Williams\u003C/a>, Nina Pavlich, Carmen Cincotti, Ben Smithgall, Andrew Fischer, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/rachel-shorey\\\">Rachel Shorey\u003C/a>, \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/blacki-migliozzi\\\">Blacki Migliozzi\u003C/a>, Alastair Coote, Jaymin Patel, John-Michael Murphy, Isaac White, Steven Speicher, Hugh Mandeville, Robin Berjon, Thu Trinh, Carolyn Price, James G. Robinson, Phil Wells, Yanxing Yang, Michael Beswetherick, Michael Robles, Nikhil Baradwaj, Ariana Giorgi, Bella Virgilio, Dylan Momplaisir, Avery Dews, Bea Malsky, Ilana Marcus, Sean Cataguni and \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/by/jason-kao\\\">Jason Kao\u003C/a>.\",\"usa_page_hospitalization_age_chart_hed\":\"Daily new hospital admissions by age\",\"usa_page_hospitalization_age_chart_summary\":\"This chart shows for each age group the number of people per 100,000 that were newly admitted to a hospital with Covid-19 each day, according to data reported by hospitals to the U.S. Department of Health and Human Services.\",\"usa_page_hospitalization_age_chart_note\":\"Sources: \u003Ca rel=\\\"external\\\" href=\\\"https://beta.healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/g62h-syeh\\\">U.S. Department of Health and Human Services\u003C/a> (daily confirmed and suspected Covid-19 hospital admissions); Census Bureau (population data). Data prior to October 2020 was unreliable. Data reported in the most recent seven days may be incomplete.\",\"state_page_hospitalization_age_chart_hed\":\"Daily new hospital admissions by age in LOCATION\",\"state_page_hospitalization_age_chart_summary\":\"This chart shows for each age group the number of people per 100,000 that were newly admitted to a hospital with Covid-19 each day, according to data from the U.S. Department of Health and Human Services. Dips and spikes could be due to inconsistent reporting by hospitals.\",\"state_page_hospitalization_age_chart_note\":\"Sources: \u003Ca rel=\\\"external\\\" href=\\\"https://beta.healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/g62h-syeh\\\">U.S. Department of Health and Human Services\u003C/a> (daily confirmed and suspected Covid-19 hospital admissions); Census Bureau (population data). Data prior to October 2020 was unreliable. Data reported in the most recent seven days may be incomplete.\",\"usa_page_rates_for_vax_unvax_hed\":\"Rates for vaccinated and unvaccinated\",\"usa_page_rate_for_vax_unvax_summary\":\"Data from the Centers for Disease Control and Prevention shows that people who are unvaccinated are at a \u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/interactive/2021/10/28/us/covid-breakthrough-cases.html\\\">much greater risk\u003C/a> than those who are fully vaccinated to die from Covid-19. These charts compare age-adjusted average daily case and death rates for vaccinated and unvaccinated people in the states and cities that provide this data.\",\"usa_page_rate_for_vax_unvax_note\":\"Source: \u003Ca rel=\\\"external\\\" href=\\\"https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status\\\">Centers for Disease Control and Prevention\u003C/a>. This data was first made available on Oct. 19 2021, and is expected to update monthly. The C.D.C. releases the data as a weekly figure per 100,000 and is presented here as a daily average per 100,000 for consistency with other population-adjusted figures on this page. See the notes on the \u003Ca rel=\\\"external\\\" href=\\\"https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status\\\">C.D.C.’s page\u003C/a> for more information.\",\"note_we_moved_regional_charts\":\"\",\"app_tab_sunset_message_body\":\"We’re moving this Covid-19 data later this month. You can still find our coronavirus trackers and pandemic coverage on the app’s homescreen.\u003Cbr>\u003Ca rel=\\\"external\\\" href=\\\"https://www.nytimes.com/newsletters/coronavirus-tracker\\\">Sign up here to get a daily email with the latest data in your inbox.\u003C/a>\"}"}</script>
	<script type="application/json" sveltekit:data-type="data" sveltekit:data-url="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/page/navigation.json">{"status":200,"statusText":"","headers":{"content-type":"application/json"},"body":"{\"sections\":[{\"icon\":\"images/maps/USA/hotspots-state.png\",\"section\":\"usa\",\"primary\":[{\"name\":\"Latest Maps and Data\",\"url\":\"https://www.nytimes.com/interactive/2021/us/covid-cases.html\",\"rel\":\"\"},{\"name\":\"Vaccinations by State\",\"url\":\"https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html\",\"rel\":\"external\"},{\"name\":\"Your Places\",\"url\":\"https://www.nytimes.com/interactive/2021/us/covid-cases-deaths-tracker.html\",\"rel\":\"\"},{\"name\":\"Hospitals\",\"url\":\"https://www.nytimes.com/interactive/2020/us/covid-hospitals-near-you.html\",\"rel\":\"external\"}],\"secondary\":[{\"name\":\"Alabama\",\"url\":\"https://www.nytimes.com/interactive/2021/us/alabama-covid-cases.html\",\"slug\":\"us/alabama-covid-cases\",\"rel\":\"\"},{\"name\":\"Alaska\",\"url\":\"https://www.nytimes.com/interactive/2021/us/alaska-covid-cases.html\",\"slug\":\"us/alaska-covid-cases\",\"rel\":\"\"},{\"name\":\"Arizona\",\"url\":\"https://www.nytimes.com/interactive/2021/us/arizona-covid-cases.html\",\"slug\":\"us/arizona-covid-cases\",\"rel\":\"\"},{\"name\":\"Arkansas\",\"url\":\"https://www.nytimes.com/interactive/2021/us/arkansas-covid-cases.html\",\"slug\":\"us/arkansas-covid-cases\",\"rel\":\"\"},{\"name\":\"California\",\"url\":\"https://www.nytimes.com/interactive/2021/us/california-covid-cases.html\",\"slug\":\"us/california-covid-cases\",\"rel\":\"\"},{\"name\":\"Colorado\",\"url\":\"https://www.nytimes.com/interactive/2021/us/colorado-covid-cases.html\",\"slug\":\"us/colorado-covid-cases\",\"rel\":\"\"},{\"name\":\"Connecticut\",\"url\":\"https://www.nytimes.com/interactive/2021/us/connecticut-covid-cases.html\",\"slug\":\"us/connecticut-covid-cases\",\"rel\":\"\"},{\"name\":\"Delaware\",\"url\":\"https://www.nytimes.com/interactive/2021/us/delaware-covid-cases.html\",\"slug\":\"us/delaware-covid-cases\",\"rel\":\"\"},{\"name\":\"Florida\",\"url\":\"https://www.nytimes.com/interactive/2021/us/florida-covid-cases.html\",\"slug\":\"us/florida-covid-cases\",\"rel\":\"\"},{\"name\":\"Georgia\",\"url\":\"https://www.nytimes.com/interactive/2021/us/georgia-covid-cases.html\",\"slug\":\"us/georgia-covid-cases\",\"rel\":\"\"},{\"name\":\"Guam\",\"url\":\"https://www.nytimes.com/interactive/2021/us/guam-covid-cases.html\",\"slug\":\"us/guam-covid-cases\",\"rel\":\"\"},{\"name\":\"Hawaii\",\"url\":\"https://www.nytimes.com/interactive/2021/us/hawaii-covid-cases.html\",\"slug\":\"us/hawaii-covid-cases\",\"rel\":\"\"},{\"name\":\"Idaho\",\"url\":\"https://www.nytimes.com/interactive/2021/us/idaho-covid-cases.html\",\"slug\":\"us/idaho-covid-cases\",\"rel\":\"\"},{\"name\":\"Illinois\",\"url\":\"https://www.nytimes.com/interactive/2021/us/illinois-covid-cases.html\",\"slug\":\"us/illinois-covid-cases\",\"rel\":\"\"},{\"name\":\"Indiana\",\"url\":\"https://www.nytimes.com/interactive/2021/us/indiana-covid-cases.html\",\"slug\":\"us/indiana-covid-cases\",\"rel\":\"\"},{\"name\":\"Iowa\",\"url\":\"https://www.nytimes.com/interactive/2021/us/iowa-covid-cases.html\",\"slug\":\"us/iowa-covid-cases\",\"rel\":\"\"},{\"name\":\"Kansas\",\"url\":\"https://www.nytimes.com/interactive/2021/us/kansas-covid-cases.html\",\"slug\":\"us/kansas-covid-cases\",\"rel\":\"\"},{\"name\":\"Kentucky\",\"url\":\"https://www.nytimes.com/interactive/2021/us/kentucky-covid-cases.html\",\"slug\":\"us/kentucky-covid-cases\",\"rel\":\"\"},{\"name\":\"Louisiana\",\"url\":\"https://www.nytimes.com/interactive/2021/us/louisiana-covid-cases.html\",\"slug\":\"us/louisiana-covid-cases\",\"rel\":\"\"},{\"name\":\"Maine\",\"url\":\"https://www.nytimes.com/interactive/2021/us/maine-covid-cases.html\",\"slug\":\"us/maine-covid-cases\",\"rel\":\"\"},{\"name\":\"Maryland\",\"url\":\"https://www.nytimes.com/interactive/2021/us/maryland-covid-cases.html\",\"slug\":\"us/maryland-covid-cases\",\"rel\":\"\"},{\"name\":\"Massachusetts\",\"url\":\"https://www.nytimes.com/interactive/2021/us/massachusetts-covid-cases.html\",\"slug\":\"us/massachusetts-covid-cases\",\"rel\":\"\"},{\"name\":\"Michigan\",\"url\":\"https://www.nytimes.com/interactive/2021/us/michigan-covid-cases.html\",\"slug\":\"us/michigan-covid-cases\",\"rel\":\"\"},{\"name\":\"Minnesota\",\"url\":\"https://www.nytimes.com/interactive/2021/us/minnesota-covid-cases.html\",\"slug\":\"us/minnesota-covid-cases\",\"rel\":\"\"},{\"name\":\"Mississippi\",\"url\":\"https://www.nytimes.com/interactive/2021/us/mississippi-covid-cases.html\",\"slug\":\"us/mississippi-covid-cases\",\"rel\":\"\"},{\"name\":\"Missouri\",\"url\":\"https://www.nytimes.com/interactive/2021/us/missouri-covid-cases.html\",\"slug\":\"us/missouri-covid-cases\",\"rel\":\"\"},{\"name\":\"Montana\",\"url\":\"https://www.nytimes.com/interactive/2021/us/montana-covid-cases.html\",\"slug\":\"us/montana-covid-cases\",\"rel\":\"\"},{\"name\":\"Nebraska\",\"url\":\"https://www.nytimes.com/interactive/2021/us/nebraska-covid-cases.html\",\"slug\":\"us/nebraska-covid-cases\",\"rel\":\"\"},{\"name\":\"Nevada\",\"url\":\"https://www.nytimes.com/interactive/2021/us/nevada-covid-cases.html\",\"slug\":\"us/nevada-covid-cases\",\"rel\":\"\"},{\"name\":\"New Hampshire\",\"url\":\"https://www.nytimes.com/interactive/2021/us/new-hampshire-covid-cases.html\",\"slug\":\"us/new-hampshire-covid-cases\",\"rel\":\"\"},{\"name\":\"New Jersey\",\"url\":\"https://www.nytimes.com/interactive/2021/us/new-jersey-covid-cases.html\",\"slug\":\"us/new-jersey-covid-cases\",\"rel\":\"\"},{\"name\":\"New Mexico\",\"url\":\"https://www.nytimes.com/interactive/2021/us/new-mexico-covid-cases.html\",\"slug\":\"us/new-mexico-covid-cases\",\"rel\":\"\"},{\"name\":\"New York\",\"url\":\"https://www.nytimes.com/interactive/2021/us/new-york-covid-cases.html\",\"slug\":\"us/new-york-covid-cases\",\"rel\":\"\"},{\"name\":\"North Carolina\",\"url\":\"https://www.nytimes.com/interactive/2021/us/north-carolina-covid-cases.html\",\"slug\":\"us/north-carolina-covid-cases\",\"rel\":\"\"},{\"name\":\"North Dakota\",\"url\":\"https://www.nytimes.com/interactive/2021/us/north-dakota-covid-cases.html\",\"slug\":\"us/north-dakota-covid-cases\",\"rel\":\"\"},{\"name\":\"Northern Mariana Islands\",\"url\":\"https://www.nytimes.com/interactive/2021/us/northern-mariana-islands-covid-cases.html\",\"slug\":\"us/northern-mariana-islands-covid-cases\",\"rel\":\"\"},{\"name\":\"Ohio\",\"url\":\"https://www.nytimes.com/interactive/2021/us/ohio-covid-cases.html\",\"slug\":\"us/ohio-covid-cases\",\"rel\":\"\"},{\"name\":\"Oklahoma\",\"url\":\"https://www.nytimes.com/interactive/2021/us/oklahoma-covid-cases.html\",\"slug\":\"us/oklahoma-covid-cases\",\"rel\":\"\"},{\"name\":\"Oregon\",\"url\":\"https://www.nytimes.com/interactive/2021/us/oregon-covid-cases.html\",\"slug\":\"us/oregon-covid-cases\",\"rel\":\"\"},{\"name\":\"Pennsylvania\",\"url\":\"https://www.nytimes.com/interactive/2021/us/pennsylvania-covid-cases.html\",\"slug\":\"us/pennsylvania-covid-cases\",\"rel\":\"\"},{\"name\":\"Puerto Rico\",\"url\":\"https://www.nytimes.com/interactive/2021/us/puerto-rico-covid-cases.html\",\"slug\":\"us/puerto-rico-covid-cases\",\"rel\":\"\"},{\"name\":\"Rhode Island\",\"url\":\"https://www.nytimes.com/interactive/2021/us/rhode-island-covid-cases.html\",\"slug\":\"us/rhode-island-covid-cases\",\"rel\":\"\"},{\"name\":\"South Carolina\",\"url\":\"https://www.nytimes.com/interactive/2021/us/south-carolina-covid-cases.html\",\"slug\":\"us/south-carolina-covid-cases\",\"rel\":\"\"},{\"name\":\"South Dakota\",\"url\":\"https://www.nytimes.com/interactive/2021/us/south-dakota-covid-cases.html\",\"slug\":\"us/south-dakota-covid-cases\",\"rel\":\"\"},{\"name\":\"Tennessee\",\"url\":\"https://www.nytimes.com/interactive/2021/us/tennessee-covid-cases.html\",\"slug\":\"us/tennessee-covid-cases\",\"rel\":\"\"},{\"name\":\"Texas\",\"url\":\"https://www.nytimes.com/interactive/2021/us/texas-covid-cases.html\",\"slug\":\"us/texas-covid-cases\",\"rel\":\"\"},{\"name\":\"U.S. Virgin Islands\",\"url\":\"https://www.nytimes.com/interactive/2021/us/virgin-islands-covid-cases.html\",\"slug\":\"us/virgin-islands-covid-cases\",\"rel\":\"\"},{\"name\":\"Utah\",\"url\":\"https://www.nytimes.com/interactive/2021/us/utah-covid-cases.html\",\"slug\":\"us/utah-covid-cases\",\"rel\":\"\"},{\"name\":\"Vermont\",\"url\":\"https://www.nytimes.com/interactive/2021/us/vermont-covid-cases.html\",\"slug\":\"us/vermont-covid-cases\",\"rel\":\"\"},{\"name\":\"Virginia\",\"url\":\"https://www.nytimes.com/interactive/2021/us/virginia-covid-cases.html\",\"slug\":\"us/virginia-covid-cases\",\"rel\":\"\"},{\"name\":\"Washington\",\"url\":\"https://www.nytimes.com/interactive/2021/us/washington-covid-cases.html\",\"slug\":\"us/washington-covid-cases\",\"rel\":\"\"},{\"name\":\"Washington, D.C.\",\"url\":\"https://www.nytimes.com/interactive/2021/us/washington-district-of-columbia-covid-cases.html\",\"slug\":\"us/washington-district-of-columbia-covid-cases\",\"rel\":\"\"},{\"name\":\"West Virginia\",\"url\":\"https://www.nytimes.com/interactive/2021/us/west-virginia-covid-cases.html\",\"slug\":\"us/west-virginia-covid-cases\",\"rel\":\"\"},{\"name\":\"Wisconsin\",\"url\":\"https://www.nytimes.com/interactive/2021/us/wisconsin-covid-cases.html\",\"slug\":\"us/wisconsin-covid-cases\",\"rel\":\"\"},{\"name\":\"Wyoming\",\"url\":\"https://www.nytimes.com/interactive/2021/us/wyoming-covid-cases.html\",\"slug\":\"us/wyoming-covid-cases\",\"rel\":\"\"}]},{\"icon\":\"images/maps/NYT-World/hotspots.png\",\"section\":\"world\",\"primary\":[{\"name\":\"Latest Maps and Data\",\"url\":\"https://www.nytimes.com/interactive/2021/world/covid-cases.html\",\"rel\":\"\"},{\"name\":\"Vaccinations by Country\",\"url\":\"https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html\",\"rel\":\"external\"}],\"secondary\":[{\"name\":\"Australia\",\"url\":\"https://www.nytimes.com/interactive/2021/world/australia-covid-cases.html\",\"slug\":\"world/australia-covid-cases\",\"rel\":\"\"},{\"name\":\"Brazil\",\"url\":\"https://www.nytimes.com/interactive/2021/world/brazil-covid-cases.html\",\"slug\":\"world/brazil-covid-cases\",\"rel\":\"\"},{\"name\":\"Canada\",\"url\":\"https://www.nytimes.com/interactive/2021/world/canada-covid-cases.html\",\"slug\":\"world/canada-covid-cases\",\"rel\":\"\"},{\"name\":\"China\",\"url\":\"https://www.nytimes.com/interactive/2021/world/china-covid-cases.html\",\"slug\":\"world/china-covid-cases\",\"rel\":\"\"},{\"name\":\"France\",\"url\":\"https://www.nytimes.com/interactive/2021/world/france-covid-cases.html\",\"slug\":\"world/france-covid-cases\",\"rel\":\"\"},{\"name\":\"Germany\",\"url\":\"https://www.nytimes.com/interactive/2021/world/germany-covid-cases.html\",\"slug\":\"world/germany-covid-cases\",\"rel\":\"\"},{\"name\":\"India\",\"url\":\"https://www.nytimes.com/interactive/2021/world/india-covid-cases.html\",\"slug\":\"world/india-covid-cases\",\"rel\":\"\"},{\"name\":\"Italy\",\"url\":\"https://www.nytimes.com/interactive/2021/world/italy-covid-cases.html\",\"slug\":\"world/italy-covid-cases\",\"rel\":\"\"},{\"name\":\"Japan\",\"url\":\"https://www.nytimes.com/interactive/2021/world/japan-covid-cases.html\",\"slug\":\"world/japan-covid-cases\",\"rel\":\"\"},{\"name\":\"Mexico\",\"url\":\"https://www.nytimes.com/interactive/2021/world/mexico-covid-cases.html\",\"slug\":\"world/mexico-covid-cases\",\"rel\":\"\"},{\"name\":\"South Africa\",\"url\":\"https://www.nytimes.com/interactive/2021/world/south-africa-covid-cases.html\",\"slug\":\"world/south-africa-covid-cases\",\"rel\":\"\"},{\"name\":\"Spain\",\"url\":\"https://www.nytimes.com/interactive/2021/world/spain-covid-cases.html\",\"slug\":\"world/spain-covid-cases\",\"rel\":\"\"},{\"name\":\"United Kingdom\",\"url\":\"https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html\",\"slug\":\"world/united-kingdom-covid-cases\",\"rel\":\"\"}]},{\"icon\":\"images/health-icon.png\",\"section\":\"health\",\"primary\":[{\"name\":\"Vaccine Development\",\"url\":\"https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html\",\"rel\":\"external\"},{\"name\":\"Coronavirus Variants\",\"url\":\"https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html\",\"rel\":\"external\"},{\"name\":\"Treatments\",\"url\":\"https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html\",\"rel\":\"external\"},{\"name\":\"Answers to Your Covid-19 Questions\",\"url\":\"https://www.nytimes.com/interactive/2020/world/coronavirus-tips-advice.html\",\"rel\":\"external\"},{\"name\":\"How the Covid-19 Vaccines Work\",\"url\":\"https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html\",\"rel\":\"external\"},{\"name\":\"Symptoms of Covid-19\",\"url\":\"https://www.nytimes.com/interactive/2020/08/05/well/covid-19-symptoms.html\",\"rel\":\"external\"},{\"name\":\"What Happens in an Infection\",\"url\":\"https://www.nytimes.com/interactive/2020/10/02/science/charting-a-coronavirus-infection.html\",\"rel\":\"external\"},{\"name\":\"How Masks Work\",\"url\":\"https://www.nytimes.com/interactive/2020/10/30/science/wear-mask-covid-particles-ul.html\",\"rel\":\"external\"}],\"secondary\":[]}]}"}</script>
	<script type="application/json" sveltekit:data-type="data" sveltekit:data-url="https://static01.nyt.com/newsgraphics/2021/coronavirus-tracking/page/footer_links.json">{"status":200,"statusText":"","headers":{"content-type":"application/json"},"body":"{\"sections\":[{\"label\":\"United States\",\"items\":[{\"hed\":\"Latest Maps and Data\",\"rel\":\"\",\"sub\":\"Cases and deaths for every county\",\"url\":\"https://www.nytimes.com/interactive/2021/us/covid-cases.html\",\"thumb\":\"images/maps/USA/hotspots-state.png\"},{\"hed\":\"Vaccinations\",\"rel\":\"external\",\"sub\":\"How many have been vaccinated, and who’s eligible\",\"url\":\"https://www.nytimes.com/interactive/2020/us/covid-19-vaccine-doses.html\",\"thumb\":\"images/scoop/covid-19-vaccine-doses-promo-1608170893853-threeByTwoSmallAt2X-v528.png\"},{\"hed\":\"Your Places\",\"rel\":\"\",\"sub\":\"Build your own dashboard to track cases\",\"url\":\"https://www.nytimes.com/interactive/2021/us/covid-cases-deaths-tracker.html\",\"thumb\":\"images/personalized.png\"},{\"hed\":\"Hospitals Near You\",\"rel\":\"external\",\"sub\":\"How many I.C.U. beds are occupied\",\"url\":\"https://www.nytimes.com/interactive/2020/us/covid-hospitals-near-you.html\",\"thumb\":\"images/scoop/covid-hospitals-near-you-promo-1608045359674-threeByTwoSmallAt2X-v5.jpg\"}]},{\"label\":\"World\",\"items\":[{\"hed\":\"Latest Maps and Data\",\"rel\":\"\",\"sub\":\"Cases and deaths for every country\",\"url\":\"https://www.nytimes.com/interactive/2021/world/covid-cases.html\",\"thumb\":\"images/maps/NYT-World/hotspots.png\"},{\"hed\":\"Global Vaccinations\",\"rel\":\"external\",\"sub\":\"How many have been vaccinated, by country\",\"url\":\"https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html\",\"thumb\":\"images/maps/NYT-World/vaccinations.png\"}]},{\"label\":\"Health\",\"items\":[{\"hed\":\"Vaccines\",\"rel\":\"external\",\"sub\":\"Track their development\",\"url\":\"https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html\",\"thumb\":\"images/vaccines.png\"},{\"hed\":\"Treatments\",\"rel\":\"external\",\"sub\":\"Rated by effectiveness and safety\",\"url\":\"https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html\",\"thumb\":\"images/treatments.png\"}]},{\"label\":\"Previous Projects\",\"items\":[{\"hed\":\"Mask Mandates\",\"rel\":\"external\",\"sub\":\"See state mask guidance for schools and indoors\",\"url\":\"https://www.nytimes.com/interactive/2021/us/cdc-mask-guidance-states.html\",\"thumb\":\"https://static01.nyt.com/newsgraphics/2021/08/02/mask-mandates/assets/promo-threeByTwoSmallAt2X.png\"},{\"hed\":\"Your County’s Risk\",\"rel\":\"external\",\"sub\":\"See guidance for your local area\",\"url\":\"https://www.nytimes.com/interactive/2021/us/covid-risk-map.html\",\"thumb\":\"images/county-risk-map.png\"},{\"hed\":\"Nursing Homes\",\"rel\":\"external\",\"sub\":\"The hardest-hit states and facilities\",\"url\":\"https://www.nytimes.com/interactive/2020/us/coronavirus-nursing-homes.html\",\"thumb\":\"images/nursing-homes.png\"},{\"hed\":\"Colleges and Universities\",\"rel\":\"external\",\"sub\":\"Cases at more than 1,800 schools\",\"url\":\"https://www.nytimes.com/interactive/2021/us/college-covid-tracker.html\",\"thumb\":\"images/colleges-map.png\"},{\"hed\":\"Deaths Above Normal\",\"rel\":\"external\",\"sub\":\"The true toll of the pandemic in the U.S.\",\"url\":\"https://www.nytimes.com/interactive/2021/01/14/us/covid-19-death-toll.html\",\"thumb\":\"images/deaths-us.jpg\"},{\"hed\":\"Deaths Above Normal\",\"rel\":\"external\",\"sub\":\"The true toll of coronavirus around the world\",\"url\":\"https://www.nytimes.com/interactive/2020/04/21/world/coronavirus-missing-deaths.html\",\"thumb\":\"images/deaths-world.jpg\"},{\"hed\":\"Early Coronavirus Outbreaks\",\"rel\":\"\",\"sub\":\"Cases in nursing homes, prisons and other places\",\"url\":\"https://www.nytimes.com/interactive/2021/us/covid-case-outbreaks.html\",\"thumb\":\"images/outbreaks.png\"}]}],\"data_links\":[{\"hed\":\"Frequently Asked Questions About the Covid Data\",\"url\":\"https://www.nytimes.com/interactive/2020/us/about-coronavirus-data-maps.html\",\"rel\":\"external\"},{\"hed\":\"Access the Open Source Covid Data\",\"url\":\"https://github.com/nytimes/covid-19-data\",\"rel\":\"external\"}]}"}</script>
</div>


<!-- asset wrapper : end -->
<!-- ASSET : END -->

</div>



</div>

<p class="g-body " >
	<br><br>
</p>
<p class="g-body " >
	<span class="g-sync" style="font-size: 17px;">Additional reporting by <a href="https://www.nytimes.com/by/farnaz-fassihi">Farnaz Fassihi</a>, <a href="https://www.nytimes.com/by/denise-grady">Denise Grady</a>, <a href="https://www.nytimes.com/by/andrew-e-kramer">Andrew E. Kramer</a>, <a href="https://www.nytimes.com/by/hari-kumar">Hari Kumar</a>, <a href="https://www.nytimes.com/by/cao-li">Cao Li</a>, Jess Ruderman and <a href="https://www.nytimes.com/by/carlos-tejada">Carlos Tejada</a>.</span>
</p>
<p class="g-body " >
	<span class="g-sync">Notes and corrections: Early versions of the tracker combined two vaccines by Sinopharm into one entry, before subsequent reporting confirmed they were two different vaccines. A previous version of the tracker stated that Pfizer had reached a deal with the E.U., when in fact the deal was made by AstraZeneca. A previous version of the tracker listed Canadian approval of the Pfizer-BioNTech and Moderna vaccines, when in fact they were conditional authorizations. A previous version of the tracker stated that Migvax-101 was the name of the candidate developed by Oravax, when in fact it is a different vaccine.</span>
</p>
<p class="g-body " >
	<span class="g-sync">Sources: World Health Organization, National Institute of Allergy and Infectious Diseases, National Center for Biotechnology Information, New England Journal of Medicine, Rollins School of Public Health at Emory University. Cahill-Keyes map projection by Gene Keyes.</span>
</p>

</div>
<!-- /end story-body -->

<!-- methodology and related content sections -->



<!-- special includes for video features, opinion section -->



<script>
  NYTG.watch('https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/build/js/main.js');
  NYTG.load('https://static01.nyt.com/newsgraphics/2020/09/10/coronavirus-vaccine-tracker/dc31a5b70764a265ec3c7b771482cad6833197db/build/js/freebird.js');
</script>

<!-- Pipeline: 2020-09-10-coronavirus-vaccine-tracker | August 31, 2022, 01:50PM | dc31a5b70764a265ec3c7b771482cad6833197db -->
</div></section></article></main><div id="standalone-footer"><div><div class="vi-gateway-container" data-testid="vi-gateway-container"><div id="interactive-footer-wrapper"><div class="css-1sm67ns"><div role="toolbar" data-testid="share-tools" aria-label="Social Media Share buttons, Save button, and Comments Panel with current comment count" class="css-mfml7"><div class="css-10i3hc"></div><div class="interactive-sharetools css-1rgojku"><ul class="css-1liwv7v"><li class="css-1gh9hw8"><div class="css-vxcmzt"><div class="css-79elbk"><button type="button" aria-label="" aria-expanded="false" class="css-1eeh360 actionbar-button" data-testid="gift-article-button"><span class="css-lu72is"><svg aria-hidden="true" width="19" height="19" viewBox="0 0 19 19" class="sha-gift-icon"><path d="M18.04 5.293h-2.725c.286-.34.493-.74.606-1.17a2.875 2.875 0 0 0-.333-2.322A2.906 2.906 0 0 0 13.64.48a3.31 3.31 0 0 0-2.372.464 3.775 3.775 0 0 0-1.534 2.483l-.141.797-.142-.847A3.745 3.745 0 0 0 7.927.923 3.31 3.31 0 0 0 5.555.459 2.907 2.907 0 0 0 3.607 1.78a2.877 2.877 0 0 0-.333 2.321c.117.429.324.828.606 1.171H1.155a.767.767 0 0 0-.757.757v3.674a.767.767 0 0 0 .757.757h.424v7.53A1.01 1.01 0 0 0 2.588 19h14.13a1.01 1.01 0 0 0 1.01-.959v-7.56h.424a.758.758 0 0 0 .757-.757V6.05a.759.759 0 0 0-.868-.757Zm-7.196-1.625a2.665 2.665 0 0 1 1.01-1.736 2.24 2.24 0 0 1 1.574-.313 1.817 1.817 0 0 1 1.211.818 1.857 1.857 0 0 1 .202 1.453 2.2 2.2 0 0 1-.838 1.191h-3.431l.272-1.413ZM4.576 2.386a1.837 1.837 0 0 1 1.221-.817 2.23 2.23 0 0 1 1.565.313 2.624 2.624 0 0 1 1.01 1.736l.242 1.453H5.182a2.2 2.2 0 0 1-.838-1.19 1.857 1.857 0 0 1 .202-1.495h.03ZM1.548 6.424h7.54V9.39h-7.58l.04-2.967Zm1.181 4.128h6.359v7.287H2.729v-7.287Zm13.777 7.287h-6.348v-7.307h6.348v7.307Zm1.181-8.468h-7.53V6.404h7.53V9.37Z" fill="#121212" fill-rule="nonzero"></path></svg><svg aria-hidden="true" width="23" height="18" viewBox="0 0 23 18" class="sha-arrow-icon"><path d="M1.357 17.192a.663.663 0 0 1-.642-.81c1.82-7.955 6.197-12.068 12.331-11.68V1.127a.779.779 0 0 1 .42-.653.726.726 0 0 1 .78.106l8.195 6.986a.81.81 0 0 1 .253.557.82.82 0 0 1-.263.547l-8.196 6.955a.83.83 0 0 1-.779.105.747.747 0 0 1-.42-.663V11.29c-8.418-.905-10.974 5.177-11.08 5.45a.662.662 0 0 1-.6.453Zm10.048-7.26a16.37 16.37 0 0 1 2.314.158.81.81 0 0 1 .642.726v3.02l6.702-5.682-6.702-5.692v2.883a.767.767 0 0 1-.242.536.747.747 0 0 1-.547.18c-4.808-.537-8.364 1.85-10.448 6.922a11.679 11.679 0 0 1 8.28-3.093v.042Z" fill="#000" fill-rule="nonzero"></path></svg>Share full article</span></button></div></div></li><li class="css-2ykviq sha-std-share"><div class="css-vxcmzt"><div class="css-79elbk"><button type="button" aria-label="More sharing options ..." aria-expanded="false" class="css-1nurhyi actionbar-button"><svg aria-hidden="true" width="23" height="18" viewBox="0 0 23 18" class="css-zd9juy"><path d="M1.357 17.192a.663.663 0 0 1-.642-.81c1.82-7.955 6.197-12.068 12.331-11.68V1.127a.779.779 0 0 1 .42-.653.726.726 0 0 1 .78.106l8.195 6.986a.81.81 0 0 1 .253.557.82.82 0 0 1-.263.547l-8.196 6.955a.83.83 0 0 1-.779.105.747.747 0 0 1-.42-.663V11.29c-8.418-.905-10.974 5.177-11.08 5.45a.662.662 0 0 1-.6.453Zm10.048-7.26a16.37 16.37 0 0 1 2.314.158.81.81 0 0 1 .642.726v3.02l6.702-5.682-6.702-5.692v2.883a.767.767 0 0 1-.242.536.747.747 0 0 1-.547.18c-4.808-.537-8.364 1.85-10.448 6.922a11.679 11.679 0 0 1 8.28-3.093v.042Z" fill="#000" fill-rule="nonzero"></path></svg></button></div></div></li><li class="css-2ykviq save-button"><button type="button" role="switch" class="css-1yhvmgx actionbar-button" data-testid="save-article-button" aria-label="Save article for reading later..." aria-checked="false" disabled="" aria-busy="false" aria-live="polite"><svg width="12" height="18" viewBox="0 0 12 18" class="css-eap6fy"><g fill-rule="nonzero"><path class="saved-fill" d="M1.157 1.268v14.288l4.96-3.813 4.753 3.843V1.268z"></path><path class="saved-stroke" d="m12 18-5.9-4.756L0 17.98V1.014C0 .745.095.487.265.297.435.107.664 0 .904 0h10.192c.24 0 .47.107.64.297.169.19.264.448.264.717V18ZM1.157 1.268v14.288l4.96-3.813 4.753 3.843V1.268H1.158Z"></path></g></svg></button></li></ul></div></div></div><div></div><div id="bottom-wrapper" class="css-sxwst7"><div id="bottom-slug" class="css-l9onyx"><p>Advertisement</p></div><a href="#after-bottom" class="css-777zgl">SKIP ADVERTISEMENT</a><div class="ad bottom-wrapper css-rfqw0c" id="bottom" style="min-height:90px"></div><div id="after-bottom"></div></div><nav class="css-1jmk4jh" id="site-index" aria-labelledby="site-index-label" data-testid="site-index"><h2 class="css-1dv1kvn" id="site-index-label">Site Index</h2><div class="css-sg7scw"><header class="css-jxzr5i"><a aria-label="New York Times" data-testid="site-index-header" href="/"><svg class="css-oylsik" viewBox="0 0 184 25" fill="#000" aria-hidden="true"><path d="M14.57,2.57C14.57,.55,12.65-.06,11.04,.01V.19c.96,.07,1.7,.46,1.7,1.11,0,.45-.32,1.01-1.28,1.01-.76,0-2.02-.45-3.2-.84-1.3-.45-2.54-.87-3.57-.87-2.02,0-3.55,1.5-3.55,3.36,0,1.5,1.16,2.02,1.63,2.21l.03-.07c-.3-.2-.49-.42-.49-1.06,0-.54,.39-1.26,1.43-1.26,.94,0,2.17,.42,3.8,.88,1.4,.39,2.91,.76,3.75,.87v3.28l-1.58,1.3,1.58,1.36v4.49c-.81,.46-1.75,.61-2.56,.61-1.5,0-2.88-.42-4.02-1.68l4.26-2.07V5.73l-5.2,2.32c.54-1.38,1.55-2.41,2.66-3.08l-.03-.08C3.31,5.73,.5,8.56,.5,12.06c0,4.19,3.35,7.3,7.22,7.3,4.19,0,6.65-3.28,6.61-6.75h-.08c-.61,1.33-1.63,2.59-2.78,3.25v-4.38l1.65-1.33-1.65-1.33v-3.28c1.53,0,3.11-1.01,3.11-2.96M5.8,14.13l-1.21,.61c-.74-.96-1.23-2.32-1.23-4.07,0-.72,.08-1.7,.32-2.39l2.14-.96-.03,6.8h0Zm19.47-5.76l-.81,.64-2.47-2.2-2.86,2.21V.48l-3.89,2.69c.45,.15,.99,.39,.99,1.43v11.81l-1.33,1.01,.12,.12,.67-.46,2.32,2.12,3.11-2.07-.1-.15-.79,.52-1.08-1.08v-7.12l.74-.54,1.7,1.48v6.19c0,3.92-.87,4.73-2.63,5.37v.1c2.93,.12,5.57-.87,5.57-5.89v-6.75l.88-.72-.12-.15h0Zm5.22,10.8l4.51-3.62-.12-.17-2.36,1.87-2.71-2.14v-1.33l4.68-3.3-2.36-3.67-5.2,2.86v6.8l-1.01,.79,.12,.15,.96-.76,3.5,2.54h-.01Zm-.69-5.67v-5.15l2.27,3.55-2.27,1.6ZM53.65,1.61c0-.32-.08-.59-.2-.96h-.07c-.32,.87-.67,1.33-1.68,1.33-.88,0-1.58-.54-1.95-.94,0,.03-2.96,3.42-2.96,3.42l.15,.12,.84-.96c.64,.49,1.21,1.06,2.63,1.08V13.34l-6.06-10.5c-.47-.79-1.28-1.97-2.66-1.97-1.63,0-2.86,1.4-2.66,3.77h.1c.12-.59,.47-1.33,1.18-1.33,.57,0,1.03,.54,1.3,1.03v3.38c-1.87,0-2.93,.87-2.93,2.34,0,.61,.45,1.94,1.72,2.17v-.07c-.17-.17-.34-.32-.34-.67,0-.57,.42-.88,1.18-.88,.12,0,.3,.03,.37,.05v4.38c-2.2,.03-3.89,1.23-3.89,3.31s1.7,2.88,3.47,2.78v-.07c-1.11-.12-1.68-.69-1.68-1.5,0-.88,.64-1.36,1.45-1.36s1.43,.52,1.95,1.11l2.96-3.33-.12-.12-.76,.87c-1.14-1.01-1.87-1.48-3.18-1.68V4.67l8.36,14.57h.45V4.72c1.6-.1,3.03-1.3,3.03-3.11m2.81,17.54l4.51-3.62-.12-.17-2.36,1.87-2.71-2.14v-1.33l4.68-3.3-2.36-3.67-5.2,2.86v6.8l-1.01,.79,.12,.15,.96-.76,3.5,2.54h0Zm-.69-5.67v-5.15l2.27,3.55-2.27,1.6Zm21.22-5.52l-.69,.52-1.97-1.68-2.29,2.07,.94,.88v7.72l-2.34-1.6v-6.26l.81-.57-2.41-2.24-2.24,2.07,.94,.88v7.46l-.15,.1-2.2-1.6v-6.13c0-1.43-.72-1.85-1.63-2.41-.76-.47-1.16-.91-1.16-1.63,0-.79,.69-1.11,.91-1.23-.79-.03-2.98,.76-3.03,2.76-.03,1.03,.47,1.48,.99,1.97,.52,.49,1.01,.96,1.01,1.83v6.01l-1.06,.84,.12,.12,1.01-.79,2.63,2.14,2.51-1.75,2.76,1.75,5.42-3.2v-6.95l1.21-.94-.1-.15h0Zm18.15-5.84l-1.03,.94-2.32-2.02-3.13,2.51V1.19h-.19V18.12c-.34-.05-1.06-.25-1.85-.37V3.58c0-1.03-.74-2.47-2.59-2.47s-3.01,1.56-3.01,2.91h.08c.1-.61,.52-1.16,1.13-1.16s1.18,.39,1.18,1.78v4.04c-1.75,.07-2.81,1.16-2.81,2.34,0,.67,.42,1.92,1.75,1.97v-.1c-.45-.19-.54-.42-.54-.67,0-.59,.57-.79,1.36-.79h.19v6.51c-1.5,.52-2.2,1.53-2.2,2.78,0,1.72,1.38,3.05,3.4,3.05,1.43,0,2.44-.25,3.75-.54,1.06-.22,2.21-.47,2.83-.47,.79,0,1.14,.35,1.14,.91,0,.72-.27,1.08-.69,1.21v.1c1.7-.32,2.69-1.3,2.69-2.83s-1.5-2.54-3.18-2.54c-.87,0-2.44,.27-3.72,.57-1.43,.32-2.66,.47-3.11,.47-.72,0-1.6-.32-1.6-1.28,0-.87,.72-1.56,2.49-1.56,.96,0,1.9,.15,3.08,.42,1.26,.27,2.12,.64,3.2,.64,1.5,0,2.71-.54,2.71-2.74V3.29l1.11-1.01-.12-.15h0Zm-4.24,6.78c-.27,.3-.59,.54-1.11,.54-.57,0-.87-.3-1.14-.54V3.81l.74-.59,1.5,1.28v4.41h0Zm0,2.41c-.25-.25-.57-.47-1.11-.47s-.91,.27-1.14,.47v-2.17c.22,.19,.59,.49,1.14,.49s.87-.25,1.11-.49v2.17Zm0,5.1c0,.84-.42,1.78-1.5,1.78-.17,0-.57-.03-.74-.05v-6.58c.25-.22,.57-.52,1.14-.52,.52,0,.81,.25,1.11,.52v4.86h0Zm8.78,2.74l5.03-3.13v-6.85l-3.25-2.39-5.03,2.88v6.78l-.99,.79,.1,.15,.81-.67,3.33,2.44h0Zm-.37-3.55v-7.3l2.51,1.87v7.3l-2.51-1.87Zm15.01-8.65c-.39,.27-.74,.42-1.11,.42-.39,0-.88-.25-1.14-.57,0,.03-1.87,2.02-1.87,2.02l-1.87-2.02-3.05,2.12,.1,.17,.81-.54,1.11,1.21v6.63l-1.33,1.01,.12,.12,.67-.46,2.49,2.12,3.15-2.09-.1-.15-.81,.49-1.28-1.16v-7.28c.52,.57,1.11,1.06,1.82,1.06,1.28,0,2.14-1.53,2.29-3.11m11.88,9.81l-.94,.59-5.2-7.76,.27-.37c.57,.34,1.08,.81,2.17,.81s2.47-1.14,2.59-3.23c-.27,.37-.81,.81-1.7,.81-.64,0-1.28-.42-1.67-.81l-3.55,5.22,4.71,7.17,3.42-2.27-.1-.17h0Zm-6.31,.19l-.79,.52-1.08-1.08V.48l-3.89,2.69c.45,.15,.99,.39,.99,1.43v11.81l-1.33,1.01,.12,.12,.67-.46,2.32,2.12,3.11-2.07-.1-.15h0Zm22.89-14.39c0-2.02-1.92-2.63-3.53-2.56V.19c.96,.07,1.7,.46,1.7,1.11,0,.45-.32,1.01-1.28,1.01-.76,0-2.02-.45-3.2-.84-1.3-.45-2.54-.87-3.57-.87-2.02,0-3.55,1.5-3.55,3.35,0,1.5,1.16,2.02,1.63,2.21l.03-.07c-.3-.2-.49-.42-.49-1.06,0-.54,.39-1.26,1.43-1.26,.94,0,2.17,.42,3.8,.88,1.4,.39,2.91,.76,3.75,.87v3.28l-1.58,1.3,1.58,1.36v4.49c-.81,.46-1.75,.61-2.56,.61-1.5,0-2.89-.42-4.02-1.68l4.26-2.07V5.73l-5.2,2.32c.54-1.38,1.55-2.41,2.66-3.08l-.03-.08c-3.08,.84-5.89,3.67-5.89,7.17,0,4.19,3.35,7.3,7.22,7.3,4.19,0,6.65-3.28,6.61-6.75h-.07c-.61,1.33-1.63,2.59-2.78,3.25v-4.38l1.65-1.33-1.65-1.33v-3.28c1.53,0,3.11-1.01,3.11-2.96m-8.78,11.56l-1.21,.61c-.74-.96-1.23-2.32-1.23-4.07,0-.72,.07-1.7,.32-2.39l2.14-.96-.03,6.8h0Zm11.93-12.31l-2.17,1.82,1.85,2.09,2.17-1.82-1.85-2.09Zm3.3,15.15l-.79,.52-1.08-1.08v-7.17l.91-.72-.12-.15-.76,.59-1.8-2.14-2.96,2.07,.1,.17,.74-.49,.99,1.23v6.61l-1.33,1.01,.12,.12,.67-.46,2.32,2.12,3.11-2.07-.1-.15h0Zm16.63-.1l-.74,.49-1.16-1.11v-7.03l.94-.72-.12-.15-.84,.64-2.47-2.2-2.78,2.17-2.44-2.17-2.74,2.14-1.85-2.14-2.96,2.07,.1,.17,.74-.49,1.06,1.21v6.61l-.81,.81,2.36,2,2.29-2.07-.94-.88v-7.04l.61-.45,1.7,1.48v6.16l-.79,.81,2.39,2,2.24-2.07-.94-.88v-7.04l.59-.47,1.72,1.5v6.06l-.69,.72,2.41,2.2,3.18-2.17-.1-.15h.02Zm8.6-1.5l-2.36,1.87-2.71-2.14v-1.33l4.68-3.3-2.36-3.67-5.2,2.86v6.93l3.57,2.59,4.51-3.62-.12-.17h0Zm-5.08-1.88v-5.15l2.27,3.55-2.27,1.6Zm14.12-.97l-2-1.53c1.33-1.16,1.8-2.63,1.8-3.69,0-.15-.03-.42-.05-.67h-.08c-.19,.54-.72,1.01-1.53,1.01s-1.26-.45-1.75-.99l-4.58,2.54v3.72l1.75,1.38c-1.75,1.55-2.09,2.51-2.09,3.4s.52,1.67,1.41,2.02l.07-.12c-.22-.19-.42-.32-.42-.79,0-.34,.35-.88,1.14-.88,1.01,0,1.63,.69,1.95,1.06,0-.03,4.38-2.69,4.38-2.69v-3.77h0Zm-1.03-3.05c-.69,1.23-2.21,2.44-3.11,3.13l-1.11-.94v-3.62c.45,.99,1.36,1.82,2.54,1.82,.69,0,1.14-.12,1.67-.39m-1.9,8.13c-.52-1.16-1.63-2-2.86-2-.3,0-1.21-.03-2,.46,.47-.79,1.87-2.21,3.65-3.28l1.21,1.01v3.8Z"></path></svg></a><div class="css-1otr2jl"><a class="css-184m8ie" data-testid="go-to-homepage" href="/">Go to Home Page »</a></div></header><div class="css-qtw155" data-testid="site-index-accordion"><div class=" " role="tablist" aria-multiselectable="true" data-testid="accordion"><div class="" data-testid="accordion-item"><header aria-controls="body-siteindex-0" id="item-siteindex-0" class="css-1a5mdf6" role="tab" tabindex="0" aria-expanded="false" data-testid="accordion-item-header">News</header><div class="css-1hyfx7x" id="body-siteindex-0" aria-labelledby="item-siteindex-0" role="tabpanel" data-testid="accordion-item-body"><ul class="css-1gprdgz" data-testid="site-index-accordion-list"><li class="css-10t7hia"><a class="css-e9w26l" href="/" data-testid="accordion-item-list-link">Home Page</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/us" data-testid="accordion-item-list-link">U.S.</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/world" data-testid="accordion-item-list-link">World</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/politics" data-testid="accordion-item-list-link">Politics</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/nyregion" data-testid="accordion-item-list-link">New York</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/education" data-testid="accordion-item-list-link">Education</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/sports" data-testid="accordion-item-list-link">Sports</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/business" data-testid="accordion-item-list-link">Business</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/technology" data-testid="accordion-item-list-link">Tech</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/science" data-testid="accordion-item-list-link">Science</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/news-event/weather-climate" data-testid="accordion-item-list-link">Weather</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/spotlight/the-great-read" data-testid="accordion-item-list-link">The Great Read</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/obituaries" data-testid="accordion-item-list-link">Obituaries</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/headway" data-testid="accordion-item-list-link">Headway</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/spotlight/visual-investigations" data-testid="accordion-item-list-link">Visual Investigations</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/magazine" data-testid="accordion-item-list-link">The Magazine</a></li></ul></div></div><div class="" data-testid="accordion-item"><header aria-controls="body-siteindex-1" id="item-siteindex-1" class="css-1a5mdf6" role="tab" tabindex="0" aria-expanded="false" data-testid="accordion-item-header">Arts</header><div class="css-1hyfx7x" id="body-siteindex-1" aria-labelledby="item-siteindex-1" role="tabpanel" data-testid="accordion-item-body"><ul class="css-1gprdgz" data-testid="site-index-accordion-list"><li class="css-10t7hia"><a class="css-e9w26l" href="/section/books/review" data-testid="accordion-item-list-link">Books</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/books/best-sellers/" data-testid="accordion-item-list-link">Best Sellers Book List</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/arts/dance" data-testid="accordion-item-list-link">Dance</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/movies" data-testid="accordion-item-list-link">Movies</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/arts/music" data-testid="accordion-item-list-link">Music</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/spotlight/pop-culture" data-testid="accordion-item-list-link">Pop Culture</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/arts/television" data-testid="accordion-item-list-link">Television</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/theater" data-testid="accordion-item-list-link">Theater</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/arts/design" data-testid="accordion-item-list-link">Visual Arts</a></li></ul></div></div><div class="" data-testid="accordion-item"><header aria-controls="body-siteindex-2" id="item-siteindex-2" class="css-1a5mdf6" role="tab" tabindex="0" aria-expanded="false" data-testid="accordion-item-header">Lifestyle</header><div class="css-1hyfx7x" id="body-siteindex-2" aria-labelledby="item-siteindex-2" role="tabpanel" data-testid="accordion-item-body"><ul class="css-1gprdgz" data-testid="site-index-accordion-list"><li class="css-10t7hia"><a class="css-e9w26l" href="/section/health" data-testid="accordion-item-list-link">Health</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/well" data-testid="accordion-item-list-link">Well</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/food" data-testid="accordion-item-list-link">Food</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/reviews/dining" data-testid="accordion-item-list-link">Restaurant Reviews</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/fashion/weddings" data-testid="accordion-item-list-link">Love</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/travel" data-testid="accordion-item-list-link">Travel</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/style" data-testid="accordion-item-list-link">Style</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/fashion" data-testid="accordion-item-list-link">Fashion</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/realestate" data-testid="accordion-item-list-link">Real Estate</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/t-magazine" data-testid="accordion-item-list-link">T Magazine</a></li></ul></div></div><div class="" data-testid="accordion-item"><header aria-controls="body-siteindex-3" id="item-siteindex-3" class="css-1a5mdf6" role="tab" tabindex="0" aria-expanded="false" data-testid="accordion-item-header">Opinion</header><div class="css-1hyfx7x" id="body-siteindex-3" aria-labelledby="item-siteindex-3" role="tabpanel" data-testid="accordion-item-body"><ul class="css-1gprdgz" data-testid="site-index-accordion-list"><li class="css-10t7hia"><a class="css-e9w26l" href="/section/opinion" data-testid="accordion-item-list-link">Today&#x27;s Opinion</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/opinion/columnists" data-testid="accordion-item-list-link">Columnists</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/opinion/editorials" data-testid="accordion-item-list-link">Editorials</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/opinion/contributors" data-testid="accordion-item-list-link">Guest Essays</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/column/op-docs" data-testid="accordion-item-list-link">Op-Docs</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/opinion/letters" data-testid="accordion-item-list-link">Letters</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/opinion/sunday" data-testid="accordion-item-list-link">Sunday Opinion</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/spotlight/opinion-video" data-testid="accordion-item-list-link">Opinion Video</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/series/opinion-audio" data-testid="accordion-item-list-link">Opinion Audio</a></li></ul></div></div><div class="" data-testid="accordion-item"><header aria-controls="body-siteindex-4" id="item-siteindex-4" class="css-1a5mdf6" role="tab" tabindex="0" aria-expanded="false" data-testid="accordion-item-header">More</header><div class="css-1hyfx7x" id="body-siteindex-4" aria-labelledby="item-siteindex-4" role="tabpanel" data-testid="accordion-item-body"><ul class="css-1gprdgz" data-testid="site-index-accordion-list"><li class="css-10t7hia"><a class="css-e9w26l" href="/spotlight/podcasts" data-testid="accordion-item-list-link">Audio</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="https://www.nytimes.com/crosswords" data-testid="accordion-item-list-link">Games</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="https://cooking.nytimes.com" data-testid="accordion-item-list-link">Cooking</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="https://www.nytimes.com/wirecutter/" data-testid="accordion-item-list-link">Wirecutter</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="https://theathletic.com" data-testid="accordion-item-list-link">The Athletic</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/jobs" data-testid="accordion-item-list-link">Jobs</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/video" data-testid="accordion-item-list-link">Video</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/spotlight/graphics" data-testid="accordion-item-list-link">Graphics</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/trending/" data-testid="accordion-item-list-link">Trending</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/spotlight/nyt-events" data-testid="accordion-item-list-link">Live Events</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/corrections" data-testid="accordion-item-list-link">Corrections</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/reader-center" data-testid="accordion-item-list-link">Reader Center</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="https://timesmachine.nytimes.com/browser" data-testid="accordion-item-list-link">TimesMachine</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/section/learning" data-testid="accordion-item-list-link">The Learning Network</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="https://nytedu.com/" data-testid="accordion-item-list-link">School of The NYT</a></li><li class="css-10t7hia"><a class="css-e9w26l" href="/spotlight/nytimesineducation" data-testid="accordion-item-list-link">inEducation</a></li></ul></div></div></div></div><div class="css-v0l3hm" data-testid="site-index-sections"><div class="css-g4gku8" data-testid="site-index-section"><section class="css-1rr4qq7" aria-labelledby="site-index-section-label-0"><h3 class="css-1onhbft" id="site-index-section-label-0">News</h3><ul class="css-1iruc8t" data-testid="site-index-section-list"><li class="css-ist4u3"><a class="css-yk8vb4" href="/" data-testid="site-index-section-list-link">Home Page</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/us" data-testid="site-index-section-list-link">U.S.</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/world" data-testid="site-index-section-list-link">World</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/politics" data-testid="site-index-section-list-link">Politics</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/nyregion" data-testid="site-index-section-list-link">New York</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/education" data-testid="site-index-section-list-link">Education</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/sports" data-testid="site-index-section-list-link">Sports</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/business" data-testid="site-index-section-list-link">Business</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/technology" data-testid="site-index-section-list-link">Tech</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/science" data-testid="site-index-section-list-link">Science</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/news-event/weather-climate" data-testid="site-index-section-list-link">Weather</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/spotlight/the-great-read" data-testid="site-index-section-list-link">The Great Read</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/obituaries" data-testid="site-index-section-list-link">Obituaries</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/headway" data-testid="site-index-section-list-link">Headway</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/spotlight/visual-investigations" data-testid="site-index-section-list-link">Visual Investigations</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/magazine" data-testid="site-index-section-list-link">The Magazine</a></li></ul></section><section class="css-1rr4qq7" aria-labelledby="site-index-section-label-1"><h3 class="css-1onhbft" id="site-index-section-label-1">Arts</h3><ul class="css-1iruc8t" data-testid="site-index-section-list"><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/books/review" data-testid="site-index-section-list-link">Books</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/books/best-sellers/" data-testid="site-index-section-list-link">Best Sellers Book List</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/arts/dance" data-testid="site-index-section-list-link">Dance</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/movies" data-testid="site-index-section-list-link">Movies</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/arts/music" data-testid="site-index-section-list-link">Music</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/spotlight/pop-culture" data-testid="site-index-section-list-link">Pop Culture</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/arts/television" data-testid="site-index-section-list-link">Television</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/theater" data-testid="site-index-section-list-link">Theater</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/arts/design" data-testid="site-index-section-list-link">Visual Arts</a></li></ul></section><section class="css-1rr4qq7" aria-labelledby="site-index-section-label-2"><h3 class="css-1onhbft" id="site-index-section-label-2">Lifestyle</h3><ul class="css-1iruc8t" data-testid="site-index-section-list"><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/health" data-testid="site-index-section-list-link">Health</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/well" data-testid="site-index-section-list-link">Well</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/food" data-testid="site-index-section-list-link">Food</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/reviews/dining" data-testid="site-index-section-list-link">Restaurant Reviews</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/fashion/weddings" data-testid="site-index-section-list-link">Love</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/travel" data-testid="site-index-section-list-link">Travel</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/style" data-testid="site-index-section-list-link">Style</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/fashion" data-testid="site-index-section-list-link">Fashion</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/realestate" data-testid="site-index-section-list-link">Real Estate</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/t-magazine" data-testid="site-index-section-list-link">T Magazine</a></li></ul></section><section class="css-1rr4qq7" aria-labelledby="site-index-section-label-3"><h3 class="css-1onhbft" id="site-index-section-label-3">Opinion</h3><ul class="css-1iruc8t" data-testid="site-index-section-list"><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/opinion" data-testid="site-index-section-list-link">Today&#x27;s Opinion</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/opinion/columnists" data-testid="site-index-section-list-link">Columnists</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/opinion/editorials" data-testid="site-index-section-list-link">Editorials</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/opinion/contributors" data-testid="site-index-section-list-link">Guest Essays</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/column/op-docs" data-testid="site-index-section-list-link">Op-Docs</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/opinion/letters" data-testid="site-index-section-list-link">Letters</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/opinion/sunday" data-testid="site-index-section-list-link">Sunday Opinion</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/spotlight/opinion-video" data-testid="site-index-section-list-link">Opinion Video</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/series/opinion-audio" data-testid="site-index-section-list-link">Opinion Audio</a></li></ul></section><section class="css-1rr4qq7" aria-labelledby="site-index-section-label-4"><h3 class="css-1onhbft" id="site-index-section-label-4">More</h3><ul class="css-1iruc8t" data-testid="site-index-section-list"><li class="css-ist4u3"><a class="css-yk8vb4" href="/spotlight/podcasts" data-testid="site-index-section-list-link">Audio</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="https://www.nytimes.com/crosswords" data-testid="site-index-section-list-link">Games</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="https://cooking.nytimes.com" data-testid="site-index-section-list-link">Cooking</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="https://www.nytimes.com/wirecutter/" data-testid="site-index-section-list-link">Wirecutter</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="https://theathletic.com" data-testid="site-index-section-list-link">The Athletic</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/jobs" data-testid="site-index-section-list-link">Jobs</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/video" data-testid="site-index-section-list-link">Video</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/spotlight/graphics" data-testid="site-index-section-list-link">Graphics</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/trending/" data-testid="site-index-section-list-link">Trending</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/spotlight/nyt-events" data-testid="site-index-section-list-link">Live Events</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/corrections" data-testid="site-index-section-list-link">Corrections</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/reader-center" data-testid="site-index-section-list-link">Reader Center</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="https://timesmachine.nytimes.com/browser" data-testid="site-index-section-list-link">TimesMachine</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/section/learning" data-testid="site-index-section-list-link">The Learning Network</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="https://nytedu.com/" data-testid="site-index-section-list-link">School of The NYT</a></li><li class="css-ist4u3"><a class="css-yk8vb4" href="/spotlight/nytimesineducation" data-testid="site-index-section-list-link">inEducation</a></li></ul></section><div class="css-6xhk3s" aria-labelledby="site-index-subscribe-label"><h3 class="css-1onhbft" id="site-index-subscribe-label">Account</h3><ul class="css-1iruc8t" data-testid="site-index-subscribe-list"><li class="css-tj0ten"><a class="css-z6qatp" href="/subscription" data-testid="site-index-subscribe-list-link"><svg class="css-1o03u4n" viewBox="0 0 10 13"><path fill="#000" d="M9.9,8c-0.4,1.1-1.2,1.9-2.3,2.4V8l1.3-1.2L7.6,5.7V4c1.2-0.1,2-1,2-2c0-1.4-1.3-1.9-2.1-1.9c-0.2,0-0.3,0-0.6,0.1v0.1c0.1,0,0.2,0,0.3,0c0.5,0,0.9,0.2,0.9,0.7c0,0.4-0.3,0.7-0.8,0.7C6,1.7,4.5,0.6,2.8,0.6c-1.5,0-2.5,1.1-2.5,2.2C0.3,4,1,4.3,1.6,4.6l0-0.1C1.4,4.4,1.3,4.1,1.3,3.8c0-0.5,0.5-0.9,1-0.9C3.7,2.9,6,4,7.4,4h0.1v1.7L6.2,6.8L7.5,8v2.4c-0.5,0.2-1.1,0.3-1.7,0.3c-2.2,0-3.6-1.3-3.6-3.5c0-0.5,0.1-1,0.2-1.5l1.1-0.5V10l2.2-1v-5L2.5,5.5c0.3-1,1-1.7,1.8-2l0,0C2.2,3.9,0.1,5.6,0.1,8c0,2.9,2.4,4.8,5.2,4.8C8.2,12.9,9.9,10.9,9.9,8L9.9,8z"></path></svg>Subscribe</a></li><li class="css-tj0ten"><a class="css-z6qatp" href="/account" data-testid="site-index-subscribe-list-link"><svg class="css-1o03u4n" viewBox="0 0 20 20" fill="#333" xmlns="http://www.w3.org/2000/svg"><path d="M14.2379 6C14.2379 8.20914 12.4471 10 10.2379 10C8.02878 10 6.23792 8.20914 6.23792 6C6.23792 3.79086 8.02878 2 10.2379 2C12.4471 2 14.2379 3.79086 14.2379 6Z" fill="#333"></path><path d="M16.2355 14.5714C16.2371 14.5477 16.2379 14.5239 16.2379 14.5C16.2379 13.1193 13.5516 12 10.2379 12C6.92421 12 4.23792 13.1193 4.23792 14.5C4.23792 14.5239 4.23872 14.5477 4.24032 14.5714H4.23792V18H16.2379V14.5714H16.2355Z" fill="#333"></path></svg>Manage My Account</a></li><li class="css-tj0ten"><a class="css-z6qatp" href="https://www.nytimes.com/subscription/home-delivery" data-testid="site-index-subscribe-list-link"><svg class="css-1o03u4n" viewBox="0 0 14 13" fill="#000"><path d="M13.1,11.7H3.5V1.2h9.6V11.7zM13.1,0.4H3.5C3,0.4,2.6,0.8,2.6,1.2v2.2H0.9C0.4,3.4,0,3.8,0,4.3v5.2v1.5c0,0.8,0.8,1.5,1.8,1.5h1.7h0h7.4h2.2c0.5,0,0.9-0.4,0.9-0.9V1.2C14,0.8,13.6,0.4,13.1,0.4"></path><polygon points="10.9,3 5.2,3 5.2,3.9 11.4,3.9 11.4,3"></polygon><rect x="5.2" y="4.7" width="6.1" height="0.9"></rect><rect x="5.2" y="6.5" width="6.1" height="0.9"></rect></svg>Home Delivery</a></li><li class="css-tj0ten"><a class="css-z6qatp" href="https://www.nytimes.com/gift" data-testid="site-index-subscribe-list-link"><svg class="css-1o03u4n" viewBox="0 0 10 13"><path fill="#000" d="M9.9,8c-0.4,1.1-1.2,1.9-2.3,2.4V8l1.3-1.2L7.6,5.7V4c1.2-0.1,2-1,2-2c0-1.4-1.3-1.9-2.1-1.9c-0.2,0-0.3,0-0.6,0.1v0.1c0.1,0,0.2,0,0.3,0c0.5,0,0.9,0.2,0.9,0.7c0,0.4-0.3,0.7-0.8,0.7C6,1.7,4.5,0.6,2.8,0.6c-1.5,0-2.5,1.1-2.5,2.2C0.3,4,1,4.3,1.6,4.6l0-0.1C1.4,4.4,1.3,4.1,1.3,3.8c0-0.5,0.5-0.9,1-0.9C3.7,2.9,6,4,7.4,4h0.1v1.7L6.2,6.8L7.5,8v2.4c-0.5,0.2-1.1,0.3-1.7,0.3c-2.2,0-3.6-1.3-3.6-3.5c0-0.5,0.1-1,0.2-1.5l1.1-0.5V10l2.2-1v-5L2.5,5.5c0.3-1,1-1.7,1.8-2l0,0C2.2,3.9,0.1,5.6,0.1,8c0,2.9,2.4,4.8,5.2,4.8C8.2,12.9,9.9,10.9,9.9,8L9.9,8z"></path></svg>Gift Subscriptions</a></li></ul><ul class="css-1iruc8t" data-testid="site-index-corporate-links"><li><a class="css-1ea6cym" href="/subscription/groups?Pardot_Campaign_Code_Form_Input=89FQX">Group Subscriptions</a></li><li><a class="css-1ea6cym" href="/gift-articles">Gift Articles</a></li><li><a class="css-1ea6cym" href="/newsletters">Email Newsletters</a></li></ul><ul class="css-6td9kr" data-testid="site-index-alternate-links"><li><a class="css-1ea6cym" href="https://nytlicensing.com/">NYT Licensing</a></li><li><a class="css-1ea6cym" href="https://nytimes.pressreader.com/">Replica Edition</a></li><li><a class="css-1ea6cym" href="https://store.nytimes.com/">Times Store</a></li></ul></div></div></div></div></nav><footer class="css-1e1s8k7" role="contentinfo"><nav data-testid="footer" class="css-1qa4qp6"><h2 class="css-1dv1kvn">Site Information Navigation</h2><ul class="css-1ho5u4o edvi3so0"><li data-testid="copyright"><a class="css-jq1cx6" href="https://help.nytimes.com/hc/en-us/articles/115014792127-Copyright-notice">© <span>2024</span> <span>The New York Times Company</span></a></li></ul><ul class="css-t8x4fj edvi3so1"><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytco.com/">NYTCo</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://help.nytimes.com/hc/en-us/articles/115015385887-Contact-Us">Contact Us</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://help.nytimes.com/hc/en-us/articles/115015727108-Accessibility">Accessibility</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytco.com/careers/">Work with us</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://advertising.nytimes.com/">Advertise</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.tbrandstudio.com/">T Brand Studio</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytimes.com/privacy/cookie-policy#how-do-i-manage-trackers">Your Ad Choices</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytimes.com/privacy/privacy-policy">Privacy Policy</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://help.nytimes.com/hc/en-us/articles/115014893428-Terms-of-service">Terms of Service</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://help.nytimes.com/hc/en-us/articles/115014893968-Terms-of-sale">Terms of Sale</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="/sitemap/">Site Map</a></li><li class="mobileOnly css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytimes.com/ca/">Canada</a></li><li class="mobileOnly css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://www.nytimes.com/international/">International</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" class="css-jq1cx6" href="https://help.nytimes.com/hc/en-us">Help</a></li><li class="css-a7htku edvi3so2"><a data-testid="footer-link" rel="nofollow" class="css-jq1cx6" href="https://www.nytimes.com/subscription?campaignId=37WXW">Subscriptions</a></li></ul><ul class="css-t8x4fj edvi3so1"><li class="css-a7htku edvi3so2"><a data-testid="privacy-preferences-link" rel="noreferrer noopener" target="_blank" class="css-jq1cx6" href="/privacy/manage-settings">Manage Privacy Preferences</a></li></ul></nav></footer></div></div></div></div></div>
    <script>window.__preloadedData = {"config":{"gqlUrlClient":"https:\u002F\u002Fsamizdat-graphql.nytimes.com\u002Fgraphql\u002Fv2","gqlRequestHeaders":{"nyt-app-type":"project-vi","nyt-app-version":"0.0.5","nyt-token":"MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEAs+\u002FoUCTBmD\u002FcLdmcecrnBMHiU\u002FpxQCn2DDyaPKUOXxi4p0uUSZQzsuq1pJ1m5z1i0YGPd1U1OeGHAChWtqoxC7bFMCXcwnE1oyui9G1uobgpm1GdhtwkR7ta7akVTcsF8zxiXx7DNXIPd2nIJFH83rmkZueKrC4JVaNzjvD+Z03piLn5bHWU6+w+rA+kyJtGgZNTXKyPh6EC6o5N+rknNMG5+CdTq35p8f99WjFawSvYgP9V64kgckbTbtdJ6YhVP58TnuYgr12urtwnIqWP9KSJ1e5vmgf3tunMqWNm6+AnsqNj8mCLdCuc5cEB74CwUeQcP2HQQmbCddBy2y0mEwIDAQAB","x-nyt-internal-meter-override":undefined},"gqlFetchTimeout":1500,"disablePersistedQueries":false,"initialDeviceType":"smartphone","fastlyAbraConfig":{".ver":"18076.000","AMS_FrictionCircumventionDesktop_cwv":"2_low-mid-truncation","AMS_FrictionCircumventionMobile_cwv":"2_low-mid-truncation","DFP_TopAd_Anon_0124":"","HOME_cwv_chartbeat":"0_Control","MX_NewArchitecture_PostLoginOffer":"1_variant","MX_NewArchitecture_WirecutterLP":"","STYLN_synth_voice_web":"1_synth"},"fastlyEntitlements":[],"internalPreviewConfig":{"meter":undefined,"swg":undefined},"webviewEnvironment":{"isInWebview":false,"isPreloaded":false},"isOptimisticallyTruncated":false,"optimisticTruncationDropzone":6,"requestPath":"\u002Finteractive\u002F2020\u002Fscience\u002Fcoronavirus-vaccine-tracker.html","isProvisionallyLoggedIn":false,"serviceWorkerFile":"service-worker-test-1714680954976.js"},"interactiveConfig":{"interactive":{"__typename":"Interactive","displayProperties":{"fullBleedDisplayStyle":"","__typename":"CreativeWorkDisplayProperties","displayForPromotionOnly":false,"displayOverrides":["HIDE_TOP_AD"],"maxWidth":1600,"minWidth":300,"template":"Standard","displayStyle":"standard","theme":"standard"},"section":{"id":"U2VjdGlvbjpueXQ6Ly9zZWN0aW9uL2ZiMjQxZTE2LWNiZGUtNWQ2MC1iZTZlLTZiY2E5ZTg2YzY5Nw==","name":"science","__typename":"Section","displayName":"Science","url":"https:\u002F\u002Fwww.nytimes.com\u002Fsection\u002Fscience","taxonomyID":"A4B35924-DB6C-4EA3-997D-450810F4FEE6","type":"section","uri":"nyt:\u002F\u002Fsection\u002Ffb241e16-cbde-5d60-be6e-6bca9e86c697"},"subsection":null,"tone":"NEWS","collections":[{"id":"TGVnYWN5Q29sbGVjdGlvbjpueXQ6Ly9sZWdhY3ljb2xsZWN0aW9uL2UzNjMwZTg4LTc4MDEtNTdiZS1hOWM1LTEyOGVmYWQ5MWRmMQ==","name":"Science","collectionType":"SECTION","__typename":"LegacyCollection","slug":"science","url":"https:\u002F\u002Fwww.nytimes.com\u002Fsection\u002Fscience","uri":"nyt:\u002F\u002Flegacycollection\u002Fe3630e88-7801-57be-a9c5-128efad91df1","tagline":""},{"id":"TGVnYWN5Q29sbGVjdGlvbjpueXQ6Ly9sZWdhY3ljb2xsZWN0aW9uLzQxZGYzYzA0LWI0ZjEtNWQ4Ni1hYTU1LWE3MDAwNDZiYmI4Ng==","name":"Health","collectionType":"SECTION","__typename":"LegacyCollection","slug":"health","url":"https:\u002F\u002Fwww.nytimes.com\u002Fsection\u002Fhealth","uri":"nyt:\u002F\u002Flegacycollection\u002F41df3c04-b4f1-5d86-aa55-a700046bbb86","tagline":""},{"id":"TGVnYWN5Q29sbGVjdGlvbjpueXQ6Ly9sZWdhY3ljb2xsZWN0aW9uLzU0YzJkNTFjLTE0ZjYtNTgyMC04MzJkLTk2ODk0NmZiMzM4ZA==","name":"Business","collectionType":"SECTION","__typename":"LegacyCollection","slug":"business","url":"https:\u002F\u002Fwww.nytimes.com\u002Fsection\u002Fbusiness","uri":"nyt:\u002F\u002Flegacycollection\u002F54c2d51c-14f6-5820-832d-968946fb338d","tagline":""},{"id":"TGVnYWN5Q29sbGVjdGlvbjpueXQ6Ly9sZWdhY3ljb2xsZWN0aW9uLzA4ZGEwNWU1LWU0YzctNWRkYS05NWIzLWRkMWQ5MmM3N2FkNA==","name":"DealBook","collectionType":"SECTION","__typename":"LegacyCollection","slug":"business-dealbook","url":"https:\u002F\u002Fwww.nytimes.com\u002Fsection\u002Fbusiness\u002Fdealbook","uri":"nyt:\u002F\u002Flegacycollection\u002F08da05e5-e4c7-5dda-95b3-dd1d92c77ad4","tagline":""}],"url":"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2020\u002Fscience\u002Fcoronavirus-vaccine-tracker.html","sourceId":"100000007182188","dfpTaxonomyException":null,"advertisingProperties":{"sensitivity":"SHOW_ADS","__typename":"CreativeWorkAdvertisingProperties"},"adTargetingParams":[{"key":"als_test","value":"1714876375743","__typename":"AdTargetingParam"},{"key":"prop","value":"nyt","__typename":"AdTargetingParam"},{"key":"plat","value":"web","__typename":"AdTargetingParam"},{"key":"edn","value":"us","__typename":"AdTargetingParam"},{"key":"brandsensitive","value":"true","__typename":"AdTargetingParam"},{"key":"per","value":"","__typename":"AdTargetingParam"},{"key":"org","value":"modernainc,biontechse,pfizerinc,shanghaifosunpharmaceuticalgro,cadilahealthcare,morningsideventuresinc,imperialcollegelondon,osakauniversity,angesmginc,takarabio,arcturustherapeutics,inoviopharmaceuticals,genexine,suzhouabogenbiosciences,chulalongkornuniversity,sanofisa,cansinobiologics,johnsonjohnson,astrazenecaplc,reitherasrl,vaxartinc,merckcompanyinc,novartisag,sinovacbiotechltd,bharatbiotechltd","__typename":"AdTargetingParam"},{"key":"geo","value":"","__typename":"AdTargetingParam"},{"key":"des","value":"coronavirus2019ncov,clinicaltrials,vaccinationandimmunization,immunesystem,publicprivatesectorcooperation","__typename":"AdTargetingParam"},{"key":"spon","value":"","__typename":"AdTargetingParam"},{"key":"auth","value":"carlzimmer,jonathancorum,matthewkristoffersen,suileewee","__typename":"AdTargetingParam"},{"key":"col","value":"","__typename":"AdTargetingParam"},{"key":"coll","value":"science,health,business,dealbook","__typename":"AdTargetingParam"},{"key":"artlen","value":"short","__typename":"AdTargetingParam"},{"key":"ledemedsz","value":"none","__typename":"AdTargetingParam"},{"key":"gui","value":"","__typename":"AdTargetingParam"},{"key":"template","value":"interactive","__typename":"AdTargetingParam"},{"key":"typ","value":"int","__typename":"AdTargetingParam"},{"key":"section","value":"science","__typename":"AdTargetingParam"},{"key":"si_section","value":"science","__typename":"AdTargetingParam"},{"key":"id","value":"100000007182188","__typename":"AdTargetingParam"},{"key":"trend","value":"","__typename":"AdTargetingParam"},{"key":"pt","value":"nt1,nt14,nt16,nt18,nt19,nt2,nt20,nt3,nt4,nt6,nt7,nt9,pt11,pt13,pt15,pt8","__typename":"AdTargetingParam"},{"key":"gscat","value":"gv_safe,neg_gg1,neg_capitalone,neg_citi_aa,gb_safe,gb_safe_from_high,gb_safe_from_high_med,gs_science,neg_kaypemg,gs_health,neg_rchmt,neg_chanel,neg_chan2,gs_science_geography,neg_hms,neg_ms_safe,neg_gg2,neg_debeer,neg_google,neg_rms,neg_mtb,neg_cme,neg_mc,neg_virus,neg_mastercard,neg_bofa,neg_ibmtest,neg_fcli,gs_health_misc,neg_njts,gs_covid19,neg_ibm,gs_predicts_outdoorsinautumn,gs_health_vaccines,neg_chan3,neg_ihw,gs_busfin,gs_predicts_coldfluseason,neg_rolex,neg_racism,gs_busfin_indus,gs_predicts_newjob,gs_predicts_midautumnfestival,gs_predicts_businessandfinance,gs_predicts_marketers,gs_predicts_womenshealth,gs_predicts_nutritionconscious,gs_predicts_backtoschool,gs_predicts_newyearseve,gs_predicts_startups,gs_predicts_graduatedegree,neg_hearts,gs_predicts_needinglegalcounci,neg_newyorkp,neg_sub0,gs_predicts_rugby_world_cup,gs_predicts_energy_topics,neg_amz_sfe,gs_predicts_charity,gs_predicts_savvyshopperscoupo,gs_predicts_pharma_compassion,gs_predicts_holidayshoppers,neg_mttl,gs_predicts_parentsteachers,gs_predicts_healthylifestyle,cc_tech_society,neg_rmw,gs_predicts_womensfitness,gs_predicts_retail_industry,gs_predicts_moms_dads_grads,gs_predicts_technology,gs_predicts_interestedmillenni,neg_ts,gs_predicts_insurance,gs_predicts_diningindelivery,gs_predicts_chinesenewyear,gs_predicts_cuttingedgetechent,gs_predicts_blackfridaycybermo,cc_tech_data,neg_samsung,gs_predicts_quitsmoking,gs_predicts_christmas,gs_predicts_software_industry,gs_predicts_veteransservice,gs_predicts_mensfitness,gs_predicts_menshealth,gs_predicts_collegebound,gs_predicts_small_med_bus,gs_predicts_nba,neg_sabic,neg_sia,gs_predicts_realestateind,neg_aramco,gs_predicts_mlb,gs_predicts_uspoliticselection,gs_predicts_oralcare,gs_predicts_legal_industry,gs_predicts_rugby,neg_amerex,neg_elec,gs_t","__typename":"AdTargetingParam"},{"key":"tt","value":"","__typename":"AdTargetingParam"},{"key":"mt","value":"MT10","__typename":"AdTargetingParam"}],"headline":{"default":"Coronavirus Vaccine Tracker","seo":"Covid-19 Vaccine Tracker: Latest Updates","__typename":"CreativeWorkHeadline"},"summary":"A look at all the vaccines that have reached trials in humans.","shortUrl":"https:\u002F\u002Fnyti.ms\u002F2MHNdRL","commentStatus":undefined,"commentProperties":{"status":"NO_COMMENTS","__typename":"CreativeWorkCommentProperties","prompt":"","approvedCommentsCount":null},"uri":"nyt:\u002F\u002Finteractive\u002F417d1099-2aac-55d9-a834-9a011581411e","associatedAssets":[],"storylines":[{"testName":"styln-coronavirus-risk-personalized","ruleName":"styln-coronavirus","storyline":{"uri":"nyt:\u002F\u002Fstoryline\u002F96ae4135-bbe2-48c4-a9fb-fefe09c1fc3b","url":"https:\u002F\u002Fwww.nytimes.com\u002Fstoryline\u002F96ae4135-bbe2-48c4-a9fb-fefe09c1fc3b","tone":"NO_TONE_SET","displayName":"Covid-19 Guidance","hubAssets":[{"asset":{"uri":"nyt:\u002F\u002Flegacycollection\u002F888dfa9a-8cb9-5ea9-8df5-951678baa62d","url":"https:\u002F\u002Fwww.nytimes.com\u002Fnews-event\u002Fcoronavirus","__typename":"LegacyCollection"},"__typename":"StorylineHubAsset"}],"primaryAssets":[{"displayName":"Symptoms and Treatment","status":null,"asset":{"uri":"nyt:\u002F\u002Farticle\u002F4a83611c-244a-59a1-a7ac-28411943f7e3","url":"https:\u002F\u002Fwww.nytimes.com\u002Farticle\u002Fcovid-symptoms-treatment.html","__typename":"Article"},"__typename":"StorylinePrimaryAsset"},{"displayName":"JN.1 Variant","status":null,"asset":{"uri":"nyt:\u002F\u002Farticle\u002F7510892a-f466-5254-8064-0071018feebc","url":"https:\u002F\u002Fwww.nytimes.com\u002F2024\u002F02\u002F14\u002Fwell\u002Flive\u002Fjn1-covid-infection-vaccine.html","__typename":"Article"},"__typename":"StorylinePrimaryAsset"},{"displayName":"A New Drug","status":null,"asset":{"uri":"nyt:\u002F\u002Farticle\u002Fc20a8df1-4820-5198-8983-05a2801c98d3","url":"https:\u002F\u002Fwww.nytimes.com\u002F2024\u002F03\u002F25\u002Fwell\u002Ffda-covid-medicine-immunocompromised.html","__typename":"Article"},"__typename":"StorylinePrimaryAsset"},{"displayName":"Updated Shots","status":null,"asset":{"uri":"nyt:\u002F\u002Farticle\u002F193d32e0-bd19-56a5-8a99-632c6d16320e","url":"https:\u002F\u002Fwww.nytimes.com\u002F2023\u002F09\u002F11\u002Fwell\u002Flive\u002Fcovid-vaccine-booster-fall.html","__typename":"Article"},"__typename":"StorylinePrimaryAsset"},{"displayName":"Long Covid in Kids","status":null,"asset":{"uri":"nyt:\u002F\u002Farticle\u002F08e8addc-773c-540a-a00b-02ed21f23320","url":"https:\u002F\u002Fwww.nytimes.com\u002F2024\u002F02\u002F07\u002Fwell\u002Flive\u002Flong-covid-children.html","__typename":"Article"},"__typename":"StorylinePrimaryAsset"},{"displayName":"Paxlovid","status":null,"asset":{"uri":"nyt:\u002F\u002Farticle\u002F8273b052-46c9-5a7b-9d85-8165f9541244","url":"https:\u002F\u002Fwww.nytimes.com\u002F2024\u002F01\u002F11\u002Fwell\u002Fcovid-paxlovid-treatment.html","__typename":"Article"},"__typename":"StorylinePrimaryAsset"},{"displayName":"Masks","status":null,"asset":{"uri":"nyt:\u002F\u002Farticle\u002F922e0689-470c-5dd9-8234-fc1ddc126f55","url":"https:\u002F\u002Fwww.nytimes.com\u002F2023\u002F08\u002F29\u002Fwell\u002Flive\u002Fcovid-masks-guidance.html","__typename":"Article"},"__typename":"StorylinePrimaryAsset"}],"__typename":"Storyline","experimentalJsonBlob":"{\"data\":[{\"version\":1,\"type\":\"experimentalJsonBlob\",\"data\":[{\"version\":1,\"type\":\"lede\",\"data\":[{\"type\":\"text\",\"value\":\"With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world.\"}]},{\"version\":1,\"type\":\"context\",\"data\":{\"title\":\"Four Years of Covid\",\"items\":[{\"subtitle\":\"\",\"text\":\"We \u003Ca href=\\\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2024\u002F03\u002F12\u002Fwell\u002Flive\u002Fcovid-pandemic-lockdown-anniversary.html\\\"\u003Easked readers\u003C\u002Fa\u003E how Covid has changed their attitudes towards life. Here is what they said:\"},{\"subtitle\":\"\",\"text\":\"“I'm a much more grateful person. Life is precious, and I see the beauty in all the little miracles that happen all around me. I'm a humbled human being now. I have more empathy and compassion towards everyone.” —\u003Cstrong\u003E Gil Gallegos, 59, Las Vegas, N.M.\u003C\u002Fstrong\u003E\"},{\"subtitle\":\"\",\"text\":\"“The pandemic has completely changed my approach to educating my child. My spouse and I had never seriously considered homeschooling until March 2020. Now, we wouldn't have it any other way.” — \u003Cstrong\u003EKim Harper, 47, Clinton, Md.\u003C\u002Fstrong\u003E\"},{\"subtitle\":\"\",\"text\":\"“I had contamination OCD before the pandemic began. The last four years have been a steady string of my worst fears coming true. I never feel safe anymore. I know very well now that my body can betray me at any time.” — \u003Cstrong\u003EAdelia Brown, 23, Madison, Wis. \u003C\u002Fstrong\u003E\"},{\"subtitle\":\"\",\"text\":\"“I don’t take for granted the pleasure of being around people. Going to a show, a road trip, a restaurant, people watching at the opera. I love it.” —\u003Cstrong\u003E Philip Gunnels, 66, Sugar Land, Texas\u003C\u002Fstrong\u003E\"},{\"subtitle\":\"\",\"text\":\"“My remaining years are limited. On the one hand, I feel cheated out of many experiences I was looking forward to; on the other hand, I do not want to live my remaining years with long Covid. It’s hard.” — \u003Cstrong\u003ESandra Wulach, 77, Edison, N.J.\u003C\u002Fstrong\u003E\"}]}},{\"version\":1,\"type\":\"topLinks\",\"data\":{\"title\":\"More on Covid-19\",\"imageUrl\":\"\",\"leadIn\":\"\",\"bulletedList\":[\"\u003Cstrong\u003EAirborne Diseases, Redefined:\u003C\u002Fstrong\u003E After a drawn-out global controversy over the coronavirus, \u003Ca href=\\\"https:\u002F\u002Fwww.nytimes.com\u002F2024\u002F04\u002F18\u002Fhealth\u002Fwho-airborne-covid.html\\\"\u003Ethe W.H.O. has updated its classification\u003C\u002Fa\u003E of how pathogens spread through the air.\",\"\u003Cstrong\u003EFour Years Later:\u003C\u002Fstrong\u003E Covid was declared a national emergency on March 13, 2020, \u003Ca href=\\\"https:\u002F\u002Fwww.nytimes.com\u002Finteractive\u002F2024\u002F03\u002F12\u002Fwell\u002Flive\u002Fcovid-pandemic-lockdown-anniversary.html\\\"\u003Ea moment that changed the world\u003C\u002Fa\u003E. But even as the threat has faded, the pandemic has \u003Ca href=\\\"https:\u002F\u002Fwww.nytimes.com\u002F2024\u002F03\u002F13\u002Fus\u002Fcovid-national-emergency-anniversary.html\\\"\u003Ereshaped life for many Americans\u003C\u002Fa\u003E.\",\"\u003Cstrong\u003EWhat’s Next?:\u003C\u002Fstrong\u003E Scientists are studying the virus’s continuing evolution and the body’s immune responses, \u003Ca href=\\\"https:\u002F\u002Fwww.nytimes.com\u002F2024\u002F03\u002F22\u002Fhealth\u002Fcoronavirus-evolution-immunity.html\\\"\u003Ehoping to head off a resurgence\u003C\u002Fa\u003E and to better understand long Covid.\",\"\u003Cstrong\u003ECovid Mysteries:\u003C\u002Fstrong\u003E In the four years since the W.H.O. declared a global pandemic, scientists have begun answering some of the biggest questions about Covid. \u003Ca href=\\\"https:\u002F\u002Fwww.nytimes.com\u002F2024\u002F03\u002F09\u002Fwell\u002Flive\u002Fcovid-symptoms-mysteries.html\\\"\u003EHere is what we have learned\u003C\u002Fa\u003E.\"]}}]}]}","guide":null},"__typename":"AssociatedStoryline"}]}},"statusCode":200,"externalAssets":undefined};</script>
    <script src="/vi-assets/static-assets/start-mark-8040d5b093282be791c41a2c38676ddb.js"></script>
    
    <script>
      setTimeout(function() {
        var script = document.createElement('script');
        script.async = true;
        script.src = '/vi-assets/static-assets/end-mark-6f0172a017e635e07fbcdf5f16886104.js';
        document.head.appendChild(script);
      }, 0);
    </script>
  
    <script>!function(){try{var e="undefined"!=typeof window?window:"undefined"!=typeof global?global:"undefined"!=typeof self?self:{},n=(new Error).stack;n&&(e._sentryDebugIds=e._sentryDebugIds||{},e._sentryDebugIds[n]="298143d8-6286-4ad4-9c8d-3b5b4f3cdd46",e._sentryDebugIdIdentifier="sentry-dbid-298143d8-6286-4ad4-9c8d-3b5b4f3cdd46")}catch(e){}}();var _global="undefined"!=typeof window?window:"undefined"!=typeof global?global:"undefined"!=typeof self?self:{};_global.SENTRY_RELEASE={id:"03cce1e7203a898cba8bffea0e231b4698a1d4eb"},function(e){function n(n){for(var r,d,u=n[0],a=n[1],l=n[2],c=0,s=[];c<u.length;c++)d=u[c],Object.prototype.hasOwnProperty.call(o,d)&&o[d]&&s.push(o[d][0]),o[d]=0;for(r in a)Object.prototype.hasOwnProperty.call(a,r)&&(e[r]=a[r]);for(i&&i(n);s.length;)s.shift()();return f.push.apply(f,l||[]),t()}function t(){for(var e,n=0;n<f.length;n++){for(var t=f[n],r=!0,u=1;u<t.length;u++){var a=t[u];0!==o[a]&&(r=!1)}r&&(f.splice(n--,1),e=d(d.s=t[0]))}return e}var r={},o={137:0},f=[];function d(n){if(r[n])return r[n].exports;var t=r[n]={i:n,l:!1,exports:{}};return e[n].call(t.exports,t,t.exports,d),t.l=!0,t.exports}d.m=e,d.c=r,d.d=function(e,n,t){d.o(e,n)||Object.defineProperty(e,n,{enumerable:!0,get:t})},d.r=function(e){"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},d.t=function(e,n){if(1&n&&(e=d(e)),8&n)return e;if(4&n&&"object"==typeof e&&e&&e.__esModule)return e;var t=Object.create(null);if(d.r(t),Object.defineProperty(t,"default",{enumerable:!0,value:e}),2&n&&"string"!=typeof e)for(var r in e)d.d(t,r,function(n){return e[n]}.bind(null,r));return t},d.n=function(e){var n=e&&e.__esModule?function(){return e.default}:function(){return e};return d.d(n,"a",n),n},d.o=function(e,n){return Object.prototype.hasOwnProperty.call(e,n)},d.p="/vi-assets/static-assets/";var u=window.webpackJsonp=window.webpackJsonp||[],a=u.push.bind(u);u.push=n,u=u.slice();for(var l=0;l<u.length;l++)n(u[l]);var i=a;t()}([]);
//# sourceMappingURL=runtime~adslot-2f3b57d144c5169f6d5f.js.map</script>
<script src="/vi-assets/static-assets/adslot-1e649f756902ef13bd8d.js"></script>
    
    <script id="adslot-config">
      (function () { var _f=function(){const o="1_block";function n(o){return window&&window.NYTD&&window.NYTD.Abra?window.NYTD.Abra(o):""}window.adClientUtils={hasActiveToggle:function(r){return n(r)!==o},getAbraVar:n,reportExposure:function(o){window&&window.NYTD&&window.NYTD.Abra&&window.NYTD.Abra.reportExposure&&window.NYTD.Abra.reportExposure(o)}}};;_f.apply(null, []); })();
      var AdSlot4=function(){"use strict";function a(){return window.AdSlot4=window.AdSlot4||{},window.AdSlot4.cmd=window.AdSlot4.cmd||[],window.AdSlot4}function t(e){return-1!==document.cookie.indexOf(e)}function n(e){var t={PURR_AcceptableTrackers:0,PURR_AdConfiguration:5,PURR_DataSaleOptOutUI:2,PURR_DataProcessingConsentUI:3,PURR_AcceptableTrackers_v2:4,PURR_AdConfiguration_v2:5,PURR_DataProcessingPreferenceUI:6,PURR_DataSaleOptOutUI_v2:7,PURR_CaliforniaNoticesUI:8,PURR_EmailMarketingOptInUI:9,PURR_DeleteIPAddress:10,PURR_AdConfiguration_v3:11,PURR_LimitSensitivePI:12,PURR_EmailMarketingOptInUI_v2:13,PURR_AdConfiguration_v4:14},n=function(e){e="; ".concat(document.cookie).split("; ".concat(e,"="));return 2===e.length?e.pop().split(";").shift():null}(e),i={};return Object.keys(t).forEach(function(e){i[e]=function(e,t){t=new RegExp("^.{".concat(t,"}(.)")),t=e.match(t);return(null==t?void 0:t[1])||""}(n,t[e])}),r.forEach(function(t){Object.keys(t.valueMapping).forEach(function(e){t.valueMapping[e]===i[t.name]&&(i[t.name]=e)})}),i}function i(){var e;try{return function(){if("undefined"==typeof window)return!1;var e=window.navigator.userAgent||window.navigator.vendor,t=-1!==e.indexOf("nyt_android"),n=-1!==e.indexOf("nytios"),i=-1!==e.indexOf("nyt_xwords_ios"),e=-1!==e.indexOf("Crosswords");return t||n||i||e}()?null!==(e=null===window||void 0===window?void 0:window.config)&&void 0!==e&&e.PurrDirectives?window.config.PurrDirectives:t("override-purr")?n("override-purr"):o({},d):t("nyt-purr")?n("nyt-purr"):o({},d)}catch(e){return console.warn("can’t get directives from cookie or config",e),o({},d)}}function e(){var e={};return"undefined"!=typeof window&&window.document&&window.document.createElement&&(e=i().PURR_AdConfiguration_v3||i().PURR_AdConfiguration_v2),e}var o=function(){return(o=Object.assign||function(e){for(var t,n=1,i=arguments.length;n<i;n++)for(var o in t=arguments[n])Object.prototype.hasOwnProperty.call(t,o)&&(e[o]=t[o]);return e}).apply(this,arguments)},r=[{name:"PURR_AcceptableTrackers",valueMapping:{controllers:"c",processors:"p"}},{name:"PURR_AdConfiguration",valueMapping:{full:"f",npa:"n","adluce-socrates":"s"}},{name:"PURR_DataSaleOptOutUI",valueMapping:{hide:"h",show:"s"}},{name:"PURR_DataProcessingConsentUI",valueMapping:{hide:"h",show:"s"}},{name:"PURR_AcceptableTrackers_v2",valueMapping:{controllers:"c",processors:"p",essentials:"e"}},{name:"PURR_AdConfiguration_v2",valueMapping:{full:"f",rdp:"r",npa:"n",adluce:"a","adluce-socrates":"s"}},{name:"PURR_DataProcessingPreferenceUI",valueMapping:{hide:"h","allow-opt-out":"o","allow-opt-in":"i","allow-opt-in-or-out":"a"}},{name:"PURR_DataSaleOptOutUI_v2",valueMapping:{hide:"h",show:"s","show-opted-out":"o"}},{name:"PURR_CaliforniaNoticesUI",valueMapping:{hide:"h",show:"s"}},{name:"PURR_EmailMarketingOptInUI",valueMapping:{checked:"c",unchecked:"u"}},{name:"PURR_DeleteIPAddress",valueMapping:{delete:"d",keep:"k"}},{name:"PURR_AdConfiguration_v3",valueMapping:{full:"f",rdp:"r",npa:"n",ltd:"l","adluce-socrates":"s"}},{name:"PURR_LimitSensitivePI",valueMapping:{hide:"h",show:"s"}},{name:"PURR_EmailMarketingOptInUI_v2",valueMapping:{checked:"c",unchecked:"u","do-not-display":"d"}},{name:"PURR_AdConfiguration_v4",valueMapping:{full:"f",rdp:"r",npa:"n",ltd:"l","adluce-socrates":"s","no-ads":"a"}}],d={PURR_DataSaleOptOutUI:"hide",PURR_DataSaleOptOutUI_v2:"hide",PURR_CaliforniaNoticesUI:"hide",PURR_DataProcessingConsentUI:"hide",PURR_DataProcessingPreferenceUI:"hide",PURR_AcceptableTrackers_v2:"controllers",PURR_AcceptableTrackers:"controllers",PURR_AdConfiguration_v2:"full",PURR_AdConfiguration:"full",PURR_EmailMarketingOptInUI:"unchecked",PURR_DeleteIPAddress:"delete",PURR_AdConfiguration_v3:"full",PURR_LimitSensitivePI:"hide",PURR_EmailMarketingOptInUI_v2:"unchecked",PURR_AdConfiguration_v4:"full"};function u(){return"full"===e()}function l(e,t,n){var i=document.getElementsByTagName("head")[0],o=document.createElement("script");t&&(o.onload=t),n&&(o.onerror=n),o.src=e,o.async=!0,i.appendChild(o)}function c(){a().cmd.push(function(){var e="".concat("GeoEdge"," failed to load");a().events.publish({name:v,value:{message:e}})})}function p(){return!window.grumi&&(l("//rumcdn.geoedge.be/b3960cc6-bfd2-4adc-910c-6e917e8a6a0e/grumi-ip.js",null,c),window.grumi={key:"b3960cc6-bfd2-4adc-910c-6e917e8a6a0e",cfg:{advs:g}})}function m(){var e;window.apstag||(e="".concat(b," not loading properly"),console.warn(e))}function f(){a().cmd.push(function(){var e="".concat(b," failed to load");a().events.publish({name:y,value:{type:b,message:e}})})}function s(){var e=0<arguments.length&&void 0!==arguments[0]?arguments[0]:window;return e.googletag=e.googletag||{},e.googletag.cmd=e.googletag.cmd||[],e.googletag}function w(e){return!(!window.apstag||!window.apstag.fetchBids)&&(window.apstag.fetchBids({slots:e},void(window.apstag&&window.apstag.setDisplayBids&&s().cmd.push(window.apstag.setDisplayBids()))),!0)}var g={32074718:!0,4792640386:!0,21966278:!0,4558311760:!0,4552626466:!0,4400775978:!0,39318518:!0,4874174581:!0,33597638:!0,38636678:!0,38637278:!0,33597998:!0,33613118:!0,30252878:!0,33597758:!0},v="script_loader_error",b="A9",_=[[320,50],[300,250],[728,90],[970,90],[970,250]],h="large",R="medium",P="small",y="BidderError",U="AdEmpty",O="AdBlockOn",A="AdDefined",k="AdRefreshed";function I(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}function x(t,e){var n,i=Object.keys(t);return Object.getOwnPropertySymbols&&(n=Object.getOwnPropertySymbols(t),e&&(n=n.filter(function(e){return Object.getOwnPropertyDescriptor(t,e).enumerable})),i.push.apply(i,n)),i}function D(t){for(var e=1;e<arguments.length;e++){var n=null!=arguments[e]?arguments[e]:{};e%2?x(Object(n),!0).forEach(function(e){I(t,e,n[e])}):Object.getOwnPropertyDescriptors?Object.defineProperties(t,Object.getOwnPropertyDescriptors(n)):x(Object(n)).forEach(function(e){Object.defineProperty(t,e,Object.getOwnPropertyDescriptor(n,e))})}return t}function j(e){return Y[e]||Y.default}function C(e,t){var n;return(e=[].concat((n=t,[].concat(e).slice().sort(function(e,t){return t[0]-e[0]}).find(function(e){return!Number.isNaN(e[0])&&e[0]<n}))).pop())&&e.length?e:null}function S(o,a){return function(){var e=0<arguments.length&&void 0!==arguments[0]?arguments[0]:{},t=e.sizes,n=void 0===t?[]:t,t=e.truePosition,e=e.id;if(a&&j(o).map(function(e){return e.id}).includes(e))return!1;var i,n=C(n,window.innerWidth),n=(i=n,Array.isArray(i)?_.filter(function(t){return i.some(function(e){return e[0]===t[0]&&e[1]===t[1]})}):(console.warn("filterSizes() did not receive an array"),[]));if(0<n.length){n=[{slotID:t||e,slotName:"".concat(t||e,"_").concat(o,"_web"),sizes:n}];return w(n),!0}return!1}}function M(n,i){return j(i).map(function(e){var t=e.id,e=e.sizes;return{slotID:t,slotName:"".concat(t,"_").concat(i,"_web"),sizes:(e=e)[n]||e[P]}})}function z(t,n){a().cmd.push(function(){var e;t&&w(M(740<(e=window.innerWidth)?h:600<e?R:P,n)),a().events.subscribe({name:A,scope:"all",callback:S(n,t)})})}function T(e,t,n){(function(){var e,n=0<arguments.length&&void 0!==arguments[0]?arguments[0]:"apstag",i=1<arguments.length&&void 0!==arguments[1]?arguments[1]:window;return i[n]||(e=function(e,t){return i[n]._Q.push([e,t])},i[n]={_Q:[],init:function(){e("i",arguments)},fetchBids:function(){e("f",arguments)},setDisplayBids:function(){},targetingKeys:function(){return[]}}),i[n]})("apstag",window).init({pubID:"3030",deals:!0,adServer:"googletag",params:{si_section:t}}),z(e,n)}function E(e,n){var t;switch(Object.values(W).reduce(function(e,t){return n.includes(t)?t:e},n)){case K:t=e.top;break;case J:t=e.mid;break;case X:t=e.bottom;break;default:t=e.default}return t}function B(e){var t;switch(e){case"livebl":t="hp";break;case"coll":t="sf";break;default:t=e}return t in F||(t="default"),t}var N=(I(me={},h,[[728,90],[970,90],[970,250]]),I(me,R,[[728,90],[300,250]]),I(me,P,[[300,250]]),me),Y={art:[{id:"top",sizes:N},{id:"mobile_top",sizes:I({},P,[[320,50]])}],hp:[{id:"dfp-ad-top",sizes:N}],games:[{id:"ad-top",sizes:N},{id:"intsl",sizes:N}],default:[{id:"top",sizes:N}]},F={art:{id:["mobile_top","top","story-ad-1","story-ad-2","story-ad-3","story-ad-4","story-ad-5","story-ad-6","bottom"],pos:["mobile_top","top","mid1","mid2","mid3","mid4","mid5","mid6","bottom"]},int:{id:["top","mid1","mid2","bottom"],pos:["top","mid1","mid2","bottom"]},hp:{id:["dfp-ad-top","dfp-ad-mid1","dfp-ad-mid2","dfp-ad-mid3","dfp-ad-bottom"],pos:["top","mid1","mid2","mid3","bottom"]},ss:{id:["right-0","right-1","right-2","right-3"],pos:["mid1","mid1","mid1","mid1"],size:{small:[[300,250]],medium:[[300,250]],large:[[300,250]]}},sf:{id:["top","mid1","mid2"],pos:["top","mid1","mid2"],size:{small:[[300,250]],medium:[[300,250]],large:[[300,250]]}},games:{id:["ad-top","ad-mid1","ad-bottom"],pos:["top","mid1","bottom"]},default:{id:["top","mid1","mid2"],pos:["top","mid1","mid2"],size:{small:[[300,250]],medium:[[728,90]],large:[[728,90],[970,90],[970,250]]}}},V={top:2088370,mid:2088372,bottom:2088374,default:2088376},G={top:544112060,mid:544112063,bottom:544112062,default:544112065},L={top:684296214,mid:190706820,bottom:932254072,default:153468583},q={top:"NYTimes_728x90_970_top_PB",mid:"NYTimes_728x90_970_mid_PB",bottom:"NYTimes_728x90_970_bot_PB",default:"NYTimes_728x90_970_mid_PB"},H={top:"nytimes_top",mid:"nytimes_mid",bottom:"nytimes_bottom",default:"nytimes_catchall"},Q={top:"995821",mid:"995822",bottom:"995823",default:"995824"},W={TOP:"top",MID:"mid",BOTTOM:"bottom"},Z={buckets:[{max:3,increment:.05},{max:10,increment:.01},{max:20,increment:.1},{max:50,increment:.5},{max:101,increment:1}]},K=W.TOP,J=W.MID,X=W.BOTTOM;function $(o,e,t){var t=2<arguments.length&&void 0!==t?t:{},a=t.sizeConfig,r=t.activeBidders,t=t.positionsToFilter,d=void 0===t?[]:t,c=B(e),s=F[c].size?c:"default";return F[c].pos.reduce(function(e,t,n){if(d.includes(t))return e;var n=F[c].id[n],i=D(D({},F[s].size),null==a||null===(i=a[n])||void 0===i?void 0:i.size),t={code:n,mediaTypes:{banner:{sizeConfig:[{minViewPort:[970,0],sizes:i.large},{minViewPort:[728,0],sizes:i.medium},{minViewPort:[0,0],sizes:i.small}]}},bids:function(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:[],e=[{bidder:"appnexus",params:{member:3661,invCode:"nyt_".concat(e,"_").concat(t)}},{bidder:"medianet",params:{cid:"8CU4WQK98",crid:E(L,t)}},{bidder:"rubicon",params:{accountId:12330,siteId:378266,inventory:{invCode:["nyt_".concat(e,"_").concat(t)]},zoneId:E(V,t),position:"top"===t?"atf":"btf"}},{bidder:"openx",params:{unit:E(G,t),delDomain:"nytimes-d.openx.net",customParams:{invCode:"nyt_".concat(e,"_").concat(t)}}},{bidder:"triplelift",params:{inventoryCode:E(q,t)}},{bidder:"pubmatic",params:{publisherId:"163427",adSlot:E(H,t)}},{bidder:"ix",params:{siteId:E(Q,t)}}],t=e.filter(function(e){return!["pubmatic","ix"].includes(e.bidder)});return n.length?e.filter(function(e){return n.includes(e.bidder)}):t}(o,t,r)};return e.push(t),e},[])}function ee(n){window.pbjs=window.pbjs||{},window.pbjs.initAdserverSet||(window.pbjs.initAdserverSet=!0,a().cmd.push(function(){a().events.subscribe({name:A,scope:"all",callback:function(t){s().cmd.push(function(){var e;(e=B(e=n),F[e].id).includes(t.id)&&window.pbjs.setTargetingForGPTAsync([t.id])})}})}))}function te(n,e,t,i){function o(e,t){window.pbjs.initAdserverSet=!1,n.requestBids({bidsBackHandler:function(){ee(e)},timeout:t})}a().cmd.push(function(){n.que.push(function(){n.addAdUnits($(e,t,i)),o(t,1e4),a().events.subscribe({name:k,scope:"all",callback:function(){o(t,800)}})})})}function ne(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:{},i=function(){var e=0<arguments.length&&void 0!==arguments[0]?arguments[0]:window;return e.pbjs=e.pbjs||{},e.pbjs.que=e.pbjs.que||[],e.pbjs}(),o=n.priceGranularity;i.setConfig({priceGranularity:o||Z}),te(i,e,t,n)}function ie(){a().cmd.push(function(){var e="".concat("PreBid"," failed to load");a().events.publish({name:y,value:{type:"PreBid",message:e}})})}function oe(e,t,n){return!window.pbjs&&(l("https://www.nytimes.com/ads/prebid8.25.0.js",(i=e,o=t,a=n,function(){window.pbjs||console.log("prebid did not load"),ne(i,o,a)}),ie),!0);var i,o,a}function ae(){try{var e=((t=document.createElement("div")).innerHTML="&nbsp;",t.className="ad adsbox pub_300x250 pub_300x250m pub_728x90 text-ad textAd text_ad ad-server",t.style="width: 1px !important; height: 1px !important; position: absolute !important; left: -10000px !important; top: -1000px !important;",document.body.prepend(t),document.getElementsByClassName("ad adsbox")[0]),t=!(!(t=e)||0!==t.offsetHeight&&0!==t.clientHeight)||function(e){if(void 0!==window.getComputedStyle){e=window.getComputedStyle(e,null);if(e&&("none"===e.getPropertyValue("display")||"hidden"===e.getPropertyValue("visibility")))return!0}return!1}(e);return e=e,document.body.removeChild(e),t}catch(e){console.error("ad class check failed",e)}var t;return!1}function re(){return!(window&&window.AdSlot&&window.AdSlot.AdSlotReady)||(!(window&&window.googletag&&window.googletag.apiReady)||ae())}function de(){var e=window&&window.nyt_et&&window.nyt_et.get_host&&window.nyt_et.get_host();return e?fetch("".concat(e,"/.status"),{credentials:"include",headers:{accept:"*/*","content-type":"text/plain;charset=UTF-8"},mode:"no-cors"}).then(function(){return{success:!0}}).catch(function(e){return console.error("et track blocked",e),{success:!1}}):Promise.resolve({success:!1})}function ce(e,t,n){var i=(o="nyt-a",(document&&document.cookie&&document.cookie.match&&(o=document.cookie.match(new RegExp("".concat(o,"=([^;]+)"))))?o[1]:"")||null),o=!!(window&&window.matchMedia&&window.matchMedia("(max-width: 739px)").matches);return"".concat("https://a-reporting.nytimes.com/report.jpg","?mobile=").concat(o,"&block=").concat(n,"&aid=").concat(i,"&pvid=").concat(e,"&et=").concat(t)}function se(e,t,n){return!!(window&&window.NYTD&&window.NYTD.Abra&&"1_network_detection"===window.NYTD.Abra("DFP_blockDetect_0221"))&&((new Image).src=ce(e,t,n),!0)}function ue(e,t){t&&a().cmd.push(function(){var e=a();e.events&&e.events.publish({name:U,value:{type:O}})});var n=!1;return de().then(function(){n=(0<arguments.length&&void 0!==arguments[0]?arguments[0]:{success:!1}).success}).catch(function(){}).finally(function(){se(e,n,t)})}function le(e){var t;window.addEventListener("load",(t=e,function(){ue(t,re())}))}var pe,me=function(){var e=0<arguments.length&&void 0!==arguments[0]?arguments[0]:{};if(pe)return!1;var t=e.loadAmazon,n=void 0===t||t,i=e.loadPrebid,o=void 0===i||i,a=e.setFastFetch,r=void 0!==a&&a,d=e.loadGeoEdge,c=void 0===d||d,s=e.section,t=void 0===s?"none":s,i=e.pageViewId,a=void 0===i?"":i,d=e.pageType,s=void 0===d?"":d,i=e.prebidOverrides,d=void 0===i?{}:i;return e=document.referrer||"",!(i=/([a-zA-Z0-9_\-.]+)(@|%40)([a-zA-Z0-9_\-.]+).([a-zA-Z]{2,5})/).test(e)&&!i.test(window.location.href)&&(u()&&(s=new RegExp(/art/).test(s)?"art":s,c&&p(),n&&(c=r,n=t,r=s,window.apstag||(l("//c.amazon-adsystem.com/aax2/apstag.js",m,f),T(c,n,r))),o&&oe(t,s,d)),le(a),pe=!0)};return(N=a()).loadScripts=N.loadScripts||me,window.AdSlot4=N}();
      (function () { var _f=function(e={}){const i=window&&window.AdSlot4;function o(){const e=window.matchMedia("(max-width: 739px)");return e&&e.matches}try{const{adToggleMap:t,pageType:n,prebidOverrides:d,section:a,isSectionHbEligible:r,setFastFetch:s,headerBidding:c={}}=e,{useAmazon:w,usePrebid:l}=c,p=Object.keys(t).reduce((e,i)=>{const o=t[i]||"";return e[i]=function(e){return!!(window&&window.adClientUtils&&window.adClientUtils.hasActiveToggle)&&window.adClientUtils.hasActiveToggle(e)}(o),e},{}),{amazon:g,geoedge:u}=p,T=d&&d.positionsToFilter||[],b=o()?T.concat(["top"]):T,h=["appnexus","medianet","rubicon","openx","triplelift","ix","pubmatic"];"function"==typeof i.loadScripts&&i.loadScripts({loadAmazon:w&&g&&r,loadPrebid:l&&r,setFastFetch:s&&!o(),section:a,prebidOverrides:{...d,positionsToFilter:b,activeBidders:h},pageType:n,pageViewId:window&&window.NYTD&&window.NYTD.PageViewId&&window.NYTD.PageViewId.current?window.NYTD.PageViewId.current:"",loadGeoEdge:u})}catch(e){console.error(e)}};;_f.apply(null, [{"adToggleMap":{"amazon":"amazon_interactive_toggle","medianet":"medianet_interactive_toggle","dfp":"dfp_interactive_toggle","geoedge":"geoedge_toggle"},"pageType":"int","section":"science","isSectionHbEligible":true,"headerBidding":{"useAmazon":true,"usePrebid":true}}]); })();
      (function () { var _f=function(t={},e={}){window.AdSlot4=window.AdSlot4||{},window.AdSlot4.cmd=window.AdSlot4.cmd||[],window.AdSlot4.clientRequirements={mergeObjects:function(t,...e){return e.reduce(function(t,e){return Object.entries(e).reduce(function(t,[e,n]){return t[e]&&null==n?t:Object.assign({},t,{[e]:n})},t)},t)},isFunction:function(t){return"[object Function]"===Object.prototype.toString.call(t)},getAbraVariant:function(t){if(!(window.NYTD&&window.NYTD.Abra&&window.NYTD.Abra.getAbraSync&&this.isFunction(window.NYTD.Abra.getAbraSync)))return void console.warn("Abra does not exist or is not a function");const e=window.NYTD.Abra.getAbraSync(t);return e&&e.variant},shouldHaltDFP:function(t){return"1_block"===this.getAbraVariant(t)},isAdsDisabled:function(t={}){const{adTargeting:{section:e}={},adsDisabled:n,adUnitPath:i=""}=t,o=i&&i.toLowerCase&&i.toLowerCase().includes("tragedy");return n||"learning"===e||o},getSov:function(t={}){return t.sov=t.sov||(Math.floor(4*Math.random())+1).toString(),{sov:t.sov}},getPageViewId:function(t){return{page_view_id:t&&t.current}},getUserData:function(t="{}"){try{const e=JSON.parse(t).data;return e&&e.user}catch(t){console.warn("userinfo data unavailable")}},getEm:function(t){return t&&t.length?{em:t.toString().toLowerCase()}:{}},getWat:function(t){return t?{wat:t.toLowerCase()}:{}},getDemographics:function(t){return this.mergeObjects(this.getEm(t&&t.emailSubscriptions),this.getWat(t&&t.wat))},isValidDfpTest:function(t){return t.toLowerCase().indexOf("dfp")>-1},joinArgumentsForVariant:function(){if(arguments.length)return[].slice.call(arguments).join("_").toLowerCase()},reduceAbraConfigKeysToDfpVariants:function(t=[],e=""){const n=this.getAbraVariant(e),i=this.joinArgumentsForVariant(e,n);return n&&i?t.concat(i):t},reduceFastlyAbraToDfpVariants:function(t=[],[e,n]=[]){const i=this.isValidDfpTest(e)&&n&&this.joinArgumentsForVariant(e,n);return i?t.concat(i):t},getDFPTestNames:function(t={}){if(!t)return[];const e=this.isValidDfpTest;return Object.keys(t).filter(function(t){return e(t)})},getAbraDfpVariants:function(t={},e={}){let n=[],i=[];if(Object.keys(e).length&&(i=Object.entries(e).reduce(this.reduceFastlyAbraToDfpVariants,[])),t.config&&t.getAbraSync){n=this.getDFPTestNames(t.config).reduce(this.reduceAbraConfigKeysToDfpVariants,[])}return{abra_dfp:[...n,...i]}},isMobile:function(t){const e=t.matchMedia("(max-width: 739px)");return e&&e.matches},isManualRefresh:function(t={}){return!(!t.navigation||1!==t.navigation.type)},getAltLangFromPathname:function(t=""){return 0===t.indexOf("/es/")?"es":""},getAdTargetingProperty:function(t=!1,e=""){let n=t?"m":"";return{prop:(n+=e)+"nyt"}},getAdTargetingPlatform:function(t=!1){return{plat:(t?"m":"")+"web"}},getAdTargetingEdition:function(t=""){return t.length?{edn:t}:{}},getAdTargetingVersion:function(t=!1){return{ver:(t?"m":"")+"vi"}},getAdTargetingHome:function(t,e,n){let i={},o={};return"hp"===t&&(i=e?{topRef:e}:{},o=n?{refresh:"manual"}:{}),this.mergeObjects(i,o)},getAdTargeting:function(t={},n={}){const i=this.isMobile(window),o=this.getAltLangFromPathname(window.location.pathname),r=this.isManualRefresh(performance);return this.mergeObjects(t,this.getDemographics(n),this.getAdTargetingProperty(i,o),this.getAdTargetingPlatform(i),this.getAdTargetingEdition(o),this.getAdTargetingVersion(i),this.getAdTargetingHome(t.typ,document.referrer,r),this.getAbraDfpVariants(window.NYTD.Abra,e),this.getSov(window),this.getPageViewId(window.NYTD.PageViewId))},init:function(t){window.AdSlot4.init&&this.isFunction(window.AdSlot4.init)?window.AdSlot4.init&&window.AdSlot4.init(t):console.warn("AdSlot4.init does not exist or is not a function")},reportExposure:function(t){window.NYTD.Abra&&this.isFunction(window.NYTD.Abra.reportExposure)?window.NYTD.Abra.reportExposure(t):console.warn("Abra.reportExposure does not exist or is not a function")},generateConfig:function(t={},e={},n={}){const i=n&&n.userInfo&&n.userInfo.demographics;return this.mergeObjects(t,e,{adTargeting:this.getAdTargeting(e.adTargeting,i),haltDFP:this.shouldHaltDFP(e.dfpToggleName||t.dfpToggleName),adsDisabled:this.isAdsDisabled(e)})}};for(let t in window.AdSlot4.clientRequirements)window.AdSlot4.clientRequirements[t]=window.AdSlot4.clientRequirements[t].bind(window.AdSlot4.clientRequirements);const n={adUnitPath:"/29390238/nyt/thisIsNotAPath",offset:400,hideTopAd:AdSlot4.clientRequirements.isMobile(window),lockdownAds:!1,sizeMapping:{top:[[970,["fluid",[728,90],[970,90],[970,250],[1605,300]]],[728,["fluid",[728,90],[1605,300]]],[0,[]]],mobile_top:[[0,[320,50]]],fp1:[[0,[[195,250],[215,270]]]],fp2:[[0,[[195,250],[215,270]]]],fp3:[[0,[[195,250],[215,270]]]],feat1:[[0,["fluid"]]],feat2:[[0,["fluid"]]],feat3:[[0,["fluid"]]],feat4:[[0,["fluid"]]],mktg:[[1020,[300,250]],[0,[]]],pencil:[[728,[[336,46]],[0,[]]]],pp_edpick:[[0,["fluid"]]],pp_morein:[[0,["fluid"],[210,218]]],ribbon:[[0,["fluid"]]],sponsor:[[765,[150,50]],[0,[320,25]]],supplemental:[[1020,[[300,250],[300,600]]],[0,[]]],chat:[[0,[[300,250],[300,420]]]],column:[[0,[[300,250],[300,420]]]],ressint:[[600,["fluid"]],[0,[[300,250]]]],mobile_top:[[0,[[320,50]]]],default:[[970,["fluid",[728,90],[970,90],[970,250],[1605,300]]],[728,["fluid",[728,90],[300,250],[1605,300]]],[0,["fluid",[300,250],[300,420]]]]},adTargeting:{},haltDFP:!1,dfpToggleName:t.dfpToggleName,lazyApi:t.lazyApi||{},adsDisabled:!1};window.AdSlot4.cmd.push(function(){const e=window.AdSlot4.clientRequirements,i=e.getUserData(window&&window.userXhrObject&&window.userXhrObject.responseText),o=e.generateConfig(n,t,i);e.init(o),e.reportExposure("dfp_adslot4v2")})};;_f.apply(null, [{"adTargeting":{"vp":"small","als_test":"1714876375743","prop":"mnyt","plat":"mweb","edn":"us","brandsensitive":"true","org":"modernainc,biontechse,pfizerinc,shanghaifosunpharmaceuticalgro,cadilahealthcare,morningsideventuresinc,imperialcollegelondon,osakauniversity,angesmginc,takarabio,arcturustherapeutics,inoviopharmaceuticals,genexine,suzhouabogenbiosciences,chulalongkornuniversity,sanofisa,cansinobiologics,johnsonjohnson,astrazenecaplc,reitherasrl,vaxartinc,merckcompanyinc,novartisag,sinovacbiotechltd,bharatbiotechltd","des":"coronavirus2019ncov,clinicaltrials,vaccinationandimmunization,immunesystem,publicprivatesectorcooperation","auth":"carlzimmer,jonathancorum,matthewkristoffersen,suileewee","coll":"science,health,business,dealbook","artlen":"short","ledemedsz":"none","template":"interactive","typ":"int","section":"science","si_section":"science","id":"100000007182188","pt":"nt1,nt14,nt16,nt18,nt19,nt2,nt20,nt3,nt4,nt6,nt7,nt9,pt11,pt13,pt15,pt8","gscat":"gv_safe,neg_gg1,neg_capitalone,neg_citi_aa,gb_safe,gb_safe_from_high,gb_safe_from_high_med,gs_science,neg_kaypemg,gs_health,neg_rchmt,neg_chanel,neg_chan2,gs_science_geography,neg_hms,neg_ms_safe,neg_gg2,neg_debeer,neg_google,neg_rms,neg_mtb,neg_cme,neg_mc,neg_virus,neg_mastercard,neg_bofa,neg_ibmtest,neg_fcli,gs_health_misc,neg_njts,gs_covid19,neg_ibm,gs_predicts_outdoorsinautumn,gs_health_vaccines,neg_chan3,neg_ihw,gs_busfin,gs_predicts_coldfluseason,neg_rolex,neg_racism,gs_busfin_indus,gs_predicts_newjob,gs_predicts_midautumnfestival,gs_predicts_businessandfinance,gs_predicts_marketers,gs_predicts_womenshealth,gs_predicts_nutritionconscious,gs_predicts_backtoschool,gs_predicts_newyearseve,gs_predicts_startups,gs_predicts_graduatedegree,neg_hearts,gs_predicts_needinglegalcounci,neg_newyorkp,neg_sub0,gs_predicts_rugby_world_cup,gs_predicts_energy_topics,neg_amz_sfe,gs_predicts_charity,gs_predicts_savvyshopperscoupo,gs_predicts_pharma_compassion,gs_predicts_holidayshoppers,neg_mttl,gs_predicts_parentsteachers,gs_predicts_healthylifestyle,cc_tech_society,neg_rmw,gs_predicts_womensfitness,gs_predicts_retail_industry,gs_predicts_moms_dads_grads,gs_predicts_technology,gs_predicts_interestedmillenni,neg_ts,gs_predicts_insurance,gs_predicts_diningindelivery,gs_predicts_chinesenewyear,gs_predicts_cuttingedgetechent,gs_predicts_blackfridaycybermo,cc_tech_data,neg_samsung,gs_predicts_quitsmoking,gs_predicts_christmas,gs_predicts_software_industry,gs_predicts_veteransservice,gs_predicts_mensfitness,gs_predicts_menshealth,gs_predicts_collegebound,gs_predicts_small_med_bus,gs_predicts_nba,neg_sabic,neg_sia,gs_predicts_realestateind,neg_aramco,gs_predicts_mlb,gs_predicts_uspoliticselection,gs_predicts_oralcare,gs_predicts_legal_industry,gs_predicts_rugby,neg_amerex,neg_elec,gs_t","mt":"MT10","ver":"mvi","sov":"2","test":"projectvi","ref":"","refdom":"","abra_dfp":"","gpt-beta":"vqwdtftx"},"adUnitPath":"/29390238/nyt/science","dfpToggleName":"dfp_interactive_toggle"}]); })();
    </script>
  
  <script id="als-svc">
    (function () {
      if (!window.NYTD || !window.NYTD.Abra) {
        return;
      }
      var alsVariant = window.NYTD.Abra('als_toggle');
      if (alsVariant != null && alsVariant.match(/(1_block)/)) {
        window.NYTD.Abra.reportExposure('als_toggle');
      }
      if (window.NYTD.Abra('als_toggle') !== '1_block') {
    (function () { var _f=function(e,t,a,n){var i;if(!(i=a,!!(window&&window.adClientUtils&&window.adClientUtils.hasActiveToggle)&&window.adClientUtils.hasActiveToggle(i)))return;!function(e){window&&window.NYTD&&window.NYTD.Abra&&window.NYTD.Abra.reportExposure(e)}(a);let o=()=>{var e=new Date,t=e.getFullYear();return e.getMonth()<9&&(t+="0"),t+=e.getMonth()+1,e.getDate()<10&&(t+="0"),t+=e.getDate(),e.getHours()<10&&(t+="0"),t+=e.getHours(),e.getMinutes()<10&&(t+="0"),t+=e.getMinutes(),e.getSeconds()<10&&(t+="0"),t+e.getSeconds()};window.googletag=window.googletag||{},googletag.cmd=googletag.cmd||[];let l=new URLSearchParams(location.search).get("alice_rules_test");var s,r=new XMLHttpRequest,d=window.vi.env.ALS_URL,g=document.querySelector('[name="nyt_uri"]');if(t)s="uri="+(c=t);else if("/"===location.pathname){var c=encodeURIComponent("https://www.nytimes.com/pages/index.html");s="uri="+c}else if(void 0===g||""===g||null===g){var u=e||location.protocol+"//"+location.hostname+location.pathname;s="url="+encodeURIComponent(u)}else{c=encodeURIComponent(g.content);s="uri="+c}var w=n;if(!w){var m=document.querySelector('[name="template"]');w=null==m||null==m.content?"":m.content}var p=document.querySelector('[name="prop"]'),_=document.querySelector('[name="plat"]'),v=null==p||null==p.content?"nyt":p.content,b=null==_||null==_.content?"web":_.content;window.innerWidth<740&&(v="mnyt",b="mweb");var f=window.localStorage.getItem("als_test_clientside"),h=null;window.googletag.cmd.push(function(){var e=f&&0!==f.length?f:"empty_empty_empty_"+o(),t=h||e;googletag.pubads().setTargeting("als_test_clientside",t)});var y=window.localStorage.getItem("mktg"),U=null;window.googletag.cmd.push(function(){var e=U||y;e&&googletag.pubads().setTargeting("mktg",e)});var L,S=window.localStorage.getItem("bt");window.googletag.cmd.push(function(){var e=null!=L?L:S;null!=e&&googletag.pubads().setTargeting("bt",e)});var T=window.localStorage.getItem("sub"),C=null;function x(e){var t=new TextEncoder("utf-8").encode(e);return crypto.subtle.digest("SHA-256",t).then(function(e){return function(e){for(var t=[],a=new DataView(e),n=0;n<a.byteLength;n+=4){var i=a.getUint32(n),o=i.toString(16),l=("00000000"+o).slice(-"00000000".length);t.push(l)}return t.join("")}(e)})}window.googletag.cmd.push(function(){var e=C||T;e&&googletag.pubads().setTargeting("sub",e)}),s=null==l?s:s+"&alice_rules_test="+l,r.open("GET",d+"/als?"+s+"&typ="+w+"&prop="+v+"&plat="+b,!0),r.withCredentials=!0,r.send(),r.onerror=function(){var e="reqfailed_reqfailed_reqfailed_"+o();h=e,window.googletag.cmd.push(function(){googletag.pubads().setTargeting("als_test_clientside",e)});var t={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-reqfail-"+s}};(window.dataLayer=window.dataLayer||[]).push(t)},r.onreadystatechange=function(){if(4===r.readyState)if(200===r.status){var e=JSON.parse(r.responseText);h=e.als_test_clientside&&0!==e.als_test_clientside.length?e.als_test_clientside:"bou_bou_bou_"+o(),void 0!==e.User&&(void 0!==e.User.mktg&&(U=e.User.mktg,window.localStorage.setItem("mktg",e.User.mktg)),void 0!==e.User.bt&&(L=e.User.bt,window.localStorage.setItem("bt",e.User.bt)),void 0!==e.User.sub&&(C=e.User.sub,window.localStorage.setItem("sub",e.User.sub)),void 0!==e.User.aid&&(server_aid=e.User.aid,window.localStorage.setItem("aid",e.User.aid))),window.googletag.cmd.push(function(){if(e.als_test_clientside&&0!==e.als_test_clientside.length)googletag.pubads().setTargeting("als_test_clientside",e.als_test_clientside),window.localStorage.setItem("als_test_clientside","ls-"+e.als_test_clientside);else{var t=void 0===e.als_test_clientside?"undefined_undefined_undefined_"+o():"blank_blank_blank_"+o();googletag.pubads().setTargeting("als_test_clientside",t);var a={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-test-client-undefined"}};(window.dataLayer=window.dataLayer||[]).push(a)}if(void 0!==e.User){if(server_aid&&x(server_aid).then(function(e){googletag.pubads().setPublisherProvidedId(e)}),U)googletag.pubads().setTargeting("mktg",U);else{a={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-mktg-undefined"}};(window.dataLayer=window.dataLayer||[]).push(a)}if(void 0!==L)googletag.pubads().setTargeting("bt",L);else{a={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-bt-undefined"}};(window.dataLayer=window.dataLayer||[]).push(a)}if(C)googletag.pubads().setTargeting("sub",C);else{a={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-sub-undefined"}};(window.dataLayer=window.dataLayer||[]).push(a)}(e.User.lucidC1||e.User.lucidC2||e.User.lucidC3||e.User.lucidC4||e.User.lucidC5)&&dataLayer.push({event:"lucidtest",c1_val:e.User.lucidC1,c2_val:e.User.lucidC2,c3_val:e.User.lucidC3,c4_val:e.User.lucidC4,c5_val:e.User.lucidC5})}else{a={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-user-undefined"}};(window.dataLayer=window.dataLayer||[]).push(a)}if(void 0!==e.Asset)for(var n in e.Asset){var i=e.Asset[n];if(i)googletag.pubads().setTargeting(n,i);else{a={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-"+n+"-undefined"}};(window.dataLayer=window.dataLayer||[]).push(a)}}else{a={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-asset-undefined"}};(window.dataLayer=window.dataLayer||[]).push(a)}})}else{r.responseText.substring(0,40);var t="error_"+r.status+"_error_"+o();window.googletag.cmd.push(function(){googletag.pubads().setTargeting("als_test_clientside",t)});var a={event:"impression",module:{name:"alice-timing",context:"script-load",label:"alice-error-ajaxreq-"+r.status+"-"+s}};(window.dataLayer=window.dataLayer||[]).push(a)}}};;_f.apply(null, ["nyt://interactive/417d1099-2aac-55d9-a834-9a011581411e","","","int"]); })();
  }
    }());
  </script>
  
    <script>!function(){try{var e="undefined"!=typeof window?window:"undefined"!=typeof global?global:"undefined"!=typeof self?self:{},a=(new Error).stack;a&&(e._sentryDebugIds=e._sentryDebugIds||{},e._sentryDebugIds[a]="77c20b06-c13d-4558-906a-2b130175bdbd",e._sentryDebugIdIdentifier="sentry-dbid-77c20b06-c13d-4558-906a-2b130175bdbd")}catch(e){}}();var _global="undefined"!=typeof window?window:"undefined"!=typeof global?global:"undefined"!=typeof self?self:{};_global.SENTRY_RELEASE={id:"03cce1e7203a898cba8bffea0e231b4698a1d4eb"},function(e){function a(a){for(var n,o,c=a[0],i=a[1],l=a[2],s=0,b=[];s<c.length;s++)o=c[s],Object.prototype.hasOwnProperty.call(r,o)&&r[o]&&b.push(r[o][0]),r[o]=0;for(n in i)Object.prototype.hasOwnProperty.call(i,n)&&(e[n]=i[n]);for(f&&f(a);b.length;)b.shift()();return t.push.apply(t,l||[]),d()}function d(){for(var e,a=0;a<t.length;a++){for(var d=t[a],n=!0,c=1;c<d.length;c++){var i=d[c];0!==r[i]&&(n=!1)}n&&(t.splice(a--,1),e=o(o.s=d[0]))}return e}var n={},r={138:0},t=[];function o(a){if(n[a])return n[a].exports;var d=n[a]={i:a,l:!1,exports:{}};return e[a].call(d.exports,d,d.exports,o),d.l=!0,d.exports}o.e=function(e){var a=[],d=r[e];if(0!==d)if(d)a.push(d[2]);else{var n=new Promise((function(a,n){d=r[e]=[a,n]}));a.push(d[2]=n);var t,c=document.createElement("script");c.charset="utf-8",c.timeout=120,o.nc&&c.setAttribute("nonce",o.nc),c.src=function(e){return o.p+""+({0:"vendor",3:"vendors~account~byline~capsule~clientSideCapsule~collections~explainer~getstarted~liveAsset~newslett~0c93273d",6:"vendors~audio~byline~capsule~card~clientSideCapsule~paidpost~slideshow~video~wellContent",9:"vendors~getstarted~newsletter~newsletters~newsletterssubscriberonly~recirculation~welcomesubscriber~~a6f3c374",13:"vendors~byline~capsule~clientSideCapsule~home~trending",19:"emailsignup~your-space",21:"vendors~CardDeck~carddeck",31:"CardDeck",53:"ask",56:"audioblock",63:"caHamburgerNestedNavData",64:"canadaHamburgerNavData",65:"canadaSiteIndexData",69:"clientSideCapsule",72:"comments",73:"commentsForm",78:"dealbook",79:"defaultHamburgerNavData",80:"defaultSiteIndexData",81:"desktopLogoNav",82:"desktopNav",83:"emailsignup",100:"headerfullbleedhorizontal",101:"headerfullbleedvertical",102:"headerlivebriefingvi",107:"internationalHamburgerNavData",108:"internationalHamburgerNestedNavData",109:"internationalSiteIndexData",110:"lens",118:"nestedNav",128:"opinion",131:"producernotes",133:"recirculation",135:"reviewheader",141:"siteIndexContent",144:"slideshowinline",152:"upshot",153:"usHamburgerNestedNavData",156:"vendors~audioblock",159:"vendors~charlatan-select",160:"vendors~commentsForm",162:"vendors~emailsignup",167:"vendors~headerfullbleedhorizontal",168:"vendors~headerfullbleedvertical",172:"vendors~producernotes",173:"vendors~recirculation",174:"vendors~reviewheader",176:"vendors~slideshowinline",178:"vendors~videoblock",181:"videoblock",187:"world-cup-2019"}[e]||e)+"-"+{0:"7c2097fe0266d898a1c1",3:"f104ba814112712f8f74",6:"363fcda24937fef7d3bd",9:"ecf11f3d788c12dd0bfc",13:"643cd529b000e5384cc2",19:"2948e415fc3c5cdec079",21:"2c49da68a20e35c2f5ff",31:"f5bf48cfbaaf90eb92b8",53:"82b0a40d99ce31659555",56:"55da77601697824fde74",63:"97cdbaafd432bdefa25b",64:"4e9381d539a79ea88d5f",65:"6196803173269417d16c",69:"c5748d5a3b0939344fa4",72:"add980bec28684b393be",73:"6766eb8015437c34c45b",78:"f11e4a13a3cad0753528",79:"4e84526b5125aa2cde67",80:"f6d8d4ff74226ecda9b2",81:"6d41a90c4e05f59c07ce",82:"e94efb95a78250e2de5d",83:"83a6f0c5c819bddc943a",100:"0b2d2ca37a50b846a1ed",101:"3dd612b7f39def08cd6a",102:"815a8e8b2221ec5a0a6a",107:"8348f68b80224394088b",108:"314c8e73d0cad3bc8cfb",109:"2b42cd4643920cb5b370",110:"c69d4856522c9efd4ed6",118:"28c421b9119645b039a0",128:"4f9dcf21aa29b026c842",131:"def79b65e86ac2be6eab",133:"95614e5f197d716bb771",135:"ec70677baf645b4c1425",141:"b00956a07ade6269aad6",144:"e73a49509126635e9e5d",152:"d5757a437939f7c38823",153:"ec9c3b8eb1fbcd28eafb",156:"99039acd87c191c5d7f4",159:"77a27a3dfe412a60f625",160:"e2c4a1fedc03eec1b435",162:"ee9acdb8ea455c9b2f43",167:"a67162d497c97ae21638",168:"35e91395ed984ea97a6e",172:"63458b86061ec62b6ed1",173:"d33d120379e0ffc4fd97",174:"de6df8e19a0b5c6a388d",176:"dd93d9ef2f7d543bfe4a",178:"7b9086577255fab87332",181:"e096286923be1eb91d6e",187:"614533f5da17e88829d0"}[e]+".js"}(e);var i=new Error;t=function(a){c.onerror=c.onload=null,clearTimeout(l);var d=r[e];if(0!==d){if(d){var n=a&&("load"===a.type?"missing":a.type),t=a&&a.target&&a.target.src;i.message="Loading chunk "+e+" failed.\n("+n+": "+t+")",i.name="ChunkLoadError",i.type=n,i.request=t,d[1](i)}r[e]=void 0}};var l=setTimeout((function(){t({type:"timeout",target:c})}),12e4);c.onerror=c.onload=t,document.head.appendChild(c)}return Promise.all(a)},o.m=e,o.c=n,o.d=function(e,a,d){o.o(e,a)||Object.defineProperty(e,a,{enumerable:!0,get:d})},o.r=function(e){"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},o.t=function(e,a){if(1&a&&(e=o(e)),8&a)return e;if(4&a&&"object"==typeof e&&e&&e.__esModule)return e;var d=Object.create(null);if(o.r(d),Object.defineProperty(d,"default",{enumerable:!0,value:e}),2&a&&"string"!=typeof e)for(var n in e)o.d(d,n,function(a){return e[a]}.bind(null,n));return d},o.n=function(e){var a=e&&e.__esModule?function(){return e.default}:function(){return e};return o.d(a,"a",a),a},o.o=function(e,a){return Object.prototype.hasOwnProperty.call(e,a)},o.p="/vi-assets/static-assets/",o.oe=function(e){throw console.error(e),e};var c=window.webpackJsonp=window.webpackJsonp||[],i=c.push.bind(c);c.push=a,c=c.slice();for(var l=0;l<c.length;l++)a(c[l]);var f=i;d()}([]);
//# sourceMappingURL=runtime~interactive-d634570339afc6b95783.js.map</script>
    <script defer src="/vi-assets/static-assets/vendor-interactive-9b9e67ab1d092a874243.js"></script>
    <script defer src="/vi-assets/static-assets/recirculation-95614e5f197d716bb771.js"></script>
<script defer src="/vi-assets/static-assets/defaultSiteIndexData-f6d8d4ff74226ecda9b2.js"></script>
<script defer src="/vi-assets/static-assets/siteIndexContent-b00956a07ade6269aad6.js"></script>
    <script defer src="/vi-assets/static-assets/interactive-7192944549c82018f106.js"></script>
    <script>(function () { var _f=function(){try{var e=["first-paint","first-contentful-paint","userBtnRender","appRenderTime"];new window.PerformanceObserver(function(r){for(var n=r.getEntries(),a=0;a<n.length;a+=1){var t=n[a];if(e.indexOf(t.name)>-1){var i={};i[t.name]=Math.round(t.duration||t.startTime),(window.dataLayer=window.dataLayer||[]).push({event:"performance",pageview:{performance:i}})}}}).observe({entryTypes:["mark","measure","paint"]})}catch(e){}};;_f.apply(null, []); })();(function () { var _f=function(){!function(){if(1===Math.floor(20*Math.random())&&(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted)){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=14,window.BOOMR.url="https://s.go-mpulse.net/boomerang/ATH8A-MAMN8-XPXCH-N5KAX-8D239";var e=(document.currentScript||document.getElementsByTagName("script")[0]).parentNode,n=!1,t=document.createElement("link");t.relList&&"function"==typeof t.relList.supports&&t.relList.supports("preload")&&"as"in t?(window.BOOMR.snippetMethod="p",t.href=window.BOOMR.url,t.rel="preload",t.as="script",t.addEventListener("load",function(){if(!n){var t=document.createElement("script");t.id="boomr-scr-as",t.src=window.BOOMR.url,t.async=!0,e.appendChild(t),n=!0}}),t.addEventListener("error",function(){o(!0)}),setTimeout(function(){n||o(!0)},3e3),BOOMR_lstart=(new Date).getTime(),e.appendChild(t)):o(!1),window.addEventListener?window.addEventListener("load",i,!1):window.attachEvent&&window.attachEvent("onload",i)}function o(t){n=!0;var o,i,d,a,r=document,s=window;if(window.BOOMR.snippetMethod=t?"if":"i",i=function(e,n){var t=r.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),(e=e||r.body).appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]./))return window.BOOMR.snippetMethod="s",void i(e,"boomr-async");(d=document.createElement("IFRAME")).src="about:blank",d.title="",d.role="presentation",d.loading="eager",(a=(d.frameElement||d).style).width=0,a.height=0,a.border=0,a.display="none",e.appendChild(d);try{s=d.contentWindow,r=s.document.open()}catch(e){o=document.domain,d.src="javascript:var d=document.open();d.domain='"+o+"';void 0;",s=d.contentWindow,r=s.document.open()}o?(r._boomrl=function(){this.domain=o,i()},r.write("<body onload='document._boomrl();'>")):(s._boomrl=function(){i()},s.addEventListener?s.addEventListener("load",s._boomrl,!1):s.attachEvent&&s.attachEvent("onload",s._boomrl)),r.close()}function i(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}}()};;_f.apply(null, []); })();</script>
    
    <script>
(function(w, l) {
  w[l] = w[l] || [];
  w[l].push({
    'gtm.start': new Date().getTime(),
    event: 'gtm.js'
  });
})(window, 'dataLayer');
</script>
<script defer src="https://www.googletagmanager.com/gtm.js?id=GTM-P528B3&gtm_auth=tfAzqo1rYDLgYhmTnSjPqw&gtm_preview=env-130&gtm_cookies_win=x"></script>
<noscript>
<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-P528B3&gtm_auth=tfAzqo1rYDLgYhmTnSjPqw&gtm_preview=env-130&gtm_cookies_win=x" height="0" width="0" style="display:none;visibility:hidden"></iframe>
</noscript>
    
    
    <script id="live-ramp">(function () { var _f=function(){var a=function(a){var e=document.cookie.match(new RegExp(a+"=([^;]+)"));if(e)return e[1]}("nyt-purr"),e=a&&a.substring(14,15)||"",n=window.navigator.userAgent.match(/(nyt)[_wd-]*(ios)/i);a&&"r"===e||n||function(){var a=document.createElement("link");a.href="https://launchpad.privacymanager.io/latest/launchpad.bundle.js",a.as="script",document.body.appendChild(a);var e=document.createElement("script");e.async=!1,e.defer=!0,e.src="https://launchpad-wrapper.privacymanager.io/9fab0bf6-df63-42ca-acc5-caf4de668f40/launchpad-liveramp.js",document.body.appendChild(e)}()};;_f.apply(null, []); })();</script>
    <!-- RELEASE 03cce1e7203a898cba8bffea0e231b4698a1d4eb -->
  </body>
</html> contentType 9 text/html url 85 https://www.nytimes.com:443/interactive/2020/science/coronavirus-vaccine-tracker.html responseCode 3 200 